
<html lang="en"     class="pb-page"  data-request-id="a421571a-dd36-4eb2-a377-c0e39d26d4ac"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2018.61.issue-6;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;article:article:10.1021/acs.jmedchem.6b01827;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Triple Reuptake Inhibitors as Potential Therapeutics for Depression and Other Disorders: Design Paradigm and Developmental Challenges" /></meta><meta name="dc.Creator" content="Murugaiah A. M.  Subbaiah" /></meta><meta name="dc.Description" content="Although first-line antidepressants offer therapeutic benefit, about 35% of depressed patients are not adequately treated, creating a large unmet medical need. These medicines mostly enhance the sy..." /></meta><meta name="Description" content="Although first-line antidepressants offer therapeutic benefit, about 35% of depressed patients are not adequately treated, creating a large unmet medical need. These medicines mostly enhance the sy..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 21, 2017" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b01827" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2017 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b01827" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b01827" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b01827" /></link>
        
    
    

<title>Triple Reuptake Inhibitors as Potential Therapeutics for Depression and Other Disorders: Design Paradigm and Developmental Challenges | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b01827" /></meta><meta property="og:title" content="Triple Reuptake Inhibitors as Potential Therapeutics for Depression and Other Disorders: Design Paradigm and Developmental Challenges" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0049.jpeg" /></meta><meta property="og:description" content="Although first-line antidepressants offer therapeutic benefit, about 35% of depressed patients are not adequately treated, creating a large unmet medical need. These medicines mostly enhance the synaptic levels of serotonin and/or norepinephrine. Evidence from preclinical and clinical studies implicate dopamine hypofunction in the pathophysiology of depression. Triple reuptake inhibitors (TRIs), which elevate dopamine in addition to serotonin and norepinephrine, may demonstrate greater efficacy, with the reversal of anhedonia and improved tolerability. Medicinal chemistry efforts have resulted in more than 10 clinical candidates, although clinical candidates have failed to demonstrate superior efficacy compared to placebo or existing antidepressants. Hence, the successful development of future TRIs for depression will demand strong translational evidence, an optimal dosing regimen, and better tolerability. TRIs also hold therapeutic potential for other indications, with four candidates under clinical development for attention deficit hyperactivity disorder, binge eating disorder, cocaine addiction, obesity, and type 2 diabetes. Clinical studies have indicated a lower abuse potential for TRIs than psychostimulants." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b01827"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b01827">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b01827&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b01827&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b01827&amp;href=/doi/10.1021/acs.jmedchem.6b01827" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 6</span><span class="cit-fg-pageRange">, 2133-2165</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/6" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.7b00315" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="article_relation"><span class="article_relation-correction"><i class="icon-asterisk"></i><span class="relation-text"><a href="/doi/10.1021/acs.jmedchem.9b01619"><span class="relation-type">ADDITION / CORRECTION</span><span class="relation-desc">This article has been corrected. View the notice.</span></a></span></span></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Triple Reuptake Inhibitors as Potential Therapeutics for Depression and Other Disorders: Design Paradigm and Developmental Challenges</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Murugaiah A. M. Subbaiah</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Murugaiah A. M. Subbaiah</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, Biocon Bristol-Myers Squibb R&D Centre, Biocon Park, Bommasandra Phase IV, Jigani Link Road, Bangalore 560099, India</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: +91-(0)9655598704. E-mail: <a href="/cdn-cgi/l/email-protection#7e130b0c0b191f171f16501f101a1f0e0e1f103e0d0710191b101b17100a12501d1113"><span class="__cf_email__" data-cfemail="4c21393e392b2d252d24622d22282d3c3c2d220c3f35222b29222925223820622f2321">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Murugaiah+A.+M.++Subbaiah">Murugaiah A. M. Subbaiah</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5707-966X" title="Orcid link">http://orcid.org/0000-0001-5707-966X</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b01827&amp;href=/doi/10.1021%2Facs.jmedchem.6b01827" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 6</span><span class="cit-pageRange">, 2133–2165</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 21, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>13 December 2016</li><li><span class="item_label"><b>Published</b> online</span>21 July 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 22 March 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b01827" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01827</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2133%26pageCount%3D33%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMurugaiah%2BA.%2BM.%2BSubbaiah%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D61%26issueNum%3D6%26contentID%3Dacs.jmedchem.6b01827%26title%3DTriple%2BReuptake%2BInhibitors%2Bas%2BPotential%2BTherapeutics%2Bfor%2BDepression%2Band%2BOther%2BDisorders%253A%2BDesign%2BParadigm%2Band%2BDevelopmental%2BChallenges%26numPages%3D33%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2165%26publicationDate%3DMarch%2B2018">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b01827"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2909</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">15</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b01827" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Triple Reuptake Inhibitors as Potential Therapeutics for Depression and Other Disorders: Design Paradigm and Developmental Challenges&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Murugaiah&quot;,&quot;last_name&quot;:&quot;A. M. Subbaiah&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;21&quot;,&quot;issue&quot;:&quot;6&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;2133-2165&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b01827&quot;},&quot;abstract&quot;:&quot;Although first-line antidepressants offer therapeutic benefit, about 35% of depressed patients are not adequately treated, creating a large unmet medical need. These medicines mostly enhance the synaptic levels of serotonin and/or norepinephrine. Evidence from preclinical and clinical studies implicate dopamine hypofunction in the pathophysiology of depression. Triple reuptake inhibitors (TRIs), which elevate dopamine in addition to serotonin and norepinephrine, may demonstrate greater efficacy, with the reversal of anhedonia and improved tolerability. Medicinal chemistry efforts have resulted in more than 10 clinical candidates, although clinical candidates have failed to demonstrate superior efficacy compared to placebo or existing antidepressants. Hence, the successful development of future TRIs for depression will demand strong translational evidence, an optimal dosing regimen, and better tolerability. TRIs also hold therapeutic potential for other indications, with four candidates under clinical developm&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01827&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01827" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01827&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01827" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01827&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01827" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b01827&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01827&amp;href=/doi/10.1021/acs.jmedchem.6b01827" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b01827" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b01827" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (8 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01827&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b01827%26sid%3Dliteratum%253Aachs%26pmid%3D28731336%26genre%3Darticle%26aulast%3DSubbaiah%26date%3D2018%26atitle%3DTriple%2BReuptake%2BInhibitors%2Bas%2BPotential%2BTherapeutics%2Bfor%2BDepression%2Band%2BOther%2BDisorders%253A%2BDesign%2BParadigm%2Band%2BDevelopmental%2BChallenges%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D6%26spage%3D2133%26epage%3D2165%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=291181" title="Amines">Amines</a>,</li><li><a href="/action/doSearch?ConceptID=291070" title="Pharmaceuticals">Pharmaceuticals</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/6" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/jmcmar.2018.61.issue-6/20180322/jmcmar.2018.61.issue-6.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0049.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0049.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Although first-line antidepressants offer therapeutic benefit, about 35% of depressed patients are not adequately treated, creating a large unmet medical need. These medicines mostly enhance the synaptic levels of serotonin and/or norepinephrine. Evidence from preclinical and clinical studies implicate dopamine hypofunction in the pathophysiology of depression. Triple reuptake inhibitors (TRIs), which elevate dopamine in addition to serotonin and norepinephrine, may demonstrate greater efficacy, with the reversal of anhedonia and improved tolerability. Medicinal chemistry efforts have resulted in more than 10 clinical candidates, although clinical candidates have failed to demonstrate superior efficacy compared to placebo or existing antidepressants. Hence, the successful development of future TRIs for depression will demand strong translational evidence, an optimal dosing regimen, and better tolerability. TRIs also hold therapeutic potential for other indications, with four candidates under clinical development for attention deficit hyperactivity disorder, binge eating disorder, cocaine addiction, obesity, and type 2 diabetes. Clinical studies have indicated a lower abuse potential for TRIs than psychostimulants.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47775" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47775" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Depression is the leading cause of disability, diminished productivity, and dependent care globally, with an estimated 350 million people affected worldwide.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Major depressive disorder (MDD) is a chronic and progressive mental disorder with heterogeneous etiology and symptoms and a high incidence of recurrence. MDD is a major risk factor for suicide, which is the tenth leading cause of death globally and is comorbid with several chronic diseases, including heart disease, stroke, diabetes, and cancer. It is estimated that about 10% of the US population are being treated with antidepressants for either depression or related disorders.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2,3)</a> Current pharmacotherapy is based on “monoamine deficiency” as the underlying etiology and pathogenesis of depression. This hypothesis was formulated around 1960 and was based on the serendipitous clinical observation of an antidepressant effect associated with tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs). Monoaminergic (serotonergic, noradrenergic, and dopaminergic) neurons are present in the midbrain and project to almost all areas of the brain, consistent with the involvement of the monoaminergic system in a broad range of brain functions, including mood, cognition, attention, appetite, sleep, and reward processing.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Marketed antidepressants elevate synaptic levels of serotonin (5-hydroxytryptamine, 5-HT; <b>1</b>) and/or norepinephrine (NE; <b>2</b>) by blocking the monoamine transporters, SERT (serotonin transporter), and/or NET (norepinephrine transporter).<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> However, dopamine (DA; <b>3</b>), for which reuptake is mediated by the dopamine transporter (DAT), has also been implicated in the pathophysiology of depression (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref4 ref6'); return false;" href="javascript:void(0);" class="ref ref4 ref6">(4,6)</a> Focusing mainly on the recent literature (2008–2016), this perspective reviews: (1) the relevance of dopamine signaling in the pathophysiology and treatment of depression in the context of the limitations of existing antidepressants, (2) the emergence of dopaminergic-inclusive TRIs as potential next-generation antidepressants, their therapeutic potential in other disorders, and the possible challenges associated with their development, and (3) the rational design and discovery of different chemical series of TRIs along with their pharmacological and pharmacokinetic evaluation.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Key monoamines involved in the pathophysiology of depression.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2.  Existing Antidepressants and Their Limitations</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20556" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20556" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">First generation TCAs (<b>4</b>–<b>8</b>) including desipramine (<b>4</b>) and imipramine (<b>5</b>) and MAOIs including tranylcypromine (<b>9</b>) were introduced in the 1950s after being serendipitously discovered to be effective in treating depression (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> They were later shown to increase monoaminergic neurotransmission either by blocking the reuptake of monoamine neurotransmitters or by preventing their metabolism. These drugs are now largely restricted to use in severe or refractory depression due to poor tolerance. While TCAs are known to cause cardiovascular, anticholinergic and sedative side effects due to the off-target pharmacology (for example, adrenergic, histaminergic, and muscarinic receptors), MAOIs produce dietary and drug–drug interactions that can be lethal.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Select examples of TCAs and MAOIs as first-generation antidepressants.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Shortcomings of TCAs led to the discovery of selective serotonin reuptake inhibitors (SSRIs; <b>10</b>–<b>15</b>), which selectively inhibit 5-HT reuptake in serotonergic neurons (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> and <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>).<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> These drugs represented a major advance in the treatment of depression with an improved safety and tolerability profile. Subsequent observations of the antidepressant or other therapeutic effects of compounds that selectively block the neurotransmitter uptake in noradrenergic neurons led to the discovery of norepinephrine reuptake inhibitors (NRIs; <b>16</b>,<b>17</b>). The combination of inhibition of reuptake in both serotonergic and noradrenergic neurons was the natural evolutionary step that led to the development of dual reuptake inhibitors, SNRIs (<b>18</b>–<b>22</b>). Second-generation agents, especially SSRIs and SNRIs, are now prescribed as the standard of care (SoC). Despite their improved safety and tolerability profile, they are not superior to TCAs and MAOIs in terms of efficacy and latency of onset.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Bupropion (<b>23</b>), which belongs to a different class of dual reuptake inhibitors as a combined norepinephrine and dopamine reuptake inhibitor (NDRI), has also been approved to treat MDD.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> While <b>23</b> also acts as a releasing agent of NE and DA, its major metabolite, hydroxybupropion, is also known to be a NET inhibitor.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Nomifensine (<b>24</b>) is another NDRI that was approved to treat depression but was later withdrawn due to safety reasons.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Monoamine transporter blockade by existing single and dual reuptake inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Structures of marketed single and dual reuptake inhibitors, including first-line antidepressants (<sup><i>a</i></sup>withdrawn from the market).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In spite of improvements in the profiles of antidepressant medications, a large unmet clinical need still exists in terms of response rate, treatment onset, residual symptoms, and side effect profile (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). As is evident from the STAR*D clinical trial, which evaluated the effectiveness of antidepressants including switching to a different medication or medication combination, only one-third of patients recover on treatment with a single antidepressant while another one-third recover only after several months of different and multiple therapy trials.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> These drugs exhibit a clinical response as measured by a mood-elevating effect only after 2–4 weeks, although their pharmacological action occurs within a few hours of drug ingestion. As high rates of morbidity and mortality are prevalent during this latent period, it poses a critical public health problem. Another major drawback is the relapse or recurrence of depression which patients may experience following an initial short-term treatment of acute depressive episodes with antidepressants. The recurrence rate is alarmingly high, with 50% or more experiencing depression within six months of remission when an initially effective treatment with antidepressants is discontinued.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Importantly, they are less effective in the treatment of depressive symptoms resulting from an impaired positive mood, particularly anhedonia, amotivation, loss of energy/enthusiasm, fatigue, and cognitive impairment.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Anhedonia, which is the loss of pleasure in rewarding activities, is one of the core symptoms of depression. Moreover, side effects associated with SSRIs and SNRIs, most notably sexual dysfunction and weight gain, can lead to poor adherence or treatment discontinuation among patients. Any new treatment that would demonstrate an improvement of efficacy and time to onset with the mitigation of residual symptoms and side effects would constitute a significant advance in the treatment paradigm. Hence, there is a compelling need to develop next-generation antidepressants.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Underlying contributors to the large unmet clinical need with first-line antidepressants.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">3.  The Role of Dopamine in the Pathophysiology of Depression</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84847" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84847" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5">3.1.  Dopaminergic System and Dysfunction</h3><div class="NLM_p">Research conducted over the past few decades has suggested that dopaminergic pathways regulate positive aspects of mood or motivational aspects of behavior.<a onclick="showRef(event, 'ref4 ref6'); return false;" href="javascript:void(0);" class="ref ref4 ref6">(4,6)</a> The nigrostriatal pathway, which transmits DA to the caudate nucleus and putamen from the substantia nigra, primarily regulates motor function that includes planning and execution of movement. The mesolimbic pathway, which transmits DA from the ventral tegmental area (VTA) to the nucleus accumbens (NAc), is linked to reward-related, hedonic, and motivational behaviors. The mesocortical pathway, which innervates the cortex from the VTA, is believed to be important for concentration and executive functions like working memory. The functional impairment of dopaminergic pathways can cause a deficiency in the behavioral aspects of positive mood, including psychomotor speed, the ability to experience pleasure, motivation, concentration, and other behaviors, which may translate into prominent symptoms for depressed patients.</div><div class="NLM_p">The regulation of DA function through homeostatic mechanisms requires a delicate balance of synthesis, storage, release, reuptake, and metabolism of the neurotransmitter that is believed to be critical for a normal positive mood state.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> DAT plays a critical role in DA recycling by removing DA from the synaptic space, leading to the termination of DA signaling and reaccumulation in the presynaptic terminals.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Consistent with the key role of the DA system in several aspects of brain function, an absence of DAT in mice was shown to cause changes in behavioral, physical, and pharmacological activities, including hyperactivity, sleep dysregulation, reduced weight, and pronounced reduction of hyperactivity with psychostimulants.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> All of these effects can be attributed to observed changes in the DA system including higher levels of extracellular DA, reduced levels of presynaptic DA synthesis and DA-synthesizing enzymes, and altered levels and function of DA receptors. The alteration of DAT function or density has been implicated in several CNS disorders, including depression, anxiety, attention deficit hyperactivity disorder (ADHD), and Parkinson’s disease (PD). Psychostimulants, including cocaine (<b>27</b>) and amphetamine (<b>29</b>), drugs like methylphenidate (<b>25</b>), <i>d</i>-amphetamine (<b>30</b>), and lisdexamfetamine (<b>31</b>; a prodrug of <b>30</b>) used to treat ADHD, and modafinil (<b>32</b>), used in the treatment of narcolepsy, elicit their behavioral effects, in part, through DAT inhibition (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a> and <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>).<a onclick="showRef(event, 'ref4 ref16'); return false;" href="javascript:void(0);" class="ref ref4 ref16">(4,16)</a> The stimulant drug <b>29</b> also competes with DA as a substrate for DAT and triggers DA release from presynaptic neurons through reverse transport by DAT.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Though <b>32</b> is known for poor in vitro DAT activity, it has demonstrated significant DAT occupancy (≥50%) in preclinical and clinical PET studies.<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18,19)</a> This compound also acts as a D<sub>2</sub> agonist.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Examples of psychostimulants and other agents, which involve DAT inhibition as part of their pharmacological actions.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6">3.2.  Preclinical Studies</h3><div class="NLM_p">Studies conducted in different rodent models of depression have indicated that the enhancement of dopaminergic neurotransmission elicits antidepressant-like effects while the suppression of this neurotransmission causes depression-like effects (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). DAT knockout (KO) mice, which are reported to experience a chronic elevation of DA, have exhibited an antidepressant-like phenotype in several behavioral models including the forced swim test (FST), the tail suspension test (TST), and the sucrose consumption test (SCT).<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Recently, inhibition of DA neuronal cells in the VTA by an optogenetic method (a technique that combines optics and genetics to control the activities of neurons in a freely moving animal and study the behavioral effect) was shown to induce depression-like phenotypes such as increased immobility time (TST) and decreased sucrose preference (SCT) in mice, thereby linking dysfunction of VTA DA neurons to depression-like behaviors.<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21,22)</a> In contrast, phasic activation of VTA DA neurons was found to reverse the depression-like behaviors in the TST and SCT models induced by chronic mild stress (CMS). Rodents showed a gradual decrease in responsiveness to rewards and in the performance of other motivated (e.g., aggressive and sexual) behaviors on exposure to CMS.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> While CMS-induced anhedonia was found to be reversible by partial DA agonists, exposure of the recovered rodents to D<sub>2</sub>/D<sub>3</sub> antagonists resulted in a decreased reward response.<a onclick="showRef(event, 'ref6 ref24'); return false;" href="javascript:void(0);" class="ref ref6 ref24">(6,24)</a></div><div class="NLM_p">Flinders sensitive line rats, a selectively bred animal model of human depression, displayed symptoms similar to those of depressed individuals, including altered sleep patterns, reduced appetite, and anhedonia. These observations are consistent with impaired DA neurotransmission that is reflected in low basal extracellular levels of DA in the limbic system, deficiency in dopaminergic tonic release in the NAc, and reduced cell activity in the VTA.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> In effort-expenditure models of depression, DA antagonism or reduced DA concentration in the NAc resulted in decreased selection of high effort/high reward choices and increased selection of low effort/low reward options.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Tetrabenazine (<b>43</b>; <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>), which is a vesicular monoamine transporter-2 (VMAT-2) inhibitor, blocks the storage of monoamines, thereby depleting levels of these neurotransmitters, with a major impact on striatal DA.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> The DAT inhibitor PRX-14040 (<b>34</b>) was recently shown to reverse the effects of <b>43</b> in rats by increasing lever pressing and decreasing chow intake, with efficacy comparable to that of the dopaminergic agents <b>23</b>, <b>25</b>, and <b>32</b>.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Compound <b>23</b> increased the motivation to work for food reinforcement in rats, consistent with a significant increase in extracellular levels of DA in the NAc at the behaviorally active doses.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></div><div class="NLM_p">Extinction of intracranial self-stimulation (ICSS), in which rodents self-administer a rewarding electrical stimulation, led to a significant decrease in goal-directed behaviors. This effect correlated with a significant decrease in cue-evoked phasic DA, while subsequent reinstatement restored cue-evoked DA release and re-establishment of ICSS behavior, suggesting a role for NAc DA in the reward-related pathways.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Intraperitoneal injection of dilute acid (ip acid), a preclinical model for pain involving a chemical noxious stimulus, depressed both ICSS and extracellular DA levels in the NAc in rats (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>).<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> In the rat FST model, DA-potentiating agents [D<sub>2</sub>/D<sub>3</sub> agonists and <b>24</b> (NDRI)] reduced immobility time, and this antidepressant-like effect was reduced by D<sub>2</sub>/D<sub>3</sub> antagonists.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Co-administration of subactive doses (ip) of the NDRI <b>23</b> along with other antidepressants, including <b>11</b>, paroxetine (<b>13</b>), fluvoxamine (<b>14</b>), venlafaxine (<b>19</b>), and <b>21</b>, at inactive doses decreased the immobility time in the mouse FST, suggesting that <b>23</b> may enhance the efficacy of SSRIs and SNRIs, consistent with preliminary clinical evidence.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Acute administration of ketamine (<b>35</b>), an NMDA receptor antagonist with clinically proven and rapidly acting antidepressant properties, and LY341495 (<b>36</b>), an mGlu<sub>2/3</sub> receptor antagonist, but not the SSRI <b>11</b>, was shown to activate dopaminergic neurotransmission in the preclinical models (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>).<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Both <b>35</b> and <b>36</b> were shown to increase the number of spontaneously active DA neurons in the VTA and increase the extracellular levels of DA in the NAc and prefrontal cortex (PFC).<named-content content-type="anchor" rid="fig8" type="simple"></named-content></div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Agents that indirectly activate dopaminergic mood circuits through NMDA or mGlu<sub>2/3</sub> receptor antagonism.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Inducement of depression-like or antidepressant-like effects based upon the potential alteration of dopaminergic neurotransmission in rodents (<sup><i>a</i></sup>intracranial self-stimulation).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7">3.3.  Clinical Studies</h3><div id="sec3_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i8" class="anchor-spacer"></div><h4 class="article-section__title" id="_i8">3.3.1.  Introduction</h4><div class="NLM_p">Although the results from cerebrospinal fluid (CSF) analyses of depressed patients and post-mortem brain studies are not concordant, there is reasonable evidence for reduced levels of homovanillic acid (HVA), the primary metabolite of DA, as a biomarker for depression.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Compared to healthy subjects, a lower concentration of HVA was found in CSF, the internal jugular vein, and the plasma of depressed patients, especially those with TRD or melancholic depression.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> DA is associated with appetitive behaviors, and this may underlie the observation that MDD patients appear to possess reward processing dysfunction, manifested as, fatigue, loss of energy, and reduced exertion of effort.<a onclick="showRef(event, 'ref26 ref35'); return false;" href="javascript:void(0);" class="ref ref26 ref35">(26,35)</a> MDD patients showed a reduced willingness to exert physical effort to secure bigger rewards. A dose-dependent increase in the willingness to work for rewards was observed upon oral dosing of <b>30</b> in the effort expenditure for rewards task.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Striatal DA deficiency is a prominent feature in the pathophysiology of PD, a neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Depression occurs with high prevalence (∼35%) in PD patients with anhedonia as a key symptom, an observation that supports the association of depression with dopaminergic dysfunction.</div><div class="NLM_p">Neuroimaging studies have indicated the prevalence of altered dopaminergic states (alteration in DA synthesis and expression of DA receptors and DAT) in depression, although conflicting results were obtained possibly due to the heterogeneity of the disorder.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> In the amygdala of post-mortem brain samples of MDD patients, reduced DAT levels and a higher percentage of D<sub>2</sub>/D<sub>3</sub> receptors were found.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> MDD patients with anhedonic symptoms showed decreased DAT binding.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Decreased striatal DAT binding was observed in MDD patients using the DAT-selective PET tracer [<sup>11</sup>C]altropane (<b>37</b>).<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Uptake of the SPECT ligand <sup>99m</sup>Tc-TRODAT-1 (<b>38</b>) was significantly reduced in the striatum compared to the cerebellum in MDD subjects (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>).<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Studies in humans and animals have provided consistent evidence that inflammatory cytokines affect DA levels in the basal ganglia to induce depressive symptoms.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Results from these studies, which included inflammation-mediated decreases in ventral striatal response to hedonic reward, reduced levels of DA and its metabolites in CSF, and reduced availability of striatal DA, correlated well with the depressive symptoms of anhedonia, fatigue, and psychomotor retardation.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Structures of DAT-binding PET and SPECT tracers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i9" class="anchor-spacer"></div><h4 class="article-section__title" id="_i9">3.3.2.  Monoamine Depletion Studies</h4><div class="NLM_p">Several clinical studies that involve an acute reduction of DA synthesis through catecholamine (NE/DA) depletion have provided support for the potential link between reduced DA levels and depression.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Administration of α-methyl-<i>para</i>-tyrosine (<b>42</b>), an inhibitor of tyrosine hydroxylase which is involved in catecholamine biosynthesis, was shown to result in increase or relapse of depressive symptoms in remitted MDD (RMDD) subjects (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>).<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> RMDD subjects but not the healthy control subjects were shown to develop performance deficits on a reward processing task upon catecholamine depletion (CD).<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> In RMDD subjects, tryptophan depletion (TD) caused a more depressive mood and deeper feelings of hopelessness and sadness than CD, while CD caused higher levels of inactivity, lassitude, problems with concentration, and somatic anxiety than TD. This suggests both common and differential roles of 5-HT and catecholamines (NE/DA) in the pathophysiology of depression.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Compound <b>43</b>, which is a monoamine-depleting agent and an approved medicine for the treatment of Huntington’s disease, is known to induce depression as a major side effect.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Reserpine (<b>44</b>), another monoamine-depleting agent, has been reported to induce clinical depression, although this has been questioned.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a></div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Agents that cause the depletion of monoamines, including DA, by blocking their synthesis or storage.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i10" class="anchor-spacer"></div><h4 class="article-section__title" id="_i10">3.3.3.  Efficacy with DA Enhancers</h4><div class="NLM_p">Different types of drugs including MAOIs, atypical TCAs (e.g., amineptine [<b>8</b>]), NDRIs (<b>23</b> and <b>24</b>), dopamine receptor agonists, and psychostimulants, all of which appear to elevate DA neurotransmission, have been suggested to be effective in the treatment of MDD (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>, and <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a>).<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Several clinical trials have indicated an antidepressant response to treatment with MAOIs in depressed and treatment-resistant subjects.<a onclick="showRef(event, 'ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref46 ref47">(46,47)</a> The DAT-selective TCA <b>8</b> was shown to be an effective therapy for depressed patients with anhedonic, apathetic, socially withdrawn, psychomotor-retarded, and melancholic features.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> The NDRI <b>23</b> is the preferred treatment for MDD patients who cannot tolerate SSRIs and/or SNRIs. A meta-analysis of comparator clinical trials supported evidence for the equivalent efficacy of <b>23</b> to SSRIs and SNRIs.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> It is frequently used as an adjunct drug with SSRIs and SNRIs in order to enhance efficacy or reduce side effects. Augmentation of the SSRI <b>11</b> with <b>23</b> showed a greater reduction in depressive symptoms with fewer side effects.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Compared to SSRIs, <b>23</b> was shown to improve the resolution of fatigue and sleepiness in RMDD patients, consistent with its pharmacology.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a></div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Examples of dopamine agonists and atypical antipsychotics, known to demonstrate the clinical antidepressant effect.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Psychostimulants that are known to act on the DAT were shown to activate the reward system, reduce fatigue and apathy, and promote alertness and wakefulness, thereby contributing to antidepressant efficacy, especially when used as adjunctive agents.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> The wakefulness-promoting agent <b>32</b> was shown to improve depression scores and remission rates as an augmentation agent, with positive effects on fatigue symptoms.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> DA receptor agonists, including ergot alkaloids (e.g., bromocriptine [<b>45</b>] and pergolide [<b>46</b>]) and nonergot agonists (for example, pramipexole [<b>47</b>] and ropinirole [<b>48</b>]) were found to show antidepressant effects in several small clinical trials for the treatment of MDD and TRD (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>).<a onclick="showRef(event, 'ref4 ref49'); return false;" href="javascript:void(0);" class="ref ref4 ref49">(4,49)</a> The DA agonist <b>47</b>, which is approved for treating PD and restless leg syndrome, was found to be efficacious in refractory unipolar depression and refractory bipolar depression as an augmentation agent for use with SSRIs.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> A recent meta-analysis of randomized clinical trials provided evidence that atypical antipsychotics significantly improved the response and remission rates when used as adjunctive therapies in TRD.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Aripiprazole (<b>49</b>), which is an atypical antipsychotic, appears to derive a therapeutic effect, in part, by alteration of the dopaminergic system (e.g., D<sub>2</sub>/D<sub>3</sub> partial agonism).<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Selected clinical observations that are potentially related to impaired dopaminergic neurotransmission in affective disorder are summarized in <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>.</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Clinical observations potentially related to impaired dopaminergic neurotransmission in affective disorder (<sup><i>a</i></sup>RMDD, remitted MDD; <sup><i>b</i></sup>dopamine reuptake inhibitors (DRIs), DA agonists, psychostimulants, and MAOIs).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">4.  TRIs/Serotonin Norepinephrine Dopamine Reuptake Inhibitors (SNDRIs)</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75677" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75677" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12">4.1.  Therapeutic Potential As Broad-Spectrum Antidepressants</h3><div class="NLM_p">Burgeoning evidence from both preclinical and clinical studies, as summarized in the preceding section, implicates the dysfunction of dopaminergic neurotransmission in the etiology of major depression. The prevalence or inducement of DA hypofunction has been shown to manifest as symptoms of depression. On the other hand, correction of DA dysfunction by therapeutic agents that act by DA potentiation through different mechanisms and those that modulate postsynaptic dopamine receptors directly or indirectly has been shown to result in antidepressant effects in various animal models and in clinical trials. While SSRIs and SNRIs lack a significant level of direct pharmacological action (e.g., DAT inhibition) to enhance DA neurotransmission, treatment with these drugs could even lead to inhibition or reduction of DA release through indirect receptor pharmacology including, for example, a reduction of the mean firing rate of VTA DA neurons by the SSRI <b>11</b> through 5-HT<sub>2C</sub> activation.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> This may partly account for the suboptimal response to SSRIs and the persistence of SSRI-resistant symptoms in some depressed patients. Augmentation of SSRIs and SNRIs with <b>23</b> or atypical antipsychotics has been shown to improve the response rate and/or reduce the side effects of SSRIs/SNRIs. While the improvement in the response rate can potentially be attributed to the added effect on dopaminergic neurotransmission which alleviates depressive symptoms (especially symptoms refractory to treatment with SSRIs and SNRIs), the reduced side effect profile is likely due to the counteracting effect of DA neurotransmission on the side effect pharmacology that arises from a chronic inhibition of SERT (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>). For example, hyperprolactinemia, which causes impotence, is less likely to occur because DA opposes the 5-HT-promoted release of prolactin, thereby normalizing sexual function.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> While SSRIs are often prescribed to treat premature ejaculation, in contrast, TRIs are expected to normalize sexual dysfunction due to the opposing effects of 5-HT and DA. The NDRI <b>23</b> is frequently used as an adjunctive therapy to reduce the sexual dysfunction associated with SSRI treatment.</div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Hypothesis that augmentation of 5-HT and NE with DA will lead to an enhanced antidepressant effect as the result of synergistic effects while minimizing side effects through an antagonist action.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Considering the factors discussed above, there appears to exist a sufficient rationale to seek a single antidepressant drug which can simultaneously enhance all three biogenic amines, thereby mitigating the limitations of single and dual reuptake inhibitors (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>). In view of the diversity of depressive symptoms and considering affective disorder as a multifactorial syndrome, TRIs, which modulate three monoaminergic pathways, constitute a potential strategy for enhancing antidepressant efficacy because all of these pathways are interrelated. Although a functional TRI regimen can be achieved by combining drugs, for example, an SNRI + a DRI or a SSRI + an NDRI, this may lead to confounding pharmacokinetic and compliance issues. TRI monotherapy could reduce the requirement for combinations of multiple antidepressants, for which there is a lack of efficacy data, poor compliance due to complex dosing regimens, the risk of drug–drug interactions, and the possibility of cumulative toxicity.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> MAOIs, which increase all three monoamines by preventing amine metabolism, represent an alternative triple acting approach that may strengthen the case for TRIs (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>).<a onclick="showRef(event, 'ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref46 ref47">(46,47)</a> The reversible MAO-A inhibitor moclobemide (<b>50</b>) was shown to demonstrate antidepressant efficacy with lower sexual side effects than SSRIs.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> The irreversible MAO-B inhibitor selegiline (<b>51</b>) has been approved for the treatment MDD and is administered as a transdermal patch.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a></div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Examples of MAO inhibitors as antidepressants that represent an alternative triple approach involving all three biogenic amines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13">4.2.  Therapeutic Potential in Other Indications</h3><div class="NLM_p">TRIs may have therapeutic potential beyond depression when considering the implications of monoamine deficiency in various disorders that involve the central nervous system (CNS). Selective SSRIs and NRIs and dual SNRIs and NDRIs have been approved for a number of indications including anxiety, pain, substance abuse, ADHD, and appetite-related disorders, and this supports the implication of monoamines in these disorders (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> Dopaminergic abnormalities are implicated in a number of disease states including pain, addiction, appetite, ADHD, PD, and schizophrenia, and some of these CNS disorders are frequently comorbid with depression. TRIs may be useful to treat many of these indications, especially, those that involve the hypofunction of all three monoamines.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. List of Disorders for Which Single and Dual Reuptake Inhibitors Are Approved, and Disorders for Which TRIs Have Been Investigated<a onclick="showRef(event, 'ref55 ref75'); return false;" href="javascript:void(0);" class="ref ref55 ref75">(55,75)</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">disorder</th><th class="colsep0 rowsep0" align="center">marketed reuptake inhibitors<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">investigational TRI</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">generalized anxiety disorder<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center">SSRI, SNRI</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">social anxiety disorder<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center">SSRI</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">panic disorder<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center">SSRI, SNRI, NRI</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">obsessive-compulsive disorder<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center">SSRI</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">post-traumatic stress disorder<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center">SSRI, SNRI</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">neuropathic pain<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="center">SNRI</td><td class="colsep0 rowsep0" align="center"><b>58</b>,<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> <b>61</b>,<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> and <b>72</b><a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">chronic musculoskeletal pain<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="center">SNRI, NDRI</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">fibromyalgia<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="center">SNRI</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">stimulant addiction (e. g., cocaine)<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"><b>64</b><a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUD<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"><b>60</b><a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> and <b>61</b><a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">tobacco addiction (nicotine dependence)<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="center">NDRI</td><td class="colsep0 rowsep0" align="center"><b>61</b><a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">obesity<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="center">SNRI, NDRI</td><td class="colsep0 rowsep0" align="center"><b>61</b><a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> and <b>63</b><a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">bulimia nervosa<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="center">SSRI</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">binge eating disorder (BED)<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"><b>65</b><a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ADHD</td><td class="colsep0 rowsep0" align="center">NRI, NDRI</td><td class="colsep0 rowsep0" align="center"><b>62</b>,<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> <b>64</b>,<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> and <b>65</b><a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PD</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"><b>63</b><a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">urinary stress continence</td><td class="colsep0 rowsep0" align="center">SNRI</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">premenstrual dysphoric disorder</td><td class="colsep0 rowsep0" align="center">SSRI</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">type 2 diabetes</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"><b>63</b><a class="ref internalNav" href="#t1fn6" aria-label="f">f</a>,<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Single or dual reuptake inhibitors.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">A type of anxiety disorder.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">A type of pain disorder.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">A type of substance dependence.</p></div><div class="footnote" id="t1fn5"><sup><sup>e</sup></sup><p class="last">An appetite-related disorder.</p></div><div class="footnote" id="t1fn6"><sup><sup>f</sup></sup><p class="last">As Tesomet in combination with <b>54</b></p></div></div></div><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15">4.2.1.  ADHD</h4><div class="NLM_p last">Although the precise etiology of ADHD is yet to be understood, several lines of evidence support the implication of catecholaminergic functional deficit in ADHD, which is consistent with the use of the NDRI <b>25</b> as the SoC for ADHD.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> In an animal model of ADHD, centanafadine (<b>62</b>) produced dose-dependent inhibition of locomotor hyperactivity in juvenile rats (ip) lesioned with the neurotoxin 6-hydroxydopamine.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> Three TRIs, <b>62</b>, NS2359 (<b>64</b>), and dasotraline (<b>65</b>), have been investigated in the clinical trials for the treatment of ADHD, while <b>62</b> and <b>65</b> have demonstrated statistically significant efficacy in small trials (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>).<a onclick="showRef(event, 'ref58 ref59 ref60'); return false;" href="javascript:void(0);" class="ref ref58 ref59 ref60">(58−60)</a></div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16">4.2.2.  Pain</h4><div class="NLM_p">About 75% of MDD patients suffer from painful symptoms, suggesting a high comorbidity and common neuronal pathways between pain and depression.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> DA is known to be involved in the regulation of pain, particularly analgesia.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> L-DOPA and <b>23</b>, which enhance DA neurotransmission, have produced analgesic effects in several models of neuropathic pain. Increasing evidence suggests that dopaminergic dysfunction may contribute to depressive effects of pain.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Acid-induced depression of ICSS was found to be blocked by DRIs but exacerbated by DA receptor antagonists. The SSRI citalopram (<b>11</b>), the TCA clomipramine (<b>6</b>), the NET-selective TCA nortriptyline (<b>7</b>), and the SNRI milnacipran (<b>21</b>) blocked acid-stimulated writhing but failed to block acid-induced depression of ICSS.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> However, the DRI RTI-113 (<b>28</b>) attenuated both acid-induced writhing and depression of ICSS in rats, reflecting a reversal of pain-stimulated and pain-depressed behavior, which suggested DRIs to be potential analgesics.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> Nefopam (<b>52</b>), which is a marketed non-narcotic analgesic drug, is believed to exert its effect through TRI pharmacology (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>).<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> The TRI bicifadine (<b>58</b>) has shown antinociceptive effects in several preclinical models of pain and select types of clinical pain.<a onclick="showRef(event, 'ref61 ref64'); return false;" href="javascript:void(0);" class="ref ref61 ref64">(61,64)</a> Amitifadine/DOV 21,947 (<b>61</b>), an analogue of <b>58</b>, was recently shown to reverse IP-acid induced depression of NAc DA, ICSS and stretching in rats (ip), supporting <b>61</b> as a potential analgesic to treat pain-related depression.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Structure of <b>52</b>, a marketed analgesic drug that is known be a TRI.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17">4.2.3.  Substance Dependence Disorders</h4><div class="NLM_p last">TRIs have been investigated for treatment of cocaine addiction, nicotine addiction, and alcohol use disorder (AUD). The TRI <b>64</b> is being investigated for the treatment of cocaine addiction.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> In a phase 1 human laboratory interaction study, <b>64</b> reduced the rewarding valence of a 20 or 40 mg dose of cocaine. The NDRI <b>23</b> has been approved for smoking cessation in addition to depression. The TRI <b>61</b> significantly decreased the amount of nicotine self-administration in rats at a dose of 30 mpk (po).<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> The significant reduction of self-administration did not diminish over 2 weeks of chronic treatment at a dose of 10 mpk and a week after enforced abstinence. This suggests that <b>61</b> may be useful for smoking cessation. DOV 102,677 (<b>60</b>) and <b>61</b> have been investigated for treating AUD. In high alcohol-preferring mice (a rodent model for studying the relationship between excessive alcohol drinking and impulsivity), <b>60</b> and <b>61</b> attenuated binge drinking, heavy drinking (24 h free choice assay), and impulsivity (delay discounting method).<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> This suggested that these inhibitors might be useful to treat alcoholism with co-occurring excessive drinking and impulsivity.</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18">4.2.4.  Metabolic and Eating Disorders</h4><div class="NLM_p">Several studies have indicated the important role of the dopaminergic system in the regulation of food consumption and the contribution of DA dysregulation to the development of obesity.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> Activation of DA neurotransmission is believed to suppress feeding activity and produce anorectic effects. A combination of <b>23</b> and the opioid receptor antagonist naltrexone (<b>53</b>) was recently approved for the treatment of obesity.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> The TRIs <b>61</b> and tesofensine (<b>63</b>) have shown weight reducing effects in clinical trials, suggesting the potential use of TRIs to treat obesity or depression that is comorbid with obesity.<a onclick="showRef(event, 'ref69 ref70'); return false;" href="javascript:void(0);" class="ref ref69 ref70">(69,70)</a> The weight reducing effects of <b>63</b> were significantly greater than that of any current antiobesity drugs and appear to be due to a pronounced decrease in appetite coupled with a slight contribution from increased energy expenditure. A combination of <b>63</b> and metoprolol (<b>54</b>) is under clinical evaluation for treating type 2 diabetes (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>).<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> Sibutramine (<b>55</b>), a formerly used antiobesity agent, is believed to exert pharmacological effects through its metabolites <b>56</b> and <b>57</b> (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>) that were found to be TRIs both in vitro and in vivo.<a onclick="showRef(event, 'ref72 ref73'); return false;" href="javascript:void(0);" class="ref ref72 ref73">(72,73)</a> Compound <b>65</b> is being investigated for the treatment of binge eating disorder (BED).<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a><named-content content-type="anchor" rid="fig18" type="simple"></named-content></div><figure id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Structures of <b>53</b> and <b>54</b>, which are combined with <b>23</b> and <b>63</b>, respectively, for treating metabolic disorders.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Metabolites of <b>55</b> that are TRIs and are believed to be responsible for weight loss effects observed with <b>55</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0018.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Structures of key TRIs that have been investigated for the treatment of depression and other indications.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19">4.3.  Potential Developmental Challenges</h3><div class="NLM_p">A significant challenge in the development of TRIs for depressive disorders is the identification of the optimal relative inhibition of SERT, NET, and DAT in the combined drug molecule that will effect an antidepressant response, a balance of properties that is still not defined. While very high NET inhibition is associated with cardiovascular side effects, including increased blood pressure and heart rate, extensive DAT blockade is associated with potential reinforcing effects/abuse liability as well as motor stimulation and stereotypic behavior. The antiobesity agent <b>55</b> was withdrawn from the market as a result of adverse cardiovascular events which could be attributed to side effects mediated by NE reuptake.<a onclick="showRef(event, 'ref54 ref78'); return false;" href="javascript:void(0);" class="ref ref54 ref78">(54,78)</a> Hence, TRIs with an inhibition profile that combines greater SERT than NET and, in turn, modest DAT, may be preferred. However, caution needs to be exercised in advancing compounds based on binding affinity in vitro because this may not accurately predict functional inhibition or efficacy in vivo. This is because in vitro assays do not adequately mimic the physiological environment of in vivo experiments, the latter being influenced by factors that include pharmacokinetic properties, blood–brain barrier permeability, and protein binding. This view is supported by the inconsistencies observed between in vitro and in vivo activities of existing antidepressants like <b>23</b> and investigational TRIs like <b>65</b> and SEP-228432 (<b>66</b>).<a onclick="showRef(event, 'ref79 ref80'); return false;" href="javascript:void(0);" class="ref ref79 ref80">(79,80)</a> Hence, the relative contribution of individual transporter blockade needs to be carefully judged based on translating in vivo activity (for example, efficacy in the behavioral model like TST or FST) which, in turn, will reflect the effect on individual transporters. Impact of TRIs on individual transporters can be assessed by (a) microdialysis experiments, which indirectly evaluate elevation of individual monoamines, and (b) transporter occupancy, which assesses a direct effect based on target engagement. In vivo transporter occupancy can be preferred for two reasons: first, transporter occupancy can be determined both in animals and in humans and, importantly, a PET study allows the in vivo estimation of the relationship between exposure and target occupancy. Second, a microdialysis experiment is associated with ambiguities because 5-HT, NE, and DA are elevated to different levels in different brain regions. Typically, SERT occupancy is at least 80% at clinically efficacious doses following chronic treatment with SSRIs.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> NET occupancy of <b>7</b>, an NET-selective TCA, was shown to be 50–70% at the efficacious doses based on PET studies conducted in MDD patients.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> In contrast, a therapeutic effect is usually achieved with DAT occupancy of ∼30%, as evident from PET studies of <b>23</b> at the therapeutically effective dose.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> Taking all of these factors into consideration, it seems appropriate to develop a TRI with SERT, NET, and DAT occupancies of ≥80%, 50–70%, and ≤30%, respectively, based on the concept that antidepressant efficacy with reduced NET and DAT inhibition will minimize adverse effects (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Potential Optimal Profile of a TRI Antidepressant (Key Criteria for Lead Identification)</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">goal</th><th class="colsep0 rowsep0" align="center">lead evaluation</th><th class="colsep0 rowsep0" align="center">desired profile</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">achieve good efficacy with minimal target-related side effects</td><td class="colsep0 rowsep0" align="left">triple affinity (in vitro)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">SERT > NET > DAT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">triple occupancy (in vivo)</td><td class="colsep0 rowsep0" align="left">≥80%/50–70%/≤30% (SERT/NET/DAT)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mitigate safety liabilities</td><td class="colsep0 rowsep0" align="left">hERG inhibition</td><td class="colsep0 rowsep0" align="left">in vitro IC<sub>50</sub> > 10 μM<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> (in vivo<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a>: ≥30-fold hERG IC<sub>50</sub>/free <i>C</i><sub>max</sub>)<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">CYP2D6 inhibition</td><td class="colsep0 rowsep0" align="left">in vitro IC<sub>50</sub> > 10 μM<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> (in vivo<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a>: <0.1 for total <i>C</i><sub>max</sub>/<i>K</i><sub>i</sub>)<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mitigate abuse potential</td><td class="colsep0 rowsep0" align="left">brain uptake</td><td class="colsep0 rowsep0" align="left">slow onset of DAT occupancy</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">brain clearance</td><td class="colsep0 rowsep0" align="left">slow [long plasma or brain <i>t</i><sub>1/2</sub>]</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">A general recommendation for in vitro screening that may require conformity to in vivo criterion at the efficacious dose.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last"><i>C</i><sub>max</sub> at the efficacious dose</p></div></div></div><div class="NLM_p">As discussed earlier, drugs which extensively inhibit DAT are associated with stimulant effects and abuse, as exemplified by <b>27</b>. Because <b>27</b> is also a TRI, this would pose a serious concern with respect to the development of any TRI which will require a clinically demonstrated low potential for addictive liability because this would otherwise restrict its utility as a controlled substance. However, DAT inhibitors have successfully been developed into drugs with manageable abuse liability, as exemplified by <b>23</b>, <b>25</b>, and dexmethylphenidate (<b>26</b>). The addictive liability of stimulants, which appears to be correlated with the magnitude and rate of enhancement of intrasynaptic DA release in the mesocorticolimbic region, is closely linked to the degree and rate of DAT occupancy, brain clearance rate, and half-life of the stimulants (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>).<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> In human PET studies, <b>23</b> and <b>25</b> exhibit <30% and 60% DAT occupancy, respectively, at clinically effective doses.<a onclick="showRef(event, 'ref54 ref84'); return false;" href="javascript:void(0);" class="ref ref54 ref84">(54,84)</a> A PET study with [<sup>11</sup>C]-cocaine (<b>39</b>) and [<sup>11</sup>C]-methylphenidate (<b>41</b>) showed that both drugs entered the brain rapidly [<10 min after iv administration], but the clearance rate from the brain was faster for <b>27</b> (<i>t</i><sub>1/2</sub>: 20 min) than for <b>25</b> (<i>t</i><sub>1/2</sub>: 90 min.).<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> The fast clearance rate of <b>27</b> correlated well with the frequency of administration by cocaine abusers (every 20–30 min.). This could explain the higher abuse potential of <b>27</b> over <b>25</b>. DAT-inhibiting drugs that show >50% of DAT occupancy within a short period of time after iv administration (<15 min) and experience rapid clearance from the brain due to a short half-life, trigger fast and repeated administration, thereby reinforcing the behavior of drug abuse (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>).<a onclick="showRef(event, 'ref83 ref84 ref85 ref86 ref87'); return false;" href="javascript:void(0);" class="ref ref83 ref84 ref85 ref86 ref87">(83−87)</a> In contrast, compounds with a slow onset and a longer duration of action in terms of dopaminergic neurotransmission that are associated with a PK profile of slow absorption and long half-life may lead to reduced reinforcing effects and hence limited abuse potential. In the operant self-administration model, PRC200-SS (<b>69</b>) was not self-administered in the rat at the behavioral doses (0.5 and 1.0 mpk), although rats significantly self-administered <b>27</b> at 1 mpk upon infusion compared to the saline control.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> While <b>59</b> showed acute self-administration in mice similar to <b>27</b>, it did not induce the place preference associated with cocaine at the same dose.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> This result, combined with a pharmacokinetic profile of slow clearance, suggested a lower potential of <b>59</b> for addiction than <b>27</b>. Compound <b>65</b> was found to show low abuse potential based on a visual analogue scale (VAS) drug-liking score comparable to placebo in a clinical trial with recreational stimulant users, consistent with its pharmacokinetic profile of slow absorption and elimination [<i>t</i><sub>max</sub>, 10–12 h; <i>t</i><sub>1/2</sub>, 44–77 h].<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> However, the psychostimulant <b>25</b> showed significantly higher drug-liking score at <i>E</i><sub>max</sub> compared to placebo and <b>65</b>. Compound <b>63</b>, which belongs to the same tropane class of compounds as <b>27</b>, showed low abuse potential in a clinical trial of recreational stimulant users, consistent with a PK profile of slow onset (<i>t</i><sub>max</sub> ∼ 6 h) and slow offset (<i>t</i><sub>1/2</sub> ∼ 9 days).<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> The abuse potential of <b>63</b> was not greater than placebo, the NRI atomoxetine (<b>17</b>), and the NDRI <b>23</b>, while it was significantly lower than that of <b>30</b>. Recently, <b>62</b> was shown to exhibit lower abuse potential than the schedule II stimulants <b>30</b> and <b>31</b> in a human abuse liability study.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> Treated subjects experienced an acute onset of dislike of the drug and aversion at single doses of 400 and 800 mg/day that may limit abuse in contrast to the liking effect that was observed with <b>30</b>. Overall, these results suggest that TRIs with appropriate transporter profiles and pharmacokinetic properties could be developed with minimal addiction potential.</div><figure id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0019.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Suggested lead optimization criteria for mitigating addiction liability by altering the propensity of DAT inhibition and brain clearance rate and examples of clinical TRIs (<b>62</b>, <b>63</b>, and <b>65</b>) with lower abuse potential than psychostimulants<a onclick="showRef(event, 'ref54 ref83 ref84 ref85 ref86 ref87 ref89'); return false;" href="javascript:void(0);" class="ref ref54 ref83 ref84 ref85 ref86 ref87 ref89">(54,83−87,89)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">5.  Discovery and Development of TRIs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28381" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28381" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The rationale behind TRIs and the history of the successful development of single or dual reuptake inhibitors has prompted discovery efforts by medicinal chemists in both industry and academia that have uncovered many series of compounds with TRI profiles based on structurally diverse chemotypes. This has paved the way for the development of more than 10 clinical candidates and several preclinical compounds for the treatment of depression and other disorders (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). The design of TRIs was largely a ligand-based approach, with the single or dual reuptake inhibitors serving as the starting points from which to build in the capacity to inhibit other monoamine transporters. In some instances, the TRI programs appeared to be an extension of previous programs seeking single or dual reuptake inhibitors that allowed taking advantage of internal leads as starting points. In a few cases, existing TRIs, including <b>27</b>, <b>61</b>, and <i>trans</i>-sertraline (<b>73</b>), were exploited for further optimization to generate novel compounds with diverse ratios of triple transporter affinity (<a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>, <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a>, <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a>, <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">25</a>, and <a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">28</a>, <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">29</a>). The key pharmacophoric features of a typical TRI consist of a positively charged moiety, two or three hydrophobic regions inclusive of an aromatic group and a putative hydrogen-bond acceptor zone (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>).<a onclick="showRef(event, 'ref90 ref91'); return false;" href="javascript:void(0);" class="ref ref90 ref91">(90,91)</a> The fundamental requirement for demonstrating inhibition of all three transporters appears to be the presence of a basic amine, preferably secondary or tertiary, in the chemotype. The decoration of the aromatic region was shown to facilitate an appropriate titration of SERT, NET, and DAT activities, with the 3,4-dichlorophenyl and 2-naphthyl groups identified as frequently used aromatic elements. However, the presence of a basic amine moiety contributes to hERG and CYP2D6 liabilities, which poses significant challenges during lead optimization. Although TRI compounds with different ratios of in vitro triple affinities have been investigated for development, the major focus has been on the identification of compounds with the triple reuptake inhibitory activity in the order of SERT > NET > DAT, a profile that reflects consideration of the side effects associated with profound inhibition of NET and DAT. In this section, relevant journal articles but not patent applications (with a few exceptions) are summarized in deference to space constraints and the recent appearance of a review of the patent literature associated with TRIs.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a></div><figure id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0020.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. A representative TRI pharmacophore, reproduced from the literature.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Compilation of TRIs as Clinical Candidates and Their Current Status</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">SERT/NET/DAT IC<sub>50</sub> or <i>K</i><sub>i</sub></th><th class="colsep0 rowsep0" align="center">company/institute</th><th class="colsep0 rowsep0" align="center">indication</th><th class="colsep0 rowsep0" align="center">highest development phase</th><th class="colsep0 rowsep0" align="center">status<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>58</b><a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a></td><td class="colsep0 rowsep0" align="left">117/55/910</td><td class="colsep0 rowsep0" align="left">DOV</td><td class="colsep0 rowsep0" align="left">pain</td><td class="colsep0 rowsep0" align="left">phase III</td><td class="colsep0 rowsep0" align="center">B<a class="ref internalNav" href="#t3fn5" aria-label="e">e</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DOV 216,303 (<b>59</b>)<a onclick="showRef(event, 'ref75 ref93'); return false;" href="javascript:void(0);" class="ref ref75 ref93">(75,93)</a></td><td class="colsep0 rowsep0" align="left">14/20/78</td><td class="colsep0 rowsep0" align="left">DOV</td><td class="colsep0 rowsep0" align="left">depression</td><td class="colsep0 rowsep0" align="left">phase II</td><td class="colsep0 rowsep0" align="center">C</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>60</b><a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a></td><td class="colsep0 rowsep0" align="left">13/100/130</td><td class="colsep0 rowsep0" align="left">DOV</td><td class="colsep0 rowsep0" align="left">AUD</td><td class="colsep0 rowsep0" align="left">phase I</td><td class="colsep0 rowsep0" align="center">C</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>61</b><a onclick="showRef(event, 'ref75 ref94'); return false;" href="javascript:void(0);" class="ref ref75 ref94">(75,94)</a></td><td class="colsep0 rowsep0" align="left">12/23/96</td><td class="colsep0 rowsep0" align="left">DOV/Euthymics</td><td class="colsep0 rowsep0" align="left">depression</td><td class="colsep0 rowsep0" align="left">phase III</td><td class="colsep0 rowsep0" align="center">C</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AUD/smoking cessation</td><td class="colsep0 rowsep0" align="left">phase II</td><td class="colsep0 rowsep0" align="center">A</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i><b>62</b><a onclick="showRef(event, 'ref58 ref75'); return false;" href="javascript:void(0);" class="ref ref58 ref75">(58,75)</a></i></td><td class="colsep0 rowsep0" align="left">84/6/38</td><td class="colsep0 rowsep0" align="left">Euthymics/Neurovance</td><td class="colsep0 rowsep0" align="left">ADHD</td><td class="colsep0 rowsep0" align="left">phase II</td><td class="colsep0 rowsep0" align="center">A</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>63</b><a onclick="showRef(event, 'ref75 ref95'); return false;" href="javascript:void(0);" class="ref ref75 ref95">(75,95)</a></td><td class="colsep0 rowsep0" align="left">11/3.2/8.0</td><td class="colsep0 rowsep0" align="left">Neurosearch/Saniona</td><td class="colsep0 rowsep0" align="left">AD</td><td class="colsep0 rowsep0" align="left">phase III</td><td class="colsep0 rowsep0" align="center">C</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">PD</td><td class="colsep0 rowsep0" align="left">phase III</td><td class="colsep0 rowsep0" align="center">C</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">obesity</td><td class="colsep0 rowsep0" align="left">phase II</td><td class="colsep0 rowsep0" align="center">A</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">type 2 diabetes<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">phase II</td><td class="colsep0 rowsep0" align="center">A</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>64</b><a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a></td><td class="colsep0 rowsep0" align="left">10/2/10</td><td class="colsep0 rowsep0" align="left">Neurosearch/Saniona</td><td class="colsep0 rowsep0" align="left">depression</td><td class="colsep0 rowsep0" align="left">phase II</td><td class="colsep0 rowsep0" align="center">C</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">ADHD</td><td class="colsep0 rowsep0" align="left">phase II</td><td class="colsep0 rowsep0" align="center">C</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">cocaine addiction</td><td class="colsep0 rowsep0" align="left">phase II</td><td class="colsep0 rowsep0" align="center">A</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>65</b><a onclick="showRef(event, 'ref60 ref75'); return false;" href="javascript:void(0);" class="ref ref60 ref75">(60,75)</a></td><td class="colsep0 rowsep0" align="left">14/4/2</td><td class="colsep0 rowsep0" align="left">Sepracor/Sunovion</td><td class="colsep0 rowsep0" align="left">depression</td><td class="colsep0 rowsep0" align="left">phase II</td><td class="colsep0 rowsep0" align="center">C</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">ADHD</td><td class="colsep0 rowsep0" align="left">phase III</td><td class="colsep0 rowsep0" align="center">A</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">BED</td><td class="colsep0 rowsep0" align="left">phase III</td><td class="colsep0 rowsep0" align="center">A</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>66</b><a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a></td><td class="colsep0 rowsep0" align="left">34/3/41</td><td class="colsep0 rowsep0" align="left">Sunovion</td><td class="colsep0 rowsep0" align="left">depression/neuropathic pain</td><td class="colsep0 rowsep0" align="left">phase I</td><td class="colsep0 rowsep0" align="center">C</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GSK1360707 (<b>67</b>)<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a></td><td class="colsep0 rowsep0" align="left">9.2/8.1/8.0<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">GSK</td><td class="colsep0 rowsep0" align="left">depression</td><td class="colsep0 rowsep0" align="left">phase I</td><td class="colsep0 rowsep0" align="center">C</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">liafensine (<b>68</b>)<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a></td><td class="colsep0 rowsep0" align="left">1.1/8.8/5.7</td><td class="colsep0 rowsep0" align="left">AMRI/BMS</td><td class="colsep0 rowsep0" align="left">depression</td><td class="colsep0 rowsep0" align="left">phase II</td><td class="colsep0 rowsep0" align="center">C</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BMS-866949<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a></td><td class="colsep0 rowsep0" align="left">NA<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">AMRI/BMS</td><td class="colsep0 rowsep0" align="left">depression</td><td class="colsep0 rowsep0" align="left">phase I</td><td class="colsep0 rowsep0" align="center">C</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RG-7166 (<b>70</b>)<a onclick="showRef(event, 'ref75 ref92'); return false;" href="javascript:void(0);" class="ref ref75 ref92">(75,92)</a></td><td class="colsep0 rowsep0" align="left">16/9/90</td><td class="colsep0 rowsep0" align="left">Roche</td><td class="colsep0 rowsep0" align="left">depression</td><td class="colsep0 rowsep0" align="left">phase I</td><td class="colsep0 rowsep0" align="center">C</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ansofaxine (<b>71</b>)<a onclick="showRef(event, 'ref75 ref96'); return false;" href="javascript:void(0);" class="ref ref75 ref96">(75,96)</a></td><td class="colsep0 rowsep0" align="left">723/763/491</td><td class="colsep0 rowsep0" align="left">Luye Pharma</td><td class="colsep0 rowsep0" align="left">depression</td><td class="colsep0 rowsep0" align="left">phase II</td><td class="colsep0 rowsep0" align="center">A</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">(A) Clinical study is planned, in progress or completed. (B) No development has been reported. (C) Development was discontinued.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">As Tesomet (in combination with <b>54</b>).</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">p<i>K</i><sub>i</sub>.</p></div><div class="footnote" id="t3fn4"><sup><sup>d</sup></sup><p class="last">Not available.</p></div><div class="footnote" id="t3fn5"><sup><sup>e</sup></sup><p class="last">Since 30 Aug 2010.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a></p></div></div></div><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23">5.1.  DOV Series</h3><div class="NLM_p">Compounds based on a 3-azabicyclo[3.1.0]hexane template were disclosed by American Cyanamid as analgesic agents in the late 1970s, with the subsequent disclosure of antidepressant properties several years later.<a onclick="showRef(event, 'ref97 ref98'); return false;" href="javascript:void(0);" class="ref ref97 ref98">(97,98)</a> DOV Pharmaceuticals progressed some of these earliest TRIs for the treatment of depression and other indications (<a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>). In the DOV series, <b>58</b> was the first compound to reach clinical development as an analgesic drug candidate.<a onclick="showRef(event, 'ref61 ref64'); return false;" href="javascript:void(0);" class="ref ref61 ref64">(61,64)</a> In a microdialysis experiment, <b>58</b> increased extracellular levels of 5-HT, NE, and DA in brain regions in rats following oral administration of doses associated with analgesia. Compound <b>58</b> attenuated pain responses in models of acute inflammatory pain conducted in rats and mice, normalized the nociceptive threshold in a model of persistent inflammatory pain, and suppressed thermal and mechanical hyperalgesia and mechanical allodynia in the spinal nerve ligation model of chronic neuropathic pain. In phase II trials, <b>58</b> has shown clinical efficacy in the treatment of acute dental and postbunionectomy pain but failed to show efficacy for chronic lower back pain or diabetic neuropathic pain.<a onclick="showRef(event, 'ref61 ref64 ref75'); return false;" href="javascript:void(0);" class="ref ref61 ref64 ref75">(61,64,75)</a></div><div class="NLM_p">Modification of the aryl group in <b>58</b> led to the identification of the additional clinical candidates <b>59</b>–<b>62</b> (<a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>). Compound <b>59</b>, studied as a racemic mixture, showed ex vivo binding affinity in the order of SERT > NET > DAT (ED<sub>50</sub>: 3, 19, and 95 mpk for SERT, NET, and DAT occupancy, respectively) in rats.<a onclick="showRef(event, 'ref89 ref99'); return false;" href="javascript:void(0);" class="ref ref89 ref99">(89,99)</a> A reduction in immobility was observed at an oral dose of 10 mpk in the mouse FST model. Following oral administration to mice, <b>59</b> reversed both motor depression (MED: 1.6 mpk) and ptosis (ED<sub>50</sub>: 2.2 mpk) induced by <b>43</b>. In rats (po), <b>59</b> was shown to induce an enhancement of brain reward activity (potential to treat anhedonia), as evident from a decreased ICSS threshold.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> In the differential reinforcement of low rate 72 s responding assay (a behavioral model that is predictive of antidepressant-like activity), <b>59</b> significantly increased the reinforcement rate at one intermediate dose but showed comparable effects to the dopaminergic agents <b>23</b> and GBR12909 (<b>33</b>) on inter-response time distribution in rats (ip).<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> This result suggested a limited antidepressant-like effect of <b>59</b>. Following single oral doses to rats and dogs, <b>59</b> showed dose-proportional exposure and was well-tolerated at doses below 100 mpk. In a double-blind phase II randomized clinical trial of 67 subjects with moderate to severe MDD, <b>59</b> demonstrated a significant (>40%) reduction in the total HAM-D scores, although the study lacked a placebo control arm.<a onclick="showRef(event, 'ref75 ref99'); return false;" href="javascript:void(0);" class="ref ref75 ref99">(75,99)</a> Its efficacy at 50 mg, b.i.d. was found to be comparable to that of the active control <b>11</b> administered at a dose of 20 mg, b.i.d. without any serious adverse events. However, further development of <b>59</b> was discontinued for IP reasons.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a></div><figure id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0021.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Exploration of the 3-azabicyclo[3.1.0]hexane chemotype to derive clinical TRIs (DOV).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>60</b> is the (−)-enantiomer of <b>59</b> (<a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>).<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> Compound <b>60</b> markedly increased the extracellular levels of 5-HT, DA, and NE in the PFC and of DA and 5-HT in the NAc at a dose of 20 mpk ip in rats. In the rat FST model, <b>60</b> exhibited an antidepressant-like activity with an MED of 20 mpk po and maximal efficacy comparable to that of <b>5</b>. In an ethanol-preferring rat strain, <b>60</b> significantly reduced the volitional consumption of ethanol with minimal alterations to food intake or body weight (20 mpk, ip).<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> In another study, <b>60</b> produced a prolonged and selective reduction of alcohol-motivated responses with a robust antidepressant-like effect and no significant alteration of sucrose consumption in alcohol-preferring rats (po), suggesting that <b>60</b> may be useful to treat comorbid AUD and depression.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> Although <b>60</b> entered a phase I clinical trial to treat alcohol abuse and alcoholism in 2006, no recent development activity has been reported.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a></div><div class="NLM_p">Compound <b>61</b>, which is the (+)-enantiomer of <b>59</b>, is being developed by Euthymics Bioscience for AUD and smoking cessation (<a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>).<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> Compound <b>61</b> showed ex vivo occupancy ED<sub>50</sub> values of 0.5, 2, and 49 mpk (ip) for SERT, NET, and DAT, respectively, in rats.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> Compound <b>61</b> exhibited high human plasma protein binding, high permeability, metabolism by MAO-A in human hepatocytes, weak inhibition of metabolizing enzymes, and a good brain-to-plasma (B/P) ratio in rats.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> Compound <b>61</b> showed a dose-dependent reduction in immobility time in both the rat FST and mouse TST models at doses of 5, 10, and 20 mpk po and did not induce locomotor activity at the active doses.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> Compound <b>61</b> demonstrated dose-dependent reduction of binge alcohol drinking but not binge sucrose drinking.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> It reversed two measures of negative impact of abstinence (immobility and increase in ICSS threshold), which suggested that <b>61</b> might be effective in treating comorbid alcoholism and depression. Compound <b>61</b> demonstrated a significant reduction in body weight and plasma triglycerides in diet-induced obesity (DIO) mice and rats (po) with a transient decrease in food consumption but a sustained decrease in fat mass.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> It also produced a sustained reduction in the rate of weight gain for up to 1 year in normal dogs and did not significantly affect blood pressure, heart rate, or ECG parameters in dog telemetry studies. Hence, <b>61</b> may be effective for the treatment of obesity or depression comorbid with obesity. In an eight-week, double-blind and placebo-controlled phase I study, <b>61</b> at doses of 50, 100, and 150 mg, qid produced statistically significant reductions in both body weight and plasma triglyceride levels.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> Compound <b>61</b> was safe and well tolerated at the dose range studied with no serious adverse events observed. In a 6-week, randomized, double-blind and placebo-controlled study of 63 patients with MDD administered with a dose of 25 mg (b.i.d.) for 2 weeks and 50 mg (b.i.d.) for the following 4 weeks, <b>61</b> showed significant efficacy at attenuating anhedonic symptoms.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> However, in a subsequent study of 342 MDD patients with TRD where <b>13</b> was used as the active control drug, no significant separation from placebo was observed at doses of 50 and 100 mg/day.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a></div><div class="NLM_p last">Compound <b>62</b>, which is a NET-preferring TRI (<a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>), is being developed by Neurovance as a potential nonstimulant drug for the treatment of ADHD.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> In a microdialysis study, <b>62</b> increased NE and DA concentrations in the PFC by 375% and 300%, respectively, at a dose of 20 mpk (ip) in rats.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> Compound <b>62</b> dose-dependently reduced immobility in the mouse TST (po) and did not stimulate locomotor activity in the efficacious dose range of 3–10 mpk in rats. In a phase 2b clinical trial, <b>62</b> met both primary and secondary end points in the treatment of adult ADHD.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> The 400 mg/day dose evaluated in this study was well-tolerated with lower rates of insomnia and loss of appetite compared to stimulants.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24">5.2.  Neurosearch (NS) Series</h3><div class="NLM_p">Neurosearch have reported a series of tropane derivatives derived by modifying the naturally occurring TRI <b>27</b> with a focus on improving both the triple reuptake inhibition profile and in vivo stability, an initiative that resulted in the identification of at least two clinical candidates (<a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>). Compound <b>63</b> is being developed by Saniona AB as a monotherapy for the treatment of obesity and as a combination therapy with <b>54</b> for the treatment of type 2 diabetes.<a onclick="showRef(event, 'ref71 ref95'); return false;" href="javascript:void(0);" class="ref ref71 ref95">(71,95)</a> Compound <b>63</b> was originally developed for the treatment of Alzheimer’s or Parkinson’s disease but did not exhibit an adequate efficacy in early clinical trials.<a onclick="showRef(event, 'ref70 ref77 ref111'); return false;" href="javascript:void(0);" class="ref ref70 ref77 ref111">(70,77,111)</a> However, significant weight loss was observed in subjects who were classified as obese. In a subsequent clinical trial, <b>63</b> induced reductions in body weight of 4.5%, 9.2%, and 10.6% at the respective doses of 0.25, 0.5, and 1.0 mg/day administered for a period of 6 months.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> However, <b>63</b> caused an increase in heart rate and blood pressure at the therapeutically relevant doses. A fixed dose combination of <b>63</b> and the antihypertensive agent <b>54</b> prevented the cardiovascular sympathetic effects of <b>63</b> without affecting the inhibitory effect on food intake in rats.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> In DIO rats, <b>63</b> produced a significant and dose-dependent weight loss following oral administration for 28 days.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> In a PET study using [<sup>11</sup>C]βCIT-FE (<b>40</b>), <b>63</b> induced a dose-dependent blockade of DAT, with occupancy determined to be between 18 and 77%, following oral doses ranging from 0.125 to 1 mg, suggesting that the dose-dependent weight loss in the clinical trials was, in part, mediated by upregulation of DA neurotransmission through DAT blockade.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a></div><figure id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0022.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Design of tropane-bearing TRIs by modifying the ester functionalities of <b>27</b> leading to the identification of two clinical candidates (Neurosearch/Saniona).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>64</b> has been investigated for the treatment of MDD and ADHD (<a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>). In two randomized, double-blind, placebo- and active-controlled studies (study 1, MDD patients; study 2, MDD patients with anhedonic symptoms), <b>64</b> failed to show significant efficacy (1–2 mg/day), although the active controls <b>13</b> (at 20–30 mg/day) and <b>19</b> (at 150–225 mg/day) showed statistically significant efficacy when compared to placebo.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> Compound <b>64</b> was not well-tolerated, with the observation of psychiatric (insomnia and anxiety), gastrointestinal (dry mouth), and cardiovascular (increase in heart rate and blood pressure) side effects. In a multicenter, double-blind, randomized, and placebo-controlled phase II trial, <b>64</b> was well-tolerated at a dose of 0.5 mg/day, but the dose was not associated with an improvement in symptoms of ADHD.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> In a SPECT imaging study conducted in healthy subjects, an 0.5 mg dose of <b>64</b> was shown to afford DA occupancy of 35%, which was in the range of other clinically effective compounds used in the treatment of ADHD. In healthy volunteers, a PET imaging study indicated SERT/DAT occupancies of 55/60% and 75/80% at doses of 1 and 2 mg, respectively.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> Compound <b>64</b> is being developed by Saniona AB for the treatment of cocaine addiction.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a></div><div class="NLM_p last">Further SAR exploration with a chromene ring as an aryl replacement and elimination of the alkoxylalkyl side chain gave a new series of tropane derivatives that included NS18283 (<b>72</b>).<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> Hache et al. have reported the antinociceptive activity of <b>72</b> in a mouse model of chemotherapy-induced neuropathic pain (<a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>).<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> This compound significantly increased extracellular concentrations of 5-HT, NE, and DA in the anterior cingulate cortex of oxaliplatin-treated mice experiencing neuropathic pain at a dose of 10 mpk (sc). In contrast, escitalopram (<b>12</b>) increased only 5-HT levels and the SNRI <b>19</b> increased only 5-HT and NE concentrations. Compound <b>72</b> reversed oxaliplatin-induced mechanical hypersensitivity and cold allodynia but failed to reverse cold hyperalgesia. The compound exhibited antidepressant-like activity in the anxious-depressive phenotype of oxaliplatin-treated mice in TST.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25">5.3.  Sepracor (SEP)/Sunovion Series</h3><div class="NLM_p">Compound <b>65</b>, which was earlier investigated for treating MDD, is being developed for ADHD and BED by Sunovion Inc. (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>).<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> Compounds <b>65</b> and <b>73</b>, which were synthesized and evaluated for triple reuptake inhibition as part of SAR development around <i>cis</i>-sertraline (<b>15</b>) in the late 1980s by Pfizer, received attention recently because of the renewed interest in TRIs.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> Compound <b>65</b> demonstrated a significant reduction of immobility in the mouse FST model at doses of 10 and 30 mpk ip with higher efficacy than <b>5</b>. However, <b>65</b> did not meet the primary end point in a phase II clinical trial of 514 patients with MDD even though the positive control arm (venlafaxine XR) achieved a statistically significant separation from placebo.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> The systemic exposure of <b>65</b> was much lower than expected at the doses tested (0.5 and 2.0 mg) relative to the exposure profiles from several phase I clinical trials. A subsequent PET study with healthy subjects indicated SERT and DAT occupancies to be 2–14% and 33–49%, respectively, over the dose range of 8–16 mg, which was at least 4-fold higher than the highest phase II clinical dose.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> In an ADHD population (phase I/II, 4–8 mg), <b>65</b> showed a long half-life (<i>t</i><sub>1/2</sub>: 47 h) with steady state plasma concentrations reached after 10 days. In a randomized, double-blind and placebo-controlled PoC clinical study, <b>65</b> demonstrated an improvement in the symptoms of ADHD at a dose of 4 mg/day that was statistically significant at a dose of 8 mg/day.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> In a phase 2/3 clinical trial for BED, <b>65</b> demonstrated statistically significant efficacy at a dose of 4–8 mg/day.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a></div><figure id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0023.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Diastereomeric switch of the SSRI <b>15</b> to enhance NET/DAT activity leading to the identification of <b>65</b> as a clinical candidate (Sepracor/Sunovion); <sup><i>a</i></sup>affinity data are taken from the literature.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Recently, <b>73</b> was exploited as the starting point to derive regioisomers by relocating the amino group on the saturated ring and homologating the spacer between the bicyclic ring and the amino group by inserting a CH<sub>2</sub> or CH<sub>2</sub>CH<sub>2</sub> linker (<a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a></a>).<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> The (<i>S</i>)-stereochemistry at the chiral center bearing 3,4-dichlorophenyl substitution imparted significantly higher SERT inhibition than the (<i>R</i>)-chirality. Relocation of the 1-amino group in <b>73</b> to the 2-position was tolerated, with <b>76</b> showing improved SERT potency. Further relocation to the 3-position, compound <b>74</b>, was tolerated at SERT/DAT but poorly tolerated at NET. Within all of the stereoisomers <b>75</b>–<b>86</b>, SERT potency increased in the order of NMe<sub>2</sub> ≥ NHMe > NH<sub>2</sub>, while NHMe showed higher potency for NET/DAT than either NMe<sub>2</sub> or NH<sub>2</sub> groups. In addition, the <i>trans</i>-isomers <b>75</b> and <b>76</b> with the (2<i>R</i>,4<i>S</i>)-configuration showed higher triple reuptake inhibitory potency than the remaining three stereoisomer pairs <b>78</b> and <b>79</b>, <b>81</b> and <b>82</b>, and <b>84</b> and <b>85</b> when the amine was NHMe or NH<sub>2</sub>. The introduction of a methylene spacer in the primary amines <b>75</b>, <b>78</b>, <b>81</b>, and <b>84</b> facilitated an improvement in triple reuptake inhibitory potency as exemplified by the homologous compounds <b>87</b>, <b>89</b>, <b>91</b>, and <b>93</b>, with the exception of the NET potency associated with <b>91</b>. Primary and secondary amines that were evaluated for in vitro ADME properties showed good human and mouse microsomal stability with the majority exhibiting <i>t</i><sub>1/2</sub> values of >300 min. The compounds showed moderate to potent CYP2D6 inhibition with nanomolar potency for compounds bearing the (<i>S</i>)-3,4-dichlorophenyl stereochemistry. The profiled compounds showed hERG IC<sub>50</sub> values of ≥1.5 μM. Compound <b>82</b>, which exhibited the best ADME profile in terms of microsomal stability and inhibition of CYP isoforms and hERG, was profiled in vivo. It showed a significant and dose-dependent reduction in immobility time in the mouse TST model at doses of 10–30 mpk po, a good B/P ratio (40), and a high brain concentration (44 μM). The observed efficacy was not due to locomotor activation because <b>82</b> did not increase spontaneous locomotor activity.</div><figure id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0024.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Expanding on <b>73</b> as a starting point to probe SAR with respect to regiomerism, chirality, amino substitution, and homologation (Sepracor/Sunovion).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Shao et al. reported the synthesis and pharmacological evaluation of bicyclic 3-aryloctahydrocyclopenta[<i>c</i>]pyrrole and 3-aryl-octahydro-1<i>H</i>-isoindole derivatives which followed a design principle of expanding the cyclopropyl ring of the 3-azabicyclo[3.1.0]hexane chemotype (<a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">25</a></a>).<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> In the case of the octahydrocyclopenta[<i>c</i>]pyrrole series with <i>N</i>-Me substitution, aryl variation indicated that the 3,4-dichlorophenyl substitution pattern in <b>101</b> and <b>102</b> and the 2-naphthyl element in <b>103</b> and <b>104</b> were the preferred aromatic substitutions on the bicyclic ring. In the case of the octahydro-1<i>H</i>-isoindole series, a two-dimensional variation of <i>N</i>-alkyl (alkyl: Me, Et) and aryl (phenyl, substituted phenyl, and 1- or 2-naphthyl) was undertaken, which resulted in the identification of <b>105</b> with the most potential for triple reuptake inhibition. The <i>trans</i>-octahydro-1<i>H</i>-isoindole compounds <b>99</b> and <b>100</b> showed lower triple potency than their <i>cis</i>-counterparts <b>97</b> and <b>98</b>, suggesting that a <i>cis</i>-ring fusion was critical for potent inhibition. The general trend of superior potency at SERT of tertiary amines compared to secondary amines was maintained throughout (e.g., <b>101</b> vs <b>95</b> and <b>105</b> vs <b>97</b>). In terms of microsomal stability, a secondary amine was favored over a tertiary amine and the 3,4-dichlorophenyl over the 2-naphthyl group. On the basis of potency and ADMET considerations, <b>95</b>, <b>101</b>, and <b>105</b> were profiled for properties in vivo. Compound <b>95</b> was a standout from the ADME perspective with excellent HLM stability (<i>t</i><sub>1/2</sub>: 262 min) and moderate CYP (>5 μM) and hERG (5.28 μM) inhibition. In the mouse TST, <b>95</b> showed statistically significant efficacy following po doses of 10 and 30 mpk with the observation of a high B/P ratio (30) and a free drug concentration of ∼2 μM in the brain at 30 mpk in the test animals. It did not significantly increase spontaneous locomotor activity at the efficacious doses in mice, suggesting that the efficacy was not due to motor stimulation. A similar efficacy profile was observed with the <i>N</i>-methyl analogues <b>101</b> and <b>105</b> but with a significant amount of <i>N</i>-desmethyl metabolites detected in brain tissue.</div><figure id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0025.jpeg" id="gr25" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. Homologation of 3-azabicyclo[3.1.0]hexane leading to the identification of 3-aryloctahydrocyclopenta[<i>c</i>]pyrrole and 3-aryl-octahydro-1<i>H</i>-isoindole derivatives (Sunovion).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Shao et al. disclosed the triple reuptake inhibitory activity and metabolic stability profiles around the amphetamine-derived chemotype, 1-aryl-1-aminomethylcyclohexane (<a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">26</a></a>).<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> Although the <i>N</i>,<i>N</i>-dimethyl compounds in the initial set gave the best activity, they suffered from rapid metabolism in vitro and in vivo to afford the <i>N</i>-monomethyl metabolites <b>107</b> and <b>108</b>. To circumvent this, α-alkyl substitution proximal to the amine was investigated as a steric shielding strategy. Scanning of aryl and α-alkyl groups (as racemates) indicated that 3,4-dichlorophenyl and 2-naphthyl were the preferred aryl components while a methyl group was the preferred α-alkyl substituent. The individual enantiomers were subsequently separated and profiled. With only a few exceptions, triple reuptake affinity increased in the order of NMe<sub>2</sub> > NHMe > NH<sub>2</sub>, while the reverse was found to be true in terms of metabolic stability. Representative compounds <b>110</b>, <b>111</b>, and <b>114</b> showed weak hERG (IC<sub>50</sub>: ≥4.3 μM) and CYP inhibition (CYP2D6 IC<sub>50</sub>, >5 μM; other isoforms IC<sub>50</sub> values, >25 μM). All three compounds showed a dose-dependent reduction in immobility time in the mouse TST model over the dose range studied, 3–30 mpk po. At efficacious doses, the brain levels were significantly higher than the IC<sub>50</sub> for the transporters, and the compounds did not alter spontaneous locomotor activity in mice.</div><figure id="fig26" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0026.jpeg" id="gr26" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. Psychostimulant <b>29</b> as the starting point to design 1-arylcyclohexylmethylamine chemotype (Sunovion).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The scope of this study (vide supra) was expanded by an investigation of substitution on the cyclohexyl ring which led to the identification of the clinical compound <b>66</b> (<a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>).<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> While the prototype <b>115</b> showed poor triple reuptake inhibitory activity, inversion of the tertiary carbinol moiety gave <b>116</b> with improved activity while subsequent <i>N</i>-methylation gave <b>117</b> and <b>66</b>, which are associated with further enhanced activity. Replacing the dichlorophenyl of <b>66</b> with a 2-naphthyl group gave <b>118</b>, a change in structure that resulted in higher SERT activity but reduced DAT potency. Recently, an exploratory biomarker study of <b>66</b> conducted at an MTD of 300 mg/day in healthy volunteers, with duloxetine (<b>18</b>) as the active control at a dose of 60 mg/day, was reported.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> On day 14, <b>66</b> showed a <i>t</i><sub>max</sub> of 4 h and <i>t</i><sub>1/2</sub> of 18 h in CSF with a B/P ratio of 0.22, while the metabolite <b>117</b> showed a <i>t</i><sub>max</sub> of 6 h and a <i>t</i><sub>1/2</sub> of 32 h with a B/P ratio of 0.46. In CSF, both <b>66</b> and <b>18</b> increased NE and significantly reduced dihydroxyphenylglycol (DHPG), a metabolite of NE and biomarker for NET inhibition, relative to placebo, confirming NET inhibition. Treatment with <b>66</b> did not significantly increase CSF 5-HT levels and failed to reduce 5-hydroxyindoleacetic acid (5-HIAA) concentrations. However, <b>18</b> displayed a statistically significant increase in CSF 5-HT levels and moderately reduced 5-HIAA levels while not altering the levels of DA metabolites in either the CSF or plasma. These results suggest that clinically meaningful SERT and DAT inhibition by <b>66</b> is unlikely. The failure to translate the in vitro data to humans may be attributed to suboptimal CNS distribution, consistent with the 10-fold lower <i>C</i><sub>max</sub> in CSF than in plasma. In a SPECT imaging study, SERT and DAT occupancies were found to be 31% and 25%, respectively. Overall, the biomarker and occupancy data suggest that <b>66</b> may not be efficacious at the MTD.</div><figure id="fig27" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0027.jpeg" id="gr27" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. Lead optimization of 1-arylcyclohexylmethylamine series resulting in the identification of NET-preferring <b>66</b> as a clinical candidate (Sepracor/Sunovion).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26">5.4.  The GlaxoSmithKline (GSK) Series</h3><div class="NLM_p">Micheli et al. investigated the introduction of a side chain to the 3-azabicyclo[3.1.0]hexane chemotype to potentially increase interactions with target proteins, a design based on the in-house TRI pharmacophore model (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>) that was developed by exploiting the structures of both selective and nonselective reuptake inhibitors.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> This led to the discovery of a new series of compounds based on a 1-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexane chemotype with the introduction of substitution at the 6-position of the scaffold; previous work had demonstrated that there was no improvement in activity with substitution on the 5-position (<a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">28</a></a>). The introduction of a CH<sub>2</sub>OMe group resulted in the identification of <b>120</b> as a lead molecule with greatly enhanced SERT/NET affinity and moderately enhanced DAT affinity relative to <b>61</b>. The <i>exo</i>-isomers <b>120</b> and <b>121</b> showed higher affinity than the <i>endo</i>-isomer <b>119</b>, consistent with the pharmacophore model. The more active enantiomer <b>120</b> of the <i>exo</i>-racemate showed low nanomolar affinity at both SERT and NET with ∼70-fold lower activity at DAT. Subsequently, several other 6-substitutions, including CH<sub>2</sub>OR (R: Et, CH<sub>2</sub>CF<sub>3</sub>, <i>n</i>-Pr, <i>i</i>-Pr, cyclopropyl, butyl, pentyl, etc.), were pursued while keeping either a 3,4-dichlorophenyl or a 2-naphthyl group at the 1-position. Profiling of these compounds led to the discovery of <b>123</b>, with CH<sub>2</sub>OEt as the preferred group (higher triple reuptake inhibitory activity than <b>120</b>, an improved CYP inhibition profile with CYP2D6 IC<sub>50</sub> 4 μM and other isoforms >9 μM, and acceptable PK). Compound <b>123</b> showed >100-fold selectivity in a receptor panel assay and moderate hERG inhibitory activity (IC<sub>50</sub>: 4.2 μM). It showed a slow onset and a long-lasting increase of levels of 5-HT/NE/DA in the rat mPFC model (0.1–1.0 mpk ip). Following administration of <b>123</b> at 3, 10, and 30 mpk po, 5-HTP stereotyped behavior was significantly increased in a dose-dependent manner, consistent with SERT inhibition in vivo. Compound <b>123</b> significantly reduced immobility time in the mouse FST model at 3 and 10 mpk. The compound also showed significant locomotor activity at 10 mpk, consistent with increased DA neurotransmission. Elongation of the CH<sub>2</sub>OMe moiety with the addition of a CH<sub>2</sub> group afforded <b>126</b>, which exhibited a 2–5-fold increase in SERT/NET/DAT activity compared to <b>120</b>. Further modification by translocation of the aryl group led to an additional series based on a 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexane scaffold. Thus, translocation of the 3,4-dichlorophenyl group at the 1-position of <b>123</b> to the 6-position gave <b>128</b>, which exhibited inferior NET potency. The <i>endo</i>-isomer <b>129</b> showed drastically reduced affinity compared to the <i>exo</i>-isomer <b>128</b>, while homologation of the side chain of <b>128</b> was tolerated, as exemplified by <b>131</b>.</div><figure id="fig28" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0028.jpeg" id="gr28" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 28. Exploration of peripheral substitution on the 3-azabicyclo[3.1.0]hexane chemotype to improve affinity (GSK).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig28"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Further structural optimization by ring homologation led to the evolution of a third series based on the two regioisomeric derivatives, 1-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[4.1.0]heptane and 6-(aryl)-1-[alkoxyalkyl]-3-azabicyclo[4.1.0]heptane, that eventually paved the way for the identification of <b>67</b> as a candidate suitable for clinical development (<a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">29</a></a>).<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> Ring homologation of <b>61</b> resulted in regioisomers <b>132</b>–<b>133</b> and the regioisomeric 6-phenyl scaffold in <b>132</b> gave higher SERT/DAT potency relative to the 1-phenyl scaffold of <b>133</b>. Further, the introduction of the CH<sub>2</sub>OMe group in <b>132</b> gave significantly higher affinity than in <b>133</b>, affirming the superiority of the 6-phenyl scaffold (compare <b>134</b> with <b>138</b>). Translocation of the side chain from the 1-position in <b>134</b> to the 7-position, as in <b>136</b> and <b>137</b>, resulted in significant reduction in TRI activity, suggesting the 1-position to be optimal. The regioisomer <b>136</b> with 6-(3,4-dichlorophenyl)-7-methoxymethyl substitution showed higher SERT potency but lower NET/DAT activity than the regioisomer <b>141</b> with a 1-(3,4-dichlorophenyl)-7-methoxymethyl substituent. Replacement of the CH<sub>2</sub>OMe in <b>67</b> with CH<sub>2</sub>OEt gave <b>134</b> and <b>135</b>, which exhibited almost superimposable activity profiles. Overall, <b>67</b> showed low nanomolar inhibitory activity, good selectivity (≥30-fold window with respect to DAT affinity) in a Cerep panel, and acceptable PK in rats. Compound <b>67</b> significantly elevated 5-HT, NE, and DA levels in the mPFC and NAc at a dose of 3 mpk ip in rats (microdialysis experiment) and significantly increased 5-HTP stereotyped behavior in a dose-dependent fashion over the range 3, 10, and 30 mpk, confirming in vivo inhibition of the 5-HT transporter. In the mouse FST model, <b>67</b> significantly reduced immobility time at all three of the doses tested (3, 10, and 30 mpk). In an ex vivo occupancy study, <b>67</b> showed a dose-dependent increase in SERT occupancy in the rat cortex while in an autoradiography experiment conducted in rats, the compound showed maximal SERT occupancy in almost all areas of the brain at a dose of 10 mpk. In a PET imaging study, the plasma concentration for half-maximal occupancy was found to be 15.16, 0.97, and 15.56 nM for SERT, NET, and DAT, respectively, in baboons, and 6.8 and 18 nM for SERT and DAT, respectively, in humans.<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> This confirmed the penetration of <b>67</b> across the BBB and triple reuptake blockade in vivo. In a phase I clinical trial, <b>67</b> was well tolerated at doses up to 150 mg/day. However, development of <b>67</b> for MDD was discontinued for business reasons.</div><figure id="fig29" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Figure 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0029.jpeg" id="gr29" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 29. Identification of <b>67</b> as a clinical candidate through sequential ring homologation of the 3-azabicyclo[3.1.0]hexane chemotype and appendage of a side chain (GSK).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig29"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Micheli et al. investigated the impact of replacement of the CH<sub>2</sub>OMe group of the clinical candidate <b>67</b> with C-linked heteroaryl or C-/N-linked, methylene-spaced heteroaryl substituents (<a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">30</a></a>).<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> Compound <b>142</b>, designed by topological mapping of CH<sub>2</sub>OMe within a five-membered heterocycle, gave lower SERT affinity and higher NET/DAT affinity than <b>134</b>. Replacement of the oxygen atom of <b>142</b> with a sulfur atom, a weaker H-bond acceptor, gave <b>143</b> which exhibited increased potency, a result consistent with the increase in clogP (3.8 vs 2.7), as explained by the authors. The racemate <b>143</b> showed subnanomolar activity (SERT/NET/DAT ratio: 3/3/1) with a 40–50-fold separation in affinity between the enantiomers <b>144</b> and <b>145</b>, respectively. Enantiomer <b>144</b>, which imparted a balanced triple reuptake inhibition profile, showed weak CYP inhibition (IC<sub>50</sub>: >4 μM) and moderate intrinsic clearance in liver microsomes (human, rat: 2.6, 5.4 mL/min/g, respectively). The introduction of a methylene spacer between the 3-azabicyclo[4.1.0]heptane scaffold and the heteroaryl group in <b>142</b> and <b>143</b> resulted in lower DAT affinity in compounds <b>146</b> and <b>147</b>. The homologated thiazole <b>147</b> furnished higher affinity than the corresponding oxazole derivative <b>146</b>, consistent with the trend in clogP (compare with <b>142</b> and <b>143</b>), as explained by the authors. Subsequently, <i>N</i>-linked heteroaryls were considered that offered an ease of synthesis in comparison to the C-linked heteroaryls. The <i>N</i>-linked pyrazoles demonstrated TRI profiles similar to the CH<sub>2</sub>OMe substituted analogues, although the affinity ratio was sensitive to the nature and position of substituents on the pyrazole ring. The 5-substituted pyrazole regioisomers <b>152</b>–<b>154</b> showed higher NET/DAT affinity than the corresponding 3-substituted regioisomers <b>148</b>–<b>150</b>. The 4-Me regioisomer <b>156</b> showed a significant reduction in NET/DAT affinity, with a SERT/NET/DAT ratio of ∼1/100/100 compared to the more active enantiomers <b>149</b> and <b>153</b> of the 3- and 5-Me regioisomers. The introduction of a second Me group resulted in a further enhancement of SERT/NET potency, as exemplified by comparing <b>153</b> and <b>159</b>. Compound <b>159</b> showed modest CYP inhibition (CYP2D6 IC<sub>50</sub>, 2 μM; other isoforms, >8 μM) and moderate to high clearance in liver microsomes (HLM, RLM: 2.4, 5.5 mL/min/g, respectively). In vivo, <b>159</b> showed a low bioavailability (<i>F</i>: 6%), a moderate <i>V</i><sub>d</sub> (6.9 L/kg), a moderate clearance (Cl<sub>b</sub>: 52 mL/min/kg), a <i>t</i><sub>1/2</sub> of 2.3 h, and a B/P ratio of 0.8, consistent with the clearance determined in vitro. Assuming that the electron-rich pyrazole ring was responsible for metabolic clearance, the methyl group was replaced with electron-poor substituents including CF<sub>3</sub> and CN (<b>150</b>, <b>151</b> and <b>154</b>, <b>155</b>). However, this change resulted in reduced NET/DAT affinity. The <i>N</i>-linked pyrroles <b>160</b>–<b>162</b> and heteroaromatics with >2 nitrogen atoms were also tolerated. The nitrile-substituted pyrrole analogues <b>161</b> and <b>162</b> showed somewhat similar profiles compared to the respective pyrazole counterparts <b>151</b> and <b>155</b>. Benzo-fused systems <b>163</b> and <b>164</b>, despite their bulky nature, were also tolerated. The indazole <b>164</b> gave higher SERT potency than the indole <b>163</b> possibly due to the presence of a potential H-bond acceptor.</div><figure id="fig30" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Figure 30</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0030.jpeg" id="gr30" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 30. Replacement of the side chain of <b>67</b> with (methylene) heteroaryls (GSK).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig30"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Modification of the ring fusion of <b>67</b> led to the discovery of two different series of constrained aryl piperidines. Profeta et al. reported 5-(3,4-dichlorophenyl)-4-[(methoxy)methyl]-2-azabicyclo[3.2.1]octane derivatives as a new class of constrained 4-arylpiperidines with a more rigid C2 linkage, as summarized in <a data-tab="pane-pcw-Figures" href="#fig31" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig31" id="" class=" internalNav">31</a></a>.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> All four isomers <b>165</b>–<b>168</b> gave relatively higher affinity for NET compared to SERT/NET. The <i>anti</i>-isomer <b>165</b> furnished the highest triple affinity with subnanomolar inhibitory activity at NET. The <i>syn</i>-isomers <b>167</b> and <b>168</b> showed a somewhat balanced profile in terms of relative potency in vitro. Another class of constrained oxa-azaspiro arylpiperidines was developed by exploiting the in-house pharmacophore model (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>) and a hypothesis that an appropriately located tetrahydrofuran (THF)/tetrahydropyran (THP) moiety on the 4-phenylpiperidine scaffold would meet the requirements of the pharmacophore (<a data-tab="pane-pcw-Figures" href="#fig31" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig31" id="" class=" internalNav">31</a></a>).<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> The spiro-THP compound <b>170</b> was found to be more potent than the spiro-THF compound <b>169</b>. Two more analogues, the oxetane <b>173</b> and the fused pyran <b>174</b>, which were made to expand the scope, gave inferior triple affinity in agreement with the poor fit of these compounds in the pharmacophore model. The spiro-THP compound <b>170</b>, which stood out in the series, was considered further with the profiling of its more active enantiomer <b>172</b>, which showed weak CYP inhibition (CYP2D6 IC<sub>50</sub>, >4 μM; other isoforms, >10 μM) and low intrinsic clearance. However, it showed poor oral bioavailability in rats due to high hepatic extraction (90%) in spite of a high fraction of absorption (91%).</div><figure id="fig31" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Figure 31</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0031.jpeg" id="gr31" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 31. Modification of the ring fusion of <b>67</b> to derive two different series of constrained arylpiperidines (GSK).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig31"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27">5.5.  AMRI/BMS Series</h3><div class="NLM_p">A NDRI/TRI discovery program that was initiated between Albany Molecular Research Incorporated (AMRI) and DuPont Pharmaceuticals was subsequently acquired by Bristol-Myers Squibb (BMS) in 2001. Inspired by the structure of NDRI <b>24</b> as a prototype tetrahydroisoquinoline (THIQ), AMRI explored lead optimization to identify dual inhibitors (for depression or ADHD) that were devoid of aromatic amino group in an attempt to avoid toxicity reported for <b>24</b>.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> This led to the identification of the NET/DAT inhibitor <b>175</b>, which was later optimized with the aim of incorporating SERT activity (<a data-tab="pane-pcw-Figures" href="#fig32" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig32" id="" class=" internalNav">32</a></a>).<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> Investigation of diverse bicyclic heteroaryl groups on the 4-position of THIQ resulted in the identification of <b>176</b> incorporating a benzothiophen-5-yl group, which showed low nanomolar triple reuptake inhibitory activity but with moderate CYP2D6 inhibition (IC<sub>50</sub>: 0.8 μM).<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> In terms of stereogenic preference, the (+)-isomer <b>176</b> was found to be more potent than the (−)-isomer. The 5-position of the benzothiophene group in <b>176</b> as the attachment point gave better overall activity than the 2-, 3-, 6-, and 7-positions. Different substitutions at the 7-position while maintaining the benzothiophen-5-yl group intact at the 4-position of the THIQ nucleus were explored in an effort to reduce the CYP2D6 inhibitory activity. This resulted in the discovery of AMR-000002 (<b>177</b>) with a morpholino group at the 7-position as a highly potent TRI with weak CYP2D6 inhibition (IC<sub>50</sub>: 11 μM).<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> Compound <b>177</b> showed significant and dose-dependent ex vivo occupancy at SERT (84–95%), NET (88–98%), and DAT (23–77%) in mice following oral dosing of 0.3, 1, and 3 mpk and significantly reduced immobility time in both the rat FST and mouse TST models (MED: 1 mpk; po). It showed no significant activity at 1 μM against a broad panel of receptors and enzymes but displayed moderate hERG inhibitory activity (IC<sub>50</sub>: 1 μM). The compound showed no mutagenic potential and was orally bioavailable in the rat and cynomolgus monkey. In the monkey, an active <i>N</i>,<i>O</i>-dealkylated metabolite <b>178</b> was detected in significant amounts (>50%) in vivo,<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> which indicated a potential DDI liability based on a CYP2D6 IC<sub>50</sub> value of 1 μM and precluded further advancement of <b>177</b>.</div><figure id="fig32" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Figure 32</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0032.jpeg" id="gr32" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 32. Optimization of substitutions at 4- and 7-positions of THIQ core resulting in the identification of <b>68</b> as a clinical candidate (AMRI/BMS).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig32"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">AMRI out-licensed promising TRIs at the preclinical stage to Bristol-Myers Squibb to further develop and commercialize this chemotype for the treatment of major depression and neuropathic pain. The collaboration resulted in the advancement of <b>68</b> and BMS-866949 (structure not disclosed) into clinical trials. Compound <b>68</b>, which arose from the THIQ series, reduced immobility time by 77% relative to placebo in the mouse TST model at a dose of 0.3 mpk.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> In a murine ex vivo model, <b>68</b> showed occupancy of 86%, 76%, and 28% for SERT, NET, and DAT, respectively, at a dose of 0.3 mpk. In a phase I clinical study, <b>68</b> demonstrated acceptable safety and tolerability in healthy subjects following oral administration (0.025–3.0 mg) with meaningful striatal SERT (0.5 and 3.0 mg: 19% and 82%, respectively) and DAT (3 mg: 19%) occupancies, slow absorption (<i>t</i><sub>max</sub>: 5.0–7.2 h), and a long <i>t</i><sub>1/2</sub> (34–57 h).<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> The half-life supported once-daily administration and predicted drug accumulation upon repeated daily dosing. However, in a phase IIb clinical trial, <b>68</b> (0.25–2 mg) failed to demonstrate superior efficacy in patients with TRD when compared to <b>12</b> or <b>18</b>.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> BMS-866949, another candidate from the collaboration, was progressed up to a phase I study that evaluated the compound in a multiple ascending dose trial.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a></div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28">5.6.  PRC Series</h3><div class="NLM_p">Using the SNRI <b>19</b> as the starting point, a collaborative team at the Mayo Clinic and Virginia Polytechnic Institute reported γ-aminoalcohol analogues designed to improve DAT affinity (<a data-tab="pane-pcw-Figures" href="#fig33" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig33" id="" class=" internalNav">33</a></a>).<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> Astra-Zeneca entered into an agreement to advance the best candidates into clinical development for the treatment of depression. The early compounds PRC025 (<b>179</b>; racemate) and PRC050 (<b>180</b>; racemate) showed higher triple transporter affinity than <b>19</b>, with a pronounced effect on DAT.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> Compounds <b>179</b> and <b>180</b> significantly reduced the immobility time in both the mouse TST and rat FST models (5 and 10 mpk; ip), and the antidepressant-like effect was comparable to that of <b>5</b> at a dose of 15 mpk (ip).</div><figure id="fig33" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Figure 33</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0033.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0033.jpeg" id="gr33" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 33. Modification of the SNRI <b>19</b> to incorporate DAT activity (Mayo Clinic/Virginia Polytechnic Institute).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig33"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Chiral separation of <b>180</b> provided <b>69</b> and PRC201-RR (<b>181</b>).<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> Compound <b>69</b> showed SERT/NET-preferring triple reuptake inhibitory activity, with good selectivity (<i>K</i><sub>i</sub> > 1 μM) against a CNS receptor panel that included 5-HT, NE, DA, histamine, and muscarinic receptors. Compound <b>69</b> produced a significant increase in the extracellular levels of 5-HT, and NE in the PFC and DA and 5-HT in the NAc with a decrease in the levels of 2,4-dihydroxyphenylacetic acid (DOPAC), HVA, and 5-HIAA in rats at doses of 5 or 10 mpk ip. In the rat FST model, doses of 1, 5, and 10 mpk (ip) of <b>69</b> induced a dose-dependent reduction of immobility, with the effect at 1 mpk comparable to that of a 15 mpk dose of imipramine (<b>5</b>). A similar dose-dependent reduction in the immobility time was observed in the mouse TST model following ip administration of the drug and <b>69</b> produced no significant locomotor activity in rats at 1 and 10 mpk. In toxicological studies, <b>69</b> produced dose-proportional kidney (distal tube) toxicity in cynomolgus monkeys, consistent with the urinary elevation of the biomarker calbindin D28.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a></div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29">5.7.  Roche Series</h3><div class="NLM_p">TRI discovery program at Roche was an extension of the SNRI program that led to the successful introduction of <b>18</b> in the market. Bannwart et al. recently reported a series of 3,3-disubstituted pyrrolidine derivatives which were arrived at by combining two discrete substructures from indolyl phenylpropanolamine (<b>182</b>; SNRI, Roche internal lead) and <b>61</b> (<a data-tab="pane-pcw-Figures" href="#fig34" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig34" id="" class=" internalNav">34</a></a>).<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> Interestingly, the first compound <b>183</b> showed significantly higher triple potency than <b>61</b> and favorable in vitro permeability and hERG inhibition, but human microsomal stability was low and there was significant inhibition of CYP2D6. The (+)-enantiomer <b>184</b>, which was found to be the more active enantiomer of <b>183</b>, showed an antidepressant-like effect in the mouse TST model at a dose of 30 mpk ip. Several modifications, including replacement of the indole moiety with other heteroaryls, introduction of substitution on the 2- or 3-position of indole ring, and replacement of the benzyl group, were subsequently explored. Isosteric replacement of the indole of <b>183</b> with an indazole or a benzothiophene was tolerated but offered no notable benefit. While the relocation of substitution at the 5-position of the indole ring to the adjacent 6-position was tolerated, further movement to the 3-position was less well tolerated. Introduction of substitutions at the 2- or 3-position of the indole ring (<b>183</b>) improved the metabolic stability by reducing microsomal clearance. Out of several substitutions (CN, CO<sub>2</sub>Et, CONH<sub>2</sub>, CONHMe, CONMe<sub>2</sub>), the introduction of a CONH<sub>2</sub> moiety at the 2-position in <b>183</b> resulted in the desired balanced activity profile (SERT/NET/DAT <i>K</i><sub>i</sub>: 2/9/18 nM), higher metabolic stability (HLM: 1.4 μL/min/mg), reduced CYP2D6 DDI potential (IC<sub>50</sub>: 4.1 μM), and weak hERG inhibition (IC<sub>50</sub>: > 10 μM) but reduced permeability with a higher efflux ratio [ER] of 28, which would limit CNS exposure. Among the alkyl groups evaluated as benzyl replacements, the <i>n</i>-Bu group in <b>70</b> (RG-7166) gave the best potency along with acceptable in vitro characteristics (CYP2D6 IC<sub>50</sub>, 3.4 μM; hERG IC<sub>50</sub>, 4.4 μM; <i>P</i><sub>app</sub> A–B, 9.4 × 10<sup>–6</sup> cm/s) but with a high metabolic clearance (HLM: 38 μL/min/mg). Although phase I development of <b>70</b> began in 4Q 2009, the compound was discontinued in 2012.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a></div><figure id="fig34" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Figure 34</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0034.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0034.jpeg" id="gr34" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 34. Hybridization of the SNRI <b>182</b> and the TRI <b>61</b> to derive pyrrolidin-3-yl-1<i>H</i>-indole derivatives (Roche).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig34"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To further mitigate metabolic clearance, CYP inhibition, and hERG liability, lowering of the clogP and p<i>K</i><sub>a</sub> was achieved by insertion of a carbonyl group into <b>183</b> (<a data-tab="pane-pcw-Figures" href="#fig35" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig35" id="" class=" internalNav">35</a></a>).<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> Compared to <b>183</b>, the ketopyrrolidine <b>186</b> showed similar SERT/DAT affinity, reduced NET activity, significant improvement in HLM stability, reduced hERG inhibition (IC<sub>20</sub>: 6.1 μM), and excellent permeability (<i>P</i><sub>app</sub> A–B: 17 × 10<sup>–6</sup> cm/s). This inspired a multipronged structural modification effort involving the pyrrolidine, benzyl, and indole elements. While replacement of the 3-pyrrolidine ring in <b>186</b> with a 3-azetidine or a 3-azepine resulted in a loss of potency, piperidine analogues showed acceptable potency but with either P-gp-mediated efflux (4-piperidine) or strong CYP2D6 and hERG inhibition (3-piperidine) as potential liabilities. This suggested retention of the 3-pyrrolidine group while optimizing the other elements. Further SAR development led to the identification of the 7-fluoroindole derivative <b>187</b> which exhibited good potency, metabolic stability, and permeability. Compound <b>187</b> showed antidepressant-like activity in the mouse TST model at doses of 10–30 mpk ip. Replacing the benzyl group with alkyl groups resulted in the identification of <b>188</b>, which incorporates a dimethylbutyl group and exhibits picomolar SERT inhibitory activity, moderate clearance, and somewhat weak CYP2D6 inhibition. Modification of the indole heterocycle by isosteric replacement, while retaining the pyrrolidine and dimethylbutyl groups, was investigated as a means of reducing the CYP2D6 inhibition liability. This resulted in the identification of several compounds with promising in vitro triple affinity profiles that incorporated substituted monoaryls and heteroaryls and bicyclic heteroaryls. Representative compound <b>189</b> furnished excellent inhibition (triple reuptake inhibitory <i>K</i><sub>i</sub> < 10 nM), acceptable SERT/DAT occupancy in rats (80/20% at 1.15 mpk ip) suggestive of good brain penetration, and good oral bioavailability in rats.</div><figure id="fig35" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Figure 35</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0035.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0035.jpeg" id="gr35" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 35. Lead optimization of <b>183</b>, involving carbonyl insertion to mitigate the liabilities by lowering clogP and p<i>K</i><sub>a</sub> (Roche).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0035.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig35"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The difficulty with enantioselective synthesis or separation of enantiomers in the earlier work (vide supra) prompted the design of achiral aminoheterocycles (<a data-tab="pane-pcw-Figures" href="#fig36" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig36" id="" class=" internalNav">36</a></a>).<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> However, abolishment of the chiral center by introducing a nitrogen atom into the Roche lead <b>190</b> resulted in a significant loss of triple reuptake inhibitory activity, as exemplified by the profile of <b>191</b>. Constraining the side chain via piperidine analogues was subsequently explored (partly to mitigate any potential <i>N</i>-demethylation metabolism), which led to a further loss of triple reuptake inhibitory activity in <b>192</b>. However, the introduction of a methylene spacer to the aminopiperidine exonitrogen resulted in a significant increase in triple inhibitor potency as exemplified by <b>193</b>. This compound showed acceptable HLM stability and permeability but with undesirable hERG (IC<sub>20</sub>: 1 μM) and CYP2D6 (IC<sub>50</sub>: 0.1 μM) inhibition. In an attempt to address these deficiencies, a three-pronged approach, in which the piperidine, benzyl, and metabolically labile indole were modified, was undertaken. However, these optimization efforts failed to afford a compound with the targeted product profile due to the liabilities associated with CYP2D6, CYP3A4, and/or hERG inhibition. Moreover, <b>193</b> was found to be inactive in a locomotor assay (LMA) and the TST model conducted in mice at 30 mpk, which was in line with the absence of DAT occupancy (0%) in mice. This might be attributable to an insufficient unbound concentration of <b>193</b> in the striatum to effectively occupy DAT. A scaffold hopping strategy was pursued in an effort to reduce the p<i>K</i><sub>a</sub> by designing the 2-substituted piperazine <b>194</b>, assuming that it would help to improve membrane permeability, brain exposure, and efficacy in vivo. Compound <b>194</b> was active in both the LMA and TST models (MED: 10 mpk), which was consistent with the high DAT occupancy (75%) observed in mice. This was likely due to the 5-fold higher free fraction of <b>194</b> in the brain compared to <b>193</b> (206 vs 37 nM). Because both <b>193</b> and <b>194</b> were not P-gp substrates, this result suggested that p<i>K</i><sub>a</sub> played a key role in boosting the free fraction of <b>194</b> in the brain. Because of the likely contribution of the 2,3-unsubstituted indole ring to the observed low metabolic stability (HLM: 43.3 μL/min/mg), modification of this potential soft spot was considered. Replacement of indole with phenyl, dichlorophenyl, and <i>N</i>-methylindole gave reduced NET and/or DAT affinity, suggesting a requirement for an indole-like chemotype for H-bonding interactions. Replacement of the indole of <b>194</b> with an indazole gave <b>195</b>, which resulted in improved metabolic stability (HLM: 3.8 μL/min/mg) while maintaining good potency. However, <b>195</b> showed potent CYP2D6 inhibition (IC<sub>50</sub>: 0.05 μM). While maintaining the indazole ring, replacing the benzyl with other groups (Ph, PhCH<sub>2</sub>CH<sub>2</sub>, alkyl, and others) was considered in an effort to develop improved CYP2D6 inhibition SARs, which afforded compound <b>196</b> with a low CYP2D6 DDI liability, albeit with reduced NET affinity.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> However, the indole and indazole compounds (e.g., <b>196</b>) showed CYP3A4 time-dependent inhibition (TDI) potential in vitro, possibly through the formation of diiminoquinones (e.g., <b>198</b>) as reactive metabolites. Even though optimized analogues were identified with a lower risk of CYP3A4-mediated TDI, the potential of these compounds to undergo <i>N</i>-acetylation to give <b>197</b> in vivo and the heightened risk of <i>N</i>-acetyl metabolites like <b>199</b> for TDI of CYP3A4 prompted a deprioritization of this series.</div><figure id="fig36" data-index="36" class="article__inlineFigure"><h2 class="fig-label">Figure 36</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0036.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0036.jpeg" id="gr36" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 36. Chirality elimination and scaffold hopping as key strategies to design substituted piperidine and piperazine derivatives and the putative mechanism of TDI liability of the series (Roche).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0036.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig36"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30">5.8.  Takeda Series</h3><div class="NLM_p">A ligand-based drug design approach was employed to arrive at 1-aryl-1,4-diazepan-2-one derivatives as hybrid compounds of <b>21</b> (SNRI) and <b>61</b> (<a data-tab="pane-pcw-Figures" href="#fig37" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig37" id="" class=" internalNav">37</a></a>).<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> The initial compound <b>200</b> was built to include the key structural features of an aryl ring, a basic amine, and an amide moiety and showed higher affinity for NET than SERT and DAT. Cyclization of <b>200</b> to give <b>201</b> resulted in improved NET/DAT affinity. Removal of the cyclopropyl group in <b>201</b> gave the benchmark compound <b>202</b> with improved SERT/NET activity but decreased DAT activity and lower metabolic stability. To enhance the metabolic stability, substitutions including F, Me, and Et were investigated on the diazepan-2-one ring of <b>202</b> while keeping 3,4-dichlorophenyl as the aryl ring. The introduction of a Me group at the 3-position (<b>203</b>) was found to be optimal for triple reuptake inhibitory activity, while Me substitution at other positions was poorly tolerated. Compound <b>203</b> showed higher metabolic stability than <b>202</b>. Replacement of the 3,4-dichlorophenyl moiety with a 2-naphthyl group gave compound <b>204</b> with enhanced SERT/NET activity and an acceptable metabolic profile. Chiral separation of <b>204</b> provided enantiomer <b>205</b>, which was characterized by low MW (<300) and a favorable overall profile with preferential NET affinity, robust metabolic stability, and an absence of CYP2D6 and hERG inhibition. Compound <b>205</b> was progressed to in vivo studies, where it demonstrated a dose-proportional reduction of immobility time in the mouse TST model with a statistically significant efficacy observed following a 3 mpk po dose. In microdialysis experiments, a significant increase in the concentration of monoamines (5-HT, 210%; NE, 750%; DA, 640%) was observed in the mouse PFC 120 min after a dose of 3 mpk po.</div><figure id="fig37" data-index="37" class="article__inlineFigure"><h2 class="fig-label">Figure 37</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0037.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0037.jpeg" id="gr37" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 37. Design of diazepanone derivatives with low potential for CYP2D6 and hERG inhibition (Takeda).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0037.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig37"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Monoamine reuptake inhibitors that incorporate a basic amine as part of the pharmacophore are known for safety liabilities associated with lipophilic amines or cationic amphiphilic drugs (CADs) such as CYP2D6 inhibition, hERG inhibition, and phospholipidosis. Ishichi et al. designed substituted 4-benzylpiperidine derivatives by including relevant structural features for TRI activity and a physicochemical filter designed to avoid the safety liabilities that required a MW of <300, an aromatic ring count [ARC] of <2, and a clogP value of <3.5 (<a data-tab="pane-pcw-Figures" href="#fig38" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig38" id="" class=" internalNav">38</a></a>).<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> A variety of substituents in the benzylic position were investigated while keeping the 3,4-dichlorophenyl as the aryl element. Substituents such as Me, CH<sub>2</sub>OMe, CH<sub>2</sub>OEt, CH<sub>2</sub>SMe, and COMe, compounds <b>207</b>–<b>213</b>, afforded good potency, while more polar substituents like CH<sub>2</sub>OH, CH<sub>2</sub>S(O)<sub>2</sub>Me, and CONMe<sub>2</sub> (<b>214</b>–<b>216</b>) led to reduced potency. The authors have stated that there is a positive correlation of the clogP value with the in vitro potency and liabilities (CYP2D6 inhibition, hERG inhibition, and phospholipidosis potential). The methyl and ether derivatives <b>207</b>–<b>209</b> showed high antidepressant-like activity in the mouse TST model. However, sulfide <b>210</b> and ketone <b>211</b> exhibited only modest efficacy despite potent activities in vitro, which might be attributed to poor pharmacokinetic properties. Replacement of the 3,4-dichlorophenyl group in <b>208</b> with 2-naphthyl, 3-chlorophenyl, 4-chlorophenyl, and 3-chloro-4-fluorophenyl resulted in reduced triple inhibitory potency with the exception of SERT affinity for 2-naphthyl derivative. Overall, these efforts led to the identification of <b>208</b> as a molecule with well-balanced properties in terms of triple reuptake inhibitory activity, efficacy in vivo, and liability profiling. Chiral separation of <b>208</b> led to <b>217</b>, the NET-preferring isomer, which showed weak CYP2D6 inhibition (14% at 10 μM), weak hERG inhibition (48% at 10 μM), and low phospholipidosis potential. Compound <b>217</b> showed antidepressant-like efficacy in the mouse TST model (MED: 10 mpk po), dose-proportional transporter occupancy in the mouse frontal cortex and striatum, and elevation of monoamine concentration (5-HT, 180%; NE, 400%; DA, 270%) in mPFC (microdialysis).</div><figure id="fig38" data-index="38" class="article__inlineFigure"><h2 class="fig-label">Figure 38</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0038.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0038.jpeg" id="gr38" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 38. Design of 4-benzylpiperidine derivatives with low risk for CAD-associated or other safety liabilities (Takeda).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0038.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig38"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31">5.9.  Luye Series</h3><div class="NLM_p">The marketed SNRI desvenlafaxine (<b>20</b>) is known for relatively low permeability, presumably due to the presence of an ionizable phenol group. Ester derivaties with TRI activity were sought assuming that they would enhance efficacy by adding a DA component and by improving the CNS exposure through enhanced permeability. These compounds can also behave as prodrugs in vivo. Hou et al. have disclosed PA01 (<b>219</b>), the benzoate ester of the SNRI <b>20</b> (<a data-tab="pane-pcw-Figures" href="#fig39" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig39" id="" class=" internalNav">39</a></a>).<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> Compound <b>219</b> showed a dose-dependent increase of mobility time in both the rat FST and mouse TST models with higher efficacy than <b>20</b> while showing no stimulatory effect on spontaneous locomotor activity. The anti-immobility effect of <b>219</b> was significantly reversed by pretreatment of the mice with 4-chlorophenylalanine, an inhibitor of 5-HT synthesis, the D<sub>1</sub> antagonist SCH23390 (<b>220</b>), and the D<sub>2</sub> antagonist sulpiride (<b>221</b>) (<a data-tab="pane-pcw-Figures" href="#fig40" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig40" id="" class=" internalNav">40</a></a>). Compound <b>71</b>, which is being developed for MDD, is a 4-methylbenzoate derivative of <b>20</b>. Compound <b>71</b> was found to partially undergo cleavage in vivo to release <b>20</b> in rats.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> Compared to <b>20</b>, <b>71</b> elevated 5-HT, NE, and DA to higher levels in rat striatum following acute or chronic administration as an oral suspension in a microdialysis experiment and exhibited increased reduction of immobility time in the rat FST model (po). Unlike <b>20</b>, <b>71</b> did not induce a reduction in the levels of extracellular 5-HT in the early phase following iv administration of a solution of the compound. In a phase I clinical trial, <b>71</b> was found to show dose-proportional plasma exposure with a good safety profile and an absence of a food effect on the bioavailability.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> A phase II clinical trial of this compound was initiated in China in September 2015.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a></div><figure id="fig39" data-index="39" class="article__inlineFigure"><h2 class="fig-label">Figure 39</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0039.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0039.jpeg" id="gr39" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 39. Conversion of the SNRI <b>20</b> into the corresponding benzoate ester derivatives to incorporate DAT affinity (Luye Pharma).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0039.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig39"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig40" data-index="40" class="article__inlineFigure"><h2 class="fig-label">Figure 40</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0040.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0040.jpeg" id="gr40" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 40. Structures of DA receptor antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0040.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig40"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32">5.10.  D Series</h3><div class="NLM_p">Dutta et al. reported the design of TRI pyran analogues based on their previous work of structurally constrained <i>cis</i>-3,6-disubstituted piperidine derivatives as selective DAT inhibitors (e.g., <b>222</b>) that were explored for cocaine antagonism (<a data-tab="pane-pcw-Figures" href="#fig41" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig41" id="" class=" internalNav">41</a></a>).<a onclick="showRef(event, 'ref139 ref140'); return false;" href="javascript:void(0);" class="ref ref139 ref140">(139,140)</a> While the benchmark pyran compound <b>223</b> showed potential as a TRI, the introduction of a H-bond acceptor/donor substituent on the phenyl ring of the benzyl group, explored in the context of <b>224</b>–<b>228</b> (D-161, D-391, D-141, D-185, and D-411) which incorporate OH, OMe, or NH<sub>2,</sub> resulted in an improvement in the affinity for SERT and NET, suggesting the importance of H-bonding interactions. Relocation of the 4-hydroxyl group in <b>224</b> to the 3-position in <b>225</b> was tolerated, but further relocation to the 2-position as in <b>226</b> was less tolerated. Compound <b>225</b> significantly reduced immobility in the rat FST model at a dose of 10 mpk with efficacy comparable to <b>5</b>. Compound <b>229</b> showed lower triple reuptake inhibitory potency than enantiomer <b>224</b>. SAR exploration of ring substitutuents resulted in trisubstituted pyran analogues D-142 (<b>230</b>) and D-165 (<b>231</b>), in which both stereochemistry and regiospecificity played an important role.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> The (−)-2<i>S</i>,4<i>R</i>,5<i>R</i> absolute configuration and a <i>cis</i>-relationship between the benzhydryl moiety and the amino group were required for acceptable potency at SERT and NET. Compound <b>230</b> demonstrated high potency with a significant antidepressant-like effect in the rat FST and mouse TST models at the doses examined, 2.5, 5, and 25 mpk.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> Compound <b>230</b> did not show appreciable locomotor stimulation at the efficacious doses and was generally selective when evaluated against a CNS receptor panel. D-473 (<b>233</b>), the difluoro analogue of <b>230</b>, showed triple reuptake inhibitory activity in the order of SERT > NET > DAT.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> This compound did not show appreciable activity in a CNS selectivity panel of GPCRs and ion channels that included DA and 5-HT receptor subtypes. While <b>233</b> showed a significant reduction in immobility time following oral doses of 10, 25, and 50 mpk in the rat FST model, it did not differentiate from the vehicle in the locomotor test (25 mpk), suggesting that the antidepressant-like effect was not due to locomotor modulation. In rats, <b>233</b> produced a <i>C</i><sub>max</sub> of 404 nM, a <i>t</i><sub>1/2</sub> of 6.4 h, and a B/P ratio of 1.54 (at 4 h) following a dose of 25 mpk po. In a microdialysis experiment, <b>233</b> significantly elevated the levels of all three monoamines in both the medial frontal cortex and the dorsolateral striatum regions. Compound <b>233</b> is said to be under development for MDD and PTSD by TRImaran Pharma.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a></div><figure id="fig41" data-index="41" class="article__inlineFigure"><h2 class="fig-label">Figure 41</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0041.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0041.jpeg" id="gr41" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 41. Evolution of DAT-selective piperidines into triple-acting pyran analogues with the introduction of SERT/NET affinity by isosteric heterocyclic replacement.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0041.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig41"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Recently, modification of the pyran derivative <b>224</b> was further explored by investigating the role of separation between the phenyl rings of the benzhydryl moiety and the <i>N</i>-benzyl group and the replacement of the pyran ring with a tetrahydrofuran (<a data-tab="pane-pcw-Figures" href="#fig42" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig42" id="" class=" internalNav">42</a></a>).<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> Insertion of a CH<sub>2</sub> group between the benzhydryl moiety and the pyran ring to give <b>234</b> resulted in a loss of triple reuptake inhibitory activity, while insertion of a second CH<sub>2</sub> (<b>235</b>) resulted in the restoration of NET/DAT affinity. Replacement of the pyran of <b>224</b> with a <i>trans</i>-substituted tetrahydrofuran gave <b>236</b>, which resulted in a significant loss of triple reuptake inhibitory activity. Replacement of the benzyl group of <b>236</b> with a phenylethyl moiety to afford <b>237</b> resulted in an improvement of potency although this compound was still weak relative to <b>224</b>. Alteration of the stereochemistry of the amine-bearing chiral center, explored in the context of <b>238</b>–<b>239</b> failed to show significant improvement.</div><figure id="fig42" data-index="42" class="article__inlineFigure"><h2 class="fig-label">Figure 42</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0042.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0042.jpeg" id="gr42" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 42. Chemical modification strategies around the pyran ring of <b>224</b> involving ring contraction or peripheral elongation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0042.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig42"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33">5.11.  Miscellaneous Series</h3><div class="NLM_p">A CNS screening program at McNeil Pharmaceuticals in the 1980s resulted in the identification of tricyclic pyrroloisoquinolines, which led to an expansion of the chemical space around the THIQ core [exemplified by the structures of <b>24</b> and diclofensine (<b>240</b>)] with the appendage of a fused ring (<a data-tab="pane-pcw-Figures" href="#fig43" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig43" id="" class=" internalNav">43</a></a>).<a onclick="showRef(event, 'ref145 ref146'); return false;" href="javascript:void(0);" class="ref ref145 ref146">(145,146)</a> However, the focus on compounds selective for SERT or NET caused interest in these compounds to wane. Because of the renewed interest in TRIs, Aluisio et al. revisited this series and profiled JNJ-792476 (racemate; <b>241</b>) as a representative compound for antidepressant effects.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a> Compound <b>241</b> demonstrated high affinity at the 5-HT, NE and DA transporters with excellent selectivity in a Cerep panel of 50 human targets (IC<sub>50</sub> > 10 μM with the exception of the μ- and κ-opioid and 5-HT<sub>7</sub> receptors). The (+)-isomer JNJ-39836966 (<b>242</b>) exhibited higher potency (∼50-fold more potent SERT/NET/DAT inhibition) than the (−)-isomer JNJ-39836732 (<b>243</b>). Following sc dosing (1 mpk), <b>241</b> was rapidly absorbed into plasma with good brain penetration (B/P ratio: 7.5). Receptor occupancy studies demonstrated 94, 95, and 50% for SERT, NET, and DAT, respectively, at 1 h post dosing of 0.1 mpk (sc). Compound <b>241</b> induced a rapid and dose-dependent (0.1–10 mpk; sc) increase in the extracellular levels of 5-HT, NE, and DA that lasted for several hours. In the mouse TST model, <b>241</b> dose-dependently increased struggling time with an ED<sub>50</sub> of 0.3 mpk (ip) with 10-fold lower dose than the SSRI <b>11</b>. At a dose of 10 mpk, <b>241</b> induced a significant increase in spontaneous locomotor activity although this effect was not apparent at a dose of 0.1 and 1 mpk.</div><figure id="fig43" data-index="43" class="article__inlineFigure"><h2 class="fig-label">Figure 43</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0043.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0043.jpeg" id="gr43" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 43. Identification of tricyclic pyrroloisoquinoline derivatives by introduction of ring fusion to the THIQ core (Johnson & Johnson); <sup><i>a</i></sup>affinity data from the literature reference<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0043.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig43"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Recently, replacement of the phenyl ring of the SNRI <b>21</b> with a diverse range of aryl groups has been investigated in the context of enantiomers <b>22</b> and <b>244</b> in an effort to improve the DAT affinity of the prototype (<a data-tab="pane-pcw-Figures" href="#fig44" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig44" id="" class=" internalNav">44</a></a>).<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> Barring few exceptions, these derivatives displayed triple reuptake inhibitory affinity that decreased in the order of NET > SERT > DAT. Replacement of the phenyl with a 3,4-dichlorophenyl or a 2-naphthyl group (<b>245</b>–<b>246</b>), led to improved triple reuptake inhibitory activity in the case of the (−)-isomers, while the corresponding (+)-isomers (<b>247</b>–<b>248</b>) displayed lower potency.</div><figure id="fig44" data-index="44" class="article__inlineFigure"><h2 class="fig-label">Figure 44</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0044.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0044.jpeg" id="gr44" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 44. Aryl modification strategy to improve the DAT affinity of the SNRI <b>21</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0044.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig44"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">On the basis of an early series of reuptake inhibitors explored at Lilly that featured a bicyclo[2.2.2]octane template (e.g., <b>249</b>), analogues with a bicyclo[2.2.1]heptane architecture were probed for TRI activity (<a data-tab="pane-pcw-Figures" href="#fig45" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig45" id="" class=" internalNav">45</a></a>).<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> Naphthyl was explored as the aryl group as it was known to improve SERT activity and the 2-naphthyl moiety conferred significantly higher activity than the 1-naphthyl isomer. Microsomal incubation indicated <i>N</i>-demethylation as a mode of metabolic modification for <b>250</b> and <b>251</b>, and the metabolite <b>252</b> was also found to be active. The activities of <b>251</b> and <b>252</b> were confirmed in vivo using 5-HTP-induced serotonin syndrome-like behavior test [5-HT]), locomotor activity test [DA], and apomorphine hypothermia test [NE] in mice (po).</div><figure id="fig45" data-index="45" class="article__inlineFigure"><h2 class="fig-label">Figure 45</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0045.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0045.jpeg" id="gr45" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 45. Evolution of conformationally constrained bicyclo[2.2.1]heptane-derived inhibitors through ring contraction (Eli Lilly).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0045.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig45"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Recently, JZAD-IV-22 (<b>254</b>) was identified by screening a library of piperidine-based hybrid molecules that were arrived at by combining the structural features of nocaine (<b>253</b>) and <b>32</b> (<a data-tab="pane-pcw-Figures" href="#fig46" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig46" id="" class=" internalNav">46</a></a>).<a onclick="showRef(event, 'ref150 ref151'); return false;" href="javascript:void(0);" class="ref ref150 ref151">(150,151)</a> Compound <b>254</b> exhibited reuptake inhibition in the order of SERT > NET > DAT with a comparable behavioral and neurochemical profile to the TRI <b>59</b>. In both the FST and TST (mouse) models, <b>254</b> reduced immobility time at doses of 30 and 60 mpk but not at 15 mpk. This observation was consistent with microdialysis results, which revealed that significant elevation of monoamines in the mouse PFC was observed at doses of 30 and 60 mpk but not at 15 mpk. Drug discrimination studies in cocaine-treated rats indicated that both <b>254</b> and <b>59</b> partially substituted for cocaine. Unlike <b>59</b>, <b>254</b> did not induce either locomotor stimulation upon short-term administration or locomotor sensitization upon repeated administration at the efficacious doses.</div><figure id="fig46" data-index="46" class="article__inlineFigure"><h2 class="fig-label">Figure 46</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0046.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0046.jpeg" id="gr46" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 46. Design of <b>254</b>, derived from hybridization of <b>253</b> and <b>32</b> (Psychogenics); <sup><i>a</i></sup>affinity data are taken from the literature.<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0046.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig46"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Han et al. explored 3-substituted azetidines, designed by the rigidification of the 3-aryl-3-oxypropylamine scaffold that is common to several monoamine reuptake inhibitors (<a data-tab="pane-pcw-Figures" href="#fig47" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig47" id="" class=" internalNav">47</a></a>).<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> Compounds bearing a naphthyl ring as the R<sub>1</sub> substituent gave very high potency. Bulky R<sub>2</sub> groups like <i>n</i>-Pr or aryl gave higher activity than smaller groups like Me and Et. Representative compounds <b>255</b>–<b>256</b> showed good reuptake inhibition with modest CYP and hERG inhibition and were progressed for profiling in vivo. The compounds showed a reasonable B/P ratio (<b>255</b>, 0.9; <b>256</b>, 2.7), but poor oral bioavailability (<i>F</i> < 6%) in rats. Compound <b>256</b> showed a dose-dependent reduction of immobility time in the mouse FST model (iv and po). Further extension of this work was recently reported with the identification of <b>257</b>, which showed good potency with modest CYP and hERG inhibition.<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a> The elimination of chirality by bioisosteric modification of 3-α-oxyazetidines to render 3-aminoazetidines and their homologated analogues was subsequently explored to avoid cumbersome chiral resolution/synthesis (<a data-tab="pane-pcw-Figures" href="#fig47" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig47" id="" class=" internalNav">47</a></a>).<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> The SERT-preferring lead compound <b>258</b> showed lower inhibition of CYP1A2, CYP2D6, and CYP3A4 (IC<sub>50</sub> values >1 μM) than <b>18</b>, weak hERG inhibition (IC<sub>50</sub>: 5.5 μM), and no pro-mutagenic or mutagenic effect. Compound <b>258</b> showed an adequate B/P ratio (2.09) and moderate oral bioavailability (<i>F</i>: 28%) in rats.</div><figure id="fig47" data-index="47" class="article__inlineFigure"><h2 class="fig-label">Figure 47</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0047.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0047.jpeg" id="gr47" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 47. Conformational restriction of 3-arylpropylamine template to derive azetidine-bearing compounds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0047.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig47"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Li et al. reported the synthesis and pharmacological evaluation of SIPI5056 (<b>259</b>) and its isomers <b>260</b>–<b>262</b> (<a data-tab="pane-pcw-Figures" href="#fig48" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig48" id="" class=" internalNav">48</a></a>).<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> While <b>259</b> showed high triple reuptake inhibitory potency with the order of SERT > NET > DAT, the isomers <b>260</b>–<b>262</b> showed lower activity at SERT/NET and were inactive at DAT. Consistent with the inhibition in vitro, <b>259</b> showed the antidepressant-like efficacy with ED<sub>50</sub> values of 12.6 and 2.9 mpk (po) in the mouse TST and FST models, respectively. The <i>erythro</i>-isomers <b>259</b> and <b>261</b> (LD<sub>50</sub>: >1000 mpk) showed lower acute toxicity than the <i>threo</i>-isomers <b>260</b> and <b>262</b> (LD<sub>50</sub>: 200–400 mpk). Structural modification of <b>259</b> led to the identification of arylpropanol piperidine derivatives with <b>263</b> and <b>264</b> as representatives.<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a> These compounds showed a significant and dose-dependent (10, 20, and 50 mpk; po) reduction of immobility in the mouse TST model. The compounds did not produce locomotor activity at the highest efficacious dose (50 mpk), suggesting that the antidepressant-like effect was not due to motor stimulation. Neither <b>263</b> nor <b>264</b> showed significant activity in a Cerep panel of CNS receptors. In rats, <b>263</b> and <b>264</b> showed good oral bioavailability (<i>F</i>: 44–56%) at a dose of 10 mpk. Structural modification of the arylalkanol piperidine chemotype led to a series of arylalkyl diamine derivatives where the 3,4-dichlorophenyl group at the C-1 position was found to be important for good triple transporter inhibition<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a> Select compounds <b>265</b>–<b>267</b> showed a statistically significant and dose-dependent reduction in immobility time in the rat FST at doses of 5, 10, and 20 mpk (po). These compounds did not alter motor activity at 20 mpk, suggesting that the antidepressant-like effect was not due to motor stimulation. In the Cerep panel of CNS receptors, <b>265</b> did not show any significant inhibition except for SERT, NET, and DAT. In a single dose toxicology study, <b>265</b> caused mortality in 60% of mice at a dose of 900 mpk, whereas lower doses of 150–450 mpk caused no abnormalities or death after 2 weeks of drug administration. Compound <b>265</b> was negative in an Ames test. At a dose of 2 mpk, <b>265</b> showed moderate oral bioavailability (<i>F</i>: 19%), and after a dose of 0.5 mpk ip, the B/P ratio was found to be 23 in rats.</div><figure id="fig48" data-index="48" class="article__inlineFigure"><h2 class="fig-label">Figure 48</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0048.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0048.jpeg" id="gr48" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 48. Evolution of 1,3-diamino-1-arylpropane derivatives.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0048.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig48"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i34">Conclusions and Future Prospects</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31645" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31645" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Currently, 350 million people globally are believed to be affected by unipolar depression, and this devastating disease is predicted to become the single biggest health burden in the next decade. Unfortunately, about 35% of depressed patients are not adequately treated by marketed drugs, resulting in the existence of a large unmet clinical need. Despite a large patient population and a huge unmet medical need, the antidepressant pipeline is relatively sparse with few candidates in development. The exact reasons for the suboptimal response to SoC (SSRI and SNRIs) with low remission rates and persistent residual symptoms are currently unknown but assumed to be the absence of a pharmacological effect of these agents on other impaired pathways. A substantial body of evidence accrued from preclinical and clinical studies supports the hypofunction of dopamine tone in the pathophysiology of depression. The inducement of DA dysfunction has been shown to produce depressive symptoms, and the correction of DA dysfunction by dopaminergic agents has been shown to alleviate depression in some clinical studies. On the basis of these data, TRIs, which concurrently elevate DA along with 5-HT and NE, would be expected to demonstrate therapeutic benefit. DA is expected to play a dual role of potentiating the therapeutic benefit of SSRIs/SNRIs and opposing the side effects of SERT blockade. As a consequence, TRIs have been hypothesized to increase the rate of remission, reduce the time of therapeutic lag, and alleviate the residual symptoms of treatment with SSRIs/SNRIs. Importantly, such a polypharmacological treatment strategy seems relevant in the context of the complex etiology and polygenetic nature of a mental illness like depression.</div><div class="NLM_p">Medicinal chemistry efforts have led to the identification of at least 10 clinical candidates, numerous preclinical candidates, and the publication of ∼150 patent applications. Two different medicinal chemistry strategies have been adopted that have either involved structural modification of selective reuptake inhibitors to broaden their effects to encompass triple reuptake activity or the exploitation of known TRIs (e.g., <b>27</b>, <b>73</b>, and <b>61</b>) to improve their properties. The history of successful development of single or dual reuptake inhibitors fostered confidence to extend efficacy into the TRI paradigm with compounds from internal collections often serving as the starting points. The salient features of a TRI pharmacophore include a positive ionizable group and 2–3 hydrophobic regions with the fundamental requirement of basic amine. The basic amine typically contributes to hERG and CYP2D6 liabilities, which has necessitated extensive structural optimization efforts. TRI compounds with a diverse spectrum of in vitro triple affinities have been advanced into clinical trials.</div><div class="NLM_p">Contrary to expectations, the outcomes from several phase II clinical trials of TRIs have not been promising. In MDD patients, compounds <b>59</b> and <b>68</b> demonstrated efficacy that was similar to active controls while <b>64</b> and <b>65</b> failed to differentiate from placebo. Although <b>59</b> showed significant efficacy with attenuation of anhedonic symptoms in a PoC clinical trial, it failed to show efficacy in a subsequent trial in MDD subjects with TRD. Overall, these clinical candidates demonstrated a lack of statistically significant efficacy compared to placebo or failed to differentiate from standard of care. This is a setback to the development of TRIs as novel medicines and has discouraged the development of additional candidates. Assuming a therapeutic benefit of adding DAT inhibition to the profile of mono and dual reuptake inhibition therapies, the suboptimal performance of clinical candidates may be assigned, based on the available data, to three key reasons: (1) suboptimal target engagement, (2) an inadequate dosing regimen, and (3) safety (intolerability) concerns. Compound <b>61</b> showed a potentially inadequate level of SERT occupancy of 48% at a dose of 150 mg, which was suggested to be one of the reasons for poor clinical efficacy.<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a> While <b>64</b> showed high SERT and DAT occupancies after doses of 1–2 mg, it was not well tolerated, with the observation of significant side effects which might have clouded the potential to observe efficacy. It is not known whether extensive DAT inhibition (60–80% occupancy) was one of the reasons for poor tolerability. Compound <b>65</b> showed inadequate SERT occupancy of 2–14% at doses that were at least 4-fold higher than the highest clinical dose for efficacy studies, which might have contributed to the inferior clinical response. In addition, plasma exposure was well below those observed in several phase I clinical trials. In the case of <b>68</b>, for which both SERT and DAT occupancies were determined, it is possible that <b>68</b> could have acted largely as a SNRI in humans due to the possibility of low DAT occupancy at the clinical dose of 2 mg (compare 19% after a single 3 mg dose in healthy subjects). Clinical NET occupancy was not determined for any of the compounds, likely due to the limited availability of NET-selective PET ligands at that time. NET occupancy data would have provided clarity about whether the cardiovascular side effects of some of the clinical compounds, especially at higher doses, was due to a high level of NET inhibition.</div><div class="NLM_p">Going forward, it appears to be indispensable to have strong translational evidence before progressing a compound into phase II clinical trials. Foremost, it is important to understand whether TRIs demonstrate adequate SERT/NET/DAT occupancy through PET imaging studies in healthy or MDD subjects to give sufficient confidence. Moreover, PET occupancy, which allows the correlation of target occupancy with plasma/free drug concentration in vivo, may inform early decision making about dose selection and therapeutic potential for various indications. Confirmation of appropriate levels of target engagement in rodents and/or nonrodents will be useful for decision making, although it cannot substitute for the clinical confirmation of target occupancy due to potential cross-species differences. TRIs were progressed to clinical trials based on the observation of antidepressant-like effects in animal models, but the failure of translation of preclinical efficacy to the clinic raises questions about the predictive validity of these models.</div><div class="NLM_p">From a development perspective, the biggest challenge is the identification of the optimal ratio of triple reuptake inhibition for an effective therapeutic response without addictive and other liabilities, and this still is not known. This is further complicated by the inconsistencies between in vitro activity and in vivo clinical outcome (target occupancy/monoamine biomarker concentration) of the compounds, as observed in the cases of <b>65</b> and <b>66</b>. This further underscores the importance of a PET study as a prerequisite for a phase II clinical trial. The current level of understanding based on clinical PET occupancy studies suggests a preference in the order of SERT > NET > DAT occupancy. However, caution needs to be exercised as this order of preference was mainly evolved based on the occupancy of selective agents at the individual transporters. The clinically appropriate relative target occupancies upon the administration of multimodal TRIs, considering the synergistic and antagonistic effect of DAT inhibition upon the inhibition of SERT/NET, remain to be determined. Evidence for central engagement of monoamine transporters by measuring monoamine biomarkers (monoamines and their primary metabolites) in the CSF of healthy or depressed subjects may add weight to the occupancy data to aid informed decisions for phase II progression. The nature of DA signaling may also influence the outcome of antidepressant efficacy. Considering those TRIs that had long half-life and failed to offer significant clinical benefit in spite of addition of DAT pharmacology and antidepressant efficacy of psychostimulants, one can assume that depressive symptoms might be best relieved by phasic DA signaling (similar to that of psychostimulants) rather than the steady DA tone likely to be provided by the long-half-life–slow-onset properties of current TRIs.</div><div class="NLM_p">Importantly, it is essential that clinical candidates demonstrate adequate tolerability without dose-limiting safety issues, especially cardiovascular side effects. Any dose-limiting intolerability may negatively impact the clinical outcome in depressed patients and potentially force the use of doses inadequate for the desired level of target engagement. Another critical factor for the successful development of TRIs is the clinical demonstration of low potential for abuse. On a positive note, all of the tested TRIs (<b>69</b>, <b>63</b>, <b>62</b>, and <b>65</b>) have shown limited abuse potential in preclinical or clinical studies. Hence, abuse potential, which appears to be controllable by the characteristic occupancy-PK pattern of current TRI candidates (modest DAT occupancy, slow onset of DAT occupancy, or late <i>t</i><sub>max</sub>, and long half-life), may not be a significant issue at this juncture.</div><div class="NLM_p">General factors that can potentially affect the efficacy in the clinical trials include placebo effect, subjective and insensitive rating scales, and heterogeneity of the patient population. While patient heterogeneity requires large and complex clinical trials, improved patient stratification may eliminate the necessity for the large trials.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> Stratification of depressive or TRD patients with a subset of anhedonic symptoms, reward network dysfunction, a high burden of reduced positive state, and psychomotor retardation, may improve clinical outcome, as these patients are expected to demonstrate reduced DA turnover.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a></div><div class="NLM_p last">In short, the successful development of TRIs will depend on strong translational evidence (e.g., target engagement in depressed subjects; impact on clinical biomarkers connected to the disease pathophysiology), optimal dosing regimen to support adequate target occupancy, adequate safety margin, and differentiated clinical outcome for dopaminergic impairment through an appropriate clinical study design. Beyond depression, TRIs hold potential to treat a wide range of medical conditions, in which the deficiency of monoamines has been implicated, including ADHD, pain, AUD, cocaine addiction, BED, and obesity, with four candidates currently under clinical development. It is hoped that the right combination of TRI profile, drug-like properties, and appropriate therapeutic indications will soon be identified to enable patients to benefit from the potential of these promising agents.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.6b01827" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53008" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53008" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Murugaiah A. M. Subbaiah</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, Biocon Bristol-Myers Squibb R&D Centre, Biocon Park, Bommasandra Phase IV,
Jigani Link Road, Bangalore 560099, India</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5707-966X" title="Orcid link">http://orcid.org/0000-0001-5707-966X</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#fc91898e899b9d959d94d29d92989d8c8c9d92bc8f85929b99929995928890d29f9391"><span class="__cf_email__" data-cfemail="4a273f383f2d2b232b22642b242e2b3a3a2b240a3933242d2f242f23243e2664292527">[email protected]</span></a></span></div></li></ul></li><li><ul></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The author declares no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i35">Biography</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41832" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41832" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="49" class="article__inlineFigure"><h2 class="fig-label">Murugaiah A. M. Subbaiah</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=BIO-d256e5206-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Murugaiah A. M. Subbaiah</b> received his Ph. D. degree under the supervision of Dr. Mukund Gurjar from the National Chemical Laboratory in 2000. His research focused on carbohydrate chemistry and asymmetric synthesis for CMI-977 and its analogues. Subsequently, he pursued postdoctoral research of the discovery of AT2 agonists and oxidative Heck chemistry under Prof. Anders Hallberg and Prof. Mats Larhed at the Department of Medicinal Chemistry, Uppsala University. In 2004, he joined the Department of Medicinal Chemistry, New Drug Discovery Research at Ranbaxy. Since 2008, he has been working at the Biocon-BMS R&D Centre. He has had the opportunity to work in therapeutic areas including CNS (depression and anxiety), metabolic disorders, infectious diseases, and oncology. His current research focusses on prodrug-mediated drug delivery, macrocyclic peptides, and chemogenomics.</p></figure></div><div class="ack" id="ACK-d256e5214-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i36">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66333" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66333" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">I thank Nicholas A. Meanwell (N.A.M.), Richard Olson (R.O.), John E. Macor, Ramakanth Sarabu (R.S.), and Murugesan Natesan (M.N.) from Bristol-Myers Squibb for strong support. I am deeply grateful to N.A.M. and R.O. for an in-depth review of this manuscript, constructive comments, and valuable insights. I also thank Michael Weed, Michael Sinz, M.N., and R.S. for their suggestions.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">AD</td><td class="NLM_def"><p class="first last">Alzheimer’s disease</p></td></tr><tr><td class="NLM_term">ADHD</td><td class="NLM_def"><p class="first last">attention deficit hyperactivity disorder</p></td></tr><tr><td class="NLM_term">AUD</td><td class="NLM_def"><p class="first last">alcohol use disorder</p></td></tr><tr><td class="NLM_term">BED</td><td class="NLM_def"><p class="first last">binge eating disorder</p></td></tr><tr><td class="NLM_term">B/P</td><td class="NLM_def"><p class="first last">brain to plasma</p></td></tr><tr><td class="NLM_term">CAD</td><td class="NLM_def"><p class="first last">cationic amphiphilic drug</p></td></tr><tr><td class="NLM_term">CD</td><td class="NLM_def"><p class="first last">catecholamine depletion</p></td></tr><tr><td class="NLM_term">CMS</td><td class="NLM_def"><p class="first last">chronic mild stress</p></td></tr><tr><td class="NLM_term">CSF</td><td class="NLM_def"><p class="first last">cerebrospinal fluid</p></td></tr><tr><td class="NLM_term">DIO</td><td class="NLM_def"><p class="first last">diet-induced obesity</p></td></tr><tr><td class="NLM_term">DHPG</td><td class="NLM_def"><p class="first last">3,4-dihydroxyphenylglycol</p></td></tr><tr><td class="NLM_term">DRI</td><td class="NLM_def"><p class="first last">dopamine reuptake inhibitor</p></td></tr><tr><td class="NLM_term">FSL</td><td class="NLM_def"><p class="first last">Flinders sensitive line</p></td></tr><tr><td class="NLM_term">FST</td><td class="NLM_def"><p class="first last">forced swimming test</p></td></tr><tr><td class="NLM_term">5-HIAA</td><td class="NLM_def"><p class="first last">5-hydroxyindoleacetic acid</p></td></tr><tr><td class="NLM_term">5-HT</td><td class="NLM_def"><p class="first last">serotonin</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsomes</p></td></tr><tr><td class="NLM_term">HVA</td><td class="NLM_def"><p class="first last">homovanillic acid</p></td></tr><tr><td class="NLM_term">ICSS</td><td class="NLM_def"><p class="first last">intracranial self-stimulation</p></td></tr><tr><td class="NLM_term">MAO</td><td class="NLM_def"><p class="first last">monoamine oxidase</p></td></tr><tr><td class="NLM_term">MAOI</td><td class="NLM_def"><p class="first last">monoamine oxidase inhibitor</p></td></tr><tr><td class="NLM_term">MDD</td><td class="NLM_def"><p class="first last">major depressive disorder</p></td></tr><tr><td class="NLM_term">MED</td><td class="NLM_def"><p class="first last">minimum effective dose</p></td></tr><tr><td class="NLM_term">mpk</td><td class="NLM_def"><p class="first last">mg/kg</p></td></tr><tr><td class="NLM_term">NAc</td><td class="NLM_def"><p class="first last">nucleus accumbens</p></td></tr><tr><td class="NLM_term">NDRI</td><td class="NLM_def"><p class="first last">norepinephrine dopamine reuptake inhibitor</p></td></tr><tr><td class="NLM_term">NE</td><td class="NLM_def"><p class="first last">norepinephrine</p></td></tr><tr><td class="NLM_term">NET</td><td class="NLM_def"><p class="first last">norepinephrine transporter</p></td></tr><tr><td class="NLM_term">NRI</td><td class="NLM_def"><p class="first last">norepinephrine reuptake inhibitor</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">Parkinson’s disease</p></td></tr><tr><td class="NLM_term">PET</td><td class="NLM_def"><p class="first last">positron emission tomography</p></td></tr><tr><td class="NLM_term">PFC</td><td class="NLM_def"><p class="first last">prefrontal cortex</p></td></tr><tr><td class="NLM_term">PoC</td><td class="NLM_def"><p class="first last">proof of concept</p></td></tr><tr><td class="NLM_term">PTSD</td><td class="NLM_def"><p class="first last">post-traumatic stress disorder</p></td></tr><tr><td class="NLM_term">rac</td><td class="NLM_def"><p class="first last">racemate</p></td></tr><tr><td class="NLM_term">RLM</td><td class="NLM_def"><p class="first last">rat liver microsomes</p></td></tr><tr><td class="NLM_term">RMDD</td><td class="NLM_def"><p class="first last">remitted major depressive disorder</p></td></tr><tr><td class="NLM_term">SoC</td><td class="NLM_def"><p class="first last">standard of care</p></td></tr><tr><td class="NLM_term">s.e.</td><td class="NLM_def"><p class="first last">single enantiomer</p></td></tr><tr><td class="NLM_term">SNRI</td><td class="NLM_def"><p class="first last">serotonin norepinephrine reuptake inhibitor</p></td></tr><tr><td class="NLM_term">TCA</td><td class="NLM_def"><p class="first last">tricyclic antidepressant</p></td></tr><tr><td class="NLM_term">TDI</td><td class="NLM_def"><p class="first last">time-dependent inhibition</p></td></tr><tr><td class="NLM_term">TRD</td><td class="NLM_def"><p class="first last">treatment-resistant depression</p></td></tr><tr><td class="NLM_term">TRI</td><td class="NLM_def"><p class="first last">triple reuptake inhibitor</p></td></tr><tr><td class="NLM_term">TST</td><td class="NLM_def"><p class="first last">tail suspension test</p></td></tr><tr><td class="NLM_term">VMAT-2</td><td class="NLM_def"><p class="first last">vesicular monoamine transporter-2</p></td></tr><tr><td class="NLM_term">VTA</td><td class="NLM_def"><p class="first last">ventral tegmental area</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i38">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63584" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63584" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 159 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span> <i>Depression Fact Sheet</i>; <span class="NLM_publisher-name">World Health Organization
(WHO)</span>: <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2017</span>; <a href="http://www.who.int/mediacentre/factsheets/fs369/en/" class="extLink">http://www.who.int/mediacentre/factsheets/fs369/en/</a> (accessed May 29, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Depression+Fact+Sheet%3B+World+Health+Organization%0A%28WHO%29%3A+Geneva%2C+2017%3B+http%3A%2F%2Fwww.who.int%2Fmediacentre%2Ffactsheets%2Ffs369%2Fen%2F+%28accessed+May+29%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DDepression%2520Fact%2520Sheet%26pub%3DWorld%2520Health%2520Organization%250A%2528WHO%2529%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span> <i>Antidepressant Use in Persons
Aged 12 and Over: United States, 2005–2008</i>; <span class="NLM_publisher-name">National Center for Health Statistics</span>: <span class="NLM_publisher-loc">Atlanta</span>, <span class="NLM_year">2011</span>; <a href="https://www.cdc.gov/nchs/products/databriefs/db76.htm" class="extLink">https://www.cdc.gov/nchs/products/databriefs/db76.htm</a> (accessed May 29, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Antidepressant+Use+in+Persons%0AAged+12+and+Over%3A+United+States%2C+2005%E2%80%932008%3B+National+Center+for+Health+Statistics%3A+Atlanta%2C+2011%3B+https%3A%2F%2Fwww.cdc.gov%2Fnchs%2Fproducts%2Fdatabriefs%2Fdb76.htm+%28accessed+May+29%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DAntidepressant%2520Use%2520in%2520Persons%250AAged%252012%2520and%2520Over%253A%2520United%2520States%252C%25202005%25E2%2580%25932008%26pub%3DNational%2520Center%2520for%2520Health%2520Statistics%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Calderone, J.</span></span> <span> </span><span class="NLM_article-title">The Rise of All-Purpose Antidepressants</span>;  <i>Scientific American</i> November 1, <span class="NLM_year">2014</span>; <a href="https://www.scientificamerican.com/article/the-rise-of-all-purpose-antidepressants/" class="extLink">https://www.scientificamerican.com/article/the-rise-of-all-purpose-antidepressants/</a> (accessed May 29, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=J.+Calderone&title=The+Rise+of+All-Purpose+Antidepressants"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3DCalderone%26aufirst%3DJ.%26atitle%3DThe%2520Rise%2520of%2520All-Purpose%2520Antidepressants%26jtitle%3DScientific%2520American%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lane, R. M.</span></span> <span> </span><span class="NLM_article-title">Antidepressant drug development: focus on triple monoamine reuptake inhibition</span>. <i>J. Psychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">526</span>– <span class="NLM_lpage">544</span>, <span class="refDoi"> DOI: 10.1177/0269881114553252</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1177%2F0269881114553252" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=25315829" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlWlu7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2015&pages=526-544&author=R.+M.+Lane&title=Antidepressant+drug+development%3A+focus+on+triple+monoamine+reuptake+inhibition&doi=10.1177%2F0269881114553252"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Antidepressant drug development: focus on triple monoamine reuptake inhibition</span></div><div class="casAuthors">Lane, Roger M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Psychopharmacology (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">526-544</span>CODEN:
                <span class="NLM_cas:coden">JOPSEQ</span>;
        ISSN:<span class="NLM_cas:issn">0269-8811</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">Many patients with major depressive disorder (MDD) only partially respond, and some have no clin. meaningful response, to current widely used antidepressant drugs.  Due to the purported role of dopamine in the pathophysiol. of depression, triple-reuptake inhibitors (TRIs) that simultaneously inhibit serotonin (5-HT), norepinephrine (NE) and dopamine reuptake could be a useful addn. to the armamentarium of treatments for MDD.  A TRI should more effectively activate mesolimbic dopamine-related reward-networks, restore pos. mood and reduce potent 5-HT reuptake blockade assocd. "hypodopaminergic" adverse effects of decreased libido, wt. gain and "blunting" of emotions.  On the other hand, dopaminergic effects raise concern over abuse liability and TRIs may have many of the cardiovascular effects assocd. with NET inhibition.  Several clin. development programs for potential TRI antidepressants have failed to demonstrate significantly greater efficacy than placebo or std. of care.  Successful late-stage clin. development of a TRI is more likely if exptl. research studies in the target population of depressed patients have demonstrated target engagement that differentially and dose-dependently improves assessments of reward-network dysfunction relative to existing antidepressants.  TRI treatment could be individualized on the basis of predictive markers such as the burden of decreased pos. mood symptoms and/or neuroimaging evidence of reward network dysfunction.  This review focuses on how the next generation of monoamine-based treatments could be efficiently developed to address unmet medical need in MDD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVyw65qm-vT7Vg90H21EOLACvtfcHk0lg-K8Af8tyliw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlWlu7%252FI&md5=43a14f56cf9bc21972ad313b1c53dd66</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1177%2F0269881114553252&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0269881114553252%26sid%3Dliteratum%253Aachs%26aulast%3DLane%26aufirst%3DR.%2BM.%26atitle%3DAntidepressant%2520drug%2520development%253A%2520focus%2520on%2520triple%2520monoamine%2520reuptake%2520inhibition%26jtitle%3DJ.%2520Psychopharmacol.%26date%3D2015%26volume%3D29%26spage%3D526%26epage%3D544%26doi%3D10.1177%2F0269881114553252" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, S. M.</span></span> <i>Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications</i>; <span class="NLM_edition">4th</span> ed.; <span class="NLM_publisher-name">Cambridge University Press</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=S.+M.+Stahl&title=Stahl%E2%80%99s+Essential+Psychopharmacology%3A+Neuroscientific+Basis+and+Practical+Applications"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DStahl%26aufirst%3DS.%2BM.%26btitle%3DStahl%25E2%2580%2599s%2520Essential%2520Psychopharmacology%253A%2520Neuroscientific%2520Basis%2520and%2520Practical%2520Applications%26pub%3DCambridge%2520University%2520Press%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dunlop, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nemeroff, C. B.</span></span> <span> </span><span class="NLM_article-title">The role of dopamine in the pathophysiology of depression</span>. <i>Arch. Gen. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">327</span>– <span class="NLM_lpage">337</span>, <span class="refDoi"> DOI: 10.1001/archpsyc.64.3.327</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1001%2Farchpsyc.64.3.327" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=17339521" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjs1yntLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2007&pages=327-337&author=B.+W.+Dunlopauthor=C.+B.+Nemeroff&title=The+role+of+dopamine+in+the+pathophysiology+of+depression&doi=10.1001%2Farchpsyc.64.3.327"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The role of dopamine in the pathophysiology of depression</span></div><div class="casAuthors">Dunlop, Boadie W.; Nemeroff, Charles B.</div><div class="citationInfo"><span class="NLM_cas:title">Archives of General Psychiatry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">327-337</span>CODEN:
                <span class="NLM_cas:coden">ARGPAQ</span>;
        ISSN:<span class="NLM_cas:issn">0003-990X</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">A review.  Multiple sources of evidence support a role for diminished dopaminergic neurotransmission in major depression.  The physiol. alterations underlying reduced dopamine (DA) signaling could result from either diminished DA release from presynaptic neurons or impaired signal transduction; either due to changes in receptor no. or function and/or altered intracellular signal processing.  There are data supporting each of these mechanisms, although interpretation of previous research is confounded by issues around study population, medication status, and technol. limitations.  In some patients with depression, DA-related disturbances improve by treatment with antidepressants, presumably by acting on serotonergic or noradrenergic circuits, which then affect DA function.  However, most antidepressant treatments do not directly enhance DA neurotransmission, which may contribute to residual symptoms, including impaired motivation, concn., and pleasure.  Animal models of major depression show considerable responsiveness to manipulations of DA neurotransmission.  Several studies, including postmortem investigations, particularly of subjects with severe depression, have demonstrated reduced concns. of DA metabolites both in the cerebrospinal fluid and in brain regions that mediate mood and motivation.  Although the neuroimaging findings are not unequivocal, several studies support the hypothesis that major depression is assocd. with a state of reduced DA transmission, possibly reflected by a compensatory up-regulation of D2 receptors.  These alternations in DA signaling may underlie the findings of increased "liking" or "high" feelings reported by severely depressed subjects treated with d-amphetamine compared with the response of less severely ill and normal control subjects.  The efficacy of medications that directly act on DA neurons or receptors, such as monoamine oxidase inhibitors and pramipexole, suggests that subtypes of depression stemming from a primary DA dysfunction exist.  Further research on the contribution of DA to the pathophysiol. of depression is justified to improve outcomes for patients with treatment-resistant and nonremitting depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpl_yra-4Ra0rVg90H21EOLACvtfcHk0lhm9ncwMPW7Cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjs1yntLY%253D&md5=5d9c7f04093533d67b4bff1f6f68f3ae</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1001%2Farchpsyc.64.3.327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchpsyc.64.3.327%26sid%3Dliteratum%253Aachs%26aulast%3DDunlop%26aufirst%3DB.%2BW.%26aulast%3DNemeroff%26aufirst%3DC.%2BB.%26atitle%3DThe%2520role%2520of%2520dopamine%2520in%2520the%2520pathophysiology%2520of%2520depression%26jtitle%3DArch.%2520Gen.%2520Psychiatry%26date%3D2007%26volume%3D64%26spage%3D327%26epage%3D337%26doi%3D10.1001%2Farchpsyc.64.3.327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marks, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pae, C.-U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patkar, A. A.</span></span> <span> </span><span class="NLM_article-title">Triple reuptake inhibitors: the next generation of antidepressants</span>. <i>Curr. Neuropharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">338</span>– <span class="NLM_lpage">343</span>, <span class="refDoi"> DOI: 10.2174/157015908787386078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.2174%2F157015908787386078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=19587855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisVSqu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2008&pages=338-343&author=D.+M.+Marksauthor=C.-U.+Paeauthor=A.+A.+Patkar&title=Triple+reuptake+inhibitors%3A+the+next+generation+of+antidepressants&doi=10.2174%2F157015908787386078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Triple reuptake inhibitors: the next generation of antidepressants</span></div><div class="casAuthors">Marks, David M.; Pae, Chi-Un; Patkar, Ashwin A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Neuropharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">338-343</span>CODEN:
                <span class="NLM_cas:coden">CNUEAN</span>;
        ISSN:<span class="NLM_cas:issn">1875-6190</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Depression has been assocd. with impaired neurotransmission of serotonergic, norepinephrinergic, and dopaminergic pathways, although most pharmacol. treatment strategies for depression enhance only serotonin and norepinephrine neurotransmission.  Current drug development efforts are aimed at a new class of antidepressants which inhibit the reuptake of all three neurotransmitters in the hope of creating medications with broader efficacy and/or quicker onset of action.  The current review explores limitations of presently available antidepressants and the history and premise behind the movement to devise triple reuptake inhibitors.  The evidence for and against the claim that broader spectrum agents are more efficacious is discussed.  Examples of triple reuptake inhibitors in development are compared, and preclin. and clin. research with these agents to date is described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGov8YVs9W5UsbVg90H21EOLACvtfcHk0lhm9ncwMPW7Cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisVSqu78%253D&md5=b8108bdcd4ddc03bc3e7c31b2ac0824f</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.2174%2F157015908787386078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157015908787386078%26sid%3Dliteratum%253Aachs%26aulast%3DMarks%26aufirst%3DD.%2BM.%26aulast%3DPae%26aufirst%3DC.-U.%26aulast%3DPatkar%26aufirst%3DA.%2BA.%26atitle%3DTriple%2520reuptake%2520inhibitors%253A%2520the%2520next%2520generation%2520of%2520antidepressants%26jtitle%3DCurr.%2520Neuropharmacol.%26date%3D2008%26volume%3D6%26spage%3D338%26epage%3D343%26doi%3D10.2174%2F157015908787386078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haque, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angelescu, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumeister, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tracy, D. K.</span></span> <span> </span><span class="NLM_article-title">Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant</span>. <i>Ther. Adv. Psychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">99</span>– <span class="NLM_lpage">144</span>, <span class="refDoi"> DOI: 10.1177/2045125316629071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1177%2F2045125316629071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=27141292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtVKisLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=99-144&author=K.+Patelauthor=S.+Allenauthor=M.+N.+Haqueauthor=I.+Angelescuauthor=D.+Baumeisterauthor=D.+K.+Tracy&title=Bupropion%3A+a+systematic+review+and+meta-analysis+of+effectiveness+as+an+antidepressant&doi=10.1177%2F2045125316629071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant</span></div><div class="casAuthors">Patel, Krisna; Allen, Sophie; Haque, Mariam N.; Angelescu, Ilinca; Baumeister, David; Tracy, Derek K.</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Advances in Psychopharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">99-144</span>CODEN:
                <span class="NLM_cas:coden">TAPHB2</span>;
        ISSN:<span class="NLM_cas:issn">2045-1261</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Bupropion has been used as an antidepressant for over 20 years, though its licence for such use varies and it is typically a third- or fourth-line agent.  It has a unique pharmacol., inhibiting the reuptake of noradrenaline and dopamine, potentially providing pharmacol. augmentation to more common antidepressants such as selective serotonergic reuptake inhibitors (SSRIs).  This systematic review and meta-anal. identified 51 studies, dividing into four categories: bupropion as a sole antidepressant, bupropion coprescribed with another antidepressant, bupropion in 'other' populations (e.g. bipolar depression, elderly populations) and primary evaluation of side effects.  Methodol. more robust trials support the superiority of bupropion over placebo, and most head-to-head antidepressant trials showed an equiv. effectiveness, though some of these are hindered by a lack of a placebo arm.  Most work on the coprescribing of bupropion with another antidepressant supports an addnl. effect, though many are open-label trials.  Several large multi-medication trials, most notably STAR*D, also support a therapeutic role for bupropion; in general, it demonstrated similar effectiveness to other medications, though this literature highlights the generally low response rates in refractory cohorts.  Effectiveness has been shown in 'other' populations, though there is an overall dearth of research.  Bupropion is generally well tolerated, it has very low rates of sexual dysfunction, and is more likely to cause wt. loss than gain.  Our findings support the use of bupropion as a sole or coprescribed antidepressant, particularly if wt. gain or sexual dysfunction are, or are likely to be, significant problems.  However there are notable gaps in the literature, including less information on treatment naive and first presentation depression, particularly when one considers the ever-reducing rates of response in more refractory illness.  There are some data to support bupropion targeting specific symptoms, but insufficient information to reliably inform such prescribing, and it remains uncertain whether bupropion pharmacodynamically truly augments other drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXRuoh6Ma-9bVg90H21EOLACvtfcHk0lhm9ncwMPW7Cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtVKisLo%253D&md5=f41bf8860711254d55a3452ad519f03c</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1177%2F2045125316629071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F2045125316629071%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DK.%26aulast%3DAllen%26aufirst%3DS.%26aulast%3DHaque%26aufirst%3DM.%2BN.%26aulast%3DAngelescu%26aufirst%3DI.%26aulast%3DBaumeister%26aufirst%3DD.%26aulast%3DTracy%26aufirst%3DD.%2BK.%26atitle%3DBupropion%253A%2520a%2520systematic%2520review%2520and%2520meta-analysis%2520of%2520effectiveness%2520as%2520an%2520antidepressant%26jtitle%3DTher.%2520Adv.%2520Psychopharmacol.%26date%3D2016%26volume%3D6%26spage%3D99%26epage%3D144%26doi%3D10.1177%2F2045125316629071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span> <i>Bupropion</i>; <span class="NLM_publisher-name">Wikipedia</span>, <span class="NLM_year">2017</span>; <a href="https://en.wikipedia.org/wiki/Bupropion" class="extLink">https://en.wikipedia.org/wiki/Bupropion</a> (accessed May 29, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Bupropion%3B+Wikipedia%2C+2017%3B+https%3A%2F%2Fen.wikipedia.org%2Fwiki%2FBupropion+%28accessed+May+29%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DBupropion%26pub%3DWikipedia%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pechulis, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curry, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harms, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opalka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweet, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vellekoop, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klos, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crocker, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laws, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitchen, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molino, B. F.</span></span> <span> </span><span class="NLM_article-title">4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">7219</span>– <span class="NLM_lpage">7222</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.09.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.bmcl.2012.09.050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=23084899" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFGjtLrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=7219-7222&author=A.+D.+Pechulisauthor=J.+P.+Beckauthor=M.+A.+Curryauthor=M.+A.+Wolfauthor=A.+E.+Harmsauthor=N.+Xiauthor=C.+Opalkaauthor=M.+P.+Sweetauthor=Z.+Yangauthor=A.+S.+Vellekoopauthor=A.+M.+Klosauthor=P.+J.+Crockerauthor=C.+Hasslerauthor=M.+Lawsauthor=D.+B.+Kitchenauthor=M.+A.+Smithauthor=R.+E.+Olsonauthor=S.+Liuauthor=B.+F.+Molino&title=4-Phenyl+tetrahydroisoquinolines+as+dual+norepinephrine+and+dopamine+reuptake+inhibitors&doi=10.1016%2Fj.bmcl.2012.09.050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors</span></div><div class="casAuthors">Pechulis, Anthony D.; Beck, James P.; Curry, Matt A.; Wolf, Mark A.; Harms, Arthur E.; Xi, Ning; Opalka, Chet; Sweet, Mark P.; Yang, Zhicai; Vellekoop, A. Samuel; Klos, Andrew M.; Crocker, Peter J.; Hassler, Carla; Laws, Mia; Kitchen, Douglas B.; Smith, Mark A.; Olson, Richard E.; Liu, Shuang; Molino, Bruce F.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7219-7222</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Aryltetrahydroisoquinolines I [and, in some cases, their (+)-enantiomers or both their (+)- and (-)-enantiomers] were prepd. as dual inhibitors of dopamine and norepinephrine transporters for potential use as nonstimulating treatments for attention deficit-hyperactivity disorder.  I were prepd. by reductive amination of benzaldehyde to N-methylarylmethylamines followed by alkylation with α-haloacetophenones to give benzylmethylamino arylethanones; redn. and acid-catalyzed cyclization yielded racemic aryltetrahydroisoquinolines which were resolved by preparative HPLC.  The inhibition of dopamine, norepinephrine, and serotonin transporters by I were detd.; the norepinephrine receptor occupancy of rat brain ex vivo after oral dosing of (S)-(+)-I (R1 = H; R2 = Me; R3 = R4 = R5 = H; R6 = F; R7 = H) was detd.  (S)-(+)-I (R1 = H; R2 = Me; R3 = R4 = R5 = H; R6 = F; R7 = H) inhibited cytochrome P450 2D6 (CYP2D6) with an IC50 value of 0.48 μM; some of the other aryltetrahydroisoquinolines prepd. also inhibited CYP2D6.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXnLksIDABmrVg90H21EOLACvtfcHk0lhpy-bQ2AhdwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFGjtLrK&md5=e64a45237245cffb08f14c80e5b9e21a</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.09.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.09.050%26sid%3Dliteratum%253Aachs%26aulast%3DPechulis%26aufirst%3DA.%2BD.%26aulast%3DBeck%26aufirst%3DJ.%2BP.%26aulast%3DCurry%26aufirst%3DM.%2BA.%26aulast%3DWolf%26aufirst%3DM.%2BA.%26aulast%3DHarms%26aufirst%3DA.%2BE.%26aulast%3DXi%26aufirst%3DN.%26aulast%3DOpalka%26aufirst%3DC.%26aulast%3DSweet%26aufirst%3DM.%2BP.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DVellekoop%26aufirst%3DA.%2BS.%26aulast%3DKlos%26aufirst%3DA.%2BM.%26aulast%3DCrocker%26aufirst%3DP.%2BJ.%26aulast%3DHassler%26aufirst%3DC.%26aulast%3DLaws%26aufirst%3DM.%26aulast%3DKitchen%26aufirst%3DD.%2BB.%26aulast%3DSmith%26aufirst%3DM.%2BA.%26aulast%3DOlson%26aufirst%3DR.%2BE.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DMolino%26aufirst%3DB.%2BF.%26atitle%3D4-Phenyl%2520tetrahydroisoquinolines%2520as%2520dual%2520norepinephrine%2520and%2520dopamine%2520reuptake%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D7219%26epage%3D7222%26doi%3D10.1016%2Fj.bmcl.2012.09.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gaynes, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warden, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trivedi, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wisniewski, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fava, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rush, A. J.</span></span> <span> </span><span class="NLM_article-title">What did STAR*D teach us? results from a large-scale, practical, clinical trial for patients with depression</span>. <i>Psychiatr. Serv.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1439</span>– <span class="NLM_lpage">1445</span>, <span class="refDoi"> DOI: 10.1176/ps.2009.60.11.1439</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1176%2Fps.2009.60.11.1439" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=19880458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A280%3ADC%252BD1MjjtFShtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2009&pages=1439-1445&author=B.+N.+Gaynesauthor=D.+Wardenauthor=M.+H.+Trivediauthor=S.+R.+Wisniewskiauthor=M.+Favaauthor=A.+J.+Rush&title=What+did+STAR*D+teach+us%3F+results+from+a+large-scale%2C+practical%2C+clinical+trial+for+patients+with+depression&doi=10.1176%2Fps.2009.60.11.1439"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression</span></div><div class="casAuthors">Gaynes Bradley N; Warden Diane; Trivedi Madhukar H; Wisniewski Stephen R; Fava Maurizio; Rush A John</div><div class="citationInfo"><span class="NLM_cas:title">Psychiatric services (Washington, D.C.)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1439-45</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The authors provide an overview of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study (www.star-d.org), a large-scale practical clinical trial to determine which of several treatments are the most effective "next-steps" for patients with major depressive disorder whose symptoms do not remit or who cannot tolerate an initial treatment and, if needed, ensuing treatments.  Entry criteria were broadly defined and inclusive, and patients were enrolled from psychiatric and primary care clinics.  All participants began on citalopram and were managed by clinic physicians, who followed an algorithm-guided acute-phase treatment through five visits over 12 weeks.  At the end of each sequence, patients whose depression had not fully remitted were eligible for subsequent randomized trials in a sequence of up to three clinical trials.  In general, remission rates in the study clinics were lower than expected, suggesting the need for several steps to achieve remission for most patients.  There was no clear medication "winner" for patients whose depression did not remit after one or more aggressive medication trials.  Both switching and augmenting appeared to be reasonable options when an initial antidepressant treatment failed, although these two strategies could not be directly compared.  Further, the likelihood of remission after two vigorous medication trials substantially decreased, and remission would likely require more complicated medication regimens for which the existing evidence base is quite thin.  STAR*D demonstrated that inclusion of more real-world patients in clinical trials is both feasible and informative.  Policy implications of the findings, as well as the study's limitations, are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTgLKw46-uNnxOk4JA3soTqfW6udTcc2eakMrLqye8g1rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MjjtFShtw%253D%253D&md5=8e843ff9d84f737d8b71493b8a12c51f</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1176%2Fps.2009.60.11.1439&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fps.2009.60.11.1439%26sid%3Dliteratum%253Aachs%26aulast%3DGaynes%26aufirst%3DB.%2BN.%26aulast%3DWarden%26aufirst%3DD.%26aulast%3DTrivedi%26aufirst%3DM.%2BH.%26aulast%3DWisniewski%26aufirst%3DS.%2BR.%26aulast%3DFava%26aufirst%3DM.%26aulast%3DRush%26aufirst%3DA.%2BJ.%26atitle%3DWhat%2520did%2520STAR%252AD%2520teach%2520us%253F%2520results%2520from%2520a%2520large-scale%252C%2520practical%252C%2520clinical%2520trial%2520for%2520patients%2520with%2520depression%26jtitle%3DPsychiatr.%2520Serv.%26date%3D2009%26volume%3D60%26spage%3D1439%26epage%3D1445%26doi%3D10.1176%2Fps.2009.60.11.1439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sum, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldessarini, R. J.</span></span> <span> </span><span class="NLM_article-title">Prevention of relapse and recurrence in adults with major depressive disorder: systematic review and meta-analyses of controlled trials</span>. <i>Int. J. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">pyv076</span>, <span class="refDoi"> DOI: 10.1093/ijnp/pyv076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1093%2Fijnp%2Fpyv076" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2016&pages=pyv076&author=K.+Simauthor=W.+K.+Lauauthor=J.+Simauthor=M.+Y.+Sumauthor=R.+J.+Baldessarini&title=Prevention+of+relapse+and+recurrence+in+adults+with+major+depressive+disorder%3A+systematic+review+and+meta-analyses+of+controlled+trials&doi=10.1093%2Fijnp%2Fpyv076"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1093%2Fijnp%2Fpyv076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fijnp%252Fpyv076%26sid%3Dliteratum%253Aachs%26aulast%3DSim%26aufirst%3DK.%26aulast%3DLau%26aufirst%3DW.%2BK.%26aulast%3DSim%26aufirst%3DJ.%26aulast%3DSum%26aufirst%3DM.%2BY.%26aulast%3DBaldessarini%26aufirst%3DR.%2BJ.%26atitle%3DPrevention%2520of%2520relapse%2520and%2520recurrence%2520in%2520adults%2520with%2520major%2520depressive%2520disorder%253A%2520systematic%2520review%2520and%2520meta-analyses%2520of%2520controlled%2520trials%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2016%26volume%3D19%26spage%3Dpyv076%26doi%3D10.1093%2Fijnp%2Fpyv076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Best, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nijhout, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, M. C.</span></span> <span> </span><span class="NLM_article-title">Homeostatic mechanisms in dopamine synthesis and release: a mathematical model</span>. <i>Theor. Biol. Med. Modell.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">21</span>, <span class="refDoi"> DOI: 10.1186/1742-4682-6-21</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1186%2F1742-4682-6-21" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=19740446" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A280%3ADC%252BD1MnmtFKjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2009&pages=21&author=J.+A.+Bestauthor=H.+F.+Nijhoutauthor=M.+C.+Reed&title=Homeostatic+mechanisms+in+dopamine+synthesis+and+release%3A+a+mathematical+model&doi=10.1186%2F1742-4682-6-21"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Homeostatic mechanisms in dopamine synthesis and release: a mathematical model</span></div><div class="casAuthors">Best Janet A; Nijhout H Frederik; Reed Michael C</div><div class="citationInfo"><span class="NLM_cas:title">Theoretical biology & medical modelling</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">21</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Dopamine is a catecholamine that is used as a neurotransmitter both in the periphery and in the central nervous system.  Dysfunction in various dopaminergic systems is known to be associated with various disorders, including schizophrenia, Parkinson's disease, and Tourette's syndrome.  Furthermore, microdialysis studies have shown that addictive drugs increase extracellular dopamine and brain imaging has shown a correlation between euphoria and psycho-stimulant-induced increases in extracellular dopamine 1.  These consequences of dopamine dysfunction indicate the importance of maintaining dopamine functionality through homeostatic mechanisms that have been attributed to the delicate balance between synthesis, storage, release, metabolism, and reuptake.  METHODS:  We construct a mathematical model of dopamine synthesis, release, and reuptake and use it to study homeostasis in single dopaminergic neuron terminals.  We investigate the substrate inhibition of tyrosine hydroxylase by tyrosine, the consequences of the rapid uptake of extracellular dopamine by the dopamine transporters, and the effects of the autoreceoptors on dopaminergic function.  The main focus is to understand the regulation and control of synthesis and release and to explicate and interpret experimental findings.  RESULTS:  We show that the substrate inhibition of tyrosine hydroxylase by tyrosine stabilizes cytosolic and vesicular dopamine against changes in tyrosine availability due to meals.  We find that the autoreceptors dampen the fluctuations in extracellular dopamine caused by changes in tyrosine hydroxylase expression and changes in the rate of firing.  We show that short bursts of action potentials create significant dopamine signals against the background of tonic firing.  We explain the observed time courses of extracellular dopamine responses to stimulation in wild type mice and mice that have genetically altered dopamine transporter densities and the observed half-lives of extracellular dopamine under various treatment protocols.  CONCLUSION:  Dopaminergic systems must respond robustly to important biological signals such as bursts, while at the same time maintaining homeostasis in the face of normal biological fluctuations in inputs, expression levels, and firing rates.  This is accomplished through the cooperative effect of many different homeostatic mechanisms including special properties of tyrosine hydroxylase, the dopamine transporters, and the dopamine autoreceptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTwS0I3gpFNW4kFb3mqPUYDfW6udTcc2eZeaU1v7DzSG7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MnmtFKjsQ%253D%253D&md5=660a643b96fdfacf63329ac2cb0dc99f</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1186%2F1742-4682-6-21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1742-4682-6-21%26sid%3Dliteratum%253Aachs%26aulast%3DBest%26aufirst%3DJ.%2BA.%26aulast%3DNijhout%26aufirst%3DH.%2BF.%26aulast%3DReed%26aufirst%3DM.%2BC.%26atitle%3DHomeostatic%2520mechanisms%2520in%2520dopamine%2520synthesis%2520and%2520release%253A%2520a%2520mathematical%2520model%26jtitle%3DTheor.%2520Biol.%2520Med.%2520Modell.%26date%3D2009%26volume%3D6%26spage%3D21%26doi%3D10.1186%2F1742-4682-6-21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McHugh, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckley, D. A.</span></span> <span> </span><span class="NLM_article-title">The structure and function of the dopamine transporter and its role in CNS diseases</span>. <i>Vitam. Horm.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">339</span>– <span class="NLM_lpage">369</span>, <span class="refDoi"> DOI: 10.1016/bs.vh.2014.12.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fbs.vh.2014.12.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=25817874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVCnsb3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2015&pages=339-369&author=P.+C.+McHughauthor=D.+A.+Buckley&title=The+structure+and+function+of+the+dopamine+transporter+and+its+role+in+CNS+diseases&doi=10.1016%2Fbs.vh.2014.12.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">The structure and function of the dopamine transporter and its role in CNS diseases</span></div><div class="casAuthors">McHugh, Patrick C.; Buckley, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Vitamins and Hormones (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">Hormones and Transport Systems</span>),
    <span class="NLM_cas:pages">339-369</span>CODEN:
                <span class="NLM_cas:coden">VIHOAQ</span>;
        ISSN:<span class="NLM_cas:issn">0083-6729</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">In this chapter, we explore the basic science of the dopamine transporter (DAT), an integral component of a system that regulates dopamine homeostasis.  Dopamine is a key neurotransmitter for several brain functions including locomotor control and reward systems.  The transporter structure, function, mechanism of action, localization, and distribution, in addn. to gene regulation, are discussed.  Over many years, a wealth of information concerning the DAT has been accrued and has led to increased interest in the role of the DAT in a plethora of central nervous system diseases.  These DAT characteristics are explored in relation to a range of neurol. and neuropsychiatric diseases, with a particular focus on the genetics of the DAT.  In addn., we discuss the pharmacol. of the DAT and how this relates to disease and addiction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJBVmxaoKu07Vg90H21EOLACvtfcHk0lgJRs6lYzL4UQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVCnsb3O&md5=c0500c7a561e0fb1d6e693aba2a905c0</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fbs.vh.2014.12.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.vh.2014.12.009%26sid%3Dliteratum%253Aachs%26aulast%3DMcHugh%26aufirst%3DP.%2BC.%26aulast%3DBuckley%26aufirst%3DD.%2BA.%26atitle%3DThe%2520structure%2520and%2520function%2520of%2520the%2520dopamine%2520transporter%2520and%2520its%2520role%2520in%2520CNS%2520diseases%26jtitle%3DVitam.%2520Horm.%26date%3D2015%26volume%3D98%26spage%3D339%26epage%3D369%26doi%3D10.1016%2Fbs.vh.2014.12.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Efimova, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gainetdinov, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Budygin, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotnikova, T. D.</span></span> <span> </span><span class="NLM_article-title">Dopamine transporter mutant animals: a translational perspective</span>. <i>J. Neurogenet.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">5</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.3109/01677063.2016.1144751</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.3109%2F01677063.2016.1144751" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=27276191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC28Xpslyis7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=5-15&author=E.+V.+Efimovaauthor=R.+R.+Gainetdinovauthor=E.+A.+Budyginauthor=T.+D.+Sotnikova&title=Dopamine+transporter+mutant+animals%3A+a+translational+perspective&doi=10.3109%2F01677063.2016.1144751"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine transporter mutant animals: a translational perspective</span></div><div class="casAuthors">Efimova, Evgeniya V.; Gainetdinov, Raul R.; Budygin, Evgeny A.; Sotnikova, Tatyana D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurogenetics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5-15</span>CODEN:
                <span class="NLM_cas:coden">JLNEDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-7063</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">The dopamine transporter (DAT) plays an important homeostatic role in the control of both the extracellular and intraneuronal concns. of dopamine, thereby providing effective control over activity of dopaminergic transmission.  Since brain dopamine is known to be involved in numerous neuropsychiatric disorders, investigations using mice with genetically altered DAT function and thus intensity of dopamine-mediated signaling have provided numerous insights into the pathol. of these disorders and novel pathol. mechanisms that could be targeted to provide new therapeutic approaches for these disorders.  In this brief overview, we discuss recent investigations involving animals with genetically altered DAT function, particularly focusing on translational studies providing new insights into pathol. and pharmacol. of dopamine-related disorders.  Perspective applications of these and newly developed models of DAT dysfunction are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUioooqPwsCLVg90H21EOLACvtfcHk0lgJRs6lYzL4UQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xpslyis7s%253D&md5=44131a75927bf32f40d580fff0b825e0</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.3109%2F01677063.2016.1144751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F01677063.2016.1144751%26sid%3Dliteratum%253Aachs%26aulast%3DEfimova%26aufirst%3DE.%2BV.%26aulast%3DGainetdinov%26aufirst%3DR.%2BR.%26aulast%3DBudygin%26aufirst%3DE.%2BA.%26aulast%3DSotnikova%26aufirst%3DT.%2BD.%26atitle%3DDopamine%2520transporter%2520mutant%2520animals%253A%2520a%2520translational%2520perspective%26jtitle%3DJ.%2520Neurogenet.%26date%3D2016%26volume%3D30%26spage%3D5%26epage%3D15%26doi%3D10.3109%2F01677063.2016.1144751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sinita, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coghill, D.</span></span> <span> </span><span class="NLM_article-title">The use of stimulant medications for non-core aspects of ADHD and in other disorders</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">172</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2014.06.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.neuropharm.2014.06.014" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2014&pages=161-172&author=E.+Sinitaauthor=D.+Coghill&title=The+use+of+stimulant+medications+for+non-core+aspects+of+ADHD+and+in+other+disorders&doi=10.1016%2Fj.neuropharm.2014.06.014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2014.06.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2014.06.014%26sid%3Dliteratum%253Aachs%26aulast%3DSinita%26aufirst%3DE.%26aulast%3DCoghill%26aufirst%3DD.%26atitle%3DThe%2520use%2520of%2520stimulant%2520medications%2520for%2520non-core%2520aspects%2520of%2520ADHD%2520and%2520in%2520other%2520disorders%26jtitle%3DNeuropharmacology%26date%3D2014%26volume%3D87%26spage%3D161%26epage%3D172%26doi%3D10.1016%2Fj.neuropharm.2014.06.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cobanoglu, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahar, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Block, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorkin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, F.</span></span> <span> </span><span class="NLM_article-title">Insights into the modulation of dopamine transporter function by amphetamine, orphenadrine, and cocaine binding</span>. <i>Front. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">134</span>, <span class="refDoi"> DOI: 10.3389/fneur.2015.00134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.3389%2Ffneur.2015.00134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=26106364" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A280%3ADC%252BC2MbmslantQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=134&author=M.+H.+Chengauthor=M.+C.+Cobanogluauthor=I.+Baharauthor=E.+Blockauthor=A.+Sorkinauthor=F.+Hu&title=Insights+into+the+modulation+of+dopamine+transporter+function+by+amphetamine%2C+orphenadrine%2C+and+cocaine+binding&doi=10.3389%2Ffneur.2015.00134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into the Modulation of Dopamine Transporter Function by Amphetamine, Orphenadrine, and Cocaine Binding</span></div><div class="casAuthors">Cheng Mary Hongying; Cobanoglu Murat Can; Bahar Ivet; Block Ethan; Sorkin Alexander; Hu Feizhuo</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in neurology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">134</span>
        ISSN:<span class="NLM_cas:issn">1664-2295</span>.
    </div><div class="casAbstract">Human dopamine (DA) transporter (hDAT) regulates dopaminergic signaling in the central nervous system by maintaining the synaptic concentration of DA at physiological levels, upon reuptake of DA into presynaptic terminals.  DA translocation involves the co-transport of two sodium ions and the channeling of a chloride ion, and it is achieved via alternating access between outward-facing (OF) and inward-facing states of DAT. hDAT is a target for addictive drugs, such as cocaine, amphetamine (AMPH), and therapeutic antidepressants.  Our recent quantitative systems pharmacology study suggested that orphenadrine (ORPH), an anticholinergic agent and anti-Parkinson drug, might be repurposable as a DAT drug.  Previous studies have shown that DAT-substrates like AMPH or -blockers like cocaine modulate the function of DAT in different ways.  However, the molecular mechanisms of modulation remained elusive due to the lack of structural data on DAT.  The newly resolved DAT structure from Drosophila melanogaster opens the way to a deeper understanding of the mechanism and time evolution of DAT-drug/ligand interactions.  Using a combination of homology modeling, docking analysis, molecular dynamics simulations, and molecular biology experiments, we performed a comparative study of the binding properties of DA, AMPH, ORPH, and cocaine and their modulation of hDAT function.  Simulations demonstrate that binding DA or AMPH drives a structural transition toward a functional form predisposed to translocate the ligand.  In contrast, ORPH appears to inhibit DAT function by arresting it in the OF open conformation.  The analysis shows that cocaine and ORPH competitively bind DAT, with the binding pose and affinity dependent on the conformational state of DAT.  Further assays show that the effect of ORPH on DAT uptake and endocytosis is comparable to that of cocaine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcThQWXPjMQFgjW1zwg2yUK5fW6udTcc2ebUF7H0hIVVTbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MbmslantQ%253D%253D&md5=ba85913d72d9a5343b37df827c0ad271</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.3389%2Ffneur.2015.00134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffneur.2015.00134%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DM.%2BH.%26aulast%3DCobanoglu%26aufirst%3DM.%2BC.%26aulast%3DBahar%26aufirst%3DI.%26aulast%3DBlock%26aufirst%3DE.%26aulast%3DSorkin%26aufirst%3DA.%26aulast%3DHu%26aufirst%3DF.%26atitle%3DInsights%2520into%2520the%2520modulation%2520of%2520dopamine%2520transporter%2520function%2520by%2520amphetamine%252C%2520orphenadrine%252C%2520and%2520cocaine%2520binding%26jtitle%3DFront.%2520Neurol.%26date%3D2015%26volume%3D6%26spage%3D134%26doi%3D10.3389%2Ffneur.2015.00134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murnane, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClung, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tufik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howell, L. L.</span></span> <span> </span><span class="NLM_article-title">Dopamine transporter-related effects of modafinil in rhesus monkeys</span>. <i>Psychopharmacology (Berl.)</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>210</i></span>,  <span class="NLM_fpage">439</span>– <span class="NLM_lpage">448</span>, <span class="refDoi"> DOI: 10.1007/s00213-010-1839-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1007%2Fs00213-010-1839-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=20386883" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A280%3ADC%252BC3czltVSmtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=210&publication_year=2010&pages=439-448&author=M.+L.+Andersenauthor=E.+Kesslerauthor=K.+S.+Murnaneauthor=J.+C.+McClungauthor=S.+Tufikauthor=L.+L.+Howell&title=Dopamine+transporter-related+effects+of+modafinil+in+rhesus+monkeys&doi=10.1007%2Fs00213-010-1839-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine transporter-related effects of modafinil in rhesus monkeys</span></div><div class="casAuthors">Andersen Monica L; Kessler Eileen; Murnane Kevin S; McClung Jessica C; Tufik Sergio; Howell Leonard L</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">210</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">439-48</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">RATIONALE:  Modafinil is currently used as a treatment for daytime sleepiness.  OBJECTIVES:  The objectives of this study were to explore the dopamine transporter (DAT)-related effects of modafinil on behavior and in vivo neurochemistry in rhesus monkeys (Macaca mulatta).  METHODS:  The effects of modafinil (3.0-10 mg/kg, i.v.) were evaluated on locomotor activity, reinstatement of cocaine-maintained behavior, extracellular dopamine levels in the caudate nucleus, and DAT occupancy in the dorsal striatum.  Eight subjects were fitted with a collar-mounted activity monitor to evaluate sleep-activity cycles, with 4 days of baseline recording preceding an injection of saline or modafinil (3.0-10 mg/kg).  The effects of modafinil (3.0-10 mg/kg) and cocaine (0.3 mg/kg) on reinstatement of behavior that was previously maintained under a second-order schedule of i.v. cocaine delivery were tested in a separate group of subjects (n = 6).  Finally, the effects of modafinil (3.0-10 mg/kg) on extracellular dopamine levels and DAT occupancy in vivo were characterized using microdialysis and positron emission tomography, respectively, in a within-subjects design (n = 4).  RESULTS:  Modafinil significantly increased nighttime locomotor activity and reinstated cocaine-maintained behavior but did not affect daytime locomotor activity.  Modafinil significantly increased striatal extracellular dopamine levels at a dose that resulted in DAT occupancy of 64.4% (putamen) and 60.2% (caudate).  CONCLUSION:  The behavioral and in vivo dopaminergic effects of modafinil are consistent with the profile of a low potency DAT inhibitor and may indicate potential for abuse at high doses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRR7q9pi3Ia6UewzGPswiWOfW6udTcc2ebUF7H0hIVVTbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3czltVSmtA%253D%253D&md5=d1a3b4f6d3775edd3846f5924cba9793</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1007%2Fs00213-010-1839-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-010-1839-2%26sid%3Dliteratum%253Aachs%26aulast%3DAndersen%26aufirst%3DM.%2BL.%26aulast%3DKessler%26aufirst%3DE.%26aulast%3DMurnane%26aufirst%3DK.%2BS.%26aulast%3DMcClung%26aufirst%3DJ.%2BC.%26aulast%3DTufik%26aufirst%3DS.%26aulast%3DHowell%26aufirst%3DL.%2BL.%26atitle%3DDopamine%2520transporter-related%2520effects%2520of%2520modafinil%2520in%2520rhesus%2520monkeys%26jtitle%3DPsychopharmacology%2520%2528Berl.%2529%26date%3D2010%26volume%3D210%26spage%3D439%26epage%3D448%26doi%3D10.1007%2Fs00213-010-1839-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tateno, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arakawa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakayori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okubo, Y.</span></span> <span> </span><span class="NLM_article-title">In vivo activity of modafinil on dopamine transporter measured with positron emission tomography and [(1)(8)F]FE-PE2I</span>. <i>Int. J. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">697</span>– <span class="NLM_lpage">703</span>, <span class="refDoi"> DOI: 10.1017/S1461145713001612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1017%2FS1461145713001612" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=24451483" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvF2htLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2014&pages=697-703&author=W.+Kimauthor=A.+Tatenoauthor=R.+Arakawaauthor=T.+Sakayoriauthor=Y.+Ikedaauthor=H.+Suzukiauthor=Y.+Okubo&title=In+vivo+activity+of+modafinil+on+dopamine+transporter+measured+with+positron+emission+tomography+and+%5B%281%29%288%29F%5DFE-PE2I&doi=10.1017%2FS1461145713001612"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo activity of modafinil on dopamine transporter measured with positron emission tomography and [18F]FE-PE2I</span></div><div class="casAuthors">Kim, Woo Chan; Tateno, Amane; Arakawa, Ryosuke; Sakayori, Takeshi; Ikeda, Yumiko; Suzuki, Hidenori; Okubo, Yoshiro</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">697-703</span>CODEN:
                <span class="NLM_cas:coden">IJNUFB</span>;
        ISSN:<span class="NLM_cas:issn">1461-1457</span>.
    
            (<span class="NLM_cas:orgname">Cambridge University Press</span>)
        </div><div class="casAbstract">Modafinil, a wake-promoting drug used to treat narcolepsy, is a dopamine transporter inhibitor and is said to have very low abuse liability; this, however, is still up for debate.  We conducted a dopamine transporter (DAT) occupancy study with modafinil (200 or 300 mg) in ten healthy volunteers using positron emission tomog. (PET) with [18F]FE-PE2I, a new PET radioligand with high affinity and selectivity for the dopamine transporter, to characterize its relation to abuse liability.  Mean striatal DAT occupancies were 51.4% at 200 mg and 56.9% at 300 mg.  There was a significant correlation between occupancy and plasma concn., indicating dose dependency of DAT inhibition by modafinil in the striatum, and esp. in the nucleus accumbens.  This study showed that DAT occupancy by modafinil was close to that of methylphenidate, indicating that modafinil may be near the same level as methylphenidate in relation to abuse liability in terms of dopaminergic transmission.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4A-U8meN0y7Vg90H21EOLACvtfcHk0lhRqHac7f1oLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvF2htLg%253D&md5=0948131da50f2e032dbd8ace110c72a5</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1017%2FS1461145713001612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS1461145713001612%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DW.%26aulast%3DTateno%26aufirst%3DA.%26aulast%3DArakawa%26aufirst%3DR.%26aulast%3DSakayori%26aufirst%3DT.%26aulast%3DIkeda%26aufirst%3DY.%26aulast%3DSuzuki%26aufirst%3DH.%26aulast%3DOkubo%26aufirst%3DY.%26atitle%3DIn%2520vivo%2520activity%2520of%2520modafinil%2520on%2520dopamine%2520transporter%2520measured%2520with%2520positron%2520emission%2520tomography%2520and%2520%255B%25281%2529%25288%2529F%255DFE-PE2I%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2014%26volume%3D17%26spage%3D697%26epage%3D703%26doi%3D10.1017%2FS1461145713001612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perona, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waters, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sora, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesch, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caron, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uhl, G. R.</span></span> <span> </span><span class="NLM_article-title">Animal models of depression in dopamine, serotonin, and norepinephrine transporter knockout mice: prominent effects of dopamine transporter deletions</span>. <i>Behav. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">566</span>– <span class="NLM_lpage">574</span>, <span class="refDoi"> DOI: 10.1097/FBP.0b013e32830cd80f</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1097%2FFBP.0b013e32830cd80f" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2008&pages=566-574&author=M.+T.+Peronaauthor=S.+Watersauthor=F.+S.+Hallauthor=I.+Soraauthor=K.+P.+Leschauthor=D.+L.+Murphyauthor=M.+Caronauthor=G.+R.+Uhl&title=Animal+models+of+depression+in+dopamine%2C+serotonin%2C+and+norepinephrine+transporter+knockout+mice%3A+prominent+effects+of+dopamine+transporter+deletions&doi=10.1097%2FFBP.0b013e32830cd80f"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1097%2FFBP.0b013e32830cd80f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FFBP.0b013e32830cd80f%26sid%3Dliteratum%253Aachs%26aulast%3DPerona%26aufirst%3DM.%2BT.%26aulast%3DWaters%26aufirst%3DS.%26aulast%3DHall%26aufirst%3DF.%2BS.%26aulast%3DSora%26aufirst%3DI.%26aulast%3DLesch%26aufirst%3DK.%2BP.%26aulast%3DMurphy%26aufirst%3DD.%2BL.%26aulast%3DCaron%26aufirst%3DM.%26aulast%3DUhl%26aufirst%3DG.%2BR.%26atitle%3DAnimal%2520models%2520of%2520depression%2520in%2520dopamine%252C%2520serotonin%252C%2520and%2520norepinephrine%2520transporter%2520knockout%2520mice%253A%2520prominent%2520effects%2520of%2520dopamine%2520transporter%2520deletions%26jtitle%3DBehav.%2520Pharmacol.%26date%3D2008%26volume%3D19%26spage%3D566%26epage%3D574%26doi%3D10.1097%2FFBP.0b013e32830cd80f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tye, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirzabekov, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warden, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferenczi, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, H.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finkelstein, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adhikari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andalman, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunaydin, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witten, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deisseroth, K.</span></span> <span> </span><span class="NLM_article-title">Dopamine neurons modulate neural encoding and expression of depression-related behaviour</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>493</i></span>,  <span class="NLM_fpage">537</span>– <span class="NLM_lpage">541</span>, <span class="refDoi"> DOI: 10.1038/nature11740</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1038%2Fnature11740" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=493&publication_year=2013&pages=537-541&author=K.+M.+Tyeauthor=J.+J.+Mirzabekovauthor=M.+R.+Wardenauthor=E.+A.+Ferencziauthor=H.-C.+Tsaiauthor=J.+Finkelsteinauthor=S.-Y.+Kimauthor=A.+Adhikariauthor=K.+R.+Thompsonauthor=A.+S.+Andalmanauthor=L.+A.+Gunaydinauthor=I.+B.+Wittenauthor=K.+Deisseroth&title=Dopamine+neurons+modulate+neural+encoding+and+expression+of+depression-related+behaviour&doi=10.1038%2Fnature11740"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnature11740&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11740%26sid%3Dliteratum%253Aachs%26aulast%3DTye%26aufirst%3DK.%2BM.%26aulast%3DMirzabekov%26aufirst%3DJ.%2BJ.%26aulast%3DWarden%26aufirst%3DM.%2BR.%26aulast%3DFerenczi%26aufirst%3DE.%2BA.%26aulast%3DTsai%26aufirst%3DH.-C.%26aulast%3DFinkelstein%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.-Y.%26aulast%3DAdhikari%26aufirst%3DA.%26aulast%3DThompson%26aufirst%3DK.%2BR.%26aulast%3DAndalman%26aufirst%3DA.%2BS.%26aulast%3DGunaydin%26aufirst%3DL.%2BA.%26aulast%3DWitten%26aufirst%3DI.%2BB.%26aulast%3DDeisseroth%26aufirst%3DK.%26atitle%3DDopamine%2520neurons%2520modulate%2520neural%2520encoding%2520and%2520expression%2520of%2520depression-related%2520behaviour%26jtitle%3DNature%26date%3D2013%26volume%3D493%26spage%3D537%26epage%3D541%26doi%3D10.1038%2Fnature11740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Witkin, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monn, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoepp, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overshiner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasmussen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rorick-Kehn, L. M.</span></span> <span> </span><span class="NLM_article-title">The rapidly acting antidepressant ketamine and the mGlu2/3 receptor antagonist LY341495 rapidly engage dopaminergic mood circuits</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>358</i></span>,  <span class="NLM_fpage">71</span>– <span class="NLM_lpage">82</span>, <span class="refDoi"> DOI: 10.1124/jpet.116.233627</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1124%2Fjpet.116.233627" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=27189960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFyjs73E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=358&publication_year=2016&pages=71-82&author=J.+M.+Witkinauthor=J.+A.+Monnauthor=D.+D.+Schoeppauthor=X.+Liauthor=C.+Overshinerauthor=S.+N.+Mitchellauthor=G.+Carterauthor=B.+Johnsonauthor=K.+Rasmussenauthor=L.+M.+Rorick-Kehn&title=The+rapidly+acting+antidepressant+ketamine+and+the+mGlu2%2F3+receptor+antagonist+LY341495+rapidly+engage+dopaminergic+mood+circuits&doi=10.1124%2Fjpet.116.233627"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The rapidly acting antidepressant ketamine and the mGlu2/3 receptor antagonist LY341495 rapidly engage dopaminergic mood circuits</span></div><div class="casAuthors">Witkin, J. M.; Monn, J. A.; Schoepp, D. D.; Li, X.; Overshiner, C.; Mitchell, S. N.; Carter, G.; Johnson, B.; Rasmussen, K.; Rorick-Kehn, L. M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">358</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">71-82</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Ketamine is a rapidly acting antidepressant in patients with treatment-resistant depression (TRD).  Although the mechanisms underlying these effects are not fully established, inquiry to date has focused on the triggering of synaptogenesis transduction pathways via glutamatergic mechanisms.  Preclin. data suggest that blockade of metabotropic glutamate (mGlu2/3) receptors shares many overlapping features and mechanisms with ketamine and may also provide rapid efficacy for TRD patients.  Central dopamine circuitry is recognized as an end target for mood regulation and hedonic valuation and yet has been largely neglected in mechanistic studies of antidepressant-relevant effects of ketamine.  Herein, we evaluated the changes in dopaminergic neurotransmission after acute administration of ketamine and the mGlu2/3 receptor antagonist LY341495 [(2S)-2-amino-2-[(1S,2S)- 2-carboxycycloprop-1-yl]-3-(xanth-9-yl) propanoic acid ] in preclin. models using electrophysiol., neurochem., and behavioral endpoints.  When given acutely, both ketamine and LY341495, but not the selective serotonin reuptake inhibitor (SSRI) citalopram, increased the no. of spontaneously active dopamine neurons in the ventral tegmental area (VTA), increased extracellular levels of dopamine in the nucleus accumbens and prefrontal cortex, and enhanced the locomotor stimulatory effects of the dopamine D2/3 receptor agonist quinpirole.  Further, both ketamine and LY341495 reduced immobility time in the tail-suspension assay in CD1 mice, which are relatively resistant to SSRI antidepressants.  Both the VTA neuronal activation and the antidepressant phenotype induced by ketamine and LY341495 were attenuated by the a-amino-3-hydroxy-5- methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist 1,2,3,4-tetrahydro-6-nitro-2,3-dioxo- (9CI)-benzo[f]quinoxaline- 7-sulfonamide, indicating AMPA-dependent effects.  These findings provide another overlapping mechanism of action of ketamine and mGlu2/3 receptor antagonism that differentiates them from conventional antidepressants and thus support the potential rapidly acting antidepressant actions of mGlu2/3 receptor antagonism in patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonDnZmZOY1HLVg90H21EOLACvtfcHk0lhNxtjMIPEIvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFyjs73E&md5=dffc0601e4cc14d711fa6291f78bf3c0</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1124%2Fjpet.116.233627&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.116.233627%26sid%3Dliteratum%253Aachs%26aulast%3DWitkin%26aufirst%3DJ.%2BM.%26aulast%3DMonn%26aufirst%3DJ.%2BA.%26aulast%3DSchoepp%26aufirst%3DD.%2BD.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DOvershiner%26aufirst%3DC.%26aulast%3DMitchell%26aufirst%3DS.%2BN.%26aulast%3DCarter%26aufirst%3DG.%26aulast%3DJohnson%26aufirst%3DB.%26aulast%3DRasmussen%26aufirst%3DK.%26aulast%3DRorick-Kehn%26aufirst%3DL.%2BM.%26atitle%3DThe%2520rapidly%2520acting%2520antidepressant%2520ketamine%2520and%2520the%2520mGlu2%252F3%2520receptor%2520antagonist%2520LY341495%2520rapidly%2520engage%2520dopaminergic%2520mood%2520circuits%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2016%26volume%3D358%26spage%3D71%26epage%3D82%26doi%3D10.1124%2Fjpet.116.233627" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Willner, P.</span></span> <span> </span><span class="NLM_article-title">The chronic mild stress (CMS) model of depression: history, evaluation and usage</span>. <i>Neurobiology of Stress</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">78</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1016/j.ynstr.2016.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.ynstr.2016.08.002" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2017&pages=78-93&author=P.+Willner&title=The+chronic+mild+stress+%28CMS%29+model+of+depression%3A+history%2C+evaluation+and+usage&doi=10.1016%2Fj.ynstr.2016.08.002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.ynstr.2016.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ynstr.2016.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DWillner%26aufirst%3DP.%26atitle%3DThe%2520chronic%2520mild%2520stress%2520%2528CMS%2529%2520model%2520of%2520depression%253A%2520history%252C%2520evaluation%2520and%2520usage%26jtitle%3DNeurobiology%2520of%2520Stress%26date%3D2017%26volume%3D6%26spage%3D78%26epage%3D93%26doi%3D10.1016%2Fj.ynstr.2016.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Papp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruca, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lason-Tyburkiewicz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adham, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiss, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gyertyan, I.</span></span> <span> </span><span class="NLM_article-title">Attenuation of anhedonia by cariprazine in the chronic mild stress model of depression</span>. <i>Behav. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">567</span>– <span class="NLM_lpage">574</span>, <span class="refDoi"> DOI: 10.1097/FBP.0000000000000070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1097%2FFBP.0000000000000070" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=567-574&author=M.+Pappauthor=P.+Grucaauthor=M.+Lason-Tyburkiewiczauthor=N.+Adhamauthor=B.+Kissauthor=I.+Gyertyan&title=Attenuation+of+anhedonia+by+cariprazine+in+the+chronic+mild+stress+model+of+depression&doi=10.1097%2FFBP.0000000000000070"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1097%2FFBP.0000000000000070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FFBP.0000000000000070%26sid%3Dliteratum%253Aachs%26aulast%3DPapp%26aufirst%3DM.%26aulast%3DGruca%26aufirst%3DP.%26aulast%3DLason-Tyburkiewicz%26aufirst%3DM.%26aulast%3DAdham%26aufirst%3DN.%26aulast%3DKiss%26aufirst%3DB.%26aulast%3DGyertyan%26aufirst%3DI.%26atitle%3DAttenuation%2520of%2520anhedonia%2520by%2520cariprazine%2520in%2520the%2520chronic%2520mild%2520stress%2520model%2520of%2520depression%26jtitle%3DBehav.%2520Pharmacol.%26date%3D2014%26volume%3D25%26spage%3D567%26epage%3D574%26doi%3D10.1097%2FFBP.0000000000000070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roth-Deri, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lax, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaumenhaft, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dikshtein, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yadid, G.</span></span> <span> </span><span class="NLM_article-title">Antidepressant treatment facilitates dopamine release and drug seeking behavior in a genetic animal model of depression</span>. <i>Eur. J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">485</span>– <span class="NLM_lpage">492</span>, <span class="refDoi"> DOI: 10.1111/j.1460-9568.2009.06840.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1111%2Fj.1460-9568.2009.06840.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=19614746" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A280%3ADC%252BD1MrlvFyhsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=485-492&author=I.+Roth-Deriauthor=A.+Friedmanauthor=L.+Abrahamauthor=E.+Laxauthor=Y.+Flaumenhaftauthor=Y.+Dikshteinauthor=G.+Yadid&title=Antidepressant+treatment+facilitates+dopamine+release+and+drug+seeking+behavior+in+a+genetic+animal+model+of+depression&doi=10.1111%2Fj.1460-9568.2009.06840.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Antidepressant treatment facilitates dopamine release and drug seeking behavior in a genetic animal model of depression</span></div><div class="casAuthors">Roth-Deri Ilana; Friedman Alexander; Abraham Lital; Lax Elad; Flaumenhaft Yakov; Dikshtein Yahav; Yadid Gal</div><div class="citationInfo"><span class="NLM_cas:title">The European journal of neuroscience</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">485-92</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Anhedonia and lack of motivation are core symptoms of depression.  In contrast, hyper-motivation and euphoria characterize intoxicated states.  In order to explore the relationship between these two behavioral states we examined cocaine self-administration tasks in an animal model of depression [Flinders Sensitive Line (FSL) rats].  We found that FSL rats exhibit sub-sensitivity in their cocaine-seeking behavior, which was normalized following a chronic treatment with the antidepressant desipramine.  However, when the cocaine dosage was increased, FSL rats demonstrated a similar cocaine-seeking behavior to that of controls.  In light of dopamine's central role in modulating cocaine reinforcement, we examined dopaminergic neurotransmission in the nucleus accumbens, a brain region implicated in the rewarding and hedonic effects of substances of misuse.  FSL rats exhibited low but dose-dependent increases in extracellular levels of dopamine in the nucleus accumbens after acute intravenous cocaine injection.  Furthermore, by using the dopamine transporter blocker GBR-12909 we were able to demonstrate that the low extracellular dopamine levels, observed in FSL rats, were a consequence of low dopamine release in the nucleus accumbens, as opposed to the possibility of increased uptake.  Treatment of FSL rats with the antidepressant desipramine raised cocaine- and GBR-12909-induced dopamine release to the level of controls.  This treatment also resulted in increased cocaine-seeking behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQgn1gwo4Mv7ENoizSOkG_FfW6udTcc2eY86AgHDnw6krntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MrlvFyhsg%253D%253D&md5=e0138cd393edff20d6a34bd0d37e4cb6</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1111%2Fj.1460-9568.2009.06840.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1460-9568.2009.06840.x%26sid%3Dliteratum%253Aachs%26aulast%3DRoth-Deri%26aufirst%3DI.%26aulast%3DFriedman%26aufirst%3DA.%26aulast%3DAbraham%26aufirst%3DL.%26aulast%3DLax%26aufirst%3DE.%26aulast%3DFlaumenhaft%26aufirst%3DY.%26aulast%3DDikshtein%26aufirst%3DY.%26aulast%3DYadid%26aufirst%3DG.%26atitle%3DAntidepressant%2520treatment%2520facilitates%2520dopamine%2520release%2520and%2520drug%2520seeking%2520behavior%2520in%2520a%2520genetic%2520animal%2520model%2520of%2520depression%26jtitle%3DEur.%2520J.%2520Neurosci.%26date%3D2009%26volume%3D30%26spage%3D485%26epage%3D492%26doi%3D10.1111%2Fj.1460-9568.2009.06840.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salamone, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yohn, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Cruz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San Miguel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correa, M.</span></span> <span> </span><span class="NLM_article-title">Activational and effort-related aspects of motivation: neural mechanisms and implications for psychopathology</span>. <i>Brain</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>139</i></span>,  <span class="NLM_fpage">1325</span>– <span class="NLM_lpage">1347</span>, <span class="refDoi"> DOI: 10.1093/brain/aww050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1093%2Fbrain%2Faww050" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2016&pages=1325-1347&author=J.+D.+Salamoneauthor=S.+E.+Yohnauthor=L.+Lopez-Cruzauthor=N.+San+Miguelauthor=M.+Correa&title=Activational+and+effort-related+aspects+of+motivation%3A+neural+mechanisms+and+implications+for+psychopathology&doi=10.1093%2Fbrain%2Faww050"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1093%2Fbrain%2Faww050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbrain%252Faww050%26sid%3Dliteratum%253Aachs%26aulast%3DSalamone%26aufirst%3DJ.%2BD.%26aulast%3DYohn%26aufirst%3DS.%2BE.%26aulast%3DLopez-Cruz%26aufirst%3DL.%26aulast%3DSan%2BMiguel%26aufirst%3DN.%26aulast%3DCorrea%26aufirst%3DM.%26atitle%3DActivational%2520and%2520effort-related%2520aspects%2520of%2520motivation%253A%2520neural%2520mechanisms%2520and%2520implications%2520for%2520psychopathology%26jtitle%3DBrain%26date%3D2016%26volume%3D139%26spage%3D1325%26epage%3D1347%26doi%3D10.1093%2Fbrain%2Faww050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yohn, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gogoj, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haque, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Cruz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haley, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huxley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baskin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salamone, J. D.</span></span> <span> </span><span class="NLM_article-title">Evaluation of the effort-related motivational effects of the novel dopamine uptake inhibitor PRX-14040</span>. <i>Pharmacol., Biochem. Behav.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>148</i></span>,  <span class="NLM_fpage">84</span>– <span class="NLM_lpage">91</span>, <span class="refDoi"> DOI: 10.1016/j.pbb.2016.06.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.pbb.2016.06.004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2016&pages=84-91&author=S.+E.+Yohnauthor=A.+Gogojauthor=A.+Haqueauthor=L.+Lopez-Cruzauthor=A.+Haleyauthor=P.+Huxleyauthor=P.+Baskinauthor=M.+Correaauthor=J.+D.+Salamone&title=Evaluation+of+the+effort-related+motivational+effects+of+the+novel+dopamine+uptake+inhibitor+PRX-14040&doi=10.1016%2Fj.pbb.2016.06.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.pbb.2016.06.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pbb.2016.06.004%26sid%3Dliteratum%253Aachs%26aulast%3DYohn%26aufirst%3DS.%2BE.%26aulast%3DGogoj%26aufirst%3DA.%26aulast%3DHaque%26aufirst%3DA.%26aulast%3DLopez-Cruz%26aufirst%3DL.%26aulast%3DHaley%26aufirst%3DA.%26aulast%3DHuxley%26aufirst%3DP.%26aulast%3DBaskin%26aufirst%3DP.%26aulast%3DCorrea%26aufirst%3DM.%26aulast%3DSalamone%26aufirst%3DJ.%2BD.%26atitle%3DEvaluation%2520of%2520the%2520effort-related%2520motivational%2520effects%2520of%2520the%2520novel%2520dopamine%2520uptake%2520inhibitor%2520PRX-14040%26jtitle%3DPharmacol.%252C%2520Biochem.%2520Behav.%26date%3D2016%26volume%3D148%26spage%3D84%26epage%3D91%26doi%3D10.1016%2Fj.pbb.2016.06.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Randall, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Podurgiel, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yohn, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowland, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Cruz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salamone, J. D.</span></span> <span> </span><span class="NLM_article-title">Bupropion increases selection of high effort activity in rats tested on a progressive ratio/chow feeding choice procedure: implications for treatment of effort-related motivational symptoms</span>. <i>Int. J. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">pyu017</span>, <span class="refDoi"> DOI: 10.1093/ijnp/pyu017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1093%2Fijnp%2Fpyu017" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2015&pages=pyu017&author=P.+A.+Randallauthor=C.+A.+Leeauthor=S.+J.+Podurgielauthor=E.+Hartauthor=S.+E.+Yohnauthor=M.+Jonesauthor=M.+Rowlandauthor=L.+Lopez-Cruzauthor=M.+Correaauthor=J.+D.+Salamone&title=Bupropion+increases+selection+of+high+effort+activity+in+rats+tested+on+a+progressive+ratio%2Fchow+feeding+choice+procedure%3A+implications+for+treatment+of+effort-related+motivational+symptoms&doi=10.1093%2Fijnp%2Fpyu017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1093%2Fijnp%2Fpyu017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fijnp%252Fpyu017%26sid%3Dliteratum%253Aachs%26aulast%3DRandall%26aufirst%3DP.%2BA.%26aulast%3DLee%26aufirst%3DC.%2BA.%26aulast%3DPodurgiel%26aufirst%3DS.%2BJ.%26aulast%3DHart%26aufirst%3DE.%26aulast%3DYohn%26aufirst%3DS.%2BE.%26aulast%3DJones%26aufirst%3DM.%26aulast%3DRowland%26aufirst%3DM.%26aulast%3DLopez-Cruz%26aufirst%3DL.%26aulast%3DCorrea%26aufirst%3DM.%26aulast%3DSalamone%26aufirst%3DJ.%2BD.%26atitle%3DBupropion%2520increases%2520selection%2520of%2520high%2520effort%2520activity%2520in%2520rats%2520tested%2520on%2520a%2520progressive%2520ratio%252Fchow%2520feeding%2520choice%2520procedure%253A%2520implications%2520for%2520treatment%2520of%2520effort-related%2520motivational%2520symptoms%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2015%26volume%3D18%26spage%3Dpyu017%26doi%3D10.1093%2Fijnp%2Fpyu017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Owesson-White, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheer, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beyene, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carelli, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wightman, R. M.</span></span> <span> </span><span class="NLM_article-title">Dynamic changes in accumbens dopamine correlate with learning during intracranial self-stimulation</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">11957</span>– <span class="NLM_lpage">11962</span>, <span class="refDoi"> DOI: 10.1073/pnas.0803896105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1073%2Fpnas.0803896105" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=11957-11962&author=C.+A.+Owesson-Whiteauthor=J.+F.+Cheerauthor=M.+Beyeneauthor=R.+M.+Carelliauthor=R.+M.+Wightman&title=Dynamic+changes+in+accumbens+dopamine+correlate+with+learning+during+intracranial+self-stimulation&doi=10.1073%2Fpnas.0803896105"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0803896105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0803896105%26sid%3Dliteratum%253Aachs%26aulast%3DOwesson-White%26aufirst%3DC.%2BA.%26aulast%3DCheer%26aufirst%3DJ.%2BF.%26aulast%3DBeyene%26aufirst%3DM.%26aulast%3DCarelli%26aufirst%3DR.%2BM.%26aulast%3DWightman%26aufirst%3DR.%2BM.%26atitle%3DDynamic%2520changes%2520in%2520accumbens%2520dopamine%2520correlate%2520with%2520learning%2520during%2520intracranial%2520self-stimulation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D11957%26epage%3D11962%26doi%3D10.1073%2Fpnas.0803896105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leitl, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banks, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blough, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negus, S. S.</span></span> <span> </span><span class="NLM_article-title">Effects of the triple monoamine uptake inhibitor amitifadine on pain-related depression of behavior and mesolimbic dopamine release in rats</span>. <i>Pain</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>156</i></span>,  <span class="NLM_fpage">175</span>– <span class="NLM_lpage">184</span>, <span class="refDoi"> DOI: 10.1016/j.pain.0000000000000018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.pain.0000000000000018" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2015&pages=175-184&author=L.+L.+Millerauthor=M.+D.+Leitlauthor=M.+L.+Banksauthor=B.+E.+Bloughauthor=S.+S.+Negus&title=Effects+of+the+triple+monoamine+uptake+inhibitor+amitifadine+on+pain-related+depression+of+behavior+and+mesolimbic+dopamine+release+in+rats&doi=10.1016%2Fj.pain.0000000000000018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.pain.0000000000000018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pain.0000000000000018%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DL.%2BL.%26aulast%3DLeitl%26aufirst%3DM.%2BD.%26aulast%3DBanks%26aufirst%3DM.%2BL.%26aulast%3DBlough%26aufirst%3DB.%2BE.%26aulast%3DNegus%26aufirst%3DS.%2BS.%26atitle%3DEffects%2520of%2520the%2520triple%2520monoamine%2520uptake%2520inhibitor%2520amitifadine%2520on%2520pain-related%2520depression%2520of%2520behavior%2520and%2520mesolimbic%2520dopamine%2520release%2520in%2520rats%26jtitle%3DPain%26date%3D2015%26volume%3D156%26spage%3D175%26epage%3D184%26doi%3D10.1016%2Fj.pain.0000000000000018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basso, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallagher, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bratcher, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brioni, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreland, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drescher, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rueter, L. E.</span></span> <span> </span><span class="NLM_article-title">Antidepressant-like effect of D(2/3) receptor-, but not D(4) receptor-activation in the rat forced swim test</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">1257</span>– <span class="NLM_lpage">1268</span>, <span class="refDoi"> DOI: 10.1038/sj.npp.1300677</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1038%2Fsj.npp.1300677" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2005&pages=1257-1268&author=A.+M.+Bassoauthor=K.+B.+Gallagherauthor=N.+A.+Bratcherauthor=J.+D.+Brioniauthor=R.+B.+Morelandauthor=G.+C.+Hsiehauthor=K.+Drescherauthor=G.+B.+Foxauthor=M.+W.+Deckerauthor=L.+E.+Rueter&title=Antidepressant-like+effect+of+D%282%2F3%29+receptor-%2C+but+not+D%284%29+receptor-activation+in+the+rat+forced+swim+test&doi=10.1038%2Fsj.npp.1300677"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fsj.npp.1300677&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.npp.1300677%26sid%3Dliteratum%253Aachs%26aulast%3DBasso%26aufirst%3DA.%2BM.%26aulast%3DGallagher%26aufirst%3DK.%2BB.%26aulast%3DBratcher%26aufirst%3DN.%2BA.%26aulast%3DBrioni%26aufirst%3DJ.%2BD.%26aulast%3DMoreland%26aufirst%3DR.%2BB.%26aulast%3DHsieh%26aufirst%3DG.%2BC.%26aulast%3DDrescher%26aufirst%3DK.%26aulast%3DFox%26aufirst%3DG.%2BB.%26aulast%3DDecker%26aufirst%3DM.%2BW.%26aulast%3DRueter%26aufirst%3DL.%2BE.%26atitle%3DAntidepressant-like%2520effect%2520of%2520D%25282%252F3%2529%2520receptor-%252C%2520but%2520not%2520D%25284%2529%2520receptor-activation%2520in%2520the%2520rat%2520forced%2520swim%2520test%26jtitle%3DNeuropsychopharmacology%26date%3D2005%26volume%3D30%26spage%3D1257%26epage%3D1268%26doi%3D10.1038%2Fsj.npp.1300677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prica, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hascoet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourin, M.</span></span> <span> </span><span class="NLM_article-title">Is co-administration of bupropion with SSRIs and SNRIs in forced swimming test in mice, predictive of efficacy in resistant depression?</span>. <i>Behav. Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>194</i></span>,  <span class="NLM_fpage">92</span>– <span class="NLM_lpage">99</span>, <span class="refDoi"> DOI: 10.1016/j.bbr.2008.06.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.bbr.2008.06.028" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=194&publication_year=2008&pages=92-99&author=C.+Pricaauthor=M.+Hascoetauthor=M.+Bourin&title=Is+co-administration+of+bupropion+with+SSRIs+and+SNRIs+in+forced+swimming+test+in+mice%2C+predictive+of+efficacy+in+resistant+depression%3F&doi=10.1016%2Fj.bbr.2008.06.028"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.bbr.2008.06.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbr.2008.06.028%26sid%3Dliteratum%253Aachs%26aulast%3DPrica%26aufirst%3DC.%26aulast%3DHascoet%26aufirst%3DM.%26aulast%3DBourin%26aufirst%3DM.%26atitle%3DIs%2520co-administration%2520of%2520bupropion%2520with%2520SSRIs%2520and%2520SNRIs%2520in%2520forced%2520swimming%2520test%2520in%2520mice%252C%2520predictive%2520of%2520efficacy%2520in%2520resistant%2520depression%253F%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D2008%26volume%3D194%26spage%3D92%26epage%3D99%26doi%3D10.1016%2Fj.bbr.2008.06.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kunugi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hori, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, S.</span></span> <span> </span><span class="NLM_article-title">Biochemical markers subtyping major depressive disorder</span>. <i>Psychiatry Clin. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">597</span>– <span class="NLM_lpage">608</span>, <span class="refDoi"> DOI: 10.1111/pcn.12299</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1111%2Fpcn.12299" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=25825158" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A280%3ADC%252BC2MnptlyjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2015&pages=597-608&author=H.+Kunugiauthor=H.+Horiauthor=S.+Ogawa&title=Biochemical+markers+subtyping+major+depressive+disorder&doi=10.1111%2Fpcn.12299"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Biochemical markers subtyping major depressive disorder</span></div><div class="casAuthors">Kunugi Hiroshi; Hori Hiroaki; Ogawa Shintaro</div><div class="citationInfo"><span class="NLM_cas:title">Psychiatry and clinical neurosciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">597-608</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The pathophysiology of major depressive disorder (MDD) remains elusive, and there is no established biochemical marker used in the daily clinical setting.  This situation may result in part from the heterogeneity of MDD, which might include heterogeneous subgroups with different biological mechanisms.  In this review, we discuss three promising biological systems/markers to potentially subtype MDD: the dopamine system, the hypothalamic-pituitary-adrenal axis, and chronic inflammatory markers.  Several lines of evidence suggest that a facet of MDD is a dopamine agonist-responsive subtype.  Focusing on the hypothalamic-pituitary-adrenal axis, depressive spectrum disorders show hypercortisolism to hypocortisolism, which could be detected by hormonal challenge tests, such as the dexamethasone/corticotrophin-releasing hormone test.  Finally, accumulating evidence suggests that at least some MDD patients show characteristics similar to those of chronic inflammatory diseases, including neuroinflammatory markers and reduced tryptophan due to the increased activation of the tryptophan-kynurenine pathway.  Future studies should examine the inter-relations between these systems/markers to subtype and integrate the pathophysiology of MDD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ6poPxhApJJ_6BottYdIAWfW6udTcc2eY68VAkHBgC67ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MnptlyjsQ%253D%253D&md5=8dc0f08e0fca8f51c5d4b0588baeda32</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1111%2Fpcn.12299&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fpcn.12299%26sid%3Dliteratum%253Aachs%26aulast%3DKunugi%26aufirst%3DH.%26aulast%3DHori%26aufirst%3DH.%26aulast%3DOgawa%26aufirst%3DS.%26atitle%3DBiochemical%2520markers%2520subtyping%2520major%2520depressive%2520disorder%26jtitle%3DPsychiatry%2520Clin.%2520Neurosci.%26date%3D2015%26volume%3D69%26spage%3D597%26epage%3D608%26doi%3D10.1111%2Fpcn.12299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pizzagalli, D. A.</span></span> <span> </span><span class="NLM_article-title">Depression, stress, and anhedonia: toward a synthesis and integrated model</span>. <i>Annu. Rev. Clin. Psychol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">393</span>– <span class="NLM_lpage">423</span>, <span class="refDoi"> DOI: 10.1146/annurev-clinpsy-050212-185606</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1146%2Fannurev-clinpsy-050212-185606" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=24471371" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A280%3ADC%252BC2czpslCnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=393-423&author=D.+A.+Pizzagalli&title=Depression%2C+stress%2C+and+anhedonia%3A+toward+a+synthesis+and+integrated+model&doi=10.1146%2Fannurev-clinpsy-050212-185606"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Depression, stress, and anhedonia: toward a synthesis and integrated model</span></div><div class="casAuthors">Pizzagalli Diego A</div><div class="citationInfo"><span class="NLM_cas:title">Annual review of clinical psychology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">393-423</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Depression is a significant public health problem, but its etiology and pathophysiology remain poorly understood.  Such incomplete understanding likely arises from the fact that depression encompasses a heterogeneous set of disorders.  To overcome these limitations, renewed interest in intermediate phenotypes (endophenotypes) has resurfaced, and anhedonia has emerged as one of the most promising endophenotypes of depression.  Here, a heuristic model is presented postulating that anhedonia arises from dysfunctional interactions between stress and brain reward systems.  To this end, we review and integrate three bodies of independent literature investigating the role of (a) anhedonia, (b) dopamine, and (c) stress in depression.  In a fourth section, we summarize animal data indicating that stress negatively affects mesocorticolimbic dopaminergic pathways critically implicated in incentive motivation and reinforcement learning.  In the last section, we provide a synthesis of these four literatures, present initial evidence consistent with our model, and discuss directions for future research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTfst3_r_GWVvx2phytoz6_fW6udTcc2eY68VAkHBgC67ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2czpslCnsQ%253D%253D&md5=71de6f8fd41080e98492ae472e5d75e3</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1146%2Fannurev-clinpsy-050212-185606&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-clinpsy-050212-185606%26sid%3Dliteratum%253Aachs%26aulast%3DPizzagalli%26aufirst%3DD.%2BA.%26atitle%3DDepression%252C%2520stress%252C%2520and%2520anhedonia%253A%2520toward%2520a%2520synthesis%2520and%2520integrated%2520model%26jtitle%3DAnnu.%2520Rev.%2520Clin.%2520Psychol.%26date%3D2014%26volume%3D10%26spage%3D393%26epage%3D423%26doi%3D10.1146%2Fannurev-clinpsy-050212-185606" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whitton, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treadway, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizzagalli, D. A.</span></span> <span> </span><span class="NLM_article-title">Reward processing dysfunction in major depression, bipolar disorder and schizophrenia</span>. <i>Curr. Opin. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1097/YCO.0000000000000122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1097%2FYCO.0000000000000122" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=25415499" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A280%3ADC%252BC2M3pvF2htg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2015&pages=7-12&author=A.+E.+Whittonauthor=M.+T.+Treadwayauthor=D.+A.+Pizzagalli&title=Reward+processing+dysfunction+in+major+depression%2C+bipolar+disorder+and+schizophrenia&doi=10.1097%2FYCO.0000000000000122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Reward processing dysfunction in major depression, bipolar disorder and schizophrenia</span></div><div class="casAuthors">Whitton Alexis E; Treadway Michael T; Pizzagalli Diego A</div><div class="citationInfo"><span class="NLM_cas:title">Current opinion in psychiatry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-12</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE OF REVIEW:  This article reviews the recent literature on reward processing dysfunction in major depression (MDD), bipolar disorder and schizophrenia, with a focus on approach motivation, reward learning and reward-based decision-making.  RECENT FINDINGS:  Emerging evidence indicates the presence of reward processing abnormalities across all three disorders, supporting a transdiagnostic approach.  In particular, findings are consistent with a role of abnormal phasic striatal dopamine signaling, which is critical for reinforcement learning, efficient mobilization of effort to obtain reward and allocation of attention to reward-predictive cues.  Specifically, reward-related striatal signaling appears blunted in MDD and the negative symptoms of schizophrenia, elevated in bipolar (hypo)mania, and contextually misallocated in the positive symptoms of psychosis.  However, whether shared or distinct pathophysiological mechanisms contribute to abnormal striatal signaling across the three disorders remains unknown.  SUMMARY:  New evidence of reward processing abnormalities in MDD, bipolar disorder and schizophrenia has led to a greater understanding of the neural processes associated with symptomatology common across these conditions (e.g., anhedonia).  Dissecting various subcomponents of reward processing that map onto partially different neurobiological pathways and investigating their dysregulation in different psychiatric disorders holds promise for developing more targeted, and hopefully efficacious treatment and intervention strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSw-jGaujpTwjQLBVDQn4bCfW6udTcc2eY68VAkHBgC67ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M3pvF2htg%253D%253D&md5=415041a6c26eff7255daa06d33ae253e</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1097%2FYCO.0000000000000122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FYCO.0000000000000122%26sid%3Dliteratum%253Aachs%26aulast%3DWhitton%26aufirst%3DA.%2BE.%26aulast%3DTreadway%26aufirst%3DM.%2BT.%26aulast%3DPizzagalli%26aufirst%3DD.%2BA.%26atitle%3DReward%2520processing%2520dysfunction%2520in%2520major%2520depression%252C%2520bipolar%2520disorder%2520and%2520schizophrenia%26jtitle%3DCurr.%2520Opin.%2520Psychiatry%26date%3D2015%26volume%3D28%26spage%3D7%26epage%3D12%26doi%3D10.1097%2FYCO.0000000000000122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wardle, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treadway, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayo, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zald, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Wit, H.</span></span> <span> </span><span class="NLM_article-title">Amping up effort: effects of d-amphetamine on human effort-based decision-making</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">16597</span>– <span class="NLM_lpage">16602</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.4387-11.2011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1523%2FJNEUROSCI.4387-11.2011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=22090487" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFaksL%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2011&pages=16597-16602&author=M.+C.+Wardleauthor=M.+T.+Treadwayauthor=L.+M.+Mayoauthor=D.+H.+Zaldauthor=H.+de+Wit&title=Amping+up+effort%3A+effects+of+d-amphetamine+on+human+effort-based+decision-making&doi=10.1523%2FJNEUROSCI.4387-11.2011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Amping up effort: effects of d-amphetamine on human effort-based decision-making</span></div><div class="casAuthors">Wardle, Margaret C.; Treadway, Michael T.; Mayo, Leah M.; Zald, David H.; de Wit, Harriet</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">16597-16602</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Animal studies suggest the neurotransmitter dopamine (DA) plays an important role in decision-making.  In rats, DA depletion decreases tolerance for effort and probability costs, while drugs enhancing DA increase tolerance for these costs.  However, data regarding the effect of DA manipulations on effort and probability costs in humans remain scarce.  The current study examd. acute effects of d-amphetamine, an indirect DA agonist, on willingness of healthy human volunteers to exert effort for monetary rewards at varying levels of reward value and reward probability.  Based on preclin. research, we predicted amphetamine would increase exertion of effort, particularly when reward probability was low.  Over three sessions, 17 healthy normal adults received placebo, d-amphetamine 10 mg, and 20 mg under counterbalanced double-blind conditions and completed the Effort Expenditure for Rewards Task.  Consistent with predictions, amphetamine enhanced willingness to exert effort, particularly when reward probability was lower.  Amphetamine did not alter effects of reward magnitude on willingness to exert effort.  Amphetamine sped task performance, but its psychomotor effects were not strongly related to its effects on decision-making.  This is the first demonstration in humans that dopaminergic manipulations alter willingness to exert effort for rewards.  These findings help elucidate neurochem. substrates of choice, with implications for neuropsychiatric diseases characterized by dopaminergic dysfunction and motivational deficits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1-ydDs_QpD7Vg90H21EOLACvtfcHk0ljcaCGdweRH0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFaksL%252FF&md5=7a965ddd1b4065ee5c1980b14add5ac3</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.4387-11.2011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.4387-11.2011%26sid%3Dliteratum%253Aachs%26aulast%3DWardle%26aufirst%3DM.%2BC.%26aulast%3DTreadway%26aufirst%3DM.%2BT.%26aulast%3DMayo%26aufirst%3DL.%2BM.%26aulast%3DZald%26aufirst%3DD.%2BH.%26aulast%3Dde%2BWit%26aufirst%3DH.%26atitle%3DAmping%2520up%2520effort%253A%2520effects%2520of%2520d-amphetamine%2520on%2520human%2520effort-based%2520decision-making%26jtitle%3DJ.%2520Neurosci.%26date%3D2011%26volume%3D31%26spage%3D16597%26epage%3D16602%26doi%3D10.1523%2FJNEUROSCI.4387-11.2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">D’Ostilio, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garraux, G.</span></span> <span> </span><span class="NLM_article-title">The network model of depression as a basis for new therapeutic strategies for treating major depressive disorder in Parkinson’s disease</span>. <i>Front. Hum. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">161</span>, <span class="refDoi"> DOI: 10.3389/fnhum.2016.00161</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.3389%2Ffnhum.2016.00161" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=27148016" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A280%3ADC%252BC28bms1enug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=161&author=K.+D%E2%80%99Ostilioauthor=G.+Garraux&title=The+network+model+of+depression+as+a+basis+for+new+therapeutic+strategies+for+treating+major+depressive+disorder+in+Parkinson%E2%80%99s+disease&doi=10.3389%2Ffnhum.2016.00161"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">The Network Model of Depression as a Basis for New Therapeutic Strategies for Treating Major Depressive Disorder in Parkinson's Disease</span></div><div class="casAuthors">D'Ostilio Kevin; Garraux Gaetan</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in human neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">161</span>
        ISSN:<span class="NLM_cas:issn">1662-5161</span>.
    </div><div class="casAbstract">The high prevalence of major depressive disorder in people with Parkinson's disease (PD), its negative impact on health-related quality of life and the low response rate to conventional pharmacological therapies call to seek innovative treatments.  Here, we review the new approaches for treating major depressive disorder in patients with PD within the framework of the network model of depression.  According to this model, major depressive disorder reflects maladaptive neuronal plasticity.  Non-invasive brain stimulation (NIBS) using high frequency repetitive transcranial magnetic stimulation (rTMS) over the prefrontal cortex has been proposed as a feasible and effective strategy with minimal risk.  The neurobiological basis of its therapeutic effect may involve neuroplastic modifications in limbic and cognitive networks.  However, the way this networks reorganize might be strongly influenced by the environment.  To address this issue, we propose a combined strategy that includes NIBS together with cognitive and behavioral interventions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSqEptU8YEMxsjl5L8hwNX0fW6udTcc2eaEJAQXcoYdibntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28bms1enug%253D%253D&md5=46fffc6d6cefd0d23e9d571c40638099</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.3389%2Ffnhum.2016.00161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnhum.2016.00161%26sid%3Dliteratum%253Aachs%26aulast%3DD%25E2%2580%2599Ostilio%26aufirst%3DK.%26aulast%3DGarraux%26aufirst%3DG.%26atitle%3DThe%2520network%2520model%2520of%2520depression%2520as%2520a%2520basis%2520for%2520new%2520therapeutic%2520strategies%2520for%2520treating%2520major%2520depressive%2520disorder%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DFront.%2520Hum.%2520Neurosci.%26date%3D2016%26volume%3D10%26spage%3D161%26doi%3D10.3389%2Ffnhum.2016.00161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Treadway, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizzagalli, D. A.</span></span> <span> </span><span class="NLM_article-title">Imaging the pathophysiology of major depressive disorder - from localist models to circuit-based analysis</span>. <i>Biol. Mood Anxiety Disord.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">5</span>, <span class="refDoi"> DOI: 10.1186/2045-5380-4-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1186%2F2045-5380-4-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=24606595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlvVygsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=5&author=M.+T.+Treadwayauthor=D.+A.+Pizzagalli&title=Imaging+the+pathophysiology+of+major+depressive+disorder+-+from+localist+models+to+circuit-based+analysis&doi=10.1186%2F2045-5380-4-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Imaging the pathophysiology of major depressive disorder - from localist models to circuit-based analysis</span></div><div class="casAuthors">Treadway, Michael T.; Pizzagalli, Diego A.</div><div class="citationInfo"><span class="NLM_cas:title">Biology of Mood & Anxiety Disorders</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">5/1-5/13</span>CODEN:
                <span class="NLM_cas:coden">BMADB5</span>;
        ISSN:<span class="NLM_cas:issn">2045-5380</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">The neuroimaging literature of Major Depressive Disorder (MDD) has grown substantially over the last several decades, facilitating great advances in the identification of specific brain regions, neurotransmitter systems and networks assocd. with depressive illness.  Despite this progress, fundamental questions remain about the pathophysiol. and etiol. of MDD.  More importantly, this body of work has yet to directly influence clin. practice.  It has long been a goal for the fields of clin. psychol. and psychiatry to have a means of making objective diagnoses of mental disorders.  Frustratingly little movement has been achieved on this front, however, and the 'gold-std.' of diagnostic validity and reliability remains expert consensus.  In light of this challenge, the focus of the current review is to provide a crit. summary of key findings from different neuroimaging approaches in MDD research, including structural, functional and neurochem. imaging studies.  Following this summary, we discuss some of the current conceptual obstacles to better understanding the pathophysiol. of depression, and conclude with recommendations for future neuroimaging research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnLApEdHlBabVg90H21EOLACvtfcHk0ljcaCGdweRH0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlvVygsQ%253D%253D&md5=1802212c72c628a7af80227ed1963b77</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1186%2F2045-5380-4-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F2045-5380-4-5%26sid%3Dliteratum%253Aachs%26aulast%3DTreadway%26aufirst%3DM.%2BT.%26aulast%3DPizzagalli%26aufirst%3DD.%2BA.%26atitle%3DImaging%2520the%2520pathophysiology%2520of%2520major%2520depressive%2520disorder%2520-%2520from%2520localist%2520models%2520to%2520circuit-based%2520analysis%26jtitle%3DBiol.%2520Mood%2520Anxiety%2520Disord.%26date%3D2014%26volume%3D4%26spage%3D5%26doi%3D10.1186%2F2045-5380-4-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sarchiapone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carli, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camardese, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuomo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Giuda, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calcagni, M.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Focacci, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Risio, S.</span></span> <span> </span><span class="NLM_article-title">Dopamine transporter binding in depressed patients with anhedonia</span>. <i>Psychiatry Res., Neuroimaging</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>147</i></span>,  <span class="NLM_fpage">243</span>– <span class="NLM_lpage">248</span>, <span class="refDoi"> DOI: 10.1016/j.pscychresns.2006.03.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.pscychresns.2006.03.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=16952448" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1SqsLfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=2006&pages=243-248&author=M.+Sarchiaponeauthor=V.+Carliauthor=G.+Camardeseauthor=C.+Cuomoauthor=D.+Di+Giudaauthor=M.-L.+Calcagniauthor=C.+Focacciauthor=S.+De+Risio&title=Dopamine+transporter+binding+in+depressed+patients+with+anhedonia&doi=10.1016%2Fj.pscychresns.2006.03.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine transporter binding in depressed patients with anhedonia</span></div><div class="casAuthors">Sarchiapone, Marco; Carli, Vladimir; Camardese, Giovanni; Cuomo, Chiara; Di Giuda, Daniela; Calcagni, Maria-Lucia; Focacci, C.; De Risio, Sergio</div><div class="citationInfo"><span class="NLM_cas:title">Psychiatry Research, Neuroimaging</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">147</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">243-248</span>CODEN:
                <span class="NLM_cas:coden">PSREEK</span>;
        ISSN:<span class="NLM_cas:issn">0925-4927</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Central dopaminergic dysfunction has been widely proposed as a common neurobiol. correlate of the psychopathol. expression of anhedonia.  The dopamine transporter (DAT) is a predominantly presynaptic receptor that may play a crit. role in the pathophysiol. of dopaminergic transmission.  The aim of our study was to evaluate DAT binding in a population of depressed patients with anhedonia.  Single photon emission computed tomog. (SPECT) with the radiotracer DATSCAN was used to evaluate DAT binding in 11 depressed patients with anhedonia and 9 healthy comparison subjects.  Compared with healthy subjects, patients showed significantly lower DAT binding.  No significant correlation was found between DAT binding ratios and scores on administered psychometric tests.  These findings suggest an alteration in DAT d. in depressed patients with anhedonia that may be a primary susceptibility factor or a secondary phenomenon to reduced dopamine concn. in the synaptic cleft.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_36OsjJn1U7Vg90H21EOLACvtfcHk0ljGiiYRiTMW_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1SqsLfO&md5=83c1d2e360460bcabf6e2665230b80fb</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.pscychresns.2006.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pscychresns.2006.03.001%26sid%3Dliteratum%253Aachs%26aulast%3DSarchiapone%26aufirst%3DM.%26aulast%3DCarli%26aufirst%3DV.%26aulast%3DCamardese%26aufirst%3DG.%26aulast%3DCuomo%26aufirst%3DC.%26aulast%3DDi%2BGiuda%26aufirst%3DD.%26aulast%3DCalcagni%26aufirst%3DM.-L.%26aulast%3DFocacci%26aufirst%3DC.%26aulast%3DDe%2BRisio%26aufirst%3DS.%26atitle%3DDopamine%2520transporter%2520binding%2520in%2520depressed%2520patients%2520with%2520anhedonia%26jtitle%3DPsychiatry%2520Res.%252C%2520Neuroimaging%26date%3D2006%26volume%3D147%26spage%3D243%26epage%3D248%26doi%3D10.1016%2Fj.pscychresns.2006.03.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wooten, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beltzer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitaliano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alpert, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Normandin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Fakhri, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizzagalli, D.</span></span> <span> </span><span class="NLM_article-title">Reduced striatal dopamine transporter binding in major depressive disorder</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">527</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2015&pages=527&author=D.+Wootenauthor=F.+Goerauthor=M.+Beltzerauthor=G.+Vitalianoauthor=B.+Brennanauthor=D.+Crowleyauthor=N.+Alpertauthor=M.+Normandinauthor=G.+El+Fakhriauthor=D.+Pizzagalli&title=Reduced+striatal+dopamine+transporter+binding+in+major+depressive+disorder"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWooten%26aufirst%3DD.%26aulast%3DGoer%26aufirst%3DF.%26aulast%3DBeltzer%26aufirst%3DM.%26aulast%3DVitaliano%26aufirst%3DG.%26aulast%3DBrennan%26aufirst%3DB.%26aulast%3DCrowley%26aufirst%3DD.%26aulast%3DAlpert%26aufirst%3DN.%26aulast%3DNormandin%26aufirst%3DM.%26aulast%3DEl%2BFakhri%26aufirst%3DG.%26aulast%3DPizzagalli%26aufirst%3DD.%26atitle%3DReduced%2520striatal%2520dopamine%2520transporter%2520binding%2520in%2520major%2520depressive%2520disorder%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2015%26volume%3D56%26spage%3D527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, G.</span></span> <span> </span><span class="NLM_article-title">SPECT imaging of dopamine transporters with 99mTc-TRODAT-1 in major depression and Parkinson’s disease</span>. <i>J. Neuropsychiatry Clin. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">67</span>, <span class="refDoi"> DOI: 10.1176/appi.neuropsych.23.1.63</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1176%2Fappi.neuropsych.23.1.63" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=21304140" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A280%3ADC%252BC3M7nvVarug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2011&pages=63-67&author=H.+Wuauthor=C.+Louauthor=Z.+Huangauthor=G.+Shi&title=SPECT+imaging+of+dopamine+transporters+with+99mTc-TRODAT-1+in+major+depression+and+Parkinson%E2%80%99s+disease&doi=10.1176%2Fappi.neuropsych.23.1.63"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">SPECT imaging of dopamine transporters with (99m)Tc-TRODAT-1 in major depression and Parkinson's disease</span></div><div class="casAuthors">Wu Hao; Lou Cen; Huang Zhongke; Shi Guohua</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of neuropsychiatry and clinical neurosciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">63-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">To investigate dopamine transporter in major depressive disorder and Parkinson's disease, the authors obtained single photon emission computed tomography (SPECT) brain images from 13 patients with major depression, 17 Parkinson's disease patients, and 10 healthy volunteers by using 99mTc-TRODAT-1.  The authors found the 99mTc-TRODAT-1 radio signal in the striatum was reduced in the majority of patients with major depressive disorder, and this decrease was even more severe in patients with Parkinson's disease.  The results support the hypothesis of dopamine hypofunction in major depressive disorder and suggest that deficient dopamine transporter may be involved in the etiology of severe major depressive disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQdQKWN72VMwWx8TEN9K18QfW6udTcc2eY9dtOwowPxpLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M7nvVarug%253D%253D&md5=d3fcba4923fd053f0f0f7931f389295d</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1176%2Fappi.neuropsych.23.1.63&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.neuropsych.23.1.63%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DH.%26aulast%3DLou%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DShi%26aufirst%3DG.%26atitle%3DSPECT%2520imaging%2520of%2520dopamine%2520transporters%2520with%252099mTc-TRODAT-1%2520in%2520major%2520depression%2520and%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Neuropsychiatry%2520Clin.%2520Neurosci.%26date%3D2011%26volume%3D23%26spage%3D63%26epage%3D67%26doi%3D10.1176%2Fappi.neuropsych.23.1.63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Felger, J. C.</span></span> <span> </span><span class="NLM_article-title">The role of dopamine in inflammation-associated depression: mechanisms and therapeutic implications</span>. <i>Curr. Top. Behav. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">199</span>– <span class="NLM_lpage">219</span>, <span class="refDoi"> DOI: 10.1007/7854_2016_13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1007%2F7854_2016_13" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2016&pages=199-219&author=J.+C.+Felger&title=The+role+of+dopamine+in+inflammation-associated+depression%3A+mechanisms+and+therapeutic+implications&doi=10.1007%2F7854_2016_13"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1007%2F7854_2016_13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F7854_2016_13%26sid%3Dliteratum%253Aachs%26aulast%3DFelger%26aufirst%3DJ.%2BC.%26atitle%3DThe%2520role%2520of%2520dopamine%2520in%2520inflammation-associated%2520depression%253A%2520mechanisms%2520and%2520therapeutic%2520implications%26jtitle%3DCurr.%2520Top.%2520Behav.%2520Neurosci.%26date%3D2016%26volume%3D31%26spage%3D199%26epage%3D219%26doi%3D10.1007%2F7854_2016_13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hasler, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luckenbaugh, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyers, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldeck, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geraci, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roiser, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knutson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charney, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drevets, W. C.</span></span> <span> </span><span class="NLM_article-title">Reward processing after catecholamine depletion in unmedicated, remitted subjects with major depressive disorder</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">201</span>– <span class="NLM_lpage">205</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2009.02.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.biopsych.2009.02.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=19393989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotF2gu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2009&pages=201-205&author=G.+Haslerauthor=D.+A.+Luckenbaughauthor=J.+Snowauthor=N.+Meyersauthor=T.+Waldeckauthor=M.+Geraciauthor=J.+Roiserauthor=B.+Knutsonauthor=D.+S.+Charneyauthor=W.+C.+Drevets&title=Reward+processing+after+catecholamine+depletion+in+unmedicated%2C+remitted+subjects+with+major+depressive+disorder&doi=10.1016%2Fj.biopsych.2009.02.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Reward Processing After Catecholamine Depletion in Unmedicated, Remitted Subjects with Major Depressive Disorder</span></div><div class="casAuthors">Hasler, Gregor; Luckenbaugh, David A.; Snow, Joseph; Meyers, Noah; Waldeck, Tracy; Geraci, Marilla; Roiser, Jonathan; Knutson, Brian; Charney, Dennis S.; Drevets, Wayne C.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">201-205</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">We investigated whether performance on a reward processing task differs between fully remitted patients with major depressive disorder (MDD) and healthy control subjects after catecholamine depletion.  Seventeen unmedicated subjects with remitted MDD (RMDD) and 13 healthy control subjects underwent catecholamine depletion with oral α-methyl-para-tyrosine (AMPT) in a randomized, placebo-controlled, double-blind crossover study.  The main outcome measure was the reaction time on the monetary incentive delay (MID) task.  A diagnosis × drug interaction was evident (p = .001), which was attributable to an increase in reaction time across all incentive levels after AMPT in RMDD subjects (p = .001) but no significant AMPT effect on reaction time in control subjects (p = .17).  There was no drug × diagnosis interaction on control tasks involving working memory or attention.  In the RMDD sample the AMPT-induced depressive symptoms correlated with AMPT-induced changes in reaction time at all incentive levels of the MID task (r values = .58-.82, p < .002).  Under catecholamine depletion the RMDD subjects were robustly differentiated from control subjects by development of performance deficits on a reward processing task.  These performance deficits correlated directly with the return of depressive symptoms after AMPT administration.  The sensitivity of central reward processing systems to redns. in brain catecholamine levels thus seems to represent a trait-like marker in MDD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8v0l2pO55kbVg90H21EOLACvtfcHk0ljGiiYRiTMW_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotF2gu7g%253D&md5=fdfb73b8fc22bdd78ebd7201bc7544bf</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2009.02.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2009.02.029%26sid%3Dliteratum%253Aachs%26aulast%3DHasler%26aufirst%3DG.%26aulast%3DLuckenbaugh%26aufirst%3DD.%2BA.%26aulast%3DSnow%26aufirst%3DJ.%26aulast%3DMeyers%26aufirst%3DN.%26aulast%3DWaldeck%26aufirst%3DT.%26aulast%3DGeraci%26aufirst%3DM.%26aulast%3DRoiser%26aufirst%3DJ.%26aulast%3DKnutson%26aufirst%3DB.%26aulast%3DCharney%26aufirst%3DD.%2BS.%26aulast%3DDrevets%26aufirst%3DW.%2BC.%26atitle%3DReward%2520processing%2520after%2520catecholamine%2520depletion%2520in%2520unmedicated%252C%2520remitted%2520subjects%2520with%2520major%2520depressive%2520disorder%26jtitle%3DBiol.%2520Psychiatry%26date%3D2009%26volume%3D66%26spage%3D201%26epage%3D205%26doi%3D10.1016%2Fj.biopsych.2009.02.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Homan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neumeister, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nugent, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charney, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drevets, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasler, G.</span></span> <span> </span><span class="NLM_article-title">Serotonin versus catecholamine deficiency: behavioral and neural effects of experimental depletion in remitted depression</span>. <i>Transl. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">e532</span>, <span class="refDoi"> DOI: 10.1038/tp.2015.25</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1038%2Ftp.2015.25" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=25781231" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvFWksLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=e532&author=P.+Homanauthor=A.+Neumeisterauthor=A.+C.+Nugentauthor=D.+S.+Charneyauthor=W.+C.+Drevetsauthor=G.+Hasler&title=Serotonin+versus+catecholamine+deficiency%3A+behavioral+and+neural+effects+of+experimental+depletion+in+remitted+depression&doi=10.1038%2Ftp.2015.25"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Serotonin versus catecholamine deficiency: behavioral and neural effects of experimental depletion in remitted depression</span></div><div class="casAuthors">Homan, P.; Neumeister, A.; Nugent, A. C.; Charney, D. S.; Drevets, W. C.; Hasler, G.</div><div class="citationInfo"><span class="NLM_cas:title">Translational Psychiatry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e532</span>CODEN:
                <span class="NLM_cas:coden">TPRSCF</span>;
        ISSN:<span class="NLM_cas:issn">2158-3188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Despite immense efforts into development of new antidepressant drugs, the increases of serotoninergic and catecholaminergic neurotransmission have remained the two major pharmacodynamic principles of current drug treatments for depression.  Consequently, psychopathol. or biol. markers that predict response to drugs that selectively increase serotonin and/or catecholamine neurotransmission hold the potential to optimize the prescriber's selection among currently available treatment options.  The aim of this study was to elucidate the differential symptomatol. and neurophysiol. in response to redns. in serotonergic vs. catecholaminergic neurotransmission in subjects at high risk of depression recurrence.  Using identical neuroimaging procedures with [18F] fluorodeoxyglucose positron emission tomog. after tryptophan depletion (TD) and catecholamine depletion (CD), subjects with remitted depression were compared with healthy controls in a double-blind, randomized, crossover design.  Although TD induced significantly more depressed mood, sadness and hopelessness than CD, CD induced more inactivity, concn. difficulties, lassitude and somatic anxiety than TD.  CD specifically increased glucose metab. in the bilateral ventral striatum and decreased glucose metab. in the bilateral orbitofrontal cortex, whereas TD specifically increased metab. in the right prefrontal cortex and the posterior cingulate cortex.  Although we found direct assocns. between changes in brain metab. and induced depressive symptoms following CD, the relationship between neural activity and symptoms was less clear after TD.  In conclusion, this study showed that serotonin and catecholamines have common and differential roles in the pathophysiol. of depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqonMopJoOLrVg90H21EOLACvtfcHk0lij3dIt0JgB6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvFWksLw%253D&md5=e62f3ee74522091e1750cb3a94f384b8</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Ftp.2015.25&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Ftp.2015.25%26sid%3Dliteratum%253Aachs%26aulast%3DHoman%26aufirst%3DP.%26aulast%3DNeumeister%26aufirst%3DA.%26aulast%3DNugent%26aufirst%3DA.%2BC.%26aulast%3DCharney%26aufirst%3DD.%2BS.%26aulast%3DDrevets%26aufirst%3DW.%2BC.%26aulast%3DHasler%26aufirst%3DG.%26atitle%3DSerotonin%2520versus%2520catecholamine%2520deficiency%253A%2520behavioral%2520and%2520neural%2520effects%2520of%2520experimental%2520depletion%2520in%2520remitted%2520depression%26jtitle%3DTransl.%2520Psychiatry%26date%3D2015%26volume%3D5%26spage%3De532%26doi%3D10.1038%2Ftp.2015.25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baumeister, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uzelac, S. M.</span></span> <span> </span><span class="NLM_article-title">The myth of reserpine-induced depression: role in the historical development of the monoamine hypothesis</span>. <i>J. Hist. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">220</span>, <span class="refDoi"> DOI: 10.1076/jhin.12.2.207.15535</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1076%2Fjhin.12.2.207.15535" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=12953623" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A280%3ADC%252BD3svhsVyhtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2003&pages=207-220&author=A.+A.+Baumeisterauthor=M.+F.+Hawkinsauthor=S.+M.+Uzelac&title=The+myth+of+reserpine-induced+depression%3A+role+in+the+historical+development+of+the+monoamine+hypothesis&doi=10.1076%2Fjhin.12.2.207.15535"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">The myth of reserpine-induced depression: role in the historical development of the monoamine hypothesis</span></div><div class="casAuthors">Baumeister Alan A; Hawkins Mike F; Uzelac Sarah M</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the history of the neurosciences</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">207-20</span>
        ISSN:<span class="NLM_cas:issn">0964-704X</span>.
    </div><div class="casAbstract">For five decades it has been generally accepted that reserpine, an antihypertensive and antipsychotic drug, causes depression.  The discovery that reserpine depletes brain monoamines was an important factor in the development of the monoamine hypothesis of depression, and it continues to be widely cited in support of this hypothesis.  The present paper argues that, contrary to prevailing belief, reserpine is not depressogenic.  The reason for perpetuation of this myth is reluctance to discard the monoamine hypothesis.  This hypothesis ushered the modern biochemical paradigm into psychiatry and is still of great importance.  It serves as a heuristic to guide research, it enhances psychiatry's prestige, and it helps to validate and promote drug therapy for depression and other mental disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSNRpUUIQyeTZQHPYJuLg8TfW6udTcc2eaS4HGTgH1mq7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3svhsVyhtA%253D%253D&md5=c6270bc360ecf43ea8468732e282004c</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1076%2Fjhin.12.2.207.15535&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1076%252Fjhin.12.2.207.15535%26sid%3Dliteratum%253Aachs%26aulast%3DBaumeister%26aufirst%3DA.%2BA.%26aulast%3DHawkins%26aufirst%3DM.%2BF.%26aulast%3DUzelac%26aufirst%3DS.%2BM.%26atitle%3DThe%2520myth%2520of%2520reserpine-induced%2520depression%253A%2520role%2520in%2520the%2520historical%2520development%2520of%2520the%2520monoamine%2520hypothesis%26jtitle%3DJ.%2520Hist.%2520Neurosci.%26date%3D2003%26volume%3D12%26spage%3D207%26epage%3D220%26doi%3D10.1076%2Fjhin.12.2.207.15535" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zajecka, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zajecka, A. M.</span></span> <span> </span><span class="NLM_article-title">A clinical overview of monoamine oxidase inhibitors: pharmacological profile, efficacy, safety/tolerability, and strategies for successful outcomes in the management of major depressive disorders</span>. <i>Psychiatr. Ann.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">513</span>– <span class="NLM_lpage">523</span>, <span class="refDoi"> DOI: 10.3928/00485713-20141106-07</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.3928%2F00485713-20141106-07" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2014&pages=513-523&author=J.+M.+Zajeckaauthor=A.+M.+Zajecka&title=A+clinical+overview+of+monoamine+oxidase+inhibitors%3A+pharmacological+profile%2C+efficacy%2C+safety%2Ftolerability%2C+and+strategies+for+successful+outcomes+in+the+management+of+major+depressive+disorders&doi=10.3928%2F00485713-20141106-07"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.3928%2F00485713-20141106-07&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3928%252F00485713-20141106-07%26sid%3Dliteratum%253Aachs%26aulast%3DZajecka%26aufirst%3DJ.%2BM.%26aulast%3DZajecka%26aufirst%3DA.%2BM.%26atitle%3DA%2520clinical%2520overview%2520of%2520monoamine%2520oxidase%2520inhibitors%253A%2520pharmacological%2520profile%252C%2520efficacy%252C%2520safety%252Ftolerability%252C%2520and%2520strategies%2520for%2520successful%2520outcomes%2520in%2520the%2520management%2520of%2520major%2520depressive%2520disorders%26jtitle%3DPsychiatr.%2520Ann.%26date%3D2014%26volume%3D44%26spage%3D513%26epage%3D523%26doi%3D10.3928%2F00485713-20141106-07" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shulman, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrmann, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, S. E.</span></span> <span> </span><span class="NLM_article-title">Current place of monoamine oxidase inhibitors in the treatment of depression</span>. <i>CNS Drugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">789</span>– <span class="NLM_lpage">797</span>, <span class="refDoi"> DOI: 10.1007/s40263-013-0097-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1007%2Fs40263-013-0097-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=789-797&author=K.+I.+Shulmanauthor=N.+Herrmannauthor=S.+E.+Walker&title=Current+place+of+monoamine+oxidase+inhibitors+in+the+treatment+of+depression&doi=10.1007%2Fs40263-013-0097-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1007%2Fs40263-013-0097-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40263-013-0097-3%26sid%3Dliteratum%253Aachs%26aulast%3DShulman%26aufirst%3DK.%2BI.%26aulast%3DHerrmann%26aufirst%3DN.%26aulast%3DWalker%26aufirst%3DS.%2BE.%26atitle%3DCurrent%2520place%2520of%2520monoamine%2520oxidase%2520inhibitors%2520in%2520the%2520treatment%2520of%2520depression%26jtitle%3DCNS%2520Drugs%26date%3D2013%26volume%3D27%26spage%3D789%26epage%3D797%26doi%3D10.1007%2Fs40263-013-0097-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papakostas, G. I.</span></span> <span> </span><span class="NLM_article-title">Resolution of sleepiness and fatigue: a comparison of bupropion and selective serotonin reuptake inhibitors in subjects with major depressive disorder achieving remission at doses approved in the European Union</span>. <i>J. Psychopharmacol. (London, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">118</span>– <span class="NLM_lpage">124</span>, <span class="refDoi"> DOI: 10.1177/0269881113514878</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1177%2F0269881113514878" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=24352716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslWgsb7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2014&pages=118-124&author=J.+A.+Cooperauthor=V.+L.+Tuckerauthor=G.+I.+Papakostas&title=Resolution+of+sleepiness+and+fatigue%3A+a+comparison+of+bupropion+and+selective+serotonin+reuptake+inhibitors+in+subjects+with+major+depressive+disorder+achieving+remission+at+doses+approved+in+the+European+Union&doi=10.1177%2F0269881113514878"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Resolution of sleepiness and fatigue: A comparison of bupropion and selective serotonin reuptake inhibitors in subjects with major depressive disorder achieving remission at doses approved in the European Union</span></div><div class="casAuthors">Cooper, James A.; Tucker, Vivian L.; Papakostas, George I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Psychopharmacology (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">118-124, 7</span>CODEN:
                <span class="NLM_cas:coden">JOPSEQ</span>;
        ISSN:<span class="NLM_cas:issn">0269-8811</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">Unlike selective serotonin reuptake inhibitors (SSRIs), bupropion may be classified as a dual noradrenaline and dopamine reuptake inhibitor, a difference with potential implications for the treatment of residual sleepiness and fatigue in major depressive disorder (MDD).  Post-hoc anal. of subjects with remitted MDD was performed on data pooled from six double-blind, randomized trials comparing the European Union (EU)-approved dose of ≤300 mg/day bupropion with SSRIs (sertraline, paroxetine or escitalopram) for the resoln. of sleepiness and fatigue.  Hypersomnia score was defined as the sum of scores of the Hamilton Depression Rating Scale (HDRS) items 22, 23, and 24; fatigue score as HDRS item 13 score; and remission as HDRS-17=7.  Similar proportions of bupropion- and SSRI-treated subjects achieved remission at study endpoint (169/343, 49.3% vs 324/656, 49.4%; last observation carried forward (LOCF), p=0.45).  Fewer bupropion-treated remitters had residual symptoms of sleepiness (32/169, 18.9% vs 104/324, 32.1%; p<0.01) and fatigue (33/169, 19.5% vs 98/324, 30.2%; p<0.05).  Bupropion-treated remitters also showed greater improvement (mean change from baseline) in sleepiness (p<0.05) and fatigue scores (p<0.01) at endpoint: benefits were evident from week 2 for sleepiness (p<0.01) and week 4 for fatigue (p<0.01).  Bupropion treatment at the EU-approved dose of =300 mg/day may offer advantages over SSRIs in the resoln. of sleepiness and fatigue in remitted MDD patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-c4AoMjJjY7Vg90H21EOLACvtfcHk0lin6QgdbXBVew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslWgsb7K&md5=4ce2989c35fcbce875d6cdb06361e1bc</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1177%2F0269881113514878&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0269881113514878%26sid%3Dliteratum%253Aachs%26aulast%3DCooper%26aufirst%3DJ.%2BA.%26aulast%3DTucker%26aufirst%3DV.%2BL.%26aulast%3DPapakostas%26aufirst%3DG.%2BI.%26atitle%3DResolution%2520of%2520sleepiness%2520and%2520fatigue%253A%2520a%2520comparison%2520of%2520bupropion%2520and%2520selective%2520serotonin%2520reuptake%2520inhibitors%2520in%2520subjects%2520with%2520major%2520depressive%2520disorder%2520achieving%2520remission%2520at%2520doses%2520approved%2520in%2520the%2520European%2520Union%26jtitle%3DJ.%2520Psychopharmacol.%2520%2528London%252C%2520U.%2520K.%2529%26date%3D2014%26volume%3D28%26spage%3D118%26epage%3D124%26doi%3D10.1177%2F0269881113514878" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hori, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunugi, H.</span></span> <span> </span><span class="NLM_article-title">Dopamine agonist-responsive depression</span>. <i>Psychogeriatrics</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">189</span>– <span class="NLM_lpage">195</span>, <span class="refDoi"> DOI: 10.1111/psyg.12014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1111%2Fpsyg.12014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=25913769" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A280%3ADC%252BC2MjovVamug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=189-195&author=H.+Horiauthor=H.+Kunugi&title=Dopamine+agonist-responsive+depression&doi=10.1111%2Fpsyg.12014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine agonist-responsive depression</span></div><div class="casAuthors">Hori Hiroaki; Kunugi Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">189-95</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Dopaminergic dysfunction is implicated in the pathophysiology of treatment-resistant depression.  In this review, we describe the putative role of dopamine in depression, summarize the evidence for the efficacy of dopamine receptor agonists in the treatment of treatment-resistant depression, and discuss the underlying mechanisms by which these medications work.  Both preclinical and clinical data suggest that adjunctive dopamine agonists could be a promising option for the treatment of such a condition, indicating that there is a dopamine agonist-responsive subgroup of depression.  Future clinical studies are warranted to clarify unresolved issues regarding dopamine agonists such as long-term efficacy, efficacy as a monotherapy, and efficacy for juvenile and senile depression.  Further basic research is also necessary to fully understand how dopamine acts in the brain of depressed patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTm5GGGQIiGainGiHuhFGv8fW6udTcc2eYkI0dayF0LQ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MjovVamug%253D%253D&md5=50d3b7006dfcae668d4c9535ce7976fd</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1111%2Fpsyg.12014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fpsyg.12014%26sid%3Dliteratum%253Aachs%26aulast%3DHori%26aufirst%3DH.%26aulast%3DKunugi%26aufirst%3DH.%26atitle%3DDopamine%2520agonist-responsive%2520depression%26jtitle%3DPsychogeriatrics%26date%3D2013%26volume%3D13%26spage%3D189%26epage%3D195%26doi%3D10.1111%2Fpsyg.12014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pae, C.-U.</span></span> <span> </span><span class="NLM_article-title">Pramipexole augmentation in treatment-resistant major depressive disorder</span>. <i>Expert Rev. Neurother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">5</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1586/14737175.2014.864556</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1586%2F14737175.2014.864556" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=24308279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1Onsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=5-8&author=C.-U.+Pae&title=Pramipexole+augmentation+in+treatment-resistant+major+depressive+disorder&doi=10.1586%2F14737175.2014.864556"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Pramipexole augmentation in treatment-resistant major depressive disorder</span></div><div class="casAuthors">Pae, Chi-Un</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Neurotherapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5-8</span>CODEN:
                <span class="NLM_cas:coden">ERNXAR</span>;
        ISSN:<span class="NLM_cas:issn">1473-7175</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">To overcome limited efficacy in antidepressants, clinicians may choose augmentation, switching to a different antidepressant, or a combination of different antidepressant drugs based on the individual patient's clin. circumstances.  Among such options for difficult-to-treat major depressive disorder (MDD) patients, augmentation therapy with atypical antipsychotics, psychostimulants, dopamine agonists, serotonin 1A partial agonists, lithium, and thyroid hormones are commonly used in clin. practice.  In fact, augmentation therapy has some clin. merits and is more convenient than switching medications and combination approaches for treating MDD.  One such augmentation agent, pramipexole has been proposed, and has been implicated in the development and treatment of MDD.  Recently, randomized controlled trials with pramipexole augmentation have been conducted and have demonstrated that pramipexole is a safe and potentially efficacious augmentation strategy.  This article will discuss currently available clin. trial data and the potential role of pramipexole in MDD treatment, including clin. significance, limitations, and future research directions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0Ntp1RkQrx7Vg90H21EOLACvtfcHk0lin6QgdbXBVew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1Onsro%253D&md5=0d62f9d9fd5fceb4a2e9507a1bb22d51</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1586%2F14737175.2014.864556&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737175.2014.864556%26sid%3Dliteratum%253Aachs%26aulast%3DPae%26aufirst%3DC.-U.%26atitle%3DPramipexole%2520augmentation%2520in%2520treatment-resistant%2520major%2520depressive%2520disorder%26jtitle%3DExpert%2520Rev.%2520Neurother.%26date%3D2014%26volume%3D14%26spage%3D5%26epage%3D8%26doi%3D10.1586%2F14737175.2014.864556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keitner, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravindran, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Giovane, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, P.</span></span> <span> </span><span class="NLM_article-title">Atypical antipsychotic augmentation for treatment-resistant depression: a systematic review and network meta-analysis</span>. <i>Int. J. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">pyv060</span>, <span class="refDoi"> DOI: 10.1093/ijnp/pyv060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1093%2Fijnp%2Fpyv060" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=26012350" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2015&pages=pyv060&author=X.+Zhouauthor=G.+I.+Keitnerauthor=B.+Qinauthor=A.+V.+Ravindranauthor=M.+Bauerauthor=C.+Del+Giovaneauthor=J.+Zhaoauthor=Y.+Liuauthor=Y.+Fangauthor=Y.+Zhangauthor=P.+Xie&title=Atypical+antipsychotic+augmentation+for+treatment-resistant+depression%3A+a+systematic+review+and+network+meta-analysis&doi=10.1093%2Fijnp%2Fpyv060"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1093%2Fijnp%2Fpyv060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fijnp%252Fpyv060%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DKeitner%26aufirst%3DG.%2BI.%26aulast%3DQin%26aufirst%3DB.%26aulast%3DRavindran%26aufirst%3DA.%2BV.%26aulast%3DBauer%26aufirst%3DM.%26aulast%3DDel%2BGiovane%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DFang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DXie%26aufirst%3DP.%26atitle%3DAtypical%2520antipsychotic%2520augmentation%2520for%2520treatment-resistant%2520depression%253A%2520a%2520systematic%2520review%2520and%2520network%2520meta-analysis%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2015%26volume%3D18%26spage%3Dpyv060%26doi%3D10.1093%2Fijnp%2Fpyv060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Bartolomeis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomasetti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iasevoli, F.</span></span> <span> </span><span class="NLM_article-title">Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism</span>. <i>CNS Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">773</span>– <span class="NLM_lpage">799</span>, <span class="refDoi"> DOI: 10.1007/s40263-015-0278-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1007%2Fs40263-015-0278-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2015&pages=773-799&author=A.+de%0ABartolomeisauthor=C.+Tomasettiauthor=F.+Iasevoli&title=Update+on+the+Mechanism+of+Action+of+Aripiprazole%3A+Translational+Insights+into+Antipsychotic+Strategies+Beyond+Dopamine+Receptor+Antagonism&doi=10.1007%2Fs40263-015-0278-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1007%2Fs40263-015-0278-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40263-015-0278-3%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BBartolomeis%26aufirst%3DA.%26aulast%3DTomasetti%26aufirst%3DC.%26aulast%3DIasevoli%26aufirst%3DF.%26atitle%3DUpdate%2520on%2520the%2520Mechanism%2520of%2520Action%2520of%2520Aripiprazole%253A%2520Translational%2520Insights%2520into%2520Antipsychotic%2520Strategies%2520Beyond%2520Dopamine%2520Receptor%2520Antagonism%26jtitle%3DCNS%2520Drugs%26date%3D2015%26volume%3D29%26spage%3D773%26epage%3D799%26doi%3D10.1007%2Fs40263-015-0278-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Mansari, M.</span></span> <span> </span><span class="NLM_article-title">Serotonin and beyond: therapeutics for major depression</span>. <i>Philos. Trans. R. Soc., B</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>368</i></span>,  <span class="NLM_fpage">20120536</span>, <span class="refDoi"> DOI: 10.1098/rstb.2012.0536</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1098%2Frstb.2012.0536" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=23440470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltVaqsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2013&pages=20120536&author=P.+Blierauthor=M.+El+Mansari&title=Serotonin+and+beyond%3A+therapeutics+for+major+depression&doi=10.1098%2Frstb.2012.0536"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Serotonin and beyond: therapeutics for major depression</span></div><div class="casAuthors">Blier, Pierre; El Mansari, Mostafa</div><div class="citationInfo"><span class="NLM_cas:title">Philosophical Transactions of the Royal Society, B: Biological Sciences</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">1615</span>),
    <span class="NLM_cas:pages">20120536/1-20120536/7</span>CODEN:
                <span class="NLM_cas:coden">PTRBAE</span>;
        ISSN:<span class="NLM_cas:issn">0962-8436</span>.
    
            (<span class="NLM_cas:orgname">Royal Society</span>)
        </div><div class="casAbstract">A review.  The serotonin (5-HT, 5-hydroxytryptamine) system has been implicated in the pathogenesis of major depressive disorder (MDD).  The case for its contribution to the therapeutic efficacy of a wide variety of antidepressant treatments is, however, much stronger.  All antidepressant strategies have been shown to enhance 5-HT transmission in the brain of lab. animals.  Catecholamines, norepinephrine (NE) and dopamine (DA) can also play a pivotal role in the mechanism of action of certain antidepressant strategies.  The enhancement of 5-HT transmission by selective serotonin reuptake inhibitors, which leads to a dampening of the activity of NE and DA neurons, may account in part for the low remission rate achieved with these medications and/or the residuals symptoms after remission is achieved.  The functional connectivity between the 5-HT, NE and DA systems can be used to understand the mechanism of action of a wide variety of augmentation strategies in treatment-resistant MDD.  Proof-of-concept studies have shown that antidepressant medications with complementary mechanisms of action on monoaminergic systems can double the remission rate achieved in a trial of std. duration.  Novel approaches are also being used to treat MDD, which also appear to involve the monoaminergic system(s) to a varying extent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo17KDnFaMn0LVg90H21EOLACvtfcHk0ljTz-t_4WVW6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltVaqsLw%253D&md5=a51d8edcf962e09bbe7fd6e4ebbcf301</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1098%2Frstb.2012.0536&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1098%252Frstb.2012.0536%26sid%3Dliteratum%253Aachs%26aulast%3DBlier%26aufirst%3DP.%26aulast%3DEl%2BMansari%26aufirst%3DM.%26atitle%3DSerotonin%2520and%2520beyond%253A%2520therapeutics%2520for%2520major%2520depression%26jtitle%3DPhilos.%2520Trans.%2520R.%2520Soc.%252C%2520B%26date%3D2013%26volume%3D368%26spage%3D20120536%26doi%3D10.1098%2Frstb.2012.0536" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Comley, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salinas, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slifstein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennacef, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shotbolt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Aart, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iavarone, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomeni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laruelle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunn, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabiner, E. A.</span></span> <span> </span><span class="NLM_article-title">Monoamine transporter occupancy of a novel triple reuptake inhibitor in baboons and humans using positron emission tomography</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>346</i></span>,  <span class="NLM_fpage">311</span>– <span class="NLM_lpage">317</span>, <span class="refDoi"> DOI: 10.1124/jpet.112.202895</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1124%2Fjpet.112.202895" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=23685546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOjsbfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=346&publication_year=2013&pages=311-317&author=R.+A.+Comleyauthor=C.+A.+Salinasauthor=M.+Slifsteinauthor=M.+Petroneauthor=C.+Marzanoauthor=I.+Bennacefauthor=P.+Shotboltauthor=J.+Van+der+Aartauthor=M.+Neveauthor=L.+Iavaroneauthor=R.+Gomeniauthor=M.+Laruelleauthor=F.+A.+Grayauthor=R.+N.+Gunnauthor=E.+A.+Rabiner&title=Monoamine+transporter+occupancy+of+a+novel+triple+reuptake+inhibitor+in+baboons+and+humans+using+positron+emission+tomography&doi=10.1124%2Fjpet.112.202895"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Monoamine transporter occupancy of a novel triple reuptake inhibitor in baboons and humans using positron emission tomography</span></div><div class="casAuthors">Comley, Robert A.; Salinas, Cristian A.; Slifstein, Mark; Petrone, Marcella; Marzano, Carmine; Bennacef, Idriss; Shotbolt, Paul; Van der Aart, Jasper; Neve, Marta; Iavarone, Laura; Gomeni, Roberto; Laruelle, Marc; Gray, Frank A.; Gunn, Roger N.; Rabiner, Eugenii A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">346</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">311-317</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The selection of a therapeutically meaningful dose of a novel pharmaceutical is a crucial step in drug development.  Positron emission tomog. (PET) allows the in vivo estn. of the relationship between the plasma concn. of a drug and its target occupancy, optimizing dose selection and reducing the time and cost of early development.  Triple reuptake inhibitors (TRIs), also referred to as serotonin-norepinephrine-dopamine reuptake inhibitors, enhance monoaminergic neurotransmission by blocking the action of the monoamine transporters, raising extracellular concns. of those neurotransmitters.  GSK1360707 [(1R,6S)-1-(3,4-dichlorophenyl)-6-(methoxymethyl)-4-azabicyclo[4.1.0]heptane] is a novel TRI that until recently was under development for the treatment of major depressive disorder; its development was put on hold for strategic reasons.  We present the results of an in vivo assessment of the relationship between plasma exposure and transporter blockade (occupancy).  Studies were performed in baboons (Papio anubis) to det. the relationship between plasma concn. and occupancy of brain serotonin reuptake transporter (SERT), dopamine reuptake transporter (DAT), and norepinephrine uptake transporter (NET) using the radioligands [11C]DASB [(N,N-dimethyl-2-(2-amino-4-cyanophenylthio) benzylamine], [11C]PE2I [N-(3-iodoprop-2E-enyl)-2β-carbomethoxy-3β-(4-methylphenyl)nortropane], and [11C]2-[(2-methoxyphenoxy)phenylmethyl]morpholine (also known as [11C]MRB) and in humans using [11C]DASB and [11C]PE2I.  In P. anubis, plasma concns. resulting in half-maximal occupancy at SERT, DAT, and NET were 15.16, 15.56, and 0.97 ng/mL, resp.  In humans, the corresponding values for SERT and DAT were 6.80 and 18.00 ng/mL.  GSK1360707 dose-dependently blocked the signal of SERT-, DAT-, and NET-selective PET ligands, confirming its penetration across the blood-brain barrier and blockade of all three monoamine transporters in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeOk3b2TA00rVg90H21EOLACvtfcHk0ljTz-t_4WVW6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOjsbfE&md5=b92262955a074c2d981015dc436127bb</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1124%2Fjpet.112.202895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.112.202895%26sid%3Dliteratum%253Aachs%26aulast%3DComley%26aufirst%3DR.%2BA.%26aulast%3DSalinas%26aufirst%3DC.%2BA.%26aulast%3DSlifstein%26aufirst%3DM.%26aulast%3DPetrone%26aufirst%3DM.%26aulast%3DMarzano%26aufirst%3DC.%26aulast%3DBennacef%26aufirst%3DI.%26aulast%3DShotbolt%26aufirst%3DP.%26aulast%3DVan%2Bder%2BAart%26aufirst%3DJ.%26aulast%3DNeve%26aufirst%3DM.%26aulast%3DIavarone%26aufirst%3DL.%26aulast%3DGomeni%26aufirst%3DR.%26aulast%3DLaruelle%26aufirst%3DM.%26aulast%3DGray%26aufirst%3DF.%2BA.%26aulast%3DGunn%26aufirst%3DR.%2BN.%26aulast%3DRabiner%26aufirst%3DE.%2BA.%26atitle%3DMonoamine%2520transporter%2520occupancy%2520of%2520a%2520novel%2520triple%2520reuptake%2520inhibitor%2520in%2520baboons%2520and%2520humans%2520using%2520positron%2520emission%2520tomography%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D346%26spage%3D311%26epage%3D317%26doi%3D10.1124%2Fjpet.112.202895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span> <i>Antidepressant</i>; <span class="NLM_publisher-name">Wikipedia</span>, <span class="NLM_year">2017</span>; <a href="https://en.wikipedia.org/wiki/Antidepressant" class="extLink">https://en.wikipedia.org/wiki/Antidepressant</a> (accessed May 29, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Antidepressant%3B+Wikipedia%2C+2017%3B+https%3A%2F%2Fen.wikipedia.org%2Fwiki%2FAntidepressant+%28accessed+May+29%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DAntidepressant%26pub%3DWikipedia%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koblan, K.
S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kollins, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loebel, A.</span></span> <span> </span><span class="NLM_article-title">Dasotraline for the treatment of attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled, proof-of-concept trial in adults</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">2745</span>– <span class="NLM_lpage">2752</span>, <span class="refDoi"> DOI: 10.1038/npp.2015.124</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1038%2Fnpp.2015.124" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2015&pages=2745-2752&author=K.%0AS.+Koblanauthor=S.+C.+Hopkinsauthor=K.+Sarmaauthor=F.+Jinauthor=R.+Goldmanauthor=S.+H.+Kollinsauthor=A.+Loebel&title=Dasotraline+for+the+treatment+of+attention-deficit%2Fhyperactivity+disorder%3A+a+randomized%2C+double-blind%2C+placebo-controlled%2C+proof-of-concept+trial+in+adults&doi=10.1038%2Fnpp.2015.124"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2015.124&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2015.124%26sid%3Dliteratum%253Aachs%26aulast%3DKoblan%26aufirst%3DK.%2BS.%26aulast%3DHopkins%26aufirst%3DS.%2BC.%26aulast%3DSarma%26aufirst%3DK.%26aulast%3DJin%26aufirst%3DF.%26aulast%3DGoldman%26aufirst%3DR.%26aulast%3DKollins%26aufirst%3DS.%2BH.%26aulast%3DLoebel%26aufirst%3DA.%26atitle%3DDasotraline%2520for%2520the%2520treatment%2520of%2520attention-deficit%252Fhyperactivity%2520disorder%253A%2520a%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%252C%2520proof-of-concept%2520trial%2520in%2520adults%26jtitle%3DNeuropsychopharmacology%26date%3D2015%26volume%3D40%26spage%3D2745%26epage%3D2752%26doi%3D10.1038%2Fnpp.2015.124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bymaster, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golembiowska, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowalska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarazi, F. I.</span></span> <span> </span><span class="NLM_article-title">Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: implications for treatment of attention-deficit hyperactivity disorder</span>. <i>Synapse</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">522</span>– <span class="NLM_lpage">532</span>, <span class="refDoi"> DOI: 10.1002/syn.21538</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1002%2Fsyn.21538" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=22298359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC38XisFyjtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2012&pages=522-532&author=F.+P.+Bymasterauthor=K.+Golembiowskaauthor=M.+Kowalskaauthor=Y.+K.+Choiauthor=F.+I.+Tarazi&title=Pharmacological+characterization+of+the+norepinephrine+and+dopamine+reuptake+inhibitor+EB-1020%3A+implications+for+treatment+of+attention-deficit+hyperactivity+disorder&doi=10.1002%2Fsyn.21538"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: Implications for treatment of attention-deficit hyperactivity disorder</span></div><div class="casAuthors">Bymaster, Frank P.; Golembiowska, Krystyna; Kowalska, Magdalena; Choi, Yong Kee; Tarazi, Frank I.</div><div class="citationInfo"><span class="NLM_cas:title">Synapse (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">522-532</span>CODEN:
                <span class="NLM_cas:coden">SYNAET</span>;
        ISSN:<span class="NLM_cas:issn">0887-4476</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">We report on the pharmacol., behavioral, and neurochem. characterization of a novel dual norepinephrine (NE)/dopamine (DA) transporter inhibitor EB-1020 (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane HCl.  EB-1020 preferentially inhibited monoamine reuptake in cloned cell lines transfected with human transporters with IC50 values of 6 and 38, resp., for NE and DA transporters.  In microdialysis studies, EB-1020 markedly increased NE, and DA concns. levels in rat prefrontal cortex in vivo with peak increases of 375 and 300%, resp. with the greatest effects on NE, and also increased DA extracellular concns. in the striatum to 400% of baseline concns.  Behavioral studies demonstrated that EB-1020 dose-dependently decreased immobility in the mouse tail suspension test of depression to 13% of control levels, and did not stimulate locomotor activity in adult rats in the optimal dose range.  EB-1020 dose-dependently inhibited locomotor hyperactivity in juvenile rats lesioned with the neurotoxin 6-hydroxydopamine (100 μg intracisternally) as neonates; a well-established animal model for attention-deficit hyperactivity disorder (ADHD).  These data suggest that EB-1020 mediates its actions by stimulating NE and DA neurotransmission, which are typically impaired in ADHD.  Synapse, 2012. © 2012 Wiley Periodicals, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYYcO1hI4sKLVg90H21EOLACvtfcHk0ljbna-ziC7jDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XisFyjtbc%253D&md5=40db856bc396bb648ca3b4c4c7318fd9</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1002%2Fsyn.21538&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fsyn.21538%26sid%3Dliteratum%253Aachs%26aulast%3DBymaster%26aufirst%3DF.%2BP.%26aulast%3DGolembiowska%26aufirst%3DK.%26aulast%3DKowalska%26aufirst%3DM.%26aulast%3DChoi%26aufirst%3DY.%2BK.%26aulast%3DTarazi%26aufirst%3DF.%2BI.%26atitle%3DPharmacological%2520characterization%2520of%2520the%2520norepinephrine%2520and%2520dopamine%2520reuptake%2520inhibitor%2520EB-1020%253A%2520implications%2520for%2520treatment%2520of%2520attention-deficit%2520hyperactivity%2520disorder%26jtitle%3DSynapse%26date%3D2012%26volume%3D66%26spage%3D522%26epage%3D532%26doi%3D10.1002%2Fsyn.21538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span> <i>Neurovance Announces Positive Centanafadine Phase
2b Results for
Adult ADHD, and Plans for Phase 3 Trials</i>; <span class="NLM_publisher-name">Neurovance, Inc.</span>: <span class="NLM_publisher-loc">Cambridge, MA</span>, July 27, <span class="NLM_year">2016</span>; <a href="http://www.neurovance.com/wp-content/uploads/2016/07/Press_Release-Neurovance_CTN_072716_Final_en.pdf" class="extLink">http://www.neurovance.com/wp-content/uploads/2016/07/Press_Release-Neurovance_CTN_072716_Final_en.pdf</a> (accessed May 29, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Neurovance+Announces+Positive+Centanafadine+Phase%0A2b+Results+for%0AAdult+ADHD%2C+and+Plans+for+Phase+3+Trials%3B+Neurovance%2C+Inc.%3A+Cambridge%2C+MA%2C+July+27%2C+2016%3B+http%3A%2F%2Fwww.neurovance.com%2Fwp-content%2Fuploads%2F2016%2F07%2FPress_Release-Neurovance_CTN_072716_Final_en.pdf+%28accessed+May+29%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DNeurovance%2520Announces%2520Positive%2520Centanafadine%2520Phase%250A2b%2520Results%2520for%250AAdult%2520ADHD%252C%2520and%2520Plans%2520for%2520Phase%25203%2520Trials%26pub%3DNeurovance%252C%2520Inc%26date%3D2016%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilens, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klint, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adler, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wesnes, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graff, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikkelsen, B.</span></span> <span> </span><span class="NLM_article-title">A randomized controlled trial of a novel mixed monoamine reuptake inhibitor in adults with ADHD</span>. <i>Behav. Brain Funct.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">24</span>, <span class="refDoi"> DOI: 10.1186/1744-9081-4-24</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1186%2F1744-9081-4-24" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=18554401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A280%3ADC%252BD1cvisVSrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=24&author=T.+E.+Wilensauthor=T.+Klintauthor=L.+Adlerauthor=S.+Westauthor=K.+Wesnesauthor=O.+Graffauthor=B.+Mikkelsen&title=A+randomized+controlled+trial+of+a+novel+mixed+monoamine+reuptake+inhibitor+in+adults+with+ADHD&doi=10.1186%2F1744-9081-4-24"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized controlled trial of a novel mixed monoamine reuptake inhibitor in adults with ADHD</span></div><div class="casAuthors">Wilens Timothy E; Klint Thorsten; Adler Lenard; West Scott; Wesnes Keith; Graff Ole; Mikkelsen Birgit</div><div class="citationInfo"><span class="NLM_cas:title">Behavioral and brain functions : BBF</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">24</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  NS2359 is a potent reuptake blocker of noradrenalin, dopamine, and serotonin.  The aim of the study was to investigate the efficacy, safety and cognitive function of NS2359 in adults with a DSM IV diagnosis of ADHD.  METHODS:  The study was a multi-centre, double-blind, randomized placebo-controlled, parallel group design in outpatient adults (18-55 years) testing 0.5 mg NS2359 vs. placebo for 8 weeks.  Multiple assessments including computerized neuropsychological evaluation were performed.  RESULTS:  There was no significant difference between NS2359 (n = 63) versus placebo (n = 63) on the primary outcome measure reduction in investigator rated ADHD-RS total score (7.8 versus 6.4; p < 0.45).  However, in subjects with the inattentive subtype, there were significantly more responders in the NS2359 group compared to placebo (41% versus 7%; p < 0.01).  For all secondary variables (ADHD-RS patient rated; The Conners Adult ADHD Scale; The Brown Adult Scale, and CGI-improvement scale) there were no significant differences between the two groups; however, in the inattentive subgroup, the response to treatment was significantly larger than to placebo.  NS2359 improved composite factor scores of attention, episodic- and working memory.  No serious adverse events were reported with insomnia, headaches and loss of appetite most commonly reported as side effects.  CONCLUSION:  No overall effect of NS2359 was found on overall symptoms of ADHD.  There was also a modest signal of improvement in the inattentive adults with ADHD and cognition warranting further exploration using differing doses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTNX0A-0CCcFQ8IxFYvehhofW6udTcc2eZlz2JFUK7cprntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cvisVSrtg%253D%253D&md5=4a56a59169e6b5dd3fc3ae13eb553a2b</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1186%2F1744-9081-4-24&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1744-9081-4-24%26sid%3Dliteratum%253Aachs%26aulast%3DWilens%26aufirst%3DT.%2BE.%26aulast%3DKlint%26aufirst%3DT.%26aulast%3DAdler%26aufirst%3DL.%26aulast%3DWest%26aufirst%3DS.%26aulast%3DWesnes%26aufirst%3DK.%26aulast%3DGraff%26aufirst%3DO.%26aulast%3DMikkelsen%26aufirst%3DB.%26atitle%3DA%2520randomized%2520controlled%2520trial%2520of%2520a%2520novel%2520mixed%2520monoamine%2520reuptake%2520inhibitor%2520in%2520adults%2520with%2520ADHD%26jtitle%3DBehav.%2520Brain%2520Funct.%26date%3D2008%26volume%3D4%26spage%3D24%26doi%3D10.1186%2F1744-9081-4-24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span> <i>Sunovion Announces
Results from Pivotal Study Evaluating Novel Drug
Candidate Dasotraline in Children with ADHD</i>; <span class="NLM_publisher-name">Sunovion Pharmaceuticals</span>: <span class="NLM_publisher-loc">Marlborough,
MA</span>, September 20, <span class="NLM_year">2016</span>; <a href="http://www.sunovion.us/featured-news/press-releases/20160920.pdf" class="extLink">http://www.sunovion.us/featured-news/press-releases/20160920.pdf</a> (accessed May 29, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Sunovion+Announces%0AResults+from+Pivotal+Study+Evaluating+Novel+Drug%0ACandidate+Dasotraline+in+Children+with+ADHD%3B+Sunovion+Pharmaceuticals%3A+Marlborough%2C%0AMA%2C+September+20%2C+2016%3B+http%3A%2F%2Fwww.sunovion.us%2Ffeatured-news%2Fpress-releases%2F20160920.pdf+%28accessed+May+29%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DSunovion%2520Announces%250AResults%2520from%2520Pivotal%2520Study%2520Evaluating%2520Novel%2520Drug%250ACandidate%2520Dasotraline%2520in%2520Children%2520with%2520ADHD%26pub%3DSunovion%2520Pharmaceuticals%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hache, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coudore, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardier, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guiard, B. P.</span></span> <span> </span><span class="NLM_article-title">Monoaminergic antidepressants in the relief of pain: potential therapeutic utility of triple reuptake inhibitors (TRIs)</span>. <i>Pharmaceuticals</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">342</span>, <span class="refDoi"> DOI: 10.3390/ph4020285</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.3390%2Fph4020285" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2011&pages=285-342&author=G.+Hacheauthor=F.+Coudoreauthor=A.+M.+Gardierauthor=B.+P.+Guiard&title=Monoaminergic+antidepressants+in+the+relief+of+pain%3A+potential+therapeutic+utility+of+triple+reuptake+inhibitors+%28TRIs%29&doi=10.3390%2Fph4020285"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.3390%2Fph4020285&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fph4020285%26sid%3Dliteratum%253Aachs%26aulast%3DHache%26aufirst%3DG.%26aulast%3DCoudore%26aufirst%3DF.%26aulast%3DGardier%26aufirst%3DA.%2BM.%26aulast%3DGuiard%26aufirst%3DB.%2BP.%26atitle%3DMonoaminergic%2520antidepressants%2520in%2520the%2520relief%2520of%2520pain%253A%2520potential%2520therapeutic%2520utility%2520of%2520triple%2520reuptake%2520inhibitors%2520%2528TRIs%2529%26jtitle%3DPharmaceuticals%26date%3D2011%26volume%3D4%26spage%3D285%26epage%3D342%26doi%3D10.3390%2Fph4020285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hache, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guiard, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quesseveur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardier, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coudore, F.</span></span> <span> </span><span class="NLM_article-title">Antinociceptive activity of the new triple reuptake inhibitor NS18283 in a mouse model of chemotherapy-induced neuropathic pain</span>. <i>Eur. J. Pain</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">322</span>– <span class="NLM_lpage">333</span>, <span class="refDoi"> DOI: 10.1002/ejp.550</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1002%2Fejp.550" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=25045036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjsVGjsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2015&pages=322-333&author=G.+Hacheauthor=B.+P.+Guiardauthor=T.+H.+Nguyenauthor=G.+Quesseveurauthor=A.+M.+Gardierauthor=D.+Petersauthor=G.+Munroauthor=F.+Coudore&title=Antinociceptive+activity+of+the+new+triple+reuptake+inhibitor+NS18283+in+a+mouse+model+of+chemotherapy-induced+neuropathic+pain&doi=10.1002%2Fejp.550"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Antinociceptive activity of the new triple reuptake inhibitor NS18283 in a mouse model of chemotherapy-induced neuropathic pain</span></div><div class="casAuthors">Hache, G.; Guiard, B. P.; Nguyen, T. H.; Quesseveur, G.; Gardier, A. M.; Peters, D.; Munro, G.; Coudore, F.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pain (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">322-333</span>CODEN:
                <span class="NLM_cas:coden">EJPAFJ</span>;
        ISSN:<span class="NLM_cas:issn">1532-2149</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background : Chronic neuropathic pain can lead to anxiety and depression.  Drugs that block reuptake of serotonin, norepinephrine and/or dopamine are widely used to treat depression, and have emerged as useful drugs in the treatment of neuropathic pain.  This study compared the acute antinociceptive effects of NS18283, a novel triple monoamine reuptake inhibitor (MRI) with indatraline, venlafaxine and escitalopram in a mouse model of neuropathic pain.  Method : Neuropathic pain-like behaviors were induced in mice by repeated injections of oxaliplatin (OXA), and assessed using the von Frey hair test, the cold plate test and the thermal preference plate test.  Anxio/depressive phenotype and antidepressant-like properties of compds. were assessed by the novelty suppressed feeding test and the tail suspension test, resp.  Results : In vivo microdialysis expts. showed that each MRI increased extracellular serotonin, norepinephrine and/or dopamine levels in the cingulate cortex, in agreement with their in vitro reuptake inhibitory properties.  Indatraline (3 mg/kg) reversed the full repertoire of OXA-induced neuropathic hypersensitivity.  NS18283 (10 mg/kg) reversed OXA-induced mechano-hypersensitivity and cold allodynia.  Venlafaxine (16 mg/kg) and escitalopram (4 mg/kg) only reversed cold allodynia and mechano-hypersensitivity, resp.  All MRIs produced antidepressant-like activity in anxio/depressive phenotype of OXA mice.  Conclusions : Acute administration of drugs that enhance the activity of serotonin, norepinephrine and dopamine neurotransmission within nociceptive pathways may provide a broader spectrum of antinociception than dual or selective reuptake inhibitors in animal models of neuropathic pain.  Whether similar observations would occur after repeated administration of such compds. in an attempt to simulate dosing in humans, or be compromised by dopaminergic-mediated adverse effects warrants further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPt5IhUs35o7Vg90H21EOLACvtfcHk0lgERo4EQ3GQig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjsVGjsb4%253D&md5=176247b9134c10b3dddbe581fd51499c</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1002%2Fejp.550&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejp.550%26sid%3Dliteratum%253Aachs%26aulast%3DHache%26aufirst%3DG.%26aulast%3DGuiard%26aufirst%3DB.%2BP.%26aulast%3DNguyen%26aufirst%3DT.%2BH.%26aulast%3DQuesseveur%26aufirst%3DG.%26aulast%3DGardier%26aufirst%3DA.%2BM.%26aulast%3DPeters%26aufirst%3DD.%26aulast%3DMunro%26aufirst%3DG.%26aulast%3DCoudore%26aufirst%3DF.%26atitle%3DAntinociceptive%2520activity%2520of%2520the%2520new%2520triple%2520reuptake%2520inhibitor%2520NS18283%2520in%2520a%2520mouse%2520model%2520of%2520chemotherapy-induced%2520neuropathic%2520pain%26jtitle%3DEur.%2520J.%2520Pain%26date%3D2015%26volume%3D19%26spage%3D322%26epage%3D333%26doi%3D10.1002%2Fejp.550" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negus, S. S.</span></span> <span> </span><span class="NLM_article-title">Effects of monoamine reuptake inhibitors in assays of acute pain-stimulated and pain-depressed behavior in rats</span>. <i>J. Pain</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">246</span>– <span class="NLM_lpage">259</span>, <span class="refDoi"> DOI: 10.1016/j.jpain.2012.11.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.jpain.2012.11.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=23332494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmslegsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=246-259&author=M.+B.+Rosenbergauthor=F.+I.+Carrollauthor=S.+S.+Negus&title=Effects+of+monoamine+reuptake+inhibitors+in+assays+of+acute+pain-stimulated+and+pain-depressed+behavior+in+rats&doi=10.1016%2Fj.jpain.2012.11.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of Monoamine Reuptake Inhibitors in Assays of Acute Pain-Stimulated and Pain-Depressed Behavior in Rats</span></div><div class="casAuthors">Rosenberg, Marisa B.; Carroll, F. Ivy; Negus, S. Stevens</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pain</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">246-259</span>CODEN:
                <span class="NLM_cas:coden">JPOAB5</span>;
        ISSN:<span class="NLM_cas:issn">1526-5900</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Pain is assocd. with stimulation of some behaviors (eg, withdrawal reflexes) but depression of many other behaviors (eg, feeding, locomotion, pos. reinforced operant behavior).  Drugs that block reuptake of serotonin, norepinephrine, and/or dopamine are widely used to treat depression, and they have also emerged as useful drugs for treatment of pain.  This study compared effects of selective and mixed-action inhibitors of serotonin, norepinephrine, and/or dopamine reuptake in assays of acute pain-stimulated and pain-depressed behavior.  I.p. injection of dil. acid served as a noxious stimulus to stimulate a writhing response or depress intracranial self-stimulation (ICSS) in Sprague Dawley rats.  Selective reuptake inhibitors of serotonin (citalopram, clomipramine) and norepinephrine (nisoxetine, nortriptyline) and a mixed-action reuptake inhibitor of serotonin and norepinephrine (milnacipran) blocked acid-stimulated writhing but failed to block acid-induced depression of ICSS.  Selective dopamine reuptake inhibitors (RTI-113 [3ss-(4-chlorophenyl)tropane-2ss-carboxylic acid Ph ester hydrochloride], bupropion) and a triple reuptake inhibitor of dopamine, serotonin, and norepinephrine (RTI-112 [3ss-(3-methyl-4-chlorophenyl)tropane-2ss-carboxylic acid Me ester hydrochloride]) blocked both acid-stimulated writhing and acid-induced depression of ICSS, although these drugs also produced an abuse-related facilitation of ICSS in the absence of the noxious stimulus.  These results support further consideration of dopamine reuptake inhibitors as candidate analgesics, although abuse liability remains a concern.  Monoamine reuptake inhibitors are used to treat depression and some forms of pain.  This study examd. effects of monoamine reuptake inhibitors in a preclin. assay of pain-related behavioral depression.  The results support further consideration of dopamine reuptake inhibitors as candidate analgesics under selected circumstances, although abuse liability remains a concern.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrV-u7Njm1pA7Vg90H21EOLACvtfcHk0lgERo4EQ3GQig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmslegsLw%253D&md5=cc04c2634511a2ab1c5bcbef8c7c2b91</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.jpain.2012.11.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpain.2012.11.006%26sid%3Dliteratum%253Aachs%26aulast%3DRosenberg%26aufirst%3DM.%2BB.%26aulast%3DCarroll%26aufirst%3DF.%2BI.%26aulast%3DNegus%26aufirst%3DS.%2BS.%26atitle%3DEffects%2520of%2520monoamine%2520reuptake%2520inhibitors%2520in%2520assays%2520of%2520acute%2520pain-stimulated%2520and%2520pain-depressed%2520behavior%2520in%2520rats%26jtitle%3DJ.%2520Pain%26date%3D2013%26volume%3D14%26spage%3D246%26epage%3D259%26doi%3D10.1016%2Fj.jpain.2012.11.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krieter, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gohdes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musick, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duncanson, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridson, W. E.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics, disposition, and metabolism of bicifadine in humans</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">252</span>– <span class="NLM_lpage">259</span>, <span class="refDoi"> DOI: 10.1124/dmd.107.017871</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1124%2Fdmd.107.017871" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=252-259&author=P.+A.+Krieterauthor=M.+Gohdesauthor=T.+J.+Musickauthor=F.+P.+Duncansonauthor=W.+E.+Bridson&title=Pharmacokinetics%2C+disposition%2C+and+metabolism+of+bicifadine+in+humans&doi=10.1124%2Fdmd.107.017871"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1124%2Fdmd.107.017871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.107.017871%26sid%3Dliteratum%253Aachs%26aulast%3DKrieter%26aufirst%3DP.%2BA.%26aulast%3DGohdes%26aufirst%3DM.%26aulast%3DMusick%26aufirst%3DT.%2BJ.%26aulast%3DDuncanson%26aufirst%3DF.%2BP.%26aulast%3DBridson%26aufirst%3DW.%2BE.%26atitle%3DPharmacokinetics%252C%2520disposition%252C%2520and%2520metabolism%2520of%2520bicifadine%2520in%2520humans%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2008%26volume%3D36%26spage%3D252%26epage%3D259%26doi%3D10.1124%2Fdmd.107.017871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span> <i>NS2359 for Treatment of Cocaine Addiction</i>; <span class="NLM_publisher-name">Saniona</span>: <span class="NLM_publisher-loc">Ballerup,
Denmark</span>, <span class="NLM_year">2017</span>; <a href="http://saniona.com/pipeline/ns2359/" class="extLink">http://saniona.com/pipeline/ns2359/</a> (accessed May 29, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+NS2359+for+Treatment+of+Cocaine+Addiction%3B+Saniona%3A+Ballerup%2C%0ADenmark%2C+2017%3B+http%3A%2F%2Fsaniona.com%2Fpipeline%2Fns2359%2F+%28accessed+May+29%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DNS2359%2520for%2520Treatment%2520of%2520Cocaine%2520Addiction%26pub%3DSaniona%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Levin, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rezvani, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bymaster, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, J. E.</span></span> <span> </span><span class="NLM_article-title">Amitifadine, a triple monoamine re-uptake inhibitor, reduces nicotine self-administration in female rats</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>764</i></span>,  <span class="NLM_fpage">30</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2015.06.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.ejphar.2015.06.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=26101069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVajtLrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=764&publication_year=2015&pages=30-37&author=E.+D.+Levinauthor=C.+Wellsauthor=J.+E.+Johnsonauthor=A.+H.+Rezvaniauthor=F.+P.+Bymasterauthor=J.+E.+Rose&title=Amitifadine%2C+a+triple+monoamine+re-uptake+inhibitor%2C+reduces+nicotine+self-administration+in+female+rats&doi=10.1016%2Fj.ejphar.2015.06.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Amitifadine, a triple monoamine re-uptake inhibitor, reduces nicotine self-administration in female rats</span></div><div class="casAuthors">Levin, Edward D.; Wells, Corinne; Johnson, Joshua E.; Rezvani, Amir H.; Bymaster, Frank P.; Rose, Jed E.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">764</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">30-37</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A wider diversity of drug treatments to aid smoking cessation is needed to help tailor the most efficacious treatment for different types of smokers.  This study was conducted to det. whether amitifadine, which inhibits re-uptake of dopamine, norepinephrine and serotonin, would decrease nicotine self-administration at doses that do not cause adverse side effects.  Adult female Sprague-Dawley rats were trained to self-administer nicotine i.v. (IV) and were given acute doses of amitifadine in a repeated measures counterbalanced design.  Effects of amitifadine on locomotor activity and food motivated responding were also evaluated.  Chronic amitifadine effects were also examd.  The 30 mg/kg amitifadine dose significantly reduced nicotine self-administration.  The 5 and 10 mg/kg doses reduced nicotine self-administration during the first 15 min of the session when the greatest amt. of nicotine was self-administered.  The 30 mg/kg amitifadine dose, but not the lower doses caused a significant redn. in locomotor activity averaged over the one-hour session and reduced food motivated responding.  The 10 mg/kg dose caused hypoactivity at the beginning of the session, but 5 mg/kg did not cause any hypoactivity.  The effects of chronic amitifadine treatment (10 mg/kg) over the course of 15 sessions was also detd.  Amitifadine caused a significant redn. in nicotine self-administration, which was not seen to diminish over two consecutive weeks of treatment and a week after enforced abstinence.  Amitifadine significantly reduced nicotine self-administration.  This prompts further research to det. if amitifadine might be an effective treatment for smoking cessation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwJ4YGTqDiJ7Vg90H21EOLACvtfcHk0ljZaKI0BsIWBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVajtLrL&md5=300c7a36802d2388964f5ccf5fc64de7</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2015.06.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2015.06.041%26sid%3Dliteratum%253Aachs%26aulast%3DLevin%26aufirst%3DE.%2BD.%26aulast%3DWells%26aufirst%3DC.%26aulast%3DJohnson%26aufirst%3DJ.%2BE.%26aulast%3DRezvani%26aufirst%3DA.%2BH.%26aulast%3DBymaster%26aufirst%3DF.%2BP.%26aulast%3DRose%26aufirst%3DJ.%2BE.%26atitle%3DAmitifadine%252C%2520a%2520triple%2520monoamine%2520re-uptake%2520inhibitor%252C%2520reduces%2520nicotine%2520self-administration%2520in%2520female%2520rats%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D764%26spage%3D30%26epage%3D37%26doi%3D10.1016%2Fj.ejphar.2015.06.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Tousa, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warnock, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matson, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namjoshi, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linn, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiruveedhula, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halcomb, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grahame, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">June, H. L.</span></span> <span> </span><span class="NLM_article-title">Triple monoamine uptake inhibitors demonstrate a pharmacologic association between excessive drinking and impulsivity in high-alcohol-preferring (HAP) mice</span>. <i>Addict. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">236</span>– <span class="NLM_lpage">247</span>, <span class="refDoi"> DOI: 10.1111/adb.12100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1111%2Fadb.12100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=24118509" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvV2hsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=236-247&author=D.+S.+O%E2%80%99Tousaauthor=K.+T.+Warnockauthor=L.+M.+Matsonauthor=O.+A.+Namjoshiauthor=M.+V.+Linnauthor=V.+V.+Tiruveedhulaauthor=M.+E.+Halcombauthor=J.+Cookauthor=N.+J.+Grahameauthor=H.+L.+June&title=Triple+monoamine+uptake+inhibitors+demonstrate+a+pharmacologic+association+between+excessive+drinking+and+impulsivity+in+high-alcohol-preferring+%28HAP%29+mice&doi=10.1111%2Fadb.12100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Triple monoamine uptake inhibitors demonstrate a pharmacologic association between excessive drinking and impulsivity in high-alcohol-preferring (HAP) mice</span></div><div class="casAuthors">O'Tousa, David S.; Warnock, Kaitlin T.; Matson, Liana M.; Namjoshi, Ojas A.; Van Linn, Michael; Tiruveedhula, Veera Venkata; Halcomb, Meredith E.; Cook, James; Grahame, Nicholas J.; June, Harry L.</div><div class="citationInfo"><span class="NLM_cas:title">Addiction Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">236-247</span>CODEN:
                <span class="NLM_cas:coden">ADBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1369-1600</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Approx. 30% of current drinkers in the United States drink excessively, and are referred to as problem/hazardous drinkers.  These individuals, who may not meet criteria for alc. abuse or dependence, comprise binge, heavy drinkers, or both.  Given their high prevalence, interventions that reduce the risk of binge and heavy drinking have important public health implications.  Impulsivity has been repeatedly assocd. with excessive drinking in the clin. literature.  As impulsivity is correlated with, and may play a crit. role in, the initiation and maintenance of excessive drinking, this behavior may be an important target for therapeutic intervention.  Hence, a better understanding of pharmacol. treatments capable of attenuating excessive drinking and impulsivity may markedly improve clin. outcomes.  The high-alc.-preferring (HAP) mice represent a strong rodent model to study the relationship between impulsivity and excessive alc. drinking, as recent evidence indicates they consume high levels of alc. throughout their active cycle and are innately impulsive.  Using this model, the present study demonstrates that the triple monoamine uptake inhibitors (TUIs) amitifadine and DOV 102, 677 effectively attenuate binge drinking, heavy drinking assessed via a 24-h free-choice assay, and impulsivity measured by the delay discounting procedure.  In contrast, 3-PBC, a GABA-A α1 preferring ligand with mixed agonist-antagonist properties, attenuates excessive drinking without affecting impulsivity.  These findings suggest that in HAP mice, monoamine pathways may predominate as a common mechanism underlying impulsivity and excessive drinking, while the GABAergic system may be more salient in regulating excessive drinking.  We further propose that TUIs such as amitifadine and DOV 102, 677 may be used to treat the co-occurrence of impulsivity and excessive drinking.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCycjkVQYAr7Vg90H21EOLACvtfcHk0ljZaKI0BsIWBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvV2hsbY%253D&md5=fbbb92625dac06fb3d4d25d1a70a5c95</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1111%2Fadb.12100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fadb.12100%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Tousa%26aufirst%3DD.%2BS.%26aulast%3DWarnock%26aufirst%3DK.%2BT.%26aulast%3DMatson%26aufirst%3DL.%2BM.%26aulast%3DNamjoshi%26aufirst%3DO.%2BA.%26aulast%3DLinn%26aufirst%3DM.%2BV.%26aulast%3DTiruveedhula%26aufirst%3DV.%2BV.%26aulast%3DHalcomb%26aufirst%3DM.%2BE.%26aulast%3DCook%26aufirst%3DJ.%26aulast%3DGrahame%26aufirst%3DN.%2BJ.%26aulast%3DJune%26aufirst%3DH.%2BL.%26atitle%3DTriple%2520monoamine%2520uptake%2520inhibitors%2520demonstrate%2520a%2520pharmacologic%2520association%2520between%2520excessive%2520drinking%2520and%2520impulsivity%2520in%2520high-alcohol-preferring%2520%2528HAP%2529%2520mice%26jtitle%3DAddict.%2520Biol.%26date%3D2015%26volume%3D20%26spage%3D236%26epage%3D247%26doi%3D10.1111%2Fadb.12100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Appel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergstrom, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buus Lassen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langstrom, B.</span></span> <span> </span><span class="NLM_article-title">Tesofensine, a novel triple monoamine re-uptake inhibitor with anti-obesity effects: dopamine transporter occupancy as measured by PET</span>. <i>Eur. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">251</span>– <span class="NLM_lpage">261</span>, <span class="refDoi"> DOI: 10.1016/j.euroneuro.2013.10.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.euroneuro.2013.10.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=24239329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslKqsLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=251-261&author=L.+Appelauthor=M.+Bergstromauthor=J.+Buus+Lassenauthor=B.+Langstrom&title=Tesofensine%2C+a+novel+triple+monoamine+re-uptake+inhibitor+with+anti-obesity+effects%3A+dopamine+transporter+occupancy+as+measured+by+PET&doi=10.1016%2Fj.euroneuro.2013.10.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Tesofensine, a novel triple monoamine re-uptake inhibitor with anti-obesity effects: Dopamine transporter occupancy as measured by PET</span></div><div class="casAuthors">Appel, Lieuwe; Bergstroem, Mats; Buus Lassen, Joergen; Laangstroem, Bengt</div><div class="citationInfo"><span class="NLM_cas:title">European Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">251-261</span>CODEN:
                <span class="NLM_cas:coden">EURNE8</span>;
        ISSN:<span class="NLM_cas:issn">0924-977X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Tesofensine (TE) is a novel triple monoamine re-uptake inhibitor inducing a potent inhibition of the re-uptake process in the synaptic cleft of the neurotransmitters dopamine, norepinephrine, and serotonin.  In recent preclin. and clin. evaluations TE showed a robust anti-obesity effect, but the specific mechanism of this triple monoamine re-uptake inhibitor still needs to be further elucidated.  This positron emission tomog. (PET) study, using [11C]βCIT-FE, aimed to assess the degree of the dopamine transporter (DAT) occupancy, at const. TE plasma levels, following different oral, multiple doses of TE during totally 8-12 days.  In addn., the relationships between DAT occupancy and TE plasma concns., or doses, were investigated to enable assessment of DAT occupancies in subsequent clin. trials.  The results demonstrated that TE induced a dose-dependent blockade of DAT following multiple doses of 0.125-1 mg TE at anticipated steady-state conditions.  The mean striatal DAT occupancy varied dose-dependently between 18% and 77%.  A sigmoid Emax model well described the relationship between striatal DAT occupancy and TE plasma concns. or doses.  It was estd. that the max. achievable DAT occupancy was about 80% and that half of this effect was accomplished by approx. 0.25 mg TE and a plasma drug concn. of 4 ng/mL.  The results indicated an important mechanism of action of TE on DAT.  Further, these results suggest that the previously reported dose-dependent wt. loss, in TE treated subjects, was in part mediated by an up-regulation of dopaminergic pathways due to enhanced amts. of synaptic dopamine after blockade of DAT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkmbZZn97khbVg90H21EOLACvtfcHk0lhAeUQ4hg6Bpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslKqsLzE&md5=3001cae6aa37ed9a4bf2c9b6b28ded04</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2Fj.euroneuro.2013.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.euroneuro.2013.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DAppel%26aufirst%3DL.%26aulast%3DBergstrom%26aufirst%3DM.%26aulast%3DBuus%2BLassen%26aufirst%3DJ.%26aulast%3DLangstrom%26aufirst%3DB.%26atitle%3DTesofensine%252C%2520a%2520novel%2520triple%2520monoamine%2520re-uptake%2520inhibitor%2520with%2520anti-obesity%2520effects%253A%2520dopamine%2520transporter%2520occupancy%2520as%2520measured%2520by%2520PET%26jtitle%3DEur.%2520Neuropsychopharmacol.%26date%3D2014%26volume%3D24%26spage%3D251%26epage%3D261%26doi%3D10.1016%2Fj.euroneuro.2013.10.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span> <i>DOV 21,947 Demonstrates Significant Body Weight
and BMI Reductions
in   Drug-Compliant Subjects in Phase Ib Clinical Study</i>; <span class="NLM_publisher-name">DOV Pharmaceutical</span>: <span class="NLM_publisher-loc">Somerset, NJ</span>, September 25, <span class="NLM_year">2007</span>; <a href="https://www.sec.gov/Archives/edgar/data/1066833/000114420407051174/v088668_ex99-1.htm" class="extLink">https://www.sec.gov/Archives/edgar/data/1066833/000114420407051174/v088668_ex99-1.htm</a> (accessed May 29, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+DOV+21%2C947+Demonstrates+Significant+Body+Weight%0Aand+BMI+Reductions%0Ain+Drug-Compliant+Subjects+in+Phase+Ib+Clinical+Study%3B+DOV+Pharmaceutical%3A+Somerset%2C+NJ%2C+September+25%2C+2007%3B+https%3A%2F%2Fwww.sec.gov%2FArchives%2Fedgar%2Fdata%2F1066833%2F000114420407051174%2Fv088668_ex99-1.htm+%28accessed+May+29%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DDOV%252021%252C947%2520Demonstrates%2520Significant%2520Body%2520Weight%250Aand%2520BMI%2520Reductions%250Ain%2520%2520%2520Drug-Compliant%2520Subjects%2520in%2520Phase%2520Ib%2520Clinical%2520Study%26pub%3DDOV%2520Pharmaceutical%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Astrup, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meier, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikkelsen, B. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villumsen, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, T. M.</span></span> <span> </span><span class="NLM_article-title">Weight loss produced by tesofensine in patients with Parkinson’s or Alzheimer’s disease</span>. <i>Obesity</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1363</span>– <span class="NLM_lpage">1369</span>, <span class="refDoi"> DOI: 10.1038/oby.2008.56</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1038%2Foby.2008.56" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=18356831" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsFCnsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2008&pages=1363-1369&author=A.+Astrupauthor=D.+H.+Meierauthor=B.+O.+Mikkelsenauthor=J.+S.+Villumsenauthor=T.+M.+Larsen&title=Weight+loss+produced+by+tesofensine+in+patients+with+Parkinson%E2%80%99s+or+Alzheimer%E2%80%99s+disease&doi=10.1038%2Foby.2008.56"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Weight Loss Produced by Tesofensine in Patients With Parkinson's or Alzheimer's Disease</span></div><div class="casAuthors">Astrup, Arne; Meier, Dieter H.; Mikkelsen, Birgit O.; Villumsen, John S.; Larsen, Thomas M.</div><div class="citationInfo"><span class="NLM_cas:title">Obesity</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1363-1369</span>CODEN:
                <span class="NLM_cas:coden">OBESAX</span>;
        ISSN:<span class="NLM_cas:issn">1930-7381</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Objective: Tesofensine (TE) is a norepinephrine, dopamine, and serotonin reuptake inhibitor.  We conducted a meta-anal. of TE's effect on body wt. in trials investigating its potential for treatment of Parkinson's or Alzheimer's disease.  Methods and Procedures: Four randomized, double-blind, multicenter trials compared TE (n = 740) and placebo (n = 228), two in each disease.  Patients received oral TE or placebo once daily for 14 wk without any wt. loss program.  Results were adjusted for baseline values, age, and study.  Results: In the placebo group, 14% were obese and 21% were in the TE group.  In the total cohort, wt. change after 14 wk was +0.5, -0.5, -0.9, -1.8, -2.8% in the placebo, 0.125, 0.25, 0.5 and 1.0 mg in the TE groups, resp. (P = 0.015 for dose effect).  In the obese subgroup, wt. changes were -0.2, -1.7, -1.6, -1.5, -3.7%, and 2.1, 8.2, 14.1, 20.9, 32.1% of the obese patients achieved ≥5% wt. loss (P < 0.001 for 0.25, 0.5, and 1.0 mg vs. placebo for both end points).  Changes in heart rate were -0.4, 2.1, 4.2, 6.0, and 6.8 bpm after 14 wk (TE vs. placebo: P < 0.001 from 0.25 mg), but no effect on blood pressure was obsd.  Discussion: TE produced a placebo-subtracted wt. loss of ∼4% for >14 wk without any diet and lifestyle therapy, which is similar to that of sibutramine, but with no effect on blood pressure.  On the basis of these results, TE is now being developed for obesity management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnawROXlX8YrVg90H21EOLACvtfcHk0lhAeUQ4hg6Bpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsFCnsrs%253D&md5=fdbd10425439c9cb5f63861803966b06</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1038%2Foby.2008.56&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Foby.2008.56%26sid%3Dliteratum%253Aachs%26aulast%3DAstrup%26aufirst%3DA.%26aulast%3DMeier%26aufirst%3DD.%2BH.%26aulast%3DMikkelsen%26aufirst%3DB.%2BO.%26aulast%3DVillumsen%26aufirst%3DJ.%2BS.%26aulast%3DLarsen%26aufirst%3DT.%2BM.%26atitle%3DWeight%2520loss%2520produced%2520by%2520tesofensine%2520in%2520patients%2520with%2520Parkinson%25E2%2580%2599s%2520or%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DObesity%26date%3D2008%26volume%3D16%26spage%3D1363%26epage%3D1369%26doi%3D10.1038%2Foby.2008.56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span> <i>Tesomet for Treatment of
Type 2 Diabetes</i>; <span class="NLM_publisher-name">Saniona</span>: <span class="NLM_publisher-loc">Ballerup, Denmark</span>, <span class="NLM_year">2017</span>; <a href="http://saniona.com/pipeline/tesomet-t2d/" class="extLink">http://saniona.com/pipeline/tesomet-t2d/</a> (accessed May 29, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Tesomet+for+Treatment+of%0AType+2+Diabetes%3B+Saniona%3A+Ballerup%2C+Denmark%2C+2017%3B+http%3A%2F%2Fsaniona.com%2Fpipeline%2Ftesomet-t2d%2F+%28accessed+May+29%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DTesomet%2520for%2520Treatment%2520of%250AType%25202%2520Diabetes%26pub%3DSaniona%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langdon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieschl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strong, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohrbach, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lelas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodge, N. J.</span></span> <span> </span><span class="NLM_article-title">Monoamine reuptake site occupancy of sibutramine: relationship to antidepressant-like and thermogenic effects in rats</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>737</i></span>,  <span class="NLM_fpage">47</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2014.03.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.ejphar.2014.03.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=24821570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVOnu7fL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=737&publication_year=2014&pages=47-56&author=Y.+W.+Liauthor=S.+Langdonauthor=R.+Pieschlauthor=T.+Strongauthor=R.+N.+Wrightauthor=K.+Rohrbachauthor=S.+Lelasauthor=N.+J.+Lodge&title=Monoamine+reuptake+site+occupancy+of+sibutramine%3A+relationship+to+antidepressant-like+and+thermogenic+effects+in+rats&doi=10.1016%2Fj.ejphar.2014.03.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Monoamine reuptake site occupancy of sibutramine: Relationship to antidepressant-like and thermogenic effects in rats</span></div><div class="casAuthors">Li, Yu-Wen; Langdon, Shaun; Pieschl, Rick; Strong, Todd; Wright, Robert N.; Rohrbach, Kenneth; Lelas, Snjezana; Lodge, Nicholas J.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">737</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">47-56</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Sibutramine was formerly marketed as an anti-obesity agent.  The current study investigated the relationships between monoamine reuptake site occupancy for sibutramine and both its antidepressant-like efficacy and thermogenic effects.  Sibutramine's effects on locomotor activity (LMA) and food intake were also evaluated.  Sibutramine occupied monoamine reuptake binding sites with the rank order of potency of NET>SERT>DAT; at 10 mg/kg, po, occupancy was 95% NET, 81% SERT and 73% DAT.  Sibutramine produced antidepressant-like behavior in the forced swim test; at the lowest ED (3 mg/kg, po) occupancy was 61%, 90% and 23% at SERT, NET and DAT sites, resp.  Sibutramine also increased body core temp. in a dose- and time-dependent manner; at the lowest ED (30 mg/kg) SERT, NET and DAT occupancies were resp. 78%, 86% and 59%.  A significant decrease in food consumption was obsd. at 3 and 10 mg/kg, po.  LMA was increased at ≥10 mg/kg, s.c.  The relationship between efficacy in the FST and occupancy was also detd. for citalopram, fluoxetine and reboxetine.  Similarly, the relationship between thermogenesis and target occupancy for several single or double/triple reuptake inhibitors was measured and showed that >40-50% DAT binding was required for thermogenesis.  Thermogenesis was blocked by the D1 antagonist SCH39166 (3 mg/kg, s.c.).  Our findings indicate that the antidepressant-like effect of sibutramine may result from additive or synergistic actions on the three reuptake binding targets.  At higher doses, sibutramine produces thermogenesis; DAT inhibition and activation of dopamine D1 receptors are required for this effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf84s-9gur8bVg90H21EOLACvtfcHk0lhAeUQ4hg6Bpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVOnu7fL&md5=1383220e1bf0d8cb9b055ee605cc8069</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2014.03.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2014.03.024%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%2BW.%26aulast%3DLangdon%26aufirst%3DS.%26aulast%3DPieschl%26aufirst%3DR.%26aulast%3DStrong%26aufirst%3DT.%26aulast%3DWright%26aufirst%3DR.%2BN.%26aulast%3DRohrbach%26aufirst%3DK.%26aulast%3DLelas%26aufirst%3DS.%26aulast%3DLodge%26aufirst%3DN.%2BJ.%26atitle%3DMonoamine%2520reuptake%2520site%2520occupancy%2520of%2520sibutramine%253A%2520relationship%2520to%2520antidepressant-like%2520and%2520thermogenic%2520effects%2520in%2520rats%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2014%26volume%3D737%26spage%3D47%26epage%3D56%26doi%3D10.1016%2Fj.ejphar.2014.03.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span> <i>Meridia (Sibutramine Hydrochloride Monohydrate)
Capsules CS-IV</i>; <span class="NLM_publisher-name">Abbott Laboratories</span>: <span class="NLM_publisher-loc">North Chicago, IL</span>, <span class="NLM_year">2017</span>; <a href="http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM130745.pdf" class="extLink">http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM130745.pdf</a> (accessed May 29, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Meridia+%28Sibutramine+Hydrochloride+Monohydrate%29%0ACapsules+CS-IV%3B+Abbott+Laboratories%3A+North+Chicago%2C+IL%2C+2017%3B+http%3A%2F%2Fwww.fda.gov%2Fdownloads%2FDrugs%2FDrugSafety%2FPostmarketDrugSafetyInformationforPatientsandProviders%2FUCM130745.pdf+%28accessed+May+29%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DMeridia%2520%2528Sibutramine%2520Hydrochloride%2520Monohydrate%2529%250ACapsules%2520CS-IV%26pub%3DAbbott%2520Laboratories%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span> <i>Our Pipeline: We’re
Focused on the Innovative Application
of Science and Medicine</i>; <span class="NLM_publisher-name">Sunovion</span>: <span class="NLM_publisher-loc">Marlborough, MA</span>, <span class="NLM_year">2017</span>; <a href="http://www.sunovion.us/research-and-development/pipeline.html" class="extLink">http://www.sunovion.us/research-and-development/pipeline.html</a> (accessed May 29, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Our+Pipeline%3A+We%E2%80%99re%0AFocused+on+the+Innovative+Application%0Aof+Science+and+Medicine%3B+Sunovion%3A+Marlborough%2C+MA%2C+2017%3B+http%3A%2F%2Fwww.sunovion.us%2Fresearch-and-development%2Fpipeline.html+%28accessed+May+29%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DOur%2520Pipeline%253A%2520We%25E2%2580%2599re%250AFocused%2520on%2520the%2520Innovative%2520Application%250Aof%2520Science%2520and%2520Medicine%26pub%3DSunovion%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span> <i>Cortellis</i>; <span class="NLM_publisher-name">Clarivate Analytics</span>: <span class="NLM_publisher-loc">Philadelphia</span>, <span class="NLM_year">2017</span>; <a href="https://cortellis.thomsonreuterslifesciences.com/" class="extLink">https://cortellis.thomsonreuterslifesciences.com/</a> (accessed May 29, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Cortellis%3B+Clarivate+Analytics%3A+Philadelphia%2C+2017%3B+https%3A%2F%2Fcortellis.thomsonreuterslifesciences.com%2F+%28accessed+May+29%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DCortellis%26pub%3DClarivate%2520Analytics%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, H.
H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang-Christensen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Axel, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raben, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikkelsen, J. D.</span></span> <span> </span><span class="NLM_article-title">The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>636</i></span>,  <span class="NLM_fpage">88</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2010.03.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.ejphar.2010.03.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=20385125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvVejs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=636&publication_year=2010&pages=88-95&author=H.%0AH.+Hansenauthor=G.+Hansenauthor=M.+Tang-Christensenauthor=P.+J.+Larsenauthor=A.+M.+Axelauthor=A.+Rabenauthor=J.+D.+Mikkelsen&title=The+novel+triple+monoamine+reuptake+inhibitor+tesofensine+induces+sustained+weight+loss+and+improves+glycemic+control+in+the+diet-induced+obese+rat%3A+comparison+to+sibutramine+and+rimonabant&doi=10.1016%2Fj.ejphar.2010.03.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: Comparison to sibutramine and rimonabant</span></div><div class="casAuthors">Hansen, Henrik H.; Hansen, Gitte; Tang-Christensen, Mads; Larsen, Philip J.; Axel, Anne Marie D.; Raben, Anne; Mikkelsen, Jens D.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">636</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">88-95</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Tesofensine, a novel triple monoamine reuptake inhibitor, produces a significant wt. loss in humans.  The present study aimed at characterizing the wt.-reducing effects of tesofensine in a rat model of diet-induced obesity.  Sibutramine and rimonabant were used as ref. comparators.  Compared to baseline, long-term treatment with tesofensine (28 days, 1.0 or 2.5 mg/kg, p.o.) resulted in a significant, dose-dependent and sustained wt. loss of 5.7 and 9.9%, resp.  Sibutramine (7.5 mg/kg, p.o.) treatment caused a sustained wt. loss of 7.6%, whereas the employed dose of rimonabant (10 mg/kg, p.o.) only produced a transient wt. redn.  While all compds. exhibited a significant inhibitory effect on food intake which gradually wore off, the hypophagic effect of tesofensine was longer lasting than sibutramine and rimonabant.  In contrast to tesofensine, the body wt. of pair-fed rats returned to baseline at the end of the study, which may indicate that tesofensine stimulated energy expenditure.  The differential efficacy on wt. redn. was also reflected in lowered body fat depots, as tesofensine and sibutramine most efficiently reduced abdominal and s.c. fat mass which was paralleled by reduced plasma lipid levels.  In an oral glucose tolerance test, only tesofensine significantly suppressed the plasma insulin response below the level that could be obtained by paired feeding, indicating that tesofensine further improved glycemic control.  In conclusion, the robust wt. loss with long-term tesofensine treatment is likely due to a combined synergistic effect of appetite suppression and increased energy expenditure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3wG9qAb2frrVg90H21EOLACvtfcHk0lg6yoCqYrbN0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvVejs74%253D&md5=85d6f07c6d9b167629741cfc3db9ff1b</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2010.03.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2010.03.026%26sid%3Dliteratum%253Aachs%26aulast%3DHansen%26aufirst%3DH.%2BH.%26aulast%3DHansen%26aufirst%3DG.%26aulast%3DTang-Christensen%26aufirst%3DM.%26aulast%3DLarsen%26aufirst%3DP.%2BJ.%26aulast%3DAxel%26aufirst%3DA.%2BM.%26aulast%3DRaben%26aufirst%3DA.%26aulast%3DMikkelsen%26aufirst%3DJ.%2BD.%26atitle%3DThe%2520novel%2520triple%2520monoamine%2520reuptake%2520inhibitor%2520tesofensine%2520induces%2520sustained%2520weight%2520loss%2520and%2520improves%2520glycemic%2520control%2520in%2520the%2520diet-induced%2520obese%2520rat%253A%2520comparison%2520to%2520sibutramine%2520and%2520rimonabant%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2010%26volume%3D636%26spage%3D88%26epage%3D95%26doi%3D10.1016%2Fj.ejphar.2010.03.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rascol, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poewe, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lees, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aristin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juhel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldhauser, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, T.</span></span>; <span class="NLM_contrib-group">ADVANS Study Group</span> <span> </span><span class="NLM_article-title">Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study</span>. <i>Arch. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">577</span>– <span class="NLM_lpage">583</span>, <span class="refDoi"> DOI: 10.1001/archneur.65.5.577</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1001%2Farchneur.65.5.577" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=18474731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A280%3ADC%252BD1czhtFOrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2008&pages=577-583&author=O.+Rascolauthor=W.+Poeweauthor=A.+Leesauthor=M.+Aristinauthor=L.+Salinauthor=N.+Juhelauthor=L.+Waldhauserauthor=T.+Schindlerauthor=ADVANS+Study+Group&title=Tesofensine+%28NS+2330%29%2C+a+monoamine+reuptake+inhibitor%2C+in+patients+with+advanced+Parkinson+disease+and+motor+fluctuations%3A+the+ADVANS+Study&doi=10.1001%2Farchneur.65.5.577"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study</span></div><div class="casAuthors">Rascol Olivier; Poewe Werner; Lees Andrew; Aristin Marina; Salin Laurence; Juhel Nolwenn; Waldhauser Lisa; Schindler Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Archives of neurology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">577-83</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  To assess the safety and efficacy of tesofensine, a triple monoamine reuptake inhibitor, in patients with advanced Parkinson disease (PD).  DESIGN:  A pilot phase 2, randomized, double-blind, placebo-controlled, parallel-group trial.  The study occurred in hospital-based outpatient clinics and in clinical trial units.  Patients with advanced PD and levodopa-related motor fluctuations were enrolled.  Tesofensine (0.125, 0.25, 0.5, or 1 mg) or placebo tablets were administered once daily for 14 weeks.  MAIN OUTCOME MEASURES:  Coprimary end points were the changes from baseline in Unified Parkinson Disease Rating Scale (UPDRS) subscale II (activities of daily living) plus subscale III (motor function) total score and in percentage of waking hours spent in "off" time noted in self-scoring diaries.  Secondary end points were safety, pharmacokinetics, responder analysis (> or =20% reduction in UPDRS score and in off time), and changes in percentage of waking hours spent in "on" time with and without troublesome dyskinesia.  RESULTS:  The adjusted mean differences (relative to placebo) were -4.7 points in UPDRS subscale II plus subscale III total score (P =.005) with tesofensine, 0.5 mg, and -7.1% in off time (-68 minutes, P =.02) with tesofensine, 0.25 mg.  Other dosages did not induce statistically significant effects.  The plasma concentration increased with the dosage, but no clear dose-response relationship was observed.  Gastrointestinal tract and neuropsychiatric adverse events were more frequent with tesofensine than with placebo, especially at the higher dosages.  CONCLUSIONS:  Patients with PD in advanced stages showed modest improvements in UPDRS subscale II plus subscale III total score and in off time when treated with tesofensine, but a dose-response relationship could not be established for efficacy, while adverse drug reactions tended to be more frequent at higher dosages.  TRIAL REGISTRATION:  clinicaltrials.gov Identifier: NCT00148512.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTwPRgr3W0hB1MGsG_HTXYFfW6udTcc2eZlQWhPz25BU7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1czhtFOrsA%253D%253D&md5=d206bdf83dd115071283939a57efb62f</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1001%2Farchneur.65.5.577&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchneur.65.5.577%26sid%3Dliteratum%253Aachs%26aulast%3DRascol%26aufirst%3DO.%26aulast%3DPoewe%26aufirst%3DW.%26aulast%3DLees%26aufirst%3DA.%26aulast%3DAristin%26aufirst%3DM.%26aulast%3DSalin%26aufirst%3DL.%26aulast%3DJuhel%26aufirst%3DN.%26aulast%3DWaldhauser%26aufirst%3DL.%26aulast%3DSchindler%26aufirst%3DT.%26aulast%3D%26atitle%3DTesofensine%2520%2528NS%25202330%2529%252C%2520a%2520monoamine%2520reuptake%2520inhibitor%252C%2520in%2520patients%2520with%2520advanced%2520Parkinson%2520disease%2520and%2520motor%2520fluctuations%253A%2520the%2520ADVANS%2520Study%26jtitle%3DArch.%2520Neurol.%26date%3D2008%26volume%3D65%26spage%3D577%26epage%3D583%26doi%3D10.1001%2Farchneur.65.5.577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, J.</span></span> <span> </span><span class="NLM_article-title">Norepinephrine transporter function and human cardiovascular disease</span>. <i>Am. J. Physiol. Heart Circ. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>303</i></span>,  <span class="NLM_fpage">H1273</span>– <span class="NLM_lpage">1282</span>, <span class="refDoi"> DOI: 10.1152/ajpheart.00492.2012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1152%2Fajpheart.00492.2012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=23023867" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=303&publication_year=2012&pages=H1273-1282&author=C.+Schroederauthor=J.+Jordan&title=Norepinephrine+transporter+function+and+human+cardiovascular+disease&doi=10.1152%2Fajpheart.00492.2012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1152%2Fajpheart.00492.2012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpheart.00492.2012%26sid%3Dliteratum%253Aachs%26aulast%3DSchroeder%26aufirst%3DC.%26aulast%3DJordan%26aufirst%3DJ.%26atitle%3DNorepinephrine%2520transporter%2520function%2520and%2520human%2520cardiovascular%2520disease%26jtitle%3DAm.%2520J.%2520Physiol.%2520Heart%2520Circ.%2520Physiol.%26date%3D2012%26volume%3D303%26spage%3DH1273%26epage%3D1282%26doi%3D10.1152%2Fajpheart.00492.2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeLorenzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichenstein, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Organisak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kharidia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsey, R. V.</span></span> <span> </span><span class="NLM_article-title">SEP-225289 serotonin and dopamine transporter occupancy: a PET study</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">1150</span>– <span class="NLM_lpage">1155</span>, <span class="refDoi"> DOI: 10.2967/jnumed.110.084525</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.2967%2Fjnumed.110.084525" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2011&pages=1150-1155&author=C.+DeLorenzoauthor=S.+Lichensteinauthor=K.+Schaeferauthor=J.+Dunnauthor=R.+Marshallauthor=L.+Organisakauthor=J.+Kharidiaauthor=B.+Robertsonauthor=J.+J.+Mannauthor=R.+V.+Parsey&title=SEP-225289+serotonin+and+dopamine+transporter+occupancy%3A+a+PET+study&doi=10.2967%2Fjnumed.110.084525"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.110.084525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.110.084525%26sid%3Dliteratum%253Aachs%26aulast%3DDeLorenzo%26aufirst%3DC.%26aulast%3DLichenstein%26aufirst%3DS.%26aulast%3DSchaefer%26aufirst%3DK.%26aulast%3DDunn%26aufirst%3DJ.%26aulast%3DMarshall%26aufirst%3DR.%26aulast%3DOrganisak%26aufirst%3DL.%26aulast%3DKharidia%26aufirst%3DJ.%26aulast%3DRobertson%26aufirst%3DB.%26aulast%3DMann%26aufirst%3DJ.%2BJ.%26aulast%3DParsey%26aufirst%3DR.%2BV.%26atitle%3DSEP-225289%2520serotonin%2520and%2520dopamine%2520transporter%2520occupancy%253A%2520a%2520PET%2520study%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2011%26volume%3D52%26spage%3D1150%26epage%3D1155%26doi%3D10.2967%2Fjnumed.110.084525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sramek, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bieck, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamora, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Versavel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kharidia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grinnell, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cutler, N. R.</span></span> <span> </span><span class="NLM_article-title">Exploratory biomarker study of the triple reuptake inhibitor SEP-432 compared to the dual reuptake inhibitor duloxetine in healthy normal subjects</span>. <i>CNS Neurosci. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">404</span>– <span class="NLM_lpage">412</span>, <span class="refDoi"> DOI: 10.1111/cns.12513</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1111%2Fcns.12513" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=26849844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtVent7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=404-412&author=J.+J.+Sramekauthor=L.+W.+Hardyauthor=P.+Bieckauthor=C.+Zamoraauthor=M.+Versavelauthor=J.+Kharidiaauthor=T.+Grinnellauthor=Y.+L.+Chenauthor=M.+Sullivanauthor=H.+Dingauthor=N.+R.+Cutler&title=Exploratory+biomarker+study+of+the+triple+reuptake+inhibitor+SEP-432+compared+to+the+dual+reuptake+inhibitor+duloxetine+in+healthy+normal+subjects&doi=10.1111%2Fcns.12513"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Exploratory Biomarker Study of the Triple Reuptake Inhibitor SEP-432 Compared to the Dual Reuptake Inhibitor Duloxetine in Healthy Normal Subjects</span></div><div class="casAuthors">Sramek, John J.; Hardy, Larry W.; Bieck, Peter; Zamora, Cynthia; Versavel, Mark; Kharidia, Jahnavi; Grinnell, Todd; Chen, Yu-Luan; Sullivan, Michael; Ding, Hong; Cutler, Neal R.</div><div class="citationInfo"><span class="NLM_cas:title">CNS Neuroscience & Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">404-412</span>CODEN:
                <span class="NLM_cas:coden">CNTNAB</span>;
        ISSN:<span class="NLM_cas:issn">1755-5930</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Introduction : SEP-432 is a triple monoamine reuptake inhibitor of norepinephrine (NE), serotonin (5-HT), and dopamine (DA), based on in vitro binding studies.  We sought evidence that SEP-432 engages these monoamine systems by measuring concns. of monoamines and/or their main metabolites in cerebrospinal fluid (CSF) and plasma and comparing results to duloxetine, a dual reuptake inhibitor of NE and 5-HT.  Methods : Eighteen healthy normal subjects received either SEP-432 (300 mg/day), duloxetine (60 mg/day), or placebo for 14 days in-clinic (double blind) with CSF and plasma collections at baseline (single lumbar puncture) and Day 14 (24-h CSF and plasma collection).  Concns. of monoamines and their metabolites, as well as pharmacokinetic concns. of SEP-432 and metabolite, were quantified by liq. chromatog.-tandem mass spectrometry.  Results : Compared to placebo in the Day 14 area under the curve 24-h (AUC0-24 h) anal., SEP-432 significantly (P < 0.05) decreased the NE metabolite dihydroxyphenylglycol (DHPG) in CSF and plasma, decreased 5-HT in plasma, and did not affect DA metabolites, while duloxetine had significant effects on DHPG and 5-HT.  Time-matched baseline to Day 14 biomarker comparisons confirmed these findings.  Conclusion : CSF monoamine biomarkers confirmed central NET activity for SEP-432 and duloxetine's dual reuptake inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMpRsq4CXinLVg90H21EOLACvtfcHk0lhMKK2cd9W54w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtVent7k%253D&md5=a7e13ad1632e45b1628116bbefa61074</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1111%2Fcns.12513&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcns.12513%26sid%3Dliteratum%253Aachs%26aulast%3DSramek%26aufirst%3DJ.%2BJ.%26aulast%3DHardy%26aufirst%3DL.%2BW.%26aulast%3DBieck%26aufirst%3DP.%26aulast%3DZamora%26aufirst%3DC.%26aulast%3DVersavel%26aufirst%3DM.%26aulast%3DKharidia%26aufirst%3DJ.%26aulast%3DGrinnell%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DY.%2BL.%26aulast%3DSullivan%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DH.%26aulast%3DCutler%26aufirst%3DN.%2BR.%26atitle%3DExploratory%2520biomarker%2520study%2520of%2520the%2520triple%2520reuptake%2520inhibitor%2520SEP-432%2520compared%2520to%2520the%2520dual%2520reuptake%2520inhibitor%2520duloxetine%2520in%2520healthy%2520normal%2520subjects%26jtitle%3DCNS%2520Neurosci.%2520Ther.%26date%3D2016%26volume%3D22%26spage%3D404%26epage%3D412%26doi%3D10.1111%2Fcns.12513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arakawa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nogami, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagashima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujiwara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodaka, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tateno, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okubo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suhara, T.</span></span> <span> </span><span class="NLM_article-title">Norepinephrine transporter occupancy by nortriptyline in patients with depression: a positron emission tomography study with (S,S)-[18F]FMeNER-D2</span>. <i>Int. J. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">553</span>– <span class="NLM_lpage">560</span>, <span class="refDoi"> DOI: 10.1017/S1461145713001521</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1017%2FS1461145713001521" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=24345533" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktV2hsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2014&pages=553-560&author=H.+Takanoauthor=R.+Arakawaauthor=T.+Nogamiauthor=M.+Suzukiauthor=T.+Nagashimaauthor=H.+Fujiwaraauthor=Y.+Kimuraauthor=F.+Kodakaauthor=K.+Takahataauthor=H.+Shimadaauthor=Y.+Murakamiauthor=A.+Tatenoauthor=M.+Yamadaauthor=H.+Itoauthor=K.+Kawamuraauthor=M.-R.+Zhangauthor=H.+Takahashiauthor=M.+Katoauthor=Y.+Okuboauthor=T.+Suhara&title=Norepinephrine+transporter+occupancy+by+nortriptyline+in+patients+with+depression%3A+a+positron+emission+tomography+study+with+%28S%2CS%29-%5B18F%5DFMeNER-D2&doi=10.1017%2FS1461145713001521"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Norepinephrine transporter occupancy by nortriptyline in patients with depression: a positron emission tomography study with (S,S)-[18F]FMeNER-D2</span></div><div class="casAuthors">Takano, Harumasa; Arakawa, Ryosuke; Nogami, Tsuyoshi; Suzuki, Masayuki; Nagashima, Tomohisa; Fujiwara, Hironobu; Kimura, Yasuyuki; Kodaka, Fumitoshi; Takahata, Keisuke; Shimada, Hitoshi; Murakami, Yoshitaka; Tateno, Amane; Yamada, Makiko; Ito, Hiroshi; Kawamura, Kazunori; Zhang, Ming-Rong; Takahashi, Hidehiko; Kato, Motoichiro; Okubo, Yoshiro; Suhara, Tetsuya</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">553-560</span>CODEN:
                <span class="NLM_cas:coden">IJNUFB</span>;
        ISSN:<span class="NLM_cas:issn">1461-1457</span>.
    
            (<span class="NLM_cas:orgname">Cambridge University Press</span>)
        </div><div class="casAbstract">Norepinephrine transporter (NET) plays important roles in the treatment of various neuropsychiatric disorders, such as depression and attention deficit hyperactivity disorder (ADHD).  Nortriptyline is a NET-selective tricyclic antidepressant (TCAs) that has been widely used for the treatment of depression.  Previous positron emission tomog. (PET) studies have reported over 80% serotonin transporter occupancy with clin. doses of selective serotonin reuptake inhibitors (SSRIs), but there has been no report of NET occupancy in patients treated with relatively NET-selective antidepressants.  In the present study, we used PET and (S,S)-[18F]FMeNER-D2 to investigate NET occupancies in the thalamus in 10 patients with major depressive disorder taking various doses of nortriptyline, who were considered to be responders to the treatment.  Ref. data for the calcn. of occupancy were derived from age-matched healthy controls.  The result showed approx. 50-70% NET occupancies in the brain as a result of the administration of 75-200 mg/d of nortriptyline.  The estd. ED (ED50) and concn. (EC50) required to induce 50% occupancy was 65.9 mg/d and 79.8 ng/mL, resp.  Furthermore, as the min. therapeutic level of plasma nortriptyline for the treatment of depression has been reported to be 70 ng/mL, our data indicate that this plasma nortriptyline concn. corresponds to approx. 50% NET occupancy measured with PET, suggesting that more than 50% of central NET occupancy would be appropriate for the nortriptyline treatment of patients with depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMoY4LOtJfObVg90H21EOLACvtfcHk0lhMKK2cd9W54w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktV2hsb0%253D&md5=d4a5190c8e0a7f0b70fc34bdef38c3e8</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1017%2FS1461145713001521&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS1461145713001521%26sid%3Dliteratum%253Aachs%26aulast%3DTakano%26aufirst%3DH.%26aulast%3DArakawa%26aufirst%3DR.%26aulast%3DNogami%26aufirst%3DT.%26aulast%3DSuzuki%26aufirst%3DM.%26aulast%3DNagashima%26aufirst%3DT.%26aulast%3DFujiwara%26aufirst%3DH.%26aulast%3DKimura%26aufirst%3DY.%26aulast%3DKodaka%26aufirst%3DF.%26aulast%3DTakahata%26aufirst%3DK.%26aulast%3DShimada%26aufirst%3DH.%26aulast%3DMurakami%26aufirst%3DY.%26aulast%3DTateno%26aufirst%3DA.%26aulast%3DYamada%26aufirst%3DM.%26aulast%3DIto%26aufirst%3DH.%26aulast%3DKawamura%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DM.-R.%26aulast%3DTakahashi%26aufirst%3DH.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DOkubo%26aufirst%3DY.%26aulast%3DSuhara%26aufirst%3DT.%26atitle%3DNorepinephrine%2520transporter%2520occupancy%2520by%2520nortriptyline%2520in%2520patients%2520with%2520depression%253A%2520a%2520positron%2520emission%2520tomography%2520study%2520with%2520%2528S%252CS%2529-%255B18F%255DFMeNER-D2%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2014%26volume%3D17%26spage%3D553%26epage%3D560%26doi%3D10.1017%2FS1461145713001521" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muller, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milton, M. N.</span></span> <span> </span><span class="NLM_article-title">The determination and interpretation of the therapeutic index in drug development</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">751</span>– <span class="NLM_lpage">761</span>, <span class="refDoi"> DOI: 10.1038/nrd3801</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1038%2Fnrd3801" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=22935759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ynt7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=751-761&author=P.+Y.+Mullerauthor=M.+N.+Milton&title=The+determination+and+interpretation+of+the+therapeutic+index+in+drug+development&doi=10.1038%2Fnrd3801"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">The determination and interpretation of the therapeutic index in drug development</span></div><div class="casAuthors">Muller, Patrick Y.; Milton, Mark N.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">751-761</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  A key part of drug discovery and development is the characterization and optimization of the safety and efficacy of drug candidates to identify those that have an appropriately balanced safety-efficacy profile for a given indication.  The therapeutic index (TI) - which is typically considered as the ratio of the highest exposure to the drug that results in no toxicity to the exposure that produces the desired efficacy - is an important parameter in efforts to achieve this balance.  Various types of safety and efficacy data are generated in vitro and in vivo (in animals and in humans), and these data can be used to predict the clin. TI of a drug candidate at an early stage.  However, approaches to systematically and quant. compare these types of data and to apply this knowledge more effectively are needed.  This article critically discusses the various aspects of TI detn. and interpretation in drug development for both small mol. drugs and biotherapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIUD30Kgdy-7Vg90H21EOLACvtfcHk0lhMKK2cd9W54w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ynt7vL&md5=a6650b73990e366d7ba144703089b2d4</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1038%2Fnrd3801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3801%26sid%3Dliteratum%253Aachs%26aulast%3DMuller%26aufirst%3DP.%2BY.%26aulast%3DMilton%26aufirst%3DM.%2BN.%26atitle%3DThe%2520determination%2520and%2520interpretation%2520of%2520the%2520therapeutic%2520index%2520in%2520drug%2520development%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D751%26epage%3D761%26doi%3D10.1038%2Fnrd3801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sorensen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husum, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennum, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bundgaard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montezinho, L. C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mork, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woertwein, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woldbye, D. P. D.</span></span> <span> </span><span class="NLM_article-title">Addiction-related effects of DOV 216,303 and cocaine: a comparative study in the mouse</span>. <i>Basic Clin. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">451</span>– <span class="NLM_lpage">459</span>, <span class="refDoi"> DOI: 10.1111/bcpt.12182</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1111%2Fbcpt.12182" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=24314270" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC2cXns12ksb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2014&pages=451-459&author=G.+Sorensenauthor=H.+Husumauthor=L.+T.+Brennumauthor=C.+Bundgaardauthor=L.+C.+P.+Montezinhoauthor=A.+Morkauthor=G.+Woertweinauthor=D.+P.+D.+Woldbye&title=Addiction-related+effects+of+DOV+216%2C303+and+cocaine%3A+a+comparative+study+in+the+mouse&doi=10.1111%2Fbcpt.12182"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Addiction-Related Effects of DOV 216,303 and Cocaine: A Comparative Study in the Mouse</span></div><div class="casAuthors">Sorensen, Gunnar; Husum, Henriette; Brennum, Lise T.; Bundgaard, Christoffer; Montezinho, Liliana C. P.; Mork, Arne; Woertwein, Gitta; Woldbye, David P. D.</div><div class="citationInfo"><span class="NLM_cas:title">Basic & Clinical Pharmacology & Toxicology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">451-459</span>CODEN:
                <span class="NLM_cas:coden">BCPTBO</span>;
        ISSN:<span class="NLM_cas:issn">1742-7835</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">DOV 216,303, an inhibitor of serotonin, noradrenaline and dopamine reuptake, belongs to a new line of drugs called 'triple reuptake inhibitors' that have been proposed for treatment of depression.  The addictive drug cocaine has similar mechanism of action and exerts rewarding effects by blocking reuptake of dopamine, leading to increased extracellular concns. of dopamine in the nucleus accumbens.  Thus, DOV 216,303 and other triple reuptake inhibitors might be speculated to exhibit abuse potential, limiting their future therapeutic use.  To further elucidate potential addictive properties of DOV 216,303, we conducted a comparative study of addiction-related effects of DOV 216,303 and cocaine in mice using acute self-administration, conditioned place preference (CPP) and drug-induced hyperlocomotion.  Effects on accumbal extracellular dopamine levels were detd. using microdialysis, and we measured monoamine receptor occupancy as well as brain and plasma exposure.  DOV 216,303 was self-administered acutely in the same dose range as cocaine.  However, in the CPP model, DOV 216,303 did not induce place preference at doses where cocaine caused place preference.  Higher doses of DOV 216,303 than cocaine were needed to induce hyperlocomotion and increase extracellular accumbal dopamine with EDs being higher than EDs used in depression models.  Moreover, DOV 216,303 displayed a pharmacokinetic profile with lower potential for addiction than cocaine.  Thus, high levels of DAT occupancy were reached slower and decayed more slowly after DOV 216,303 than cocaine administration.  The present study shows that acute administration of DOV 216,303 displays some addictive-like properties in mice, but these were less pronounced than cocaine, most likely due to different pharmacokinetic profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLmmoaUXJJR7Vg90H21EOLACvtfcHk0lhPXPNI3ARuPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXns12ksb4%253D&md5=7bdcc848ab22ac5b32da27a46719a27b</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1111%2Fbcpt.12182&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcpt.12182%26sid%3Dliteratum%253Aachs%26aulast%3DSorensen%26aufirst%3DG.%26aulast%3DHusum%26aufirst%3DH.%26aulast%3DBrennum%26aufirst%3DL.%2BT.%26aulast%3DBundgaard%26aufirst%3DC.%26aulast%3DMontezinho%26aufirst%3DL.%2BC.%2BP.%26aulast%3DMork%26aufirst%3DA.%26aulast%3DWoertwein%26aufirst%3DG.%26aulast%3DWoldbye%26aufirst%3DD.%2BP.%2BD.%26atitle%3DAddiction-related%2520effects%2520of%2520DOV%2520216%252C303%2520and%2520cocaine%253A%2520a%2520comparative%2520study%2520in%2520the%2520mouse%26jtitle%3DBasic%2520Clin.%2520Pharmacol.%2520Toxicol.%26date%3D2014%26volume%3D114%26spage%3D451%26epage%3D459%26doi%3D10.1111%2Fbcpt.12182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Volkow, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowler, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swanson, J. M.</span></span> <span> </span><span class="NLM_article-title">Dopamine in drug abuse and addiction: results from imaging studies and treatment implications</span>. <i>Mol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">557</span>– <span class="NLM_lpage">569</span>, <span class="refDoi"> DOI: 10.1038/sj.mp.4001507</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1038%2Fsj.mp.4001507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=15098002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkt1Gnt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=557-569&author=N.+D.+Volkowauthor=J.+S.+Fowlerauthor=G.+J.+Wangauthor=J.+M.+Swanson&title=Dopamine+in+drug+abuse+and+addiction%3A+results+from+imaging+studies+and+treatment+implications&doi=10.1038%2Fsj.mp.4001507"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine in drug abuse and addiction: results from imaging studies and treatment implications</span></div><div class="casAuthors">Volkow, N. D.; Fowler, J. S.; Wang, G-J.; Swanson, J. M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Psychiatry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">557-569</span>CODEN:
                <span class="NLM_cas:coden">MOPSFQ</span>;
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The involvement of dopamine in drug reinforcement is well recognized but its role in drug addiction is much less clear.  Imaging studies have shown that the reinforcing effects of drugs of abuse in humans are contingent upon large and fast increases in dopamine that mimic but exceed in the intensity and duration those induced by dopamine cell firing to environmental events.  In addn., imaging studies have also documented a role of dopamine in motivation, which appears to be encoded both by fast as well as smooth DA increases.  Since dopamine cells fire in response to salient stimuli, the supraphysiol. activation by drugs is likely to be experienced as highly salient (driving attention, arousal conditioned learning and motivation) and may also reset the thresholds required for environmental events to activate dopamine cells.  Indeed, imaging studies have shown that in drug-addicted subjects, dopamine function is markedly disrupted (decreases in dopamine release and in dopamine D2 receptors in striatum) and this is assocd. with reduced activity of the orbitofrontal cortex (neuroanatomical region involved with salience attribution and motivation and implicated in compulsive behaviors) and the cingulate gyrus (neuroanatomical region involved with inhibitory control and attention and implicated in impulsivity).  However, when addicted subjects are exposed to drug-related stimuli, these hypoactive regions become hyperactive in proportion to the expressed desire for the drug.  We postulate that decreased dopamine function in addicted subjects results in decreased sensitivity to nondrug-related stimuli (including natural reinforcers) and disrupts frontal inhibition, both of which contribute to compulsive drug intake and impaired inhibitory control.  These findings suggest new strategies for pharmacol. and behavioral treatments, which focus on enhancing DA function and restoring brain circuits disrupted by chronic drug use to help motivate the addicted subject in activities that provide alternative sources of reinforcement, counteract conditioned responses, enhance their ability to control their drive to take drugs and interfere with their compulsive administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZHeX9A089TbVg90H21EOLACvtfcHk0lhPXPNI3ARuPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkt1Gnt7Y%253D&md5=6e1b785207fb3003b50f19491ca9413e</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1038%2Fsj.mp.4001507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.mp.4001507%26sid%3Dliteratum%253Aachs%26aulast%3DVolkow%26aufirst%3DN.%2BD.%26aulast%3DFowler%26aufirst%3DJ.%2BS.%26aulast%3DWang%26aufirst%3DG.%2BJ.%26aulast%3DSwanson%26aufirst%3DJ.%2BM.%26atitle%3DDopamine%2520in%2520drug%2520abuse%2520and%2520addiction%253A%2520results%2520from%2520imaging%2520studies%2520and%2520treatment%2520implications%26jtitle%3DMol.%2520Psychiatry%26date%3D2004%26volume%3D9%26spage%3D557%26epage%3D569%26doi%3D10.1038%2Fsj.mp.4001507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boules, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briody, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliveros, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blazar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlier, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richelson, E.</span></span> <span> </span><span class="NLM_article-title">Antidepressant-like pharmacological profile of a novel triple reuptake inhibitor, (1S,2S)-3-(methylamino)-2-(naphthalen-2-yl)-1-phenylpropan-1-ol (PRC200-SS)</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>327</i></span>,  <span class="NLM_fpage">573</span>– <span class="NLM_lpage">583</span>, <span class="refDoi"> DOI: 10.1124/jpet.108.143610</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1124%2Fjpet.108.143610" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=18689611" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlWns7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=327&publication_year=2008&pages=573-583&author=Y.+Liangauthor=A.+M.+Shawauthor=M.+Boulesauthor=S.+Briodyauthor=J.+Robinsonauthor=A.+Oliverosauthor=E.+Blazarauthor=K.+Williamsauthor=Y.+Zhangauthor=P.+R.+Carlierauthor=E.+Richelson&title=Antidepressant-like+pharmacological+profile+of+a+novel+triple+reuptake+inhibitor%2C+%281S%2C2S%29-3-%28methylamino%29-2-%28naphthalen-2-yl%29-1-phenylpropan-1-ol+%28PRC200-SS%29&doi=10.1124%2Fjpet.108.143610"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Antidepressant-like pharmacological profile of a novel triple reuptake inhibitor, (1S,2S)-3-(methylamino)-2-(naphthalen-2-yl)-1-phenylpropan-1-ol (PRC200-SS)</span></div><div class="casAuthors">Liang, Yanqi; Shaw, Amanda M.; Boules, Mona; Briody, Siobhan; Robinson, Jessica; Oliveros, Alfredo; Blazar, Eric; Williams, Katrina; Zhang, Yiqun; Carlier, Paul R.; Richelson, Elliott</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">327</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">573-583</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Due to the putative involvement of dopaminergic circuits in depression, triple reuptake inhibitors are being developed as a new class of antidepressant, which is hypothesized to produce a more rapid onset and better efficacy than current antidepressants selective for serotonin or norepinephrine neurotransmission.  (1S,2S)-3-(Methylamino)-2-(naphthalen-2-yl)-1-phenylpropan-1-ol (PRC 200SS), a new triple reuptake inhibitor, potently bound to the human serotonin, norepinephrine, and dopamine transporters with Kd values of 2.3, 0.63, and 18 nM, resp.  Inhibition of serotonin, norepinephrine, and dopamine uptake by PRC 200SS was also shown in cells expressing the corresponding transporter (Ki values of 2.1, 1.5, and 61 nM, resp.).  In vivo, PRC 200SS dose-dependently decreased immobility in the forced-swim test in rats and in the tail-suspension test in mice, models predictive of antidepressant activity, with effects comparable with imipramine.  These results in the behavioral models did not seem to result from the stimulation of locomotor activity.  Consistent with the in vitro data and behavioral effects, peripheral administration of PRC 200SS (5 and 10 mg/kg i.p.) significantly increased extracellular levels of serotonin and norepinephrine in the medial prefrontal cortex, and of serotonin and dopamine in the core of nucleus accumbens, with redn. of levels of 3,4-dihydroxyphenylacetic acid, homovanillic acid, and 5-hydroxyindoleacetic acid compared with levels for saline control.  Furthermore, PRC 200SS self-administration, which was used as a marker of abuse liability, was not obsd. with rats.  Therefore, it seems that PRC 200SS may represent a novel triple reuptake inhibitor and possess antidepressant activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsjq1Ko19NBbVg90H21EOLACvtfcHk0lhPXPNI3ARuPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlWns7vJ&md5=1cfb6ece94bf5fa1187219d03f676d09</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1124%2Fjpet.108.143610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.108.143610%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DShaw%26aufirst%3DA.%2BM.%26aulast%3DBoules%26aufirst%3DM.%26aulast%3DBriody%26aufirst%3DS.%26aulast%3DRobinson%26aufirst%3DJ.%26aulast%3DOliveros%26aufirst%3DA.%26aulast%3DBlazar%26aufirst%3DE.%26aulast%3DWilliams%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DCarlier%26aufirst%3DP.%2BR.%26aulast%3DRichelson%26aufirst%3DE.%26atitle%3DAntidepressant-like%2520pharmacological%2520profile%2520of%2520a%2520novel%2520triple%2520reuptake%2520inhibitor%252C%2520%25281S%252C2S%2529-3-%2528methylamino%2529-2-%2528naphthalen-2-yl%2529-1-phenylpropan-1-ol%2520%2528PRC200-SS%2529%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2008%26volume%3D327%26spage%3D573%26epage%3D583%26doi%3D10.1124%2Fjpet.108.143610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koblan, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallina, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy-Cooperman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoedel, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loebel, A.</span></span> <span> </span><span class="NLM_article-title">Assessment of human abuse potential of dasotraline compared to methylphenidate and placebo in recreational stimulant users</span>. <i>Drug Alcohol Depend.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>159</i></span>,  <span class="NLM_fpage">26</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1016/j.drugalcdep.2015.10.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.drugalcdep.2015.10.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=26794682" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFCqurjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=2016&pages=26-34&author=K.+S.+Koblanauthor=S.+C.+Hopkinsauthor=K.+Sarmaauthor=N.+Gallinaauthor=F.+Jinauthor=N.+Levy-Coopermanauthor=K.+A.+Schoedelauthor=A.+Loebel&title=Assessment+of+human+abuse+potential+of+dasotraline+compared+to+methylphenidate+and+placebo+in+recreational+stimulant+users&doi=10.1016%2Fj.drugalcdep.2015.10.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Assessment of human abuse potential of dasotraline compared to methylphenidate and placebo in recreational stimulant users</span></div><div class="casAuthors">Koblan, K. S.; Hopkins, S. C.; Sarma, K.; Gallina, N.; Jin, F.; Levy-Cooperman, N.; Schoedel, K. A.; Loebel, A.</div><div class="citationInfo"><span class="NLM_cas:title">Drug and Alcohol Dependence</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">159</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">26-34</span>CODEN:
                <span class="NLM_cas:coden">DADEDV</span>;
        ISSN:<span class="NLM_cas:issn">0376-8716</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">The aim of this study was to evaluate the abuse potential of dasotraline, a novel dopamine and norepinephrine reuptake inhibitor with slow absorption (tmax, 10-12 h) and elimination (t1/2 = 47-77 h) that is in development for the treatment of attention deficit hyperactivity disorder (ADHD).  Recreational stimulant users (N = 48) who had specific experience with cocaine, and who were able to distinguish methylphenidate (60 mg) vs. placebo in a qualification session, were randomized, in a 6-period, double-blind, crossover design, to receive single doses of dasotraline 8 mg, 16 mg, and 36 mg, methylphenidate (MPH) 40 mg and 80 mg, and placebo.  The primary endpoint was the Drug Liking Visual Analog Scale (VAS) score at the time of peak effect (Emax).  There were no significant differences between the 3 doses of dasotraline and placebo on the drug liking VAS at Emax, and on most secondary endpoints.  Both doses of MPH had significantly higher VAS-drug liking scores at Emax relative to both placebo (P < 0.001 for all comparisons) and dasotraline 8 mg (P < 0.001), 16 mg (P < 0.001) and 36 mg (P < 0.01).  The increase in heart rate for MPH and dasotraline 36 mg showed a time-course that closely matched subject-rated measures such as Any Effects VAS.  In this study, dasotraline was found to have low potential for abuse, which may be, in part, related to its established pharmacokinetics (PK) profile, which is characterized by slow absorption and gradual elimination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9cXlgfxYCRrVg90H21EOLACvtfcHk0ljgYwcSFLu4Kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFCqurjI&md5=7786128edd70cc8929948d723cbd0b51</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2Fj.drugalcdep.2015.10.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drugalcdep.2015.10.029%26sid%3Dliteratum%253Aachs%26aulast%3DKoblan%26aufirst%3DK.%2BS.%26aulast%3DHopkins%26aufirst%3DS.%2BC.%26aulast%3DSarma%26aufirst%3DK.%26aulast%3DGallina%26aufirst%3DN.%26aulast%3DJin%26aufirst%3DF.%26aulast%3DLevy-Cooperman%26aufirst%3DN.%26aulast%3DSchoedel%26aufirst%3DK.%2BA.%26aulast%3DLoebel%26aufirst%3DA.%26atitle%3DAssessment%2520of%2520human%2520abuse%2520potential%2520of%2520dasotraline%2520compared%2520to%2520methylphenidate%2520and%2520placebo%2520in%2520recreational%2520stimulant%2520users%26jtitle%3DDrug%2520Alcohol%2520Depend.%26date%3D2016%26volume%3D159%26spage%3D26%26epage%3D34%26doi%3D10.1016%2Fj.drugalcdep.2015.10.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schoedel, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meier, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakraborty, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manniche, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, E. M.</span></span> <span> </span><span class="NLM_article-title">Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">69</span>– <span class="NLM_lpage">78</span>, <span class="refDoi"> DOI: 10.1038/clpt.2010.67</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1038%2Fclpt.2010.67" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=20520602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC3cXns1Gjsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2010&pages=69-78&author=K.+A.+Schoedelauthor=D.+Meierauthor=B.+Chakrabortyauthor=P.+M.+Mannicheauthor=E.+M.+Sellers&title=Subjective+and+objective+effects+of+the+novel+triple+reuptake+inhibitor+tesofensine+in+recreational+stimulant+users&doi=10.1038%2Fclpt.2010.67"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Subjective and Objective Effects of the Novel Triple Reuptake Inhibitor Tesofensine in Recreational Stimulant Users</span></div><div class="casAuthors">Schoedel, K. A.; Meier, D.; Chakraborty, B.; Manniche, P. M.; Sellers, E. M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">69-78</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Tesofensine is a (triple) reuptake inhibitor of noradrenaline, dopamine, and serotonin that is in development for the treatment of obesity.  The abuse potential of triple reuptake inhibitors is not yet known, and so this study was undertaken to evaluate the potential abuse-related effects of tesofensine in humans.  It was designed as a single-dose, randomized, double-blind, crossover study involving tesofensine vs. placebo, -amphetamine (pos. control for dopaminergic/stimulant effects), bupropion, and atomoxetine (neg./unscheduled controls) in recreational stimulant users (N = 52).  Subjective and objective measures were assessed for 48 h after drug administration.  The study results show that the effects of -amphetamine were significantly greater than those of placebo on all primary and secondary subjective measures.  The effects of tesofensine were not significantly different from those of placebo and were lower than those of -amphetamine 30 mg on all primary and most secondary measures.  The effects of tesofensine were either lower than or not different from those of bupropion or atomoxetine.  These results demonstrate that the abuse potential for tesofensine is no greater than that of bupropion or atomoxetine, and tesofensine is therefore unlikely to be recreationally abused.  Clin. Pharmacol. & Therapeutics (2010) 88 1, 69-78. doi:10.1038/clpt.2010.67.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPtqgt3Y92_rVg90H21EOLACvtfcHk0ljgYwcSFLu4Kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXns1Gjsrw%253D&md5=efcef974ffdec57839bb39fdc032fac1</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2010.67&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2010.67%26sid%3Dliteratum%253Aachs%26aulast%3DSchoedel%26aufirst%3DK.%2BA.%26aulast%3DMeier%26aufirst%3DD.%26aulast%3DChakraborty%26aufirst%3DB.%26aulast%3DManniche%26aufirst%3DP.%2BM.%26aulast%3DSellers%26aufirst%3DE.%2BM.%26atitle%3DSubjective%2520and%2520objective%2520effects%2520of%2520the%2520novel%2520triple%2520reuptake%2520inhibitor%2520tesofensine%2520in%2520recreational%2520stimulant%2520users%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2010%26volume%3D88%26spage%3D69%26epage%3D78%26doi%3D10.1038%2Fclpt.2010.67" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span> <i>Neurovance Announces Top-Line
Study Results Suggest Lower Abuse Potential
for Centanafadine Compared to Stimulants Used for Adult ADHD</i>; <span class="NLM_publisher-name">Neurovance</span>: <span class="NLM_publisher-loc">Cambridge,
MA</span>, <span class="NLM_year">2014</span>; <a href="http://www.neurovance.com/wp-content/uploads/2014/08/Press-Release_-Neurovance_HAL-results.-BWire-FINAL.pdf" class="extLink">http://www.neurovance.com/wp-content/uploads/2014/08/Press-Release_-Neurovance_HAL-results.-BWire-FINAL.pdf</a> (accessed May 29, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Neurovance+Announces+Top-Line%0AStudy+Results+Suggest+Lower+Abuse+Potential%0Afor+Centanafadine+Compared+to+Stimulants+Used+for+Adult+ADHD%3B+Neurovance%3A+Cambridge%2C%0AMA%2C+2014%3B+http%3A%2F%2Fwww.neurovance.com%2Fwp-content%2Fuploads%2F2014%2F08%2FPress-Release_-Neurovance_HAL-results.-BWire-FINAL.pdf+%28accessed+May+29%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DNeurovance%2520Announces%2520Top-Line%250AStudy%2520Results%2520Suggest%2520Lower%2520Abuse%2520Potential%250Afor%2520Centanafadine%2520Compared%2520to%2520Stimulants%2520Used%2520for%2520Adult%2520ADHD%26pub%3DNeurovance%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lengyel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieschl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strong, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodge, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. W.</span></span> <span> </span><span class="NLM_article-title">Ex vivo assessment of binding site occupancy of monoamine reuptake inhibitors: methodology and biological significance</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2008.04.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.neuropharm.2008.04.014" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2008&pages=63-70&author=K.+Lengyelauthor=R.+Pieschlauthor=T.+Strongauthor=T.+Molskiauthor=G.+Mattsonauthor=N.+J.+Lodgeauthor=Y.+W.+Li&title=Ex+vivo+assessment+of+binding+site+occupancy+of+monoamine+reuptake+inhibitors%3A+methodology+and+biological+significance&doi=10.1016%2Fj.neuropharm.2008.04.014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2008.04.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2008.04.014%26sid%3Dliteratum%253Aachs%26aulast%3DLengyel%26aufirst%3DK.%26aulast%3DPieschl%26aufirst%3DR.%26aulast%3DStrong%26aufirst%3DT.%26aulast%3DMolski%26aufirst%3DT.%26aulast%3DMattson%26aufirst%3DG.%26aulast%3DLodge%26aufirst%3DN.%2BJ.%26aulast%3DLi%26aufirst%3DY.%2BW.%26atitle%3DEx%2520vivo%2520assessment%2520of%2520binding%2520site%2520occupancy%2520of%2520monoamine%2520reuptake%2520inhibitors%253A%2520methodology%2520and%2520biological%2520significance%26jtitle%3DNeuropharmacology%26date%3D2008%26volume%3D55%26spage%3D63%26epage%3D70%26doi%3D10.1016%2Fj.neuropharm.2008.04.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Micheli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavanni, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arban, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benedetti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertani, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bettati, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bettelini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonanomi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braggio, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Checchia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davalli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Fabio, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fazzolari, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchioro, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minick, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliosi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sartori, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tedesco, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarsi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terreni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visentini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zocchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zonzini, L.</span></span> <span> </span><span class="NLM_article-title">1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2534</span>– <span class="NLM_lpage">2551</span>, <span class="refDoi"> DOI: 10.1021/jm901818u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901818u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitFyhsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2534-2551&author=F.+Micheliauthor=P.+Cavanniauthor=R.+Arbanauthor=R.+Benedettiauthor=B.+Bertaniauthor=M.+Bettatiauthor=L.+Betteliniauthor=G.+Bonanomiauthor=S.+Braggioauthor=A.+Checchiaauthor=S.+Davalliauthor=R.+Di+Fabioauthor=E.+Fazzolariauthor=S.+Fontanaauthor=C.+Marchioroauthor=D.+Minickauthor=M.+Negriauthor=B.+Oliosiauthor=K.+D.+Readauthor=I.+Sartoriauthor=G.+Tedescoauthor=L.+Tarsiauthor=S.+Terreniauthor=F.+Visentiniauthor=A.+Zocchiauthor=L.+Zonzini&title=1-%28Aryl%29-6-%5Balkoxyalkyl%5D-3-azabicyclo%5B3.1.0%5Dhexanes+and+6-%28aryl%29-6-%5Balkoxyalkyl%5D-3-azabicyclo%5B3.1.0%5Dhexanes%3A+a+new+series+of+potent+and+selective+triple+reuptake+inhibitors&doi=10.1021%2Fjm901818u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: A New Series of Potent and Selective Triple Reuptake Inhibitors</span></div><div class="casAuthors">Micheli, Fabrizio; Cavanni, Paolo; Arban, Roberto; Benedetti, Roberto; Bertani, Barbara; Bettati, Michela; Bettelini, Letizia; Bonanomi, Giorgio; Braggio, Simone; Checchia, Anna; Davalli, Silvia; Di Fabio, Romano; Fazzolari, Elettra; Fontana, Stefano; Marchioro, Carla; Minick, Doug; Negri, Michele; Oliosi, Beatrice; Read, Kevin D.; Sartori, Ilaria; Tedesco, Giovanna; Tarsi, Luca; Terreni, Silvia; Visentini, Filippo; Zocchi, Alessandro; Zonzini, Laura</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2534-2551</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of new highly potent and selective triple reuptake inhibitors is reported.  The new classes of 1-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes are described together with detailed SAR.  Appropriate decoration of the scaffolds was achieved with the help of a triple reuptake inhibitor pharmacophore model detailed here.  Selected derivs. showed good oral bioavailability (>30%) and brain penetration (B/B > 4) in rats assocd. with high in vitro potency and selectivity at SERT, NET, and DAT.  Among these compds., microdialysis and in vivo expts. confirm that deriv. 15 has an appropriate developability profile to be considered for further progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoD-IzrnTZWyLVg90H21EOLACvtfcHk0lgD5ZbP4DJfXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitFyhsbk%253D&md5=233ea2bd7c94826f351abafcde62da0d</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1021%2Fjm901818u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901818u%26sid%3Dliteratum%253Aachs%26aulast%3DMicheli%26aufirst%3DF.%26aulast%3DCavanni%26aufirst%3DP.%26aulast%3DArban%26aufirst%3DR.%26aulast%3DBenedetti%26aufirst%3DR.%26aulast%3DBertani%26aufirst%3DB.%26aulast%3DBettati%26aufirst%3DM.%26aulast%3DBettelini%26aufirst%3DL.%26aulast%3DBonanomi%26aufirst%3DG.%26aulast%3DBraggio%26aufirst%3DS.%26aulast%3DChecchia%26aufirst%3DA.%26aulast%3DDavalli%26aufirst%3DS.%26aulast%3DDi%2BFabio%26aufirst%3DR.%26aulast%3DFazzolari%26aufirst%3DE.%26aulast%3DFontana%26aufirst%3DS.%26aulast%3DMarchioro%26aufirst%3DC.%26aulast%3DMinick%26aufirst%3DD.%26aulast%3DNegri%26aufirst%3DM.%26aulast%3DOliosi%26aufirst%3DB.%26aulast%3DRead%26aufirst%3DK.%2BD.%26aulast%3DSartori%26aufirst%3DI.%26aulast%3DTedesco%26aufirst%3DG.%26aulast%3DTarsi%26aufirst%3DL.%26aulast%3DTerreni%26aufirst%3DS.%26aulast%3DVisentini%26aufirst%3DF.%26aulast%3DZocchi%26aufirst%3DA.%26aulast%3DZonzini%26aufirst%3DL.%26atitle%3D1-%2528Aryl%2529-6-%255Balkoxyalkyl%255D-3-azabicyclo%255B3.1.0%255Dhexanes%2520and%25206-%2528aryl%2529-6-%255Balkoxyalkyl%255D-3-azabicyclo%255B3.1.0%255Dhexanes%253A%2520a%2520new%2520series%2520of%2520potent%2520and%2520selective%2520triple%2520reuptake%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2534%26epage%3D2551%26doi%3D10.1021%2Fjm901818u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Micheli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavanni, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreotti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arban, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benedetti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertani, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bettati, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bettelini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonanomi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braggio, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carletti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Checchia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corsi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fazzolari, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchioro, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlo-Pich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliosi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roscic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sartori, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tedesco, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarsi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terreni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visentini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zocchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zonzini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Fabio, R.</span></span> <span> </span><span class="NLM_article-title">6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">4989</span>– <span class="NLM_lpage">5001</span>, <span class="refDoi"> DOI: 10.1021/jm100481d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100481d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntF2jtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4989-5001&author=F.+Micheliauthor=P.+Cavanniauthor=D.+Andreottiauthor=R.+Arbanauthor=R.+Benedettiauthor=B.+Bertaniauthor=M.+Bettatiauthor=L.+Betteliniauthor=G.+Bonanomiauthor=S.+Braggioauthor=R.+Carlettiauthor=A.+Checchiaauthor=M.+Corsiauthor=E.+Fazzolariauthor=S.+Fontanaauthor=C.+Marchioroauthor=E.+Merlo-Pichauthor=M.+Negriauthor=B.+Oliosiauthor=E.+Rattiauthor=K.+D.+Readauthor=M.+Roscicauthor=I.+Sartoriauthor=S.+Spadaauthor=G.+Tedescoauthor=L.+Tarsiauthor=S.+Terreniauthor=F.+Visentiniauthor=A.+Zocchiauthor=L.+Zonziniauthor=R.+Di+Fabio&title=6-%283%2C4-dichlorophenyl%29-1-%5B%28methyloxy%29methyl%5D-3-azabicyclo%5B4.1.0%5Dheptane%3A+a+new+potent+and+selective+triple+reuptake+inhibitor&doi=10.1021%2Fjm100481d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">6-(3,4-Dichlorophenyl)-1-[(Methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: A New Potent and Selective Triple Reuptake Inhibitor</span></div><div class="casAuthors">Micheli, Fabrizio; Cavanni, Paolo; Andreotti, Daniele; Arban, Roberto; Benedetti, Roberto; Bertani, Barbara; Bettati, Michela; Bettelini, Letizia; Bonanomi, Giorgio; Braggio, Simone; Carletti, Renzo; Checchia, Anna; Corsi, Mauro; Fazzolari, Elettra; Fontana, Stefano; Marchioro, Carla; Merlo-Pich, Emilio; Negri, Michele; Oliosi, Beatrice; Ratti, Emiliangelo; Read, Kevin D.; Roscic, Maja; Sartori, Ilaria; Spada, Simone; Tedesco, Giovanna; Tarsi, Luca; Terreni, Silvia; Visentini, Filippo; Zocchi, Alessandro; Zonzini, Laura; Di Fabio, Romano</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4989-5001</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A pharmacophore model for triple reuptake inhibitors and the new class of 1-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes were recently reported.  Further investigation in this area led to the identification of a new series of potent and selective triple reuptake inhibitors endowed with good developability characteristics.  Excellent bioavailability and brain penetration are assocd. with this series of 6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptanes together with high in vitro potency and selectivity at SERT, NET, and DAT.  In vivo microdialysis expts. in different animal models and receptor occupancy studies in rat confirmed that deriv. 17 (I) showed an appropriate profile to guarantee further progression of the compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0NYLPRsborLVg90H21EOLACvtfcHk0lgD5ZbP4DJfXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntF2jtbo%253D&md5=b250a9a4f7772f81ab2702180348b254</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1021%2Fjm100481d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100481d%26sid%3Dliteratum%253Aachs%26aulast%3DMicheli%26aufirst%3DF.%26aulast%3DCavanni%26aufirst%3DP.%26aulast%3DAndreotti%26aufirst%3DD.%26aulast%3DArban%26aufirst%3DR.%26aulast%3DBenedetti%26aufirst%3DR.%26aulast%3DBertani%26aufirst%3DB.%26aulast%3DBettati%26aufirst%3DM.%26aulast%3DBettelini%26aufirst%3DL.%26aulast%3DBonanomi%26aufirst%3DG.%26aulast%3DBraggio%26aufirst%3DS.%26aulast%3DCarletti%26aufirst%3DR.%26aulast%3DChecchia%26aufirst%3DA.%26aulast%3DCorsi%26aufirst%3DM.%26aulast%3DFazzolari%26aufirst%3DE.%26aulast%3DFontana%26aufirst%3DS.%26aulast%3DMarchioro%26aufirst%3DC.%26aulast%3DMerlo-Pich%26aufirst%3DE.%26aulast%3DNegri%26aufirst%3DM.%26aulast%3DOliosi%26aufirst%3DB.%26aulast%3DRatti%26aufirst%3DE.%26aulast%3DRead%26aufirst%3DK.%2BD.%26aulast%3DRoscic%26aufirst%3DM.%26aulast%3DSartori%26aufirst%3DI.%26aulast%3DSpada%26aufirst%3DS.%26aulast%3DTedesco%26aufirst%3DG.%26aulast%3DTarsi%26aufirst%3DL.%26aulast%3DTerreni%26aufirst%3DS.%26aulast%3DVisentini%26aufirst%3DF.%26aulast%3DZocchi%26aufirst%3DA.%26aulast%3DZonzini%26aufirst%3DL.%26aulast%3DDi%2BFabio%26aufirst%3DR.%26atitle%3D6-%25283%252C4-dichlorophenyl%2529-1-%255B%2528methyloxy%2529methyl%255D-3-azabicyclo%255B4.1.0%255Dheptane%253A%2520a%2520new%2520potent%2520and%2520selective%2520triple%2520reuptake%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D4989%26epage%3D5001%26doi%3D10.1021%2Fjm100481d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, H.</span></span> <span> </span><span class="NLM_article-title">Triple reuptake inhibitors: a patent review (2006 - 2012)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">131</span>– <span class="NLM_lpage">154</span>, <span class="refDoi"> DOI: 10.1517/13543776.2014.859676</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1517%2F13543776.2014.859676" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=24289044" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC2cXptlWgtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=131-154&author=L.+Shaoauthor=W.+Liauthor=Q.+Xieauthor=H.+Yin&title=Triple+reuptake+inhibitors%3A+a+patent+review+%282006+-+2012%29&doi=10.1517%2F13543776.2014.859676"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Triple reuptake inhibitors: a patent review (2006 - 2012)</span></div><div class="casAuthors">Shao, Liming; Li, Wei; Xie, Qiong; Yin, Hong</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">131-154</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: The dysfunctions of three very important monoamine neurotransmitters, serotonin (5-HT), norepinephrine (NE) and dopamine (DA), are assocd. with some of important CNS diseases such as depression; developing the triple reuptake inhibitors (TRIs) that can rebalance 5-HT, NE and DA through the inhibition of the monoamine reuptake transporters will lead to a more effective and safer antidepressant.  Areas covered: This article reviews past 7 years' advances in the development of TRIs; a patent review (2006 - 2012), covering the discovery of new chem. entities, and development status of leading TRI clin. candidates.  Expert opinion: The development of TRIs has several challenges, including discovering a "single" agent that has the activities against all three monoamine reuptake transporters SERT, NET and DAT.  More important is that the agent must have a "right ratio" to be safer and better tolerated for the treatment of depression.  The TRIs can potentially be used for the treatment of other CNS diseases, such as pain, Parkinson's and attention deficit hyperactivity disorder (ADHD), depending on ratios of SERT, NET and DAT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfRC27A4PQmLVg90H21EOLACvtfcHk0ljlP8gre2YGdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXptlWgtw%253D%253D&md5=ab7d85d58c69476b3f0a4eff944d24ac</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1517%2F13543776.2014.859676&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2014.859676%26sid%3Dliteratum%253Aachs%26aulast%3DShao%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DXie%26aufirst%3DQ.%26aulast%3DYin%26aufirst%3DH.%26atitle%3DTriple%2520reuptake%2520inhibitors%253A%2520a%2520patent%2520review%2520%25282006%2520-%25202012%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2014%26volume%3D24%26spage%3D131%26epage%3D154%26doi%3D10.1517%2F13543776.2014.859676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span> <i>DOV Pharmaceutical</i>; <span class="NLM_publisher-name">Wikipedia</span>, <span class="NLM_year">2017</span>; <a href="https://en.wikipedia.org/wiki/DOV_Pharmaceutical" class="extLink">https://en.wikipedia.org/wiki/DOV_Pharmaceutical</a> (accessed May 29, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+DOV+Pharmaceutical%3B+Wikipedia%2C+2017%3B+https%3A%2F%2Fen.wikipedia.org%2Fwiki%2FDOV_Pharmaceutical+%28accessed+May+29%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DDOV%2520Pharmaceutical%26pub%3DWikipedia%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span> <i>Amitifadine</i>; <span class="NLM_publisher-name">Euthymics Bioscience</span>: <span class="NLM_publisher-loc">Cambridge,
MA</span>, <span class="NLM_year">2017</span>; <a href="http://euthymics.com/amitifadine/" class="extLink">http://euthymics.com/amitifadine/</a> (accessed May 29, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Amitifadine%3B+Euthymics+Bioscience%3A+Cambridge%2C%0AMA%2C+2017%3B+http%3A%2F%2Feuthymics.com%2Famitifadine%2F+%28accessed+May+29%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DAmitifadine%26pub%3DEuthymics%2520Bioscience%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span> <i>Tesofensine Monotherapy
for Treatment of Obesity</i>; <span class="NLM_publisher-name">Saniona</span>: <span class="NLM_publisher-loc">Ballerup, Denmark</span>, <span class="NLM_year">2017</span>; <a href="http://saniona.com/pipeline/tesofensine/" class="extLink">http://saniona.com/pipeline/tesofensine/</a> (accessed May 29, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Tesofensine+Monotherapy%0Afor+Treatment+of+Obesity%3B+Saniona%3A+Ballerup%2C+Denmark%2C+2017%3B+http%3A%2F%2Fsaniona.com%2Fpipeline%2Ftesofensine%2F+%28accessed+May+29%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DTesofensine%2520Monotherapy%250Afor%2520Treatment%2520of%2520Obesity%26pub%3DSaniona%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span> <i>Completion of Phase 1 Clinical
Studies of Ansofaxine Hydrochloride
Extended Release Tablets (LY03005) in the U.S.</i>; <span class="NLM_publisher-name">Luye Pharma</span>: <span class="NLM_publisher-loc">Shanghai</span>, August 13, <span class="NLM_year">2015</span>; <a href="http://www.luye.cn/lvye_en/newsshow.php?id=138" class="extLink">http://www.luye.cn/lvye_en/newsshow.php?id=138</a> (accessed May 29, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Completion+of+Phase+1+Clinical%0AStudies+of+Ansofaxine+Hydrochloride%0AExtended+Release+Tablets+%28LY03005%29+in+the+U.S.%3B+Luye+Pharma%3A+Shanghai%2C+August+13%2C+2015%3B+http%3A%2F%2Fwww.luye.cn%2Flvye_en%2Fnewsshow.php%3Fid%3D138+%28accessed+May+29%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DCompletion%2520of%2520Phase%25201%2520Clinical%250AStudies%2520of%2520Ansofaxine%2520Hydrochloride%250AExtended%2520Release%2520Tablets%2520%2528LY03005%2529%2520in%2520the%2520U.S.%26pub%3DLuye%2520Pharma%26date%3D2015%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Epstein, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brabander, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanshawe, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenzie, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safir, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osterberg, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosulich, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovell, F. M.</span></span> <span> </span><span class="NLM_article-title">1-Aryl-3-azabicyclo[3.1.0]hexanes, a new series of nonnarcotic analgesic agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1981</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">481</span>– <span class="NLM_lpage">490</span>, <span class="refDoi"> DOI: 10.1021/jm00137a002</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00137a002" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADyaL3MXhslCrsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1981&pages=481-490&author=J.+W.+Epsteinauthor=H.+J.+Brabanderauthor=W.+J.+Fanshaweauthor=C.+M.+Hofmannauthor=T.+C.+McKenzieauthor=S.+R.+Safirauthor=A.+C.+Osterbergauthor=D.+B.+Cosulichauthor=F.+M.+Lovell&title=1-Aryl-3-azabicyclo%5B3.1.0%5Dhexanes%2C+a+new+series+of+nonnarcotic+analgesic+agents&doi=10.1021%2Fjm00137a002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">1-Aryl-3-azabicyclo[3.1.0]hexanes, a new series of nonnarcotic analgesic agents</span></div><div class="casAuthors">Epstein, Joseph W.; Brabander, Herbert J.; Fanshawe, William J.; Hofmann, Corris M.; McKenzie, Thomas C.; Safir, Sidney R.; Osterberg, Arnold C.; Cosulich, D. B.; Lovell, F. M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1981</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">481-90</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">The title analgesics I (R = organo substituent) were prepd. by insertion reaction of RC6H4CHBrCO2R with acrylate esters followed by cyclocondensation of the resultant cyclopropanedicarboxylic acid derivs. with urea, than redn. of the resultant amides.  The more potent I are the para-substituted derivs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJZnZ8CYX3_rVg90H21EOLACvtfcHk0ljlP8gre2YGdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3MXhslCrsr8%253D&md5=16dc7e8543fee35a4a5f4c873d3da3ab</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1021%2Fjm00137a002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00137a002%26sid%3Dliteratum%253Aachs%26aulast%3DEpstein%26aufirst%3DJ.%2BW.%26aulast%3DBrabander%26aufirst%3DH.%2BJ.%26aulast%3DFanshawe%26aufirst%3DW.%2BJ.%26aulast%3DHofmann%26aufirst%3DC.%2BM.%26aulast%3DMcKenzie%26aufirst%3DT.%2BC.%26aulast%3DSafir%26aufirst%3DS.%2BR.%26aulast%3DOsterberg%26aufirst%3DA.%2BC.%26aulast%3DCosulich%26aufirst%3DD.%2BB.%26aulast%3DLovell%26aufirst%3DF.%2BM.%26atitle%3D1-Aryl-3-azabicyclo%255B3.1.0%255Dhexanes%252C%2520a%2520new%2520series%2520of%2520nonnarcotic%2520analgesic%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1981%26volume%3D24%26spage%3D481%26epage%3D490%26doi%3D10.1021%2Fjm00137a002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Epstein, J. W.</span>; <span class="NLM_string-name">Osterberg, A. C.</span>; <span class="NLM_string-name">Brabander, H. J.</span></span> <span> </span><span class="NLM_article-title">Treating Depression Using Azabicyclohexanes</span>. <span class="NLM_patent">US4435419A</span>, <span class="NLM_year">1984</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1984&author=J.+W.+Epstein&author=A.+C.+Osterberg&author=H.+J.+Brabander&title=Treating+Depression+Using+Azabicyclohexanes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DEpstein%26aufirst%3DJ.%2BW.%26atitle%3DTreating%2520Depression%2520Using%2520Azabicyclohexanes%26date%3D1984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skolnick, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krieter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tizzano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basile, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popik, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czobor, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippa, A.</span></span> <span> </span><span class="NLM_article-title">Preclinical and clinical pharmacology of DOV 216,303, a ″triple″ reuptake inhibitor</span>. <i>CNS Drug Rev.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">134</span>, <span class="refDoi"> DOI: 10.1111/j.1527-3458.2006.00123.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1111%2Fj.1527-3458.2006.00123.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=123-134&author=P.+Skolnickauthor=P.+Krieterauthor=J.+Tizzanoauthor=A.+Basileauthor=P.+Popikauthor=P.+Czoborauthor=A.+Lippa&title=Preclinical+and+clinical+pharmacology+of+DOV+216%2C303%2C+a+%E2%80%B3triple%E2%80%B3+reuptake+inhibitor&doi=10.1111%2Fj.1527-3458.2006.00123.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1111%2Fj.1527-3458.2006.00123.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1527-3458.2006.00123.x%26sid%3Dliteratum%253Aachs%26aulast%3DSkolnick%26aufirst%3DP.%26aulast%3DKrieter%26aufirst%3DP.%26aulast%3DTizzano%26aufirst%3DJ.%26aulast%3DBasile%26aufirst%3DA.%26aulast%3DPopik%26aufirst%3DP.%26aulast%3DCzobor%26aufirst%3DP.%26aulast%3DLippa%26aufirst%3DA.%26atitle%3DPreclinical%2520and%2520clinical%2520pharmacology%2520of%2520DOV%2520216%252C303%252C%2520a%2520%25E2%2580%25B3triple%25E2%2580%25B3%2520reuptake%2520inhibitor%26jtitle%3DCNS%2520Drug%2520Rev.%26date%3D2006%26volume%3D12%26spage%3D123%26epage%3D134%26doi%3D10.1111%2Fj.1527-3458.2006.00123.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prins, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenny, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doomernik, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mechiel Korte, S.</span></span> <span> </span><span class="NLM_article-title">The triple reuptake inhibitor DOV 216,303 induces long-lasting enhancement of brain reward activity as measured by intracranial self-stimulation in rats</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>693</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2012.07.047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.ejphar.2012.07.047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=23010469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht12jsr7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=693&publication_year=2012&pages=51-56&author=J.+Prinsauthor=P.+J.+Kennyauthor=I.+Doomernikauthor=R.+Schreiberauthor=B.+Olivierauthor=S.+Mechiel+Korte&title=The+triple+reuptake+inhibitor+DOV+216%2C303+induces+long-lasting+enhancement+of+brain+reward+activity+as+measured+by+intracranial+self-stimulation+in+rats&doi=10.1016%2Fj.ejphar.2012.07.047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">The triple reuptake inhibitor DOV 216,303 induces long-lasting enhancement of brain reward activity as measured by intracranial self-stimulation in rats</span></div><div class="casAuthors">Prins, Jolanda; Kenny, Paul J.; Doomernik, Ivo; Schreiber, Rudy; Olivier, Berend; Mechiel Korte, S.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">693</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">51-56</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Triple reuptake inhibitors (TRIs) are potential new antidepressants, which not only enhance brain serotonin and norepinephrine concns. but also increase dopamine levels.  Therefore TRIs are believed to have faster therapeutic onset than SSRIs, and may be particularly useful for the treatment of anhedonia (i.e. inability to experience pleasure), one of the core symptoms of major depression.  The current study aimed at getting better insight into the rewarding properties of DOV 216,303, which is a TRI, regarding its possible use to treat anhedonia.  It is known that psychostimulant drugs lower intracranial self-stimulation (ICSS) reward thresholds, reflecting enhanced brain reward activity, whereas withdrawal from those compds. mostly results in increased ICSS thresholds.  Therefore we assessed the effects of DOV 216,303 on ICSS thresholds in rats.  Animals were trained in the discrete-trial current-threshold procedure and after stable ICSS reward thresholds were established, animals received one injection per day of DOV 216,303 (20 mg/kg) or amphetamine (5 mg/kg) for four consecutive days.  ICSS thresholds were assessed 3, 6, and 23 h after each injection.  DOV 216,303 decreased ICSS thresholds up to 6 h after drug treatment.  To our knowledge this is the first time that a triple reuptake inhibitor, DOV 216,303, induces relatively long-lasting enhancement of brain reward activity.  Elevated ICSS thresholds were found after amphetamine administration, which is consistent with previously reported reward deficits induced after amphetamine-withdrawal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMZ8xkC7HvdLVg90H21EOLACvtfcHk0ljVVCuFIbSopQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht12jsr7N&md5=933f19e586383e7bbf46eb4c2ab0d5ca</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2012.07.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2012.07.047%26sid%3Dliteratum%253Aachs%26aulast%3DPrins%26aufirst%3DJ.%26aulast%3DKenny%26aufirst%3DP.%2BJ.%26aulast%3DDoomernik%26aufirst%3DI.%26aulast%3DSchreiber%26aufirst%3DR.%26aulast%3DOlivier%26aufirst%3DB.%26aulast%3DMechiel%2BKorte%26aufirst%3DS.%26atitle%3DThe%2520triple%2520reuptake%2520inhibitor%2520DOV%2520216%252C303%2520induces%2520long-lasting%2520enhancement%2520of%2520brain%2520reward%2520activity%2520as%2520measured%2520by%2520intracranial%2520self-stimulation%2520in%2520rats%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2012%26volume%3D693%26spage%3D51%26epage%3D56%26doi%3D10.1016%2Fj.ejphar.2012.07.047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paterson, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balci, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivier, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanania, T.</span></span> <span> </span><span class="NLM_article-title">The triple reuptake inhibitor DOV216,303 exhibits limited antidepressant-like properties in the differential reinforcement of low-rate 72-second responding assay, likely due to dopamine reuptake inhibition</span>. <i>J. Psychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1357</span>– <span class="NLM_lpage">1364</span>, <span class="refDoi"> DOI: 10.1177/0269881110364272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1177%2F0269881110364272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=20305042" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1Wgt7zJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2011&pages=1357-1364&author=N.+E.+Patersonauthor=F.+Balciauthor=U.+Campbellauthor=B.+E.+Olivierauthor=T.+Hanania&title=The+triple+reuptake+inhibitor+DOV216%2C303+exhibits+limited+antidepressant-like+properties+in+the+differential+reinforcement+of+low-rate+72-second+responding+assay%2C+likely+due+to+dopamine+reuptake+inhibition&doi=10.1177%2F0269881110364272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">The triple reuptake inhibitor DOV216, 303 exhibits limited antidepressant-like properties in the differential reinforcement of low-rate 72-second responding assay, likely due to dopamine reuptake inhibition</span></div><div class="casAuthors">Paterson, Neil E.; Balci, Fuat; Campbell, Una; Olivier, Berend E.; Hanania, Taleen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Psychopharmacology (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1357-1364</span>CODEN:
                <span class="NLM_cas:coden">JOPSEQ</span>;
        ISSN:<span class="NLM_cas:issn">0269-8811</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">There is a need for antidepressants with novel mechanisms of action.  One approach has been to develop compds. that inhibit reuptake of all three monoamines in the central nervous system, for example DOV216,303.  Differential reinforcement of low-rate (72-s) responding is a behavioral test that is predictive of antidepressant-like properties.  The effects of antidepressant compds. belonging to multiple classes, the anxiolytic diazepam and the antipsychotic haloperidol, were assessed in the DRL-72S task.  Subsequently, the antidepressant-like properties of acute DOV216,303 were assessed.  The selective serotonin reuptake inhibitor fluvoxamine, the preferential norepinephrine reuptake inhibitor desipramine and the tricyclic antidepressant imipramine exhibited antidepressant-like properties in the DRL-72S task.  The atypical antidepressant bupropion, which inhibits dopamine and norepinephrine reuptake, and the selective dopamine transporter inhibitor GBR12909, changed reinforcement and response rates and inter-response time distribution in an opposite direction compared with the antidepressant compds. tested.  The antipsychotic haloperidol exhibited antidepressant-like properties by increasing reinforcement rate, but failed to alter inter-response time distribution.  Diazepam did not change reinforcement or response rates or inter-response time distribution.  The triple reuptake inhibitor DOV216,303 significantly enhanced reinforcement rate at one intermediate dose, but exhibited similar effects as bupropion and GBR12909 on inter-response time distribution.  The studies identified limited antidepressant-like properties of the triple reuptake inhibitor DOV216,303, likely due to dopamine transporter inhibition counteracting the effects of norepinephrine and serotonin transporter inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLD-HoWXRRD7Vg90H21EOLACvtfcHk0ljVVCuFIbSopQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1Wgt7zJ&md5=23ad988e985ee6924ab863252601d1bd</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1177%2F0269881110364272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0269881110364272%26sid%3Dliteratum%253Aachs%26aulast%3DPaterson%26aufirst%3DN.%2BE.%26aulast%3DBalci%26aufirst%3DF.%26aulast%3DCampbell%26aufirst%3DU.%26aulast%3DOlivier%26aufirst%3DB.%2BE.%26aulast%3DHanania%26aufirst%3DT.%26atitle%3DThe%2520triple%2520reuptake%2520inhibitor%2520DOV216%252C303%2520exhibits%2520limited%2520antidepressant-like%2520properties%2520in%2520the%2520differential%2520reinforcement%2520of%2520low-rate%252072-second%2520responding%2520assay%252C%2520likely%2520due%2520to%2520dopamine%2520reuptake%2520inhibition%26jtitle%3DJ.%2520Psychopharmacol.%26date%3D2011%26volume%3D25%26spage%3D1357%26epage%3D1364%26doi%3D10.1177%2F0269881110364272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Popik, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krawczyk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golembiowska, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowak, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janowsky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skolnick, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basile, A. S.</span></span> <span> </span><span class="NLM_article-title">Pharmacological profile of the ″triple″ monoamine neurotransmitter uptake inhibitor, DOV 102,677</span>. <i>Cell. Mol. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">855</span>– <span class="NLM_lpage">871</span>, <span class="refDoi"> DOI: 10.1007/s10571-006-9012-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1007%2Fs10571-006-9012-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2006&pages=855-871&author=P.+Popikauthor=M.+Krawczykauthor=K.+Golembiowskaauthor=G.+Nowakauthor=A.+Janowskyauthor=P.+Skolnickauthor=A.+Lippaauthor=A.+S.+Basile&title=Pharmacological+profile+of+the+%E2%80%B3triple%E2%80%B3+monoamine+neurotransmitter+uptake+inhibitor%2C+DOV+102%2C677&doi=10.1007%2Fs10571-006-9012-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1007%2Fs10571-006-9012-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10571-006-9012-5%26sid%3Dliteratum%253Aachs%26aulast%3DPopik%26aufirst%3DP.%26aulast%3DKrawczyk%26aufirst%3DM.%26aulast%3DGolembiowska%26aufirst%3DK.%26aulast%3DNowak%26aufirst%3DG.%26aulast%3DJanowsky%26aufirst%3DA.%26aulast%3DSkolnick%26aufirst%3DP.%26aulast%3DLippa%26aufirst%3DA.%26aulast%3DBasile%26aufirst%3DA.%2BS.%26atitle%3DPharmacological%2520profile%2520of%2520the%2520%25E2%2580%25B3triple%25E2%2580%25B3%2520monoamine%2520neurotransmitter%2520uptake%2520inhibitor%252C%2520DOV%2520102%252C677%26jtitle%3DCell.%2520Mol.%2520Neurobiol.%26date%3D2006%26volume%3D26%26spage%3D855%26epage%3D871%26doi%3D10.1007%2Fs10571-006-9012-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McMillen, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shank, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basile, A. S.</span></span> <span> </span><span class="NLM_article-title">Effect of DOV 102,677 on the volitional consumption of ethanol by Myers’ high ethanol-preferring rat</span>. <i>Alcohol.: Clin. Exp. Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">1866</span>– <span class="NLM_lpage">1871</span>, <span class="refDoi"> DOI: 10.1111/j.1530-0277.2007.00513.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1111%2Fj.1530-0277.2007.00513.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=17908267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtleru7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2007&pages=1866-1871&author=B.+A.+McMillenauthor=J.+E.+Shankauthor=K.+B.+Jordanauthor=H.+L.+Williamsauthor=A.+S.+Basile&title=Effect+of+DOV+102%2C677+on+the+volitional+consumption+of+ethanol+by+Myers%E2%80%99+high+ethanol-preferring+rat&doi=10.1111%2Fj.1530-0277.2007.00513.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of DOV 102, 677 on the volitional consumption of ethanol by Myer's high ethanol-preferring rat</span></div><div class="casAuthors">McMillen, Brian A.; Shank, J. Elizabeth; Jordan, Kirstin B.; Williams, Helen L.; Basile, A. S.</div><div class="citationInfo"><span class="NLM_cas:title">Alcoholism: Clinical & Experimental Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1866-1871</span>CODEN:
                <span class="NLM_cas:coden">ACRSDM</span>;
        ISSN:<span class="NLM_cas:issn">0145-6008</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing, Inc.</span>)
        </div><div class="casAbstract">Background: Inhibitors of monoamine neurotransmitter transporters are well established as antidepressants.  However, the evidence that single (serotonin) or dual (serotonin-norepinephrine) neurotransmitter uptake inhibitors can treat ethanol abuse, either as a comorbidity with depression or as a sep. entity, is inconsistent.  Drugs that have, in addn., the ability to inhibit dopamine uptake may have an advantage in the treatment of alc. abuse.  Therefore, the inhibitor of norepinephrine, serotonin and dopamine uptake, DOV 102,677, was tested for its effects on the volitional consumption of ethanol by an ethanol-preferring rat strain.  Methods: Myers' high ethanol-preferring rats were screened by a 10-day, 3 to 30% step-up test and then given free access to the preferred concn. of ethanol in a 3-bottle choice task.  Consumption of ethanol (g/kg), water, food, and body wt. were measured daily during a 3-day predrug treatment period, a 3-day treatment period, and a 3-day posttreatment period.  Addnl. Sprague-Dawley rats were obsd. for 24 h for the behavioral effects of 2.0 mg/kg s.c. reserpine after a 30-min pretreatment with different doses of DOV 102,677.  Results: The triple monoamine uptake inhibitor DOV 102,677 dose-dependently decreased the volitional consumption of ethanol by as much as 71.2% (20 mg/kg i.p., b.i.d.) over 3 days of administration.  This effect carried over into the posttreatment period.  Similarly, the proportion of ethanol to total fluids consumed declined by 66.2% (20 mg/kg s.c., b.i.d.), while food consumption and body wt. were unaltered.  In contrast, amperozide (2 mg/kg i.p., b.i.d.) suppressed the amt. of ethanol consumed by 56%, while naltrexone (5 mg/kg i.p., b.i.d.) was without effect.  DOV 102,677 (40 mg/kg s.c.) inhibited reserpine-induced akinesia and ptosis, but not hypothermia in Sprague-Dawley rats, consistent with its transient inhibition of serotonin transport, and more long-lived inhibition of norepinephrine and dopamine uptake.  Conclusions: DOV 102,677 significantly decreased the volitional consumption of ethanol with minimal alterations in the intake of food or on body wt. in an ethanol-preferring rat strain, suggesting that triple reuptake inhibitors may find utility in treating alc. abuse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8DSfm_oPUJLVg90H21EOLACvtfcHk0ljVVCuFIbSopQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtleru7fN&md5=0ae9d47bd669525cd81941552faa1bbd</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1111%2Fj.1530-0277.2007.00513.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1530-0277.2007.00513.x%26sid%3Dliteratum%253Aachs%26aulast%3DMcMillen%26aufirst%3DB.%2BA.%26aulast%3DShank%26aufirst%3DJ.%2BE.%26aulast%3DJordan%26aufirst%3DK.%2BB.%26aulast%3DWilliams%26aufirst%3DH.%2BL.%26aulast%3DBasile%26aufirst%3DA.%2BS.%26atitle%3DEffect%2520of%2520DOV%2520102%252C677%2520on%2520the%2520volitional%2520consumption%2520of%2520ethanol%2520by%2520Myers%25E2%2580%2599%2520high%2520ethanol-preferring%2520rat%26jtitle%3DAlcohol.%253A%2520Clin.%2520Exp.%2520Res.%26date%3D2007%26volume%3D31%26spage%3D1866%26epage%3D1871%26doi%3D10.1111%2Fj.1530-0277.2007.00513.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warnock, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamczarz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">June, H. L.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallick, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krieter, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skolnick, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basile, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">June, H. L.,  Sr.</span></span> <span> </span><span class="NLM_article-title">Effects of the triple monoamine uptake inhibitor DOV 102,677 on alcohol-motivated responding and antidepressant activity in alcohol-preferring (P) rats</span>. <i>Alcohol.: Clin. Exp. Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">863</span>– <span class="NLM_lpage">873</span>, <span class="refDoi"> DOI: 10.1111/j.1530-0277.2011.01671.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1111%2Fj.1530-0277.2011.01671.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=22150508" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC38Xpt12ntrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2012&pages=863-873&author=A.+R.+Yangauthor=H.+S.+Yiauthor=K.+T.+Warnockauthor=J.+Mamczarzauthor=H.+L.+Juneauthor=N.+Mallickauthor=P.+A.+Krieterauthor=L.+Tonelliauthor=P.+Skolnickauthor=A.+S.+Basileauthor=H.+L.+June&title=Effects+of+the+triple+monoamine+uptake+inhibitor+DOV+102%2C677+on+alcohol-motivated+responding+and+antidepressant+activity+in+alcohol-preferring+%28P%29+rats&doi=10.1111%2Fj.1530-0277.2011.01671.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of the triple monoamine uptake inhibitor DOV 102,677 on alcohol-motivated responding and antidepressant activity in alcohol-preferring (P) rats</span></div><div class="casAuthors">Yang, Andrew R. S. T.; Yi, Heon S.; Warnock, Kaitlin T.; Mamczarz, Jacek; June, Harry L., Jr.; Mallick, Nikhil; Krieter, Philip A.; Tonelli, Leonardo; Skolnick, Phil; Basile, Anthony S.; June, Harry L., Sr.</div><div class="citationInfo"><span class="NLM_cas:title">Alcoholism: Clinical & Experimental Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">863-873</span>CODEN:
                <span class="NLM_cas:coden">ACRSDM</span>;
        ISSN:<span class="NLM_cas:issn">0145-6008</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background: Concurrent inhibitors of dopamine, norepinephrine, and serotonin uptake have been proposed as novel antidepressants.  Given the high comorbidity between alcoholism and depression, we evaluated the activity of DOV 102,677 (DOV) on alc.-maintained responding and performance in the forced swim test (FST), a model of antidepressant (AD) activity, using alc.-preferring (P) rats.  Methods: Following training to lever press for either alc. (10% vol./vol.) or sucrose (3, 2%, w/v) on a fixed-ratio 4 (FR4) schedule, DOV (1.56 to 50 mg/kg; PO) was given 25 min or 24 h prior to evaluation.  The effects of DOV (12.5 to 50 mg/kg; PO) in the FST were evaluated 25 min posttreatment.  Results: DOV (6.25 to 50 mg/kg) dose-dependently reduced alc.-maintained responding by 59 to 88% at 25 min posttreatment, without significantly altering sucrose responding.  The redn. in alc. responding (44% at 50 mg/kg) was sustained for up to 120 h after a single dose.  Administration of a single dose of DOV (25, 50 mg/kg) 24 h before testing suppressed alc. responding for 48 h by 59 to 62%.  DOV (12.5 to 50 mg/kg) also dose-dependently reduced immobility of P rats in the FST.  Conclusions: DOV produces both prolonged and selective redns. of alc.-motivated behaviors in P rats.  The elimination kinetics of DOV suggests that its long duration of action may be due to an active metabolite.  DOV also produced robust AD-like effects in P rats.  We propose that DOV may be useful in treating comorbid alcoholism and depression in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVZ08SO9LzLbVg90H21EOLACvtfcHk0lhDyBaGRWI90A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xpt12ntrc%253D&md5=19dbe12c6263ef88de30de25475dbe81</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1111%2Fj.1530-0277.2011.01671.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1530-0277.2011.01671.x%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DA.%2BR.%26aulast%3DYi%26aufirst%3DH.%2BS.%26aulast%3DWarnock%26aufirst%3DK.%2BT.%26aulast%3DMamczarz%26aufirst%3DJ.%26aulast%3DJune%26aufirst%3DH.%2BL.%26aulast%3DMallick%26aufirst%3DN.%26aulast%3DKrieter%26aufirst%3DP.%2BA.%26aulast%3DTonelli%26aufirst%3DL.%26aulast%3DSkolnick%26aufirst%3DP.%26aulast%3DBasile%26aufirst%3DA.%2BS.%26aulast%3DJune%26aufirst%3DH.%2BL.%26atitle%3DEffects%2520of%2520the%2520triple%2520monoamine%2520uptake%2520inhibitor%2520DOV%2520102%252C677%2520on%2520alcohol-motivated%2520responding%2520and%2520antidepressant%2520activity%2520in%2520alcohol-preferring%2520%2528P%2529%2520rats%26jtitle%3DAlcohol.%253A%2520Clin.%2520Exp.%2520Res.%26date%3D2012%26volume%3D36%26spage%3D863%26epage%3D873%26doi%3D10.1111%2Fj.1530-0277.2011.01671.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bymaster, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulze, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, R. D.</span></span> <span> </span><span class="NLM_article-title">Biopharmaceutical characterization, metabolism, and brain penetration of the triple reuptake inhibitor amitifadine</span>. <i>Drug Metab. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">23</span>– <span class="NLM_lpage">33</span>, <span class="refDoi"> DOI: 10.2174/18723128112069990010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.2174%2F18723128112069990010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=23826879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisFajtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2013&pages=23-33&author=F.+P.+Bymasterauthor=P.+Chaoauthor=H.+Schulzeauthor=P.+V.+Tranauthor=R.+D.+Marshall&title=Biopharmaceutical+characterization%2C+metabolism%2C+and+brain+penetration+of+the+triple+reuptake+inhibitor+amitifadine&doi=10.2174%2F18723128112069990010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Biopharmaceutical characterization, metabolism, and brain penetration of the triple reuptake inhibitor amitifadine</span></div><div class="casAuthors">Bymaster, Frank P.; Chao, Piyun; Schulze, Heidi; Tran, Pierre V.; Marshall, Randall D.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">23-33</span>CODEN:
                <span class="NLM_cas:coden">DMLRBM</span>;
        ISSN:<span class="NLM_cas:issn">1872-3128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Amitifadine (EB-1010, formerly DOV 21,947) is a serotonin-preferring triple reuptake inhibitor that is a drug candidate for major depressive disorder.  We investigated several relevant biopharmaceutic and drug-like characteristics of amitifadine using in vitro methodol. and addnl. detd. the in vivo brain to plasma ratio of the drug in rats.  Amitifadine was highly plasma protein bound with over 99% of drug bound to human plasma proteins.  Using Caco-2 cell lines, amitifadine was bidirectionally highly permeable and showed no evidence of active secretion.  Amitifadine was metabolized slowly by human hepatocytes and the major metabolite was the lactam EB-10101.  In vitro studies using human liver microsomes demonstrated that EB-10101 was formed by monoamine oxidase A (MAO-A) and a NADPHdependent enzyme, possibly a cytochrome P 450 (CYP) isoform.  Amitifadine was a moderate inhibitor of the human isoforms of the major drug metabolizing enzymes CYP2D6, CYP3A4, CYP2C9, and CYP2C19 (IC50 = 9 - 100 μM), but was a potent inhibitor of human CYP2B6 (IC50 = 1.8 μM).  The brain to plasma ratio for amitifadine varied from 3.7 - 6.5 at various time points, indicating preferential partitioning into rat brain vs. plasma.  The low affinity for the major drug metabolizing CYP enzymes and metab. by multiple pathways may reduce pharmacokinetic drug-drug interactions and effects of enzyme polymorphisms.  Overall, these studies suggest that amitifadine has drug-like characteristics favorable for drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZuI6J8IwbJLVg90H21EOLACvtfcHk0lhDyBaGRWI90A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisFajtL0%253D&md5=aaa87242ed782dd93198de5a9950b96d</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.2174%2F18723128112069990010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F18723128112069990010%26sid%3Dliteratum%253Aachs%26aulast%3DBymaster%26aufirst%3DF.%2BP.%26aulast%3DChao%26aufirst%3DP.%26aulast%3DSchulze%26aufirst%3DH.%26aulast%3DTran%26aufirst%3DP.%2BV.%26aulast%3DMarshall%26aufirst%3DR.%2BD.%26atitle%3DBiopharmaceutical%2520characterization%252C%2520metabolism%252C%2520and%2520brain%2520penetration%2520of%2520the%2520triple%2520reuptake%2520inhibitor%2520amitifadine%26jtitle%3DDrug%2520Metab.%2520Lett.%26date%3D2013%26volume%3D7%26spage%3D23%26epage%3D33%26doi%3D10.2174%2F18723128112069990010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skolnick, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popik, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janowsky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippa, A. S.</span></span> <span> </span><span class="NLM_article-title">Antidepressant-like actions of DOV 21,947: a ″triple″ reuptake inhibitor</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>461</i></span>,  <span class="NLM_fpage">99</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.1016/S0014-2999(03)01310-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2FS0014-2999%2803%2901310-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=12586204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhtVanu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=461&publication_year=2003&pages=99-104&author=P.+Skolnickauthor=P.+Popikauthor=A.+Janowskyauthor=B.+Beerauthor=A.+S.+Lippa&title=Antidepressant-like+actions+of+DOV+21%2C947%3A+a+%E2%80%B3triple%E2%80%B3+reuptake+inhibitor&doi=10.1016%2FS0014-2999%2803%2901310-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor</span></div><div class="casAuthors">Skolnick, Phil; Popik, Piotr; Janowsky, Aaron; Beer, Bernard; Lippa, Arnold S.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">461</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">99-104</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">DOV 21,947 [(+)-1-(3,4-dichlorophenyl)-3-azabicyclo-[3.1.0]hexane hydrochloride] inhibits the reuptake of [3H]serotonin, [3H]norepinephrine, and [3H]dopamine in human embryonic kidney (HEK) 293 cells expressing the corresponding human recombinant transporters (IC50 values of 12, 23, and 96 nM, resp.).  This compd. also inhibits [125I]RTI 55 (3β-(4-iodophenyl)tropane-2β-carboxylic acid Me ester) binding to the corresponding transporter proteins in membranes prepd. from these cells (Ki values of 99, 262, and 213 nM, resp.).  DOV 21,947 reduces the duration of immobility in the forced swim test (using rats) with an oral min. ED of 5 mg/kg.  This antidepressant-like effect manifests in the absence of significant increases in motor activity at doses of up to 20 mg/kg.  DOV 21,947 also produces a dose-dependent redn. in immobility in the tail suspension test, with a min. effective oral dose of 5 mg/kg.  The ability of DOV 21,947 to inhibit the reuptake of three biogenic amines closely linked to the etiol. of depression may result in a therapeutic profile different from antidepressants that inhibit the reuptake of serotonin and/or norepinephrine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2Q0j1ranmerVg90H21EOLACvtfcHk0lhFnvWGLyv3GQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhtVanu7s%253D&md5=6d48dc293c8237d42932da3effa40b8a</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2803%2901310-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252803%252901310-4%26sid%3Dliteratum%253Aachs%26aulast%3DSkolnick%26aufirst%3DP.%26aulast%3DPopik%26aufirst%3DP.%26aulast%3DJanowsky%26aufirst%3DA.%26aulast%3DBeer%26aufirst%3DB.%26aulast%3DLippa%26aufirst%3DA.%2BS.%26atitle%3DAntidepressant-like%2520actions%2520of%2520DOV%252021%252C947%253A%2520a%2520%25E2%2580%25B3triple%25E2%2580%25B3%2520reuptake%2520inhibitor%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2003%26volume%3D461%26spage%3D99%26epage%3D104%26doi%3D10.1016%2FS0014-2999%2803%2901310-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Warnock, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">June, H. L.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basile, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skolnick, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">June, H. L.</span></span> <span> </span><span class="NLM_article-title">Amitifadine, a triple monoamine uptake inhibitor, reduces binge drinking and negative affect in an animal model of co-occurring alcoholism and depression symptomatology</span>. <i>Pharmacol., Biochem. Behav.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">118</span>, <span class="refDoi"> DOI: 10.1016/j.pbb.2012.07.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.pbb.2012.07.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=22884707" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlGqtL7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2012&pages=111-118&author=K.+T.+Warnockauthor=A.+R.+Yangauthor=H.+S.+Yiauthor=H.+L.+Juneauthor=T.+Kellyauthor=A.+S.+Basileauthor=P.+Skolnickauthor=H.+L.+June&title=Amitifadine%2C+a+triple+monoamine+uptake+inhibitor%2C+reduces+binge+drinking+and+negative+affect+in+an+animal+model+of+co-occurring+alcoholism+and+depression+symptomatology&doi=10.1016%2Fj.pbb.2012.07.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Amitifadine, a triple monoamine uptake inhibitor, reduces binge drinking and negative affect in an animal model of co-occurring alcoholism and depression symptomatology</span></div><div class="casAuthors">Warnock, Kaitlin T.; Yang, Andrew R. S. T.; Yi, Heon S.; June, Harry L., Jr.; Kelly, Timothy; Basile, Anthony S.; Skolnick, Phil; June, Harry L., Sr.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology, Biochemistry and Behavior</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">111-118</span>CODEN:
                <span class="NLM_cas:coden">PBBHAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-3057</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The co-occurrence of alcoholism and depression is highly prevalent and difficult to treat.  In an animal model of binge drinking that exhibits abstinence-induced behaviors reminiscent of neg. affective states, the triple monoamine uptake inhibitor, amitifadine, produced a selective, dose dependent attenuation of binge drinking.  Amitifadine also reversed abstinence-induced increases in the intracranial self-stimulation threshold, a model of anhedonia, and immobility in the forced swim test, reflecting behavioral despair.  In view of the safety profile of amitifadine in humans, including low risk for wt. gain, lack of sexual side effects, and low potential for abuse, we hypothesize that amitifadine will be effective in treating co-occurring alcoholism and depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorH3-qgzywA7Vg90H21EOLACvtfcHk0lhFnvWGLyv3GQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlGqtL7L&md5=94866704cecdcda652b1a1bf647e4120</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1016%2Fj.pbb.2012.07.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pbb.2012.07.014%26sid%3Dliteratum%253Aachs%26aulast%3DWarnock%26aufirst%3DK.%2BT.%26aulast%3DYang%26aufirst%3DA.%2BR.%26aulast%3DYi%26aufirst%3DH.%2BS.%26aulast%3DJune%26aufirst%3DH.%2BL.%26aulast%3DKelly%26aufirst%3DT.%26aulast%3DBasile%26aufirst%3DA.%2BS.%26aulast%3DSkolnick%26aufirst%3DP.%26aulast%3DJune%26aufirst%3DH.%2BL.%26atitle%3DAmitifadine%252C%2520a%2520triple%2520monoamine%2520uptake%2520inhibitor%252C%2520reduces%2520binge%2520drinking%2520and%2520negative%2520affect%2520in%2520an%2520animal%2520model%2520of%2520co-occurring%2520alcoholism%2520and%2520depression%2520symptomatology%26jtitle%3DPharmacol.%252C%2520Biochem.%2520Behav.%26date%3D2012%26volume%3D103%26spage%3D111%26epage%3D118%26doi%3D10.1016%2Fj.pbb.2012.07.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tizzano, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stribling, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Tilve, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strack, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frassetto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, R. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shearman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krieter, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschop, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skolnick, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basile, A. S.</span></span> <span> </span><span class="NLM_article-title">The triple uptake inhibitor (1R,5S)-(+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0] hexane hydrochloride (DOV 21947) reduces body weight and plasma triglycerides in rodent models of diet-induced obesity</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>324</i></span>,  <span class="NLM_fpage">1111</span>– <span class="NLM_lpage">1126</span>, <span class="refDoi"> DOI: 10.1124/jpet.107.133132</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1124%2Fjpet.107.133132" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=18089843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BD1cXivVajsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=324&publication_year=2008&pages=1111-1126&author=J.+P.+Tizzanoauthor=D.+S.+Striblingauthor=D.+Perez-Tilveauthor=A.+Strackauthor=A.+Frassettoauthor=R.+Z.+Chenauthor=T.+M.+Fongauthor=L.+Shearmanauthor=P.+A.+Krieterauthor=M.+H.+Tschopauthor=P.+Skolnickauthor=A.+S.+Basile&title=The+triple+uptake+inhibitor+%281R%2C5S%29-%28%2B%29-1-%283%2C4-dichlorophenyl%29-3-azabicyclo%5B3.1.0%5D+hexane+hydrochloride+%28DOV+21947%29+reduces+body+weight+and+plasma+triglycerides+in+rodent+models+of+diet-induced+obesity&doi=10.1124%2Fjpet.107.133132"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">The triple uptake inhibitor (1R,5S)-(+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane hydrochloride (DOV 21947) reduces body weight and plasma triglycerides in rodent models of diet-induced obesity</span></div><div class="casAuthors">Tizzano, Joseph P.; Stribling, D. Sloan; Perez-Tilve, Diego; Strack, Alison; Frassetto, Andrea; Chen, Richard Z.; Fong, Tung M.; Shearman, Lauren; Krieter, Philip A.; Tschop, Matthias H.; Skolnick, Phil; Basile, Anthony S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">324</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1111-1126</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Selective inhibitors of biogenic amine (e.g., serotonin, norepinephrine, and dopamine) uptake exhibit varying degrees of safety and efficacy as antiobesity agents.  Moreover, preclin. findings suggest that the combined inhibition of monoamine neurotransmitter transporters synergistically enhances antiobesity activity.  (1R,5S)-(+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0] hexane hydrochloride (DOV 21947) inhibits norepinephrine, 5-hydroxytryptamine, and dopamine uptake, and it reduces body wt. in rodent models of diet-induced obesity (DIO).  DIO rats treated orally with DOV 21947 for 1 to 24 days showed significantly lower body wts. than vehicle-treated DIO rats.  The decrease in body wt. resulted specifically from a loss of retroperitoneal and mesenteric depots of white adipose tissue.  DOV 21947 also reduced daily food intake in DIO rats, but consumption returned to control levels after 11 days of treatment.  With the exception of a decrease in triglyceride levels, blood chem. was unaltered after 24 days of DOV 21947 treatments.  DOV 21947 had no effect on motor activity.  Although DOV 21947 increased respiratory rate and decreased the tidal vol. of normal rats, it did not alter the minute vol.  In addn., DOV 21947 did not significantly affect blood pressure, heart rate, electrocardiog. indexes or body temp. in telemeterized dogs.  However, it caused a sustained, but reversible redn. in the rate of body wt. gain for as long as 6 mo in normal rats, and for up to 1 yr in normal dogs.  In summary, DOV 21947 is effective in causing a sustained and selective redn. in fat content and triglyceride levels in animal models of obesity without significantly altering vital organ function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAGaRULYopOrVg90H21EOLACvtfcHk0lhFnvWGLyv3GQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXivVajsLk%253D&md5=07f9fe5d76f9695fa8c8be51f0019493</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1124%2Fjpet.107.133132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.107.133132%26sid%3Dliteratum%253Aachs%26aulast%3DTizzano%26aufirst%3DJ.%2BP.%26aulast%3DStribling%26aufirst%3DD.%2BS.%26aulast%3DPerez-Tilve%26aufirst%3DD.%26aulast%3DStrack%26aufirst%3DA.%26aulast%3DFrassetto%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DR.%2BZ.%26aulast%3DFong%26aufirst%3DT.%2BM.%26aulast%3DShearman%26aufirst%3DL.%26aulast%3DKrieter%26aufirst%3DP.%2BA.%26aulast%3DTschop%26aufirst%3DM.%2BH.%26aulast%3DSkolnick%26aufirst%3DP.%26aulast%3DBasile%26aufirst%3DA.%2BS.%26atitle%3DThe%2520triple%2520uptake%2520inhibitor%2520%25281R%252C5S%2529-%2528%252B%2529-1-%25283%252C4-dichlorophenyl%2529-3-azabicyclo%255B3.1.0%255D%2520hexane%2520hydrochloride%2520%2528DOV%252021947%2529%2520reduces%2520body%2520weight%2520and%2520plasma%2520triglycerides%2520in%2520rodent%2520models%2520of%2520diet-induced%2520obesity%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2008%26volume%3D324%26spage%3D1111%26epage%3D1126%26doi%3D10.1124%2Fjpet.107.133132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tran, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skolnick, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czobor, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, N. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradshaw, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKinney, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fava, M.</span></span> <span> </span><span class="NLM_article-title">Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial</span>. <i>J. Psychiatr. Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">64</span>– <span class="NLM_lpage">71</span>, <span class="refDoi"> DOI: 10.1016/j.jpsychires.2011.09.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.jpsychires.2011.09.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=21925682" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A280%3ADC%252BC38%252Fit1egtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2012&pages=64-71&author=P.+Tranauthor=P.+Skolnickauthor=P.+Czoborauthor=N.+Y.+Huangauthor=M.+Bradshawauthor=A.+McKinneyauthor=M.+Fava&title=Efficacy+and+tolerability+of+the+novel+triple+reuptake+inhibitor+amitifadine+in+the+treatment+of+patients+with+major+depressive+disorder%3A+a+randomized%2C+double-blind%2C+placebo-controlled+trial&doi=10.1016%2Fj.jpsychires.2011.09.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial</span></div><div class="casAuthors">Tran Pierre; Skolnick Phil; Czobor Pal; Huang N Y; Bradshaw Mark; McKinney Anthony; Fava Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of psychiatric research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">64-71</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Amitifadine (EB-1010, formerly DOV 21,947) is a serotonin-preferring triple reuptake inhibitor with a relative potency to inhibit serotonin, norepinephrine, and dopamine uptake of ∼1:2:8, respectively.  This 6-week, multicenter, randomized, double-blind, parallel, placebo-controlled study evaluated the efficacy and tolerability of amitifadine in 63 patients with major depressive disorder.  Eligible patients (17-item Hamilton Depression Rating Scale [HAMD-17] ≥ 22 at baseline) were randomized to amitifadine 25 mg twice daily (BID) for 2 weeks, then 50 mg BID for 4 weeks or placebo.  Mean baseline scores in the modified intent-to-treat population (n = 56) were 31.4 for the Montgomery-ÅAsberg Depression Rating Scale (MADRS), 29.6 for the HAMD-17, and 25.4 for the Derogatis Interview for Sexual Functioning - Self Report (DISF-SR).  At the end of the 6-week double-blind treatment, estimated least squares mean change from baseline (mixed-model repeated measures [MMRM]) in MADRS total score was statistically significantly superior for amitifadine compared to placebo (18.2 vs. 22.0; p = 0.028), with an overall statistical effect size of -0.601 (Cohen's d).  Amitifadine also was statistically significantly superior to placebo (p = 0.03) for the Clinical Global Impression of Change - Improvement.  An anhedonia factor score grouping of MADRS Items 1 (apparent sadness), 2 (reported sadness), 6 (concentration difficulties), 7 (lassitude), and 8 (inability to feel) demonstrated a statistically significant difference in favor of amitifadine compared to placebo (p = 0.049).  No differences were observed between treatments in DISF-SR scores.  Amitifadine was well-tolerated.  Two patients on each treatment discontinued the study early due to adverse events; however, no serious adverse events were reported.  This initial clinical trial in patients with severe major depression demonstrated significant antidepressant activity with amitifadine, including attenuating symptoms of anhedonia, and a tolerability profile that was comparable to placebo.  The efficacy and tolerability of amitifadine for major depressive disorder are being investigated in additional clinical trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTmctIp6zqMcTjk2McQZ6XmfW6udTcc2eZLSMYC86Bdo7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38%252Fit1egtg%253D%253D&md5=b5d126b873f147394eecae3c1172332d</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1016%2Fj.jpsychires.2011.09.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpsychires.2011.09.003%26sid%3Dliteratum%253Aachs%26aulast%3DTran%26aufirst%3DP.%26aulast%3DSkolnick%26aufirst%3DP.%26aulast%3DCzobor%26aufirst%3DP.%26aulast%3DHuang%26aufirst%3DN.%2BY.%26aulast%3DBradshaw%26aufirst%3DM.%26aulast%3DMcKinney%26aufirst%3DA.%26aulast%3DFava%26aufirst%3DM.%26atitle%3DEfficacy%2520and%2520tolerability%2520of%2520the%2520novel%2520triple%2520reuptake%2520inhibitor%2520amitifadine%2520in%2520the%2520treatment%2520of%2520patients%2520with%2520major%2520depressive%2520disorder%253A%2520a%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520trial%26jtitle%3DJ.%2520Psychiatr.%2520Res.%26date%3D2012%26volume%3D46%26spage%3D64%26epage%3D71%26doi%3D10.1016%2Fj.jpsychires.2011.09.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span> <i>Euthymics Reports Top-Line Results from Triade
Trial of Amitifadine
for Major Depressive Disorder</i>; <span class="NLM_publisher-name">Euthymics
Bioscience</span>: <span class="NLM_publisher-loc">Cambridge, MA</span>, May 29, <span class="NLM_year">2013</span>; <a href="http://euthymics.com/wp-content/uploads/2013/05/FINAL_Euthymics_TRIADE_Results_052913.pdf" class="extLink">http://euthymics.com/wp-content/uploads/2013/05/FINAL_Euthymics_TRIADE_Results_052913.pdf</a> (accessed May 29, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Euthymics+Reports+Top-Line+Results+from+Triade%0ATrial+of+Amitifadine%0Afor+Major+Depressive+Disorder%3B+Euthymics%0ABioscience%3A+Cambridge%2C+MA%2C+May+29%2C+2013%3B+http%3A%2F%2Feuthymics.com%2Fwp-content%2Fuploads%2F2013%2F05%2FFINAL_Euthymics_TRIADE_Results_052913.pdf+%28accessed+May+29%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DEuthymics%2520Reports%2520Top-Line%2520Results%2520from%2520Triade%250ATrial%2520of%2520Amitifadine%250Afor%2520Major%2520Depressive%2520Disorder%26pub%3DEuthymics%250ABioscience%26date%3D2013%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lehr, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staab, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tillmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trommeshauser, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raschig, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kloft, C.</span></span> <span> </span><span class="NLM_article-title">Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer’s disease</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">36</span>– <span class="NLM_lpage">48</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2125.2007.02855.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1111%2Fj.1365-2125.2007.02855.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=17324246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BD2sXosFSns70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2007&pages=36-48&author=T.+Lehrauthor=A.+Staabauthor=C.+Tillmannauthor=D.+Trommeshauserauthor=A.+Raschigauthor=H.+G.+Schaeferauthor=C.+Kloft&title=Population+pharmacokinetic+modelling+of+NS2330+%28tesofensine%29+and+its+major+metabolite+in+patients+with+Alzheimer%E2%80%99s+disease&doi=10.1111%2Fj.1365-2125.2007.02855.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's disease</span></div><div class="casAuthors">Lehr, Thorsten; Staab, Alexander; Tillmann, Christiane; Trommeshauser, Dirk; Raschig, Andreas; Schaefer, Hans Guenter; Kloft, Charlotte</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">36-48</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">To develop a population pharmacokinetic model for NS2330 and its major metabolite M1 based on data from a 14 wk proof of concept study in patients with Alzheimer's disease, and to identify covariates that might influence the pharmacokinetic characteristics of the drug and/or its metabolite.  Plasma data from 320 subjects undergoing multiple oral dosing, and consisting of 1969 NS2330 and 1714 metabolite concns. were fitted simultaneously using NONMEM.  Plasma concn.-time profiles of NS2330 and M1 were best described by one-compartment models with first-order elimination for both compds.  Absorption of NS2330 was best modelled by a first-order process.  Low apparent clearances together with large apparent vols. of distribution resulted in long half-lives of 234 h (NS2330) and 374 h (M1).  The covariate anal. identified wt., sex, CLCR, BMI and age as influencing the pharmacokinetics of NS2330 and/or M1.  However, simulations performed revealed that only CLCR and sex had a significant effect on the steady-state plasma concn.-time profiles.  Females with a creatinine clearance of 35.6 mL min-1 showed a 62% increased exposure compared with males without renal impairment.  The robustness and accuracy of the model were demonstrated by the successful predictivity of an external dataset.  A descriptive, robust and predictive model for NS2330 and its M1 metabolite was developed.  Important covariates influencing pharmacokinetics were identified, which might guide the further development of NS2330 and optimize its long-term use in the treatment of Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvoTGTNOJg7LVg90H21EOLACvtfcHk0lhh5JROU1RRpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXosFSns70%253D&md5=14979b8efaad2481febe1ef463f51b7e</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2007.02855.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2007.02855.x%26sid%3Dliteratum%253Aachs%26aulast%3DLehr%26aufirst%3DT.%26aulast%3DStaab%26aufirst%3DA.%26aulast%3DTillmann%26aufirst%3DC.%26aulast%3DTrommeshauser%26aufirst%3DD.%26aulast%3DRaschig%26aufirst%3DA.%26aulast%3DSchaefer%26aufirst%3DH.%2BG.%26aulast%3DKloft%26aufirst%3DC.%26atitle%3DPopulation%2520pharmacokinetic%2520modelling%2520of%2520NS2330%2520%2528tesofensine%2529%2520and%2520its%2520major%2520metabolite%2520in%2520patients%2520with%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2007%26volume%3D64%26spage%3D36%26epage%3D48%26doi%3D10.1111%2Fj.1365-2125.2007.02855.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sjodin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasteyger, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raben, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikkelsen, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meier, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Astrup, A.</span></span> <span> </span><span class="NLM_article-title">The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men</span>. <i>Int. J. Obes.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">1634</span>– <span class="NLM_lpage">1643</span>, <span class="refDoi"> DOI: 10.1038/ijo.2010.87</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1038%2Fijo.2010.87" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A280%3ADC%252BC3cbms1ChsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2010&pages=1634-1643&author=A.+Sjodinauthor=C.+Gasteygerauthor=A.+L.+Nielsenauthor=A.+Rabenauthor=J.+D.+Mikkelsenauthor=J.+K.+Jensenauthor=D.+Meierauthor=A.+Astrup&title=The+effect+of+the+triple+monoamine+reuptake+inhibitor+tesofensine+on+energy+metabolism+and+appetite+in+overweight+and+moderately+obese+men&doi=10.1038%2Fijo.2010.87"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men</span></div><div class="casAuthors">Sjodin A; Gasteyger C; Nielsen A-Lh; Raben A; Mikkelsen J D; Jensen J K S; Meier D; Astrup A</div><div class="citationInfo"><span class="NLM_cas:title">International journal of obesity (2005)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1634-43</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Tesofensine (TE) is a new drug producing twice the weight loss in obese individuals as seen with currently marketed drugs.  It inhibits the presynaptic reuptake of the neurotransmitters noradrenaline, dopamine and serotonin, and is thought to enhance the neurotransmission of all three monoamines.  The mechanisms by which it produces weight loss in humans are unresolved.  OBJECTIVE:  The aim of this study is to investigate the mechanism(s) behind weight reduction by measuring energy expenditure and appetite sensations in overweight and obese individuals.  DESIGN:  Thirty-two healthy, overweight or moderately obese men were treated with 2.0 mg TE daily for 7 days followed by an additional 7 days with 1.0 mg TE daily or corresponding placebo (PL) in a randomized, controlled trial.  They were instructed to maintain habitual food intake and physical activity throughout.  Twenty-four-hour energy expenditure (24-h EE), fat oxidation and spontaneous physical activity were measured in a respiration chamber before and after treatment.  Body composition was assessed by dual-energy X-ray absorption and appetite was evaluated by visual analogue scales in conjunction with a standardized dinner.  RESULTS:  Despite efforts to keep body weight and composition constant, TE induced a 1.8 kg weight loss above PL after 2 weeks' treatment (P<0.0001).  TE also induced higher ratings of satiety and fullness and concomitantly lower prospective food intake than placebo.  No significant effect of TE on total 24-h EE could be demonstrated compared with PL, but higher energy expenditure was observed during the night period (4.6%; P<0.05) when adjusted for changes in body composition.  Furthermore, TE increased 24-h fat oxidation as compared with PL (18 g; P<0.001).  CONCLUSION:  TE has a pronounced effect on appetite sensations and a slight effect on energy expenditure at night-both effects can contribute to the strong weight-reducing effect of TE.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR_wBLt_dxV7jMsgLhIoICsfW6udTcc2eZLSMYC86Bdo7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cbms1ChsA%253D%253D&md5=59ca0be72654f390c5e85283b5dcb676</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1038%2Fijo.2010.87&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fijo.2010.87%26sid%3Dliteratum%253Aachs%26aulast%3DSjodin%26aufirst%3DA.%26aulast%3DGasteyger%26aufirst%3DC.%26aulast%3DNielsen%26aufirst%3DA.%2BL.%26aulast%3DRaben%26aufirst%3DA.%26aulast%3DMikkelsen%26aufirst%3DJ.%2BD.%26aulast%3DJensen%26aufirst%3DJ.%2BK.%26aulast%3DMeier%26aufirst%3DD.%26aulast%3DAstrup%26aufirst%3DA.%26atitle%3DThe%2520effect%2520of%2520the%2520triple%2520monoamine%2520reuptake%2520inhibitor%2520tesofensine%2520on%2520energy%2520metabolism%2520and%2520appetite%2520in%2520overweight%2520and%2520moderately%2520obese%2520men%26jtitle%3DInt.%2520J.%2520Obes.%26date%3D2010%26volume%3D34%26spage%3D1634%26epage%3D1643%26doi%3D10.1038%2Fijo.2010.87" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bentzen, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grunnet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyveled-Nielsen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundgreen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lassen, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, H. H.</span></span> <span> </span><span class="NLM_article-title">Anti-hypertensive treatment preserves appetite suppression while preventing cardiovascular adverse effects of tesofensine in rats</span>. <i>Obesity</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">985</span>– <span class="NLM_lpage">992</span>, <span class="refDoi"> DOI: 10.1002/oby.20122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1002%2Foby.20122" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=23784901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvFaksb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=985-992&author=B.+H.+Bentzenauthor=M.+Grunnetauthor=L.+Hyveled-Nielsenauthor=C.+Sundgreenauthor=J.+B.+Lassenauthor=H.+H.+Hansen&title=Anti-hypertensive+treatment+preserves+appetite+suppression+while+preventing+cardiovascular+adverse+effects+of+tesofensine+in+rats&doi=10.1002%2Foby.20122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-hypertensive treatment preserves appetite suppression while preventing cardiovascular adverse effects of tesofensine in rats</span></div><div class="casAuthors">Bentzen, Bo Hjorth; Grunnet, Morten; Hyveled-Nielsen, Lars; Sundgreen, Claus; Lassen, Jorgen Buus; Hansen, Henrik H.</div><div class="citationInfo"><span class="NLM_cas:title">Obesity</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">985-992</span>CODEN:
                <span class="NLM_cas:coden">OBESAX</span>;
        ISSN:<span class="NLM_cas:issn">1930-7381</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Tesofensine is a novel triple monoamine reuptake inhibitor which is in development for the treatment of obesity.  Preclin. and clin. data suggest that appetite suppression is an important mechanism by which tesofensine exerts its robust wt. reducing effect.  Notably, the strong hypophagic response to tesofensine treatment is demonstrated to be linked to central stimulation of noradrenergic and dopaminergic neurotransmission.  The sympathomimetic mode of action of tesofensine may also assoc. with the elevated heart rate and blood pressure obsd. in clin. settings, and we therefore sought exptl. to address this issue.  The anorexigenic and cardiovascular effects of tesofensine were studied simultaneously in telemetrized conscious rats in a combined real-time food intake and cardiovascular telemetry monitoring system.  Acute administration of tesofensine caused a dose-dependent hypophagic effect as well as increased heart rate and blood pressure.  Interestingly, combined treatment with metoprolol (b1 adrenoceptor blocker, 10-20 mg/kg, p.o.) fully prevented the cardiovascular sympathetic effects of tesofensine while leaving the robust inhibitory efficacy on food intake unaffected.  Similarly, the angiotensin AT1 receptor antagonist telmisartan (1.0-3.0 mg/kg, p.o.) did not interfere with the anti-obesity effects of tesofensine, however, telmisartan only partially reversed the increase in systolic blood pressure and had no effect on the elevated heart rate induced by tesofensine.  These data suggests that tesofensine causes elevations in heart rate and blood pressure by increasing sympathetic activity, and that different adrenoceptor subtypes may be responsible for the anti-obesity and cardiovascular effects of tesofensine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYdI04qUz3SLVg90H21EOLACvtfcHk0ljoGWL13Nc2Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvFaksb8%253D&md5=ffd4c6fccca0796e37be27ef6c13deb1</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1002%2Foby.20122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Foby.20122%26sid%3Dliteratum%253Aachs%26aulast%3DBentzen%26aufirst%3DB.%2BH.%26aulast%3DGrunnet%26aufirst%3DM.%26aulast%3DHyveled-Nielsen%26aufirst%3DL.%26aulast%3DSundgreen%26aufirst%3DC.%26aulast%3DLassen%26aufirst%3DJ.%2BB.%26aulast%3DHansen%26aufirst%3DH.%2BH.%26atitle%3DAnti-hypertensive%2520treatment%2520preserves%2520appetite%2520suppression%2520while%2520preventing%2520cardiovascular%2520adverse%2520effects%2520of%2520tesofensine%2520in%2520rats%26jtitle%3DObesity%26date%3D2013%26volume%3D21%26spage%3D985%26epage%3D992%26doi%3D10.1002%2Foby.20122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Learned, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graff, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roychowdhury, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moate, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnan, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Archer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modell, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamuner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavergne, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evoniuk, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratti, E.</span></span> <span> </span><span class="NLM_article-title">Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials</span>. <i>J. Psychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">653</span>– <span class="NLM_lpage">662</span>, <span class="refDoi"> DOI: 10.1177/0269881111424931</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1177%2F0269881111424931" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=22048884" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsVCgtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=653-662&author=S.+Learnedauthor=O.+Graffauthor=S.+Roychowdhuryauthor=R.+Moateauthor=K.+R.+Krishnanauthor=G.+Archerauthor=J.+G.+Modellauthor=R.+Alexanderauthor=S.+Zamunerauthor=A.+Lavergneauthor=G.+Evoniukauthor=E.+Ratti&title=Efficacy%2C+safety%2C+and+tolerability+of+a+triple+reuptake+inhibitor+GSK372475+in+the+treatment+of+patients+with+major+depressive+disorder%3A+two+randomized%2C+placebo-+and+active-controlled+clinical+trials&doi=10.1177%2F0269881111424931"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials</span></div><div class="casAuthors">Learned, Susan; Graff, Ole; Roychowdhury, Suraja; Moate, Rachel; Krishnan, K. Ranga; Archer, Graeme; Modell, Jack G.; Alexander, Robert; Zamuner, Stefano; Lavergne, Agnes; Evoniuk, Gary; Ratti, Emiliangelo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Psychopharmacology (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">653-662, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">JOPSEQ</span>;
        ISSN:<span class="NLM_cas:issn">0269-8811</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">GSK372475 is a triple reuptake inhibitor with approx. equipotent inhibition of serotonin, norepinephrine, and dopamine transporters.  Two randomized, placebo- and active-controlled, double-blind studies examd. the efficacy and safety of GSK372475 in outpatients (aged 18-64 years) with a diagnosis of major depressive episode assocd. with major depressive disorder (MDD).  Patients were randomized 1:1:1 to placebo, GSK372475 (1-2 mg/d), or active control (Study 1: venlafaxine XR 150-225 mg/d; Study 2: paroxetine 20-30 mg/d).  GSK372475 did not significantly differ from placebo on any of the key efficacy endpoints (six-item Bech scale, IDS-Clinician Rated, MADRS) in either study.  Both active controls demonstrated significant antidepressant activity compared with placebo on both primary and secondary endpoints.  The most common adverse effects (AEs) with GSK372475 were dry mouth, headache, insomnia, and nausea.  AEs were more frequent for GSK372475 vs. placebo for sleep, anxiety-related, gastrointestinal, and tachycardia events.  Increases in mean change from baseline in heart rate and sitting blood pressure were greater for GSK372475 than obsd. for either placebo or active control groups.  Completion rates were lower for GSK372475 (49%, 58%) compared with placebo (67%, 74%), venlafaxine XR (63%), or paroxetine (77%).  GSK372475 was neither efficacious nor well tolerated in patients with MDD in two 10-wk studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqc_gZoKR0_G7Vg90H21EOLACvtfcHk0ljoGWL13Nc2Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsVCgtL4%253D&md5=eea1c4e6cfaf50ef27fb632cae119034</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1177%2F0269881111424931&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0269881111424931%26sid%3Dliteratum%253Aachs%26aulast%3DLearned%26aufirst%3DS.%26aulast%3DGraff%26aufirst%3DO.%26aulast%3DRoychowdhury%26aufirst%3DS.%26aulast%3DMoate%26aufirst%3DR.%26aulast%3DKrishnan%26aufirst%3DK.%2BR.%26aulast%3DArcher%26aufirst%3DG.%26aulast%3DModell%26aufirst%3DJ.%2BG.%26aulast%3DAlexander%26aufirst%3DR.%26aulast%3DZamuner%26aufirst%3DS.%26aulast%3DLavergne%26aufirst%3DA.%26aulast%3DEvoniuk%26aufirst%3DG.%26aulast%3DRatti%26aufirst%3DE.%26atitle%3DEfficacy%252C%2520safety%252C%2520and%2520tolerability%2520of%2520a%2520triple%2520reuptake%2520inhibitor%2520GSK372475%2520in%2520the%2520treatment%2520of%2520patients%2520with%2520major%2520depressive%2520disorder%253A%2520two%2520randomized%252C%2520placebo-%2520and%2520active-controlled%2520clinical%2520trials%26jtitle%3DJ.%2520Psychopharmacol.%26date%3D2012%26volume%3D26%26spage%3D653%26epage%3D662%26doi%3D10.1177%2F0269881111424931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peters, D.</span>; <span class="NLM_string-name">Nielsen, E. O.</span>; <span class="NLM_string-name">Nielsen, K. S.</span>; <span class="NLM_string-name">Munro, G.</span></span> <span> </span><span class="NLM_article-title">Chromen-2-one Derivatives of Tropine, and Their Preparation and Use as Monoamine Neurotransmitter Re-uptake Inhibitors</span>. <span class="NLM_patent">WO2010130620A1</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=D.+Peters&author=E.+O.+Nielsen&author=K.+S.+Nielsen&author=G.+Munro&title=Chromen-2-one+Derivatives+of+Tropine%2C+and+Their+Preparation+and+Use+as+Monoamine+Neurotransmitter+Re-uptake+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DD.%26atitle%3DChromen-2-one%2520Derivatives%2520of%2520Tropine%252C%2520and%2520Their%2520Preparation%2520and%2520Use%2520as%2520Monoamine%2520Neurotransmitter%2520Re-uptake%2520Inhibitors%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jerussi, T. P.</span>; <span class="NLM_string-name">Fang, Q. K.</span>; <span class="NLM_string-name">Currie, M.</span></span> <span> </span><span class="NLM_article-title">Preparation of <i>trans</i>-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine for Treatment of CNS Disorders</span>. <span class="NLM_patent">WO2004024669A1</span>, <span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=T.+P.+Jerussi&author=Q.+K.+Fang&author=M.+Currie&title=Preparation+of+trans-4-%283%2C4-Dichlorophenyl%29-1%2C2%2C3%2C4-tetrahydro-1-naphthalenamine+for+Treatment+of+CNS+Disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJerussi%26aufirst%3DT.%2BP.%26atitle%3DPreparation%2520of%2520trans-4-%25283%252C4-Dichlorophenyl%2529-1%252C2%252C3%252C4-tetrahydro-1-naphthalenamine%2520for%2520Treatment%2520of%2520CNS%2520Disorders%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malcolm, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hewitt, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, U. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bush, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spicer, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engel, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saraswat, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spear, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varney, M. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">663</span>– <span class="NLM_lpage">676</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2010.10.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.bmc.2010.10.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=21093273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1ejtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=663-676&author=L.+Shaoauthor=F.+Wangauthor=S.+C.+Malcolmauthor=J.+Maauthor=M.+C.+Hewittauthor=U.+C.+Campbellauthor=L.+R.+Bushauthor=N.+A.+Spicerauthor=S.+R.+Engelauthor=L.+D.+Saraswatauthor=L.+W.+Hardyauthor=P.+Kochauthor=R.+Schreiberauthor=K.+L.+Spearauthor=M.+A.+Varney&title=Synthesis+and+pharmacological+evaluation+of+4-%283%2C4-dichlorophenyl%29-N-methyl-1%2C2%2C3%2C4-tetrahydronaphthalenyl+amines+as+triple+reuptake+inhibitors&doi=10.1016%2Fj.bmc.2010.10.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors</span></div><div class="casAuthors">Shao, Liming; Wang, Fengjiang; Malcolm, Scott C.; Ma, Jianguo; Hewitt, Michael C.; Campbell, Una C.; Bush, Larry R.; Spicer, Nancy A.; Engel, Sharon R.; Saraswat, Lakshmi D.; Hardy, Larry W.; Koch, Patrick; Schreiber, Rudy; Spear, Kerry L.; Varney, Mark A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">663-676</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The present work describes a series of novel chiral amines that potently inhibit the in vitro reuptake of serotonin, norepinephrine and dopamine (triple reuptake inhibitors) and were active in vivo in a mouse model predictive of antidepressant like activity.  The detailed synthesis and in vitro activity and ADME profile of compds. is described, which represent a previously undisclosed triple reuptake inhibitor chemotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpb6Xgrr_h6-bVg90H21EOLACvtfcHk0ljJkIvLgexuNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1ejtg%253D%253D&md5=e8088a4fff884e9ac83dc4d597395595</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.10.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.10.034%26sid%3Dliteratum%253Aachs%26aulast%3DShao%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DMalcolm%26aufirst%3DS.%2BC.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DHewitt%26aufirst%3DM.%2BC.%26aulast%3DCampbell%26aufirst%3DU.%2BC.%26aulast%3DBush%26aufirst%3DL.%2BR.%26aulast%3DSpicer%26aufirst%3DN.%2BA.%26aulast%3DEngel%26aufirst%3DS.%2BR.%26aulast%3DSaraswat%26aufirst%3DL.%2BD.%26aulast%3DHardy%26aufirst%3DL.%2BW.%26aulast%3DKoch%26aufirst%3DP.%26aulast%3DSchreiber%26aufirst%3DR.%26aulast%3DSpear%26aufirst%3DK.%2BL.%26aulast%3DVarney%26aufirst%3DM.%2BA.%26atitle%3DSynthesis%2520and%2520pharmacological%2520evaluation%2520of%25204-%25283%252C4-dichlorophenyl%2529-N-methyl-1%252C2%252C3%252C4-tetrahydronaphthalenyl%2520amines%2520as%2520triple%2520reuptake%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2011%26volume%3D19%26spage%3D663%26epage%3D676%26doi%3D10.1016%2Fj.bmc.2010.10.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hewitt, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malcolm, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, U. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spicer, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engel, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Z. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spear, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varney, M. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">5283</span>– <span class="NLM_lpage">5295</span>, <span class="refDoi"> DOI: 10.1021/jm101312a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101312a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=5283-5295&author=L.+Shaoauthor=M.+C.+Hewittauthor=S.+C.+Malcolmauthor=F.+Wangauthor=J.+Maauthor=U.+C.+Campbellauthor=N.+A.+Spicerauthor=S.+R.+Engelauthor=L.+W.+Hardyauthor=Z.+D.+Jiangauthor=R.+Schreiberauthor=K.+L.+Spearauthor=M.+A.+Varney&title=Synthesis+and+pharmacological+characterization+of+bicyclic+triple+reuptake+inhibitor+3-aryl+octahydrocyclopenta%5Bc%5Dpyrrole+analogues&doi=10.1021%2Fjm101312a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1021%2Fjm101312a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101312a%26sid%3Dliteratum%253Aachs%26aulast%3DShao%26aufirst%3DL.%26aulast%3DHewitt%26aufirst%3DM.%2BC.%26aulast%3DMalcolm%26aufirst%3DS.%2BC.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DCampbell%26aufirst%3DU.%2BC.%26aulast%3DSpicer%26aufirst%3DN.%2BA.%26aulast%3DEngel%26aufirst%3DS.%2BR.%26aulast%3DHardy%26aufirst%3DL.%2BW.%26aulast%3DJiang%26aufirst%3DZ.%2BD.%26aulast%3DSchreiber%26aufirst%3DR.%26aulast%3DSpear%26aufirst%3DK.%2BL.%26aulast%3DVarney%26aufirst%3DM.%2BA.%26atitle%3DSynthesis%2520and%2520pharmacological%2520characterization%2520of%2520bicyclic%2520triple%2520reuptake%2520inhibitor%25203-aryl%2520octahydrocyclopenta%255Bc%255Dpyrrole%2520analogues%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D5283%26epage%3D5295%26doi%3D10.1021%2Fjm101312a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hewitt, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malcolm, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, U. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engel, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spicer, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spear, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varney, M. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of N-methyl-1-(1-phenylcyclohexyl)ethanamine, a novel triple serotonin, norepinephrine and dopamine reuptake inhibitor</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1434</span>– <span class="NLM_lpage">1437</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.01.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.bmcl.2011.01.019" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=1434-1437&author=L.+Shaoauthor=M.+C.+Hewittauthor=F.+Wangauthor=S.+C.+Malcolmauthor=J.+Maauthor=J.+E.+Campbellauthor=U.+C.+Campbellauthor=S.+R.+Engelauthor=N.+A.+Spicerauthor=L.+W.+Hardyauthor=R.+Schreiberauthor=K.+L.+Spearauthor=M.+A.+Varney&title=Discovery+of+N-methyl-1-%281-phenylcyclohexyl%29ethanamine%2C+a+novel+triple+serotonin%2C+norepinephrine+and+dopamine+reuptake+inhibitor&doi=10.1016%2Fj.bmcl.2011.01.019"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.01.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.01.019%26sid%3Dliteratum%253Aachs%26aulast%3DShao%26aufirst%3DL.%26aulast%3DHewitt%26aufirst%3DM.%2BC.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DMalcolm%26aufirst%3DS.%2BC.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DCampbell%26aufirst%3DJ.%2BE.%26aulast%3DCampbell%26aufirst%3DU.%2BC.%26aulast%3DEngel%26aufirst%3DS.%2BR.%26aulast%3DSpicer%26aufirst%3DN.%2BA.%26aulast%3DHardy%26aufirst%3DL.%2BW.%26aulast%3DSchreiber%26aufirst%3DR.%26aulast%3DSpear%26aufirst%3DK.%2BL.%26aulast%3DVarney%26aufirst%3DM.%2BA.%26atitle%3DDiscovery%2520of%2520N-methyl-1-%25281-phenylcyclohexyl%2529ethanamine%252C%2520a%2520novel%2520triple%2520serotonin%252C%2520norepinephrine%2520and%2520dopamine%2520reuptake%2520inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D1434%26epage%3D1437%26doi%3D10.1016%2Fj.bmcl.2011.01.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shao, L.</span>; <span class="NLM_string-name">Wang, F.</span>; <span class="NLM_string-name">Malcolm, S. C.</span>; <span class="NLM_string-name">Hewitt, M. C.</span>; <span class="NLM_string-name">Bush, L. R.</span>; <span class="NLM_string-name">Ma, J.</span>; <span class="NLM_string-name">Varney, M. A.</span>; <span class="NLM_string-name">Campbell, U.</span>; <span class="NLM_string-name">Engel, S. R.</span>; <span class="NLM_string-name">Hardy, L. W.</span>; <span class="NLM_string-name">Koch, P.</span>; <span class="NLM_string-name">Campbell, J. E.</span></span> <span> </span><span class="NLM_article-title">Cycloalkylamines as Monoamine Reuptake Inhibitors and Their Preparation, Pharmaceutical Compositions and Use in the Treatment of nervous system agents</span>. <span class="NLM_patent">WO2007081857A2</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=L.+Shao&author=F.+Wang&author=S.+C.+Malcolm&author=M.+C.+Hewitt&author=L.+R.+Bush&author=J.+Ma&author=M.+A.+Varney&author=U.+Campbell&author=S.+R.+Engel&author=L.+W.+Hardy&author=P.+Koch&author=J.+E.+Campbell&title=Cycloalkylamines+as+Monoamine+Reuptake+Inhibitors+and+Their+Preparation%2C+Pharmaceutical+Compositions+and+Use+in+the+Treatment+of+nervous+system+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DShao%26aufirst%3DL.%26atitle%3DCycloalkylamines%2520as%2520Monoamine%2520Reuptake%2520Inhibitors%2520and%2520Their%2520Preparation%252C%2520Pharmaceutical%2520Compositions%2520and%2520Use%2520in%2520the%2520Treatment%2520of%2520nervous%2520system%2520agents%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Comley, R.
A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salinas, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slifstein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennacef, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shotbolt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Aart, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iavarone, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomeni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laruelle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunn, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabiner, E. A.</span></span> <span> </span><span class="NLM_article-title">Monoamine transporter occupancy of a novel triple reuptake inhibitor in baboons and humans using positron emission tomography</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>346</i></span>,  <span class="NLM_fpage">311</span>– <span class="NLM_lpage">317</span>, <span class="refDoi"> DOI: 10.1124/jpet.112.202895</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1124%2Fjpet.112.202895" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=23685546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOjsbfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=346&publication_year=2013&pages=311-317&author=R.%0AA.+Comleyauthor=C.+A.+Salinasauthor=M.+Slifsteinauthor=M.+Petroneauthor=C.+Marzanoauthor=I.+Bennacefauthor=P.+Shotboltauthor=J.+Van+der+Aartauthor=M.+Neveauthor=L.+Iavaroneauthor=R.+Gomeniauthor=M.+Laruelleauthor=F.+A.+Grayauthor=R.+N.+Gunnauthor=E.+A.+Rabiner&title=Monoamine+transporter+occupancy+of+a+novel+triple+reuptake+inhibitor+in+baboons+and+humans+using+positron+emission+tomography&doi=10.1124%2Fjpet.112.202895"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Monoamine transporter occupancy of a novel triple reuptake inhibitor in baboons and humans using positron emission tomography</span></div><div class="casAuthors">Comley, Robert A.; Salinas, Cristian A.; Slifstein, Mark; Petrone, Marcella; Marzano, Carmine; Bennacef, Idriss; Shotbolt, Paul; Van der Aart, Jasper; Neve, Marta; Iavarone, Laura; Gomeni, Roberto; Laruelle, Marc; Gray, Frank A.; Gunn, Roger N.; Rabiner, Eugenii A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">346</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">311-317</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The selection of a therapeutically meaningful dose of a novel pharmaceutical is a crucial step in drug development.  Positron emission tomog. (PET) allows the in vivo estn. of the relationship between the plasma concn. of a drug and its target occupancy, optimizing dose selection and reducing the time and cost of early development.  Triple reuptake inhibitors (TRIs), also referred to as serotonin-norepinephrine-dopamine reuptake inhibitors, enhance monoaminergic neurotransmission by blocking the action of the monoamine transporters, raising extracellular concns. of those neurotransmitters.  GSK1360707 [(1R,6S)-1-(3,4-dichlorophenyl)-6-(methoxymethyl)-4-azabicyclo[4.1.0]heptane] is a novel TRI that until recently was under development for the treatment of major depressive disorder; its development was put on hold for strategic reasons.  We present the results of an in vivo assessment of the relationship between plasma exposure and transporter blockade (occupancy).  Studies were performed in baboons (Papio anubis) to det. the relationship between plasma concn. and occupancy of brain serotonin reuptake transporter (SERT), dopamine reuptake transporter (DAT), and norepinephrine uptake transporter (NET) using the radioligands [11C]DASB [(N,N-dimethyl-2-(2-amino-4-cyanophenylthio) benzylamine], [11C]PE2I [N-(3-iodoprop-2E-enyl)-2β-carbomethoxy-3β-(4-methylphenyl)nortropane], and [11C]2-[(2-methoxyphenoxy)phenylmethyl]morpholine (also known as [11C]MRB) and in humans using [11C]DASB and [11C]PE2I.  In P. anubis, plasma concns. resulting in half-maximal occupancy at SERT, DAT, and NET were 15.16, 15.56, and 0.97 ng/mL, resp.  In humans, the corresponding values for SERT and DAT were 6.80 and 18.00 ng/mL.  GSK1360707 dose-dependently blocked the signal of SERT-, DAT-, and NET-selective PET ligands, confirming its penetration across the blood-brain barrier and blockade of all three monoamine transporters in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeOk3b2TA00rVg90H21EOLACvtfcHk0ljJkIvLgexuNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOjsbfE&md5=b92262955a074c2d981015dc436127bb</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1124%2Fjpet.112.202895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.112.202895%26sid%3Dliteratum%253Aachs%26aulast%3DComley%26aufirst%3DR.%2BA.%26aulast%3DSalinas%26aufirst%3DC.%2BA.%26aulast%3DSlifstein%26aufirst%3DM.%26aulast%3DPetrone%26aufirst%3DM.%26aulast%3DMarzano%26aufirst%3DC.%26aulast%3DBennacef%26aufirst%3DI.%26aulast%3DShotbolt%26aufirst%3DP.%26aulast%3DVan%2Bder%2BAart%26aufirst%3DJ.%26aulast%3DNeve%26aufirst%3DM.%26aulast%3DIavarone%26aufirst%3DL.%26aulast%3DGomeni%26aufirst%3DR.%26aulast%3DLaruelle%26aufirst%3DM.%26aulast%3DGray%26aufirst%3DF.%2BA.%26aulast%3DGunn%26aufirst%3DR.%2BN.%26aulast%3DRabiner%26aufirst%3DE.%2BA.%26atitle%3DMonoamine%2520transporter%2520occupancy%2520of%2520a%2520novel%2520triple%2520reuptake%2520inhibitor%2520in%2520baboons%2520and%2520humans%2520using%2520positron%2520emission%2520tomography%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D346%26spage%3D311%26epage%3D317%26doi%3D10.1124%2Fjpet.112.202895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Micheli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavanni, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bettati, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonanomi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Fabio, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fazzolari, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchioro, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roscic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarsi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visentini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zonzini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Worby, A.</span></span> <span> </span><span class="NLM_article-title">1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: further insights into a class of triple re-uptake inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">3451</span>– <span class="NLM_lpage">3461</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2011.04.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.bmc.2011.04.032" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=3451-3461&author=F.+Micheliauthor=P.+Cavanniauthor=M.+Bettatiauthor=G.+Bonanomiauthor=R.+Di+Fabioauthor=E.+Fazzolariauthor=C.+Marchioroauthor=M.+Roscicauthor=L.+Tarsiauthor=F.+Visentiniauthor=L.+Zonziniauthor=A.+Worby&title=1-Heteroaryl-6-%283%2C4-dichlorophenyl%29-3-azabicyclo%5B4.1.0%5Dheptane%3A+further+insights+into+a+class+of+triple+re-uptake+inhibitors&doi=10.1016%2Fj.bmc.2011.04.032"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2011.04.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2011.04.032%26sid%3Dliteratum%253Aachs%26aulast%3DMicheli%26aufirst%3DF.%26aulast%3DCavanni%26aufirst%3DP.%26aulast%3DBettati%26aufirst%3DM.%26aulast%3DBonanomi%26aufirst%3DG.%26aulast%3DDi%2BFabio%26aufirst%3DR.%26aulast%3DFazzolari%26aufirst%3DE.%26aulast%3DMarchioro%26aufirst%3DC.%26aulast%3DRoscic%26aufirst%3DM.%26aulast%3DTarsi%26aufirst%3DL.%26aulast%3DVisentini%26aufirst%3DF.%26aulast%3DZonzini%26aufirst%3DL.%26aulast%3DWorby%26aufirst%3DA.%26atitle%3D1-Heteroaryl-6-%25283%252C4-dichlorophenyl%2529-3-azabicyclo%255B4.1.0%255Dheptane%253A%2520further%2520insights%2520into%2520a%2520class%2520of%2520triple%2520re-uptake%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2011%26volume%3D19%26spage%3D3451%26epage%3D3461%26doi%3D10.1016%2Fj.bmc.2011.04.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Profeta, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferroni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreotti, D.</span></span> <span> </span><span class="NLM_article-title">Synthesis of 5-(3,4-dichlorophenyl)-4-[(methyloxy)methyl]-2-azabicyclo[3.2.1]octane derivatives as constrained aryl-piperidines with activity as triple re-uptake inhibitors</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">5521</span>– <span class="NLM_lpage">5524</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2010.07.145</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.tetlet.2010.07.145" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2010&pages=5521-5524&author=R.+Profetaauthor=J.+Kleinauthor=S.+Spadaauthor=F.+Ferroniauthor=A.+Paioauthor=D.+Andreotti&title=Synthesis+of+5-%283%2C4-dichlorophenyl%29-4-%5B%28methyloxy%29methyl%5D-2-azabicyclo%5B3.2.1%5Doctane+derivatives+as+constrained+aryl-piperidines+with+activity+as+triple+re-uptake+inhibitors&doi=10.1016%2Fj.tetlet.2010.07.145"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2010.07.145&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2010.07.145%26sid%3Dliteratum%253Aachs%26aulast%3DProfeta%26aufirst%3DR.%26aulast%3DKlein%26aufirst%3DJ.%26aulast%3DSpada%26aufirst%3DS.%26aulast%3DFerroni%26aufirst%3DF.%26aulast%3DPaio%26aufirst%3DA.%26aulast%3DAndreotti%26aufirst%3DD.%26atitle%3DSynthesis%2520of%25205-%25283%252C4-dichlorophenyl%2529-4-%255B%2528methyloxy%2529methyl%255D-2-azabicyclo%255B3.2.1%255Doctane%2520derivatives%2520as%2520constrained%2520aryl-piperidines%2520with%2520activity%2520as%2520triple%2520re-uptake%2520inhibitors%26jtitle%3DTetrahedron%2520Lett.%26date%3D2010%26volume%3D51%26spage%3D5521%26epage%3D5524%26doi%3D10.1016%2Fj.tetlet.2010.07.145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bettati, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavanni, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Fabio, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliosi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perini, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheid, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tedesco, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zonzini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Micheli, F.</span></span> <span> </span><span class="NLM_article-title">Oxa-azaspiro derivatives: a novel class of triple re-uptake inhibitors</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">361</span>– <span class="NLM_lpage">366</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200900482</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1002%2Fcmdc.200900482" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=361-366&author=M.+Bettatiauthor=P.+Cavanniauthor=R.+Di+Fabioauthor=B.+Oliosiauthor=O.+Periniauthor=G.+Scheidauthor=G.+Tedescoauthor=L.+Zonziniauthor=F.+Micheli&title=Oxa-azaspiro+derivatives%3A+a+novel+class+of+triple+re-uptake+inhibitors&doi=10.1002%2Fcmdc.200900482"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200900482&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200900482%26sid%3Dliteratum%253Aachs%26aulast%3DBettati%26aufirst%3DM.%26aulast%3DCavanni%26aufirst%3DP.%26aulast%3DDi%2BFabio%26aufirst%3DR.%26aulast%3DOliosi%26aufirst%3DB.%26aulast%3DPerini%26aufirst%3DO.%26aulast%3DScheid%26aufirst%3DG.%26aulast%3DTedesco%26aufirst%3DG.%26aulast%3DZonzini%26aufirst%3DL.%26aulast%3DMicheli%26aufirst%3DF.%26atitle%3DOxa-azaspiro%2520derivatives%253A%2520a%2520novel%2520class%2520of%2520triple%2520re-uptake%2520inhibitors%26jtitle%3DChemMedChem%26date%3D2010%26volume%3D5%26spage%3D361%26epage%3D366%26doi%3D10.1002%2Fcmdc.200900482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zha, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacro, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatt, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sambandam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isherwood, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herr, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebeltoft, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pechulis, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payen-Fornicola, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milanowski, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cotterill, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mozhaev, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khmelnitsky, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzzo, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sargent, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molino, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lelas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haskell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertekap, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodge, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaczek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of 4-heteroaryl 1,2,3,4-tetrahydroisoquinolines as triple reuptake inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">760</span>– <span class="NLM_lpage">765</span>, <span class="refDoi"> DOI: 10.1021/ml500053b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500053b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVaht7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=760-765&author=S.+Liuauthor=C.+Zhaauthor=K.+Nacroauthor=M.+Huauthor=W.+Cuiauthor=Y.+L.+Yangauthor=U.+Bhattauthor=A.+Sambandamauthor=M.+Isherwoodauthor=L.+Yetauthor=M.+T.+Herrauthor=S.+Ebeltoftauthor=C.+Hasslerauthor=L.+Flemingauthor=A.+D.+Pechulisauthor=A.+Payen-Fornicolaauthor=N.+Holmanauthor=D.+Milanowskiauthor=I.+Cotterillauthor=V.+Mozhaevauthor=Y.+Khmelnitskyauthor=P.+R.+Guzzoauthor=B.+J.+Sargentauthor=B.+F.+Molinoauthor=R.+Olsonauthor=D.+Kingauthor=S.+Lelasauthor=Y.+W.+Liauthor=K.+Johnsonauthor=T.+Molskiauthor=A.+Orieauthor=A.+Ngauthor=R.+Haskellauthor=W.+Clarkeauthor=R.+Bertekapauthor=J.+O%E2%80%99Connellauthor=N.+Lodgeauthor=M.+Sinzauthor=S.+Adamsauthor=R.+Zaczekauthor=J.+E.+Macor&title=Design+and+synthesis+of+4-heteroaryl+1%2C2%2C3%2C4-tetrahydroisoquinolines+as+triple+reuptake+inhibitors&doi=10.1021%2Fml500053b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of 4-Heteroaryl 1,2,3,4-Tetrahydroisoquinolines as Triple Reuptake Inhibitors</span></div><div class="casAuthors">Liu, Shuang; Zha, Congxiang; Nacro, Kassoum; Hu, Min; Cui, Wenge; Yang, Yuh-Lin; Bhatt, Ulhas; Sambandam, Aruna; Isherwood, Matthew; Yet, Larry; Herr, Michael T.; Ebeltoft, Sarah; Hassler, Carla; Fleming, Linda; Pechulis, Anthony D.; Payen-Fornicola, Anne; Holman, Nicholas; Milanowski, Dennis; Cotterill, Ian; Mozhaev, Vadim; Khmelnitsky, Yuri; Guzzo, Peter R.; Sargent, Bruce J.; Molino, Bruce F.; Olson, Richard; King, Dalton; Lelas, Snjezana; Li, Yu-Wen; Johnson, Kim; Molski, Thaddeus; Orie, Anitra; Ng, Alicia; Haskell, Roy; Clarke, Wendy; Bertekap, Robert; O'Connell, Jonathan; Lodge, Nicholas; Sinz, Michael; Adams, Stephen; Zaczek, Robert; Macor, John E.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">760-765</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">4-(Bicycloheteroaryl)-7-substituted 1,2,3,4-tetrahydroisoquinolines such as I (R = 4-morpholinyl) were prepd. as serotonin-, norepinephrine-, and dopamine-reuptake inhibitors for potential use as antidepressant agents; their structure-activity relations were detd.  I (R = 4-morpholinyl) inhibited serotonin, norepinephrine, and dopamine transporters with IC50 values of 3.0 nM, 8.3 nM, and 3.1 nM, inhibited depression in rodent models, and exhibited substantial occupancy levels at the three transporters in both rat and mouse brain after efficacious oral doses; its pharmacokinetics (clearance, vol. of distribution, and bioavailability) in rats and monkeys was detd.  I (R = 4-morpholinyl) generated a metabolite I (R = HOCH2CH2NH) in monkeys which inhibited serotonin, norepinephrine, and dopamine transporters with similar IC50 values to I (R = 4-morpholinyl), was present in rat brain at significant concns. after direct administration, and inhibited CYP2D6 with IC50 = 1 μM.  The structure of the monomaleate salt of I (R = 4-morpholinyl) was detd. by X-ray crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbllrIpn3vqbVg90H21EOLACvtfcHk0lixzaaN0lAgvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVaht7k%253D&md5=9b0a3838c9f22fb12e2630ec8b917662</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1021%2Fml500053b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500053b%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DZha%26aufirst%3DC.%26aulast%3DNacro%26aufirst%3DK.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DCui%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DY.%2BL.%26aulast%3DBhatt%26aufirst%3DU.%26aulast%3DSambandam%26aufirst%3DA.%26aulast%3DIsherwood%26aufirst%3DM.%26aulast%3DYet%26aufirst%3DL.%26aulast%3DHerr%26aufirst%3DM.%2BT.%26aulast%3DEbeltoft%26aufirst%3DS.%26aulast%3DHassler%26aufirst%3DC.%26aulast%3DFleming%26aufirst%3DL.%26aulast%3DPechulis%26aufirst%3DA.%2BD.%26aulast%3DPayen-Fornicola%26aufirst%3DA.%26aulast%3DHolman%26aufirst%3DN.%26aulast%3DMilanowski%26aufirst%3DD.%26aulast%3DCotterill%26aufirst%3DI.%26aulast%3DMozhaev%26aufirst%3DV.%26aulast%3DKhmelnitsky%26aufirst%3DY.%26aulast%3DGuzzo%26aufirst%3DP.%2BR.%26aulast%3DSargent%26aufirst%3DB.%2BJ.%26aulast%3DMolino%26aufirst%3DB.%2BF.%26aulast%3DOlson%26aufirst%3DR.%26aulast%3DKing%26aufirst%3DD.%26aulast%3DLelas%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DY.%2BW.%26aulast%3DJohnson%26aufirst%3DK.%26aulast%3DMolski%26aufirst%3DT.%26aulast%3DOrie%26aufirst%3DA.%26aulast%3DNg%26aufirst%3DA.%26aulast%3DHaskell%26aufirst%3DR.%26aulast%3DClarke%26aufirst%3DW.%26aulast%3DBertekap%26aufirst%3DR.%26aulast%3DO%25E2%2580%2599Connell%26aufirst%3DJ.%26aulast%3DLodge%26aufirst%3DN.%26aulast%3DSinz%26aufirst%3DM.%26aulast%3DAdams%26aufirst%3DS.%26aulast%3DZaczek%26aufirst%3DR.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26atitle%3DDesign%2520and%2520synthesis%2520of%25204-heteroaryl%25201%252C2%252C3%252C4-tetrahydroisoquinolines%2520as%2520triple%2520reuptake%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26spage%3D760%26epage%3D765%26doi%3D10.1021%2Fml500053b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhagwagar, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torbeyns, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennicken, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunlop, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisler, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shelton, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thase, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, R.</span></span> <span> </span><span class="NLM_article-title">Assessment of the efficacy and safety of BMS-820836 in patients with treatment-resistant major depression: results from 2 randomized, double-blind studies</span>. <i>J. Clin. Psychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">454</span>– <span class="NLM_lpage">459</span>, <span class="refDoi"> DOI: 10.1097/JCP.0000000000000335</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1097%2FJCP.0000000000000335" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=25961781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFWhu7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2015&pages=454-459&author=Z.+Bhagwagarauthor=A.+Torbeynsauthor=D.+Hennickenauthor=M.+Zhengauthor=B.+W.+Dunlopauthor=S.+J.+Mathewauthor=A.+Khanauthor=R.+Weislerauthor=C.+Nelsonauthor=R.+Sheltonauthor=M.+E.+Thaseauthor=R.+Lane&title=Assessment+of+the+efficacy+and+safety+of+BMS-820836+in+patients+with+treatment-resistant+major+depression%3A+results+from+2+randomized%2C+double-blind+studies&doi=10.1097%2FJCP.0000000000000335"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Assessment of the Efficacy and Safety of BMS-820836 in Patients With Treatment-Resistant Major Depression: Results From 2 Randomized, Double-Blind Studies</span></div><div class="casAuthors">Bhagwagar, Zubin; Torbeyns, Anne; Hennicken, Delphine; Zheng, Ming; Dunlop, Boadie W.; Mathew, Sanjay J.; Khan, Arif; Weisler, Richard; Nelson, Craig; Shelton, Richard; Thase, Michael E.; Lane, Roger</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Psychopharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">454-459</span>CODEN:
                <span class="NLM_cas:coden">JCPYDR</span>;
        ISSN:<span class="NLM_cas:issn">0271-0749</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Two phase 2B, randomized, double-blind studies assessed the efficacy and safety of fixed or flexible dose of triple monoamine uptake inhibitor BMS-820836 in patients with treatment-resistant depression to demonstrate whether switching to BMS-820836 was superior to the continuation of std. antidepressant treatment.  Patients with a history of inadequate response to 1 to 3 adequate trials of antidepressant therapies were prospectively treated with duloxetine 60 mg/d for 8 wk (CN162-006) or duloxetine 60 mg/d or escitalopram 20 mg/d for 7 wk (CN162-007).  Inadequate responders were randomized to continue their prospective phase treatment or switch to flexible-dose (0.5-2 mg/d; CN162-006) or fixed-dose (0.25, 0.5, 1, or 2 mg/d; CN162-007) BMS-820836 for 6 wk.  The primary end point in both studies was mean change in Montgomery-Åsberg Depression Rating Scale (MADRS) total score from randomization to study end point.  BMS-820836 flexible (0.5-2 mg/d) or fixed dose of 1 mg/d or greater showed efficacy similar to the continuation of antidepressant treatment, with no statistically significant or clin. meaningful differences.  In the CN162-006 study, the adjusted mean (SE) change in MADRS total score was -8.7 (0.661) and -8.1 (0.656) for BMS-820836 and duloxetine, resp. (P = 0.526).  In the CN162-007 study, the adjusted mean (SE) change in MADRS total score was -7.3 (0.830) and -6.6 (0.842) for BMS-820836 of 1 and 2 mg, resp., and -6.9 (0.602) for the continuation group (P = 0.910).  Thus, BMS-820836 was well tolerated, with no evidence of dose-dependent discontinuations due to adverse events, but it failed to demonstrate superiority to the continuation of an existing antidepressant in patients with treatment-resistant depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEz-lABCAwwbVg90H21EOLACvtfcHk0lgdSbjEX2M89w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFWhu7vP&md5=6abe3efb9009a4a27e28494372765848</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1097%2FJCP.0000000000000335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJCP.0000000000000335%26sid%3Dliteratum%253Aachs%26aulast%3DBhagwagar%26aufirst%3DZ.%26aulast%3DTorbeyns%26aufirst%3DA.%26aulast%3DHennicken%26aufirst%3DD.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DDunlop%26aufirst%3DB.%2BW.%26aulast%3DMathew%26aufirst%3DS.%2BJ.%26aulast%3DKhan%26aufirst%3DA.%26aulast%3DWeisler%26aufirst%3DR.%26aulast%3DNelson%26aufirst%3DC.%26aulast%3DShelton%26aufirst%3DR.%26aulast%3DThase%26aufirst%3DM.%2BE.%26aulast%3DLane%26aufirst%3DR.%26atitle%3DAssessment%2520of%2520the%2520efficacy%2520and%2520safety%2520of%2520BMS-820836%2520in%2520patients%2520with%2520treatment-resistant%2520major%2520depression%253A%2520results%2520from%25202%2520randomized%252C%2520double-blind%2520studies%26jtitle%3DJ.%2520Clin.%2520Psychopharmacol.%26date%3D2015%26volume%3D35%26spage%3D454%26epage%3D459%26doi%3D10.1097%2FJCP.0000000000000335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Risinger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhagwagar, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cahir, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miler, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendonza, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, W.</span></span> <span> </span><span class="NLM_article-title">Evaluation of safety and tolerability, pharmacokinetics, and pharmacodynamics of BMS-820836 in healthy subjects: a placebo-controlled, ascending single-dose study</span>. <i>Psychopharmacology (Berl.)</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>231</i></span>,  <span class="NLM_fpage">2299</span>– <span class="NLM_lpage">2310</span>, <span class="refDoi"> DOI: 10.1007/s00213-013-3391-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1007%2Fs00213-013-3391-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=24337079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A280%3ADC%252BC2c3mtlyitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=231&publication_year=2014&pages=2299-2310&author=R.+Risingerauthor=Z.+Bhagwagarauthor=F.+Luoauthor=M.+Cahirauthor=L.+Milerauthor=A.+E.+Mendonzaauthor=J.+H.+Meyerauthor=M.+Zhengauthor=W.+Hayes&title=Evaluation+of+safety+and+tolerability%2C+pharmacokinetics%2C+and+pharmacodynamics+of+BMS-820836+in+healthy+subjects%3A+a+placebo-controlled%2C+ascending+single-dose+study&doi=10.1007%2Fs00213-013-3391-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of safety and tolerability, pharmacokinetics, and pharmacodynamics of BMS-820836 in healthy subjects: a placebo-controlled, ascending single-dose study</span></div><div class="casAuthors">Risinger Robert; Bhagwagar Zubin; Luo Feng; Cahir Matthew; Miler Laura; Mendonza Anisha E; Meyer Jeffrey H; Zheng Ming; Hayes Wendy</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">231</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2299-310</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">RATIONALE:  BMS-820836, a novel triple monoamine reuptake inhibitor, is an experimental monotherapy for sufferers of major depressive disorder who have had an inadequate response to an existing antidepressant treatment.  OBJECTIVES:  This study was conducted to evaluate the safety and tolerability, pharmacokinetics (PK), and serotonin transporter (SERT) and dopamine transporter (DAT) occupancy for single doses of BMS-820836 in healthy subjects.  METHODS:  Healthy subjects were assigned to seven BMS-820836 dose panels (0.025, 0.1, 0.5, 1, 2, 3, and 5 mg; n = 8 each), in which subjects were randomly allocated 3:1 to a single BMS-820836 dose or matched placebo.  Serial blood samples were collected on Days 1, 2, 3, 4, 7, and 14 to characterize the PK of BMS-820836.  Following evaluation of the maximum tolerated dose, SERT occupancy was determined by applying [(11)C]DASB positron emission tomography (PET) after single-dose BMS-820836 (0.5 or 3 mg; n = 3 each) and DAT occupancy by applying [(11)C]PE2I PET after single-dose BMS-820836 (3 mg; n = 6).  RESULTS:  Single oral doses of BMS-820836 (0.025-3 mg) were generally safe and well tolerated.  BMS-820836 had a median T max of 5.0-7.2 h and a mean apparent terminal T 1/2 of 34-57 h.  Mean striatal SERT occupancies were 19 ± 9 % and 82 ± 8 % after single doses of 0.5 and 3 mg BMS-820836, respectively.  The mean striatal DAT occupancy was 19 ± 9 % after a single 3 mg BMS-820836 dose.  CONCLUSIONS:  Single doses of BMS-820836 have meaningful SERT and DAT occupancy and demonstrate an acceptable safety and tolerability profile in healthy control subjects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQKcK_Pc4CY0vcsfMJQC1ZdfW6udTcc2eZDVWC5ixEgz7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c3mtlyitQ%253D%253D&md5=f570b71231063bc297942d5ba657adb7</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1007%2Fs00213-013-3391-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-013-3391-3%26sid%3Dliteratum%253Aachs%26aulast%3DRisinger%26aufirst%3DR.%26aulast%3DBhagwagar%26aufirst%3DZ.%26aulast%3DLuo%26aufirst%3DF.%26aulast%3DCahir%26aufirst%3DM.%26aulast%3DMiler%26aufirst%3DL.%26aulast%3DMendonza%26aufirst%3DA.%2BE.%26aulast%3DMeyer%26aufirst%3DJ.%2BH.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DHayes%26aufirst%3DW.%26atitle%3DEvaluation%2520of%2520safety%2520and%2520tolerability%252C%2520pharmacokinetics%252C%2520and%2520pharmacodynamics%2520of%2520BMS-820836%2520in%2520healthy%2520subjects%253A%2520a%2520placebo-controlled%252C%2520ascending%2520single-dose%2520study%26jtitle%3DPsychopharmacology%2520%2528Berl.%2529%26date%3D2014%26volume%3D231%26spage%3D2299%26epage%3D2310%26doi%3D10.1007%2Fs00213-013-3391-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carlier, P. R.</span>; <span class="NLM_string-name">Richelson, E.</span></span> <span> </span><span class="NLM_article-title">Preparation of <i>N</i>,<i>N</i>-Dimethyl-3-cyclohexyl-3-hydroxy-2-(2-naphthyl)propylamines as Neurotransmitter Reuptake Inhibitors</span>. <span class="NLM_patent">WO2005120200A2</span>, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=P.+R.+Carlier&author=E.+Richelson&title=Preparation+of+N%2CN-Dimethyl-3-cyclohexyl-3-hydroxy-2-%282-naphthyl%29propylamines+as+Neurotransmitter+Reuptake+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCarlier%26aufirst%3DP.%2BR.%26atitle%3DPreparation%2520of%2520N%252CN-Dimethyl-3-cyclohexyl-3-hydroxy-2-%25282-naphthyl%2529propylamines%2520as%2520Neurotransmitter%2520Reuptake%2520Inhibitors%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boules, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlier, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richelson, E.</span></span> <span> </span><span class="NLM_article-title">Antidepressant-like effects of novel triple reuptake inhibitors, PRC025 and PRC050</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>555</i></span>,  <span class="NLM_fpage">30</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2006.10.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.ejphar.2006.10.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=17109850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsFKhtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=555&publication_year=2007&pages=30-36&author=A.+M.+Shawauthor=M.+Boulesauthor=Y.+Zhangauthor=K.+Williamsauthor=J.+Robinsonauthor=P.+R.+Carlierauthor=E.+Richelson&title=Antidepressant-like+effects+of+novel+triple+reuptake+inhibitors%2C+PRC025+and+PRC050&doi=10.1016%2Fj.ejphar.2006.10.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Antidepressant-like effects of novel triple reuptake inhibitors, PRC025 and PRC050</span></div><div class="casAuthors">Shaw, Amanda M.; Boules, Mona; Zhang, Yiqun; Williams, Katrina; Robinson, Jessica; Carlier, Paul R.; Richelson, Elliott</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">555</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">30-36</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Most currently prescribed antidepressants act by selectively increasing the synaptic availability of serotonin or norepinephrine, or through action on both serotonin and norepinephrine.  However, most therapies require several weeks of treatment before improvement of symptoms is obsd. and not all patients respond to antidepressant treatment.  One strategy that has emerged in new antidepressant development is the use of triple reuptake inhibitors, which inhibit reuptake of serotonin, norepinephrine, and dopamine.  These compds. have been hypothesized to have a more rapid onset of activity and better efficacy over single or dual reuptake inhibitor antidepressants in part due to the addn. of the dopamine component.  The authors have developed novel compds. that are analogs of venlafaxine, of which two, racemic PRC025 ((2SR, 3RS)-N,N-dimethyl-3-cyclohexyl-3-hydroxy-2-(2'-naphthyl)propylamine) and PRC050 ((2RS,3RS)-N-methyl-3-hydroxy-2-(2'-naphthyl)-3-phenylpropylamine), are highly potent at human serotonin, norepinephrine, and dopamine transporters and inhibit the reuptake of serotonin, norepinephrine, and dopamine into rat brain synaptosomes.  These compds. were tested in animal models used to evaluate potential antidepressants: the forced swim test in rats and the tail suspension test in mice.  In the forced swim test, both PRC025 and PRC050 reduced the time spent immobile and increased the time spent swimming, comparable to the effects seen with imipramine, a tricyclic antidepressant.  In addn., both PRC025 and PRC050 were effective in reducing the time spent immobile in the tail suspension test, again with effects comparable to imipramine.  Therefore it appears that our compds. may possess antidepressant activity and represent a new class of triple reuptake inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNFgOGIhoBvLVg90H21EOLACvtfcHk0lgCHbDcHx7lAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsFKhtw%253D%253D&md5=27ba548eac72b50abedf771e55174fab</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2006.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2006.10.004%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BM.%26aulast%3DBoules%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWilliams%26aufirst%3DK.%26aulast%3DRobinson%26aufirst%3DJ.%26aulast%3DCarlier%26aufirst%3DP.%2BR.%26aulast%3DRichelson%26aufirst%3DE.%26atitle%3DAntidepressant-like%2520effects%2520of%2520novel%2520triple%2520reuptake%2520inhibitors%252C%2520PRC025%2520and%2520PRC050%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2007%26volume%3D555%26spage%3D30%26epage%3D36%26doi%3D10.1016%2Fj.ejphar.2006.10.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielenstein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caccese, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heathcote, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stong, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bodes, E.</span></span> <span> </span><span class="NLM_article-title">Assessment of biomarkers of drug-induced kidney injury in cynomolgus monkeys treated with a triple reuptake inhibitor</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">269</span>– <span class="NLM_lpage">283</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfr013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1093%2Ftoxsci%2Fkfr013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=21258088" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvFejt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2011&pages=269-283&author=M.+Guhaauthor=A.+Heierauthor=S.+Priceauthor=M.+Bielensteinauthor=R.+G.+Cacceseauthor=D.+I.+Heathcoteauthor=T.+R.+Simpsonauthor=D.+B.+Stongauthor=E.+Bodes&title=Assessment+of+biomarkers+of+drug-induced+kidney+injury+in+cynomolgus+monkeys+treated+with+a+triple+reuptake+inhibitor&doi=10.1093%2Ftoxsci%2Fkfr013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Assessment of Biomarkers of Drug-Induced Kidney Injury in Cynomolgus Monkeys Treated with a Triple Reuptake Inhibitor</span></div><div class="casAuthors">Guha, Mausumee; Heier, Annabelle; Price, Sally; Bielenstein, Margareta; Caccese, Robert G.; Heathcote, Daniel I.; Simpson, Thomas R.; Stong, David B.; Bodes, Elmarie</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">269-283</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-6080</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Drug-induced kidney injury (DIKI) results in attrition during drug development; new DIKI urinary biomarkers offer potential to detect and monitor DIKI progression and regression, but frequently only in rats.  The triple reuptake inhibitor (TRI) PRC200-SS represents a new class of antidepressants that elevate synaptic levels of serotonin, norepinephrine, and dopamine and is expected to produce more rapid onset and better antidepressant efficacy than single or dual inhibitors.  Although preclin. studies and recent clin. trials lend support to this concept of superior efficacy for TRIs, there is little information on the safety profile of this class of compds.  Using histopathol. and DIKI biomarkers, in single- and repeat dose toxicol. studies in cynomolgus monkeys, PRC200-SS demonstrated dose-proportional kidney toxicity.  Characterization of the histopathol. lesions, using a combination of immunohistochem. (IHC) and urinary biomarker anal., indicated that the compd. is a distal tubule and collecting duct toxicant.  Segment specificity for the lesions was shown using a newly developed triple IHC combination method with antibodies against calbindin D28, aquaporin 2, and aquaporin 1.  Urinary biomarker analyses, using multiplex immunoassays, confirmed a dose-proportional increase in the excretion of calbindin D28 and clusterin in compd.-treated monkeys with levels returning to baseline during the drug-free recovery period.  These results constitute the validation of distal nephron DIKI biomarkers in the cynomolgus monkey and demonstrate the utility of calbindin D28 and clusterin to monitor the progression of distal nephron DIKI, representing potential early biomarkers of DIKI for the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq19x9Km6Ry67Vg90H21EOLACvtfcHk0lgCHbDcHx7lAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvFejt74%253D&md5=76bfb7b4e85b62055221eaa1930c6ad3</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfr013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfr013%26sid%3Dliteratum%253Aachs%26aulast%3DGuha%26aufirst%3DM.%26aulast%3DHeier%26aufirst%3DA.%26aulast%3DPrice%26aufirst%3DS.%26aulast%3DBielenstein%26aufirst%3DM.%26aulast%3DCaccese%26aufirst%3DR.%2BG.%26aulast%3DHeathcote%26aufirst%3DD.%2BI.%26aulast%3DSimpson%26aufirst%3DT.%2BR.%26aulast%3DStong%26aufirst%3DD.%2BB.%26aulast%3DBodes%26aufirst%3DE.%26atitle%3DAssessment%2520of%2520biomarkers%2520of%2520drug-induced%2520kidney%2520injury%2520in%2520cynomolgus%2520monkeys%2520treated%2520with%2520a%2520triple%2520reuptake%2520inhibitor%26jtitle%3DToxicol.%2520Sci.%26date%3D2011%26volume%3D120%26spage%3D269%26epage%3D283%26doi%3D10.1093%2Ftoxsci%2Fkfr013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bannwart, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choy, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenhouse, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaime-Figueroa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madera, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozboya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raptova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roetz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoenfeld, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weikert, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, Y.</span></span> <span> </span><span class="NLM_article-title">Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">6062</span>– <span class="NLM_lpage">6066</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.10.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.bmcl.2008.10.025" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=6062-6066&author=L.+M.+Bannwartauthor=D.+S.+Carterauthor=H.-Y.+Caiauthor=J.+C.+Choyauthor=R.+Greenhouseauthor=S.+Jaime-Figueroaauthor=P.+S.+Iyerauthor=C.+J.+Linauthor=E.+K.+Leeauthor=M.+C.+Lucasauthor=S.+M.+Lynchauthor=A.+M.+Maderaauthor=A.+Mooreauthor=K.+Ozboyaauthor=L.+Raptovaauthor=R.+Roetzauthor=R.+C.+Schoenfeldauthor=K.+A.+Steinauthor=S.+Steinerauthor=M.+Villaauthor=R.+J.+Weikertauthor=Y.+Zhai&title=Novel+3%2C3-disubstituted+pyrrolidines+as+selective+triple+serotonin%2Fnorepinephrine%2Fdopamine+reuptake+inhibitors&doi=10.1016%2Fj.bmcl.2008.10.025"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.10.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.10.025%26sid%3Dliteratum%253Aachs%26aulast%3DBannwart%26aufirst%3DL.%2BM.%26aulast%3DCarter%26aufirst%3DD.%2BS.%26aulast%3DCai%26aufirst%3DH.-Y.%26aulast%3DChoy%26aufirst%3DJ.%2BC.%26aulast%3DGreenhouse%26aufirst%3DR.%26aulast%3DJaime-Figueroa%26aufirst%3DS.%26aulast%3DIyer%26aufirst%3DP.%2BS.%26aulast%3DLin%26aufirst%3DC.%2BJ.%26aulast%3DLee%26aufirst%3DE.%2BK.%26aulast%3DLucas%26aufirst%3DM.%2BC.%26aulast%3DLynch%26aufirst%3DS.%2BM.%26aulast%3DMadera%26aufirst%3DA.%2BM.%26aulast%3DMoore%26aufirst%3DA.%26aulast%3DOzboya%26aufirst%3DK.%26aulast%3DRaptova%26aufirst%3DL.%26aulast%3DRoetz%26aufirst%3DR.%26aulast%3DSchoenfeld%26aufirst%3DR.%2BC.%26aulast%3DStein%26aufirst%3DK.%2BA.%26aulast%3DSteiner%26aufirst%3DS.%26aulast%3DVilla%26aufirst%3DM.%26aulast%3DWeikert%26aufirst%3DR.%2BJ.%26aulast%3DZhai%26aufirst%3DY.%26atitle%3DNovel%25203%252C3-disubstituted%2520pyrrolidines%2520as%2520selective%2520triple%2520serotonin%252Fnorepinephrine%252Fdopamine%2520reuptake%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D6062%26epage%3D6066%26doi%3D10.1016%2Fj.bmcl.2008.10.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weikert, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenhouse, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madera, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozboya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoenfeld, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, S. M.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">5559</span>– <span class="NLM_lpage">5566</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.07.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.bmcl.2010.07.020" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=5559-5566&author=M.+C.+Lucasauthor=R.+J.+Weikertauthor=D.+S.+Carterauthor=H.-Y.+Caiauthor=R.+Greenhouseauthor=P.+S.+Iyerauthor=C.+J.+Linauthor=E.+K.+Leeauthor=A.+M.+Maderaauthor=A.+Mooreauthor=K.+Ozboyaauthor=R.+C.+Schoenfeldauthor=S.+Steinerauthor=Y.+Zhaiauthor=S.+M.+Lynch&title=Design%2C+synthesis%2C+and+biological+evaluation+of+new+monoamine+reuptake+inhibitors+with+potential+therapeutic+utility+in+depression+and+pain&doi=10.1016%2Fj.bmcl.2010.07.020"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.07.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.07.020%26sid%3Dliteratum%253Aachs%26aulast%3DLucas%26aufirst%3DM.%2BC.%26aulast%3DWeikert%26aufirst%3DR.%2BJ.%26aulast%3DCarter%26aufirst%3DD.%2BS.%26aulast%3DCai%26aufirst%3DH.-Y.%26aulast%3DGreenhouse%26aufirst%3DR.%26aulast%3DIyer%26aufirst%3DP.%2BS.%26aulast%3DLin%26aufirst%3DC.%2BJ.%26aulast%3DLee%26aufirst%3DE.%2BK.%26aulast%3DMadera%26aufirst%3DA.%2BM.%26aulast%3DMoore%26aufirst%3DA.%26aulast%3DOzboya%26aufirst%3DK.%26aulast%3DSchoenfeld%26aufirst%3DR.%2BC.%26aulast%3DSteiner%26aufirst%3DS.%26aulast%3DZhai%26aufirst%3DY.%26aulast%3DLynch%26aufirst%3DS.%2BM.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520new%2520monoamine%2520reuptake%2520inhibitors%2520with%2520potential%2520therapeutic%2520utility%2520in%2520depression%2520and%2520pain%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D5559%26epage%3D5566%26doi%3D10.1016%2Fj.bmcl.2010.07.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoenfeld, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weikert, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, P. S.</span></span> <span> </span><span class="NLM_article-title">Novel, achiral aminoheterocycles as selective monoamine reuptake inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">4630</span>– <span class="NLM_lpage">4633</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.06.076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.bmcl.2009.06.076" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=4630-4633&author=M.+C.+Lucasauthor=D.+S.+Carterauthor=H.-Y.+Caiauthor=E.+K.+Leeauthor=R.+C.+Schoenfeldauthor=S.+Steinerauthor=M.+Villaauthor=R.+J.+Weikertauthor=P.+S.+Iyer&title=Novel%2C+achiral+aminoheterocycles+as+selective+monoamine+reuptake+inhibitors&doi=10.1016%2Fj.bmcl.2009.06.076"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.06.076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.06.076%26sid%3Dliteratum%253Aachs%26aulast%3DLucas%26aufirst%3DM.%2BC.%26aulast%3DCarter%26aufirst%3DD.%2BS.%26aulast%3DCai%26aufirst%3DH.-Y.%26aulast%3DLee%26aufirst%3DE.%2BK.%26aulast%3DSchoenfeld%26aufirst%3DR.%2BC.%26aulast%3DSteiner%26aufirst%3DS.%26aulast%3DVilla%26aufirst%3DM.%26aulast%3DWeikert%26aufirst%3DR.%2BJ.%26aulast%3DIyer%26aufirst%3DP.%2BS.%26atitle%3DNovel%252C%2520achiral%2520aminoheterocycles%2520as%2520selective%2520monoamine%2520reuptake%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D4630%26epage%3D4633%26doi%3D10.1016%2Fj.bmcl.2009.06.076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carter, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roetz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoenfeld, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weikert, R. J.</span></span> <span> </span><span class="NLM_article-title">2-Substituted N-aryl piperazines as novel triple reuptake inhibitors for the treatment of depression</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">3941</span>– <span class="NLM_lpage">3945</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.05.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.bmcl.2010.05.008" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=3941-3945&author=D.+S.+Carterauthor=H.-Y.+Caiauthor=E.+K.+Leeauthor=P.+S.+Iyerauthor=M.+C.+Lucasauthor=R.+Roetzauthor=R.+C.+Schoenfeldauthor=R.+J.+Weikert&title=2-Substituted+N-aryl+piperazines+as+novel+triple+reuptake+inhibitors+for+the+treatment+of+depression&doi=10.1016%2Fj.bmcl.2010.05.008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.05.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.05.008%26sid%3Dliteratum%253Aachs%26aulast%3DCarter%26aufirst%3DD.%2BS.%26aulast%3DCai%26aufirst%3DH.-Y.%26aulast%3DLee%26aufirst%3DE.%2BK.%26aulast%3DIyer%26aufirst%3DP.%2BS.%26aulast%3DLucas%26aufirst%3DM.%2BC.%26aulast%3DRoetz%26aufirst%3DR.%26aulast%3DSchoenfeld%26aufirst%3DR.%2BC.%26aulast%3DWeikert%26aufirst%3DR.%2BJ.%26atitle%3D2-Substituted%2520N-aryl%2520piperazines%2520as%2520novel%2520triple%2520reuptake%2520inhibitors%2520for%2520the%2520treatment%2520of%2520depression%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D3941%26epage%3D3945%26doi%3D10.1016%2Fj.bmcl.2010.05.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Honda, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishichi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshikawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanzaki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arakawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terauchi, J.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological activities of 1-aryl-1,4-diazepan-2-one derivatives as novel triple reuptake inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">3898</span>– <span class="NLM_lpage">3902</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.06.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.bmcl.2014.06.046" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=3898-3902&author=E.+Hondaauthor=Y.+Ishichiauthor=E.+Kimuraauthor=M.+Yoshikawaauthor=N.+Kanzakiauthor=H.+Nakagawaauthor=Y.+Teraoauthor=A.+Suzukiauthor=T.+Kawaiauthor=Y.+Arakawaauthor=H.+Ohtaauthor=J.+Terauchi&title=Design%2C+synthesis%2C+and+biological+activities+of+1-aryl-1%2C4-diazepan-2-one+derivatives+as+novel+triple+reuptake+inhibitors&doi=10.1016%2Fj.bmcl.2014.06.046"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.06.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.06.046%26sid%3Dliteratum%253Aachs%26aulast%3DHonda%26aufirst%3DE.%26aulast%3DIshichi%26aufirst%3DY.%26aulast%3DKimura%26aufirst%3DE.%26aulast%3DYoshikawa%26aufirst%3DM.%26aulast%3DKanzaki%26aufirst%3DN.%26aulast%3DNakagawa%26aufirst%3DH.%26aulast%3DTerao%26aufirst%3DY.%26aulast%3DSuzuki%26aufirst%3DA.%26aulast%3DKawai%26aufirst%3DT.%26aulast%3DArakawa%26aufirst%3DY.%26aulast%3DOhta%26aufirst%3DH.%26aulast%3DTerauchi%26aufirst%3DJ.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520activities%2520of%25201-aryl-1%252C4-diazepan-2-one%2520derivatives%2520as%2520novel%2520triple%2520reuptake%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D3898%26epage%3D3902%26doi%3D10.1016%2Fj.bmcl.2014.06.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishichi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honda, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshikawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakahata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arakawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanzaki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terauchi, J.</span></span> <span> </span><span class="NLM_article-title">Novel triple reuptake inhibitors with low risk of CAD associated liabilities: design, synthesis and biological activities of 4-[(1S)-1-(3,4-dichlorophenyl)-2-methoxyethyl]piperidine and related compounds</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">4600</span>– <span class="NLM_lpage">4613</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.05.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.bmc.2013.05.025" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=4600-4613&author=Y.+Ishichiauthor=E.+Kimuraauthor=E.+Hondaauthor=M.+Yoshikawaauthor=T.+Nakahataauthor=Y.+Teraoauthor=A.+Suzukiauthor=T.+Kawaiauthor=Y.+Arakawaauthor=H.+Ohtaauthor=N.+Kanzakiauthor=H.+Nakagawaauthor=J.+Terauchi&title=Novel+triple+reuptake+inhibitors+with+low+risk+of+CAD+associated+liabilities%3A+design%2C+synthesis+and+biological+activities+of+4-%5B%281S%29-1-%283%2C4-dichlorophenyl%29-2-methoxyethyl%5Dpiperidine+and+related+compounds&doi=10.1016%2Fj.bmc.2013.05.025"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.05.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.05.025%26sid%3Dliteratum%253Aachs%26aulast%3DIshichi%26aufirst%3DY.%26aulast%3DKimura%26aufirst%3DE.%26aulast%3DHonda%26aufirst%3DE.%26aulast%3DYoshikawa%26aufirst%3DM.%26aulast%3DNakahata%26aufirst%3DT.%26aulast%3DTerao%26aufirst%3DY.%26aulast%3DSuzuki%26aufirst%3DA.%26aulast%3DKawai%26aufirst%3DT.%26aulast%3DArakawa%26aufirst%3DY.%26aulast%3DOhta%26aufirst%3DH.%26aulast%3DKanzaki%26aufirst%3DN.%26aulast%3DNakagawa%26aufirst%3DH.%26aulast%3DTerauchi%26aufirst%3DJ.%26atitle%3DNovel%2520triple%2520reuptake%2520inhibitors%2520with%2520low%2520risk%2520of%2520CAD%2520associated%2520liabilities%253A%2520design%252C%2520synthesis%2520and%2520biological%2520activities%2520of%25204-%255B%25281S%2529-1-%25283%252C4-dichlorophenyl%2529-2-methoxyethyl%255Dpiperidine%2520and%2520related%2520compounds%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D4600%26epage%3D4613%26doi%3D10.1016%2Fj.bmc.2013.05.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo characterization of PA01, a novel promising triple reuptake inhibitor</span>. <i>Physiol. Behav.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">149</span>, <span class="refDoi"> DOI: 10.1016/j.physbeh.2014.10.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.physbeh.2014.10.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2015&pages=141-149&author=J.+Houauthor=Y.+Xingauthor=D.+Zuoauthor=Y.+Wuauthor=J.+Tianauthor=Q.+Mengauthor=M.+Yang&title=In+vitro+and+in+vivo+characterization+of+PA01%2C+a+novel+promising+triple+reuptake+inhibitor&doi=10.1016%2Fj.physbeh.2014.10.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1016%2Fj.physbeh.2014.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.physbeh.2014.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DXing%26aufirst%3DY.%26aulast%3DZuo%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DTian%26aufirst%3DJ.%26aulast%3DMeng%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DM.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520characterization%2520of%2520PA01%252C%2520a%2520novel%2520promising%2520triple%2520reuptake%2520inhibitor%26jtitle%3DPhysiol.%2520Behav.%26date%3D2015%26volume%3D138%26spage%3D141%26epage%3D149%26doi%3D10.1016%2Fj.physbeh.2014.10.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span> <span> </span><span class="NLM_article-title">The effects of LPM570065, a novel triple reuptake inhibitor, on extracellular serotonin, dopamine and norepinephrine levels in rats</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">e91775</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0091775</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1371%2Fjournal.pone.0091775" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=e91775&author=R.+Zhangauthor=X.+Liauthor=Y.+Shiauthor=Y.+Shaoauthor=K.+Sunauthor=A.+Wangauthor=F.+Sunauthor=W.+Liuauthor=D.+Wangauthor=J.+Jinauthor=Y.+Li&title=The+effects+of+LPM570065%2C+a+novel+triple+reuptake+inhibitor%2C+on+extracellular+serotonin%2C+dopamine+and+norepinephrine+levels+in+rats&doi=10.1371%2Fjournal.pone.0091775"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0091775&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0091775%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DShao%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26atitle%3DThe%2520effects%2520of%2520LPM570065%252C%2520a%2520novel%2520triple%2520reuptake%2520inhibitor%252C%2520on%2520extracellular%2520serotonin%252C%2520dopamine%2520and%2520norepinephrine%2520levels%2520in%2520rats%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26spage%3De91775%26doi%3D10.1371%2Fjournal.pone.0091775" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debnath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonio, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reith, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutta, A.</span></span> <span> </span><span class="NLM_article-title">Flexible and biomimetic analogs of triple uptake inhibitor 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: Synthesis, biological characterization, and development of a pharmacophore model</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">311</span>– <span class="NLM_lpage">324</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.11.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.bmc.2013.11.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=24315194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFOhu7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=311-324&author=H.+Sharmaauthor=S.+Santraauthor=J.+Debnathauthor=T.+Antonioauthor=M.+Reithauthor=A.+Dutta&title=Flexible+and+biomimetic+analogs+of+triple+uptake+inhibitor+4-%28%28%28%283S%2C6S%29-6-benzhydryltetrahydro-2H-pyran-3-yl%29amino%29methyl%29phenol%3A+Synthesis%2C+biological+characterization%2C+and+development+of+a+pharmacophore+model&doi=10.1016%2Fj.bmc.2013.11.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Flexible and biomimetic analogs of triple uptake inhibitor 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: Synthesis, biological characterization, and development of a pharmacophore model</span></div><div class="casAuthors">Sharma, Horrick; Santra, Soumava; Debnath, Joy; Antonio, Tamara; Reith, Maarten; Dutta, Aloke</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">311-324</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In this study we have generated a pharmacophore model of triple uptake inhibitor compds. based on novel asym. pyran derivs. and the newly developed asym. furan derivs.  The model revealed features important for inhibitors to exhibit a balanced activity against dopamine transporter (DAT), serotonin transporter (SERT), and norepinephrine transporter (NET).  In particular, a 'folded' conformation was found common to the active pyran compds. in the training set and was crucial to triple uptake inhibitory activity.  Furthermore, the distances between the benzhydryl moiety and the N-benzyl group as well as the orientation of the secondary nitrogen were also important for TUI activity.  We have validated our findings by synthesizing and testing novel asym. pyran analogs.  The present work has also resulted in the discovery of a new series of asym. THF derivs. as novel TUIs.  Lead compds. I (R = OH, OMe) exhibited moderate TUI activity.  Interestingly, the highest TUI activity by lead THF compds. for example, I (R = OH, OMe), was exhibited in a stereochem. preference similar to pyran TUI for example, D-161 (II).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpoPTnQdBuWLVg90H21EOLACvtfcHk0lj4O5ud66x0Sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFOhu7%252FM&md5=0594221d44641fce17db71101d075cb2</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.11.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.11.017%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DH.%26aulast%3DSantra%26aufirst%3DS.%26aulast%3DDebnath%26aufirst%3DJ.%26aulast%3DAntonio%26aufirst%3DT.%26aulast%3DReith%26aufirst%3DM.%26aulast%3DDutta%26aufirst%3DA.%26atitle%3DFlexible%2520and%2520biomimetic%2520analogs%2520of%2520triple%2520uptake%2520inhibitor%25204-%2528%2528%2528%25283S%252C6S%2529-6-benzhydryltetrahydro-2H-pyran-3-yl%2529amino%2529methyl%2529phenol%253A%2520Synthesis%252C%2520biological%2520characterization%252C%2520and%2520development%2520of%2520a%2520pharmacophore%2520model%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D311%26epage%3D324%26doi%3D10.1016%2Fj.bmc.2013.11.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutta, A.</span></span> <span> </span><span class="NLM_article-title">Triple reuptake inhibitors as potential next-generation antidepressants: a new hope?</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">2385</span>– <span class="NLM_lpage">2406</span>, <span class="refDoi"> DOI: 10.4155/fmc.15.134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.4155%2Ffmc.15.134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=26619226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFKlu77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=2385-2406&author=H.+Sharmaauthor=S.+Santraauthor=A.+Dutta&title=Triple+reuptake+inhibitors+as+potential+next-generation+antidepressants%3A+a+new+hope%3F&doi=10.4155%2Ffmc.15.134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Triple reuptake inhibitors as potential next-generation antidepressants: a new hope?</span></div><div class="casAuthors">Sharma, Horrick; Santra, Soumava; Dutta, Aloke</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2385-2406</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">The current therapy for depression is less than ideal with remission rates of only 25-35% and a slow onset of action with other assocd. side effects.  The persistence of anhedonia originating from depressed dopaminergic activity is one of the most treatment-resistant symptoms of depression.  Therefore, it has been hypothesized that triple reuptake inhibitors (TRIs) with potency to block dopamine reuptake in addn. to serotonin and norepinephrine transporters should produce higher efficacy.  The current review comprehensively describes the development of TRIs and discusses the importance of evaluation of in vivo transporter occupancy of TRIs, which should correlate with efficacy in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrShosMLktZJbVg90H21EOLACvtfcHk0lj4O5ud66x0Sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFKlu77I&md5=1130f331ad0e8ecfcdf5a8c3fe915596</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.4155%2Ffmc.15.134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.15.134%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DH.%26aulast%3DSantra%26aufirst%3DS.%26aulast%3DDutta%26aufirst%3DA.%26atitle%3DTriple%2520reuptake%2520inhibitors%2520as%2520potential%2520next-generation%2520antidepressants%253A%2520a%2520new%2520hope%253F%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2015%26volume%3D7%26spage%3D2385%26epage%3D2406%26doi%3D10.4155%2Ffmc.15.134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reith, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutta, A. K.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel trisubstituted asymmetric derivatives of (2S,4R,5R)-2-benzhydryl-5-benzylaminotetrahydropyran-4-ol, exhibiting high affinity for serotonin and norepinephrine transporters in a stereospecific manner</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">4962</span>– <span class="NLM_lpage">4971</span>, <span class="refDoi"> DOI: 10.1021/jm049021k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049021k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltlGhtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=4962-4971&author=S.+Zhangauthor=J.+Zhenauthor=M.+E.+Reithauthor=A.+K.+Dutta&title=Discovery+of+novel+trisubstituted+asymmetric+derivatives+of+%282S%2C4R%2C5R%29-2-benzhydryl-5-benzylaminotetrahydropyran-4-ol%2C+exhibiting+high+affinity+for+serotonin+and+norepinephrine+transporters+in+a+stereospecific+manner&doi=10.1021%2Fjm049021k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Trisubstituted Asymmetric Derivatives of (2S,4R,5R)-2-benzhydryl-5-benzylaminotetrahydropyran-4-ol, Exhibiting High Affinity for Serotonin and Norepinephrine Transporters in a Stereospecific Manner</span></div><div class="casAuthors">Zhang, Shijun; Zhen, Juan; Reith, Maarten E. A.; Dutta, Aloke K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4962-4971</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In a structure-activity relationship study on 3,6-disubstituted pyran derivs., the asym. synthesis and biol. characterization of trisubstituted (2S,4R,5R)-2-benzhydryl-5-benzylaminotetrahydropyran-4-ol and (3S,4R,6S)-6-benzhydryl-4-benzylaminotetrahydropyran-3-ol derivs. and their enantiomers were carried out.  All synthesized derivs. were tested for their affinities for the dopamine transporter (DAT), serotonin transporter (SERT), and norepinephrine transporter (NET) in the brain by measuring their potency in inhibiting the uptake of [3H]DA, [3H]-5-HT, and [3H]NE, resp.  Compds. were also tested for their binding affinity at the DAT by their inhibition of [3H]WIN 35,428.  Biol. results indicated that regioselectivity and stereoselectivity played important roles in detg. activity for monoamine transporters as only (-)-isomers of 2-benzhydryl-5-benzylaminotetrahydropyran-4-ol derivs. exhibited appreciable potency for the monoamine transporters, in particular for the SERT and NET.  Among the active analogs, (2S,4R,5R)-(-)-2-benzhydryl-5-benzylaminotetrahydropyran-4-ol exhibited potent and selective affinity at the NET (Ki, [3H]NE = 4.92 nM; DAT/NET = 91 and SERT/NET = 140).  (2S,4R,5R)-(-)-2-benzhydryl-5-(4-methoxybenzylamino)tetrahydropyran-4-ol was potent at both SERT and NET (Ki, [3H]-5-HT = 25.9 and [3H]NE = 15.8 nM, resp.).  In the analogs of these compds. a cis-relationship between the biphenyl and the amino moiety was maintained for the SERT and NET interactions, as was obsd. earlier for 3,6-disubstituted pyran compds. for the DAT interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWGm1U2Ni3vLVg90H21EOLACvtfcHk0lj4O5ud66x0Sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltlGhtb0%253D&md5=a48e2fe37663009c240415df18d64c94</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1021%2Fjm049021k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049021k%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DZhen%26aufirst%3DJ.%26aulast%3DReith%26aufirst%3DM.%2BE.%26aulast%3DDutta%26aufirst%3DA.%2BK.%26atitle%3DDiscovery%2520of%2520novel%2520trisubstituted%2520asymmetric%2520derivatives%2520of%2520%25282S%252C4R%252C5R%2529-2-benzhydryl-5-benzylaminotetrahydropyran-4-ol%252C%2520exhibiting%2520high%2520affinity%2520for%2520serotonin%2520and%2520norepinephrine%2520transporters%2520in%2520a%2520stereospecific%2520manner%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D4962%26epage%3D4971%26doi%3D10.1021%2Fjm049021k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dutta, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopishetty, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gogoi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reith, M.</span></span> <span> </span><span class="NLM_article-title">The novel trisubstituted pyran derivative D-142 has triple monoamine reuptake inhibitory activity and exerts potent antidepressant-like activity in rodents</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>671</i></span>,  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">44</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2011.09.162</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.ejphar.2011.09.162" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=21963455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVaqurzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=671&publication_year=2011&pages=39-44&author=A.+K.+Duttaauthor=B.+Gopishettyauthor=S.+Gogoiauthor=S.+Aliauthor=J.+Zhenauthor=M.+Reith&title=The+novel+trisubstituted+pyran+derivative+D-142+has+triple+monoamine+reuptake+inhibitory+activity+and+exerts+potent+antidepressant-like+activity+in+rodents&doi=10.1016%2Fj.ejphar.2011.09.162"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">The novel trisubstituted pyran derivative D-142 has triple monoamine reuptake inhibitory activity and exerts potent antidepressant-like activity in rodents</span></div><div class="casAuthors">Dutta, Aloke K.; Gopishetty, Bhaskar; Gogoi, Sanjib; Ali, Solav; Zhen, Juan; Reith, Maarten</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">671</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">39-44</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Major depression disorder is a significant health problem with 10-20% of all adults suffering from this disease.  The underlying causes of depression are still unclear and 15% of depressed patients are resistant to all known therapies.  Monoamine therapies have so far been the most successful approach for treating depression.  Triple monoamine reuptake inhibitors have recently been implicated in generation of potent antidepressant activity while possibly exhibiting a low side-effect profile in addn. to treating anhedonia.  The addnl., previously under-appreciated involvement of dopaminergic systems in depression prompted our efforts to develop novel asym. trisubstituted and disubstituted pyran derivs. as triple reuptake inhibitors.  One of the lead compds., D-142, exhibited uptake inhibition (Ki) values of 29.3 nM, 14.7 nM and 59.3 ± 13.7 nM for norepinephrine, serotonin and dopamine transporters, resp.  Its affinity for serotonin transporter was comparable to fluoxetine, a well known SSRI.  In the rat forced swimming test, compd. D-142 exhibited potent antidepressant activity in the dose range tested (2.5, 5 and 10 mg/kg) and was far more efficacious than the ref. compd. imipramine.  In the mouse tail suspension test, compd. D-142 reduced immobility in a dose (2.5, 5 and 10 mg/kg) dependent manner, indicating a potent antidepressant effect.  In locomotor activity tests, compd. D-142 did not exhibit any stimulation in the same dose ranges.  In the extended CNS receptors screening assay this mol. exhibited little or no non-specific interaction in the CNS, indicating high specificity for monoamine transporters.  These results advance D-142 as a potential potent antidepressant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGPlqH4cledLVg90H21EOLACvtfcHk0lgU0zZhcvwLhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVaqurzE&md5=69a1504c78c1083e7980c26a7179ac89</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2011.09.162&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2011.09.162%26sid%3Dliteratum%253Aachs%26aulast%3DDutta%26aufirst%3DA.%2BK.%26aulast%3DGopishetty%26aufirst%3DB.%26aulast%3DGogoi%26aufirst%3DS.%26aulast%3DAli%26aufirst%3DS.%26aulast%3DZhen%26aufirst%3DJ.%26aulast%3DReith%26aufirst%3DM.%26atitle%3DThe%2520novel%2520trisubstituted%2520pyran%2520derivative%2520D-142%2520has%2520triple%2520monoamine%2520reuptake%2520inhibitory%2520activity%2520and%2520exerts%2520potent%2520antidepressant-like%2520activity%2520in%2520rodents%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D671%26spage%3D39%26epage%3D44%26doi%3D10.1016%2Fj.ejphar.2011.09.162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dutta, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voshavar, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mabrouk, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonio, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reith, M. E. A.</span></span> <span> </span><span class="NLM_article-title">Pharmacological and behavioral characterization of D-473, an orally active triple reuptake inhibitor targeting dopamine, serotonin and norepinephrine transporters</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">e113420</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0113420</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1371%2Fjournal.pone.0113420" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=25427177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFOlsL%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=e113420&author=A.+K.+Duttaauthor=S.+Santraauthor=H.+Sharmaauthor=C.+Voshavarauthor=L.+Xuauthor=O.+Mabroukauthor=T.+Antonioauthor=M.+E.+A.+Reith&title=Pharmacological+and+behavioral+characterization+of+D-473%2C+an+orally+active+triple+reuptake+inhibitor+targeting+dopamine%2C+serotonin+and+norepinephrine+transporters&doi=10.1371%2Fjournal.pone.0113420"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological and behavioral characterization of D-473, an orally active triple reuptake inhibitor targeting dopamine, serotonin and norepinephrine transporters</span></div><div class="casAuthors">Dutta, Aloke K.; Santra, Soumava; Sharma, Horrick; Voshavar, Chandrashekhar; Xu, Liping; Mabrouk, Omar; Antonio, Tamara; Reith, Maarten E. A.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e113420/1-e113420/23, 23 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Major depressive disorder (MDD) is a debilitating disease affecting a wide cross section of people around the world.  The current therapy for depression is less than adequate and there is a considerable unmet need for more efficacious treatment.  Dopamine has been shown to play a significant role in depression including prodn. of anhedonia which has been one of the untreated symptoms in MDD.  It has been hypothesized that drugs acting at all three monoamine transporters including dopamine transporter should provide more efficacious antidepressants activity.  This has led to the development of triple reuptake inhibitor D-473 which is a novel pyran based mol. and interacts with all three monoamine transporters.  The monoamine uptake inhibition activity in the cloned human transporters expressed in HEK-293 cells (70.4, 9.18 and 39.7 for DAT, SERT and NET, resp.) indicates a serotonin preferring triple reuptake inhibition profile for this drug.  The drug D-473 exhibited good brain penetration and produced efficacious activity in rat forced swim test under oral administration.  The optimal efficacy dose did not produce any locomotor activation.  Microdialysis expt. demonstrated that systemic administration of D-473 elevated extracellular level of the three monoamines DA, 5-HT, and NE efficaciously in the dorsal lateral striatum (DLS) and the medial prefrontal cortex (mPFC) area, indicating in vivo blockade of all three monoamine transporters by D-473.  Thus, the current biol. data from D-473 indicate potent antidepressant activity of the mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgZUFxM6yY0LVg90H21EOLACvtfcHk0lgU0zZhcvwLhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFOlsL%252FO&md5=1ac592d450a1d6bce9bff124bf891b3b</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0113420&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0113420%26sid%3Dliteratum%253Aachs%26aulast%3DDutta%26aufirst%3DA.%2BK.%26aulast%3DSantra%26aufirst%3DS.%26aulast%3DSharma%26aufirst%3DH.%26aulast%3DVoshavar%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DMabrouk%26aufirst%3DO.%26aulast%3DAntonio%26aufirst%3DT.%26aulast%3DReith%26aufirst%3DM.%2BE.%2BA.%26atitle%3DPharmacological%2520and%2520behavioral%2520characterization%2520of%2520D-473%252C%2520an%2520orally%2520active%2520triple%2520reuptake%2520inhibitor%2520targeting%2520dopamine%252C%2520serotonin%2520and%2520norepinephrine%2520transporters%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26spage%3De113420%26doi%3D10.1371%2Fjournal.pone.0113420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span> <i>Wayne State University Technology Enters Exclusive License
Agreement
with TRImaran Pharma Inc. to Develop New Class of Drugs</i>; <span class="NLM_publisher-name">Wayne State University</span>: <span class="NLM_publisher-loc">Detroit,
MI</span>, February 6, <span class="NLM_year">2016</span>; <a href="http://www.trimaranpharmainc.com/news.html" class="extLink">http://www.trimaranpharmainc.com/news.html</a> (accessed May 29, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Wayne+State+University+Technology+Enters+Exclusive+License%0AAgreement%0Awith+TRImaran+Pharma+Inc.+to+Develop+New+Class+of+Drugs%3B+Wayne+State+University%3A+Detroit%2C%0AMI%2C+February+6%2C+2016%3B+http%3A%2F%2Fwww.trimaranpharmainc.com%2Fnews.html+%28accessed+May+29%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DWayne%2520State%2520University%2520Technology%2520Enters%2520Exclusive%2520License%250AAgreement%250Awith%2520TRImaran%2520Pharma%2520Inc.%2520to%2520Develop%2520New%2520Class%2520of%2520Drugs%26pub%3DWayne%2520State%2520University%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maryanoff, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McComsey, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costanzo, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setler, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardocki, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shank, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, C. R.</span></span> <span> </span><span class="NLM_article-title">Pyrroloisoquinoline antidepressants. potent, enantioselective inhibition of tetrabenazine-induced ptosis and neuronal uptake of norepinephrine, dopamine, and serotonin</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">943</span>– <span class="NLM_lpage">946</span>, <span class="refDoi"> DOI: 10.1021/jm00374a001</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00374a001" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1984&pages=943-946&author=B.+E.+Maryanoffauthor=D.+F.+McComseyauthor=M.+J.+Costanzoauthor=P.+E.+Setlerauthor=J.+F.+Gardockiauthor=R.+P.+Shankauthor=C.+R.+Schneider&title=Pyrroloisoquinoline+antidepressants.+potent%2C+enantioselective+inhibition+of+tetrabenazine-induced+ptosis+and+neuronal+uptake+of+norepinephrine%2C+dopamine%2C+and+serotonin&doi=10.1021%2Fjm00374a001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1021%2Fjm00374a001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00374a001%26sid%3Dliteratum%253Aachs%26aulast%3DMaryanoff%26aufirst%3DB.%2BE.%26aulast%3DMcComsey%26aufirst%3DD.%2BF.%26aulast%3DCostanzo%26aufirst%3DM.%2BJ.%26aulast%3DSetler%26aufirst%3DP.%2BE.%26aulast%3DGardocki%26aufirst%3DJ.%2BF.%26aulast%3DShank%26aufirst%3DR.%2BP.%26aulast%3DSchneider%26aufirst%3DC.%2BR.%26atitle%3DPyrroloisoquinoline%2520antidepressants.%2520potent%252C%2520enantioselective%2520inhibition%2520of%2520tetrabenazine-induced%2520ptosis%2520and%2520neuronal%2520uptake%2520of%2520norepinephrine%252C%2520dopamine%252C%2520and%2520serotonin%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1984%26volume%3D27%26spage%3D943%26epage%3D946%26doi%3D10.1021%2Fjm00374a001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maryanoff, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McComsey, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardocki, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shank, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costanzo, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nortey, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setler, P. E.</span></span> <span> </span><span class="NLM_article-title">Pyrroloisoquinoline antidepressants. 2. in-depth exploration of structure-activity relationships</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">1433</span>– <span class="NLM_lpage">1454</span>, <span class="refDoi"> DOI: 10.1021/jm00391a028</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00391a028" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1987&pages=1433-1454&author=B.+E.+Maryanoffauthor=D.+F.+McComseyauthor=J.+F.+Gardockiauthor=R.+P.+Shankauthor=M.+J.+Costanzoauthor=S.+O.+Norteyauthor=C.+R.+Schneiderauthor=P.+E.+Setler&title=Pyrroloisoquinoline+antidepressants.+2.+in-depth+exploration+of+structure-activity+relationships&doi=10.1021%2Fjm00391a028"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1021%2Fjm00391a028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00391a028%26sid%3Dliteratum%253Aachs%26aulast%3DMaryanoff%26aufirst%3DB.%2BE.%26aulast%3DMcComsey%26aufirst%3DD.%2BF.%26aulast%3DGardocki%26aufirst%3DJ.%2BF.%26aulast%3DShank%26aufirst%3DR.%2BP.%26aulast%3DCostanzo%26aufirst%3DM.%2BJ.%26aulast%3DNortey%26aufirst%3DS.%2BO.%26aulast%3DSchneider%26aufirst%3DC.%2BR.%26aulast%3DSetler%26aufirst%3DP.%2BE.%26atitle%3DPyrroloisoquinoline%2520antidepressants.%25202.%2520in-depth%2520exploration%2520of%2520structure-activity%2520relationships%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1987%26volume%3D30%26spage%3D1433%26epage%3D1454%26doi%3D10.1021%2Fjm00391a028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aluisio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lord, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbier, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraser, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggs, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dvorak, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Letavic, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maryanoff, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carruthers, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonaventure, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovenberg, T. W.</span></span> <span> </span><span class="NLM_article-title">In-vitro and in-vivo characterization of JNJ-7925476, a novel triple monoamine uptake inhibitor</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>587</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">146</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2008.04.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.ejphar.2008.04.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=18499098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsFGltbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=587&publication_year=2008&pages=141-146&author=L.+Aluisioauthor=B.+Lordauthor=A.+J.+Barbierauthor=I.+C.+Fraserauthor=S.+J.+Wilsonauthor=J.+Boggsauthor=L.+K.+Dvorakauthor=M.+A.+Letavicauthor=B.+E.+Maryanoffauthor=N.+I.+Carruthersauthor=P.+Bonaventureauthor=T.+W.+Lovenberg&title=In-vitro+and+in-vivo+characterization+of+JNJ-7925476%2C+a+novel+triple+monoamine+uptake+inhibitor&doi=10.1016%2Fj.ejphar.2008.04.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">In-vitro and in-vivo characterization of JNJ-7925476, a novel triple monoamine uptake inhibitor</span></div><div class="casAuthors">Aluisio, Leah; Lord, Brian; Barbier, Ann J.; Fraser, Ian C.; Wilson, Sandy J.; Boggs, Jamin; Dvorak, Lisa K.; Letavic, Michael A.; Maryanoff, Bruce E.; Carruthers, Nicholas I.; Bonaventure, Pascal; Lovenberg, Timothy W.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">587</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">141-146</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Triple reuptake inhibitors, which block the serotonin transporter (SERT), norepinephrine transporter (NET) and dopamine transporter (DAT) in the central nervous system have been described as therapeutic alternatives for classical selective serotonin reuptake inhibitors, with advantages due to their multiple mechanisms of action.  JNJ-7925476 (trans-6-(4-ethynylphenyl)-1,2,3,5,6,10b-hexahydropyrrolo[2,1-a]isoquinoline) is a selective and potent inhibitor of the SERT, NET, and DAT (K i = 0.9, 17 and 5.2 nM, resp.).  Following s.c. dosing in rat, JNJ-7925476 was rapidly absorbed into the plasma, and drug concns. in the brain tracked with those in the plasma but were 7-fold higher.  The ED50 values for JNJ-7925476 occupancy of the SERT, NET, and DAT in rat brain were 0.18, 0.09 and 2.4 mg/kg, resp.  JNJ-7925476 (0.1-10 mg/kg, s.c.) rapidly induced a robust, dose-dependent increase in extracellular serotonin, dopamine, and norepinephrine levels in rat cerebral cortex.  The compd. also showed potent antidepressant-like activity in the mouse tail suspension test (ED50 = 0.3 mg/kg, i.p.).  These results demonstrate that JNJ-7925476 is a triple reuptake inhibitor with in-vivo efficacy in biochem. and behavioral models of depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrLdkhiOEPU7Vg90H21EOLACvtfcHk0ljd9FqbbWCB2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsFGltbc%253D&md5=e55497330670d8ce48403bb2283efe3d</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2008.04.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2008.04.008%26sid%3Dliteratum%253Aachs%26aulast%3DAluisio%26aufirst%3DL.%26aulast%3DLord%26aufirst%3DB.%26aulast%3DBarbier%26aufirst%3DA.%2BJ.%26aulast%3DFraser%26aufirst%3DI.%2BC.%26aulast%3DWilson%26aufirst%3DS.%2BJ.%26aulast%3DBoggs%26aufirst%3DJ.%26aulast%3DDvorak%26aufirst%3DL.%2BK.%26aulast%3DLetavic%26aufirst%3DM.%2BA.%26aulast%3DMaryanoff%26aufirst%3DB.%2BE.%26aulast%3DCarruthers%26aufirst%3DN.%2BI.%26aulast%3DBonaventure%26aufirst%3DP.%26aulast%3DLovenberg%26aufirst%3DT.%2BW.%26atitle%3DIn-vitro%2520and%2520in-vivo%2520characterization%2520of%2520JNJ-7925476%252C%2520a%2520novel%2520triple%2520monoamine%2520uptake%2520inhibitor%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2008%26volume%3D587%26spage%3D141%26epage%3D146%26doi%3D10.1016%2Fj.ejphar.2008.04.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roggen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kehler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stensbol, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, T.</span></span> <span> </span><span class="NLM_article-title">Synthesis of enantiomerically pure milnacipran analogs and inhibition of dopamine, serotonin, and norepinephrine transporters</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">2834</span>– <span class="NLM_lpage">2837</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2007.02.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.bmcl.2007.02.054" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=2834-2837&author=H.+Roggenauthor=J.+Kehlerauthor=T.+B.+Stensbolauthor=T.+Hansen&title=Synthesis+of+enantiomerically+pure+milnacipran+analogs+and+inhibition+of+dopamine%2C+serotonin%2C+and+norepinephrine+transporters&doi=10.1016%2Fj.bmcl.2007.02.054"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.02.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.02.054%26sid%3Dliteratum%253Aachs%26aulast%3DRoggen%26aufirst%3DH.%26aulast%3DKehler%26aufirst%3DJ.%26aulast%3DStensbol%26aufirst%3DT.%2BB.%26aulast%3DHansen%26aufirst%3DT.%26atitle%3DSynthesis%2520of%2520enantiomerically%2520pure%2520milnacipran%2520analogs%2520and%2520inhibition%2520of%2520dopamine%252C%2520serotonin%252C%2520and%2520norepinephrine%2520transporters%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D2834%26epage%3D2837%26doi%3D10.1016%2Fj.bmcl.2007.02.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Axford, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boot, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hotten, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keenan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milutinovic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pullar, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tupper, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Belle, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vivien, V.</span></span> <span> </span><span class="NLM_article-title">Bicyclo[2.2.1]heptanes as novel triple re-uptake inhibitors for the treatment of depression</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">3277</span>– <span class="NLM_lpage">3280</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(03)00660-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2FS0960-894X%2803%2900660-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=3277-3280&author=L.+Axfordauthor=J.+R.+Bootauthor=T.+M.+Hottenauthor=M.+Keenanauthor=F.+M.+Martinauthor=S.+Milutinovicauthor=N.+A.+Mooreauthor=M.+F.+O%E2%80%99Neillauthor=I.+A.+Pullarauthor=D.+E.+Tupperauthor=K.+R.+Van+Belleauthor=V.+Vivien&title=Bicyclo%5B2.2.1%5Dheptanes+as+novel+triple+re-uptake+inhibitors+for+the+treatment+of+depression&doi=10.1016%2FS0960-894X%2803%2900660-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2803%2900660-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252803%252900660-7%26sid%3Dliteratum%253Aachs%26aulast%3DAxford%26aufirst%3DL.%26aulast%3DBoot%26aufirst%3DJ.%2BR.%26aulast%3DHotten%26aufirst%3DT.%2BM.%26aulast%3DKeenan%26aufirst%3DM.%26aulast%3DMartin%26aufirst%3DF.%2BM.%26aulast%3DMilutinovic%26aufirst%3DS.%26aulast%3DMoore%26aufirst%3DN.%2BA.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DM.%2BF.%26aulast%3DPullar%26aufirst%3DI.%2BA.%26aulast%3DTupper%26aufirst%3DD.%2BE.%26aulast%3DVan%2BBelle%26aufirst%3DK.%2BR.%26aulast%3DVivien%26aufirst%3DV.%26atitle%3DBicyclo%255B2.2.1%255Dheptanes%2520as%2520novel%2520triple%2520re-uptake%2520inhibitors%2520for%2520the%2520treatment%2520of%2520depression%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2003%26volume%3D13%26spage%3D3277%26epage%3D3280%26doi%3D10.1016%2FS0960-894X%2803%2900660-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caldarone, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paterson, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westphal, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korte-Bouws, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prins, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korte, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghavami, A.</span></span> <span> </span><span class="NLM_article-title">The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>335</i></span>,  <span class="NLM_fpage">762</span>– <span class="NLM_lpage">770</span>, <span class="refDoi"> DOI: 10.1124/jpet.110.174011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1124%2Fjpet.110.174011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=20864506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFOmsrfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=335&publication_year=2010&pages=762-770&author=B.+J.+Caldaroneauthor=N.+E.+Patersonauthor=J.+Zhouauthor=D.+Brunnerauthor=A.+P.+Kozikowskiauthor=K.+G.+Westphalauthor=G.+A.+Korte-Bouwsauthor=J.+Prinsauthor=S.+M.+Korteauthor=B.+Olivierauthor=A.+Ghavami&title=The+novel+triple+reuptake+inhibitor+JZAD-IV-22+exhibits+an+antidepressant+pharmacological+profile+without+locomotor+stimulant+or+sensitization+properties&doi=10.1124%2Fjpet.110.174011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties</span></div><div class="casAuthors">Caldarone, Barbara J.; Paterson, Neil E.; Zhou, Jia; Brunner, Daniela; Kozikowski, Alan P.; Westphal, Koen G. C.; Korte-Bouws, Gerdien A. H.; Prins, Jolanda; Korte, S. Mechiel; Olivier, Berend; Ghavami, Afshin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">335</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">762-770</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Triple reuptake inhibitors (TRIs) that block the dopamine transporter (DAT), norepinephrine transporter, and serotonin transporter are being developed as a new class of antidepressant that may have better efficacy and fewer side effects compared with traditional antidepressants.  We describe a novel TRI, 2-[4-(4-chlorophenyl)-1-methylpiperidin-3-ylmethylsulfanyl]-1-(3-methylpiperidin-1-yl)-ethanone (JZAD-IV-22), that inhibits all three monoamine transporters with approx. equal potency in vitro.  (+/-)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane hydrochloride (DOV 216,303), a TRI shown to be an effective antidepressant in a clin. trial, shows reuptake inhibition similar to that of JZAD-IV-22 in vitro.  Furthermore, both JZAD-IV-22 and DOV 216,303 increase levels of dopamine, norepinephrine, and serotonin in the mouse prefrontal cortex when administered by peripheral injection.  JZAD-IV-22 and DOV 216,303 exhibited antidepressant-like efficacy in the mouse forced-swim and tail-suspension tests at doses that increased neurotransmitter levels.  Because development of DAT inhibitors could be hindered by abuse liability, both JZAD-IV-22 and DOV 216,303 were compared in two assays that are markers of abuse potential.  Both JZAD-IV-22 and DOV 216,303 partially substituted for cocaine in a drug discrimination assay in rats, and high doses of DOV 216,303 produced locomotor sensitization in mice.  JZAD-IV-22 showed no evidence of sensitization at any dose tested.  These results demonstrate that JZAD-IV-22 is a TRI with antidepressant-like activity similar to that of DOV 216,303.  The striking feature that distinguishes the two TRIs is that locomotor sensitization, a common underlying feature of drugs of abuse, is seen with DOV 216,303 but is completely lacking in JZAD-IV-22.  These findings may have implications for the potential for abuse liability in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdzWmAhCBC4rVg90H21EOLACvtfcHk0lgJ50FVUAGBSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFOmsrfM&md5=ae8ba4e5786c465f14068e5c3a59ab80</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1124%2Fjpet.110.174011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.110.174011%26sid%3Dliteratum%253Aachs%26aulast%3DCaldarone%26aufirst%3DB.%2BJ.%26aulast%3DPaterson%26aufirst%3DN.%2BE.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DBrunner%26aufirst%3DD.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26aulast%3DWestphal%26aufirst%3DK.%2BG.%26aulast%3DKorte-Bouws%26aufirst%3DG.%2BA.%26aulast%3DPrins%26aufirst%3DJ.%26aulast%3DKorte%26aufirst%3DS.%2BM.%26aulast%3DOlivier%26aufirst%3DB.%26aulast%3DGhavami%26aufirst%3DA.%26atitle%3DThe%2520novel%2520triple%2520reuptake%2520inhibitor%2520JZAD-IV-22%2520exhibits%2520an%2520antidepressant%2520pharmacological%2520profile%2520without%2520locomotor%2520stimulant%2520or%2520sensitization%2520properties%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2010%26volume%3D335%26spage%3D762%26epage%3D770%26doi%3D10.1124%2Fjpet.110.174011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Piperidine-based nocaine/modafinil hybrid ligands as highly potent monoamine transporter inhibitors: efficient drug discovery by rational lead hybridization</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">5821</span>– <span class="NLM_lpage">5824</span>, <span class="refDoi"> DOI: 10.1021/jm040117o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm040117o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=5821-5824&author=J.+Zhouauthor=R.+Heauthor=K.+M.+Johnsonauthor=Y.+Yeauthor=A.+P.+Kozikowski&title=Piperidine-based+nocaine%2Fmodafinil+hybrid+ligands+as+highly+potent+monoamine+transporter+inhibitors%3A+efficient+drug+discovery+by+rational+lead+hybridization&doi=10.1021%2Fjm040117o"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1021%2Fjm040117o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040117o%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DR.%26aulast%3DJohnson%26aufirst%3DK.%2BM.%26aulast%3DYe%26aufirst%3DY.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DPiperidine-based%2520nocaine%252Fmodafinil%2520hybrid%2520ligands%2520as%2520highly%2520potent%2520monoamine%2520transporter%2520inhibitors%253A%2520efficient%2520drug%2520discovery%2520by%2520rational%2520lead%2520hybridization%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D5821%26epage%3D5824%26doi%3D10.1021%2Fjm040117o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, H.-G.</span></span> <span> </span><span class="NLM_article-title">Exploration of novel 3-substituted azetidine derivatives as triple reuptake inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">8188</span>– <span class="NLM_lpage">8192</span>, <span class="refDoi"> DOI: 10.1021/jm3008294</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3008294" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht12it77L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8188-8192&author=Y.+Hanauthor=M.+Hanauthor=D.+Shinauthor=C.+Songauthor=H.-G.+Hahn&title=Exploration+of+novel+3-substituted+azetidine+derivatives+as+triple+reuptake+inhibitors&doi=10.1021%2Fjm3008294"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Exploration of Novel 3-Substituted Azetidine Derivatives As Triple Reuptake Inhibitors</span></div><div class="casAuthors">Han, Younghue; Han, Minsoo; Shin, Dongyun; Song, Chiman; Hahn, Hoh-Gyu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8188-8192</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">α-Aryl and α-benzyl azetidinemethanol hydrochlorides I•HCl (R = H; R1 = Ph, 4-ClC6H4, 3,4-Cl2C6H3, PhCH2), (aryl)azetidinemethyl ether hydrochlorides I•HCl (R = Me, Et, EtCH2, PhCH2, Ph, 2-MeC6H4, 3-MeC6H4, 4-MeC6H4, 2-FC6H4, 3-FC6H4, 4-FC6H4, 2-ClC6H4, 3-ClC6H4, 4-ClC6H4, 2-F3COC6H4, 3-F3COC6H4, 4-F3COC6H4, 3,4-F2C6H3, 3,4-Cl2C6H3; R1 = Ph, 4-ClC6H4, 3,4-Cl2C6H3, 2-MeC6H4, 2-naphthyl, 4-Cl-3-FC6H3, 3-Cl-4-FC6H3, 3,4-F2C6H3), and α-arylazetidinemethanol benzoate hydrochlorides I•HCl (R = PhCOO; R1 = Ph, 4-ClC6H4, 3,4-Cl2C6H3, 4-Cl-3-FC6H3) were prepd. and tested as simultaneous inhibitors of norepinephrine, serotonin, and dopamine transporters (triple reuptake inhibitors).  1-Boc-3-azetidinecarboxylic acid was converted in three steps to Boc-protected α-substituted azetidinemethanols; direct deprotection provided the free alc. hydrochlorides.  Alternatively, O-alkylation of Boc-protected α-substituted azetidinemethanols using alkyl halides or benzyl bromide followed by deprotection yielded (aryl)azetidinemethyl alkyl ether hydrochlorides; Mitsunobu reactions of Boc-protected α-substituted azetidinemethanols with phenols followed by deprotection yielded (aryl)azetidinemethyl aryl ether hydrochlorides.  Benzoylation of the Boc-protected α-substituted azetidinemethanols and Boc group cleavage yielded α-arylazetidinemethanol benzoate hydrochlorides.  The inhibition of human cytochrome P450 isoforms 1A2, 2D6, 2C9, and 3A4, the microsomal stabilities, and the inhibition of hERG by selected compds. were detd.  Of the compds. prepd., I•HCl (R = 2-naphthyl; R1 = EtCH2, Ph) were found to be the most promising triple reuptake inhibitors; their blood-brain barrier penetration, oral pharmacokinetics, and their antidepressant activities upon oral and i.v. administration (using the rat forced swimming test) were detd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEA0JC6_2D8LVg90H21EOLACvtfcHk0lgJ50FVUAGBSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht12it77L&md5=9a1c7e86cf7fc4fbd8b4536416e1d311</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1021%2Fjm3008294&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3008294%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DM.%26aulast%3DShin%26aufirst%3DD.%26aulast%3DSong%26aufirst%3DC.%26aulast%3DHahn%26aufirst%3DH.-G.%26atitle%3DExploration%2520of%2520novel%25203-substituted%2520azetidine%2520derivatives%2520as%2520triple%2520reuptake%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8188%26epage%3D8192%26doi%3D10.1021%2Fjm3008294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheon, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, H. G.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">3234</span>– <span class="NLM_lpage">3237</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.06.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.bmcl.2014.06.026" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=3234-3237&author=J.+Yunauthor=M.+Hanauthor=C.+Songauthor=S.+H.+Cheonauthor=K.+Choiauthor=H.+G.+Hahn&title=Synthesis+and+biological+evaluation+of+3-phenethylazetidine+derivatives+as+triple+reuptake+inhibitors&doi=10.1016%2Fj.bmcl.2014.06.026"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.06.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.06.026%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DJ.%26aulast%3DHan%26aufirst%3DM.%26aulast%3DSong%26aufirst%3DC.%26aulast%3DCheon%26aufirst%3DS.%2BH.%26aulast%3DChoi%26aufirst%3DK.%26aulast%3DHahn%26aufirst%3DH.%2BG.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%25203-phenethylazetidine%2520derivatives%2520as%2520triple%2520reuptake%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D3234%26epage%3D3237%26doi%3D10.1016%2Fj.bmcl.2014.06.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, H. G.</span></span> <span> </span><span class="NLM_article-title">Exploration of 3-aminoazetidines as triple reuptake inhibitors by bioisosteric modification of 3-alpha-oxyazetidine</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">999</span>– <span class="NLM_lpage">1004</span>, <span class="refDoi"> DOI: 10.1021/ml500187a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500187a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=999-1004&author=M.+Hanauthor=C.+Songauthor=N.+Jeongauthor=H.+G.+Hahn&title=Exploration+of+3-aminoazetidines+as+triple+reuptake+inhibitors+by+bioisosteric+modification+of+3-alpha-oxyazetidine&doi=10.1021%2Fml500187a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1021%2Fml500187a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500187a%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DM.%26aulast%3DSong%26aufirst%3DC.%26aulast%3DJeong%26aufirst%3DN.%26aulast%3DHahn%26aufirst%3DH.%2BG.%26atitle%3DExploration%2520of%25203-aminoazetidines%2520as%2520triple%2520reuptake%2520inhibitors%2520by%2520bioisosteric%2520modification%2520of%25203-alpha-oxyazetidine%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26spage%3D999%26epage%3D1004%26doi%3D10.1021%2Fml500187a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antidepressant activity of optical isomers of 2-(4-benzylpiperazin-1-yl)-1-(5-chloro-6-methoxynaphthalen-2-yl) propan-1-ol (SIPI5056)</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1256</span>– <span class="NLM_lpage">1259</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.11.108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.bmcl.2009.11.108" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1256-1259&author=Z.+Wengauthor=J.+Li&title=Synthesis+and+antidepressant+activity+of+optical+isomers+of+2-%284-benzylpiperazin-1-yl%29-1-%285-chloro-6-methoxynaphthalen-2-yl%29+propan-1-ol+%28SIPI5056%29&doi=10.1016%2Fj.bmcl.2009.11.108"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.11.108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.11.108%26sid%3Dliteratum%253Aachs%26aulast%3DWeng%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DSynthesis%2520and%2520antidepressant%2520activity%2520of%2520optical%2520isomers%2520of%25202-%25284-benzylpiperazin-1-yl%2529-1-%25285-chloro-6-methoxynaphthalen-2-yl%2529%2520propan-1-ol%2520%2528SIPI5056%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D1256%26epage%3D1259%26doi%3D10.1016%2Fj.bmcl.2009.11.108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhen, X. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. Q.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antidepressant activity of arylalkanol-piperidine derivatives as triple reuptake inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">136</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2012.04.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.ejmech.2012.04.030" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2012&pages=123-136&author=Y.+Y.+Zhengauthor=L.+Guoauthor=X.+C.+Zhenauthor=J.+Q.+Li&title=Synthesis+and+antidepressant+activity+of+arylalkanol-piperidine+derivatives+as+triple+reuptake+inhibitors&doi=10.1016%2Fj.ejmech.2012.04.030"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2012.04.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2012.04.030%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DY.%2BY.%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DZhen%26aufirst%3DX.%2BC.%26aulast%3DLi%26aufirst%3DJ.%2BQ.%26atitle%3DSynthesis%2520and%2520antidepressant%2520activity%2520of%2520arylalkanol-piperidine%2520derivatives%2520as%2520triple%2520reuptake%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2012%26volume%3D54%26spage%3D123%26epage%3D136%26doi%3D10.1016%2Fj.ejmech.2012.04.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, Z. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, L. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. Q.</span></span> <span> </span><span class="NLM_article-title">Synthesis and pharmacological investigation of aralkyl diamine derivatives as potential triple reuptake inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">234</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.08.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.ejmech.2014.08.045" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2014&pages=219-234&author=Y.+Y.+Zhengauthor=Z.+J.+Wengauthor=P.+Xieauthor=M.+Y.+Zhuauthor=L.+X.+Xingauthor=J.+Q.+Li&title=Synthesis+and+pharmacological+investigation+of+aralkyl+diamine+derivatives+as+potential+triple+reuptake+inhibitors&doi=10.1016%2Fj.ejmech.2014.08.045"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.08.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.08.045%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DY.%2BY.%26aulast%3DWeng%26aufirst%3DZ.%2BJ.%26aulast%3DXie%26aufirst%3DP.%26aulast%3DZhu%26aufirst%3DM.%2BY.%26aulast%3DXing%26aufirst%3DL.%2BX.%26aulast%3DLi%26aufirst%3DJ.%2BQ.%26atitle%3DSynthesis%2520and%2520pharmacological%2520investigation%2520of%2520aralkyl%2520diamine%2520derivatives%2520as%2520potential%2520triple%2520reuptake%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D86%26spage%3D219%26epage%3D234%26doi%3D10.1016%2Fj.ejmech.2014.08.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McKinney, A.</span>; <span class="NLM_string-name">Bymaster, F.</span></span> <span> </span><span class="NLM_article-title">Methods for Inhibiting Native and Promiscuous Uptake of Monoamine Neurotransmitters Using a Triple Reuptake Inhibitor</span>. <span class="NLM_patent">US20140228421A1</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=A.+McKinney&author=F.+Bymaster&title=Methods+for+Inhibiting+Native+and+Promiscuous+Uptake+of+Monoamine+Neurotransmitters+Using+a+Triple+Reuptake+Inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMcKinney%26aufirst%3DA.%26atitle%3DMethods%2520for%2520Inhibiting%2520Native%2520and%2520Promiscuous%2520Uptake%2520of%2520Monoamine%2520Neurotransmitters%2520Using%2520a%2520Triple%2520Reuptake%2520Inhibitor%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pankevich, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altevogt, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunlop, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gage, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyman, S. E.</span></span> <span> </span><span class="NLM_article-title">Improving and accelerating drug development for nervous system disorders</span>. <i>Neuron</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">546</span>– <span class="NLM_lpage">553</span>, <span class="refDoi"> DOI: 10.1016/j.neuron.2014.10.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.neuron.2014.10.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=25442933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvV2mtrfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2014&pages=546-553&author=D.+E.+Pankevichauthor=B.+M.+Altevogtauthor=J.+Dunlopauthor=F.+H.+Gageauthor=S.+E.+Hyman&title=Improving+and+accelerating+drug+development+for+nervous+system+disorders&doi=10.1016%2Fj.neuron.2014.10.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Improving and Accelerating Drug Development for Nervous System Disorders</span></div><div class="casAuthors">Pankevich, Diana E.; Altevogt, Bruce M.; Dunlop, John; Gage, Fred H.; Hyman, Steve E.</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">546-553</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Advances in the neurosciences have placed the field in the position where it is poised to significantly reduce the burden of nervous system disorders.  However, drug discovery, development, and translation for nervous system disorders still pose many unique challenges.  The key scientific challenges can be summarized as follows: mechanisms of disease, target identification and validation, predictive models, biomarkers for patient stratification and as endpoints for clin. trials, clear regulatory pathways, reliability and reproducibility of published data, and data sharing and collaboration.  To accelerate nervous system drug development, the Institute of Medicine's Forum on Neuroscience and Nervous System Disorders has hosted a series of public workshops that brought together representatives of industry, government (including both research funding and regulatory agencies), academia, and patient groups to discuss these challenges and offer potential strategies to improve the translational neuroscience.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOqebkslCjwLVg90H21EOLACvtfcHk0lhdHeg1c1wEXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvV2mtrfN&md5=05ec61c206c935d6a4ffd3adbdaba808</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1016%2Fj.neuron.2014.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuron.2014.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DPankevich%26aufirst%3DD.%2BE.%26aulast%3DAltevogt%26aufirst%3DB.%2BM.%26aulast%3DDunlop%26aufirst%3DJ.%26aulast%3DGage%26aufirst%3DF.%2BH.%26aulast%3DHyman%26aufirst%3DS.%2BE.%26atitle%3DImproving%2520and%2520accelerating%2520drug%2520development%2520for%2520nervous%2520system%2520disorders%26jtitle%3DNeuron%26date%3D2014%26volume%3D84%26spage%3D546%26epage%3D553%26doi%3D10.1016%2Fj.neuron.2014.10.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 15 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Gao Tu, Tingting Fu, Fengyuan Yang, Jingyi Yang, Zhao Zhang, Xiaojun Yao, Weiwei Xue, <span class="NLM_string-name hlFld-ContribAuthor">Feng Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Understanding the Polypharmacological Profiles of Triple Reuptake Inhibitors by Molecular Simulation. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Neuroscience</span><span> <strong>2021,</strong> <em>12 </em>
                                    (11)
                                     , 2013-2026. <a href="https://doi.org/10.1021/acschemneuro.1c00127" title="DOI URL">https://doi.org/10.1021/acschemneuro.1c00127</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschemneuro.1c00127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschemneuro.1c00127%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Neuroscience%26atitle%3DUnderstanding%252Bthe%252BPolypharmacological%252BProfiles%252Bof%252BTriple%252BReuptake%252BInhibitors%252Bby%252BMolecular%252BSimulation%26aulast%3DTu%26aufirst%3DGao%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D08032021%26date%3D07052021%26date%3D12052021%26volume%3D12%26issue%3D11%26spage%3D2013%26epage%3D2026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Sheng Zhao, Zhong-Lin Zang, Siyu Li, Xumei Wen, Chenhui Wang, Jian Guo, <span class="NLM_string-name hlFld-ContribAuthor">Yun He</span>. </span><span class="cited-content_cbyCitation_article-title">Iridium-Catalyzed Cycloisomerization of N-Tethered 1,7-Enynes: Construction of an Azabicyclo[5.1.0]octene System. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>85 </em>
                                    (14)
                                     , 9321-9330. <a href="https://doi.org/10.1021/acs.joc.0c00516" title="DOI URL">https://doi.org/10.1021/acs.joc.0c00516</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.0c00516&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.0c00516%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DIridium-Catalyzed%252BCycloisomerization%252Bof%252BN-Tethered%252B1%25252C7-Enynes%25253A%252BConstruction%252Bof%252Ban%252BAzabicyclo%25255B5.1.0%25255Doctene%252BSystem%26aulast%3DZhao%26aufirst%3DSheng%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D27022020%26date%3D02072020%26date%3D17062020%26volume%3D85%26issue%3D14%26spage%3D9321%26epage%3D9330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Bichu Cheng, Johannes Morstein, Lucy Kate Ladefoged, Jannick Bang Maesen, Birgit Schiøtt, Steffen Sinning, <span class="NLM_string-name hlFld-ContribAuthor">Dirk Trauner</span>. </span><span class="cited-content_cbyCitation_article-title">A Photoswitchable Inhibitor of the Human Serotonin Transporter. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Neuroscience</span><span> <strong>2020,</strong> <em>11 </em>
                                    (9)
                                     , 1231-1237. <a href="https://doi.org/10.1021/acschemneuro.9b00521" title="DOI URL">https://doi.org/10.1021/acschemneuro.9b00521</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschemneuro.9b00521&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschemneuro.9b00521%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Neuroscience%26atitle%3DA%252BPhotoswitchable%252BInhibitor%252Bof%252Bthe%252BHuman%252BSerotonin%252BTransporter%26aulast%3DCheng%26aufirst%3DBichu%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D24092019%26date%3D10042020%26date%3D23042020%26date%3D10042020%26volume%3D11%26issue%3D9%26spage%3D1231%26epage%3D1237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zhenmin Li, Junrong Chen, Li Wu, Anni Ren, Ping Lu, <span class="NLM_string-name hlFld-ContribAuthor">Yanguang Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Preparation of 4-Diazoisoquinolin-3-ones via Dimroth Rearrangement and Their Extension to 4-Aryltetrahydroisoquinolin-3-ones. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2020,</strong> <em>22 </em>
                                    (1)
                                     , 26-30. <a href="https://doi.org/10.1021/acs.orglett.9b03708" title="DOI URL">https://doi.org/10.1021/acs.orglett.9b03708</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.9b03708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.9b03708%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DPreparation%252Bof%252B4-Diazoisoquinolin-3-ones%252Bvia%252BDimroth%252BRearrangement%252Band%252BTheir%252BExtension%252Bto%252B4-Aryltetrahydroisoquinolin-3-ones%26aulast%3DLi%26aufirst%3DZhenmin%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D19102019%26date%3D12122019%26volume%3D22%26issue%3D1%26spage%3D26%26epage%3D30" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David  Martín-Hernández</span>, <span class="hlFld-ContribAuthor ">Cristina  Ulecia-Morón</span>, <span class="hlFld-ContribAuthor ">Álvaro G.  Bris</span>, <span class="hlFld-ContribAuthor ">Marta P.  Pereira</span>, <span class="hlFld-ContribAuthor ">Javier R.  Caso</span>. </span><span class="cited-content_cbyCitation_article-title">Monoaminergic system and antidepressants. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 345-355. <a href="https://doi.org/10.1016/B978-0-12-817933-8.00093-1" title="DOI URL">https://doi.org/10.1016/B978-0-12-817933-8.00093-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-817933-8.00093-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-817933-8.00093-1%26sid%3Dliteratum%253Aachs%26atitle%3DMonoaminergic%252Bsystem%252Band%252Bantidepressants%26aulast%3DMart%25C3%25ADn-Hern%25C3%25A1ndez%26aufirst%3DDavid%26date%3D2021%26spage%3D345%26epage%3D355%26pub%3DElsevier%26atitle%3DThe%252BNeuroscience%252Bof%252BDepression%26date%3D2021%26volume%3D4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christopher  Cerda-Cavieres</span>, <span class="hlFld-ContribAuthor ">Gabriel  Quiroz</span>, <span class="hlFld-ContribAuthor ">Patricio  Iturriaga-Vásquez</span>, <span class="hlFld-ContribAuthor ">Julio  Rodríguez-Lavado</span>, <span class="hlFld-ContribAuthor ">Jazmín  Alarcón-Espósito</span>, <span class="hlFld-ContribAuthor ">Claudio  Saitz</span>, <span class="hlFld-ContribAuthor ">Carlos D.  Pessoa-Mahana</span>, <span class="hlFld-ContribAuthor ">Hery  Chung</span>, <span class="hlFld-ContribAuthor ">Ramiro  Araya-Maturana</span>, <span class="hlFld-ContribAuthor ">Jaime  Mella-Raipán</span>, <span class="hlFld-ContribAuthor ">David  Cabezas</span>, <span class="hlFld-ContribAuthor ">Claudia  Ojeda-Gómez</span>, <span class="hlFld-ContribAuthor ">Miguel  Reyes-Parada</span>, <span class="hlFld-ContribAuthor ">Hernán  Pessoa-Mahana</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, Docking, 3-D-Qsar, and Biological Assays of Novel Indole Derivatives Targeting Serotonin Transporter, Dopamine D2 Receptor, and Mao-A Enzyme: In the Pursuit for Potential Multitarget Directed Ligands. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (20)
                                     , 4614. <a href="https://doi.org/10.3390/molecules25204614" title="DOI URL">https://doi.org/10.3390/molecules25204614</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25204614&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25204614%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DSynthesis%25252C%252BDocking%25252C%252B3-D-Qsar%25252C%252Band%252BBiological%252BAssays%252Bof%252BNovel%252BIndole%252BDerivatives%252BTargeting%252BSerotonin%252BTransporter%25252C%252BDopamine%252BD2%252BReceptor%25252C%252Band%252BMao-A%252BEnzyme%25253A%252BIn%252Bthe%252BPursuit%252Bfor%252BPotential%252BMultitarget%252BDirected%252BLigands%26aulast%3DCerda-Cavieres%26aufirst%3DChristopher%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D20%26spage%3D4614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Weiwei  Xue</span>, <span class="hlFld-ContribAuthor ">Tingting  Fu</span>, <span class="hlFld-ContribAuthor ">Guoxun  Zheng</span>, <span class="hlFld-ContribAuthor ">Gao  Tu</span>, <span class="hlFld-ContribAuthor ">Yang  Zhang</span>, <span class="hlFld-ContribAuthor ">Fengyuan  Yang</span>, <span class="hlFld-ContribAuthor ">Lin  Tao</span>, <span class="hlFld-ContribAuthor ">Lixia  Yao</span>, <span class="hlFld-ContribAuthor ">Feng  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances and Challenges of the Drugs Acting on Monoamine Transporters. </span><span class="cited-content_cbyCitation_journal-name">Current Medicinal Chemistry</span><span> <strong>2020,</strong> <em>27 </em>
                                    (23)
                                     , 3830-3876. <a href="https://doi.org/10.2174/0929867325666181009123218" title="DOI URL">https://doi.org/10.2174/0929867325666181009123218</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/0929867325666181009123218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F0929867325666181009123218%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Medicinal%2520Chemistry%26atitle%3DRecent%252BAdvances%252Band%252BChallenges%252Bof%252Bthe%252BDrugs%252BActing%252Bon%252BMonoamine%252BTransporters%26aulast%3DXue%26aufirst%3DWeiwei%26date%3D2020%26volume%3D27%26issue%3D23%26spage%3D3830%26epage%3D3876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stephanie M.  Matt</span>, <span class="hlFld-ContribAuthor ">Peter J.  Gaskill</span>. </span><span class="cited-content_cbyCitation_article-title">Dopaminergic impact of cART and anti-depressants on HIV neuropathogenesis in older adults. </span><span class="cited-content_cbyCitation_journal-name">Brain Research</span><span> <strong>2019,</strong> <em>1723 </em>, 146398. <a href="https://doi.org/10.1016/j.brainres.2019.146398" title="DOI URL">https://doi.org/10.1016/j.brainres.2019.146398</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.brainres.2019.146398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.brainres.2019.146398%26sid%3Dliteratum%253Aachs%26jtitle%3DBrain%2520Research%26atitle%3DDopaminergic%252Bimpact%252Bof%252BcART%252Band%252Banti-depressants%252Bon%252BHIV%252Bneuropathogenesis%252Bin%252Bolder%252Badults%26aulast%3DMatt%26aufirst%3DStephanie%2BM.%26date%3D2019%26volume%3D1723%26spage%3D146398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hui  Wen</span>, <span class="hlFld-ContribAuthor ">Wen  Qin</span>, <span class="hlFld-ContribAuthor ">Guangzhong  Yang</span>, <span class="hlFld-ContribAuthor ">Yanshen  Guo</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of Arylamidine Derivatives as Serotonin/Norepinephrine Dual Reuptake Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2019,</strong> <em>24 </em>
                                    (3)
                                     , 497. <a href="https://doi.org/10.3390/molecules24030497" title="DOI URL">https://doi.org/10.3390/molecules24030497</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules24030497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules24030497%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252BArylamidine%252BDerivatives%252Bas%252BSerotonin%25252FNorepinephrine%252BDual%252BReuptake%252BInhibitors%26aulast%3DWen%26aufirst%3DHui%26date%3D2019%26date%3D2019%26volume%3D24%26issue%3D3%26spage%3D497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">SethW  Perry</span>, <span class="hlFld-ContribAuthor ">Julio  Licinio</span>, <span class="hlFld-ContribAuthor ">Ma-Li  Wong</span>. </span><span class="cited-content_cbyCitation_article-title">The depressed heart. </span><span class="cited-content_cbyCitation_journal-name">Heart and Mind</span><span> <strong>2019,</strong> <em>3 </em>
                                    (2)
                                     , 35. <a href="https://doi.org/10.4103/hm.hm_13_19" title="DOI URL">https://doi.org/10.4103/hm.hm_13_19</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4103/hm.hm_13_19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4103%2Fhm.hm_13_19%26sid%3Dliteratum%253Aachs%26jtitle%3DHeart%2520and%2520Mind%26atitle%3DThe%252Bdepressed%252Bheart%26aulast%3DPerry%26aufirst%3DSethW%26date%3D2019%26volume%3D3%26issue%3D2%26spage%3D35" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wei  Guo</span>, <span class="hlFld-ContribAuthor ">Yonglin  Gao</span>, <span class="hlFld-ContribAuthor ">Wanglin  Jiang</span>, <span class="hlFld-ContribAuthor ">Chunmei  Li</span>, <span class="hlFld-ContribAuthor ">Fei  Lin</span>, <span class="hlFld-ContribAuthor ">Haibo  Zhu</span>, <span class="hlFld-ContribAuthor ">Hongbo  Wang</span>, <span class="hlFld-ContribAuthor ">Liang  Ye</span>, <span class="hlFld-ContribAuthor ">Jia Grace  Qi</span>, <span class="hlFld-ContribAuthor ">Xiaobo  Cen</span>, <span class="hlFld-ContribAuthor ">Jingwei  Tian</span>. </span><span class="cited-content_cbyCitation_article-title">Toxicity effects of a novel potent triple reuptake inhibitor, LPM570065, on the fertility and early embryonic development in Sprague-Dawley rats. </span><span class="cited-content_cbyCitation_journal-name">Regulatory Toxicology and Pharmacology</span><span> <strong>2018,</strong> <em>100 </em>, 45-51. <a href="https://doi.org/10.1016/j.yrtph.2018.10.008" title="DOI URL">https://doi.org/10.1016/j.yrtph.2018.10.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.yrtph.2018.10.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.yrtph.2018.10.008%26sid%3Dliteratum%253Aachs%26jtitle%3DRegulatory%2520Toxicology%2520and%2520Pharmacology%26atitle%3DToxicity%252Beffects%252Bof%252Ba%252Bnovel%252Bpotent%252Btriple%252Breuptake%252Binhibitor%25252C%252BLPM570065%25252C%252Bon%252Bthe%252Bfertility%252Band%252Bearly%252Bembryonic%252Bdevelopment%252Bin%252BSprague-Dawley%252Brats%26aulast%3DGuo%26aufirst%3DWei%26date%3D2018%26volume%3D100%26spage%3D45%26epage%3D51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Suresh  Paudel</span>, <span class="hlFld-ContribAuthor ">Xiao  Min</span>, <span class="hlFld-ContribAuthor ">Srijan  Acharya</span>, <span class="hlFld-ContribAuthor ">Daulat Bikram  Khadka</span>, <span class="hlFld-ContribAuthor ">Goon  Yoon</span>, <span class="hlFld-ContribAuthor ">Kyeong-Man  Kim</span>, <span class="hlFld-ContribAuthor ">Seung Hoon  Cheon</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and systematic evaluation of 4-arylpiperazine- and 4-benzylpiperidine napthyl ethers as inhibitors of monoamine neurotransmitters reuptake. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2018,</strong> <em>26 </em>
                                    (20)
                                     , 5538-5546. <a href="https://doi.org/10.1016/j.bmc.2018.09.033" title="DOI URL">https://doi.org/10.1016/j.bmc.2018.09.033</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2018.09.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2018.09.033%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bsystematic%252Bevaluation%252Bof%252B4-arylpiperazine-%252Band%252B4-benzylpiperidine%252Bnapthyl%252Bethers%252Bas%252Binhibitors%252Bof%252Bmonoamine%252Bneurotransmitters%252Breuptake%26aulast%3DPaudel%26aufirst%3DSuresh%26date%3D2018%26volume%3D26%26issue%3D20%26spage%3D5538%26epage%3D5546" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">D.M.  Osborne</span>, <span class="hlFld-ContribAuthor ">U.S.  Sandau</span>, <span class="hlFld-ContribAuthor ">A.T.  Jones</span>, <span class="hlFld-ContribAuthor ">J.W.  Vander Velden</span>, <span class="hlFld-ContribAuthor ">A.M.  Weingarten</span>, <span class="hlFld-ContribAuthor ">N.  Etesami</span>, <span class="hlFld-ContribAuthor ">Y.  Huo</span>, <span class="hlFld-ContribAuthor ">H.Y.  Shen</span>, <span class="hlFld-ContribAuthor ">D.  Boison</span>. </span><span class="cited-content_cbyCitation_article-title">Developmental role of adenosine kinase for the expression of sex-dependent neuropsychiatric behavior. </span><span class="cited-content_cbyCitation_journal-name">Neuropharmacology</span><span> <strong>2018,</strong> <em>141 </em>, 89-97. <a href="https://doi.org/10.1016/j.neuropharm.2018.08.025" title="DOI URL">https://doi.org/10.1016/j.neuropharm.2018.08.025</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.neuropharm.2018.08.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.neuropharm.2018.08.025%26sid%3Dliteratum%253Aachs%26jtitle%3DNeuropharmacology%26atitle%3DDevelopmental%252Brole%252Bof%252Badenosine%252Bkinase%252Bfor%252Bthe%252Bexpression%252Bof%252Bsex-dependent%252Bneuropsychiatric%252Bbehavior%26aulast%3DOsborne%26aufirst%3DD.M.%26date%3D2018%26volume%3D141%26spage%3D89%26epage%3D97" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chunmei  Li</span>, <span class="hlFld-ContribAuthor ">Wanglin  Jiang</span>, <span class="hlFld-ContribAuthor ">Yonglin  Gao</span>, <span class="hlFld-ContribAuthor ">Fei  Lin</span>, <span class="hlFld-ContribAuthor ">Haibo  Zhu</span>, <span class="hlFld-ContribAuthor ">Hongbo  Wang</span>, <span class="hlFld-ContribAuthor ">Liang  Ye</span>, <span class="hlFld-ContribAuthor ">Jia Grace  Qi</span>, <span class="hlFld-ContribAuthor ">Jingwei  Tian</span>. </span><span class="cited-content_cbyCitation_article-title">Acute, subchronic oral toxicity, and genotoxicity evaluations of LPM570065, a new potent triple reuptake inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Regulatory Toxicology and Pharmacology</span><span> <strong>2018,</strong> <em>98 </em>, 129-139. <a href="https://doi.org/10.1016/j.yrtph.2018.07.011" title="DOI URL">https://doi.org/10.1016/j.yrtph.2018.07.011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.yrtph.2018.07.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.yrtph.2018.07.011%26sid%3Dliteratum%253Aachs%26jtitle%3DRegulatory%2520Toxicology%2520and%2520Pharmacology%26atitle%3DAcute%25252C%252Bsubchronic%252Boral%252Btoxicity%25252C%252Band%252Bgenotoxicity%252Bevaluations%252Bof%252BLPM570065%25252C%252Ba%252Bnew%252Bpotent%252Btriple%252Breuptake%252Binhibitor%26aulast%3DLi%26aufirst%3DChunmei%26date%3D2018%26volume%3D98%26spage%3D129%26epage%3D139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Weiwei  Xue</span>, <span class="hlFld-ContribAuthor ">Panpan  Wang</span>, <span class="hlFld-ContribAuthor ">Gao  Tu</span>, <span class="hlFld-ContribAuthor ">Fengyuan  Yang</span>, <span class="hlFld-ContribAuthor ">Guoxun  Zheng</span>, <span class="hlFld-ContribAuthor ">Xiaofeng  Li</span>, <span class="hlFld-ContribAuthor ">Xiaoxu  Li</span>, <span class="hlFld-ContribAuthor ">Yuzong  Chen</span>, <span class="hlFld-ContribAuthor ">Xiaojun  Yao</span>, <span class="hlFld-ContribAuthor ">Feng  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Computational identification of the binding mechanism of a triple reuptake inhibitor amitifadine for the treatment of major depressive disorder. </span><span class="cited-content_cbyCitation_journal-name">Physical Chemistry Chemical Physics</span><span> <strong>2018,</strong> <em>20 </em>
                                    (9)
                                     , 6606-6616. <a href="https://doi.org/10.1039/C7CP07869B" title="DOI URL">https://doi.org/10.1039/C7CP07869B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7CP07869B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7CP07869B%26sid%3Dliteratum%253Aachs%26jtitle%3DPhysical%2520Chemistry%2520Chemical%2520Physics%26atitle%3DComputational%252Bidentification%252Bof%252Bthe%252Bbinding%252Bmechanism%252Bof%252Ba%252Btriple%252Breuptake%252Binhibitor%252Bamitifadine%252Bfor%252Bthe%252Btreatment%252Bof%252Bmajor%252Bdepressive%252Bdisorder%26aulast%3DXue%26aufirst%3DWeiwei%26date%3D2018%26date%3D2018%26volume%3D20%26issue%3D9%26spage%3D6606%26epage%3D6616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0049.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0049.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Key monoamines involved in the pathophysiology of depression.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Select examples of TCAs and MAOIs as first-generation antidepressants.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Monoamine transporter blockade by existing single and dual reuptake inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Structures of marketed single and dual reuptake inhibitors, including first-line antidepressants (<sup><i>a</i></sup>withdrawn from the market).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Underlying contributors to the large unmet clinical need with first-line antidepressants.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Examples of psychostimulants and other agents, which involve DAT inhibition as part of their pharmacological actions.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Agents that indirectly activate dopaminergic mood circuits through NMDA or mGlu<sub>2/3</sub> receptor antagonism.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Inducement of depression-like or antidepressant-like effects based upon the potential alteration of dopaminergic neurotransmission in rodents (<sup><i>a</i></sup>intracranial self-stimulation).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Structures of DAT-binding PET and SPECT tracers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Agents that cause the depletion of monoamines, including DA, by blocking their synthesis or storage.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Examples of dopamine agonists and atypical antipsychotics, known to demonstrate the clinical antidepressant effect.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Clinical observations potentially related to impaired dopaminergic neurotransmission in affective disorder (<sup><i>a</i></sup>RMDD, remitted MDD; <sup><i>b</i></sup>dopamine reuptake inhibitors (DRIs), DA agonists, psychostimulants, and MAOIs).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Hypothesis that augmentation of 5-HT and NE with DA will lead to an enhanced antidepressant effect as the result of synergistic effects while minimizing side effects through an antagonist action.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Examples of MAO inhibitors as antidepressants that represent an alternative triple approach involving all three biogenic amines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Structure of <b>52</b>, a marketed analgesic drug that is known be a TRI.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Structures of <b>53</b> and <b>54</b>, which are combined with <b>23</b> and <b>63</b>, respectively, for treating metabolic disorders.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Metabolites of <b>55</b> that are TRIs and are believed to be responsible for weight loss effects observed with <b>55</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0018.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Structures of key TRIs that have been investigated for the treatment of depression and other indications.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0019.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Suggested lead optimization criteria for mitigating addiction liability by altering the propensity of DAT inhibition and brain clearance rate and examples of clinical TRIs (<b>62</b>, <b>63</b>, and <b>65</b>) with lower abuse potential than psychostimulants<a onclick="showRef(event, 'ref54 ref83 ref84 ref85 ref86 ref87 ref89'); return false;" href="javascript:void(0);" class="ref ref54 ref83 ref84 ref85 ref86 ref87 ref89">(54,83−87,89)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0020.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. A representative TRI pharmacophore, reproduced from the literature.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0021.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Exploration of the 3-azabicyclo[3.1.0]hexane chemotype to derive clinical TRIs (DOV).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0022.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Design of tropane-bearing TRIs by modifying the ester functionalities of <b>27</b> leading to the identification of two clinical candidates (Neurosearch/Saniona).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0023.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Diastereomeric switch of the SSRI <b>15</b> to enhance NET/DAT activity leading to the identification of <b>65</b> as a clinical candidate (Sepracor/Sunovion); <sup><i>a</i></sup>affinity data are taken from the literature.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0024.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Expanding on <b>73</b> as a starting point to probe SAR with respect to regiomerism, chirality, amino substitution, and homologation (Sepracor/Sunovion).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0025.jpeg" id="rightTab-gr25" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. Homologation of 3-azabicyclo[3.1.0]hexane leading to the identification of 3-aryloctahydrocyclopenta[<i>c</i>]pyrrole and 3-aryl-octahydro-1<i>H</i>-isoindole derivatives (Sunovion).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig26" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0026.jpeg" id="rightTab-gr26" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. Psychostimulant <b>29</b> as the starting point to design 1-arylcyclohexylmethylamine chemotype (Sunovion).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig27" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0027.jpeg" id="rightTab-gr27" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. Lead optimization of 1-arylcyclohexylmethylamine series resulting in the identification of NET-preferring <b>66</b> as a clinical candidate (Sepracor/Sunovion).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig28" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0028.jpeg" id="rightTab-gr28" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 28. Exploration of peripheral substitution on the 3-azabicyclo[3.1.0]hexane chemotype to improve affinity (GSK).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig28"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig29" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Figure 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0029.jpeg" id="rightTab-gr29" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 29. Identification of <b>67</b> as a clinical candidate through sequential ring homologation of the 3-azabicyclo[3.1.0]hexane chemotype and appendage of a side chain (GSK).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig29"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig30" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Figure 30</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0030.jpeg" id="rightTab-gr30" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 30. Replacement of the side chain of <b>67</b> with (methylene) heteroaryls (GSK).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig30"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig31" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Figure 31</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0031.jpeg" id="rightTab-gr31" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 31. Modification of the ring fusion of <b>67</b> to derive two different series of constrained arylpiperidines (GSK).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig31"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig32" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Figure 32</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0032.jpeg" id="rightTab-gr32" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 32. Optimization of substitutions at 4- and 7-positions of THIQ core resulting in the identification of <b>68</b> as a clinical candidate (AMRI/BMS).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig32"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig33" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Figure 33</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0033.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0033.jpeg" id="rightTab-gr33" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 33. Modification of the SNRI <b>19</b> to incorporate DAT activity (Mayo Clinic/Virginia Polytechnic Institute).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig33"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig34" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Figure 34</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0034.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0034.jpeg" id="rightTab-gr34" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 34. Hybridization of the SNRI <b>182</b> and the TRI <b>61</b> to derive pyrrolidin-3-yl-1<i>H</i>-indole derivatives (Roche).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig34"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig35" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Figure 35</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0035.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0035.jpeg" id="rightTab-gr35" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 35. Lead optimization of <b>183</b>, involving carbonyl insertion to mitigate the liabilities by lowering clogP and p<i>K</i><sub>a</sub> (Roche).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0035.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig35"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig36" data-index="36" class="article__inlineFigure"><h2 class="fig-label">Figure 36</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0036.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0036.jpeg" id="rightTab-gr36" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 36. Chirality elimination and scaffold hopping as key strategies to design substituted piperidine and piperazine derivatives and the putative mechanism of TDI liability of the series (Roche).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0036.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig36"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig37" data-index="37" class="article__inlineFigure"><h2 class="fig-label">Figure 37</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0037.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0037.jpeg" id="rightTab-gr37" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 37. Design of diazepanone derivatives with low potential for CYP2D6 and hERG inhibition (Takeda).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0037.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig37"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig38" data-index="38" class="article__inlineFigure"><h2 class="fig-label">Figure 38</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0038.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0038.jpeg" id="rightTab-gr38" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 38. Design of 4-benzylpiperidine derivatives with low risk for CAD-associated or other safety liabilities (Takeda).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0038.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig38"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig39" data-index="39" class="article__inlineFigure"><h2 class="fig-label">Figure 39</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0039.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0039.jpeg" id="rightTab-gr39" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 39. Conversion of the SNRI <b>20</b> into the corresponding benzoate ester derivatives to incorporate DAT affinity (Luye Pharma).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0039.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig39"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig40" data-index="40" class="article__inlineFigure"><h2 class="fig-label">Figure 40</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0040.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0040.jpeg" id="rightTab-gr40" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 40. Structures of DA receptor antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0040.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig40"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig41" data-index="41" class="article__inlineFigure"><h2 class="fig-label">Figure 41</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0041.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0041.jpeg" id="rightTab-gr41" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 41. Evolution of DAT-selective piperidines into triple-acting pyran analogues with the introduction of SERT/NET affinity by isosteric heterocyclic replacement.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0041.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig41"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig42" data-index="42" class="article__inlineFigure"><h2 class="fig-label">Figure 42</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0042.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0042.jpeg" id="rightTab-gr42" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 42. Chemical modification strategies around the pyran ring of <b>224</b> involving ring contraction or peripheral elongation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0042.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig42"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig43" data-index="43" class="article__inlineFigure"><h2 class="fig-label">Figure 43</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0043.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0043.jpeg" id="rightTab-gr43" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 43. Identification of tricyclic pyrroloisoquinoline derivatives by introduction of ring fusion to the THIQ core (Johnson & Johnson); <sup><i>a</i></sup>affinity data from the literature reference<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0043.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig43"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig44" data-index="44" class="article__inlineFigure"><h2 class="fig-label">Figure 44</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0044.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0044.jpeg" id="rightTab-gr44" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 44. Aryl modification strategy to improve the DAT affinity of the SNRI <b>21</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0044.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig44"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig45" data-index="45" class="article__inlineFigure"><h2 class="fig-label">Figure 45</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0045.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0045.jpeg" id="rightTab-gr45" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 45. Evolution of conformationally constrained bicyclo[2.2.1]heptane-derived inhibitors through ring contraction (Eli Lilly).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0045.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig45"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig46" data-index="46" class="article__inlineFigure"><h2 class="fig-label">Figure 46</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0046.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0046.jpeg" id="rightTab-gr46" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 46. Design of <b>254</b>, derived from hybridization of <b>253</b> and <b>32</b> (Psychogenics); <sup><i>a</i></sup>affinity data are taken from the literature.<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0046.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig46"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig47" data-index="47" class="article__inlineFigure"><h2 class="fig-label">Figure 47</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0047.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0047.jpeg" id="rightTab-gr47" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 47. Conformational restriction of 3-arylpropylamine template to derive azetidine-bearing compounds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0047.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig47"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig48" data-index="48" class="article__inlineFigure"><h2 class="fig-label">Figure 48</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/medium/jm-2016-01827a_0048.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0048.jpeg" id="rightTab-gr48" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 48. Evolution of 1,3-diamino-1-arylpropane derivatives.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.6b01827/20180315/images/large/jm-2016-01827a_0048.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01827&amp;id=fig48"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i38">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60142" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60142" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 159 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span> <i>Depression Fact Sheet</i>; <span class="NLM_publisher-name">World Health Organization
(WHO)</span>: <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2017</span>; <a href="http://www.who.int/mediacentre/factsheets/fs369/en/" class="extLink">http://www.who.int/mediacentre/factsheets/fs369/en/</a> (accessed May 29, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Depression+Fact+Sheet%3B+World+Health+Organization%0A%28WHO%29%3A+Geneva%2C+2017%3B+http%3A%2F%2Fwww.who.int%2Fmediacentre%2Ffactsheets%2Ffs369%2Fen%2F+%28accessed+May+29%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DDepression%2520Fact%2520Sheet%26pub%3DWorld%2520Health%2520Organization%250A%2528WHO%2529%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span> <i>Antidepressant Use in Persons
Aged 12 and Over: United States, 2005–2008</i>; <span class="NLM_publisher-name">National Center for Health Statistics</span>: <span class="NLM_publisher-loc">Atlanta</span>, <span class="NLM_year">2011</span>; <a href="https://www.cdc.gov/nchs/products/databriefs/db76.htm" class="extLink">https://www.cdc.gov/nchs/products/databriefs/db76.htm</a> (accessed May 29, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Antidepressant+Use+in+Persons%0AAged+12+and+Over%3A+United+States%2C+2005%E2%80%932008%3B+National+Center+for+Health+Statistics%3A+Atlanta%2C+2011%3B+https%3A%2F%2Fwww.cdc.gov%2Fnchs%2Fproducts%2Fdatabriefs%2Fdb76.htm+%28accessed+May+29%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DAntidepressant%2520Use%2520in%2520Persons%250AAged%252012%2520and%2520Over%253A%2520United%2520States%252C%25202005%25E2%2580%25932008%26pub%3DNational%2520Center%2520for%2520Health%2520Statistics%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Calderone, J.</span></span> <span> </span><span class="NLM_article-title">The Rise of All-Purpose Antidepressants</span>;  <i>Scientific American</i> November 1, <span class="NLM_year">2014</span>; <a href="https://www.scientificamerican.com/article/the-rise-of-all-purpose-antidepressants/" class="extLink">https://www.scientificamerican.com/article/the-rise-of-all-purpose-antidepressants/</a> (accessed May 29, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=J.+Calderone&title=The+Rise+of+All-Purpose+Antidepressants"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3DCalderone%26aufirst%3DJ.%26atitle%3DThe%2520Rise%2520of%2520All-Purpose%2520Antidepressants%26jtitle%3DScientific%2520American%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lane, R. M.</span></span> <span> </span><span class="NLM_article-title">Antidepressant drug development: focus on triple monoamine reuptake inhibition</span>. <i>J. Psychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">526</span>– <span class="NLM_lpage">544</span>, <span class="refDoi"> DOI: 10.1177/0269881114553252</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1177%2F0269881114553252" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=25315829" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlWlu7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2015&pages=526-544&author=R.+M.+Lane&title=Antidepressant+drug+development%3A+focus+on+triple+monoamine+reuptake+inhibition&doi=10.1177%2F0269881114553252"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Antidepressant drug development: focus on triple monoamine reuptake inhibition</span></div><div class="casAuthors">Lane, Roger M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Psychopharmacology (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">526-544</span>CODEN:
                <span class="NLM_cas:coden">JOPSEQ</span>;
        ISSN:<span class="NLM_cas:issn">0269-8811</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">Many patients with major depressive disorder (MDD) only partially respond, and some have no clin. meaningful response, to current widely used antidepressant drugs.  Due to the purported role of dopamine in the pathophysiol. of depression, triple-reuptake inhibitors (TRIs) that simultaneously inhibit serotonin (5-HT), norepinephrine (NE) and dopamine reuptake could be a useful addn. to the armamentarium of treatments for MDD.  A TRI should more effectively activate mesolimbic dopamine-related reward-networks, restore pos. mood and reduce potent 5-HT reuptake blockade assocd. "hypodopaminergic" adverse effects of decreased libido, wt. gain and "blunting" of emotions.  On the other hand, dopaminergic effects raise concern over abuse liability and TRIs may have many of the cardiovascular effects assocd. with NET inhibition.  Several clin. development programs for potential TRI antidepressants have failed to demonstrate significantly greater efficacy than placebo or std. of care.  Successful late-stage clin. development of a TRI is more likely if exptl. research studies in the target population of depressed patients have demonstrated target engagement that differentially and dose-dependently improves assessments of reward-network dysfunction relative to existing antidepressants.  TRI treatment could be individualized on the basis of predictive markers such as the burden of decreased pos. mood symptoms and/or neuroimaging evidence of reward network dysfunction.  This review focuses on how the next generation of monoamine-based treatments could be efficiently developed to address unmet medical need in MDD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVyw65qm-vT7Vg90H21EOLACvtfcHk0lgNgqlgt1dLKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlWlu7%252FI&md5=43a14f56cf9bc21972ad313b1c53dd66</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1177%2F0269881114553252&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0269881114553252%26sid%3Dliteratum%253Aachs%26aulast%3DLane%26aufirst%3DR.%2BM.%26atitle%3DAntidepressant%2520drug%2520development%253A%2520focus%2520on%2520triple%2520monoamine%2520reuptake%2520inhibition%26jtitle%3DJ.%2520Psychopharmacol.%26date%3D2015%26volume%3D29%26spage%3D526%26epage%3D544%26doi%3D10.1177%2F0269881114553252" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, S. M.</span></span> <i>Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications</i>; <span class="NLM_edition">4th</span> ed.; <span class="NLM_publisher-name">Cambridge University Press</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=S.+M.+Stahl&title=Stahl%E2%80%99s+Essential+Psychopharmacology%3A+Neuroscientific+Basis+and+Practical+Applications"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DStahl%26aufirst%3DS.%2BM.%26btitle%3DStahl%25E2%2580%2599s%2520Essential%2520Psychopharmacology%253A%2520Neuroscientific%2520Basis%2520and%2520Practical%2520Applications%26pub%3DCambridge%2520University%2520Press%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dunlop, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nemeroff, C. B.</span></span> <span> </span><span class="NLM_article-title">The role of dopamine in the pathophysiology of depression</span>. <i>Arch. Gen. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">327</span>– <span class="NLM_lpage">337</span>, <span class="refDoi"> DOI: 10.1001/archpsyc.64.3.327</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1001%2Farchpsyc.64.3.327" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=17339521" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjs1yntLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2007&pages=327-337&author=B.+W.+Dunlopauthor=C.+B.+Nemeroff&title=The+role+of+dopamine+in+the+pathophysiology+of+depression&doi=10.1001%2Farchpsyc.64.3.327"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The role of dopamine in the pathophysiology of depression</span></div><div class="casAuthors">Dunlop, Boadie W.; Nemeroff, Charles B.</div><div class="citationInfo"><span class="NLM_cas:title">Archives of General Psychiatry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">327-337</span>CODEN:
                <span class="NLM_cas:coden">ARGPAQ</span>;
        ISSN:<span class="NLM_cas:issn">0003-990X</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">A review.  Multiple sources of evidence support a role for diminished dopaminergic neurotransmission in major depression.  The physiol. alterations underlying reduced dopamine (DA) signaling could result from either diminished DA release from presynaptic neurons or impaired signal transduction; either due to changes in receptor no. or function and/or altered intracellular signal processing.  There are data supporting each of these mechanisms, although interpretation of previous research is confounded by issues around study population, medication status, and technol. limitations.  In some patients with depression, DA-related disturbances improve by treatment with antidepressants, presumably by acting on serotonergic or noradrenergic circuits, which then affect DA function.  However, most antidepressant treatments do not directly enhance DA neurotransmission, which may contribute to residual symptoms, including impaired motivation, concn., and pleasure.  Animal models of major depression show considerable responsiveness to manipulations of DA neurotransmission.  Several studies, including postmortem investigations, particularly of subjects with severe depression, have demonstrated reduced concns. of DA metabolites both in the cerebrospinal fluid and in brain regions that mediate mood and motivation.  Although the neuroimaging findings are not unequivocal, several studies support the hypothesis that major depression is assocd. with a state of reduced DA transmission, possibly reflected by a compensatory up-regulation of D2 receptors.  These alternations in DA signaling may underlie the findings of increased "liking" or "high" feelings reported by severely depressed subjects treated with d-amphetamine compared with the response of less severely ill and normal control subjects.  The efficacy of medications that directly act on DA neurons or receptors, such as monoamine oxidase inhibitors and pramipexole, suggests that subtypes of depression stemming from a primary DA dysfunction exist.  Further research on the contribution of DA to the pathophysiol. of depression is justified to improve outcomes for patients with treatment-resistant and nonremitting depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpl_yra-4Ra0rVg90H21EOLACvtfcHk0lg22Ejz61FymQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjs1yntLY%253D&md5=5d9c7f04093533d67b4bff1f6f68f3ae</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1001%2Farchpsyc.64.3.327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchpsyc.64.3.327%26sid%3Dliteratum%253Aachs%26aulast%3DDunlop%26aufirst%3DB.%2BW.%26aulast%3DNemeroff%26aufirst%3DC.%2BB.%26atitle%3DThe%2520role%2520of%2520dopamine%2520in%2520the%2520pathophysiology%2520of%2520depression%26jtitle%3DArch.%2520Gen.%2520Psychiatry%26date%3D2007%26volume%3D64%26spage%3D327%26epage%3D337%26doi%3D10.1001%2Farchpsyc.64.3.327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marks, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pae, C.-U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patkar, A. A.</span></span> <span> </span><span class="NLM_article-title">Triple reuptake inhibitors: the next generation of antidepressants</span>. <i>Curr. Neuropharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">338</span>– <span class="NLM_lpage">343</span>, <span class="refDoi"> DOI: 10.2174/157015908787386078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.2174%2F157015908787386078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=19587855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisVSqu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2008&pages=338-343&author=D.+M.+Marksauthor=C.-U.+Paeauthor=A.+A.+Patkar&title=Triple+reuptake+inhibitors%3A+the+next+generation+of+antidepressants&doi=10.2174%2F157015908787386078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Triple reuptake inhibitors: the next generation of antidepressants</span></div><div class="casAuthors">Marks, David M.; Pae, Chi-Un; Patkar, Ashwin A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Neuropharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">338-343</span>CODEN:
                <span class="NLM_cas:coden">CNUEAN</span>;
        ISSN:<span class="NLM_cas:issn">1875-6190</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Depression has been assocd. with impaired neurotransmission of serotonergic, norepinephrinergic, and dopaminergic pathways, although most pharmacol. treatment strategies for depression enhance only serotonin and norepinephrine neurotransmission.  Current drug development efforts are aimed at a new class of antidepressants which inhibit the reuptake of all three neurotransmitters in the hope of creating medications with broader efficacy and/or quicker onset of action.  The current review explores limitations of presently available antidepressants and the history and premise behind the movement to devise triple reuptake inhibitors.  The evidence for and against the claim that broader spectrum agents are more efficacious is discussed.  Examples of triple reuptake inhibitors in development are compared, and preclin. and clin. research with these agents to date is described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGov8YVs9W5UsbVg90H21EOLACvtfcHk0ljzGrgfROUOCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisVSqu78%253D&md5=b8108bdcd4ddc03bc3e7c31b2ac0824f</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.2174%2F157015908787386078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157015908787386078%26sid%3Dliteratum%253Aachs%26aulast%3DMarks%26aufirst%3DD.%2BM.%26aulast%3DPae%26aufirst%3DC.-U.%26aulast%3DPatkar%26aufirst%3DA.%2BA.%26atitle%3DTriple%2520reuptake%2520inhibitors%253A%2520the%2520next%2520generation%2520of%2520antidepressants%26jtitle%3DCurr.%2520Neuropharmacol.%26date%3D2008%26volume%3D6%26spage%3D338%26epage%3D343%26doi%3D10.2174%2F157015908787386078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haque, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angelescu, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumeister, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tracy, D. K.</span></span> <span> </span><span class="NLM_article-title">Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant</span>. <i>Ther. Adv. Psychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">99</span>– <span class="NLM_lpage">144</span>, <span class="refDoi"> DOI: 10.1177/2045125316629071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1177%2F2045125316629071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=27141292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtVKisLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=99-144&author=K.+Patelauthor=S.+Allenauthor=M.+N.+Haqueauthor=I.+Angelescuauthor=D.+Baumeisterauthor=D.+K.+Tracy&title=Bupropion%3A+a+systematic+review+and+meta-analysis+of+effectiveness+as+an+antidepressant&doi=10.1177%2F2045125316629071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant</span></div><div class="casAuthors">Patel, Krisna; Allen, Sophie; Haque, Mariam N.; Angelescu, Ilinca; Baumeister, David; Tracy, Derek K.</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Advances in Psychopharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">99-144</span>CODEN:
                <span class="NLM_cas:coden">TAPHB2</span>;
        ISSN:<span class="NLM_cas:issn">2045-1261</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Bupropion has been used as an antidepressant for over 20 years, though its licence for such use varies and it is typically a third- or fourth-line agent.  It has a unique pharmacol., inhibiting the reuptake of noradrenaline and dopamine, potentially providing pharmacol. augmentation to more common antidepressants such as selective serotonergic reuptake inhibitors (SSRIs).  This systematic review and meta-anal. identified 51 studies, dividing into four categories: bupropion as a sole antidepressant, bupropion coprescribed with another antidepressant, bupropion in 'other' populations (e.g. bipolar depression, elderly populations) and primary evaluation of side effects.  Methodol. more robust trials support the superiority of bupropion over placebo, and most head-to-head antidepressant trials showed an equiv. effectiveness, though some of these are hindered by a lack of a placebo arm.  Most work on the coprescribing of bupropion with another antidepressant supports an addnl. effect, though many are open-label trials.  Several large multi-medication trials, most notably STAR*D, also support a therapeutic role for bupropion; in general, it demonstrated similar effectiveness to other medications, though this literature highlights the generally low response rates in refractory cohorts.  Effectiveness has been shown in 'other' populations, though there is an overall dearth of research.  Bupropion is generally well tolerated, it has very low rates of sexual dysfunction, and is more likely to cause wt. loss than gain.  Our findings support the use of bupropion as a sole or coprescribed antidepressant, particularly if wt. gain or sexual dysfunction are, or are likely to be, significant problems.  However there are notable gaps in the literature, including less information on treatment naive and first presentation depression, particularly when one considers the ever-reducing rates of response in more refractory illness.  There are some data to support bupropion targeting specific symptoms, but insufficient information to reliably inform such prescribing, and it remains uncertain whether bupropion pharmacodynamically truly augments other drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXRuoh6Ma-9bVg90H21EOLACvtfcHk0ljzGrgfROUOCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtVKisLo%253D&md5=f41bf8860711254d55a3452ad519f03c</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1177%2F2045125316629071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F2045125316629071%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DK.%26aulast%3DAllen%26aufirst%3DS.%26aulast%3DHaque%26aufirst%3DM.%2BN.%26aulast%3DAngelescu%26aufirst%3DI.%26aulast%3DBaumeister%26aufirst%3DD.%26aulast%3DTracy%26aufirst%3DD.%2BK.%26atitle%3DBupropion%253A%2520a%2520systematic%2520review%2520and%2520meta-analysis%2520of%2520effectiveness%2520as%2520an%2520antidepressant%26jtitle%3DTher.%2520Adv.%2520Psychopharmacol.%26date%3D2016%26volume%3D6%26spage%3D99%26epage%3D144%26doi%3D10.1177%2F2045125316629071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span> <i>Bupropion</i>; <span class="NLM_publisher-name">Wikipedia</span>, <span class="NLM_year">2017</span>; <a href="https://en.wikipedia.org/wiki/Bupropion" class="extLink">https://en.wikipedia.org/wiki/Bupropion</a> (accessed May 29, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Bupropion%3B+Wikipedia%2C+2017%3B+https%3A%2F%2Fen.wikipedia.org%2Fwiki%2FBupropion+%28accessed+May+29%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DBupropion%26pub%3DWikipedia%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pechulis, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curry, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harms, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opalka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweet, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vellekoop, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klos, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crocker, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laws, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitchen, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molino, B. F.</span></span> <span> </span><span class="NLM_article-title">4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">7219</span>– <span class="NLM_lpage">7222</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.09.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.bmcl.2012.09.050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=23084899" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFGjtLrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=7219-7222&author=A.+D.+Pechulisauthor=J.+P.+Beckauthor=M.+A.+Curryauthor=M.+A.+Wolfauthor=A.+E.+Harmsauthor=N.+Xiauthor=C.+Opalkaauthor=M.+P.+Sweetauthor=Z.+Yangauthor=A.+S.+Vellekoopauthor=A.+M.+Klosauthor=P.+J.+Crockerauthor=C.+Hasslerauthor=M.+Lawsauthor=D.+B.+Kitchenauthor=M.+A.+Smithauthor=R.+E.+Olsonauthor=S.+Liuauthor=B.+F.+Molino&title=4-Phenyl+tetrahydroisoquinolines+as+dual+norepinephrine+and+dopamine+reuptake+inhibitors&doi=10.1016%2Fj.bmcl.2012.09.050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors</span></div><div class="casAuthors">Pechulis, Anthony D.; Beck, James P.; Curry, Matt A.; Wolf, Mark A.; Harms, Arthur E.; Xi, Ning; Opalka, Chet; Sweet, Mark P.; Yang, Zhicai; Vellekoop, A. Samuel; Klos, Andrew M.; Crocker, Peter J.; Hassler, Carla; Laws, Mia; Kitchen, Douglas B.; Smith, Mark A.; Olson, Richard E.; Liu, Shuang; Molino, Bruce F.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7219-7222</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Aryltetrahydroisoquinolines I [and, in some cases, their (+)-enantiomers or both their (+)- and (-)-enantiomers] were prepd. as dual inhibitors of dopamine and norepinephrine transporters for potential use as nonstimulating treatments for attention deficit-hyperactivity disorder.  I were prepd. by reductive amination of benzaldehyde to N-methylarylmethylamines followed by alkylation with α-haloacetophenones to give benzylmethylamino arylethanones; redn. and acid-catalyzed cyclization yielded racemic aryltetrahydroisoquinolines which were resolved by preparative HPLC.  The inhibition of dopamine, norepinephrine, and serotonin transporters by I were detd.; the norepinephrine receptor occupancy of rat brain ex vivo after oral dosing of (S)-(+)-I (R1 = H; R2 = Me; R3 = R4 = R5 = H; R6 = F; R7 = H) was detd.  (S)-(+)-I (R1 = H; R2 = Me; R3 = R4 = R5 = H; R6 = F; R7 = H) inhibited cytochrome P450 2D6 (CYP2D6) with an IC50 value of 0.48 μM; some of the other aryltetrahydroisoquinolines prepd. also inhibited CYP2D6.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXnLksIDABmrVg90H21EOLACvtfcHk0lgI9YUhwCuKqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFGjtLrK&md5=e64a45237245cffb08f14c80e5b9e21a</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.09.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.09.050%26sid%3Dliteratum%253Aachs%26aulast%3DPechulis%26aufirst%3DA.%2BD.%26aulast%3DBeck%26aufirst%3DJ.%2BP.%26aulast%3DCurry%26aufirst%3DM.%2BA.%26aulast%3DWolf%26aufirst%3DM.%2BA.%26aulast%3DHarms%26aufirst%3DA.%2BE.%26aulast%3DXi%26aufirst%3DN.%26aulast%3DOpalka%26aufirst%3DC.%26aulast%3DSweet%26aufirst%3DM.%2BP.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DVellekoop%26aufirst%3DA.%2BS.%26aulast%3DKlos%26aufirst%3DA.%2BM.%26aulast%3DCrocker%26aufirst%3DP.%2BJ.%26aulast%3DHassler%26aufirst%3DC.%26aulast%3DLaws%26aufirst%3DM.%26aulast%3DKitchen%26aufirst%3DD.%2BB.%26aulast%3DSmith%26aufirst%3DM.%2BA.%26aulast%3DOlson%26aufirst%3DR.%2BE.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DMolino%26aufirst%3DB.%2BF.%26atitle%3D4-Phenyl%2520tetrahydroisoquinolines%2520as%2520dual%2520norepinephrine%2520and%2520dopamine%2520reuptake%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D7219%26epage%3D7222%26doi%3D10.1016%2Fj.bmcl.2012.09.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gaynes, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warden, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trivedi, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wisniewski, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fava, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rush, A. J.</span></span> <span> </span><span class="NLM_article-title">What did STAR*D teach us? results from a large-scale, practical, clinical trial for patients with depression</span>. <i>Psychiatr. Serv.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1439</span>– <span class="NLM_lpage">1445</span>, <span class="refDoi"> DOI: 10.1176/ps.2009.60.11.1439</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1176%2Fps.2009.60.11.1439" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=19880458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A280%3ADC%252BD1MjjtFShtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2009&pages=1439-1445&author=B.+N.+Gaynesauthor=D.+Wardenauthor=M.+H.+Trivediauthor=S.+R.+Wisniewskiauthor=M.+Favaauthor=A.+J.+Rush&title=What+did+STAR*D+teach+us%3F+results+from+a+large-scale%2C+practical%2C+clinical+trial+for+patients+with+depression&doi=10.1176%2Fps.2009.60.11.1439"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression</span></div><div class="casAuthors">Gaynes Bradley N; Warden Diane; Trivedi Madhukar H; Wisniewski Stephen R; Fava Maurizio; Rush A John</div><div class="citationInfo"><span class="NLM_cas:title">Psychiatric services (Washington, D.C.)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1439-45</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The authors provide an overview of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study (www.star-d.org), a large-scale practical clinical trial to determine which of several treatments are the most effective "next-steps" for patients with major depressive disorder whose symptoms do not remit or who cannot tolerate an initial treatment and, if needed, ensuing treatments.  Entry criteria were broadly defined and inclusive, and patients were enrolled from psychiatric and primary care clinics.  All participants began on citalopram and were managed by clinic physicians, who followed an algorithm-guided acute-phase treatment through five visits over 12 weeks.  At the end of each sequence, patients whose depression had not fully remitted were eligible for subsequent randomized trials in a sequence of up to three clinical trials.  In general, remission rates in the study clinics were lower than expected, suggesting the need for several steps to achieve remission for most patients.  There was no clear medication "winner" for patients whose depression did not remit after one or more aggressive medication trials.  Both switching and augmenting appeared to be reasonable options when an initial antidepressant treatment failed, although these two strategies could not be directly compared.  Further, the likelihood of remission after two vigorous medication trials substantially decreased, and remission would likely require more complicated medication regimens for which the existing evidence base is quite thin.  STAR*D demonstrated that inclusion of more real-world patients in clinical trials is both feasible and informative.  Policy implications of the findings, as well as the study's limitations, are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTgLKw46-uNnxOk4JA3soTqfW6udTcc2eYqQgx9bt6rXbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MjjtFShtw%253D%253D&md5=8e843ff9d84f737d8b71493b8a12c51f</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1176%2Fps.2009.60.11.1439&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fps.2009.60.11.1439%26sid%3Dliteratum%253Aachs%26aulast%3DGaynes%26aufirst%3DB.%2BN.%26aulast%3DWarden%26aufirst%3DD.%26aulast%3DTrivedi%26aufirst%3DM.%2BH.%26aulast%3DWisniewski%26aufirst%3DS.%2BR.%26aulast%3DFava%26aufirst%3DM.%26aulast%3DRush%26aufirst%3DA.%2BJ.%26atitle%3DWhat%2520did%2520STAR%252AD%2520teach%2520us%253F%2520results%2520from%2520a%2520large-scale%252C%2520practical%252C%2520clinical%2520trial%2520for%2520patients%2520with%2520depression%26jtitle%3DPsychiatr.%2520Serv.%26date%3D2009%26volume%3D60%26spage%3D1439%26epage%3D1445%26doi%3D10.1176%2Fps.2009.60.11.1439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sum, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldessarini, R. J.</span></span> <span> </span><span class="NLM_article-title">Prevention of relapse and recurrence in adults with major depressive disorder: systematic review and meta-analyses of controlled trials</span>. <i>Int. J. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">pyv076</span>, <span class="refDoi"> DOI: 10.1093/ijnp/pyv076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1093%2Fijnp%2Fpyv076" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2016&pages=pyv076&author=K.+Simauthor=W.+K.+Lauauthor=J.+Simauthor=M.+Y.+Sumauthor=R.+J.+Baldessarini&title=Prevention+of+relapse+and+recurrence+in+adults+with+major+depressive+disorder%3A+systematic+review+and+meta-analyses+of+controlled+trials&doi=10.1093%2Fijnp%2Fpyv076"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1093%2Fijnp%2Fpyv076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fijnp%252Fpyv076%26sid%3Dliteratum%253Aachs%26aulast%3DSim%26aufirst%3DK.%26aulast%3DLau%26aufirst%3DW.%2BK.%26aulast%3DSim%26aufirst%3DJ.%26aulast%3DSum%26aufirst%3DM.%2BY.%26aulast%3DBaldessarini%26aufirst%3DR.%2BJ.%26atitle%3DPrevention%2520of%2520relapse%2520and%2520recurrence%2520in%2520adults%2520with%2520major%2520depressive%2520disorder%253A%2520systematic%2520review%2520and%2520meta-analyses%2520of%2520controlled%2520trials%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2016%26volume%3D19%26spage%3Dpyv076%26doi%3D10.1093%2Fijnp%2Fpyv076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Best, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nijhout, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, M. C.</span></span> <span> </span><span class="NLM_article-title">Homeostatic mechanisms in dopamine synthesis and release: a mathematical model</span>. <i>Theor. Biol. Med. Modell.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">21</span>, <span class="refDoi"> DOI: 10.1186/1742-4682-6-21</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1186%2F1742-4682-6-21" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=19740446" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A280%3ADC%252BD1MnmtFKjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2009&pages=21&author=J.+A.+Bestauthor=H.+F.+Nijhoutauthor=M.+C.+Reed&title=Homeostatic+mechanisms+in+dopamine+synthesis+and+release%3A+a+mathematical+model&doi=10.1186%2F1742-4682-6-21"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Homeostatic mechanisms in dopamine synthesis and release: a mathematical model</span></div><div class="casAuthors">Best Janet A; Nijhout H Frederik; Reed Michael C</div><div class="citationInfo"><span class="NLM_cas:title">Theoretical biology & medical modelling</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">21</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Dopamine is a catecholamine that is used as a neurotransmitter both in the periphery and in the central nervous system.  Dysfunction in various dopaminergic systems is known to be associated with various disorders, including schizophrenia, Parkinson's disease, and Tourette's syndrome.  Furthermore, microdialysis studies have shown that addictive drugs increase extracellular dopamine and brain imaging has shown a correlation between euphoria and psycho-stimulant-induced increases in extracellular dopamine 1.  These consequences of dopamine dysfunction indicate the importance of maintaining dopamine functionality through homeostatic mechanisms that have been attributed to the delicate balance between synthesis, storage, release, metabolism, and reuptake.  METHODS:  We construct a mathematical model of dopamine synthesis, release, and reuptake and use it to study homeostasis in single dopaminergic neuron terminals.  We investigate the substrate inhibition of tyrosine hydroxylase by tyrosine, the consequences of the rapid uptake of extracellular dopamine by the dopamine transporters, and the effects of the autoreceoptors on dopaminergic function.  The main focus is to understand the regulation and control of synthesis and release and to explicate and interpret experimental findings.  RESULTS:  We show that the substrate inhibition of tyrosine hydroxylase by tyrosine stabilizes cytosolic and vesicular dopamine against changes in tyrosine availability due to meals.  We find that the autoreceptors dampen the fluctuations in extracellular dopamine caused by changes in tyrosine hydroxylase expression and changes in the rate of firing.  We show that short bursts of action potentials create significant dopamine signals against the background of tonic firing.  We explain the observed time courses of extracellular dopamine responses to stimulation in wild type mice and mice that have genetically altered dopamine transporter densities and the observed half-lives of extracellular dopamine under various treatment protocols.  CONCLUSION:  Dopaminergic systems must respond robustly to important biological signals such as bursts, while at the same time maintaining homeostasis in the face of normal biological fluctuations in inputs, expression levels, and firing rates.  This is accomplished through the cooperative effect of many different homeostatic mechanisms including special properties of tyrosine hydroxylase, the dopamine transporters, and the dopamine autoreceptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTwS0I3gpFNW4kFb3mqPUYDfW6udTcc2eZl1Ex637aWobntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MnmtFKjsQ%253D%253D&md5=660a643b96fdfacf63329ac2cb0dc99f</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1186%2F1742-4682-6-21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1742-4682-6-21%26sid%3Dliteratum%253Aachs%26aulast%3DBest%26aufirst%3DJ.%2BA.%26aulast%3DNijhout%26aufirst%3DH.%2BF.%26aulast%3DReed%26aufirst%3DM.%2BC.%26atitle%3DHomeostatic%2520mechanisms%2520in%2520dopamine%2520synthesis%2520and%2520release%253A%2520a%2520mathematical%2520model%26jtitle%3DTheor.%2520Biol.%2520Med.%2520Modell.%26date%3D2009%26volume%3D6%26spage%3D21%26doi%3D10.1186%2F1742-4682-6-21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McHugh, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckley, D. A.</span></span> <span> </span><span class="NLM_article-title">The structure and function of the dopamine transporter and its role in CNS diseases</span>. <i>Vitam. Horm.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">339</span>– <span class="NLM_lpage">369</span>, <span class="refDoi"> DOI: 10.1016/bs.vh.2014.12.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fbs.vh.2014.12.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=25817874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVCnsb3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2015&pages=339-369&author=P.+C.+McHughauthor=D.+A.+Buckley&title=The+structure+and+function+of+the+dopamine+transporter+and+its+role+in+CNS+diseases&doi=10.1016%2Fbs.vh.2014.12.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">The structure and function of the dopamine transporter and its role in CNS diseases</span></div><div class="casAuthors">McHugh, Patrick C.; Buckley, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Vitamins and Hormones (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">Hormones and Transport Systems</span>),
    <span class="NLM_cas:pages">339-369</span>CODEN:
                <span class="NLM_cas:coden">VIHOAQ</span>;
        ISSN:<span class="NLM_cas:issn">0083-6729</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">In this chapter, we explore the basic science of the dopamine transporter (DAT), an integral component of a system that regulates dopamine homeostasis.  Dopamine is a key neurotransmitter for several brain functions including locomotor control and reward systems.  The transporter structure, function, mechanism of action, localization, and distribution, in addn. to gene regulation, are discussed.  Over many years, a wealth of information concerning the DAT has been accrued and has led to increased interest in the role of the DAT in a plethora of central nervous system diseases.  These DAT characteristics are explored in relation to a range of neurol. and neuropsychiatric diseases, with a particular focus on the genetics of the DAT.  In addn., we discuss the pharmacol. of the DAT and how this relates to disease and addiction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJBVmxaoKu07Vg90H21EOLACvtfcHk0limjn3jPK-Rfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVCnsb3O&md5=c0500c7a561e0fb1d6e693aba2a905c0</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fbs.vh.2014.12.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.vh.2014.12.009%26sid%3Dliteratum%253Aachs%26aulast%3DMcHugh%26aufirst%3DP.%2BC.%26aulast%3DBuckley%26aufirst%3DD.%2BA.%26atitle%3DThe%2520structure%2520and%2520function%2520of%2520the%2520dopamine%2520transporter%2520and%2520its%2520role%2520in%2520CNS%2520diseases%26jtitle%3DVitam.%2520Horm.%26date%3D2015%26volume%3D98%26spage%3D339%26epage%3D369%26doi%3D10.1016%2Fbs.vh.2014.12.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Efimova, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gainetdinov, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Budygin, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotnikova, T. D.</span></span> <span> </span><span class="NLM_article-title">Dopamine transporter mutant animals: a translational perspective</span>. <i>J. Neurogenet.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">5</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.3109/01677063.2016.1144751</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.3109%2F01677063.2016.1144751" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=27276191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC28Xpslyis7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=5-15&author=E.+V.+Efimovaauthor=R.+R.+Gainetdinovauthor=E.+A.+Budyginauthor=T.+D.+Sotnikova&title=Dopamine+transporter+mutant+animals%3A+a+translational+perspective&doi=10.3109%2F01677063.2016.1144751"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine transporter mutant animals: a translational perspective</span></div><div class="casAuthors">Efimova, Evgeniya V.; Gainetdinov, Raul R.; Budygin, Evgeny A.; Sotnikova, Tatyana D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurogenetics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5-15</span>CODEN:
                <span class="NLM_cas:coden">JLNEDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-7063</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">The dopamine transporter (DAT) plays an important homeostatic role in the control of both the extracellular and intraneuronal concns. of dopamine, thereby providing effective control over activity of dopaminergic transmission.  Since brain dopamine is known to be involved in numerous neuropsychiatric disorders, investigations using mice with genetically altered DAT function and thus intensity of dopamine-mediated signaling have provided numerous insights into the pathol. of these disorders and novel pathol. mechanisms that could be targeted to provide new therapeutic approaches for these disorders.  In this brief overview, we discuss recent investigations involving animals with genetically altered DAT function, particularly focusing on translational studies providing new insights into pathol. and pharmacol. of dopamine-related disorders.  Perspective applications of these and newly developed models of DAT dysfunction are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUioooqPwsCLVg90H21EOLACvtfcHk0lhUZBF3C1zTbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xpslyis7s%253D&md5=44131a75927bf32f40d580fff0b825e0</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.3109%2F01677063.2016.1144751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F01677063.2016.1144751%26sid%3Dliteratum%253Aachs%26aulast%3DEfimova%26aufirst%3DE.%2BV.%26aulast%3DGainetdinov%26aufirst%3DR.%2BR.%26aulast%3DBudygin%26aufirst%3DE.%2BA.%26aulast%3DSotnikova%26aufirst%3DT.%2BD.%26atitle%3DDopamine%2520transporter%2520mutant%2520animals%253A%2520a%2520translational%2520perspective%26jtitle%3DJ.%2520Neurogenet.%26date%3D2016%26volume%3D30%26spage%3D5%26epage%3D15%26doi%3D10.3109%2F01677063.2016.1144751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sinita, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coghill, D.</span></span> <span> </span><span class="NLM_article-title">The use of stimulant medications for non-core aspects of ADHD and in other disorders</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">172</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2014.06.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.neuropharm.2014.06.014" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2014&pages=161-172&author=E.+Sinitaauthor=D.+Coghill&title=The+use+of+stimulant+medications+for+non-core+aspects+of+ADHD+and+in+other+disorders&doi=10.1016%2Fj.neuropharm.2014.06.014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2014.06.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2014.06.014%26sid%3Dliteratum%253Aachs%26aulast%3DSinita%26aufirst%3DE.%26aulast%3DCoghill%26aufirst%3DD.%26atitle%3DThe%2520use%2520of%2520stimulant%2520medications%2520for%2520non-core%2520aspects%2520of%2520ADHD%2520and%2520in%2520other%2520disorders%26jtitle%3DNeuropharmacology%26date%3D2014%26volume%3D87%26spage%3D161%26epage%3D172%26doi%3D10.1016%2Fj.neuropharm.2014.06.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cobanoglu, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahar, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Block, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorkin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, F.</span></span> <span> </span><span class="NLM_article-title">Insights into the modulation of dopamine transporter function by amphetamine, orphenadrine, and cocaine binding</span>. <i>Front. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">134</span>, <span class="refDoi"> DOI: 10.3389/fneur.2015.00134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.3389%2Ffneur.2015.00134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=26106364" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A280%3ADC%252BC2MbmslantQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=134&author=M.+H.+Chengauthor=M.+C.+Cobanogluauthor=I.+Baharauthor=E.+Blockauthor=A.+Sorkinauthor=F.+Hu&title=Insights+into+the+modulation+of+dopamine+transporter+function+by+amphetamine%2C+orphenadrine%2C+and+cocaine+binding&doi=10.3389%2Ffneur.2015.00134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into the Modulation of Dopamine Transporter Function by Amphetamine, Orphenadrine, and Cocaine Binding</span></div><div class="casAuthors">Cheng Mary Hongying; Cobanoglu Murat Can; Bahar Ivet; Block Ethan; Sorkin Alexander; Hu Feizhuo</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in neurology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">134</span>
        ISSN:<span class="NLM_cas:issn">1664-2295</span>.
    </div><div class="casAbstract">Human dopamine (DA) transporter (hDAT) regulates dopaminergic signaling in the central nervous system by maintaining the synaptic concentration of DA at physiological levels, upon reuptake of DA into presynaptic terminals.  DA translocation involves the co-transport of two sodium ions and the channeling of a chloride ion, and it is achieved via alternating access between outward-facing (OF) and inward-facing states of DAT. hDAT is a target for addictive drugs, such as cocaine, amphetamine (AMPH), and therapeutic antidepressants.  Our recent quantitative systems pharmacology study suggested that orphenadrine (ORPH), an anticholinergic agent and anti-Parkinson drug, might be repurposable as a DAT drug.  Previous studies have shown that DAT-substrates like AMPH or -blockers like cocaine modulate the function of DAT in different ways.  However, the molecular mechanisms of modulation remained elusive due to the lack of structural data on DAT.  The newly resolved DAT structure from Drosophila melanogaster opens the way to a deeper understanding of the mechanism and time evolution of DAT-drug/ligand interactions.  Using a combination of homology modeling, docking analysis, molecular dynamics simulations, and molecular biology experiments, we performed a comparative study of the binding properties of DA, AMPH, ORPH, and cocaine and their modulation of hDAT function.  Simulations demonstrate that binding DA or AMPH drives a structural transition toward a functional form predisposed to translocate the ligand.  In contrast, ORPH appears to inhibit DAT function by arresting it in the OF open conformation.  The analysis shows that cocaine and ORPH competitively bind DAT, with the binding pose and affinity dependent on the conformational state of DAT.  Further assays show that the effect of ORPH on DAT uptake and endocytosis is comparable to that of cocaine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcThQWXPjMQFgjW1zwg2yUK5fW6udTcc2ebTT7t_ZVhtoLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MbmslantQ%253D%253D&md5=ba85913d72d9a5343b37df827c0ad271</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.3389%2Ffneur.2015.00134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffneur.2015.00134%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DM.%2BH.%26aulast%3DCobanoglu%26aufirst%3DM.%2BC.%26aulast%3DBahar%26aufirst%3DI.%26aulast%3DBlock%26aufirst%3DE.%26aulast%3DSorkin%26aufirst%3DA.%26aulast%3DHu%26aufirst%3DF.%26atitle%3DInsights%2520into%2520the%2520modulation%2520of%2520dopamine%2520transporter%2520function%2520by%2520amphetamine%252C%2520orphenadrine%252C%2520and%2520cocaine%2520binding%26jtitle%3DFront.%2520Neurol.%26date%3D2015%26volume%3D6%26spage%3D134%26doi%3D10.3389%2Ffneur.2015.00134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murnane, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClung, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tufik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howell, L. L.</span></span> <span> </span><span class="NLM_article-title">Dopamine transporter-related effects of modafinil in rhesus monkeys</span>. <i>Psychopharmacology (Berl.)</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>210</i></span>,  <span class="NLM_fpage">439</span>– <span class="NLM_lpage">448</span>, <span class="refDoi"> DOI: 10.1007/s00213-010-1839-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1007%2Fs00213-010-1839-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=20386883" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A280%3ADC%252BC3czltVSmtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=210&publication_year=2010&pages=439-448&author=M.+L.+Andersenauthor=E.+Kesslerauthor=K.+S.+Murnaneauthor=J.+C.+McClungauthor=S.+Tufikauthor=L.+L.+Howell&title=Dopamine+transporter-related+effects+of+modafinil+in+rhesus+monkeys&doi=10.1007%2Fs00213-010-1839-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine transporter-related effects of modafinil in rhesus monkeys</span></div><div class="casAuthors">Andersen Monica L; Kessler Eileen; Murnane Kevin S; McClung Jessica C; Tufik Sergio; Howell Leonard L</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">210</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">439-48</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">RATIONALE:  Modafinil is currently used as a treatment for daytime sleepiness.  OBJECTIVES:  The objectives of this study were to explore the dopamine transporter (DAT)-related effects of modafinil on behavior and in vivo neurochemistry in rhesus monkeys (Macaca mulatta).  METHODS:  The effects of modafinil (3.0-10 mg/kg, i.v.) were evaluated on locomotor activity, reinstatement of cocaine-maintained behavior, extracellular dopamine levels in the caudate nucleus, and DAT occupancy in the dorsal striatum.  Eight subjects were fitted with a collar-mounted activity monitor to evaluate sleep-activity cycles, with 4 days of baseline recording preceding an injection of saline or modafinil (3.0-10 mg/kg).  The effects of modafinil (3.0-10 mg/kg) and cocaine (0.3 mg/kg) on reinstatement of behavior that was previously maintained under a second-order schedule of i.v. cocaine delivery were tested in a separate group of subjects (n = 6).  Finally, the effects of modafinil (3.0-10 mg/kg) on extracellular dopamine levels and DAT occupancy in vivo were characterized using microdialysis and positron emission tomography, respectively, in a within-subjects design (n = 4).  RESULTS:  Modafinil significantly increased nighttime locomotor activity and reinstated cocaine-maintained behavior but did not affect daytime locomotor activity.  Modafinil significantly increased striatal extracellular dopamine levels at a dose that resulted in DAT occupancy of 64.4% (putamen) and 60.2% (caudate).  CONCLUSION:  The behavioral and in vivo dopaminergic effects of modafinil are consistent with the profile of a low potency DAT inhibitor and may indicate potential for abuse at high doses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRR7q9pi3Ia6UewzGPswiWOfW6udTcc2ebQ3CmuSInlxrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3czltVSmtA%253D%253D&md5=d1a3b4f6d3775edd3846f5924cba9793</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1007%2Fs00213-010-1839-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-010-1839-2%26sid%3Dliteratum%253Aachs%26aulast%3DAndersen%26aufirst%3DM.%2BL.%26aulast%3DKessler%26aufirst%3DE.%26aulast%3DMurnane%26aufirst%3DK.%2BS.%26aulast%3DMcClung%26aufirst%3DJ.%2BC.%26aulast%3DTufik%26aufirst%3DS.%26aulast%3DHowell%26aufirst%3DL.%2BL.%26atitle%3DDopamine%2520transporter-related%2520effects%2520of%2520modafinil%2520in%2520rhesus%2520monkeys%26jtitle%3DPsychopharmacology%2520%2528Berl.%2529%26date%3D2010%26volume%3D210%26spage%3D439%26epage%3D448%26doi%3D10.1007%2Fs00213-010-1839-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tateno, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arakawa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakayori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okubo, Y.</span></span> <span> </span><span class="NLM_article-title">In vivo activity of modafinil on dopamine transporter measured with positron emission tomography and [(1)(8)F]FE-PE2I</span>. <i>Int. J. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">697</span>– <span class="NLM_lpage">703</span>, <span class="refDoi"> DOI: 10.1017/S1461145713001612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1017%2FS1461145713001612" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=24451483" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvF2htLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2014&pages=697-703&author=W.+Kimauthor=A.+Tatenoauthor=R.+Arakawaauthor=T.+Sakayoriauthor=Y.+Ikedaauthor=H.+Suzukiauthor=Y.+Okubo&title=In+vivo+activity+of+modafinil+on+dopamine+transporter+measured+with+positron+emission+tomography+and+%5B%281%29%288%29F%5DFE-PE2I&doi=10.1017%2FS1461145713001612"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo activity of modafinil on dopamine transporter measured with positron emission tomography and [18F]FE-PE2I</span></div><div class="casAuthors">Kim, Woo Chan; Tateno, Amane; Arakawa, Ryosuke; Sakayori, Takeshi; Ikeda, Yumiko; Suzuki, Hidenori; Okubo, Yoshiro</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">697-703</span>CODEN:
                <span class="NLM_cas:coden">IJNUFB</span>;
        ISSN:<span class="NLM_cas:issn">1461-1457</span>.
    
            (<span class="NLM_cas:orgname">Cambridge University Press</span>)
        </div><div class="casAbstract">Modafinil, a wake-promoting drug used to treat narcolepsy, is a dopamine transporter inhibitor and is said to have very low abuse liability; this, however, is still up for debate.  We conducted a dopamine transporter (DAT) occupancy study with modafinil (200 or 300 mg) in ten healthy volunteers using positron emission tomog. (PET) with [18F]FE-PE2I, a new PET radioligand with high affinity and selectivity for the dopamine transporter, to characterize its relation to abuse liability.  Mean striatal DAT occupancies were 51.4% at 200 mg and 56.9% at 300 mg.  There was a significant correlation between occupancy and plasma concn., indicating dose dependency of DAT inhibition by modafinil in the striatum, and esp. in the nucleus accumbens.  This study showed that DAT occupancy by modafinil was close to that of methylphenidate, indicating that modafinil may be near the same level as methylphenidate in relation to abuse liability in terms of dopaminergic transmission.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4A-U8meN0y7Vg90H21EOLACvtfcHk0lgI7B8SoUdSjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvF2htLg%253D&md5=0948131da50f2e032dbd8ace110c72a5</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1017%2FS1461145713001612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS1461145713001612%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DW.%26aulast%3DTateno%26aufirst%3DA.%26aulast%3DArakawa%26aufirst%3DR.%26aulast%3DSakayori%26aufirst%3DT.%26aulast%3DIkeda%26aufirst%3DY.%26aulast%3DSuzuki%26aufirst%3DH.%26aulast%3DOkubo%26aufirst%3DY.%26atitle%3DIn%2520vivo%2520activity%2520of%2520modafinil%2520on%2520dopamine%2520transporter%2520measured%2520with%2520positron%2520emission%2520tomography%2520and%2520%255B%25281%2529%25288%2529F%255DFE-PE2I%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2014%26volume%3D17%26spage%3D697%26epage%3D703%26doi%3D10.1017%2FS1461145713001612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perona, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waters, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sora, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesch, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caron, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uhl, G. R.</span></span> <span> </span><span class="NLM_article-title">Animal models of depression in dopamine, serotonin, and norepinephrine transporter knockout mice: prominent effects of dopamine transporter deletions</span>. <i>Behav. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">566</span>– <span class="NLM_lpage">574</span>, <span class="refDoi"> DOI: 10.1097/FBP.0b013e32830cd80f</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1097%2FFBP.0b013e32830cd80f" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2008&pages=566-574&author=M.+T.+Peronaauthor=S.+Watersauthor=F.+S.+Hallauthor=I.+Soraauthor=K.+P.+Leschauthor=D.+L.+Murphyauthor=M.+Caronauthor=G.+R.+Uhl&title=Animal+models+of+depression+in+dopamine%2C+serotonin%2C+and+norepinephrine+transporter+knockout+mice%3A+prominent+effects+of+dopamine+transporter+deletions&doi=10.1097%2FFBP.0b013e32830cd80f"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1097%2FFBP.0b013e32830cd80f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FFBP.0b013e32830cd80f%26sid%3Dliteratum%253Aachs%26aulast%3DPerona%26aufirst%3DM.%2BT.%26aulast%3DWaters%26aufirst%3DS.%26aulast%3DHall%26aufirst%3DF.%2BS.%26aulast%3DSora%26aufirst%3DI.%26aulast%3DLesch%26aufirst%3DK.%2BP.%26aulast%3DMurphy%26aufirst%3DD.%2BL.%26aulast%3DCaron%26aufirst%3DM.%26aulast%3DUhl%26aufirst%3DG.%2BR.%26atitle%3DAnimal%2520models%2520of%2520depression%2520in%2520dopamine%252C%2520serotonin%252C%2520and%2520norepinephrine%2520transporter%2520knockout%2520mice%253A%2520prominent%2520effects%2520of%2520dopamine%2520transporter%2520deletions%26jtitle%3DBehav.%2520Pharmacol.%26date%3D2008%26volume%3D19%26spage%3D566%26epage%3D574%26doi%3D10.1097%2FFBP.0b013e32830cd80f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tye, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirzabekov, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warden, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferenczi, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, H.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finkelstein, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adhikari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andalman, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunaydin, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witten, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deisseroth, K.</span></span> <span> </span><span class="NLM_article-title">Dopamine neurons modulate neural encoding and expression of depression-related behaviour</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>493</i></span>,  <span class="NLM_fpage">537</span>– <span class="NLM_lpage">541</span>, <span class="refDoi"> DOI: 10.1038/nature11740</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1038%2Fnature11740" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=493&publication_year=2013&pages=537-541&author=K.+M.+Tyeauthor=J.+J.+Mirzabekovauthor=M.+R.+Wardenauthor=E.+A.+Ferencziauthor=H.-C.+Tsaiauthor=J.+Finkelsteinauthor=S.-Y.+Kimauthor=A.+Adhikariauthor=K.+R.+Thompsonauthor=A.+S.+Andalmanauthor=L.+A.+Gunaydinauthor=I.+B.+Wittenauthor=K.+Deisseroth&title=Dopamine+neurons+modulate+neural+encoding+and+expression+of+depression-related+behaviour&doi=10.1038%2Fnature11740"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnature11740&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11740%26sid%3Dliteratum%253Aachs%26aulast%3DTye%26aufirst%3DK.%2BM.%26aulast%3DMirzabekov%26aufirst%3DJ.%2BJ.%26aulast%3DWarden%26aufirst%3DM.%2BR.%26aulast%3DFerenczi%26aufirst%3DE.%2BA.%26aulast%3DTsai%26aufirst%3DH.-C.%26aulast%3DFinkelstein%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.-Y.%26aulast%3DAdhikari%26aufirst%3DA.%26aulast%3DThompson%26aufirst%3DK.%2BR.%26aulast%3DAndalman%26aufirst%3DA.%2BS.%26aulast%3DGunaydin%26aufirst%3DL.%2BA.%26aulast%3DWitten%26aufirst%3DI.%2BB.%26aulast%3DDeisseroth%26aufirst%3DK.%26atitle%3DDopamine%2520neurons%2520modulate%2520neural%2520encoding%2520and%2520expression%2520of%2520depression-related%2520behaviour%26jtitle%3DNature%26date%3D2013%26volume%3D493%26spage%3D537%26epage%3D541%26doi%3D10.1038%2Fnature11740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Witkin, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monn, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoepp, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overshiner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasmussen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rorick-Kehn, L. M.</span></span> <span> </span><span class="NLM_article-title">The rapidly acting antidepressant ketamine and the mGlu2/3 receptor antagonist LY341495 rapidly engage dopaminergic mood circuits</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>358</i></span>,  <span class="NLM_fpage">71</span>– <span class="NLM_lpage">82</span>, <span class="refDoi"> DOI: 10.1124/jpet.116.233627</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1124%2Fjpet.116.233627" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=27189960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFyjs73E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=358&publication_year=2016&pages=71-82&author=J.+M.+Witkinauthor=J.+A.+Monnauthor=D.+D.+Schoeppauthor=X.+Liauthor=C.+Overshinerauthor=S.+N.+Mitchellauthor=G.+Carterauthor=B.+Johnsonauthor=K.+Rasmussenauthor=L.+M.+Rorick-Kehn&title=The+rapidly+acting+antidepressant+ketamine+and+the+mGlu2%2F3+receptor+antagonist+LY341495+rapidly+engage+dopaminergic+mood+circuits&doi=10.1124%2Fjpet.116.233627"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The rapidly acting antidepressant ketamine and the mGlu2/3 receptor antagonist LY341495 rapidly engage dopaminergic mood circuits</span></div><div class="casAuthors">Witkin, J. M.; Monn, J. A.; Schoepp, D. D.; Li, X.; Overshiner, C.; Mitchell, S. N.; Carter, G.; Johnson, B.; Rasmussen, K.; Rorick-Kehn, L. M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">358</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">71-82</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Ketamine is a rapidly acting antidepressant in patients with treatment-resistant depression (TRD).  Although the mechanisms underlying these effects are not fully established, inquiry to date has focused on the triggering of synaptogenesis transduction pathways via glutamatergic mechanisms.  Preclin. data suggest that blockade of metabotropic glutamate (mGlu2/3) receptors shares many overlapping features and mechanisms with ketamine and may also provide rapid efficacy for TRD patients.  Central dopamine circuitry is recognized as an end target for mood regulation and hedonic valuation and yet has been largely neglected in mechanistic studies of antidepressant-relevant effects of ketamine.  Herein, we evaluated the changes in dopaminergic neurotransmission after acute administration of ketamine and the mGlu2/3 receptor antagonist LY341495 [(2S)-2-amino-2-[(1S,2S)- 2-carboxycycloprop-1-yl]-3-(xanth-9-yl) propanoic acid ] in preclin. models using electrophysiol., neurochem., and behavioral endpoints.  When given acutely, both ketamine and LY341495, but not the selective serotonin reuptake inhibitor (SSRI) citalopram, increased the no. of spontaneously active dopamine neurons in the ventral tegmental area (VTA), increased extracellular levels of dopamine in the nucleus accumbens and prefrontal cortex, and enhanced the locomotor stimulatory effects of the dopamine D2/3 receptor agonist quinpirole.  Further, both ketamine and LY341495 reduced immobility time in the tail-suspension assay in CD1 mice, which are relatively resistant to SSRI antidepressants.  Both the VTA neuronal activation and the antidepressant phenotype induced by ketamine and LY341495 were attenuated by the a-amino-3-hydroxy-5- methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist 1,2,3,4-tetrahydro-6-nitro-2,3-dioxo- (9CI)-benzo[f]quinoxaline- 7-sulfonamide, indicating AMPA-dependent effects.  These findings provide another overlapping mechanism of action of ketamine and mGlu2/3 receptor antagonism that differentiates them from conventional antidepressants and thus support the potential rapidly acting antidepressant actions of mGlu2/3 receptor antagonism in patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonDnZmZOY1HLVg90H21EOLACvtfcHk0lhx1dLflvdPaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFyjs73E&md5=dffc0601e4cc14d711fa6291f78bf3c0</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1124%2Fjpet.116.233627&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.116.233627%26sid%3Dliteratum%253Aachs%26aulast%3DWitkin%26aufirst%3DJ.%2BM.%26aulast%3DMonn%26aufirst%3DJ.%2BA.%26aulast%3DSchoepp%26aufirst%3DD.%2BD.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DOvershiner%26aufirst%3DC.%26aulast%3DMitchell%26aufirst%3DS.%2BN.%26aulast%3DCarter%26aufirst%3DG.%26aulast%3DJohnson%26aufirst%3DB.%26aulast%3DRasmussen%26aufirst%3DK.%26aulast%3DRorick-Kehn%26aufirst%3DL.%2BM.%26atitle%3DThe%2520rapidly%2520acting%2520antidepressant%2520ketamine%2520and%2520the%2520mGlu2%252F3%2520receptor%2520antagonist%2520LY341495%2520rapidly%2520engage%2520dopaminergic%2520mood%2520circuits%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2016%26volume%3D358%26spage%3D71%26epage%3D82%26doi%3D10.1124%2Fjpet.116.233627" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Willner, P.</span></span> <span> </span><span class="NLM_article-title">The chronic mild stress (CMS) model of depression: history, evaluation and usage</span>. <i>Neurobiology of Stress</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">78</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1016/j.ynstr.2016.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.ynstr.2016.08.002" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2017&pages=78-93&author=P.+Willner&title=The+chronic+mild+stress+%28CMS%29+model+of+depression%3A+history%2C+evaluation+and+usage&doi=10.1016%2Fj.ynstr.2016.08.002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.ynstr.2016.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ynstr.2016.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DWillner%26aufirst%3DP.%26atitle%3DThe%2520chronic%2520mild%2520stress%2520%2528CMS%2529%2520model%2520of%2520depression%253A%2520history%252C%2520evaluation%2520and%2520usage%26jtitle%3DNeurobiology%2520of%2520Stress%26date%3D2017%26volume%3D6%26spage%3D78%26epage%3D93%26doi%3D10.1016%2Fj.ynstr.2016.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Papp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruca, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lason-Tyburkiewicz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adham, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiss, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gyertyan, I.</span></span> <span> </span><span class="NLM_article-title">Attenuation of anhedonia by cariprazine in the chronic mild stress model of depression</span>. <i>Behav. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">567</span>– <span class="NLM_lpage">574</span>, <span class="refDoi"> DOI: 10.1097/FBP.0000000000000070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1097%2FFBP.0000000000000070" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=567-574&author=M.+Pappauthor=P.+Grucaauthor=M.+Lason-Tyburkiewiczauthor=N.+Adhamauthor=B.+Kissauthor=I.+Gyertyan&title=Attenuation+of+anhedonia+by+cariprazine+in+the+chronic+mild+stress+model+of+depression&doi=10.1097%2FFBP.0000000000000070"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1097%2FFBP.0000000000000070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FFBP.0000000000000070%26sid%3Dliteratum%253Aachs%26aulast%3DPapp%26aufirst%3DM.%26aulast%3DGruca%26aufirst%3DP.%26aulast%3DLason-Tyburkiewicz%26aufirst%3DM.%26aulast%3DAdham%26aufirst%3DN.%26aulast%3DKiss%26aufirst%3DB.%26aulast%3DGyertyan%26aufirst%3DI.%26atitle%3DAttenuation%2520of%2520anhedonia%2520by%2520cariprazine%2520in%2520the%2520chronic%2520mild%2520stress%2520model%2520of%2520depression%26jtitle%3DBehav.%2520Pharmacol.%26date%3D2014%26volume%3D25%26spage%3D567%26epage%3D574%26doi%3D10.1097%2FFBP.0000000000000070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roth-Deri, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lax, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaumenhaft, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dikshtein, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yadid, G.</span></span> <span> </span><span class="NLM_article-title">Antidepressant treatment facilitates dopamine release and drug seeking behavior in a genetic animal model of depression</span>. <i>Eur. J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">485</span>– <span class="NLM_lpage">492</span>, <span class="refDoi"> DOI: 10.1111/j.1460-9568.2009.06840.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1111%2Fj.1460-9568.2009.06840.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=19614746" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A280%3ADC%252BD1MrlvFyhsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=485-492&author=I.+Roth-Deriauthor=A.+Friedmanauthor=L.+Abrahamauthor=E.+Laxauthor=Y.+Flaumenhaftauthor=Y.+Dikshteinauthor=G.+Yadid&title=Antidepressant+treatment+facilitates+dopamine+release+and+drug+seeking+behavior+in+a+genetic+animal+model+of+depression&doi=10.1111%2Fj.1460-9568.2009.06840.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Antidepressant treatment facilitates dopamine release and drug seeking behavior in a genetic animal model of depression</span></div><div class="casAuthors">Roth-Deri Ilana; Friedman Alexander; Abraham Lital; Lax Elad; Flaumenhaft Yakov; Dikshtein Yahav; Yadid Gal</div><div class="citationInfo"><span class="NLM_cas:title">The European journal of neuroscience</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">485-92</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Anhedonia and lack of motivation are core symptoms of depression.  In contrast, hyper-motivation and euphoria characterize intoxicated states.  In order to explore the relationship between these two behavioral states we examined cocaine self-administration tasks in an animal model of depression [Flinders Sensitive Line (FSL) rats].  We found that FSL rats exhibit sub-sensitivity in their cocaine-seeking behavior, which was normalized following a chronic treatment with the antidepressant desipramine.  However, when the cocaine dosage was increased, FSL rats demonstrated a similar cocaine-seeking behavior to that of controls.  In light of dopamine's central role in modulating cocaine reinforcement, we examined dopaminergic neurotransmission in the nucleus accumbens, a brain region implicated in the rewarding and hedonic effects of substances of misuse.  FSL rats exhibited low but dose-dependent increases in extracellular levels of dopamine in the nucleus accumbens after acute intravenous cocaine injection.  Furthermore, by using the dopamine transporter blocker GBR-12909 we were able to demonstrate that the low extracellular dopamine levels, observed in FSL rats, were a consequence of low dopamine release in the nucleus accumbens, as opposed to the possibility of increased uptake.  Treatment of FSL rats with the antidepressant desipramine raised cocaine- and GBR-12909-induced dopamine release to the level of controls.  This treatment also resulted in increased cocaine-seeking behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQgn1gwo4Mv7ENoizSOkG_FfW6udTcc2eYdAd783DCT9Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MrlvFyhsg%253D%253D&md5=e0138cd393edff20d6a34bd0d37e4cb6</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1111%2Fj.1460-9568.2009.06840.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1460-9568.2009.06840.x%26sid%3Dliteratum%253Aachs%26aulast%3DRoth-Deri%26aufirst%3DI.%26aulast%3DFriedman%26aufirst%3DA.%26aulast%3DAbraham%26aufirst%3DL.%26aulast%3DLax%26aufirst%3DE.%26aulast%3DFlaumenhaft%26aufirst%3DY.%26aulast%3DDikshtein%26aufirst%3DY.%26aulast%3DYadid%26aufirst%3DG.%26atitle%3DAntidepressant%2520treatment%2520facilitates%2520dopamine%2520release%2520and%2520drug%2520seeking%2520behavior%2520in%2520a%2520genetic%2520animal%2520model%2520of%2520depression%26jtitle%3DEur.%2520J.%2520Neurosci.%26date%3D2009%26volume%3D30%26spage%3D485%26epage%3D492%26doi%3D10.1111%2Fj.1460-9568.2009.06840.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salamone, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yohn, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Cruz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San Miguel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correa, M.</span></span> <span> </span><span class="NLM_article-title">Activational and effort-related aspects of motivation: neural mechanisms and implications for psychopathology</span>. <i>Brain</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>139</i></span>,  <span class="NLM_fpage">1325</span>– <span class="NLM_lpage">1347</span>, <span class="refDoi"> DOI: 10.1093/brain/aww050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1093%2Fbrain%2Faww050" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2016&pages=1325-1347&author=J.+D.+Salamoneauthor=S.+E.+Yohnauthor=L.+Lopez-Cruzauthor=N.+San+Miguelauthor=M.+Correa&title=Activational+and+effort-related+aspects+of+motivation%3A+neural+mechanisms+and+implications+for+psychopathology&doi=10.1093%2Fbrain%2Faww050"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1093%2Fbrain%2Faww050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbrain%252Faww050%26sid%3Dliteratum%253Aachs%26aulast%3DSalamone%26aufirst%3DJ.%2BD.%26aulast%3DYohn%26aufirst%3DS.%2BE.%26aulast%3DLopez-Cruz%26aufirst%3DL.%26aulast%3DSan%2BMiguel%26aufirst%3DN.%26aulast%3DCorrea%26aufirst%3DM.%26atitle%3DActivational%2520and%2520effort-related%2520aspects%2520of%2520motivation%253A%2520neural%2520mechanisms%2520and%2520implications%2520for%2520psychopathology%26jtitle%3DBrain%26date%3D2016%26volume%3D139%26spage%3D1325%26epage%3D1347%26doi%3D10.1093%2Fbrain%2Faww050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yohn, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gogoj, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haque, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Cruz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haley, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huxley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baskin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salamone, J. D.</span></span> <span> </span><span class="NLM_article-title">Evaluation of the effort-related motivational effects of the novel dopamine uptake inhibitor PRX-14040</span>. <i>Pharmacol., Biochem. Behav.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>148</i></span>,  <span class="NLM_fpage">84</span>– <span class="NLM_lpage">91</span>, <span class="refDoi"> DOI: 10.1016/j.pbb.2016.06.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.pbb.2016.06.004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2016&pages=84-91&author=S.+E.+Yohnauthor=A.+Gogojauthor=A.+Haqueauthor=L.+Lopez-Cruzauthor=A.+Haleyauthor=P.+Huxleyauthor=P.+Baskinauthor=M.+Correaauthor=J.+D.+Salamone&title=Evaluation+of+the+effort-related+motivational+effects+of+the+novel+dopamine+uptake+inhibitor+PRX-14040&doi=10.1016%2Fj.pbb.2016.06.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.pbb.2016.06.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pbb.2016.06.004%26sid%3Dliteratum%253Aachs%26aulast%3DYohn%26aufirst%3DS.%2BE.%26aulast%3DGogoj%26aufirst%3DA.%26aulast%3DHaque%26aufirst%3DA.%26aulast%3DLopez-Cruz%26aufirst%3DL.%26aulast%3DHaley%26aufirst%3DA.%26aulast%3DHuxley%26aufirst%3DP.%26aulast%3DBaskin%26aufirst%3DP.%26aulast%3DCorrea%26aufirst%3DM.%26aulast%3DSalamone%26aufirst%3DJ.%2BD.%26atitle%3DEvaluation%2520of%2520the%2520effort-related%2520motivational%2520effects%2520of%2520the%2520novel%2520dopamine%2520uptake%2520inhibitor%2520PRX-14040%26jtitle%3DPharmacol.%252C%2520Biochem.%2520Behav.%26date%3D2016%26volume%3D148%26spage%3D84%26epage%3D91%26doi%3D10.1016%2Fj.pbb.2016.06.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Randall, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Podurgiel, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yohn, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowland, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Cruz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salamone, J. D.</span></span> <span> </span><span class="NLM_article-title">Bupropion increases selection of high effort activity in rats tested on a progressive ratio/chow feeding choice procedure: implications for treatment of effort-related motivational symptoms</span>. <i>Int. J. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">pyu017</span>, <span class="refDoi"> DOI: 10.1093/ijnp/pyu017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1093%2Fijnp%2Fpyu017" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2015&pages=pyu017&author=P.+A.+Randallauthor=C.+A.+Leeauthor=S.+J.+Podurgielauthor=E.+Hartauthor=S.+E.+Yohnauthor=M.+Jonesauthor=M.+Rowlandauthor=L.+Lopez-Cruzauthor=M.+Correaauthor=J.+D.+Salamone&title=Bupropion+increases+selection+of+high+effort+activity+in+rats+tested+on+a+progressive+ratio%2Fchow+feeding+choice+procedure%3A+implications+for+treatment+of+effort-related+motivational+symptoms&doi=10.1093%2Fijnp%2Fpyu017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1093%2Fijnp%2Fpyu017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fijnp%252Fpyu017%26sid%3Dliteratum%253Aachs%26aulast%3DRandall%26aufirst%3DP.%2BA.%26aulast%3DLee%26aufirst%3DC.%2BA.%26aulast%3DPodurgiel%26aufirst%3DS.%2BJ.%26aulast%3DHart%26aufirst%3DE.%26aulast%3DYohn%26aufirst%3DS.%2BE.%26aulast%3DJones%26aufirst%3DM.%26aulast%3DRowland%26aufirst%3DM.%26aulast%3DLopez-Cruz%26aufirst%3DL.%26aulast%3DCorrea%26aufirst%3DM.%26aulast%3DSalamone%26aufirst%3DJ.%2BD.%26atitle%3DBupropion%2520increases%2520selection%2520of%2520high%2520effort%2520activity%2520in%2520rats%2520tested%2520on%2520a%2520progressive%2520ratio%252Fchow%2520feeding%2520choice%2520procedure%253A%2520implications%2520for%2520treatment%2520of%2520effort-related%2520motivational%2520symptoms%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2015%26volume%3D18%26spage%3Dpyu017%26doi%3D10.1093%2Fijnp%2Fpyu017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Owesson-White, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheer, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beyene, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carelli, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wightman, R. M.</span></span> <span> </span><span class="NLM_article-title">Dynamic changes in accumbens dopamine correlate with learning during intracranial self-stimulation</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">11957</span>– <span class="NLM_lpage">11962</span>, <span class="refDoi"> DOI: 10.1073/pnas.0803896105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1073%2Fpnas.0803896105" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=11957-11962&author=C.+A.+Owesson-Whiteauthor=J.+F.+Cheerauthor=M.+Beyeneauthor=R.+M.+Carelliauthor=R.+M.+Wightman&title=Dynamic+changes+in+accumbens+dopamine+correlate+with+learning+during+intracranial+self-stimulation&doi=10.1073%2Fpnas.0803896105"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0803896105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0803896105%26sid%3Dliteratum%253Aachs%26aulast%3DOwesson-White%26aufirst%3DC.%2BA.%26aulast%3DCheer%26aufirst%3DJ.%2BF.%26aulast%3DBeyene%26aufirst%3DM.%26aulast%3DCarelli%26aufirst%3DR.%2BM.%26aulast%3DWightman%26aufirst%3DR.%2BM.%26atitle%3DDynamic%2520changes%2520in%2520accumbens%2520dopamine%2520correlate%2520with%2520learning%2520during%2520intracranial%2520self-stimulation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D11957%26epage%3D11962%26doi%3D10.1073%2Fpnas.0803896105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leitl, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banks, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blough, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negus, S. S.</span></span> <span> </span><span class="NLM_article-title">Effects of the triple monoamine uptake inhibitor amitifadine on pain-related depression of behavior and mesolimbic dopamine release in rats</span>. <i>Pain</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>156</i></span>,  <span class="NLM_fpage">175</span>– <span class="NLM_lpage">184</span>, <span class="refDoi"> DOI: 10.1016/j.pain.0000000000000018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.pain.0000000000000018" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2015&pages=175-184&author=L.+L.+Millerauthor=M.+D.+Leitlauthor=M.+L.+Banksauthor=B.+E.+Bloughauthor=S.+S.+Negus&title=Effects+of+the+triple+monoamine+uptake+inhibitor+amitifadine+on+pain-related+depression+of+behavior+and+mesolimbic+dopamine+release+in+rats&doi=10.1016%2Fj.pain.0000000000000018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.pain.0000000000000018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pain.0000000000000018%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DL.%2BL.%26aulast%3DLeitl%26aufirst%3DM.%2BD.%26aulast%3DBanks%26aufirst%3DM.%2BL.%26aulast%3DBlough%26aufirst%3DB.%2BE.%26aulast%3DNegus%26aufirst%3DS.%2BS.%26atitle%3DEffects%2520of%2520the%2520triple%2520monoamine%2520uptake%2520inhibitor%2520amitifadine%2520on%2520pain-related%2520depression%2520of%2520behavior%2520and%2520mesolimbic%2520dopamine%2520release%2520in%2520rats%26jtitle%3DPain%26date%3D2015%26volume%3D156%26spage%3D175%26epage%3D184%26doi%3D10.1016%2Fj.pain.0000000000000018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basso, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallagher, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bratcher, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brioni, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreland, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drescher, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rueter, L. E.</span></span> <span> </span><span class="NLM_article-title">Antidepressant-like effect of D(2/3) receptor-, but not D(4) receptor-activation in the rat forced swim test</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">1257</span>– <span class="NLM_lpage">1268</span>, <span class="refDoi"> DOI: 10.1038/sj.npp.1300677</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1038%2Fsj.npp.1300677" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2005&pages=1257-1268&author=A.+M.+Bassoauthor=K.+B.+Gallagherauthor=N.+A.+Bratcherauthor=J.+D.+Brioniauthor=R.+B.+Morelandauthor=G.+C.+Hsiehauthor=K.+Drescherauthor=G.+B.+Foxauthor=M.+W.+Deckerauthor=L.+E.+Rueter&title=Antidepressant-like+effect+of+D%282%2F3%29+receptor-%2C+but+not+D%284%29+receptor-activation+in+the+rat+forced+swim+test&doi=10.1038%2Fsj.npp.1300677"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fsj.npp.1300677&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.npp.1300677%26sid%3Dliteratum%253Aachs%26aulast%3DBasso%26aufirst%3DA.%2BM.%26aulast%3DGallagher%26aufirst%3DK.%2BB.%26aulast%3DBratcher%26aufirst%3DN.%2BA.%26aulast%3DBrioni%26aufirst%3DJ.%2BD.%26aulast%3DMoreland%26aufirst%3DR.%2BB.%26aulast%3DHsieh%26aufirst%3DG.%2BC.%26aulast%3DDrescher%26aufirst%3DK.%26aulast%3DFox%26aufirst%3DG.%2BB.%26aulast%3DDecker%26aufirst%3DM.%2BW.%26aulast%3DRueter%26aufirst%3DL.%2BE.%26atitle%3DAntidepressant-like%2520effect%2520of%2520D%25282%252F3%2529%2520receptor-%252C%2520but%2520not%2520D%25284%2529%2520receptor-activation%2520in%2520the%2520rat%2520forced%2520swim%2520test%26jtitle%3DNeuropsychopharmacology%26date%3D2005%26volume%3D30%26spage%3D1257%26epage%3D1268%26doi%3D10.1038%2Fsj.npp.1300677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prica, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hascoet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourin, M.</span></span> <span> </span><span class="NLM_article-title">Is co-administration of bupropion with SSRIs and SNRIs in forced swimming test in mice, predictive of efficacy in resistant depression?</span>. <i>Behav. Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>194</i></span>,  <span class="NLM_fpage">92</span>– <span class="NLM_lpage">99</span>, <span class="refDoi"> DOI: 10.1016/j.bbr.2008.06.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.bbr.2008.06.028" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=194&publication_year=2008&pages=92-99&author=C.+Pricaauthor=M.+Hascoetauthor=M.+Bourin&title=Is+co-administration+of+bupropion+with+SSRIs+and+SNRIs+in+forced+swimming+test+in+mice%2C+predictive+of+efficacy+in+resistant+depression%3F&doi=10.1016%2Fj.bbr.2008.06.028"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.bbr.2008.06.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbr.2008.06.028%26sid%3Dliteratum%253Aachs%26aulast%3DPrica%26aufirst%3DC.%26aulast%3DHascoet%26aufirst%3DM.%26aulast%3DBourin%26aufirst%3DM.%26atitle%3DIs%2520co-administration%2520of%2520bupropion%2520with%2520SSRIs%2520and%2520SNRIs%2520in%2520forced%2520swimming%2520test%2520in%2520mice%252C%2520predictive%2520of%2520efficacy%2520in%2520resistant%2520depression%253F%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D2008%26volume%3D194%26spage%3D92%26epage%3D99%26doi%3D10.1016%2Fj.bbr.2008.06.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kunugi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hori, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, S.</span></span> <span> </span><span class="NLM_article-title">Biochemical markers subtyping major depressive disorder</span>. <i>Psychiatry Clin. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">597</span>– <span class="NLM_lpage">608</span>, <span class="refDoi"> DOI: 10.1111/pcn.12299</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1111%2Fpcn.12299" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=25825158" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A280%3ADC%252BC2MnptlyjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2015&pages=597-608&author=H.+Kunugiauthor=H.+Horiauthor=S.+Ogawa&title=Biochemical+markers+subtyping+major+depressive+disorder&doi=10.1111%2Fpcn.12299"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Biochemical markers subtyping major depressive disorder</span></div><div class="casAuthors">Kunugi Hiroshi; Hori Hiroaki; Ogawa Shintaro</div><div class="citationInfo"><span class="NLM_cas:title">Psychiatry and clinical neurosciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">597-608</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The pathophysiology of major depressive disorder (MDD) remains elusive, and there is no established biochemical marker used in the daily clinical setting.  This situation may result in part from the heterogeneity of MDD, which might include heterogeneous subgroups with different biological mechanisms.  In this review, we discuss three promising biological systems/markers to potentially subtype MDD: the dopamine system, the hypothalamic-pituitary-adrenal axis, and chronic inflammatory markers.  Several lines of evidence suggest that a facet of MDD is a dopamine agonist-responsive subtype.  Focusing on the hypothalamic-pituitary-adrenal axis, depressive spectrum disorders show hypercortisolism to hypocortisolism, which could be detected by hormonal challenge tests, such as the dexamethasone/corticotrophin-releasing hormone test.  Finally, accumulating evidence suggests that at least some MDD patients show characteristics similar to those of chronic inflammatory diseases, including neuroinflammatory markers and reduced tryptophan due to the increased activation of the tryptophan-kynurenine pathway.  Future studies should examine the inter-relations between these systems/markers to subtype and integrate the pathophysiology of MDD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ6poPxhApJJ_6BottYdIAWfW6udTcc2eYoTZYHvWcYqbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MnptlyjsQ%253D%253D&md5=8dc0f08e0fca8f51c5d4b0588baeda32</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1111%2Fpcn.12299&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fpcn.12299%26sid%3Dliteratum%253Aachs%26aulast%3DKunugi%26aufirst%3DH.%26aulast%3DHori%26aufirst%3DH.%26aulast%3DOgawa%26aufirst%3DS.%26atitle%3DBiochemical%2520markers%2520subtyping%2520major%2520depressive%2520disorder%26jtitle%3DPsychiatry%2520Clin.%2520Neurosci.%26date%3D2015%26volume%3D69%26spage%3D597%26epage%3D608%26doi%3D10.1111%2Fpcn.12299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pizzagalli, D. A.</span></span> <span> </span><span class="NLM_article-title">Depression, stress, and anhedonia: toward a synthesis and integrated model</span>. <i>Annu. Rev. Clin. Psychol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">393</span>– <span class="NLM_lpage">423</span>, <span class="refDoi"> DOI: 10.1146/annurev-clinpsy-050212-185606</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1146%2Fannurev-clinpsy-050212-185606" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=24471371" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A280%3ADC%252BC2czpslCnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=393-423&author=D.+A.+Pizzagalli&title=Depression%2C+stress%2C+and+anhedonia%3A+toward+a+synthesis+and+integrated+model&doi=10.1146%2Fannurev-clinpsy-050212-185606"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Depression, stress, and anhedonia: toward a synthesis and integrated model</span></div><div class="casAuthors">Pizzagalli Diego A</div><div class="citationInfo"><span class="NLM_cas:title">Annual review of clinical psychology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">393-423</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Depression is a significant public health problem, but its etiology and pathophysiology remain poorly understood.  Such incomplete understanding likely arises from the fact that depression encompasses a heterogeneous set of disorders.  To overcome these limitations, renewed interest in intermediate phenotypes (endophenotypes) has resurfaced, and anhedonia has emerged as one of the most promising endophenotypes of depression.  Here, a heuristic model is presented postulating that anhedonia arises from dysfunctional interactions between stress and brain reward systems.  To this end, we review and integrate three bodies of independent literature investigating the role of (a) anhedonia, (b) dopamine, and (c) stress in depression.  In a fourth section, we summarize animal data indicating that stress negatively affects mesocorticolimbic dopaminergic pathways critically implicated in incentive motivation and reinforcement learning.  In the last section, we provide a synthesis of these four literatures, present initial evidence consistent with our model, and discuss directions for future research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTfst3_r_GWVvx2phytoz6_fW6udTcc2ea8GV7krJI6z7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2czpslCnsQ%253D%253D&md5=71de6f8fd41080e98492ae472e5d75e3</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1146%2Fannurev-clinpsy-050212-185606&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-clinpsy-050212-185606%26sid%3Dliteratum%253Aachs%26aulast%3DPizzagalli%26aufirst%3DD.%2BA.%26atitle%3DDepression%252C%2520stress%252C%2520and%2520anhedonia%253A%2520toward%2520a%2520synthesis%2520and%2520integrated%2520model%26jtitle%3DAnnu.%2520Rev.%2520Clin.%2520Psychol.%26date%3D2014%26volume%3D10%26spage%3D393%26epage%3D423%26doi%3D10.1146%2Fannurev-clinpsy-050212-185606" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whitton, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treadway, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizzagalli, D. A.</span></span> <span> </span><span class="NLM_article-title">Reward processing dysfunction in major depression, bipolar disorder and schizophrenia</span>. <i>Curr. Opin. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1097/YCO.0000000000000122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1097%2FYCO.0000000000000122" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=25415499" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A280%3ADC%252BC2M3pvF2htg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2015&pages=7-12&author=A.+E.+Whittonauthor=M.+T.+Treadwayauthor=D.+A.+Pizzagalli&title=Reward+processing+dysfunction+in+major+depression%2C+bipolar+disorder+and+schizophrenia&doi=10.1097%2FYCO.0000000000000122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Reward processing dysfunction in major depression, bipolar disorder and schizophrenia</span></div><div class="casAuthors">Whitton Alexis E; Treadway Michael T; Pizzagalli Diego A</div><div class="citationInfo"><span class="NLM_cas:title">Current opinion in psychiatry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-12</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE OF REVIEW:  This article reviews the recent literature on reward processing dysfunction in major depression (MDD), bipolar disorder and schizophrenia, with a focus on approach motivation, reward learning and reward-based decision-making.  RECENT FINDINGS:  Emerging evidence indicates the presence of reward processing abnormalities across all three disorders, supporting a transdiagnostic approach.  In particular, findings are consistent with a role of abnormal phasic striatal dopamine signaling, which is critical for reinforcement learning, efficient mobilization of effort to obtain reward and allocation of attention to reward-predictive cues.  Specifically, reward-related striatal signaling appears blunted in MDD and the negative symptoms of schizophrenia, elevated in bipolar (hypo)mania, and contextually misallocated in the positive symptoms of psychosis.  However, whether shared or distinct pathophysiological mechanisms contribute to abnormal striatal signaling across the three disorders remains unknown.  SUMMARY:  New evidence of reward processing abnormalities in MDD, bipolar disorder and schizophrenia has led to a greater understanding of the neural processes associated with symptomatology common across these conditions (e.g., anhedonia).  Dissecting various subcomponents of reward processing that map onto partially different neurobiological pathways and investigating their dysregulation in different psychiatric disorders holds promise for developing more targeted, and hopefully efficacious treatment and intervention strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSw-jGaujpTwjQLBVDQn4bCfW6udTcc2ea8GV7krJI6z7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M3pvF2htg%253D%253D&md5=415041a6c26eff7255daa06d33ae253e</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1097%2FYCO.0000000000000122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FYCO.0000000000000122%26sid%3Dliteratum%253Aachs%26aulast%3DWhitton%26aufirst%3DA.%2BE.%26aulast%3DTreadway%26aufirst%3DM.%2BT.%26aulast%3DPizzagalli%26aufirst%3DD.%2BA.%26atitle%3DReward%2520processing%2520dysfunction%2520in%2520major%2520depression%252C%2520bipolar%2520disorder%2520and%2520schizophrenia%26jtitle%3DCurr.%2520Opin.%2520Psychiatry%26date%3D2015%26volume%3D28%26spage%3D7%26epage%3D12%26doi%3D10.1097%2FYCO.0000000000000122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wardle, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treadway, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayo, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zald, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Wit, H.</span></span> <span> </span><span class="NLM_article-title">Amping up effort: effects of d-amphetamine on human effort-based decision-making</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">16597</span>– <span class="NLM_lpage">16602</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.4387-11.2011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1523%2FJNEUROSCI.4387-11.2011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=22090487" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFaksL%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2011&pages=16597-16602&author=M.+C.+Wardleauthor=M.+T.+Treadwayauthor=L.+M.+Mayoauthor=D.+H.+Zaldauthor=H.+de+Wit&title=Amping+up+effort%3A+effects+of+d-amphetamine+on+human+effort-based+decision-making&doi=10.1523%2FJNEUROSCI.4387-11.2011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Amping up effort: effects of d-amphetamine on human effort-based decision-making</span></div><div class="casAuthors">Wardle, Margaret C.; Treadway, Michael T.; Mayo, Leah M.; Zald, David H.; de Wit, Harriet</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">16597-16602</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Animal studies suggest the neurotransmitter dopamine (DA) plays an important role in decision-making.  In rats, DA depletion decreases tolerance for effort and probability costs, while drugs enhancing DA increase tolerance for these costs.  However, data regarding the effect of DA manipulations on effort and probability costs in humans remain scarce.  The current study examd. acute effects of d-amphetamine, an indirect DA agonist, on willingness of healthy human volunteers to exert effort for monetary rewards at varying levels of reward value and reward probability.  Based on preclin. research, we predicted amphetamine would increase exertion of effort, particularly when reward probability was low.  Over three sessions, 17 healthy normal adults received placebo, d-amphetamine 10 mg, and 20 mg under counterbalanced double-blind conditions and completed the Effort Expenditure for Rewards Task.  Consistent with predictions, amphetamine enhanced willingness to exert effort, particularly when reward probability was lower.  Amphetamine did not alter effects of reward magnitude on willingness to exert effort.  Amphetamine sped task performance, but its psychomotor effects were not strongly related to its effects on decision-making.  This is the first demonstration in humans that dopaminergic manipulations alter willingness to exert effort for rewards.  These findings help elucidate neurochem. substrates of choice, with implications for neuropsychiatric diseases characterized by dopaminergic dysfunction and motivational deficits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1-ydDs_QpD7Vg90H21EOLACvtfcHk0li0kheHdtDPhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFaksL%252FF&md5=7a965ddd1b4065ee5c1980b14add5ac3</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.4387-11.2011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.4387-11.2011%26sid%3Dliteratum%253Aachs%26aulast%3DWardle%26aufirst%3DM.%2BC.%26aulast%3DTreadway%26aufirst%3DM.%2BT.%26aulast%3DMayo%26aufirst%3DL.%2BM.%26aulast%3DZald%26aufirst%3DD.%2BH.%26aulast%3Dde%2BWit%26aufirst%3DH.%26atitle%3DAmping%2520up%2520effort%253A%2520effects%2520of%2520d-amphetamine%2520on%2520human%2520effort-based%2520decision-making%26jtitle%3DJ.%2520Neurosci.%26date%3D2011%26volume%3D31%26spage%3D16597%26epage%3D16602%26doi%3D10.1523%2FJNEUROSCI.4387-11.2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">D’Ostilio, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garraux, G.</span></span> <span> </span><span class="NLM_article-title">The network model of depression as a basis for new therapeutic strategies for treating major depressive disorder in Parkinson’s disease</span>. <i>Front. Hum. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">161</span>, <span class="refDoi"> DOI: 10.3389/fnhum.2016.00161</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.3389%2Ffnhum.2016.00161" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=27148016" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A280%3ADC%252BC28bms1enug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=161&author=K.+D%E2%80%99Ostilioauthor=G.+Garraux&title=The+network+model+of+depression+as+a+basis+for+new+therapeutic+strategies+for+treating+major+depressive+disorder+in+Parkinson%E2%80%99s+disease&doi=10.3389%2Ffnhum.2016.00161"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">The Network Model of Depression as a Basis for New Therapeutic Strategies for Treating Major Depressive Disorder in Parkinson's Disease</span></div><div class="casAuthors">D'Ostilio Kevin; Garraux Gaetan</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in human neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">161</span>
        ISSN:<span class="NLM_cas:issn">1662-5161</span>.
    </div><div class="casAbstract">The high prevalence of major depressive disorder in people with Parkinson's disease (PD), its negative impact on health-related quality of life and the low response rate to conventional pharmacological therapies call to seek innovative treatments.  Here, we review the new approaches for treating major depressive disorder in patients with PD within the framework of the network model of depression.  According to this model, major depressive disorder reflects maladaptive neuronal plasticity.  Non-invasive brain stimulation (NIBS) using high frequency repetitive transcranial magnetic stimulation (rTMS) over the prefrontal cortex has been proposed as a feasible and effective strategy with minimal risk.  The neurobiological basis of its therapeutic effect may involve neuroplastic modifications in limbic and cognitive networks.  However, the way this networks reorganize might be strongly influenced by the environment.  To address this issue, we propose a combined strategy that includes NIBS together with cognitive and behavioral interventions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSqEptU8YEMxsjl5L8hwNX0fW6udTcc2eZUc2fR2Ubbvbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28bms1enug%253D%253D&md5=46fffc6d6cefd0d23e9d571c40638099</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.3389%2Ffnhum.2016.00161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnhum.2016.00161%26sid%3Dliteratum%253Aachs%26aulast%3DD%25E2%2580%2599Ostilio%26aufirst%3DK.%26aulast%3DGarraux%26aufirst%3DG.%26atitle%3DThe%2520network%2520model%2520of%2520depression%2520as%2520a%2520basis%2520for%2520new%2520therapeutic%2520strategies%2520for%2520treating%2520major%2520depressive%2520disorder%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DFront.%2520Hum.%2520Neurosci.%26date%3D2016%26volume%3D10%26spage%3D161%26doi%3D10.3389%2Ffnhum.2016.00161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Treadway, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizzagalli, D. A.</span></span> <span> </span><span class="NLM_article-title">Imaging the pathophysiology of major depressive disorder - from localist models to circuit-based analysis</span>. <i>Biol. Mood Anxiety Disord.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">5</span>, <span class="refDoi"> DOI: 10.1186/2045-5380-4-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1186%2F2045-5380-4-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=24606595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlvVygsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=5&author=M.+T.+Treadwayauthor=D.+A.+Pizzagalli&title=Imaging+the+pathophysiology+of+major+depressive+disorder+-+from+localist+models+to+circuit-based+analysis&doi=10.1186%2F2045-5380-4-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Imaging the pathophysiology of major depressive disorder - from localist models to circuit-based analysis</span></div><div class="casAuthors">Treadway, Michael T.; Pizzagalli, Diego A.</div><div class="citationInfo"><span class="NLM_cas:title">Biology of Mood & Anxiety Disorders</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">5/1-5/13</span>CODEN:
                <span class="NLM_cas:coden">BMADB5</span>;
        ISSN:<span class="NLM_cas:issn">2045-5380</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">The neuroimaging literature of Major Depressive Disorder (MDD) has grown substantially over the last several decades, facilitating great advances in the identification of specific brain regions, neurotransmitter systems and networks assocd. with depressive illness.  Despite this progress, fundamental questions remain about the pathophysiol. and etiol. of MDD.  More importantly, this body of work has yet to directly influence clin. practice.  It has long been a goal for the fields of clin. psychol. and psychiatry to have a means of making objective diagnoses of mental disorders.  Frustratingly little movement has been achieved on this front, however, and the 'gold-std.' of diagnostic validity and reliability remains expert consensus.  In light of this challenge, the focus of the current review is to provide a crit. summary of key findings from different neuroimaging approaches in MDD research, including structural, functional and neurochem. imaging studies.  Following this summary, we discuss some of the current conceptual obstacles to better understanding the pathophysiol. of depression, and conclude with recommendations for future neuroimaging research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnLApEdHlBabVg90H21EOLACvtfcHk0li0kheHdtDPhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlvVygsQ%253D%253D&md5=1802212c72c628a7af80227ed1963b77</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1186%2F2045-5380-4-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F2045-5380-4-5%26sid%3Dliteratum%253Aachs%26aulast%3DTreadway%26aufirst%3DM.%2BT.%26aulast%3DPizzagalli%26aufirst%3DD.%2BA.%26atitle%3DImaging%2520the%2520pathophysiology%2520of%2520major%2520depressive%2520disorder%2520-%2520from%2520localist%2520models%2520to%2520circuit-based%2520analysis%26jtitle%3DBiol.%2520Mood%2520Anxiety%2520Disord.%26date%3D2014%26volume%3D4%26spage%3D5%26doi%3D10.1186%2F2045-5380-4-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sarchiapone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carli, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camardese, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuomo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Giuda, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calcagni, M.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Focacci, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Risio, S.</span></span> <span> </span><span class="NLM_article-title">Dopamine transporter binding in depressed patients with anhedonia</span>. <i>Psychiatry Res., Neuroimaging</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>147</i></span>,  <span class="NLM_fpage">243</span>– <span class="NLM_lpage">248</span>, <span class="refDoi"> DOI: 10.1016/j.pscychresns.2006.03.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.pscychresns.2006.03.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=16952448" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1SqsLfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=2006&pages=243-248&author=M.+Sarchiaponeauthor=V.+Carliauthor=G.+Camardeseauthor=C.+Cuomoauthor=D.+Di+Giudaauthor=M.-L.+Calcagniauthor=C.+Focacciauthor=S.+De+Risio&title=Dopamine+transporter+binding+in+depressed+patients+with+anhedonia&doi=10.1016%2Fj.pscychresns.2006.03.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine transporter binding in depressed patients with anhedonia</span></div><div class="casAuthors">Sarchiapone, Marco; Carli, Vladimir; Camardese, Giovanni; Cuomo, Chiara; Di Giuda, Daniela; Calcagni, Maria-Lucia; Focacci, C.; De Risio, Sergio</div><div class="citationInfo"><span class="NLM_cas:title">Psychiatry Research, Neuroimaging</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">147</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">243-248</span>CODEN:
                <span class="NLM_cas:coden">PSREEK</span>;
        ISSN:<span class="NLM_cas:issn">0925-4927</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Central dopaminergic dysfunction has been widely proposed as a common neurobiol. correlate of the psychopathol. expression of anhedonia.  The dopamine transporter (DAT) is a predominantly presynaptic receptor that may play a crit. role in the pathophysiol. of dopaminergic transmission.  The aim of our study was to evaluate DAT binding in a population of depressed patients with anhedonia.  Single photon emission computed tomog. (SPECT) with the radiotracer DATSCAN was used to evaluate DAT binding in 11 depressed patients with anhedonia and 9 healthy comparison subjects.  Compared with healthy subjects, patients showed significantly lower DAT binding.  No significant correlation was found between DAT binding ratios and scores on administered psychometric tests.  These findings suggest an alteration in DAT d. in depressed patients with anhedonia that may be a primary susceptibility factor or a secondary phenomenon to reduced dopamine concn. in the synaptic cleft.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_36OsjJn1U7Vg90H21EOLACvtfcHk0lgzvTHq9Q6fXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1SqsLfO&md5=83c1d2e360460bcabf6e2665230b80fb</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.pscychresns.2006.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pscychresns.2006.03.001%26sid%3Dliteratum%253Aachs%26aulast%3DSarchiapone%26aufirst%3DM.%26aulast%3DCarli%26aufirst%3DV.%26aulast%3DCamardese%26aufirst%3DG.%26aulast%3DCuomo%26aufirst%3DC.%26aulast%3DDi%2BGiuda%26aufirst%3DD.%26aulast%3DCalcagni%26aufirst%3DM.-L.%26aulast%3DFocacci%26aufirst%3DC.%26aulast%3DDe%2BRisio%26aufirst%3DS.%26atitle%3DDopamine%2520transporter%2520binding%2520in%2520depressed%2520patients%2520with%2520anhedonia%26jtitle%3DPsychiatry%2520Res.%252C%2520Neuroimaging%26date%3D2006%26volume%3D147%26spage%3D243%26epage%3D248%26doi%3D10.1016%2Fj.pscychresns.2006.03.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wooten, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beltzer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitaliano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alpert, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Normandin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Fakhri, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizzagalli, D.</span></span> <span> </span><span class="NLM_article-title">Reduced striatal dopamine transporter binding in major depressive disorder</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">527</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2015&pages=527&author=D.+Wootenauthor=F.+Goerauthor=M.+Beltzerauthor=G.+Vitalianoauthor=B.+Brennanauthor=D.+Crowleyauthor=N.+Alpertauthor=M.+Normandinauthor=G.+El+Fakhriauthor=D.+Pizzagalli&title=Reduced+striatal+dopamine+transporter+binding+in+major+depressive+disorder"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWooten%26aufirst%3DD.%26aulast%3DGoer%26aufirst%3DF.%26aulast%3DBeltzer%26aufirst%3DM.%26aulast%3DVitaliano%26aufirst%3DG.%26aulast%3DBrennan%26aufirst%3DB.%26aulast%3DCrowley%26aufirst%3DD.%26aulast%3DAlpert%26aufirst%3DN.%26aulast%3DNormandin%26aufirst%3DM.%26aulast%3DEl%2BFakhri%26aufirst%3DG.%26aulast%3DPizzagalli%26aufirst%3DD.%26atitle%3DReduced%2520striatal%2520dopamine%2520transporter%2520binding%2520in%2520major%2520depressive%2520disorder%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2015%26volume%3D56%26spage%3D527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, G.</span></span> <span> </span><span class="NLM_article-title">SPECT imaging of dopamine transporters with 99mTc-TRODAT-1 in major depression and Parkinson’s disease</span>. <i>J. Neuropsychiatry Clin. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">67</span>, <span class="refDoi"> DOI: 10.1176/appi.neuropsych.23.1.63</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1176%2Fappi.neuropsych.23.1.63" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=21304140" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A280%3ADC%252BC3M7nvVarug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2011&pages=63-67&author=H.+Wuauthor=C.+Louauthor=Z.+Huangauthor=G.+Shi&title=SPECT+imaging+of+dopamine+transporters+with+99mTc-TRODAT-1+in+major+depression+and+Parkinson%E2%80%99s+disease&doi=10.1176%2Fappi.neuropsych.23.1.63"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">SPECT imaging of dopamine transporters with (99m)Tc-TRODAT-1 in major depression and Parkinson's disease</span></div><div class="casAuthors">Wu Hao; Lou Cen; Huang Zhongke; Shi Guohua</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of neuropsychiatry and clinical neurosciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">63-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">To investigate dopamine transporter in major depressive disorder and Parkinson's disease, the authors obtained single photon emission computed tomography (SPECT) brain images from 13 patients with major depression, 17 Parkinson's disease patients, and 10 healthy volunteers by using 99mTc-TRODAT-1.  The authors found the 99mTc-TRODAT-1 radio signal in the striatum was reduced in the majority of patients with major depressive disorder, and this decrease was even more severe in patients with Parkinson's disease.  The results support the hypothesis of dopamine hypofunction in major depressive disorder and suggest that deficient dopamine transporter may be involved in the etiology of severe major depressive disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQdQKWN72VMwWx8TEN9K18QfW6udTcc2eYaDLVMxPhg7Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M7nvVarug%253D%253D&md5=d3fcba4923fd053f0f0f7931f389295d</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1176%2Fappi.neuropsych.23.1.63&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.neuropsych.23.1.63%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DH.%26aulast%3DLou%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DShi%26aufirst%3DG.%26atitle%3DSPECT%2520imaging%2520of%2520dopamine%2520transporters%2520with%252099mTc-TRODAT-1%2520in%2520major%2520depression%2520and%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Neuropsychiatry%2520Clin.%2520Neurosci.%26date%3D2011%26volume%3D23%26spage%3D63%26epage%3D67%26doi%3D10.1176%2Fappi.neuropsych.23.1.63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Felger, J. C.</span></span> <span> </span><span class="NLM_article-title">The role of dopamine in inflammation-associated depression: mechanisms and therapeutic implications</span>. <i>Curr. Top. Behav. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">199</span>– <span class="NLM_lpage">219</span>, <span class="refDoi"> DOI: 10.1007/7854_2016_13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1007%2F7854_2016_13" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2016&pages=199-219&author=J.+C.+Felger&title=The+role+of+dopamine+in+inflammation-associated+depression%3A+mechanisms+and+therapeutic+implications&doi=10.1007%2F7854_2016_13"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1007%2F7854_2016_13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F7854_2016_13%26sid%3Dliteratum%253Aachs%26aulast%3DFelger%26aufirst%3DJ.%2BC.%26atitle%3DThe%2520role%2520of%2520dopamine%2520in%2520inflammation-associated%2520depression%253A%2520mechanisms%2520and%2520therapeutic%2520implications%26jtitle%3DCurr.%2520Top.%2520Behav.%2520Neurosci.%26date%3D2016%26volume%3D31%26spage%3D199%26epage%3D219%26doi%3D10.1007%2F7854_2016_13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hasler, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luckenbaugh, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyers, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldeck, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geraci, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roiser, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knutson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charney, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drevets, W. C.</span></span> <span> </span><span class="NLM_article-title">Reward processing after catecholamine depletion in unmedicated, remitted subjects with major depressive disorder</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">201</span>– <span class="NLM_lpage">205</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2009.02.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.biopsych.2009.02.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=19393989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotF2gu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2009&pages=201-205&author=G.+Haslerauthor=D.+A.+Luckenbaughauthor=J.+Snowauthor=N.+Meyersauthor=T.+Waldeckauthor=M.+Geraciauthor=J.+Roiserauthor=B.+Knutsonauthor=D.+S.+Charneyauthor=W.+C.+Drevets&title=Reward+processing+after+catecholamine+depletion+in+unmedicated%2C+remitted+subjects+with+major+depressive+disorder&doi=10.1016%2Fj.biopsych.2009.02.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Reward Processing After Catecholamine Depletion in Unmedicated, Remitted Subjects with Major Depressive Disorder</span></div><div class="casAuthors">Hasler, Gregor; Luckenbaugh, David A.; Snow, Joseph; Meyers, Noah; Waldeck, Tracy; Geraci, Marilla; Roiser, Jonathan; Knutson, Brian; Charney, Dennis S.; Drevets, Wayne C.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">201-205</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">We investigated whether performance on a reward processing task differs between fully remitted patients with major depressive disorder (MDD) and healthy control subjects after catecholamine depletion.  Seventeen unmedicated subjects with remitted MDD (RMDD) and 13 healthy control subjects underwent catecholamine depletion with oral α-methyl-para-tyrosine (AMPT) in a randomized, placebo-controlled, double-blind crossover study.  The main outcome measure was the reaction time on the monetary incentive delay (MID) task.  A diagnosis × drug interaction was evident (p = .001), which was attributable to an increase in reaction time across all incentive levels after AMPT in RMDD subjects (p = .001) but no significant AMPT effect on reaction time in control subjects (p = .17).  There was no drug × diagnosis interaction on control tasks involving working memory or attention.  In the RMDD sample the AMPT-induced depressive symptoms correlated with AMPT-induced changes in reaction time at all incentive levels of the MID task (r values = .58-.82, p < .002).  Under catecholamine depletion the RMDD subjects were robustly differentiated from control subjects by development of performance deficits on a reward processing task.  These performance deficits correlated directly with the return of depressive symptoms after AMPT administration.  The sensitivity of central reward processing systems to redns. in brain catecholamine levels thus seems to represent a trait-like marker in MDD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8v0l2pO55kbVg90H21EOLACvtfcHk0lhGv0ih2kwMQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotF2gu7g%253D&md5=fdfb73b8fc22bdd78ebd7201bc7544bf</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2009.02.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2009.02.029%26sid%3Dliteratum%253Aachs%26aulast%3DHasler%26aufirst%3DG.%26aulast%3DLuckenbaugh%26aufirst%3DD.%2BA.%26aulast%3DSnow%26aufirst%3DJ.%26aulast%3DMeyers%26aufirst%3DN.%26aulast%3DWaldeck%26aufirst%3DT.%26aulast%3DGeraci%26aufirst%3DM.%26aulast%3DRoiser%26aufirst%3DJ.%26aulast%3DKnutson%26aufirst%3DB.%26aulast%3DCharney%26aufirst%3DD.%2BS.%26aulast%3DDrevets%26aufirst%3DW.%2BC.%26atitle%3DReward%2520processing%2520after%2520catecholamine%2520depletion%2520in%2520unmedicated%252C%2520remitted%2520subjects%2520with%2520major%2520depressive%2520disorder%26jtitle%3DBiol.%2520Psychiatry%26date%3D2009%26volume%3D66%26spage%3D201%26epage%3D205%26doi%3D10.1016%2Fj.biopsych.2009.02.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Homan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neumeister, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nugent, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charney, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drevets, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasler, G.</span></span> <span> </span><span class="NLM_article-title">Serotonin versus catecholamine deficiency: behavioral and neural effects of experimental depletion in remitted depression</span>. <i>Transl. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">e532</span>, <span class="refDoi"> DOI: 10.1038/tp.2015.25</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1038%2Ftp.2015.25" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=25781231" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvFWksLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=e532&author=P.+Homanauthor=A.+Neumeisterauthor=A.+C.+Nugentauthor=D.+S.+Charneyauthor=W.+C.+Drevetsauthor=G.+Hasler&title=Serotonin+versus+catecholamine+deficiency%3A+behavioral+and+neural+effects+of+experimental+depletion+in+remitted+depression&doi=10.1038%2Ftp.2015.25"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Serotonin versus catecholamine deficiency: behavioral and neural effects of experimental depletion in remitted depression</span></div><div class="casAuthors">Homan, P.; Neumeister, A.; Nugent, A. C.; Charney, D. S.; Drevets, W. C.; Hasler, G.</div><div class="citationInfo"><span class="NLM_cas:title">Translational Psychiatry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e532</span>CODEN:
                <span class="NLM_cas:coden">TPRSCF</span>;
        ISSN:<span class="NLM_cas:issn">2158-3188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Despite immense efforts into development of new antidepressant drugs, the increases of serotoninergic and catecholaminergic neurotransmission have remained the two major pharmacodynamic principles of current drug treatments for depression.  Consequently, psychopathol. or biol. markers that predict response to drugs that selectively increase serotonin and/or catecholamine neurotransmission hold the potential to optimize the prescriber's selection among currently available treatment options.  The aim of this study was to elucidate the differential symptomatol. and neurophysiol. in response to redns. in serotonergic vs. catecholaminergic neurotransmission in subjects at high risk of depression recurrence.  Using identical neuroimaging procedures with [18F] fluorodeoxyglucose positron emission tomog. after tryptophan depletion (TD) and catecholamine depletion (CD), subjects with remitted depression were compared with healthy controls in a double-blind, randomized, crossover design.  Although TD induced significantly more depressed mood, sadness and hopelessness than CD, CD induced more inactivity, concn. difficulties, lassitude and somatic anxiety than TD.  CD specifically increased glucose metab. in the bilateral ventral striatum and decreased glucose metab. in the bilateral orbitofrontal cortex, whereas TD specifically increased metab. in the right prefrontal cortex and the posterior cingulate cortex.  Although we found direct assocns. between changes in brain metab. and induced depressive symptoms following CD, the relationship between neural activity and symptoms was less clear after TD.  In conclusion, this study showed that serotonin and catecholamines have common and differential roles in the pathophysiol. of depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqonMopJoOLrVg90H21EOLACvtfcHk0lg_XevHfMtp4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvFWksLw%253D&md5=e62f3ee74522091e1750cb3a94f384b8</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Ftp.2015.25&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Ftp.2015.25%26sid%3Dliteratum%253Aachs%26aulast%3DHoman%26aufirst%3DP.%26aulast%3DNeumeister%26aufirst%3DA.%26aulast%3DNugent%26aufirst%3DA.%2BC.%26aulast%3DCharney%26aufirst%3DD.%2BS.%26aulast%3DDrevets%26aufirst%3DW.%2BC.%26aulast%3DHasler%26aufirst%3DG.%26atitle%3DSerotonin%2520versus%2520catecholamine%2520deficiency%253A%2520behavioral%2520and%2520neural%2520effects%2520of%2520experimental%2520depletion%2520in%2520remitted%2520depression%26jtitle%3DTransl.%2520Psychiatry%26date%3D2015%26volume%3D5%26spage%3De532%26doi%3D10.1038%2Ftp.2015.25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baumeister, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uzelac, S. M.</span></span> <span> </span><span class="NLM_article-title">The myth of reserpine-induced depression: role in the historical development of the monoamine hypothesis</span>. <i>J. Hist. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">220</span>, <span class="refDoi"> DOI: 10.1076/jhin.12.2.207.15535</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1076%2Fjhin.12.2.207.15535" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=12953623" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A280%3ADC%252BD3svhsVyhtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2003&pages=207-220&author=A.+A.+Baumeisterauthor=M.+F.+Hawkinsauthor=S.+M.+Uzelac&title=The+myth+of+reserpine-induced+depression%3A+role+in+the+historical+development+of+the+monoamine+hypothesis&doi=10.1076%2Fjhin.12.2.207.15535"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">The myth of reserpine-induced depression: role in the historical development of the monoamine hypothesis</span></div><div class="casAuthors">Baumeister Alan A; Hawkins Mike F; Uzelac Sarah M</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the history of the neurosciences</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">207-20</span>
        ISSN:<span class="NLM_cas:issn">0964-704X</span>.
    </div><div class="casAbstract">For five decades it has been generally accepted that reserpine, an antihypertensive and antipsychotic drug, causes depression.  The discovery that reserpine depletes brain monoamines was an important factor in the development of the monoamine hypothesis of depression, and it continues to be widely cited in support of this hypothesis.  The present paper argues that, contrary to prevailing belief, reserpine is not depressogenic.  The reason for perpetuation of this myth is reluctance to discard the monoamine hypothesis.  This hypothesis ushered the modern biochemical paradigm into psychiatry and is still of great importance.  It serves as a heuristic to guide research, it enhances psychiatry's prestige, and it helps to validate and promote drug therapy for depression and other mental disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSNRpUUIQyeTZQHPYJuLg8TfW6udTcc2eYQv8N_E6P0Zbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3svhsVyhtA%253D%253D&md5=c6270bc360ecf43ea8468732e282004c</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1076%2Fjhin.12.2.207.15535&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1076%252Fjhin.12.2.207.15535%26sid%3Dliteratum%253Aachs%26aulast%3DBaumeister%26aufirst%3DA.%2BA.%26aulast%3DHawkins%26aufirst%3DM.%2BF.%26aulast%3DUzelac%26aufirst%3DS.%2BM.%26atitle%3DThe%2520myth%2520of%2520reserpine-induced%2520depression%253A%2520role%2520in%2520the%2520historical%2520development%2520of%2520the%2520monoamine%2520hypothesis%26jtitle%3DJ.%2520Hist.%2520Neurosci.%26date%3D2003%26volume%3D12%26spage%3D207%26epage%3D220%26doi%3D10.1076%2Fjhin.12.2.207.15535" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zajecka, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zajecka, A. M.</span></span> <span> </span><span class="NLM_article-title">A clinical overview of monoamine oxidase inhibitors: pharmacological profile, efficacy, safety/tolerability, and strategies for successful outcomes in the management of major depressive disorders</span>. <i>Psychiatr. Ann.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">513</span>– <span class="NLM_lpage">523</span>, <span class="refDoi"> DOI: 10.3928/00485713-20141106-07</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.3928%2F00485713-20141106-07" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2014&pages=513-523&author=J.+M.+Zajeckaauthor=A.+M.+Zajecka&title=A+clinical+overview+of+monoamine+oxidase+inhibitors%3A+pharmacological+profile%2C+efficacy%2C+safety%2Ftolerability%2C+and+strategies+for+successful+outcomes+in+the+management+of+major+depressive+disorders&doi=10.3928%2F00485713-20141106-07"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.3928%2F00485713-20141106-07&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3928%252F00485713-20141106-07%26sid%3Dliteratum%253Aachs%26aulast%3DZajecka%26aufirst%3DJ.%2BM.%26aulast%3DZajecka%26aufirst%3DA.%2BM.%26atitle%3DA%2520clinical%2520overview%2520of%2520monoamine%2520oxidase%2520inhibitors%253A%2520pharmacological%2520profile%252C%2520efficacy%252C%2520safety%252Ftolerability%252C%2520and%2520strategies%2520for%2520successful%2520outcomes%2520in%2520the%2520management%2520of%2520major%2520depressive%2520disorders%26jtitle%3DPsychiatr.%2520Ann.%26date%3D2014%26volume%3D44%26spage%3D513%26epage%3D523%26doi%3D10.3928%2F00485713-20141106-07" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shulman, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrmann, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, S. E.</span></span> <span> </span><span class="NLM_article-title">Current place of monoamine oxidase inhibitors in the treatment of depression</span>. <i>CNS Drugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">789</span>– <span class="NLM_lpage">797</span>, <span class="refDoi"> DOI: 10.1007/s40263-013-0097-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1007%2Fs40263-013-0097-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=789-797&author=K.+I.+Shulmanauthor=N.+Herrmannauthor=S.+E.+Walker&title=Current+place+of+monoamine+oxidase+inhibitors+in+the+treatment+of+depression&doi=10.1007%2Fs40263-013-0097-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1007%2Fs40263-013-0097-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40263-013-0097-3%26sid%3Dliteratum%253Aachs%26aulast%3DShulman%26aufirst%3DK.%2BI.%26aulast%3DHerrmann%26aufirst%3DN.%26aulast%3DWalker%26aufirst%3DS.%2BE.%26atitle%3DCurrent%2520place%2520of%2520monoamine%2520oxidase%2520inhibitors%2520in%2520the%2520treatment%2520of%2520depression%26jtitle%3DCNS%2520Drugs%26date%3D2013%26volume%3D27%26spage%3D789%26epage%3D797%26doi%3D10.1007%2Fs40263-013-0097-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papakostas, G. I.</span></span> <span> </span><span class="NLM_article-title">Resolution of sleepiness and fatigue: a comparison of bupropion and selective serotonin reuptake inhibitors in subjects with major depressive disorder achieving remission at doses approved in the European Union</span>. <i>J. Psychopharmacol. (London, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">118</span>– <span class="NLM_lpage">124</span>, <span class="refDoi"> DOI: 10.1177/0269881113514878</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1177%2F0269881113514878" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=24352716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslWgsb7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2014&pages=118-124&author=J.+A.+Cooperauthor=V.+L.+Tuckerauthor=G.+I.+Papakostas&title=Resolution+of+sleepiness+and+fatigue%3A+a+comparison+of+bupropion+and+selective+serotonin+reuptake+inhibitors+in+subjects+with+major+depressive+disorder+achieving+remission+at+doses+approved+in+the+European+Union&doi=10.1177%2F0269881113514878"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Resolution of sleepiness and fatigue: A comparison of bupropion and selective serotonin reuptake inhibitors in subjects with major depressive disorder achieving remission at doses approved in the European Union</span></div><div class="casAuthors">Cooper, James A.; Tucker, Vivian L.; Papakostas, George I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Psychopharmacology (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">118-124, 7</span>CODEN:
                <span class="NLM_cas:coden">JOPSEQ</span>;
        ISSN:<span class="NLM_cas:issn">0269-8811</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">Unlike selective serotonin reuptake inhibitors (SSRIs), bupropion may be classified as a dual noradrenaline and dopamine reuptake inhibitor, a difference with potential implications for the treatment of residual sleepiness and fatigue in major depressive disorder (MDD).  Post-hoc anal. of subjects with remitted MDD was performed on data pooled from six double-blind, randomized trials comparing the European Union (EU)-approved dose of ≤300 mg/day bupropion with SSRIs (sertraline, paroxetine or escitalopram) for the resoln. of sleepiness and fatigue.  Hypersomnia score was defined as the sum of scores of the Hamilton Depression Rating Scale (HDRS) items 22, 23, and 24; fatigue score as HDRS item 13 score; and remission as HDRS-17=7.  Similar proportions of bupropion- and SSRI-treated subjects achieved remission at study endpoint (169/343, 49.3% vs 324/656, 49.4%; last observation carried forward (LOCF), p=0.45).  Fewer bupropion-treated remitters had residual symptoms of sleepiness (32/169, 18.9% vs 104/324, 32.1%; p<0.01) and fatigue (33/169, 19.5% vs 98/324, 30.2%; p<0.05).  Bupropion-treated remitters also showed greater improvement (mean change from baseline) in sleepiness (p<0.05) and fatigue scores (p<0.01) at endpoint: benefits were evident from week 2 for sleepiness (p<0.01) and week 4 for fatigue (p<0.01).  Bupropion treatment at the EU-approved dose of =300 mg/day may offer advantages over SSRIs in the resoln. of sleepiness and fatigue in remitted MDD patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-c4AoMjJjY7Vg90H21EOLACvtfcHk0lh_fSkyeDrjzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslWgsb7K&md5=4ce2989c35fcbce875d6cdb06361e1bc</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1177%2F0269881113514878&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0269881113514878%26sid%3Dliteratum%253Aachs%26aulast%3DCooper%26aufirst%3DJ.%2BA.%26aulast%3DTucker%26aufirst%3DV.%2BL.%26aulast%3DPapakostas%26aufirst%3DG.%2BI.%26atitle%3DResolution%2520of%2520sleepiness%2520and%2520fatigue%253A%2520a%2520comparison%2520of%2520bupropion%2520and%2520selective%2520serotonin%2520reuptake%2520inhibitors%2520in%2520subjects%2520with%2520major%2520depressive%2520disorder%2520achieving%2520remission%2520at%2520doses%2520approved%2520in%2520the%2520European%2520Union%26jtitle%3DJ.%2520Psychopharmacol.%2520%2528London%252C%2520U.%2520K.%2529%26date%3D2014%26volume%3D28%26spage%3D118%26epage%3D124%26doi%3D10.1177%2F0269881113514878" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hori, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunugi, H.</span></span> <span> </span><span class="NLM_article-title">Dopamine agonist-responsive depression</span>. <i>Psychogeriatrics</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">189</span>– <span class="NLM_lpage">195</span>, <span class="refDoi"> DOI: 10.1111/psyg.12014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1111%2Fpsyg.12014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=25913769" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A280%3ADC%252BC2MjovVamug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=189-195&author=H.+Horiauthor=H.+Kunugi&title=Dopamine+agonist-responsive+depression&doi=10.1111%2Fpsyg.12014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine agonist-responsive depression</span></div><div class="casAuthors">Hori Hiroaki; Kunugi Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">189-95</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Dopaminergic dysfunction is implicated in the pathophysiology of treatment-resistant depression.  In this review, we describe the putative role of dopamine in depression, summarize the evidence for the efficacy of dopamine receptor agonists in the treatment of treatment-resistant depression, and discuss the underlying mechanisms by which these medications work.  Both preclinical and clinical data suggest that adjunctive dopamine agonists could be a promising option for the treatment of such a condition, indicating that there is a dopamine agonist-responsive subgroup of depression.  Future clinical studies are warranted to clarify unresolved issues regarding dopamine agonists such as long-term efficacy, efficacy as a monotherapy, and efficacy for juvenile and senile depression.  Further basic research is also necessary to fully understand how dopamine acts in the brain of depressed patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTm5GGGQIiGainGiHuhFGv8fW6udTcc2ealcSjNWx3Vhrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MjovVamug%253D%253D&md5=50d3b7006dfcae668d4c9535ce7976fd</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1111%2Fpsyg.12014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fpsyg.12014%26sid%3Dliteratum%253Aachs%26aulast%3DHori%26aufirst%3DH.%26aulast%3DKunugi%26aufirst%3DH.%26atitle%3DDopamine%2520agonist-responsive%2520depression%26jtitle%3DPsychogeriatrics%26date%3D2013%26volume%3D13%26spage%3D189%26epage%3D195%26doi%3D10.1111%2Fpsyg.12014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pae, C.-U.</span></span> <span> </span><span class="NLM_article-title">Pramipexole augmentation in treatment-resistant major depressive disorder</span>. <i>Expert Rev. Neurother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">5</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1586/14737175.2014.864556</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1586%2F14737175.2014.864556" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=24308279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1Onsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=5-8&author=C.-U.+Pae&title=Pramipexole+augmentation+in+treatment-resistant+major+depressive+disorder&doi=10.1586%2F14737175.2014.864556"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Pramipexole augmentation in treatment-resistant major depressive disorder</span></div><div class="casAuthors">Pae, Chi-Un</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Neurotherapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5-8</span>CODEN:
                <span class="NLM_cas:coden">ERNXAR</span>;
        ISSN:<span class="NLM_cas:issn">1473-7175</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">To overcome limited efficacy in antidepressants, clinicians may choose augmentation, switching to a different antidepressant, or a combination of different antidepressant drugs based on the individual patient's clin. circumstances.  Among such options for difficult-to-treat major depressive disorder (MDD) patients, augmentation therapy with atypical antipsychotics, psychostimulants, dopamine agonists, serotonin 1A partial agonists, lithium, and thyroid hormones are commonly used in clin. practice.  In fact, augmentation therapy has some clin. merits and is more convenient than switching medications and combination approaches for treating MDD.  One such augmentation agent, pramipexole has been proposed, and has been implicated in the development and treatment of MDD.  Recently, randomized controlled trials with pramipexole augmentation have been conducted and have demonstrated that pramipexole is a safe and potentially efficacious augmentation strategy.  This article will discuss currently available clin. trial data and the potential role of pramipexole in MDD treatment, including clin. significance, limitations, and future research directions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0Ntp1RkQrx7Vg90H21EOLACvtfcHk0lh_fSkyeDrjzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1Onsro%253D&md5=0d62f9d9fd5fceb4a2e9507a1bb22d51</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1586%2F14737175.2014.864556&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737175.2014.864556%26sid%3Dliteratum%253Aachs%26aulast%3DPae%26aufirst%3DC.-U.%26atitle%3DPramipexole%2520augmentation%2520in%2520treatment-resistant%2520major%2520depressive%2520disorder%26jtitle%3DExpert%2520Rev.%2520Neurother.%26date%3D2014%26volume%3D14%26spage%3D5%26epage%3D8%26doi%3D10.1586%2F14737175.2014.864556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keitner, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravindran, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Giovane, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, P.</span></span> <span> </span><span class="NLM_article-title">Atypical antipsychotic augmentation for treatment-resistant depression: a systematic review and network meta-analysis</span>. <i>Int. J. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">pyv060</span>, <span class="refDoi"> DOI: 10.1093/ijnp/pyv060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1093%2Fijnp%2Fpyv060" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=26012350" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2015&pages=pyv060&author=X.+Zhouauthor=G.+I.+Keitnerauthor=B.+Qinauthor=A.+V.+Ravindranauthor=M.+Bauerauthor=C.+Del+Giovaneauthor=J.+Zhaoauthor=Y.+Liuauthor=Y.+Fangauthor=Y.+Zhangauthor=P.+Xie&title=Atypical+antipsychotic+augmentation+for+treatment-resistant+depression%3A+a+systematic+review+and+network+meta-analysis&doi=10.1093%2Fijnp%2Fpyv060"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1093%2Fijnp%2Fpyv060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fijnp%252Fpyv060%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DKeitner%26aufirst%3DG.%2BI.%26aulast%3DQin%26aufirst%3DB.%26aulast%3DRavindran%26aufirst%3DA.%2BV.%26aulast%3DBauer%26aufirst%3DM.%26aulast%3DDel%2BGiovane%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DFang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DXie%26aufirst%3DP.%26atitle%3DAtypical%2520antipsychotic%2520augmentation%2520for%2520treatment-resistant%2520depression%253A%2520a%2520systematic%2520review%2520and%2520network%2520meta-analysis%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2015%26volume%3D18%26spage%3Dpyv060%26doi%3D10.1093%2Fijnp%2Fpyv060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Bartolomeis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomasetti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iasevoli, F.</span></span> <span> </span><span class="NLM_article-title">Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism</span>. <i>CNS Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">773</span>– <span class="NLM_lpage">799</span>, <span class="refDoi"> DOI: 10.1007/s40263-015-0278-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1007%2Fs40263-015-0278-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2015&pages=773-799&author=A.+de%0ABartolomeisauthor=C.+Tomasettiauthor=F.+Iasevoli&title=Update+on+the+Mechanism+of+Action+of+Aripiprazole%3A+Translational+Insights+into+Antipsychotic+Strategies+Beyond+Dopamine+Receptor+Antagonism&doi=10.1007%2Fs40263-015-0278-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1007%2Fs40263-015-0278-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40263-015-0278-3%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BBartolomeis%26aufirst%3DA.%26aulast%3DTomasetti%26aufirst%3DC.%26aulast%3DIasevoli%26aufirst%3DF.%26atitle%3DUpdate%2520on%2520the%2520Mechanism%2520of%2520Action%2520of%2520Aripiprazole%253A%2520Translational%2520Insights%2520into%2520Antipsychotic%2520Strategies%2520Beyond%2520Dopamine%2520Receptor%2520Antagonism%26jtitle%3DCNS%2520Drugs%26date%3D2015%26volume%3D29%26spage%3D773%26epage%3D799%26doi%3D10.1007%2Fs40263-015-0278-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Mansari, M.</span></span> <span> </span><span class="NLM_article-title">Serotonin and beyond: therapeutics for major depression</span>. <i>Philos. Trans. R. Soc., B</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>368</i></span>,  <span class="NLM_fpage">20120536</span>, <span class="refDoi"> DOI: 10.1098/rstb.2012.0536</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1098%2Frstb.2012.0536" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=23440470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltVaqsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2013&pages=20120536&author=P.+Blierauthor=M.+El+Mansari&title=Serotonin+and+beyond%3A+therapeutics+for+major+depression&doi=10.1098%2Frstb.2012.0536"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Serotonin and beyond: therapeutics for major depression</span></div><div class="casAuthors">Blier, Pierre; El Mansari, Mostafa</div><div class="citationInfo"><span class="NLM_cas:title">Philosophical Transactions of the Royal Society, B: Biological Sciences</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">1615</span>),
    <span class="NLM_cas:pages">20120536/1-20120536/7</span>CODEN:
                <span class="NLM_cas:coden">PTRBAE</span>;
        ISSN:<span class="NLM_cas:issn">0962-8436</span>.
    
            (<span class="NLM_cas:orgname">Royal Society</span>)
        </div><div class="casAbstract">A review.  The serotonin (5-HT, 5-hydroxytryptamine) system has been implicated in the pathogenesis of major depressive disorder (MDD).  The case for its contribution to the therapeutic efficacy of a wide variety of antidepressant treatments is, however, much stronger.  All antidepressant strategies have been shown to enhance 5-HT transmission in the brain of lab. animals.  Catecholamines, norepinephrine (NE) and dopamine (DA) can also play a pivotal role in the mechanism of action of certain antidepressant strategies.  The enhancement of 5-HT transmission by selective serotonin reuptake inhibitors, which leads to a dampening of the activity of NE and DA neurons, may account in part for the low remission rate achieved with these medications and/or the residuals symptoms after remission is achieved.  The functional connectivity between the 5-HT, NE and DA systems can be used to understand the mechanism of action of a wide variety of augmentation strategies in treatment-resistant MDD.  Proof-of-concept studies have shown that antidepressant medications with complementary mechanisms of action on monoaminergic systems can double the remission rate achieved in a trial of std. duration.  Novel approaches are also being used to treat MDD, which also appear to involve the monoaminergic system(s) to a varying extent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo17KDnFaMn0LVg90H21EOLACvtfcHk0liA3n9NEmRlcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltVaqsLw%253D&md5=a51d8edcf962e09bbe7fd6e4ebbcf301</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1098%2Frstb.2012.0536&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1098%252Frstb.2012.0536%26sid%3Dliteratum%253Aachs%26aulast%3DBlier%26aufirst%3DP.%26aulast%3DEl%2BMansari%26aufirst%3DM.%26atitle%3DSerotonin%2520and%2520beyond%253A%2520therapeutics%2520for%2520major%2520depression%26jtitle%3DPhilos.%2520Trans.%2520R.%2520Soc.%252C%2520B%26date%3D2013%26volume%3D368%26spage%3D20120536%26doi%3D10.1098%2Frstb.2012.0536" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Comley, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salinas, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slifstein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennacef, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shotbolt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Aart, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iavarone, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomeni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laruelle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunn, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabiner, E. A.</span></span> <span> </span><span class="NLM_article-title">Monoamine transporter occupancy of a novel triple reuptake inhibitor in baboons and humans using positron emission tomography</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>346</i></span>,  <span class="NLM_fpage">311</span>– <span class="NLM_lpage">317</span>, <span class="refDoi"> DOI: 10.1124/jpet.112.202895</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1124%2Fjpet.112.202895" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=23685546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOjsbfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=346&publication_year=2013&pages=311-317&author=R.+A.+Comleyauthor=C.+A.+Salinasauthor=M.+Slifsteinauthor=M.+Petroneauthor=C.+Marzanoauthor=I.+Bennacefauthor=P.+Shotboltauthor=J.+Van+der+Aartauthor=M.+Neveauthor=L.+Iavaroneauthor=R.+Gomeniauthor=M.+Laruelleauthor=F.+A.+Grayauthor=R.+N.+Gunnauthor=E.+A.+Rabiner&title=Monoamine+transporter+occupancy+of+a+novel+triple+reuptake+inhibitor+in+baboons+and+humans+using+positron+emission+tomography&doi=10.1124%2Fjpet.112.202895"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Monoamine transporter occupancy of a novel triple reuptake inhibitor in baboons and humans using positron emission tomography</span></div><div class="casAuthors">Comley, Robert A.; Salinas, Cristian A.; Slifstein, Mark; Petrone, Marcella; Marzano, Carmine; Bennacef, Idriss; Shotbolt, Paul; Van der Aart, Jasper; Neve, Marta; Iavarone, Laura; Gomeni, Roberto; Laruelle, Marc; Gray, Frank A.; Gunn, Roger N.; Rabiner, Eugenii A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">346</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">311-317</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The selection of a therapeutically meaningful dose of a novel pharmaceutical is a crucial step in drug development.  Positron emission tomog. (PET) allows the in vivo estn. of the relationship between the plasma concn. of a drug and its target occupancy, optimizing dose selection and reducing the time and cost of early development.  Triple reuptake inhibitors (TRIs), also referred to as serotonin-norepinephrine-dopamine reuptake inhibitors, enhance monoaminergic neurotransmission by blocking the action of the monoamine transporters, raising extracellular concns. of those neurotransmitters.  GSK1360707 [(1R,6S)-1-(3,4-dichlorophenyl)-6-(methoxymethyl)-4-azabicyclo[4.1.0]heptane] is a novel TRI that until recently was under development for the treatment of major depressive disorder; its development was put on hold for strategic reasons.  We present the results of an in vivo assessment of the relationship between plasma exposure and transporter blockade (occupancy).  Studies were performed in baboons (Papio anubis) to det. the relationship between plasma concn. and occupancy of brain serotonin reuptake transporter (SERT), dopamine reuptake transporter (DAT), and norepinephrine uptake transporter (NET) using the radioligands [11C]DASB [(N,N-dimethyl-2-(2-amino-4-cyanophenylthio) benzylamine], [11C]PE2I [N-(3-iodoprop-2E-enyl)-2β-carbomethoxy-3β-(4-methylphenyl)nortropane], and [11C]2-[(2-methoxyphenoxy)phenylmethyl]morpholine (also known as [11C]MRB) and in humans using [11C]DASB and [11C]PE2I.  In P. anubis, plasma concns. resulting in half-maximal occupancy at SERT, DAT, and NET were 15.16, 15.56, and 0.97 ng/mL, resp.  In humans, the corresponding values for SERT and DAT were 6.80 and 18.00 ng/mL.  GSK1360707 dose-dependently blocked the signal of SERT-, DAT-, and NET-selective PET ligands, confirming its penetration across the blood-brain barrier and blockade of all three monoamine transporters in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeOk3b2TA00rVg90H21EOLACvtfcHk0liA3n9NEmRlcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOjsbfE&md5=b92262955a074c2d981015dc436127bb</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1124%2Fjpet.112.202895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.112.202895%26sid%3Dliteratum%253Aachs%26aulast%3DComley%26aufirst%3DR.%2BA.%26aulast%3DSalinas%26aufirst%3DC.%2BA.%26aulast%3DSlifstein%26aufirst%3DM.%26aulast%3DPetrone%26aufirst%3DM.%26aulast%3DMarzano%26aufirst%3DC.%26aulast%3DBennacef%26aufirst%3DI.%26aulast%3DShotbolt%26aufirst%3DP.%26aulast%3DVan%2Bder%2BAart%26aufirst%3DJ.%26aulast%3DNeve%26aufirst%3DM.%26aulast%3DIavarone%26aufirst%3DL.%26aulast%3DGomeni%26aufirst%3DR.%26aulast%3DLaruelle%26aufirst%3DM.%26aulast%3DGray%26aufirst%3DF.%2BA.%26aulast%3DGunn%26aufirst%3DR.%2BN.%26aulast%3DRabiner%26aufirst%3DE.%2BA.%26atitle%3DMonoamine%2520transporter%2520occupancy%2520of%2520a%2520novel%2520triple%2520reuptake%2520inhibitor%2520in%2520baboons%2520and%2520humans%2520using%2520positron%2520emission%2520tomography%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D346%26spage%3D311%26epage%3D317%26doi%3D10.1124%2Fjpet.112.202895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span> <i>Antidepressant</i>; <span class="NLM_publisher-name">Wikipedia</span>, <span class="NLM_year">2017</span>; <a href="https://en.wikipedia.org/wiki/Antidepressant" class="extLink">https://en.wikipedia.org/wiki/Antidepressant</a> (accessed May 29, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Antidepressant%3B+Wikipedia%2C+2017%3B+https%3A%2F%2Fen.wikipedia.org%2Fwiki%2FAntidepressant+%28accessed+May+29%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DAntidepressant%26pub%3DWikipedia%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koblan, K.
S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kollins, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loebel, A.</span></span> <span> </span><span class="NLM_article-title">Dasotraline for the treatment of attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled, proof-of-concept trial in adults</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">2745</span>– <span class="NLM_lpage">2752</span>, <span class="refDoi"> DOI: 10.1038/npp.2015.124</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1038%2Fnpp.2015.124" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2015&pages=2745-2752&author=K.%0AS.+Koblanauthor=S.+C.+Hopkinsauthor=K.+Sarmaauthor=F.+Jinauthor=R.+Goldmanauthor=S.+H.+Kollinsauthor=A.+Loebel&title=Dasotraline+for+the+treatment+of+attention-deficit%2Fhyperactivity+disorder%3A+a+randomized%2C+double-blind%2C+placebo-controlled%2C+proof-of-concept+trial+in+adults&doi=10.1038%2Fnpp.2015.124"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2015.124&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2015.124%26sid%3Dliteratum%253Aachs%26aulast%3DKoblan%26aufirst%3DK.%2BS.%26aulast%3DHopkins%26aufirst%3DS.%2BC.%26aulast%3DSarma%26aufirst%3DK.%26aulast%3DJin%26aufirst%3DF.%26aulast%3DGoldman%26aufirst%3DR.%26aulast%3DKollins%26aufirst%3DS.%2BH.%26aulast%3DLoebel%26aufirst%3DA.%26atitle%3DDasotraline%2520for%2520the%2520treatment%2520of%2520attention-deficit%252Fhyperactivity%2520disorder%253A%2520a%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%252C%2520proof-of-concept%2520trial%2520in%2520adults%26jtitle%3DNeuropsychopharmacology%26date%3D2015%26volume%3D40%26spage%3D2745%26epage%3D2752%26doi%3D10.1038%2Fnpp.2015.124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bymaster, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golembiowska, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowalska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarazi, F. I.</span></span> <span> </span><span class="NLM_article-title">Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: implications for treatment of attention-deficit hyperactivity disorder</span>. <i>Synapse</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">522</span>– <span class="NLM_lpage">532</span>, <span class="refDoi"> DOI: 10.1002/syn.21538</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1002%2Fsyn.21538" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=22298359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC38XisFyjtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2012&pages=522-532&author=F.+P.+Bymasterauthor=K.+Golembiowskaauthor=M.+Kowalskaauthor=Y.+K.+Choiauthor=F.+I.+Tarazi&title=Pharmacological+characterization+of+the+norepinephrine+and+dopamine+reuptake+inhibitor+EB-1020%3A+implications+for+treatment+of+attention-deficit+hyperactivity+disorder&doi=10.1002%2Fsyn.21538"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: Implications for treatment of attention-deficit hyperactivity disorder</span></div><div class="casAuthors">Bymaster, Frank P.; Golembiowska, Krystyna; Kowalska, Magdalena; Choi, Yong Kee; Tarazi, Frank I.</div><div class="citationInfo"><span class="NLM_cas:title">Synapse (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">522-532</span>CODEN:
                <span class="NLM_cas:coden">SYNAET</span>;
        ISSN:<span class="NLM_cas:issn">0887-4476</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">We report on the pharmacol., behavioral, and neurochem. characterization of a novel dual norepinephrine (NE)/dopamine (DA) transporter inhibitor EB-1020 (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane HCl.  EB-1020 preferentially inhibited monoamine reuptake in cloned cell lines transfected with human transporters with IC50 values of 6 and 38, resp., for NE and DA transporters.  In microdialysis studies, EB-1020 markedly increased NE, and DA concns. levels in rat prefrontal cortex in vivo with peak increases of 375 and 300%, resp. with the greatest effects on NE, and also increased DA extracellular concns. in the striatum to 400% of baseline concns.  Behavioral studies demonstrated that EB-1020 dose-dependently decreased immobility in the mouse tail suspension test of depression to 13% of control levels, and did not stimulate locomotor activity in adult rats in the optimal dose range.  EB-1020 dose-dependently inhibited locomotor hyperactivity in juvenile rats lesioned with the neurotoxin 6-hydroxydopamine (100 μg intracisternally) as neonates; a well-established animal model for attention-deficit hyperactivity disorder (ADHD).  These data suggest that EB-1020 mediates its actions by stimulating NE and DA neurotransmission, which are typically impaired in ADHD.  Synapse, 2012. © 2012 Wiley Periodicals, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYYcO1hI4sKLVg90H21EOLACvtfcHk0lgBmTqQoNoBJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XisFyjtbc%253D&md5=40db856bc396bb648ca3b4c4c7318fd9</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1002%2Fsyn.21538&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fsyn.21538%26sid%3Dliteratum%253Aachs%26aulast%3DBymaster%26aufirst%3DF.%2BP.%26aulast%3DGolembiowska%26aufirst%3DK.%26aulast%3DKowalska%26aufirst%3DM.%26aulast%3DChoi%26aufirst%3DY.%2BK.%26aulast%3DTarazi%26aufirst%3DF.%2BI.%26atitle%3DPharmacological%2520characterization%2520of%2520the%2520norepinephrine%2520and%2520dopamine%2520reuptake%2520inhibitor%2520EB-1020%253A%2520implications%2520for%2520treatment%2520of%2520attention-deficit%2520hyperactivity%2520disorder%26jtitle%3DSynapse%26date%3D2012%26volume%3D66%26spage%3D522%26epage%3D532%26doi%3D10.1002%2Fsyn.21538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span> <i>Neurovance Announces Positive Centanafadine Phase
2b Results for
Adult ADHD, and Plans for Phase 3 Trials</i>; <span class="NLM_publisher-name">Neurovance, Inc.</span>: <span class="NLM_publisher-loc">Cambridge, MA</span>, July 27, <span class="NLM_year">2016</span>; <a href="http://www.neurovance.com/wp-content/uploads/2016/07/Press_Release-Neurovance_CTN_072716_Final_en.pdf" class="extLink">http://www.neurovance.com/wp-content/uploads/2016/07/Press_Release-Neurovance_CTN_072716_Final_en.pdf</a> (accessed May 29, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Neurovance+Announces+Positive+Centanafadine+Phase%0A2b+Results+for%0AAdult+ADHD%2C+and+Plans+for+Phase+3+Trials%3B+Neurovance%2C+Inc.%3A+Cambridge%2C+MA%2C+July+27%2C+2016%3B+http%3A%2F%2Fwww.neurovance.com%2Fwp-content%2Fuploads%2F2016%2F07%2FPress_Release-Neurovance_CTN_072716_Final_en.pdf+%28accessed+May+29%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DNeurovance%2520Announces%2520Positive%2520Centanafadine%2520Phase%250A2b%2520Results%2520for%250AAdult%2520ADHD%252C%2520and%2520Plans%2520for%2520Phase%25203%2520Trials%26pub%3DNeurovance%252C%2520Inc%26date%3D2016%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilens, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klint, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adler, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wesnes, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graff, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikkelsen, B.</span></span> <span> </span><span class="NLM_article-title">A randomized controlled trial of a novel mixed monoamine reuptake inhibitor in adults with ADHD</span>. <i>Behav. Brain Funct.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">24</span>, <span class="refDoi"> DOI: 10.1186/1744-9081-4-24</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1186%2F1744-9081-4-24" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=18554401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A280%3ADC%252BD1cvisVSrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=24&author=T.+E.+Wilensauthor=T.+Klintauthor=L.+Adlerauthor=S.+Westauthor=K.+Wesnesauthor=O.+Graffauthor=B.+Mikkelsen&title=A+randomized+controlled+trial+of+a+novel+mixed+monoamine+reuptake+inhibitor+in+adults+with+ADHD&doi=10.1186%2F1744-9081-4-24"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized controlled trial of a novel mixed monoamine reuptake inhibitor in adults with ADHD</span></div><div class="casAuthors">Wilens Timothy E; Klint Thorsten; Adler Lenard; West Scott; Wesnes Keith; Graff Ole; Mikkelsen Birgit</div><div class="citationInfo"><span class="NLM_cas:title">Behavioral and brain functions : BBF</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">24</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  NS2359 is a potent reuptake blocker of noradrenalin, dopamine, and serotonin.  The aim of the study was to investigate the efficacy, safety and cognitive function of NS2359 in adults with a DSM IV diagnosis of ADHD.  METHODS:  The study was a multi-centre, double-blind, randomized placebo-controlled, parallel group design in outpatient adults (18-55 years) testing 0.5 mg NS2359 vs. placebo for 8 weeks.  Multiple assessments including computerized neuropsychological evaluation were performed.  RESULTS:  There was no significant difference between NS2359 (n = 63) versus placebo (n = 63) on the primary outcome measure reduction in investigator rated ADHD-RS total score (7.8 versus 6.4; p < 0.45).  However, in subjects with the inattentive subtype, there were significantly more responders in the NS2359 group compared to placebo (41% versus 7%; p < 0.01).  For all secondary variables (ADHD-RS patient rated; The Conners Adult ADHD Scale; The Brown Adult Scale, and CGI-improvement scale) there were no significant differences between the two groups; however, in the inattentive subgroup, the response to treatment was significantly larger than to placebo.  NS2359 improved composite factor scores of attention, episodic- and working memory.  No serious adverse events were reported with insomnia, headaches and loss of appetite most commonly reported as side effects.  CONCLUSION:  No overall effect of NS2359 was found on overall symptoms of ADHD.  There was also a modest signal of improvement in the inattentive adults with ADHD and cognition warranting further exploration using differing doses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTNX0A-0CCcFQ8IxFYvehhofW6udTcc2eZNQCvaENnTsrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cvisVSrtg%253D%253D&md5=4a56a59169e6b5dd3fc3ae13eb553a2b</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1186%2F1744-9081-4-24&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1744-9081-4-24%26sid%3Dliteratum%253Aachs%26aulast%3DWilens%26aufirst%3DT.%2BE.%26aulast%3DKlint%26aufirst%3DT.%26aulast%3DAdler%26aufirst%3DL.%26aulast%3DWest%26aufirst%3DS.%26aulast%3DWesnes%26aufirst%3DK.%26aulast%3DGraff%26aufirst%3DO.%26aulast%3DMikkelsen%26aufirst%3DB.%26atitle%3DA%2520randomized%2520controlled%2520trial%2520of%2520a%2520novel%2520mixed%2520monoamine%2520reuptake%2520inhibitor%2520in%2520adults%2520with%2520ADHD%26jtitle%3DBehav.%2520Brain%2520Funct.%26date%3D2008%26volume%3D4%26spage%3D24%26doi%3D10.1186%2F1744-9081-4-24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span> <i>Sunovion Announces
Results from Pivotal Study Evaluating Novel Drug
Candidate Dasotraline in Children with ADHD</i>; <span class="NLM_publisher-name">Sunovion Pharmaceuticals</span>: <span class="NLM_publisher-loc">Marlborough,
MA</span>, September 20, <span class="NLM_year">2016</span>; <a href="http://www.sunovion.us/featured-news/press-releases/20160920.pdf" class="extLink">http://www.sunovion.us/featured-news/press-releases/20160920.pdf</a> (accessed May 29, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Sunovion+Announces%0AResults+from+Pivotal+Study+Evaluating+Novel+Drug%0ACandidate+Dasotraline+in+Children+with+ADHD%3B+Sunovion+Pharmaceuticals%3A+Marlborough%2C%0AMA%2C+September+20%2C+2016%3B+http%3A%2F%2Fwww.sunovion.us%2Ffeatured-news%2Fpress-releases%2F20160920.pdf+%28accessed+May+29%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DSunovion%2520Announces%250AResults%2520from%2520Pivotal%2520Study%2520Evaluating%2520Novel%2520Drug%250ACandidate%2520Dasotraline%2520in%2520Children%2520with%2520ADHD%26pub%3DSunovion%2520Pharmaceuticals%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hache, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coudore, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardier, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guiard, B. P.</span></span> <span> </span><span class="NLM_article-title">Monoaminergic antidepressants in the relief of pain: potential therapeutic utility of triple reuptake inhibitors (TRIs)</span>. <i>Pharmaceuticals</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">342</span>, <span class="refDoi"> DOI: 10.3390/ph4020285</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.3390%2Fph4020285" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2011&pages=285-342&author=G.+Hacheauthor=F.+Coudoreauthor=A.+M.+Gardierauthor=B.+P.+Guiard&title=Monoaminergic+antidepressants+in+the+relief+of+pain%3A+potential+therapeutic+utility+of+triple+reuptake+inhibitors+%28TRIs%29&doi=10.3390%2Fph4020285"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.3390%2Fph4020285&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fph4020285%26sid%3Dliteratum%253Aachs%26aulast%3DHache%26aufirst%3DG.%26aulast%3DCoudore%26aufirst%3DF.%26aulast%3DGardier%26aufirst%3DA.%2BM.%26aulast%3DGuiard%26aufirst%3DB.%2BP.%26atitle%3DMonoaminergic%2520antidepressants%2520in%2520the%2520relief%2520of%2520pain%253A%2520potential%2520therapeutic%2520utility%2520of%2520triple%2520reuptake%2520inhibitors%2520%2528TRIs%2529%26jtitle%3DPharmaceuticals%26date%3D2011%26volume%3D4%26spage%3D285%26epage%3D342%26doi%3D10.3390%2Fph4020285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hache, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guiard, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quesseveur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardier, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coudore, F.</span></span> <span> </span><span class="NLM_article-title">Antinociceptive activity of the new triple reuptake inhibitor NS18283 in a mouse model of chemotherapy-induced neuropathic pain</span>. <i>Eur. J. Pain</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">322</span>– <span class="NLM_lpage">333</span>, <span class="refDoi"> DOI: 10.1002/ejp.550</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1002%2Fejp.550" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=25045036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjsVGjsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2015&pages=322-333&author=G.+Hacheauthor=B.+P.+Guiardauthor=T.+H.+Nguyenauthor=G.+Quesseveurauthor=A.+M.+Gardierauthor=D.+Petersauthor=G.+Munroauthor=F.+Coudore&title=Antinociceptive+activity+of+the+new+triple+reuptake+inhibitor+NS18283+in+a+mouse+model+of+chemotherapy-induced+neuropathic+pain&doi=10.1002%2Fejp.550"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Antinociceptive activity of the new triple reuptake inhibitor NS18283 in a mouse model of chemotherapy-induced neuropathic pain</span></div><div class="casAuthors">Hache, G.; Guiard, B. P.; Nguyen, T. H.; Quesseveur, G.; Gardier, A. M.; Peters, D.; Munro, G.; Coudore, F.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pain (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">322-333</span>CODEN:
                <span class="NLM_cas:coden">EJPAFJ</span>;
        ISSN:<span class="NLM_cas:issn">1532-2149</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background : Chronic neuropathic pain can lead to anxiety and depression.  Drugs that block reuptake of serotonin, norepinephrine and/or dopamine are widely used to treat depression, and have emerged as useful drugs in the treatment of neuropathic pain.  This study compared the acute antinociceptive effects of NS18283, a novel triple monoamine reuptake inhibitor (MRI) with indatraline, venlafaxine and escitalopram in a mouse model of neuropathic pain.  Method : Neuropathic pain-like behaviors were induced in mice by repeated injections of oxaliplatin (OXA), and assessed using the von Frey hair test, the cold plate test and the thermal preference plate test.  Anxio/depressive phenotype and antidepressant-like properties of compds. were assessed by the novelty suppressed feeding test and the tail suspension test, resp.  Results : In vivo microdialysis expts. showed that each MRI increased extracellular serotonin, norepinephrine and/or dopamine levels in the cingulate cortex, in agreement with their in vitro reuptake inhibitory properties.  Indatraline (3 mg/kg) reversed the full repertoire of OXA-induced neuropathic hypersensitivity.  NS18283 (10 mg/kg) reversed OXA-induced mechano-hypersensitivity and cold allodynia.  Venlafaxine (16 mg/kg) and escitalopram (4 mg/kg) only reversed cold allodynia and mechano-hypersensitivity, resp.  All MRIs produced antidepressant-like activity in anxio/depressive phenotype of OXA mice.  Conclusions : Acute administration of drugs that enhance the activity of serotonin, norepinephrine and dopamine neurotransmission within nociceptive pathways may provide a broader spectrum of antinociception than dual or selective reuptake inhibitors in animal models of neuropathic pain.  Whether similar observations would occur after repeated administration of such compds. in an attempt to simulate dosing in humans, or be compromised by dopaminergic-mediated adverse effects warrants further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPt5IhUs35o7Vg90H21EOLACvtfcHk0litpwKa9SOaEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjsVGjsb4%253D&md5=176247b9134c10b3dddbe581fd51499c</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1002%2Fejp.550&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejp.550%26sid%3Dliteratum%253Aachs%26aulast%3DHache%26aufirst%3DG.%26aulast%3DGuiard%26aufirst%3DB.%2BP.%26aulast%3DNguyen%26aufirst%3DT.%2BH.%26aulast%3DQuesseveur%26aufirst%3DG.%26aulast%3DGardier%26aufirst%3DA.%2BM.%26aulast%3DPeters%26aufirst%3DD.%26aulast%3DMunro%26aufirst%3DG.%26aulast%3DCoudore%26aufirst%3DF.%26atitle%3DAntinociceptive%2520activity%2520of%2520the%2520new%2520triple%2520reuptake%2520inhibitor%2520NS18283%2520in%2520a%2520mouse%2520model%2520of%2520chemotherapy-induced%2520neuropathic%2520pain%26jtitle%3DEur.%2520J.%2520Pain%26date%3D2015%26volume%3D19%26spage%3D322%26epage%3D333%26doi%3D10.1002%2Fejp.550" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negus, S. S.</span></span> <span> </span><span class="NLM_article-title">Effects of monoamine reuptake inhibitors in assays of acute pain-stimulated and pain-depressed behavior in rats</span>. <i>J. Pain</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">246</span>– <span class="NLM_lpage">259</span>, <span class="refDoi"> DOI: 10.1016/j.jpain.2012.11.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.jpain.2012.11.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=23332494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmslegsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=246-259&author=M.+B.+Rosenbergauthor=F.+I.+Carrollauthor=S.+S.+Negus&title=Effects+of+monoamine+reuptake+inhibitors+in+assays+of+acute+pain-stimulated+and+pain-depressed+behavior+in+rats&doi=10.1016%2Fj.jpain.2012.11.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of Monoamine Reuptake Inhibitors in Assays of Acute Pain-Stimulated and Pain-Depressed Behavior in Rats</span></div><div class="casAuthors">Rosenberg, Marisa B.; Carroll, F. Ivy; Negus, S. Stevens</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pain</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">246-259</span>CODEN:
                <span class="NLM_cas:coden">JPOAB5</span>;
        ISSN:<span class="NLM_cas:issn">1526-5900</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Pain is assocd. with stimulation of some behaviors (eg, withdrawal reflexes) but depression of many other behaviors (eg, feeding, locomotion, pos. reinforced operant behavior).  Drugs that block reuptake of serotonin, norepinephrine, and/or dopamine are widely used to treat depression, and they have also emerged as useful drugs for treatment of pain.  This study compared effects of selective and mixed-action inhibitors of serotonin, norepinephrine, and/or dopamine reuptake in assays of acute pain-stimulated and pain-depressed behavior.  I.p. injection of dil. acid served as a noxious stimulus to stimulate a writhing response or depress intracranial self-stimulation (ICSS) in Sprague Dawley rats.  Selective reuptake inhibitors of serotonin (citalopram, clomipramine) and norepinephrine (nisoxetine, nortriptyline) and a mixed-action reuptake inhibitor of serotonin and norepinephrine (milnacipran) blocked acid-stimulated writhing but failed to block acid-induced depression of ICSS.  Selective dopamine reuptake inhibitors (RTI-113 [3ss-(4-chlorophenyl)tropane-2ss-carboxylic acid Ph ester hydrochloride], bupropion) and a triple reuptake inhibitor of dopamine, serotonin, and norepinephrine (RTI-112 [3ss-(3-methyl-4-chlorophenyl)tropane-2ss-carboxylic acid Me ester hydrochloride]) blocked both acid-stimulated writhing and acid-induced depression of ICSS, although these drugs also produced an abuse-related facilitation of ICSS in the absence of the noxious stimulus.  These results support further consideration of dopamine reuptake inhibitors as candidate analgesics, although abuse liability remains a concern.  Monoamine reuptake inhibitors are used to treat depression and some forms of pain.  This study examd. effects of monoamine reuptake inhibitors in a preclin. assay of pain-related behavioral depression.  The results support further consideration of dopamine reuptake inhibitors as candidate analgesics under selected circumstances, although abuse liability remains a concern.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrV-u7Njm1pA7Vg90H21EOLACvtfcHk0litpwKa9SOaEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmslegsLw%253D&md5=cc04c2634511a2ab1c5bcbef8c7c2b91</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.jpain.2012.11.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpain.2012.11.006%26sid%3Dliteratum%253Aachs%26aulast%3DRosenberg%26aufirst%3DM.%2BB.%26aulast%3DCarroll%26aufirst%3DF.%2BI.%26aulast%3DNegus%26aufirst%3DS.%2BS.%26atitle%3DEffects%2520of%2520monoamine%2520reuptake%2520inhibitors%2520in%2520assays%2520of%2520acute%2520pain-stimulated%2520and%2520pain-depressed%2520behavior%2520in%2520rats%26jtitle%3DJ.%2520Pain%26date%3D2013%26volume%3D14%26spage%3D246%26epage%3D259%26doi%3D10.1016%2Fj.jpain.2012.11.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krieter, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gohdes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musick, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duncanson, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridson, W. E.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics, disposition, and metabolism of bicifadine in humans</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">252</span>– <span class="NLM_lpage">259</span>, <span class="refDoi"> DOI: 10.1124/dmd.107.017871</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1124%2Fdmd.107.017871" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=252-259&author=P.+A.+Krieterauthor=M.+Gohdesauthor=T.+J.+Musickauthor=F.+P.+Duncansonauthor=W.+E.+Bridson&title=Pharmacokinetics%2C+disposition%2C+and+metabolism+of+bicifadine+in+humans&doi=10.1124%2Fdmd.107.017871"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1124%2Fdmd.107.017871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.107.017871%26sid%3Dliteratum%253Aachs%26aulast%3DKrieter%26aufirst%3DP.%2BA.%26aulast%3DGohdes%26aufirst%3DM.%26aulast%3DMusick%26aufirst%3DT.%2BJ.%26aulast%3DDuncanson%26aufirst%3DF.%2BP.%26aulast%3DBridson%26aufirst%3DW.%2BE.%26atitle%3DPharmacokinetics%252C%2520disposition%252C%2520and%2520metabolism%2520of%2520bicifadine%2520in%2520humans%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2008%26volume%3D36%26spage%3D252%26epage%3D259%26doi%3D10.1124%2Fdmd.107.017871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span> <i>NS2359 for Treatment of Cocaine Addiction</i>; <span class="NLM_publisher-name">Saniona</span>: <span class="NLM_publisher-loc">Ballerup,
Denmark</span>, <span class="NLM_year">2017</span>; <a href="http://saniona.com/pipeline/ns2359/" class="extLink">http://saniona.com/pipeline/ns2359/</a> (accessed May 29, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+NS2359+for+Treatment+of+Cocaine+Addiction%3B+Saniona%3A+Ballerup%2C%0ADenmark%2C+2017%3B+http%3A%2F%2Fsaniona.com%2Fpipeline%2Fns2359%2F+%28accessed+May+29%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DNS2359%2520for%2520Treatment%2520of%2520Cocaine%2520Addiction%26pub%3DSaniona%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Levin, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rezvani, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bymaster, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, J. E.</span></span> <span> </span><span class="NLM_article-title">Amitifadine, a triple monoamine re-uptake inhibitor, reduces nicotine self-administration in female rats</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>764</i></span>,  <span class="NLM_fpage">30</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2015.06.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.ejphar.2015.06.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=26101069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVajtLrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=764&publication_year=2015&pages=30-37&author=E.+D.+Levinauthor=C.+Wellsauthor=J.+E.+Johnsonauthor=A.+H.+Rezvaniauthor=F.+P.+Bymasterauthor=J.+E.+Rose&title=Amitifadine%2C+a+triple+monoamine+re-uptake+inhibitor%2C+reduces+nicotine+self-administration+in+female+rats&doi=10.1016%2Fj.ejphar.2015.06.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Amitifadine, a triple monoamine re-uptake inhibitor, reduces nicotine self-administration in female rats</span></div><div class="casAuthors">Levin, Edward D.; Wells, Corinne; Johnson, Joshua E.; Rezvani, Amir H.; Bymaster, Frank P.; Rose, Jed E.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">764</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">30-37</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A wider diversity of drug treatments to aid smoking cessation is needed to help tailor the most efficacious treatment for different types of smokers.  This study was conducted to det. whether amitifadine, which inhibits re-uptake of dopamine, norepinephrine and serotonin, would decrease nicotine self-administration at doses that do not cause adverse side effects.  Adult female Sprague-Dawley rats were trained to self-administer nicotine i.v. (IV) and were given acute doses of amitifadine in a repeated measures counterbalanced design.  Effects of amitifadine on locomotor activity and food motivated responding were also evaluated.  Chronic amitifadine effects were also examd.  The 30 mg/kg amitifadine dose significantly reduced nicotine self-administration.  The 5 and 10 mg/kg doses reduced nicotine self-administration during the first 15 min of the session when the greatest amt. of nicotine was self-administered.  The 30 mg/kg amitifadine dose, but not the lower doses caused a significant redn. in locomotor activity averaged over the one-hour session and reduced food motivated responding.  The 10 mg/kg dose caused hypoactivity at the beginning of the session, but 5 mg/kg did not cause any hypoactivity.  The effects of chronic amitifadine treatment (10 mg/kg) over the course of 15 sessions was also detd.  Amitifadine caused a significant redn. in nicotine self-administration, which was not seen to diminish over two consecutive weeks of treatment and a week after enforced abstinence.  Amitifadine significantly reduced nicotine self-administration.  This prompts further research to det. if amitifadine might be an effective treatment for smoking cessation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwJ4YGTqDiJ7Vg90H21EOLACvtfcHk0litpwKa9SOaEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVajtLrL&md5=300c7a36802d2388964f5ccf5fc64de7</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2015.06.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2015.06.041%26sid%3Dliteratum%253Aachs%26aulast%3DLevin%26aufirst%3DE.%2BD.%26aulast%3DWells%26aufirst%3DC.%26aulast%3DJohnson%26aufirst%3DJ.%2BE.%26aulast%3DRezvani%26aufirst%3DA.%2BH.%26aulast%3DBymaster%26aufirst%3DF.%2BP.%26aulast%3DRose%26aufirst%3DJ.%2BE.%26atitle%3DAmitifadine%252C%2520a%2520triple%2520monoamine%2520re-uptake%2520inhibitor%252C%2520reduces%2520nicotine%2520self-administration%2520in%2520female%2520rats%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D764%26spage%3D30%26epage%3D37%26doi%3D10.1016%2Fj.ejphar.2015.06.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Tousa, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warnock, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matson, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namjoshi, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linn, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiruveedhula, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halcomb, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grahame, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">June, H. L.</span></span> <span> </span><span class="NLM_article-title">Triple monoamine uptake inhibitors demonstrate a pharmacologic association between excessive drinking and impulsivity in high-alcohol-preferring (HAP) mice</span>. <i>Addict. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">236</span>– <span class="NLM_lpage">247</span>, <span class="refDoi"> DOI: 10.1111/adb.12100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1111%2Fadb.12100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=24118509" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvV2hsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=236-247&author=D.+S.+O%E2%80%99Tousaauthor=K.+T.+Warnockauthor=L.+M.+Matsonauthor=O.+A.+Namjoshiauthor=M.+V.+Linnauthor=V.+V.+Tiruveedhulaauthor=M.+E.+Halcombauthor=J.+Cookauthor=N.+J.+Grahameauthor=H.+L.+June&title=Triple+monoamine+uptake+inhibitors+demonstrate+a+pharmacologic+association+between+excessive+drinking+and+impulsivity+in+high-alcohol-preferring+%28HAP%29+mice&doi=10.1111%2Fadb.12100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Triple monoamine uptake inhibitors demonstrate a pharmacologic association between excessive drinking and impulsivity in high-alcohol-preferring (HAP) mice</span></div><div class="casAuthors">O'Tousa, David S.; Warnock, Kaitlin T.; Matson, Liana M.; Namjoshi, Ojas A.; Van Linn, Michael; Tiruveedhula, Veera Venkata; Halcomb, Meredith E.; Cook, James; Grahame, Nicholas J.; June, Harry L.</div><div class="citationInfo"><span class="NLM_cas:title">Addiction Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">236-247</span>CODEN:
                <span class="NLM_cas:coden">ADBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1369-1600</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Approx. 30% of current drinkers in the United States drink excessively, and are referred to as problem/hazardous drinkers.  These individuals, who may not meet criteria for alc. abuse or dependence, comprise binge, heavy drinkers, or both.  Given their high prevalence, interventions that reduce the risk of binge and heavy drinking have important public health implications.  Impulsivity has been repeatedly assocd. with excessive drinking in the clin. literature.  As impulsivity is correlated with, and may play a crit. role in, the initiation and maintenance of excessive drinking, this behavior may be an important target for therapeutic intervention.  Hence, a better understanding of pharmacol. treatments capable of attenuating excessive drinking and impulsivity may markedly improve clin. outcomes.  The high-alc.-preferring (HAP) mice represent a strong rodent model to study the relationship between impulsivity and excessive alc. drinking, as recent evidence indicates they consume high levels of alc. throughout their active cycle and are innately impulsive.  Using this model, the present study demonstrates that the triple monoamine uptake inhibitors (TUIs) amitifadine and DOV 102, 677 effectively attenuate binge drinking, heavy drinking assessed via a 24-h free-choice assay, and impulsivity measured by the delay discounting procedure.  In contrast, 3-PBC, a GABA-A α1 preferring ligand with mixed agonist-antagonist properties, attenuates excessive drinking without affecting impulsivity.  These findings suggest that in HAP mice, monoamine pathways may predominate as a common mechanism underlying impulsivity and excessive drinking, while the GABAergic system may be more salient in regulating excessive drinking.  We further propose that TUIs such as amitifadine and DOV 102, 677 may be used to treat the co-occurrence of impulsivity and excessive drinking.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCycjkVQYAr7Vg90H21EOLACvtfcHk0lgUeMbxKLtExA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvV2hsbY%253D&md5=fbbb92625dac06fb3d4d25d1a70a5c95</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1111%2Fadb.12100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fadb.12100%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Tousa%26aufirst%3DD.%2BS.%26aulast%3DWarnock%26aufirst%3DK.%2BT.%26aulast%3DMatson%26aufirst%3DL.%2BM.%26aulast%3DNamjoshi%26aufirst%3DO.%2BA.%26aulast%3DLinn%26aufirst%3DM.%2BV.%26aulast%3DTiruveedhula%26aufirst%3DV.%2BV.%26aulast%3DHalcomb%26aufirst%3DM.%2BE.%26aulast%3DCook%26aufirst%3DJ.%26aulast%3DGrahame%26aufirst%3DN.%2BJ.%26aulast%3DJune%26aufirst%3DH.%2BL.%26atitle%3DTriple%2520monoamine%2520uptake%2520inhibitors%2520demonstrate%2520a%2520pharmacologic%2520association%2520between%2520excessive%2520drinking%2520and%2520impulsivity%2520in%2520high-alcohol-preferring%2520%2528HAP%2529%2520mice%26jtitle%3DAddict.%2520Biol.%26date%3D2015%26volume%3D20%26spage%3D236%26epage%3D247%26doi%3D10.1111%2Fadb.12100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Appel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergstrom, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buus Lassen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langstrom, B.</span></span> <span> </span><span class="NLM_article-title">Tesofensine, a novel triple monoamine re-uptake inhibitor with anti-obesity effects: dopamine transporter occupancy as measured by PET</span>. <i>Eur. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">251</span>– <span class="NLM_lpage">261</span>, <span class="refDoi"> DOI: 10.1016/j.euroneuro.2013.10.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.euroneuro.2013.10.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=24239329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslKqsLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=251-261&author=L.+Appelauthor=M.+Bergstromauthor=J.+Buus+Lassenauthor=B.+Langstrom&title=Tesofensine%2C+a+novel+triple+monoamine+re-uptake+inhibitor+with+anti-obesity+effects%3A+dopamine+transporter+occupancy+as+measured+by+PET&doi=10.1016%2Fj.euroneuro.2013.10.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Tesofensine, a novel triple monoamine re-uptake inhibitor with anti-obesity effects: Dopamine transporter occupancy as measured by PET</span></div><div class="casAuthors">Appel, Lieuwe; Bergstroem, Mats; Buus Lassen, Joergen; Laangstroem, Bengt</div><div class="citationInfo"><span class="NLM_cas:title">European Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">251-261</span>CODEN:
                <span class="NLM_cas:coden">EURNE8</span>;
        ISSN:<span class="NLM_cas:issn">0924-977X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Tesofensine (TE) is a novel triple monoamine re-uptake inhibitor inducing a potent inhibition of the re-uptake process in the synaptic cleft of the neurotransmitters dopamine, norepinephrine, and serotonin.  In recent preclin. and clin. evaluations TE showed a robust anti-obesity effect, but the specific mechanism of this triple monoamine re-uptake inhibitor still needs to be further elucidated.  This positron emission tomog. (PET) study, using [11C]βCIT-FE, aimed to assess the degree of the dopamine transporter (DAT) occupancy, at const. TE plasma levels, following different oral, multiple doses of TE during totally 8-12 days.  In addn., the relationships between DAT occupancy and TE plasma concns., or doses, were investigated to enable assessment of DAT occupancies in subsequent clin. trials.  The results demonstrated that TE induced a dose-dependent blockade of DAT following multiple doses of 0.125-1 mg TE at anticipated steady-state conditions.  The mean striatal DAT occupancy varied dose-dependently between 18% and 77%.  A sigmoid Emax model well described the relationship between striatal DAT occupancy and TE plasma concns. or doses.  It was estd. that the max. achievable DAT occupancy was about 80% and that half of this effect was accomplished by approx. 0.25 mg TE and a plasma drug concn. of 4 ng/mL.  The results indicated an important mechanism of action of TE on DAT.  Further, these results suggest that the previously reported dose-dependent wt. loss, in TE treated subjects, was in part mediated by an up-regulation of dopaminergic pathways due to enhanced amts. of synaptic dopamine after blockade of DAT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkmbZZn97khbVg90H21EOLACvtfcHk0lgUeMbxKLtExA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslKqsLzE&md5=3001cae6aa37ed9a4bf2c9b6b28ded04</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2Fj.euroneuro.2013.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.euroneuro.2013.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DAppel%26aufirst%3DL.%26aulast%3DBergstrom%26aufirst%3DM.%26aulast%3DBuus%2BLassen%26aufirst%3DJ.%26aulast%3DLangstrom%26aufirst%3DB.%26atitle%3DTesofensine%252C%2520a%2520novel%2520triple%2520monoamine%2520re-uptake%2520inhibitor%2520with%2520anti-obesity%2520effects%253A%2520dopamine%2520transporter%2520occupancy%2520as%2520measured%2520by%2520PET%26jtitle%3DEur.%2520Neuropsychopharmacol.%26date%3D2014%26volume%3D24%26spage%3D251%26epage%3D261%26doi%3D10.1016%2Fj.euroneuro.2013.10.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span> <i>DOV 21,947 Demonstrates Significant Body Weight
and BMI Reductions
in   Drug-Compliant Subjects in Phase Ib Clinical Study</i>; <span class="NLM_publisher-name">DOV Pharmaceutical</span>: <span class="NLM_publisher-loc">Somerset, NJ</span>, September 25, <span class="NLM_year">2007</span>; <a href="https://www.sec.gov/Archives/edgar/data/1066833/000114420407051174/v088668_ex99-1.htm" class="extLink">https://www.sec.gov/Archives/edgar/data/1066833/000114420407051174/v088668_ex99-1.htm</a> (accessed May 29, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+DOV+21%2C947+Demonstrates+Significant+Body+Weight%0Aand+BMI+Reductions%0Ain+Drug-Compliant+Subjects+in+Phase+Ib+Clinical+Study%3B+DOV+Pharmaceutical%3A+Somerset%2C+NJ%2C+September+25%2C+2007%3B+https%3A%2F%2Fwww.sec.gov%2FArchives%2Fedgar%2Fdata%2F1066833%2F000114420407051174%2Fv088668_ex99-1.htm+%28accessed+May+29%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DDOV%252021%252C947%2520Demonstrates%2520Significant%2520Body%2520Weight%250Aand%2520BMI%2520Reductions%250Ain%2520%2520%2520Drug-Compliant%2520Subjects%2520in%2520Phase%2520Ib%2520Clinical%2520Study%26pub%3DDOV%2520Pharmaceutical%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Astrup, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meier, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikkelsen, B. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villumsen, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, T. M.</span></span> <span> </span><span class="NLM_article-title">Weight loss produced by tesofensine in patients with Parkinson’s or Alzheimer’s disease</span>. <i>Obesity</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1363</span>– <span class="NLM_lpage">1369</span>, <span class="refDoi"> DOI: 10.1038/oby.2008.56</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1038%2Foby.2008.56" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=18356831" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsFCnsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2008&pages=1363-1369&author=A.+Astrupauthor=D.+H.+Meierauthor=B.+O.+Mikkelsenauthor=J.+S.+Villumsenauthor=T.+M.+Larsen&title=Weight+loss+produced+by+tesofensine+in+patients+with+Parkinson%E2%80%99s+or+Alzheimer%E2%80%99s+disease&doi=10.1038%2Foby.2008.56"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Weight Loss Produced by Tesofensine in Patients With Parkinson's or Alzheimer's Disease</span></div><div class="casAuthors">Astrup, Arne; Meier, Dieter H.; Mikkelsen, Birgit O.; Villumsen, John S.; Larsen, Thomas M.</div><div class="citationInfo"><span class="NLM_cas:title">Obesity</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1363-1369</span>CODEN:
                <span class="NLM_cas:coden">OBESAX</span>;
        ISSN:<span class="NLM_cas:issn">1930-7381</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Objective: Tesofensine (TE) is a norepinephrine, dopamine, and serotonin reuptake inhibitor.  We conducted a meta-anal. of TE's effect on body wt. in trials investigating its potential for treatment of Parkinson's or Alzheimer's disease.  Methods and Procedures: Four randomized, double-blind, multicenter trials compared TE (n = 740) and placebo (n = 228), two in each disease.  Patients received oral TE or placebo once daily for 14 wk without any wt. loss program.  Results were adjusted for baseline values, age, and study.  Results: In the placebo group, 14% were obese and 21% were in the TE group.  In the total cohort, wt. change after 14 wk was +0.5, -0.5, -0.9, -1.8, -2.8% in the placebo, 0.125, 0.25, 0.5 and 1.0 mg in the TE groups, resp. (P = 0.015 for dose effect).  In the obese subgroup, wt. changes were -0.2, -1.7, -1.6, -1.5, -3.7%, and 2.1, 8.2, 14.1, 20.9, 32.1% of the obese patients achieved ≥5% wt. loss (P < 0.001 for 0.25, 0.5, and 1.0 mg vs. placebo for both end points).  Changes in heart rate were -0.4, 2.1, 4.2, 6.0, and 6.8 bpm after 14 wk (TE vs. placebo: P < 0.001 from 0.25 mg), but no effect on blood pressure was obsd.  Discussion: TE produced a placebo-subtracted wt. loss of ∼4% for >14 wk without any diet and lifestyle therapy, which is similar to that of sibutramine, but with no effect on blood pressure.  On the basis of these results, TE is now being developed for obesity management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnawROXlX8YrVg90H21EOLACvtfcHk0lgCue6rwCeIeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsFCnsrs%253D&md5=fdbd10425439c9cb5f63861803966b06</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1038%2Foby.2008.56&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Foby.2008.56%26sid%3Dliteratum%253Aachs%26aulast%3DAstrup%26aufirst%3DA.%26aulast%3DMeier%26aufirst%3DD.%2BH.%26aulast%3DMikkelsen%26aufirst%3DB.%2BO.%26aulast%3DVillumsen%26aufirst%3DJ.%2BS.%26aulast%3DLarsen%26aufirst%3DT.%2BM.%26atitle%3DWeight%2520loss%2520produced%2520by%2520tesofensine%2520in%2520patients%2520with%2520Parkinson%25E2%2580%2599s%2520or%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DObesity%26date%3D2008%26volume%3D16%26spage%3D1363%26epage%3D1369%26doi%3D10.1038%2Foby.2008.56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span> <i>Tesomet for Treatment of
Type 2 Diabetes</i>; <span class="NLM_publisher-name">Saniona</span>: <span class="NLM_publisher-loc">Ballerup, Denmark</span>, <span class="NLM_year">2017</span>; <a href="http://saniona.com/pipeline/tesomet-t2d/" class="extLink">http://saniona.com/pipeline/tesomet-t2d/</a> (accessed May 29, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Tesomet+for+Treatment+of%0AType+2+Diabetes%3B+Saniona%3A+Ballerup%2C+Denmark%2C+2017%3B+http%3A%2F%2Fsaniona.com%2Fpipeline%2Ftesomet-t2d%2F+%28accessed+May+29%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DTesomet%2520for%2520Treatment%2520of%250AType%25202%2520Diabetes%26pub%3DSaniona%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langdon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieschl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strong, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohrbach, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lelas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodge, N. J.</span></span> <span> </span><span class="NLM_article-title">Monoamine reuptake site occupancy of sibutramine: relationship to antidepressant-like and thermogenic effects in rats</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>737</i></span>,  <span class="NLM_fpage">47</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2014.03.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.ejphar.2014.03.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=24821570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVOnu7fL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=737&publication_year=2014&pages=47-56&author=Y.+W.+Liauthor=S.+Langdonauthor=R.+Pieschlauthor=T.+Strongauthor=R.+N.+Wrightauthor=K.+Rohrbachauthor=S.+Lelasauthor=N.+J.+Lodge&title=Monoamine+reuptake+site+occupancy+of+sibutramine%3A+relationship+to+antidepressant-like+and+thermogenic+effects+in+rats&doi=10.1016%2Fj.ejphar.2014.03.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Monoamine reuptake site occupancy of sibutramine: Relationship to antidepressant-like and thermogenic effects in rats</span></div><div class="casAuthors">Li, Yu-Wen; Langdon, Shaun; Pieschl, Rick; Strong, Todd; Wright, Robert N.; Rohrbach, Kenneth; Lelas, Snjezana; Lodge, Nicholas J.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">737</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">47-56</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Sibutramine was formerly marketed as an anti-obesity agent.  The current study investigated the relationships between monoamine reuptake site occupancy for sibutramine and both its antidepressant-like efficacy and thermogenic effects.  Sibutramine's effects on locomotor activity (LMA) and food intake were also evaluated.  Sibutramine occupied monoamine reuptake binding sites with the rank order of potency of NET>SERT>DAT; at 10 mg/kg, po, occupancy was 95% NET, 81% SERT and 73% DAT.  Sibutramine produced antidepressant-like behavior in the forced swim test; at the lowest ED (3 mg/kg, po) occupancy was 61%, 90% and 23% at SERT, NET and DAT sites, resp.  Sibutramine also increased body core temp. in a dose- and time-dependent manner; at the lowest ED (30 mg/kg) SERT, NET and DAT occupancies were resp. 78%, 86% and 59%.  A significant decrease in food consumption was obsd. at 3 and 10 mg/kg, po.  LMA was increased at ≥10 mg/kg, s.c.  The relationship between efficacy in the FST and occupancy was also detd. for citalopram, fluoxetine and reboxetine.  Similarly, the relationship between thermogenesis and target occupancy for several single or double/triple reuptake inhibitors was measured and showed that >40-50% DAT binding was required for thermogenesis.  Thermogenesis was blocked by the D1 antagonist SCH39166 (3 mg/kg, s.c.).  Our findings indicate that the antidepressant-like effect of sibutramine may result from additive or synergistic actions on the three reuptake binding targets.  At higher doses, sibutramine produces thermogenesis; DAT inhibition and activation of dopamine D1 receptors are required for this effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf84s-9gur8bVg90H21EOLACvtfcHk0lgCue6rwCeIeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVOnu7fL&md5=1383220e1bf0d8cb9b055ee605cc8069</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2014.03.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2014.03.024%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%2BW.%26aulast%3DLangdon%26aufirst%3DS.%26aulast%3DPieschl%26aufirst%3DR.%26aulast%3DStrong%26aufirst%3DT.%26aulast%3DWright%26aufirst%3DR.%2BN.%26aulast%3DRohrbach%26aufirst%3DK.%26aulast%3DLelas%26aufirst%3DS.%26aulast%3DLodge%26aufirst%3DN.%2BJ.%26atitle%3DMonoamine%2520reuptake%2520site%2520occupancy%2520of%2520sibutramine%253A%2520relationship%2520to%2520antidepressant-like%2520and%2520thermogenic%2520effects%2520in%2520rats%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2014%26volume%3D737%26spage%3D47%26epage%3D56%26doi%3D10.1016%2Fj.ejphar.2014.03.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span> <i>Meridia (Sibutramine Hydrochloride Monohydrate)
Capsules CS-IV</i>; <span class="NLM_publisher-name">Abbott Laboratories</span>: <span class="NLM_publisher-loc">North Chicago, IL</span>, <span class="NLM_year">2017</span>; <a href="http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM130745.pdf" class="extLink">http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM130745.pdf</a> (accessed May 29, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Meridia+%28Sibutramine+Hydrochloride+Monohydrate%29%0ACapsules+CS-IV%3B+Abbott+Laboratories%3A+North+Chicago%2C+IL%2C+2017%3B+http%3A%2F%2Fwww.fda.gov%2Fdownloads%2FDrugs%2FDrugSafety%2FPostmarketDrugSafetyInformationforPatientsandProviders%2FUCM130745.pdf+%28accessed+May+29%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DMeridia%2520%2528Sibutramine%2520Hydrochloride%2520Monohydrate%2529%250ACapsules%2520CS-IV%26pub%3DAbbott%2520Laboratories%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span> <i>Our Pipeline: We’re
Focused on the Innovative Application
of Science and Medicine</i>; <span class="NLM_publisher-name">Sunovion</span>: <span class="NLM_publisher-loc">Marlborough, MA</span>, <span class="NLM_year">2017</span>; <a href="http://www.sunovion.us/research-and-development/pipeline.html" class="extLink">http://www.sunovion.us/research-and-development/pipeline.html</a> (accessed May 29, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Our+Pipeline%3A+We%E2%80%99re%0AFocused+on+the+Innovative+Application%0Aof+Science+and+Medicine%3B+Sunovion%3A+Marlborough%2C+MA%2C+2017%3B+http%3A%2F%2Fwww.sunovion.us%2Fresearch-and-development%2Fpipeline.html+%28accessed+May+29%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DOur%2520Pipeline%253A%2520We%25E2%2580%2599re%250AFocused%2520on%2520the%2520Innovative%2520Application%250Aof%2520Science%2520and%2520Medicine%26pub%3DSunovion%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span> <i>Cortellis</i>; <span class="NLM_publisher-name">Clarivate Analytics</span>: <span class="NLM_publisher-loc">Philadelphia</span>, <span class="NLM_year">2017</span>; <a href="https://cortellis.thomsonreuterslifesciences.com/" class="extLink">https://cortellis.thomsonreuterslifesciences.com/</a> (accessed May 29, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Cortellis%3B+Clarivate+Analytics%3A+Philadelphia%2C+2017%3B+https%3A%2F%2Fcortellis.thomsonreuterslifesciences.com%2F+%28accessed+May+29%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DCortellis%26pub%3DClarivate%2520Analytics%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, H.
H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang-Christensen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Axel, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raben, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikkelsen, J. D.</span></span> <span> </span><span class="NLM_article-title">The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>636</i></span>,  <span class="NLM_fpage">88</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2010.03.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.ejphar.2010.03.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=20385125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvVejs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=636&publication_year=2010&pages=88-95&author=H.%0AH.+Hansenauthor=G.+Hansenauthor=M.+Tang-Christensenauthor=P.+J.+Larsenauthor=A.+M.+Axelauthor=A.+Rabenauthor=J.+D.+Mikkelsen&title=The+novel+triple+monoamine+reuptake+inhibitor+tesofensine+induces+sustained+weight+loss+and+improves+glycemic+control+in+the+diet-induced+obese+rat%3A+comparison+to+sibutramine+and+rimonabant&doi=10.1016%2Fj.ejphar.2010.03.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: Comparison to sibutramine and rimonabant</span></div><div class="casAuthors">Hansen, Henrik H.; Hansen, Gitte; Tang-Christensen, Mads; Larsen, Philip J.; Axel, Anne Marie D.; Raben, Anne; Mikkelsen, Jens D.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">636</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">88-95</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Tesofensine, a novel triple monoamine reuptake inhibitor, produces a significant wt. loss in humans.  The present study aimed at characterizing the wt.-reducing effects of tesofensine in a rat model of diet-induced obesity.  Sibutramine and rimonabant were used as ref. comparators.  Compared to baseline, long-term treatment with tesofensine (28 days, 1.0 or 2.5 mg/kg, p.o.) resulted in a significant, dose-dependent and sustained wt. loss of 5.7 and 9.9%, resp.  Sibutramine (7.5 mg/kg, p.o.) treatment caused a sustained wt. loss of 7.6%, whereas the employed dose of rimonabant (10 mg/kg, p.o.) only produced a transient wt. redn.  While all compds. exhibited a significant inhibitory effect on food intake which gradually wore off, the hypophagic effect of tesofensine was longer lasting than sibutramine and rimonabant.  In contrast to tesofensine, the body wt. of pair-fed rats returned to baseline at the end of the study, which may indicate that tesofensine stimulated energy expenditure.  The differential efficacy on wt. redn. was also reflected in lowered body fat depots, as tesofensine and sibutramine most efficiently reduced abdominal and s.c. fat mass which was paralleled by reduced plasma lipid levels.  In an oral glucose tolerance test, only tesofensine significantly suppressed the plasma insulin response below the level that could be obtained by paired feeding, indicating that tesofensine further improved glycemic control.  In conclusion, the robust wt. loss with long-term tesofensine treatment is likely due to a combined synergistic effect of appetite suppression and increased energy expenditure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3wG9qAb2frrVg90H21EOLACvtfcHk0lgCue6rwCeIeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvVejs74%253D&md5=85d6f07c6d9b167629741cfc3db9ff1b</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2010.03.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2010.03.026%26sid%3Dliteratum%253Aachs%26aulast%3DHansen%26aufirst%3DH.%2BH.%26aulast%3DHansen%26aufirst%3DG.%26aulast%3DTang-Christensen%26aufirst%3DM.%26aulast%3DLarsen%26aufirst%3DP.%2BJ.%26aulast%3DAxel%26aufirst%3DA.%2BM.%26aulast%3DRaben%26aufirst%3DA.%26aulast%3DMikkelsen%26aufirst%3DJ.%2BD.%26atitle%3DThe%2520novel%2520triple%2520monoamine%2520reuptake%2520inhibitor%2520tesofensine%2520induces%2520sustained%2520weight%2520loss%2520and%2520improves%2520glycemic%2520control%2520in%2520the%2520diet-induced%2520obese%2520rat%253A%2520comparison%2520to%2520sibutramine%2520and%2520rimonabant%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2010%26volume%3D636%26spage%3D88%26epage%3D95%26doi%3D10.1016%2Fj.ejphar.2010.03.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rascol, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poewe, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lees, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aristin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juhel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldhauser, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, T.</span></span>; <span class="NLM_contrib-group">ADVANS Study Group</span> <span> </span><span class="NLM_article-title">Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study</span>. <i>Arch. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">577</span>– <span class="NLM_lpage">583</span>, <span class="refDoi"> DOI: 10.1001/archneur.65.5.577</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1001%2Farchneur.65.5.577" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=18474731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A280%3ADC%252BD1czhtFOrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2008&pages=577-583&author=O.+Rascolauthor=W.+Poeweauthor=A.+Leesauthor=M.+Aristinauthor=L.+Salinauthor=N.+Juhelauthor=L.+Waldhauserauthor=T.+Schindlerauthor=ADVANS+Study+Group&title=Tesofensine+%28NS+2330%29%2C+a+monoamine+reuptake+inhibitor%2C+in+patients+with+advanced+Parkinson+disease+and+motor+fluctuations%3A+the+ADVANS+Study&doi=10.1001%2Farchneur.65.5.577"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study</span></div><div class="casAuthors">Rascol Olivier; Poewe Werner; Lees Andrew; Aristin Marina; Salin Laurence; Juhel Nolwenn; Waldhauser Lisa; Schindler Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Archives of neurology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">577-83</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  To assess the safety and efficacy of tesofensine, a triple monoamine reuptake inhibitor, in patients with advanced Parkinson disease (PD).  DESIGN:  A pilot phase 2, randomized, double-blind, placebo-controlled, parallel-group trial.  The study occurred in hospital-based outpatient clinics and in clinical trial units.  Patients with advanced PD and levodopa-related motor fluctuations were enrolled.  Tesofensine (0.125, 0.25, 0.5, or 1 mg) or placebo tablets were administered once daily for 14 weeks.  MAIN OUTCOME MEASURES:  Coprimary end points were the changes from baseline in Unified Parkinson Disease Rating Scale (UPDRS) subscale II (activities of daily living) plus subscale III (motor function) total score and in percentage of waking hours spent in "off" time noted in self-scoring diaries.  Secondary end points were safety, pharmacokinetics, responder analysis (> or =20% reduction in UPDRS score and in off time), and changes in percentage of waking hours spent in "on" time with and without troublesome dyskinesia.  RESULTS:  The adjusted mean differences (relative to placebo) were -4.7 points in UPDRS subscale II plus subscale III total score (P =.005) with tesofensine, 0.5 mg, and -7.1% in off time (-68 minutes, P =.02) with tesofensine, 0.25 mg.  Other dosages did not induce statistically significant effects.  The plasma concentration increased with the dosage, but no clear dose-response relationship was observed.  Gastrointestinal tract and neuropsychiatric adverse events were more frequent with tesofensine than with placebo, especially at the higher dosages.  CONCLUSIONS:  Patients with PD in advanced stages showed modest improvements in UPDRS subscale II plus subscale III total score and in off time when treated with tesofensine, but a dose-response relationship could not be established for efficacy, while adverse drug reactions tended to be more frequent at higher dosages.  TRIAL REGISTRATION:  clinicaltrials.gov Identifier: NCT00148512.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTwPRgr3W0hB1MGsG_HTXYFfW6udTcc2eZfjr58Pbq6ALntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1czhtFOrsA%253D%253D&md5=d206bdf83dd115071283939a57efb62f</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1001%2Farchneur.65.5.577&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchneur.65.5.577%26sid%3Dliteratum%253Aachs%26aulast%3DRascol%26aufirst%3DO.%26aulast%3DPoewe%26aufirst%3DW.%26aulast%3DLees%26aufirst%3DA.%26aulast%3DAristin%26aufirst%3DM.%26aulast%3DSalin%26aufirst%3DL.%26aulast%3DJuhel%26aufirst%3DN.%26aulast%3DWaldhauser%26aufirst%3DL.%26aulast%3DSchindler%26aufirst%3DT.%26aulast%3D%26atitle%3DTesofensine%2520%2528NS%25202330%2529%252C%2520a%2520monoamine%2520reuptake%2520inhibitor%252C%2520in%2520patients%2520with%2520advanced%2520Parkinson%2520disease%2520and%2520motor%2520fluctuations%253A%2520the%2520ADVANS%2520Study%26jtitle%3DArch.%2520Neurol.%26date%3D2008%26volume%3D65%26spage%3D577%26epage%3D583%26doi%3D10.1001%2Farchneur.65.5.577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, J.</span></span> <span> </span><span class="NLM_article-title">Norepinephrine transporter function and human cardiovascular disease</span>. <i>Am. J. Physiol. Heart Circ. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>303</i></span>,  <span class="NLM_fpage">H1273</span>– <span class="NLM_lpage">1282</span>, <span class="refDoi"> DOI: 10.1152/ajpheart.00492.2012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1152%2Fajpheart.00492.2012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=23023867" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=303&publication_year=2012&pages=H1273-1282&author=C.+Schroederauthor=J.+Jordan&title=Norepinephrine+transporter+function+and+human+cardiovascular+disease&doi=10.1152%2Fajpheart.00492.2012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1152%2Fajpheart.00492.2012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpheart.00492.2012%26sid%3Dliteratum%253Aachs%26aulast%3DSchroeder%26aufirst%3DC.%26aulast%3DJordan%26aufirst%3DJ.%26atitle%3DNorepinephrine%2520transporter%2520function%2520and%2520human%2520cardiovascular%2520disease%26jtitle%3DAm.%2520J.%2520Physiol.%2520Heart%2520Circ.%2520Physiol.%26date%3D2012%26volume%3D303%26spage%3DH1273%26epage%3D1282%26doi%3D10.1152%2Fajpheart.00492.2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeLorenzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichenstein, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Organisak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kharidia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsey, R. V.</span></span> <span> </span><span class="NLM_article-title">SEP-225289 serotonin and dopamine transporter occupancy: a PET study</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">1150</span>– <span class="NLM_lpage">1155</span>, <span class="refDoi"> DOI: 10.2967/jnumed.110.084525</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.2967%2Fjnumed.110.084525" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2011&pages=1150-1155&author=C.+DeLorenzoauthor=S.+Lichensteinauthor=K.+Schaeferauthor=J.+Dunnauthor=R.+Marshallauthor=L.+Organisakauthor=J.+Kharidiaauthor=B.+Robertsonauthor=J.+J.+Mannauthor=R.+V.+Parsey&title=SEP-225289+serotonin+and+dopamine+transporter+occupancy%3A+a+PET+study&doi=10.2967%2Fjnumed.110.084525"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.110.084525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.110.084525%26sid%3Dliteratum%253Aachs%26aulast%3DDeLorenzo%26aufirst%3DC.%26aulast%3DLichenstein%26aufirst%3DS.%26aulast%3DSchaefer%26aufirst%3DK.%26aulast%3DDunn%26aufirst%3DJ.%26aulast%3DMarshall%26aufirst%3DR.%26aulast%3DOrganisak%26aufirst%3DL.%26aulast%3DKharidia%26aufirst%3DJ.%26aulast%3DRobertson%26aufirst%3DB.%26aulast%3DMann%26aufirst%3DJ.%2BJ.%26aulast%3DParsey%26aufirst%3DR.%2BV.%26atitle%3DSEP-225289%2520serotonin%2520and%2520dopamine%2520transporter%2520occupancy%253A%2520a%2520PET%2520study%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2011%26volume%3D52%26spage%3D1150%26epage%3D1155%26doi%3D10.2967%2Fjnumed.110.084525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sramek, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bieck, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamora, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Versavel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kharidia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grinnell, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cutler, N. R.</span></span> <span> </span><span class="NLM_article-title">Exploratory biomarker study of the triple reuptake inhibitor SEP-432 compared to the dual reuptake inhibitor duloxetine in healthy normal subjects</span>. <i>CNS Neurosci. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">404</span>– <span class="NLM_lpage">412</span>, <span class="refDoi"> DOI: 10.1111/cns.12513</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1111%2Fcns.12513" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=26849844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtVent7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=404-412&author=J.+J.+Sramekauthor=L.+W.+Hardyauthor=P.+Bieckauthor=C.+Zamoraauthor=M.+Versavelauthor=J.+Kharidiaauthor=T.+Grinnellauthor=Y.+L.+Chenauthor=M.+Sullivanauthor=H.+Dingauthor=N.+R.+Cutler&title=Exploratory+biomarker+study+of+the+triple+reuptake+inhibitor+SEP-432+compared+to+the+dual+reuptake+inhibitor+duloxetine+in+healthy+normal+subjects&doi=10.1111%2Fcns.12513"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Exploratory Biomarker Study of the Triple Reuptake Inhibitor SEP-432 Compared to the Dual Reuptake Inhibitor Duloxetine in Healthy Normal Subjects</span></div><div class="casAuthors">Sramek, John J.; Hardy, Larry W.; Bieck, Peter; Zamora, Cynthia; Versavel, Mark; Kharidia, Jahnavi; Grinnell, Todd; Chen, Yu-Luan; Sullivan, Michael; Ding, Hong; Cutler, Neal R.</div><div class="citationInfo"><span class="NLM_cas:title">CNS Neuroscience & Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">404-412</span>CODEN:
                <span class="NLM_cas:coden">CNTNAB</span>;
        ISSN:<span class="NLM_cas:issn">1755-5930</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Introduction : SEP-432 is a triple monoamine reuptake inhibitor of norepinephrine (NE), serotonin (5-HT), and dopamine (DA), based on in vitro binding studies.  We sought evidence that SEP-432 engages these monoamine systems by measuring concns. of monoamines and/or their main metabolites in cerebrospinal fluid (CSF) and plasma and comparing results to duloxetine, a dual reuptake inhibitor of NE and 5-HT.  Methods : Eighteen healthy normal subjects received either SEP-432 (300 mg/day), duloxetine (60 mg/day), or placebo for 14 days in-clinic (double blind) with CSF and plasma collections at baseline (single lumbar puncture) and Day 14 (24-h CSF and plasma collection).  Concns. of monoamines and their metabolites, as well as pharmacokinetic concns. of SEP-432 and metabolite, were quantified by liq. chromatog.-tandem mass spectrometry.  Results : Compared to placebo in the Day 14 area under the curve 24-h (AUC0-24 h) anal., SEP-432 significantly (P < 0.05) decreased the NE metabolite dihydroxyphenylglycol (DHPG) in CSF and plasma, decreased 5-HT in plasma, and did not affect DA metabolites, while duloxetine had significant effects on DHPG and 5-HT.  Time-matched baseline to Day 14 biomarker comparisons confirmed these findings.  Conclusion : CSF monoamine biomarkers confirmed central NET activity for SEP-432 and duloxetine's dual reuptake inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMpRsq4CXinLVg90H21EOLACvtfcHk0ljNVmcgxo82Ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtVent7k%253D&md5=a7e13ad1632e45b1628116bbefa61074</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1111%2Fcns.12513&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcns.12513%26sid%3Dliteratum%253Aachs%26aulast%3DSramek%26aufirst%3DJ.%2BJ.%26aulast%3DHardy%26aufirst%3DL.%2BW.%26aulast%3DBieck%26aufirst%3DP.%26aulast%3DZamora%26aufirst%3DC.%26aulast%3DVersavel%26aufirst%3DM.%26aulast%3DKharidia%26aufirst%3DJ.%26aulast%3DGrinnell%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DY.%2BL.%26aulast%3DSullivan%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DH.%26aulast%3DCutler%26aufirst%3DN.%2BR.%26atitle%3DExploratory%2520biomarker%2520study%2520of%2520the%2520triple%2520reuptake%2520inhibitor%2520SEP-432%2520compared%2520to%2520the%2520dual%2520reuptake%2520inhibitor%2520duloxetine%2520in%2520healthy%2520normal%2520subjects%26jtitle%3DCNS%2520Neurosci.%2520Ther.%26date%3D2016%26volume%3D22%26spage%3D404%26epage%3D412%26doi%3D10.1111%2Fcns.12513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arakawa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nogami, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagashima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujiwara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodaka, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tateno, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okubo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suhara, T.</span></span> <span> </span><span class="NLM_article-title">Norepinephrine transporter occupancy by nortriptyline in patients with depression: a positron emission tomography study with (S,S)-[18F]FMeNER-D2</span>. <i>Int. J. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">553</span>– <span class="NLM_lpage">560</span>, <span class="refDoi"> DOI: 10.1017/S1461145713001521</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1017%2FS1461145713001521" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=24345533" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktV2hsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2014&pages=553-560&author=H.+Takanoauthor=R.+Arakawaauthor=T.+Nogamiauthor=M.+Suzukiauthor=T.+Nagashimaauthor=H.+Fujiwaraauthor=Y.+Kimuraauthor=F.+Kodakaauthor=K.+Takahataauthor=H.+Shimadaauthor=Y.+Murakamiauthor=A.+Tatenoauthor=M.+Yamadaauthor=H.+Itoauthor=K.+Kawamuraauthor=M.-R.+Zhangauthor=H.+Takahashiauthor=M.+Katoauthor=Y.+Okuboauthor=T.+Suhara&title=Norepinephrine+transporter+occupancy+by+nortriptyline+in+patients+with+depression%3A+a+positron+emission+tomography+study+with+%28S%2CS%29-%5B18F%5DFMeNER-D2&doi=10.1017%2FS1461145713001521"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Norepinephrine transporter occupancy by nortriptyline in patients with depression: a positron emission tomography study with (S,S)-[18F]FMeNER-D2</span></div><div class="casAuthors">Takano, Harumasa; Arakawa, Ryosuke; Nogami, Tsuyoshi; Suzuki, Masayuki; Nagashima, Tomohisa; Fujiwara, Hironobu; Kimura, Yasuyuki; Kodaka, Fumitoshi; Takahata, Keisuke; Shimada, Hitoshi; Murakami, Yoshitaka; Tateno, Amane; Yamada, Makiko; Ito, Hiroshi; Kawamura, Kazunori; Zhang, Ming-Rong; Takahashi, Hidehiko; Kato, Motoichiro; Okubo, Yoshiro; Suhara, Tetsuya</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">553-560</span>CODEN:
                <span class="NLM_cas:coden">IJNUFB</span>;
        ISSN:<span class="NLM_cas:issn">1461-1457</span>.
    
            (<span class="NLM_cas:orgname">Cambridge University Press</span>)
        </div><div class="casAbstract">Norepinephrine transporter (NET) plays important roles in the treatment of various neuropsychiatric disorders, such as depression and attention deficit hyperactivity disorder (ADHD).  Nortriptyline is a NET-selective tricyclic antidepressant (TCAs) that has been widely used for the treatment of depression.  Previous positron emission tomog. (PET) studies have reported over 80% serotonin transporter occupancy with clin. doses of selective serotonin reuptake inhibitors (SSRIs), but there has been no report of NET occupancy in patients treated with relatively NET-selective antidepressants.  In the present study, we used PET and (S,S)-[18F]FMeNER-D2 to investigate NET occupancies in the thalamus in 10 patients with major depressive disorder taking various doses of nortriptyline, who were considered to be responders to the treatment.  Ref. data for the calcn. of occupancy were derived from age-matched healthy controls.  The result showed approx. 50-70% NET occupancies in the brain as a result of the administration of 75-200 mg/d of nortriptyline.  The estd. ED (ED50) and concn. (EC50) required to induce 50% occupancy was 65.9 mg/d and 79.8 ng/mL, resp.  Furthermore, as the min. therapeutic level of plasma nortriptyline for the treatment of depression has been reported to be 70 ng/mL, our data indicate that this plasma nortriptyline concn. corresponds to approx. 50% NET occupancy measured with PET, suggesting that more than 50% of central NET occupancy would be appropriate for the nortriptyline treatment of patients with depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMoY4LOtJfObVg90H21EOLACvtfcHk0lj7awi3QrC1nA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktV2hsb0%253D&md5=d4a5190c8e0a7f0b70fc34bdef38c3e8</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1017%2FS1461145713001521&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS1461145713001521%26sid%3Dliteratum%253Aachs%26aulast%3DTakano%26aufirst%3DH.%26aulast%3DArakawa%26aufirst%3DR.%26aulast%3DNogami%26aufirst%3DT.%26aulast%3DSuzuki%26aufirst%3DM.%26aulast%3DNagashima%26aufirst%3DT.%26aulast%3DFujiwara%26aufirst%3DH.%26aulast%3DKimura%26aufirst%3DY.%26aulast%3DKodaka%26aufirst%3DF.%26aulast%3DTakahata%26aufirst%3DK.%26aulast%3DShimada%26aufirst%3DH.%26aulast%3DMurakami%26aufirst%3DY.%26aulast%3DTateno%26aufirst%3DA.%26aulast%3DYamada%26aufirst%3DM.%26aulast%3DIto%26aufirst%3DH.%26aulast%3DKawamura%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DM.-R.%26aulast%3DTakahashi%26aufirst%3DH.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DOkubo%26aufirst%3DY.%26aulast%3DSuhara%26aufirst%3DT.%26atitle%3DNorepinephrine%2520transporter%2520occupancy%2520by%2520nortriptyline%2520in%2520patients%2520with%2520depression%253A%2520a%2520positron%2520emission%2520tomography%2520study%2520with%2520%2528S%252CS%2529-%255B18F%255DFMeNER-D2%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2014%26volume%3D17%26spage%3D553%26epage%3D560%26doi%3D10.1017%2FS1461145713001521" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muller, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milton, M. N.</span></span> <span> </span><span class="NLM_article-title">The determination and interpretation of the therapeutic index in drug development</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">751</span>– <span class="NLM_lpage">761</span>, <span class="refDoi"> DOI: 10.1038/nrd3801</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1038%2Fnrd3801" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=22935759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ynt7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=751-761&author=P.+Y.+Mullerauthor=M.+N.+Milton&title=The+determination+and+interpretation+of+the+therapeutic+index+in+drug+development&doi=10.1038%2Fnrd3801"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">The determination and interpretation of the therapeutic index in drug development</span></div><div class="casAuthors">Muller, Patrick Y.; Milton, Mark N.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">751-761</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  A key part of drug discovery and development is the characterization and optimization of the safety and efficacy of drug candidates to identify those that have an appropriately balanced safety-efficacy profile for a given indication.  The therapeutic index (TI) - which is typically considered as the ratio of the highest exposure to the drug that results in no toxicity to the exposure that produces the desired efficacy - is an important parameter in efforts to achieve this balance.  Various types of safety and efficacy data are generated in vitro and in vivo (in animals and in humans), and these data can be used to predict the clin. TI of a drug candidate at an early stage.  However, approaches to systematically and quant. compare these types of data and to apply this knowledge more effectively are needed.  This article critically discusses the various aspects of TI detn. and interpretation in drug development for both small mol. drugs and biotherapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIUD30Kgdy-7Vg90H21EOLACvtfcHk0lj7awi3QrC1nA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ynt7vL&md5=a6650b73990e366d7ba144703089b2d4</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1038%2Fnrd3801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3801%26sid%3Dliteratum%253Aachs%26aulast%3DMuller%26aufirst%3DP.%2BY.%26aulast%3DMilton%26aufirst%3DM.%2BN.%26atitle%3DThe%2520determination%2520and%2520interpretation%2520of%2520the%2520therapeutic%2520index%2520in%2520drug%2520development%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D751%26epage%3D761%26doi%3D10.1038%2Fnrd3801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sorensen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husum, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennum, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bundgaard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montezinho, L. C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mork, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woertwein, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woldbye, D. P. D.</span></span> <span> </span><span class="NLM_article-title">Addiction-related effects of DOV 216,303 and cocaine: a comparative study in the mouse</span>. <i>Basic Clin. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">451</span>– <span class="NLM_lpage">459</span>, <span class="refDoi"> DOI: 10.1111/bcpt.12182</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1111%2Fbcpt.12182" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=24314270" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC2cXns12ksb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2014&pages=451-459&author=G.+Sorensenauthor=H.+Husumauthor=L.+T.+Brennumauthor=C.+Bundgaardauthor=L.+C.+P.+Montezinhoauthor=A.+Morkauthor=G.+Woertweinauthor=D.+P.+D.+Woldbye&title=Addiction-related+effects+of+DOV+216%2C303+and+cocaine%3A+a+comparative+study+in+the+mouse&doi=10.1111%2Fbcpt.12182"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Addiction-Related Effects of DOV 216,303 and Cocaine: A Comparative Study in the Mouse</span></div><div class="casAuthors">Sorensen, Gunnar; Husum, Henriette; Brennum, Lise T.; Bundgaard, Christoffer; Montezinho, Liliana C. P.; Mork, Arne; Woertwein, Gitta; Woldbye, David P. D.</div><div class="citationInfo"><span class="NLM_cas:title">Basic & Clinical Pharmacology & Toxicology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">451-459</span>CODEN:
                <span class="NLM_cas:coden">BCPTBO</span>;
        ISSN:<span class="NLM_cas:issn">1742-7835</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">DOV 216,303, an inhibitor of serotonin, noradrenaline and dopamine reuptake, belongs to a new line of drugs called 'triple reuptake inhibitors' that have been proposed for treatment of depression.  The addictive drug cocaine has similar mechanism of action and exerts rewarding effects by blocking reuptake of dopamine, leading to increased extracellular concns. of dopamine in the nucleus accumbens.  Thus, DOV 216,303 and other triple reuptake inhibitors might be speculated to exhibit abuse potential, limiting their future therapeutic use.  To further elucidate potential addictive properties of DOV 216,303, we conducted a comparative study of addiction-related effects of DOV 216,303 and cocaine in mice using acute self-administration, conditioned place preference (CPP) and drug-induced hyperlocomotion.  Effects on accumbal extracellular dopamine levels were detd. using microdialysis, and we measured monoamine receptor occupancy as well as brain and plasma exposure.  DOV 216,303 was self-administered acutely in the same dose range as cocaine.  However, in the CPP model, DOV 216,303 did not induce place preference at doses where cocaine caused place preference.  Higher doses of DOV 216,303 than cocaine were needed to induce hyperlocomotion and increase extracellular accumbal dopamine with EDs being higher than EDs used in depression models.  Moreover, DOV 216,303 displayed a pharmacokinetic profile with lower potential for addiction than cocaine.  Thus, high levels of DAT occupancy were reached slower and decayed more slowly after DOV 216,303 than cocaine administration.  The present study shows that acute administration of DOV 216,303 displays some addictive-like properties in mice, but these were less pronounced than cocaine, most likely due to different pharmacokinetic profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLmmoaUXJJR7Vg90H21EOLACvtfcHk0lj7awi3QrC1nA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXns12ksb4%253D&md5=7bdcc848ab22ac5b32da27a46719a27b</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1111%2Fbcpt.12182&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcpt.12182%26sid%3Dliteratum%253Aachs%26aulast%3DSorensen%26aufirst%3DG.%26aulast%3DHusum%26aufirst%3DH.%26aulast%3DBrennum%26aufirst%3DL.%2BT.%26aulast%3DBundgaard%26aufirst%3DC.%26aulast%3DMontezinho%26aufirst%3DL.%2BC.%2BP.%26aulast%3DMork%26aufirst%3DA.%26aulast%3DWoertwein%26aufirst%3DG.%26aulast%3DWoldbye%26aufirst%3DD.%2BP.%2BD.%26atitle%3DAddiction-related%2520effects%2520of%2520DOV%2520216%252C303%2520and%2520cocaine%253A%2520a%2520comparative%2520study%2520in%2520the%2520mouse%26jtitle%3DBasic%2520Clin.%2520Pharmacol.%2520Toxicol.%26date%3D2014%26volume%3D114%26spage%3D451%26epage%3D459%26doi%3D10.1111%2Fbcpt.12182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Volkow, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowler, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swanson, J. M.</span></span> <span> </span><span class="NLM_article-title">Dopamine in drug abuse and addiction: results from imaging studies and treatment implications</span>. <i>Mol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">557</span>– <span class="NLM_lpage">569</span>, <span class="refDoi"> DOI: 10.1038/sj.mp.4001507</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1038%2Fsj.mp.4001507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=15098002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkt1Gnt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=557-569&author=N.+D.+Volkowauthor=J.+S.+Fowlerauthor=G.+J.+Wangauthor=J.+M.+Swanson&title=Dopamine+in+drug+abuse+and+addiction%3A+results+from+imaging+studies+and+treatment+implications&doi=10.1038%2Fsj.mp.4001507"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine in drug abuse and addiction: results from imaging studies and treatment implications</span></div><div class="casAuthors">Volkow, N. D.; Fowler, J. S.; Wang, G-J.; Swanson, J. M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Psychiatry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">557-569</span>CODEN:
                <span class="NLM_cas:coden">MOPSFQ</span>;
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The involvement of dopamine in drug reinforcement is well recognized but its role in drug addiction is much less clear.  Imaging studies have shown that the reinforcing effects of drugs of abuse in humans are contingent upon large and fast increases in dopamine that mimic but exceed in the intensity and duration those induced by dopamine cell firing to environmental events.  In addn., imaging studies have also documented a role of dopamine in motivation, which appears to be encoded both by fast as well as smooth DA increases.  Since dopamine cells fire in response to salient stimuli, the supraphysiol. activation by drugs is likely to be experienced as highly salient (driving attention, arousal conditioned learning and motivation) and may also reset the thresholds required for environmental events to activate dopamine cells.  Indeed, imaging studies have shown that in drug-addicted subjects, dopamine function is markedly disrupted (decreases in dopamine release and in dopamine D2 receptors in striatum) and this is assocd. with reduced activity of the orbitofrontal cortex (neuroanatomical region involved with salience attribution and motivation and implicated in compulsive behaviors) and the cingulate gyrus (neuroanatomical region involved with inhibitory control and attention and implicated in impulsivity).  However, when addicted subjects are exposed to drug-related stimuli, these hypoactive regions become hyperactive in proportion to the expressed desire for the drug.  We postulate that decreased dopamine function in addicted subjects results in decreased sensitivity to nondrug-related stimuli (including natural reinforcers) and disrupts frontal inhibition, both of which contribute to compulsive drug intake and impaired inhibitory control.  These findings suggest new strategies for pharmacol. and behavioral treatments, which focus on enhancing DA function and restoring brain circuits disrupted by chronic drug use to help motivate the addicted subject in activities that provide alternative sources of reinforcement, counteract conditioned responses, enhance their ability to control their drive to take drugs and interfere with their compulsive administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZHeX9A089TbVg90H21EOLACvtfcHk0ljBqf9-ODqKKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkt1Gnt7Y%253D&md5=6e1b785207fb3003b50f19491ca9413e</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1038%2Fsj.mp.4001507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.mp.4001507%26sid%3Dliteratum%253Aachs%26aulast%3DVolkow%26aufirst%3DN.%2BD.%26aulast%3DFowler%26aufirst%3DJ.%2BS.%26aulast%3DWang%26aufirst%3DG.%2BJ.%26aulast%3DSwanson%26aufirst%3DJ.%2BM.%26atitle%3DDopamine%2520in%2520drug%2520abuse%2520and%2520addiction%253A%2520results%2520from%2520imaging%2520studies%2520and%2520treatment%2520implications%26jtitle%3DMol.%2520Psychiatry%26date%3D2004%26volume%3D9%26spage%3D557%26epage%3D569%26doi%3D10.1038%2Fsj.mp.4001507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boules, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briody, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliveros, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blazar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlier, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richelson, E.</span></span> <span> </span><span class="NLM_article-title">Antidepressant-like pharmacological profile of a novel triple reuptake inhibitor, (1S,2S)-3-(methylamino)-2-(naphthalen-2-yl)-1-phenylpropan-1-ol (PRC200-SS)</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>327</i></span>,  <span class="NLM_fpage">573</span>– <span class="NLM_lpage">583</span>, <span class="refDoi"> DOI: 10.1124/jpet.108.143610</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1124%2Fjpet.108.143610" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=18689611" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlWns7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=327&publication_year=2008&pages=573-583&author=Y.+Liangauthor=A.+M.+Shawauthor=M.+Boulesauthor=S.+Briodyauthor=J.+Robinsonauthor=A.+Oliverosauthor=E.+Blazarauthor=K.+Williamsauthor=Y.+Zhangauthor=P.+R.+Carlierauthor=E.+Richelson&title=Antidepressant-like+pharmacological+profile+of+a+novel+triple+reuptake+inhibitor%2C+%281S%2C2S%29-3-%28methylamino%29-2-%28naphthalen-2-yl%29-1-phenylpropan-1-ol+%28PRC200-SS%29&doi=10.1124%2Fjpet.108.143610"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Antidepressant-like pharmacological profile of a novel triple reuptake inhibitor, (1S,2S)-3-(methylamino)-2-(naphthalen-2-yl)-1-phenylpropan-1-ol (PRC200-SS)</span></div><div class="casAuthors">Liang, Yanqi; Shaw, Amanda M.; Boules, Mona; Briody, Siobhan; Robinson, Jessica; Oliveros, Alfredo; Blazar, Eric; Williams, Katrina; Zhang, Yiqun; Carlier, Paul R.; Richelson, Elliott</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">327</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">573-583</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Due to the putative involvement of dopaminergic circuits in depression, triple reuptake inhibitors are being developed as a new class of antidepressant, which is hypothesized to produce a more rapid onset and better efficacy than current antidepressants selective for serotonin or norepinephrine neurotransmission.  (1S,2S)-3-(Methylamino)-2-(naphthalen-2-yl)-1-phenylpropan-1-ol (PRC 200SS), a new triple reuptake inhibitor, potently bound to the human serotonin, norepinephrine, and dopamine transporters with Kd values of 2.3, 0.63, and 18 nM, resp.  Inhibition of serotonin, norepinephrine, and dopamine uptake by PRC 200SS was also shown in cells expressing the corresponding transporter (Ki values of 2.1, 1.5, and 61 nM, resp.).  In vivo, PRC 200SS dose-dependently decreased immobility in the forced-swim test in rats and in the tail-suspension test in mice, models predictive of antidepressant activity, with effects comparable with imipramine.  These results in the behavioral models did not seem to result from the stimulation of locomotor activity.  Consistent with the in vitro data and behavioral effects, peripheral administration of PRC 200SS (5 and 10 mg/kg i.p.) significantly increased extracellular levels of serotonin and norepinephrine in the medial prefrontal cortex, and of serotonin and dopamine in the core of nucleus accumbens, with redn. of levels of 3,4-dihydroxyphenylacetic acid, homovanillic acid, and 5-hydroxyindoleacetic acid compared with levels for saline control.  Furthermore, PRC 200SS self-administration, which was used as a marker of abuse liability, was not obsd. with rats.  Therefore, it seems that PRC 200SS may represent a novel triple reuptake inhibitor and possess antidepressant activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsjq1Ko19NBbVg90H21EOLACvtfcHk0ljBqf9-ODqKKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlWns7vJ&md5=1cfb6ece94bf5fa1187219d03f676d09</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1124%2Fjpet.108.143610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.108.143610%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DShaw%26aufirst%3DA.%2BM.%26aulast%3DBoules%26aufirst%3DM.%26aulast%3DBriody%26aufirst%3DS.%26aulast%3DRobinson%26aufirst%3DJ.%26aulast%3DOliveros%26aufirst%3DA.%26aulast%3DBlazar%26aufirst%3DE.%26aulast%3DWilliams%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DCarlier%26aufirst%3DP.%2BR.%26aulast%3DRichelson%26aufirst%3DE.%26atitle%3DAntidepressant-like%2520pharmacological%2520profile%2520of%2520a%2520novel%2520triple%2520reuptake%2520inhibitor%252C%2520%25281S%252C2S%2529-3-%2528methylamino%2529-2-%2528naphthalen-2-yl%2529-1-phenylpropan-1-ol%2520%2528PRC200-SS%2529%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2008%26volume%3D327%26spage%3D573%26epage%3D583%26doi%3D10.1124%2Fjpet.108.143610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koblan, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallina, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy-Cooperman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoedel, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loebel, A.</span></span> <span> </span><span class="NLM_article-title">Assessment of human abuse potential of dasotraline compared to methylphenidate and placebo in recreational stimulant users</span>. <i>Drug Alcohol Depend.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>159</i></span>,  <span class="NLM_fpage">26</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1016/j.drugalcdep.2015.10.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.drugalcdep.2015.10.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=26794682" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFCqurjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=2016&pages=26-34&author=K.+S.+Koblanauthor=S.+C.+Hopkinsauthor=K.+Sarmaauthor=N.+Gallinaauthor=F.+Jinauthor=N.+Levy-Coopermanauthor=K.+A.+Schoedelauthor=A.+Loebel&title=Assessment+of+human+abuse+potential+of+dasotraline+compared+to+methylphenidate+and+placebo+in+recreational+stimulant+users&doi=10.1016%2Fj.drugalcdep.2015.10.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Assessment of human abuse potential of dasotraline compared to methylphenidate and placebo in recreational stimulant users</span></div><div class="casAuthors">Koblan, K. S.; Hopkins, S. C.; Sarma, K.; Gallina, N.; Jin, F.; Levy-Cooperman, N.; Schoedel, K. A.; Loebel, A.</div><div class="citationInfo"><span class="NLM_cas:title">Drug and Alcohol Dependence</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">159</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">26-34</span>CODEN:
                <span class="NLM_cas:coden">DADEDV</span>;
        ISSN:<span class="NLM_cas:issn">0376-8716</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">The aim of this study was to evaluate the abuse potential of dasotraline, a novel dopamine and norepinephrine reuptake inhibitor with slow absorption (tmax, 10-12 h) and elimination (t1/2 = 47-77 h) that is in development for the treatment of attention deficit hyperactivity disorder (ADHD).  Recreational stimulant users (N = 48) who had specific experience with cocaine, and who were able to distinguish methylphenidate (60 mg) vs. placebo in a qualification session, were randomized, in a 6-period, double-blind, crossover design, to receive single doses of dasotraline 8 mg, 16 mg, and 36 mg, methylphenidate (MPH) 40 mg and 80 mg, and placebo.  The primary endpoint was the Drug Liking Visual Analog Scale (VAS) score at the time of peak effect (Emax).  There were no significant differences between the 3 doses of dasotraline and placebo on the drug liking VAS at Emax, and on most secondary endpoints.  Both doses of MPH had significantly higher VAS-drug liking scores at Emax relative to both placebo (P < 0.001 for all comparisons) and dasotraline 8 mg (P < 0.001), 16 mg (P < 0.001) and 36 mg (P < 0.01).  The increase in heart rate for MPH and dasotraline 36 mg showed a time-course that closely matched subject-rated measures such as Any Effects VAS.  In this study, dasotraline was found to have low potential for abuse, which may be, in part, related to its established pharmacokinetics (PK) profile, which is characterized by slow absorption and gradual elimination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9cXlgfxYCRrVg90H21EOLACvtfcHk0ljBqf9-ODqKKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFCqurjI&md5=7786128edd70cc8929948d723cbd0b51</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2Fj.drugalcdep.2015.10.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drugalcdep.2015.10.029%26sid%3Dliteratum%253Aachs%26aulast%3DKoblan%26aufirst%3DK.%2BS.%26aulast%3DHopkins%26aufirst%3DS.%2BC.%26aulast%3DSarma%26aufirst%3DK.%26aulast%3DGallina%26aufirst%3DN.%26aulast%3DJin%26aufirst%3DF.%26aulast%3DLevy-Cooperman%26aufirst%3DN.%26aulast%3DSchoedel%26aufirst%3DK.%2BA.%26aulast%3DLoebel%26aufirst%3DA.%26atitle%3DAssessment%2520of%2520human%2520abuse%2520potential%2520of%2520dasotraline%2520compared%2520to%2520methylphenidate%2520and%2520placebo%2520in%2520recreational%2520stimulant%2520users%26jtitle%3DDrug%2520Alcohol%2520Depend.%26date%3D2016%26volume%3D159%26spage%3D26%26epage%3D34%26doi%3D10.1016%2Fj.drugalcdep.2015.10.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schoedel, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meier, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakraborty, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manniche, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, E. M.</span></span> <span> </span><span class="NLM_article-title">Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">69</span>– <span class="NLM_lpage">78</span>, <span class="refDoi"> DOI: 10.1038/clpt.2010.67</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1038%2Fclpt.2010.67" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=20520602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC3cXns1Gjsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2010&pages=69-78&author=K.+A.+Schoedelauthor=D.+Meierauthor=B.+Chakrabortyauthor=P.+M.+Mannicheauthor=E.+M.+Sellers&title=Subjective+and+objective+effects+of+the+novel+triple+reuptake+inhibitor+tesofensine+in+recreational+stimulant+users&doi=10.1038%2Fclpt.2010.67"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Subjective and Objective Effects of the Novel Triple Reuptake Inhibitor Tesofensine in Recreational Stimulant Users</span></div><div class="casAuthors">Schoedel, K. A.; Meier, D.; Chakraborty, B.; Manniche, P. M.; Sellers, E. M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">69-78</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Tesofensine is a (triple) reuptake inhibitor of noradrenaline, dopamine, and serotonin that is in development for the treatment of obesity.  The abuse potential of triple reuptake inhibitors is not yet known, and so this study was undertaken to evaluate the potential abuse-related effects of tesofensine in humans.  It was designed as a single-dose, randomized, double-blind, crossover study involving tesofensine vs. placebo, -amphetamine (pos. control for dopaminergic/stimulant effects), bupropion, and atomoxetine (neg./unscheduled controls) in recreational stimulant users (N = 52).  Subjective and objective measures were assessed for 48 h after drug administration.  The study results show that the effects of -amphetamine were significantly greater than those of placebo on all primary and secondary subjective measures.  The effects of tesofensine were not significantly different from those of placebo and were lower than those of -amphetamine 30 mg on all primary and most secondary measures.  The effects of tesofensine were either lower than or not different from those of bupropion or atomoxetine.  These results demonstrate that the abuse potential for tesofensine is no greater than that of bupropion or atomoxetine, and tesofensine is therefore unlikely to be recreationally abused.  Clin. Pharmacol. & Therapeutics (2010) 88 1, 69-78. doi:10.1038/clpt.2010.67.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPtqgt3Y92_rVg90H21EOLACvtfcHk0lgx65zyHZu68g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXns1Gjsrw%253D&md5=efcef974ffdec57839bb39fdc032fac1</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2010.67&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2010.67%26sid%3Dliteratum%253Aachs%26aulast%3DSchoedel%26aufirst%3DK.%2BA.%26aulast%3DMeier%26aufirst%3DD.%26aulast%3DChakraborty%26aufirst%3DB.%26aulast%3DManniche%26aufirst%3DP.%2BM.%26aulast%3DSellers%26aufirst%3DE.%2BM.%26atitle%3DSubjective%2520and%2520objective%2520effects%2520of%2520the%2520novel%2520triple%2520reuptake%2520inhibitor%2520tesofensine%2520in%2520recreational%2520stimulant%2520users%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2010%26volume%3D88%26spage%3D69%26epage%3D78%26doi%3D10.1038%2Fclpt.2010.67" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span> <i>Neurovance Announces Top-Line
Study Results Suggest Lower Abuse Potential
for Centanafadine Compared to Stimulants Used for Adult ADHD</i>; <span class="NLM_publisher-name">Neurovance</span>: <span class="NLM_publisher-loc">Cambridge,
MA</span>, <span class="NLM_year">2014</span>; <a href="http://www.neurovance.com/wp-content/uploads/2014/08/Press-Release_-Neurovance_HAL-results.-BWire-FINAL.pdf" class="extLink">http://www.neurovance.com/wp-content/uploads/2014/08/Press-Release_-Neurovance_HAL-results.-BWire-FINAL.pdf</a> (accessed May 29, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Neurovance+Announces+Top-Line%0AStudy+Results+Suggest+Lower+Abuse+Potential%0Afor+Centanafadine+Compared+to+Stimulants+Used+for+Adult+ADHD%3B+Neurovance%3A+Cambridge%2C%0AMA%2C+2014%3B+http%3A%2F%2Fwww.neurovance.com%2Fwp-content%2Fuploads%2F2014%2F08%2FPress-Release_-Neurovance_HAL-results.-BWire-FINAL.pdf+%28accessed+May+29%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DNeurovance%2520Announces%2520Top-Line%250AStudy%2520Results%2520Suggest%2520Lower%2520Abuse%2520Potential%250Afor%2520Centanafadine%2520Compared%2520to%2520Stimulants%2520Used%2520for%2520Adult%2520ADHD%26pub%3DNeurovance%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lengyel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieschl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strong, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodge, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. W.</span></span> <span> </span><span class="NLM_article-title">Ex vivo assessment of binding site occupancy of monoamine reuptake inhibitors: methodology and biological significance</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2008.04.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.neuropharm.2008.04.014" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2008&pages=63-70&author=K.+Lengyelauthor=R.+Pieschlauthor=T.+Strongauthor=T.+Molskiauthor=G.+Mattsonauthor=N.+J.+Lodgeauthor=Y.+W.+Li&title=Ex+vivo+assessment+of+binding+site+occupancy+of+monoamine+reuptake+inhibitors%3A+methodology+and+biological+significance&doi=10.1016%2Fj.neuropharm.2008.04.014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2008.04.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2008.04.014%26sid%3Dliteratum%253Aachs%26aulast%3DLengyel%26aufirst%3DK.%26aulast%3DPieschl%26aufirst%3DR.%26aulast%3DStrong%26aufirst%3DT.%26aulast%3DMolski%26aufirst%3DT.%26aulast%3DMattson%26aufirst%3DG.%26aulast%3DLodge%26aufirst%3DN.%2BJ.%26aulast%3DLi%26aufirst%3DY.%2BW.%26atitle%3DEx%2520vivo%2520assessment%2520of%2520binding%2520site%2520occupancy%2520of%2520monoamine%2520reuptake%2520inhibitors%253A%2520methodology%2520and%2520biological%2520significance%26jtitle%3DNeuropharmacology%26date%3D2008%26volume%3D55%26spage%3D63%26epage%3D70%26doi%3D10.1016%2Fj.neuropharm.2008.04.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Micheli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavanni, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arban, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benedetti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertani, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bettati, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bettelini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonanomi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braggio, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Checchia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davalli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Fabio, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fazzolari, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchioro, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minick, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliosi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sartori, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tedesco, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarsi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terreni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visentini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zocchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zonzini, L.</span></span> <span> </span><span class="NLM_article-title">1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2534</span>– <span class="NLM_lpage">2551</span>, <span class="refDoi"> DOI: 10.1021/jm901818u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901818u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitFyhsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2534-2551&author=F.+Micheliauthor=P.+Cavanniauthor=R.+Arbanauthor=R.+Benedettiauthor=B.+Bertaniauthor=M.+Bettatiauthor=L.+Betteliniauthor=G.+Bonanomiauthor=S.+Braggioauthor=A.+Checchiaauthor=S.+Davalliauthor=R.+Di+Fabioauthor=E.+Fazzolariauthor=S.+Fontanaauthor=C.+Marchioroauthor=D.+Minickauthor=M.+Negriauthor=B.+Oliosiauthor=K.+D.+Readauthor=I.+Sartoriauthor=G.+Tedescoauthor=L.+Tarsiauthor=S.+Terreniauthor=F.+Visentiniauthor=A.+Zocchiauthor=L.+Zonzini&title=1-%28Aryl%29-6-%5Balkoxyalkyl%5D-3-azabicyclo%5B3.1.0%5Dhexanes+and+6-%28aryl%29-6-%5Balkoxyalkyl%5D-3-azabicyclo%5B3.1.0%5Dhexanes%3A+a+new+series+of+potent+and+selective+triple+reuptake+inhibitors&doi=10.1021%2Fjm901818u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: A New Series of Potent and Selective Triple Reuptake Inhibitors</span></div><div class="casAuthors">Micheli, Fabrizio; Cavanni, Paolo; Arban, Roberto; Benedetti, Roberto; Bertani, Barbara; Bettati, Michela; Bettelini, Letizia; Bonanomi, Giorgio; Braggio, Simone; Checchia, Anna; Davalli, Silvia; Di Fabio, Romano; Fazzolari, Elettra; Fontana, Stefano; Marchioro, Carla; Minick, Doug; Negri, Michele; Oliosi, Beatrice; Read, Kevin D.; Sartori, Ilaria; Tedesco, Giovanna; Tarsi, Luca; Terreni, Silvia; Visentini, Filippo; Zocchi, Alessandro; Zonzini, Laura</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2534-2551</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of new highly potent and selective triple reuptake inhibitors is reported.  The new classes of 1-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes are described together with detailed SAR.  Appropriate decoration of the scaffolds was achieved with the help of a triple reuptake inhibitor pharmacophore model detailed here.  Selected derivs. showed good oral bioavailability (>30%) and brain penetration (B/B > 4) in rats assocd. with high in vitro potency and selectivity at SERT, NET, and DAT.  Among these compds., microdialysis and in vivo expts. confirm that deriv. 15 has an appropriate developability profile to be considered for further progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoD-IzrnTZWyLVg90H21EOLACvtfcHk0lgx65zyHZu68g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitFyhsbk%253D&md5=233ea2bd7c94826f351abafcde62da0d</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1021%2Fjm901818u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901818u%26sid%3Dliteratum%253Aachs%26aulast%3DMicheli%26aufirst%3DF.%26aulast%3DCavanni%26aufirst%3DP.%26aulast%3DArban%26aufirst%3DR.%26aulast%3DBenedetti%26aufirst%3DR.%26aulast%3DBertani%26aufirst%3DB.%26aulast%3DBettati%26aufirst%3DM.%26aulast%3DBettelini%26aufirst%3DL.%26aulast%3DBonanomi%26aufirst%3DG.%26aulast%3DBraggio%26aufirst%3DS.%26aulast%3DChecchia%26aufirst%3DA.%26aulast%3DDavalli%26aufirst%3DS.%26aulast%3DDi%2BFabio%26aufirst%3DR.%26aulast%3DFazzolari%26aufirst%3DE.%26aulast%3DFontana%26aufirst%3DS.%26aulast%3DMarchioro%26aufirst%3DC.%26aulast%3DMinick%26aufirst%3DD.%26aulast%3DNegri%26aufirst%3DM.%26aulast%3DOliosi%26aufirst%3DB.%26aulast%3DRead%26aufirst%3DK.%2BD.%26aulast%3DSartori%26aufirst%3DI.%26aulast%3DTedesco%26aufirst%3DG.%26aulast%3DTarsi%26aufirst%3DL.%26aulast%3DTerreni%26aufirst%3DS.%26aulast%3DVisentini%26aufirst%3DF.%26aulast%3DZocchi%26aufirst%3DA.%26aulast%3DZonzini%26aufirst%3DL.%26atitle%3D1-%2528Aryl%2529-6-%255Balkoxyalkyl%255D-3-azabicyclo%255B3.1.0%255Dhexanes%2520and%25206-%2528aryl%2529-6-%255Balkoxyalkyl%255D-3-azabicyclo%255B3.1.0%255Dhexanes%253A%2520a%2520new%2520series%2520of%2520potent%2520and%2520selective%2520triple%2520reuptake%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2534%26epage%3D2551%26doi%3D10.1021%2Fjm901818u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Micheli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavanni, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreotti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arban, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benedetti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertani, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bettati, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bettelini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonanomi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braggio, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carletti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Checchia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corsi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fazzolari, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchioro, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlo-Pich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliosi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roscic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sartori, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tedesco, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarsi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terreni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visentini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zocchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zonzini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Fabio, R.</span></span> <span> </span><span class="NLM_article-title">6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">4989</span>– <span class="NLM_lpage">5001</span>, <span class="refDoi"> DOI: 10.1021/jm100481d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100481d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntF2jtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4989-5001&author=F.+Micheliauthor=P.+Cavanniauthor=D.+Andreottiauthor=R.+Arbanauthor=R.+Benedettiauthor=B.+Bertaniauthor=M.+Bettatiauthor=L.+Betteliniauthor=G.+Bonanomiauthor=S.+Braggioauthor=R.+Carlettiauthor=A.+Checchiaauthor=M.+Corsiauthor=E.+Fazzolariauthor=S.+Fontanaauthor=C.+Marchioroauthor=E.+Merlo-Pichauthor=M.+Negriauthor=B.+Oliosiauthor=E.+Rattiauthor=K.+D.+Readauthor=M.+Roscicauthor=I.+Sartoriauthor=S.+Spadaauthor=G.+Tedescoauthor=L.+Tarsiauthor=S.+Terreniauthor=F.+Visentiniauthor=A.+Zocchiauthor=L.+Zonziniauthor=R.+Di+Fabio&title=6-%283%2C4-dichlorophenyl%29-1-%5B%28methyloxy%29methyl%5D-3-azabicyclo%5B4.1.0%5Dheptane%3A+a+new+potent+and+selective+triple+reuptake+inhibitor&doi=10.1021%2Fjm100481d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">6-(3,4-Dichlorophenyl)-1-[(Methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: A New Potent and Selective Triple Reuptake Inhibitor</span></div><div class="casAuthors">Micheli, Fabrizio; Cavanni, Paolo; Andreotti, Daniele; Arban, Roberto; Benedetti, Roberto; Bertani, Barbara; Bettati, Michela; Bettelini, Letizia; Bonanomi, Giorgio; Braggio, Simone; Carletti, Renzo; Checchia, Anna; Corsi, Mauro; Fazzolari, Elettra; Fontana, Stefano; Marchioro, Carla; Merlo-Pich, Emilio; Negri, Michele; Oliosi, Beatrice; Ratti, Emiliangelo; Read, Kevin D.; Roscic, Maja; Sartori, Ilaria; Spada, Simone; Tedesco, Giovanna; Tarsi, Luca; Terreni, Silvia; Visentini, Filippo; Zocchi, Alessandro; Zonzini, Laura; Di Fabio, Romano</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4989-5001</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A pharmacophore model for triple reuptake inhibitors and the new class of 1-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes were recently reported.  Further investigation in this area led to the identification of a new series of potent and selective triple reuptake inhibitors endowed with good developability characteristics.  Excellent bioavailability and brain penetration are assocd. with this series of 6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptanes together with high in vitro potency and selectivity at SERT, NET, and DAT.  In vivo microdialysis expts. in different animal models and receptor occupancy studies in rat confirmed that deriv. 17 (I) showed an appropriate profile to guarantee further progression of the compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0NYLPRsborLVg90H21EOLACvtfcHk0lj2w7MJT5bfGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntF2jtbo%253D&md5=b250a9a4f7772f81ab2702180348b254</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1021%2Fjm100481d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100481d%26sid%3Dliteratum%253Aachs%26aulast%3DMicheli%26aufirst%3DF.%26aulast%3DCavanni%26aufirst%3DP.%26aulast%3DAndreotti%26aufirst%3DD.%26aulast%3DArban%26aufirst%3DR.%26aulast%3DBenedetti%26aufirst%3DR.%26aulast%3DBertani%26aufirst%3DB.%26aulast%3DBettati%26aufirst%3DM.%26aulast%3DBettelini%26aufirst%3DL.%26aulast%3DBonanomi%26aufirst%3DG.%26aulast%3DBraggio%26aufirst%3DS.%26aulast%3DCarletti%26aufirst%3DR.%26aulast%3DChecchia%26aufirst%3DA.%26aulast%3DCorsi%26aufirst%3DM.%26aulast%3DFazzolari%26aufirst%3DE.%26aulast%3DFontana%26aufirst%3DS.%26aulast%3DMarchioro%26aufirst%3DC.%26aulast%3DMerlo-Pich%26aufirst%3DE.%26aulast%3DNegri%26aufirst%3DM.%26aulast%3DOliosi%26aufirst%3DB.%26aulast%3DRatti%26aufirst%3DE.%26aulast%3DRead%26aufirst%3DK.%2BD.%26aulast%3DRoscic%26aufirst%3DM.%26aulast%3DSartori%26aufirst%3DI.%26aulast%3DSpada%26aufirst%3DS.%26aulast%3DTedesco%26aufirst%3DG.%26aulast%3DTarsi%26aufirst%3DL.%26aulast%3DTerreni%26aufirst%3DS.%26aulast%3DVisentini%26aufirst%3DF.%26aulast%3DZocchi%26aufirst%3DA.%26aulast%3DZonzini%26aufirst%3DL.%26aulast%3DDi%2BFabio%26aufirst%3DR.%26atitle%3D6-%25283%252C4-dichlorophenyl%2529-1-%255B%2528methyloxy%2529methyl%255D-3-azabicyclo%255B4.1.0%255Dheptane%253A%2520a%2520new%2520potent%2520and%2520selective%2520triple%2520reuptake%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D4989%26epage%3D5001%26doi%3D10.1021%2Fjm100481d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, H.</span></span> <span> </span><span class="NLM_article-title">Triple reuptake inhibitors: a patent review (2006 - 2012)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">131</span>– <span class="NLM_lpage">154</span>, <span class="refDoi"> DOI: 10.1517/13543776.2014.859676</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1517%2F13543776.2014.859676" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=24289044" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC2cXptlWgtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=131-154&author=L.+Shaoauthor=W.+Liauthor=Q.+Xieauthor=H.+Yin&title=Triple+reuptake+inhibitors%3A+a+patent+review+%282006+-+2012%29&doi=10.1517%2F13543776.2014.859676"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Triple reuptake inhibitors: a patent review (2006 - 2012)</span></div><div class="casAuthors">Shao, Liming; Li, Wei; Xie, Qiong; Yin, Hong</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">131-154</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: The dysfunctions of three very important monoamine neurotransmitters, serotonin (5-HT), norepinephrine (NE) and dopamine (DA), are assocd. with some of important CNS diseases such as depression; developing the triple reuptake inhibitors (TRIs) that can rebalance 5-HT, NE and DA through the inhibition of the monoamine reuptake transporters will lead to a more effective and safer antidepressant.  Areas covered: This article reviews past 7 years' advances in the development of TRIs; a patent review (2006 - 2012), covering the discovery of new chem. entities, and development status of leading TRI clin. candidates.  Expert opinion: The development of TRIs has several challenges, including discovering a "single" agent that has the activities against all three monoamine reuptake transporters SERT, NET and DAT.  More important is that the agent must have a "right ratio" to be safer and better tolerated for the treatment of depression.  The TRIs can potentially be used for the treatment of other CNS diseases, such as pain, Parkinson's and attention deficit hyperactivity disorder (ADHD), depending on ratios of SERT, NET and DAT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfRC27A4PQmLVg90H21EOLACvtfcHk0lj2w7MJT5bfGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXptlWgtw%253D%253D&md5=ab7d85d58c69476b3f0a4eff944d24ac</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1517%2F13543776.2014.859676&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2014.859676%26sid%3Dliteratum%253Aachs%26aulast%3DShao%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DXie%26aufirst%3DQ.%26aulast%3DYin%26aufirst%3DH.%26atitle%3DTriple%2520reuptake%2520inhibitors%253A%2520a%2520patent%2520review%2520%25282006%2520-%25202012%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2014%26volume%3D24%26spage%3D131%26epage%3D154%26doi%3D10.1517%2F13543776.2014.859676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span> <i>DOV Pharmaceutical</i>; <span class="NLM_publisher-name">Wikipedia</span>, <span class="NLM_year">2017</span>; <a href="https://en.wikipedia.org/wiki/DOV_Pharmaceutical" class="extLink">https://en.wikipedia.org/wiki/DOV_Pharmaceutical</a> (accessed May 29, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+DOV+Pharmaceutical%3B+Wikipedia%2C+2017%3B+https%3A%2F%2Fen.wikipedia.org%2Fwiki%2FDOV_Pharmaceutical+%28accessed+May+29%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DDOV%2520Pharmaceutical%26pub%3DWikipedia%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span> <i>Amitifadine</i>; <span class="NLM_publisher-name">Euthymics Bioscience</span>: <span class="NLM_publisher-loc">Cambridge,
MA</span>, <span class="NLM_year">2017</span>; <a href="http://euthymics.com/amitifadine/" class="extLink">http://euthymics.com/amitifadine/</a> (accessed May 29, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Amitifadine%3B+Euthymics+Bioscience%3A+Cambridge%2C%0AMA%2C+2017%3B+http%3A%2F%2Feuthymics.com%2Famitifadine%2F+%28accessed+May+29%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DAmitifadine%26pub%3DEuthymics%2520Bioscience%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span> <i>Tesofensine Monotherapy
for Treatment of Obesity</i>; <span class="NLM_publisher-name">Saniona</span>: <span class="NLM_publisher-loc">Ballerup, Denmark</span>, <span class="NLM_year">2017</span>; <a href="http://saniona.com/pipeline/tesofensine/" class="extLink">http://saniona.com/pipeline/tesofensine/</a> (accessed May 29, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Tesofensine+Monotherapy%0Afor+Treatment+of+Obesity%3B+Saniona%3A+Ballerup%2C+Denmark%2C+2017%3B+http%3A%2F%2Fsaniona.com%2Fpipeline%2Ftesofensine%2F+%28accessed+May+29%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DTesofensine%2520Monotherapy%250Afor%2520Treatment%2520of%2520Obesity%26pub%3DSaniona%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span> <i>Completion of Phase 1 Clinical
Studies of Ansofaxine Hydrochloride
Extended Release Tablets (LY03005) in the U.S.</i>; <span class="NLM_publisher-name">Luye Pharma</span>: <span class="NLM_publisher-loc">Shanghai</span>, August 13, <span class="NLM_year">2015</span>; <a href="http://www.luye.cn/lvye_en/newsshow.php?id=138" class="extLink">http://www.luye.cn/lvye_en/newsshow.php?id=138</a> (accessed May 29, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Completion+of+Phase+1+Clinical%0AStudies+of+Ansofaxine+Hydrochloride%0AExtended+Release+Tablets+%28LY03005%29+in+the+U.S.%3B+Luye+Pharma%3A+Shanghai%2C+August+13%2C+2015%3B+http%3A%2F%2Fwww.luye.cn%2Flvye_en%2Fnewsshow.php%3Fid%3D138+%28accessed+May+29%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DCompletion%2520of%2520Phase%25201%2520Clinical%250AStudies%2520of%2520Ansofaxine%2520Hydrochloride%250AExtended%2520Release%2520Tablets%2520%2528LY03005%2529%2520in%2520the%2520U.S.%26pub%3DLuye%2520Pharma%26date%3D2015%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Epstein, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brabander, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanshawe, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenzie, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safir, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osterberg, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosulich, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovell, F. M.</span></span> <span> </span><span class="NLM_article-title">1-Aryl-3-azabicyclo[3.1.0]hexanes, a new series of nonnarcotic analgesic agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1981</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">481</span>– <span class="NLM_lpage">490</span>, <span class="refDoi"> DOI: 10.1021/jm00137a002</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00137a002" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADyaL3MXhslCrsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1981&pages=481-490&author=J.+W.+Epsteinauthor=H.+J.+Brabanderauthor=W.+J.+Fanshaweauthor=C.+M.+Hofmannauthor=T.+C.+McKenzieauthor=S.+R.+Safirauthor=A.+C.+Osterbergauthor=D.+B.+Cosulichauthor=F.+M.+Lovell&title=1-Aryl-3-azabicyclo%5B3.1.0%5Dhexanes%2C+a+new+series+of+nonnarcotic+analgesic+agents&doi=10.1021%2Fjm00137a002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">1-Aryl-3-azabicyclo[3.1.0]hexanes, a new series of nonnarcotic analgesic agents</span></div><div class="casAuthors">Epstein, Joseph W.; Brabander, Herbert J.; Fanshawe, William J.; Hofmann, Corris M.; McKenzie, Thomas C.; Safir, Sidney R.; Osterberg, Arnold C.; Cosulich, D. B.; Lovell, F. M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1981</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">481-90</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">The title analgesics I (R = organo substituent) were prepd. by insertion reaction of RC6H4CHBrCO2R with acrylate esters followed by cyclocondensation of the resultant cyclopropanedicarboxylic acid derivs. with urea, than redn. of the resultant amides.  The more potent I are the para-substituted derivs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJZnZ8CYX3_rVg90H21EOLACvtfcHk0lgp57u0psklOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3MXhslCrsr8%253D&md5=16dc7e8543fee35a4a5f4c873d3da3ab</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1021%2Fjm00137a002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00137a002%26sid%3Dliteratum%253Aachs%26aulast%3DEpstein%26aufirst%3DJ.%2BW.%26aulast%3DBrabander%26aufirst%3DH.%2BJ.%26aulast%3DFanshawe%26aufirst%3DW.%2BJ.%26aulast%3DHofmann%26aufirst%3DC.%2BM.%26aulast%3DMcKenzie%26aufirst%3DT.%2BC.%26aulast%3DSafir%26aufirst%3DS.%2BR.%26aulast%3DOsterberg%26aufirst%3DA.%2BC.%26aulast%3DCosulich%26aufirst%3DD.%2BB.%26aulast%3DLovell%26aufirst%3DF.%2BM.%26atitle%3D1-Aryl-3-azabicyclo%255B3.1.0%255Dhexanes%252C%2520a%2520new%2520series%2520of%2520nonnarcotic%2520analgesic%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1981%26volume%3D24%26spage%3D481%26epage%3D490%26doi%3D10.1021%2Fjm00137a002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Epstein, J. W.</span>; <span class="NLM_string-name">Osterberg, A. C.</span>; <span class="NLM_string-name">Brabander, H. J.</span></span> <span> </span><span class="NLM_article-title">Treating Depression Using Azabicyclohexanes</span>. <span class="NLM_patent">US4435419A</span>, <span class="NLM_year">1984</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1984&author=J.+W.+Epstein&author=A.+C.+Osterberg&author=H.+J.+Brabander&title=Treating+Depression+Using+Azabicyclohexanes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DEpstein%26aufirst%3DJ.%2BW.%26atitle%3DTreating%2520Depression%2520Using%2520Azabicyclohexanes%26date%3D1984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skolnick, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krieter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tizzano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basile, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popik, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czobor, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippa, A.</span></span> <span> </span><span class="NLM_article-title">Preclinical and clinical pharmacology of DOV 216,303, a ″triple″ reuptake inhibitor</span>. <i>CNS Drug Rev.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">134</span>, <span class="refDoi"> DOI: 10.1111/j.1527-3458.2006.00123.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1111%2Fj.1527-3458.2006.00123.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=123-134&author=P.+Skolnickauthor=P.+Krieterauthor=J.+Tizzanoauthor=A.+Basileauthor=P.+Popikauthor=P.+Czoborauthor=A.+Lippa&title=Preclinical+and+clinical+pharmacology+of+DOV+216%2C303%2C+a+%E2%80%B3triple%E2%80%B3+reuptake+inhibitor&doi=10.1111%2Fj.1527-3458.2006.00123.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1111%2Fj.1527-3458.2006.00123.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1527-3458.2006.00123.x%26sid%3Dliteratum%253Aachs%26aulast%3DSkolnick%26aufirst%3DP.%26aulast%3DKrieter%26aufirst%3DP.%26aulast%3DTizzano%26aufirst%3DJ.%26aulast%3DBasile%26aufirst%3DA.%26aulast%3DPopik%26aufirst%3DP.%26aulast%3DCzobor%26aufirst%3DP.%26aulast%3DLippa%26aufirst%3DA.%26atitle%3DPreclinical%2520and%2520clinical%2520pharmacology%2520of%2520DOV%2520216%252C303%252C%2520a%2520%25E2%2580%25B3triple%25E2%2580%25B3%2520reuptake%2520inhibitor%26jtitle%3DCNS%2520Drug%2520Rev.%26date%3D2006%26volume%3D12%26spage%3D123%26epage%3D134%26doi%3D10.1111%2Fj.1527-3458.2006.00123.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prins, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenny, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doomernik, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mechiel Korte, S.</span></span> <span> </span><span class="NLM_article-title">The triple reuptake inhibitor DOV 216,303 induces long-lasting enhancement of brain reward activity as measured by intracranial self-stimulation in rats</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>693</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2012.07.047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.ejphar.2012.07.047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=23010469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht12jsr7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=693&publication_year=2012&pages=51-56&author=J.+Prinsauthor=P.+J.+Kennyauthor=I.+Doomernikauthor=R.+Schreiberauthor=B.+Olivierauthor=S.+Mechiel+Korte&title=The+triple+reuptake+inhibitor+DOV+216%2C303+induces+long-lasting+enhancement+of+brain+reward+activity+as+measured+by+intracranial+self-stimulation+in+rats&doi=10.1016%2Fj.ejphar.2012.07.047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">The triple reuptake inhibitor DOV 216,303 induces long-lasting enhancement of brain reward activity as measured by intracranial self-stimulation in rats</span></div><div class="casAuthors">Prins, Jolanda; Kenny, Paul J.; Doomernik, Ivo; Schreiber, Rudy; Olivier, Berend; Mechiel Korte, S.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">693</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">51-56</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Triple reuptake inhibitors (TRIs) are potential new antidepressants, which not only enhance brain serotonin and norepinephrine concns. but also increase dopamine levels.  Therefore TRIs are believed to have faster therapeutic onset than SSRIs, and may be particularly useful for the treatment of anhedonia (i.e. inability to experience pleasure), one of the core symptoms of major depression.  The current study aimed at getting better insight into the rewarding properties of DOV 216,303, which is a TRI, regarding its possible use to treat anhedonia.  It is known that psychostimulant drugs lower intracranial self-stimulation (ICSS) reward thresholds, reflecting enhanced brain reward activity, whereas withdrawal from those compds. mostly results in increased ICSS thresholds.  Therefore we assessed the effects of DOV 216,303 on ICSS thresholds in rats.  Animals were trained in the discrete-trial current-threshold procedure and after stable ICSS reward thresholds were established, animals received one injection per day of DOV 216,303 (20 mg/kg) or amphetamine (5 mg/kg) for four consecutive days.  ICSS thresholds were assessed 3, 6, and 23 h after each injection.  DOV 216,303 decreased ICSS thresholds up to 6 h after drug treatment.  To our knowledge this is the first time that a triple reuptake inhibitor, DOV 216,303, induces relatively long-lasting enhancement of brain reward activity.  Elevated ICSS thresholds were found after amphetamine administration, which is consistent with previously reported reward deficits induced after amphetamine-withdrawal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMZ8xkC7HvdLVg90H21EOLACvtfcHk0lgp57u0psklOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht12jsr7N&md5=933f19e586383e7bbf46eb4c2ab0d5ca</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2012.07.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2012.07.047%26sid%3Dliteratum%253Aachs%26aulast%3DPrins%26aufirst%3DJ.%26aulast%3DKenny%26aufirst%3DP.%2BJ.%26aulast%3DDoomernik%26aufirst%3DI.%26aulast%3DSchreiber%26aufirst%3DR.%26aulast%3DOlivier%26aufirst%3DB.%26aulast%3DMechiel%2BKorte%26aufirst%3DS.%26atitle%3DThe%2520triple%2520reuptake%2520inhibitor%2520DOV%2520216%252C303%2520induces%2520long-lasting%2520enhancement%2520of%2520brain%2520reward%2520activity%2520as%2520measured%2520by%2520intracranial%2520self-stimulation%2520in%2520rats%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2012%26volume%3D693%26spage%3D51%26epage%3D56%26doi%3D10.1016%2Fj.ejphar.2012.07.047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paterson, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balci, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivier, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanania, T.</span></span> <span> </span><span class="NLM_article-title">The triple reuptake inhibitor DOV216,303 exhibits limited antidepressant-like properties in the differential reinforcement of low-rate 72-second responding assay, likely due to dopamine reuptake inhibition</span>. <i>J. Psychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1357</span>– <span class="NLM_lpage">1364</span>, <span class="refDoi"> DOI: 10.1177/0269881110364272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1177%2F0269881110364272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=20305042" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1Wgt7zJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2011&pages=1357-1364&author=N.+E.+Patersonauthor=F.+Balciauthor=U.+Campbellauthor=B.+E.+Olivierauthor=T.+Hanania&title=The+triple+reuptake+inhibitor+DOV216%2C303+exhibits+limited+antidepressant-like+properties+in+the+differential+reinforcement+of+low-rate+72-second+responding+assay%2C+likely+due+to+dopamine+reuptake+inhibition&doi=10.1177%2F0269881110364272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">The triple reuptake inhibitor DOV216, 303 exhibits limited antidepressant-like properties in the differential reinforcement of low-rate 72-second responding assay, likely due to dopamine reuptake inhibition</span></div><div class="casAuthors">Paterson, Neil E.; Balci, Fuat; Campbell, Una; Olivier, Berend E.; Hanania, Taleen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Psychopharmacology (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1357-1364</span>CODEN:
                <span class="NLM_cas:coden">JOPSEQ</span>;
        ISSN:<span class="NLM_cas:issn">0269-8811</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">There is a need for antidepressants with novel mechanisms of action.  One approach has been to develop compds. that inhibit reuptake of all three monoamines in the central nervous system, for example DOV216,303.  Differential reinforcement of low-rate (72-s) responding is a behavioral test that is predictive of antidepressant-like properties.  The effects of antidepressant compds. belonging to multiple classes, the anxiolytic diazepam and the antipsychotic haloperidol, were assessed in the DRL-72S task.  Subsequently, the antidepressant-like properties of acute DOV216,303 were assessed.  The selective serotonin reuptake inhibitor fluvoxamine, the preferential norepinephrine reuptake inhibitor desipramine and the tricyclic antidepressant imipramine exhibited antidepressant-like properties in the DRL-72S task.  The atypical antidepressant bupropion, which inhibits dopamine and norepinephrine reuptake, and the selective dopamine transporter inhibitor GBR12909, changed reinforcement and response rates and inter-response time distribution in an opposite direction compared with the antidepressant compds. tested.  The antipsychotic haloperidol exhibited antidepressant-like properties by increasing reinforcement rate, but failed to alter inter-response time distribution.  Diazepam did not change reinforcement or response rates or inter-response time distribution.  The triple reuptake inhibitor DOV216,303 significantly enhanced reinforcement rate at one intermediate dose, but exhibited similar effects as bupropion and GBR12909 on inter-response time distribution.  The studies identified limited antidepressant-like properties of the triple reuptake inhibitor DOV216,303, likely due to dopamine transporter inhibition counteracting the effects of norepinephrine and serotonin transporter inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLD-HoWXRRD7Vg90H21EOLACvtfcHk0ljnaGs3PNxtZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1Wgt7zJ&md5=23ad988e985ee6924ab863252601d1bd</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1177%2F0269881110364272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0269881110364272%26sid%3Dliteratum%253Aachs%26aulast%3DPaterson%26aufirst%3DN.%2BE.%26aulast%3DBalci%26aufirst%3DF.%26aulast%3DCampbell%26aufirst%3DU.%26aulast%3DOlivier%26aufirst%3DB.%2BE.%26aulast%3DHanania%26aufirst%3DT.%26atitle%3DThe%2520triple%2520reuptake%2520inhibitor%2520DOV216%252C303%2520exhibits%2520limited%2520antidepressant-like%2520properties%2520in%2520the%2520differential%2520reinforcement%2520of%2520low-rate%252072-second%2520responding%2520assay%252C%2520likely%2520due%2520to%2520dopamine%2520reuptake%2520inhibition%26jtitle%3DJ.%2520Psychopharmacol.%26date%3D2011%26volume%3D25%26spage%3D1357%26epage%3D1364%26doi%3D10.1177%2F0269881110364272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Popik, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krawczyk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golembiowska, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowak, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janowsky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skolnick, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basile, A. S.</span></span> <span> </span><span class="NLM_article-title">Pharmacological profile of the ″triple″ monoamine neurotransmitter uptake inhibitor, DOV 102,677</span>. <i>Cell. Mol. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">855</span>– <span class="NLM_lpage">871</span>, <span class="refDoi"> DOI: 10.1007/s10571-006-9012-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1007%2Fs10571-006-9012-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2006&pages=855-871&author=P.+Popikauthor=M.+Krawczykauthor=K.+Golembiowskaauthor=G.+Nowakauthor=A.+Janowskyauthor=P.+Skolnickauthor=A.+Lippaauthor=A.+S.+Basile&title=Pharmacological+profile+of+the+%E2%80%B3triple%E2%80%B3+monoamine+neurotransmitter+uptake+inhibitor%2C+DOV+102%2C677&doi=10.1007%2Fs10571-006-9012-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1007%2Fs10571-006-9012-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10571-006-9012-5%26sid%3Dliteratum%253Aachs%26aulast%3DPopik%26aufirst%3DP.%26aulast%3DKrawczyk%26aufirst%3DM.%26aulast%3DGolembiowska%26aufirst%3DK.%26aulast%3DNowak%26aufirst%3DG.%26aulast%3DJanowsky%26aufirst%3DA.%26aulast%3DSkolnick%26aufirst%3DP.%26aulast%3DLippa%26aufirst%3DA.%26aulast%3DBasile%26aufirst%3DA.%2BS.%26atitle%3DPharmacological%2520profile%2520of%2520the%2520%25E2%2580%25B3triple%25E2%2580%25B3%2520monoamine%2520neurotransmitter%2520uptake%2520inhibitor%252C%2520DOV%2520102%252C677%26jtitle%3DCell.%2520Mol.%2520Neurobiol.%26date%3D2006%26volume%3D26%26spage%3D855%26epage%3D871%26doi%3D10.1007%2Fs10571-006-9012-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McMillen, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shank, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basile, A. S.</span></span> <span> </span><span class="NLM_article-title">Effect of DOV 102,677 on the volitional consumption of ethanol by Myers’ high ethanol-preferring rat</span>. <i>Alcohol.: Clin. Exp. Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">1866</span>– <span class="NLM_lpage">1871</span>, <span class="refDoi"> DOI: 10.1111/j.1530-0277.2007.00513.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1111%2Fj.1530-0277.2007.00513.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=17908267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtleru7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2007&pages=1866-1871&author=B.+A.+McMillenauthor=J.+E.+Shankauthor=K.+B.+Jordanauthor=H.+L.+Williamsauthor=A.+S.+Basile&title=Effect+of+DOV+102%2C677+on+the+volitional+consumption+of+ethanol+by+Myers%E2%80%99+high+ethanol-preferring+rat&doi=10.1111%2Fj.1530-0277.2007.00513.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of DOV 102, 677 on the volitional consumption of ethanol by Myer's high ethanol-preferring rat</span></div><div class="casAuthors">McMillen, Brian A.; Shank, J. Elizabeth; Jordan, Kirstin B.; Williams, Helen L.; Basile, A. S.</div><div class="citationInfo"><span class="NLM_cas:title">Alcoholism: Clinical & Experimental Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1866-1871</span>CODEN:
                <span class="NLM_cas:coden">ACRSDM</span>;
        ISSN:<span class="NLM_cas:issn">0145-6008</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing, Inc.</span>)
        </div><div class="casAbstract">Background: Inhibitors of monoamine neurotransmitter transporters are well established as antidepressants.  However, the evidence that single (serotonin) or dual (serotonin-norepinephrine) neurotransmitter uptake inhibitors can treat ethanol abuse, either as a comorbidity with depression or as a sep. entity, is inconsistent.  Drugs that have, in addn., the ability to inhibit dopamine uptake may have an advantage in the treatment of alc. abuse.  Therefore, the inhibitor of norepinephrine, serotonin and dopamine uptake, DOV 102,677, was tested for its effects on the volitional consumption of ethanol by an ethanol-preferring rat strain.  Methods: Myers' high ethanol-preferring rats were screened by a 10-day, 3 to 30% step-up test and then given free access to the preferred concn. of ethanol in a 3-bottle choice task.  Consumption of ethanol (g/kg), water, food, and body wt. were measured daily during a 3-day predrug treatment period, a 3-day treatment period, and a 3-day posttreatment period.  Addnl. Sprague-Dawley rats were obsd. for 24 h for the behavioral effects of 2.0 mg/kg s.c. reserpine after a 30-min pretreatment with different doses of DOV 102,677.  Results: The triple monoamine uptake inhibitor DOV 102,677 dose-dependently decreased the volitional consumption of ethanol by as much as 71.2% (20 mg/kg i.p., b.i.d.) over 3 days of administration.  This effect carried over into the posttreatment period.  Similarly, the proportion of ethanol to total fluids consumed declined by 66.2% (20 mg/kg s.c., b.i.d.), while food consumption and body wt. were unaltered.  In contrast, amperozide (2 mg/kg i.p., b.i.d.) suppressed the amt. of ethanol consumed by 56%, while naltrexone (5 mg/kg i.p., b.i.d.) was without effect.  DOV 102,677 (40 mg/kg s.c.) inhibited reserpine-induced akinesia and ptosis, but not hypothermia in Sprague-Dawley rats, consistent with its transient inhibition of serotonin transport, and more long-lived inhibition of norepinephrine and dopamine uptake.  Conclusions: DOV 102,677 significantly decreased the volitional consumption of ethanol with minimal alterations in the intake of food or on body wt. in an ethanol-preferring rat strain, suggesting that triple reuptake inhibitors may find utility in treating alc. abuse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8DSfm_oPUJLVg90H21EOLACvtfcHk0ljnaGs3PNxtZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtleru7fN&md5=0ae9d47bd669525cd81941552faa1bbd</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1111%2Fj.1530-0277.2007.00513.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1530-0277.2007.00513.x%26sid%3Dliteratum%253Aachs%26aulast%3DMcMillen%26aufirst%3DB.%2BA.%26aulast%3DShank%26aufirst%3DJ.%2BE.%26aulast%3DJordan%26aufirst%3DK.%2BB.%26aulast%3DWilliams%26aufirst%3DH.%2BL.%26aulast%3DBasile%26aufirst%3DA.%2BS.%26atitle%3DEffect%2520of%2520DOV%2520102%252C677%2520on%2520the%2520volitional%2520consumption%2520of%2520ethanol%2520by%2520Myers%25E2%2580%2599%2520high%2520ethanol-preferring%2520rat%26jtitle%3DAlcohol.%253A%2520Clin.%2520Exp.%2520Res.%26date%3D2007%26volume%3D31%26spage%3D1866%26epage%3D1871%26doi%3D10.1111%2Fj.1530-0277.2007.00513.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warnock, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamczarz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">June, H. L.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallick, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krieter, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skolnick, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basile, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">June, H. L.,  Sr.</span></span> <span> </span><span class="NLM_article-title">Effects of the triple monoamine uptake inhibitor DOV 102,677 on alcohol-motivated responding and antidepressant activity in alcohol-preferring (P) rats</span>. <i>Alcohol.: Clin. Exp. Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">863</span>– <span class="NLM_lpage">873</span>, <span class="refDoi"> DOI: 10.1111/j.1530-0277.2011.01671.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1111%2Fj.1530-0277.2011.01671.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=22150508" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC38Xpt12ntrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2012&pages=863-873&author=A.+R.+Yangauthor=H.+S.+Yiauthor=K.+T.+Warnockauthor=J.+Mamczarzauthor=H.+L.+Juneauthor=N.+Mallickauthor=P.+A.+Krieterauthor=L.+Tonelliauthor=P.+Skolnickauthor=A.+S.+Basileauthor=H.+L.+June&title=Effects+of+the+triple+monoamine+uptake+inhibitor+DOV+102%2C677+on+alcohol-motivated+responding+and+antidepressant+activity+in+alcohol-preferring+%28P%29+rats&doi=10.1111%2Fj.1530-0277.2011.01671.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of the triple monoamine uptake inhibitor DOV 102,677 on alcohol-motivated responding and antidepressant activity in alcohol-preferring (P) rats</span></div><div class="casAuthors">Yang, Andrew R. S. T.; Yi, Heon S.; Warnock, Kaitlin T.; Mamczarz, Jacek; June, Harry L., Jr.; Mallick, Nikhil; Krieter, Philip A.; Tonelli, Leonardo; Skolnick, Phil; Basile, Anthony S.; June, Harry L., Sr.</div><div class="citationInfo"><span class="NLM_cas:title">Alcoholism: Clinical & Experimental Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">863-873</span>CODEN:
                <span class="NLM_cas:coden">ACRSDM</span>;
        ISSN:<span class="NLM_cas:issn">0145-6008</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background: Concurrent inhibitors of dopamine, norepinephrine, and serotonin uptake have been proposed as novel antidepressants.  Given the high comorbidity between alcoholism and depression, we evaluated the activity of DOV 102,677 (DOV) on alc.-maintained responding and performance in the forced swim test (FST), a model of antidepressant (AD) activity, using alc.-preferring (P) rats.  Methods: Following training to lever press for either alc. (10% vol./vol.) or sucrose (3, 2%, w/v) on a fixed-ratio 4 (FR4) schedule, DOV (1.56 to 50 mg/kg; PO) was given 25 min or 24 h prior to evaluation.  The effects of DOV (12.5 to 50 mg/kg; PO) in the FST were evaluated 25 min posttreatment.  Results: DOV (6.25 to 50 mg/kg) dose-dependently reduced alc.-maintained responding by 59 to 88% at 25 min posttreatment, without significantly altering sucrose responding.  The redn. in alc. responding (44% at 50 mg/kg) was sustained for up to 120 h after a single dose.  Administration of a single dose of DOV (25, 50 mg/kg) 24 h before testing suppressed alc. responding for 48 h by 59 to 62%.  DOV (12.5 to 50 mg/kg) also dose-dependently reduced immobility of P rats in the FST.  Conclusions: DOV produces both prolonged and selective redns. of alc.-motivated behaviors in P rats.  The elimination kinetics of DOV suggests that its long duration of action may be due to an active metabolite.  DOV also produced robust AD-like effects in P rats.  We propose that DOV may be useful in treating comorbid alcoholism and depression in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVZ08SO9LzLbVg90H21EOLACvtfcHk0ljnaGs3PNxtZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xpt12ntrc%253D&md5=19dbe12c6263ef88de30de25475dbe81</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1111%2Fj.1530-0277.2011.01671.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1530-0277.2011.01671.x%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DA.%2BR.%26aulast%3DYi%26aufirst%3DH.%2BS.%26aulast%3DWarnock%26aufirst%3DK.%2BT.%26aulast%3DMamczarz%26aufirst%3DJ.%26aulast%3DJune%26aufirst%3DH.%2BL.%26aulast%3DMallick%26aufirst%3DN.%26aulast%3DKrieter%26aufirst%3DP.%2BA.%26aulast%3DTonelli%26aufirst%3DL.%26aulast%3DSkolnick%26aufirst%3DP.%26aulast%3DBasile%26aufirst%3DA.%2BS.%26aulast%3DJune%26aufirst%3DH.%2BL.%26atitle%3DEffects%2520of%2520the%2520triple%2520monoamine%2520uptake%2520inhibitor%2520DOV%2520102%252C677%2520on%2520alcohol-motivated%2520responding%2520and%2520antidepressant%2520activity%2520in%2520alcohol-preferring%2520%2528P%2529%2520rats%26jtitle%3DAlcohol.%253A%2520Clin.%2520Exp.%2520Res.%26date%3D2012%26volume%3D36%26spage%3D863%26epage%3D873%26doi%3D10.1111%2Fj.1530-0277.2011.01671.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bymaster, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulze, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, R. D.</span></span> <span> </span><span class="NLM_article-title">Biopharmaceutical characterization, metabolism, and brain penetration of the triple reuptake inhibitor amitifadine</span>. <i>Drug Metab. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">23</span>– <span class="NLM_lpage">33</span>, <span class="refDoi"> DOI: 10.2174/18723128112069990010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.2174%2F18723128112069990010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=23826879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisFajtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2013&pages=23-33&author=F.+P.+Bymasterauthor=P.+Chaoauthor=H.+Schulzeauthor=P.+V.+Tranauthor=R.+D.+Marshall&title=Biopharmaceutical+characterization%2C+metabolism%2C+and+brain+penetration+of+the+triple+reuptake+inhibitor+amitifadine&doi=10.2174%2F18723128112069990010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Biopharmaceutical characterization, metabolism, and brain penetration of the triple reuptake inhibitor amitifadine</span></div><div class="casAuthors">Bymaster, Frank P.; Chao, Piyun; Schulze, Heidi; Tran, Pierre V.; Marshall, Randall D.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">23-33</span>CODEN:
                <span class="NLM_cas:coden">DMLRBM</span>;
        ISSN:<span class="NLM_cas:issn">1872-3128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Amitifadine (EB-1010, formerly DOV 21,947) is a serotonin-preferring triple reuptake inhibitor that is a drug candidate for major depressive disorder.  We investigated several relevant biopharmaceutic and drug-like characteristics of amitifadine using in vitro methodol. and addnl. detd. the in vivo brain to plasma ratio of the drug in rats.  Amitifadine was highly plasma protein bound with over 99% of drug bound to human plasma proteins.  Using Caco-2 cell lines, amitifadine was bidirectionally highly permeable and showed no evidence of active secretion.  Amitifadine was metabolized slowly by human hepatocytes and the major metabolite was the lactam EB-10101.  In vitro studies using human liver microsomes demonstrated that EB-10101 was formed by monoamine oxidase A (MAO-A) and a NADPHdependent enzyme, possibly a cytochrome P 450 (CYP) isoform.  Amitifadine was a moderate inhibitor of the human isoforms of the major drug metabolizing enzymes CYP2D6, CYP3A4, CYP2C9, and CYP2C19 (IC50 = 9 - 100 μM), but was a potent inhibitor of human CYP2B6 (IC50 = 1.8 μM).  The brain to plasma ratio for amitifadine varied from 3.7 - 6.5 at various time points, indicating preferential partitioning into rat brain vs. plasma.  The low affinity for the major drug metabolizing CYP enzymes and metab. by multiple pathways may reduce pharmacokinetic drug-drug interactions and effects of enzyme polymorphisms.  Overall, these studies suggest that amitifadine has drug-like characteristics favorable for drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZuI6J8IwbJLVg90H21EOLACvtfcHk0lheTnC1lkWkcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisFajtL0%253D&md5=aaa87242ed782dd93198de5a9950b96d</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.2174%2F18723128112069990010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F18723128112069990010%26sid%3Dliteratum%253Aachs%26aulast%3DBymaster%26aufirst%3DF.%2BP.%26aulast%3DChao%26aufirst%3DP.%26aulast%3DSchulze%26aufirst%3DH.%26aulast%3DTran%26aufirst%3DP.%2BV.%26aulast%3DMarshall%26aufirst%3DR.%2BD.%26atitle%3DBiopharmaceutical%2520characterization%252C%2520metabolism%252C%2520and%2520brain%2520penetration%2520of%2520the%2520triple%2520reuptake%2520inhibitor%2520amitifadine%26jtitle%3DDrug%2520Metab.%2520Lett.%26date%3D2013%26volume%3D7%26spage%3D23%26epage%3D33%26doi%3D10.2174%2F18723128112069990010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skolnick, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popik, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janowsky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippa, A. S.</span></span> <span> </span><span class="NLM_article-title">Antidepressant-like actions of DOV 21,947: a ″triple″ reuptake inhibitor</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>461</i></span>,  <span class="NLM_fpage">99</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.1016/S0014-2999(03)01310-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2FS0014-2999%2803%2901310-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=12586204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhtVanu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=461&publication_year=2003&pages=99-104&author=P.+Skolnickauthor=P.+Popikauthor=A.+Janowskyauthor=B.+Beerauthor=A.+S.+Lippa&title=Antidepressant-like+actions+of+DOV+21%2C947%3A+a+%E2%80%B3triple%E2%80%B3+reuptake+inhibitor&doi=10.1016%2FS0014-2999%2803%2901310-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor</span></div><div class="casAuthors">Skolnick, Phil; Popik, Piotr; Janowsky, Aaron; Beer, Bernard; Lippa, Arnold S.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">461</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">99-104</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">DOV 21,947 [(+)-1-(3,4-dichlorophenyl)-3-azabicyclo-[3.1.0]hexane hydrochloride] inhibits the reuptake of [3H]serotonin, [3H]norepinephrine, and [3H]dopamine in human embryonic kidney (HEK) 293 cells expressing the corresponding human recombinant transporters (IC50 values of 12, 23, and 96 nM, resp.).  This compd. also inhibits [125I]RTI 55 (3β-(4-iodophenyl)tropane-2β-carboxylic acid Me ester) binding to the corresponding transporter proteins in membranes prepd. from these cells (Ki values of 99, 262, and 213 nM, resp.).  DOV 21,947 reduces the duration of immobility in the forced swim test (using rats) with an oral min. ED of 5 mg/kg.  This antidepressant-like effect manifests in the absence of significant increases in motor activity at doses of up to 20 mg/kg.  DOV 21,947 also produces a dose-dependent redn. in immobility in the tail suspension test, with a min. effective oral dose of 5 mg/kg.  The ability of DOV 21,947 to inhibit the reuptake of three biogenic amines closely linked to the etiol. of depression may result in a therapeutic profile different from antidepressants that inhibit the reuptake of serotonin and/or norepinephrine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2Q0j1ranmerVg90H21EOLACvtfcHk0lheTnC1lkWkcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhtVanu7s%253D&md5=6d48dc293c8237d42932da3effa40b8a</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2803%2901310-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252803%252901310-4%26sid%3Dliteratum%253Aachs%26aulast%3DSkolnick%26aufirst%3DP.%26aulast%3DPopik%26aufirst%3DP.%26aulast%3DJanowsky%26aufirst%3DA.%26aulast%3DBeer%26aufirst%3DB.%26aulast%3DLippa%26aufirst%3DA.%2BS.%26atitle%3DAntidepressant-like%2520actions%2520of%2520DOV%252021%252C947%253A%2520a%2520%25E2%2580%25B3triple%25E2%2580%25B3%2520reuptake%2520inhibitor%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2003%26volume%3D461%26spage%3D99%26epage%3D104%26doi%3D10.1016%2FS0014-2999%2803%2901310-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Warnock, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">June, H. L.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basile, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skolnick, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">June, H. L.</span></span> <span> </span><span class="NLM_article-title">Amitifadine, a triple monoamine uptake inhibitor, reduces binge drinking and negative affect in an animal model of co-occurring alcoholism and depression symptomatology</span>. <i>Pharmacol., Biochem. Behav.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">118</span>, <span class="refDoi"> DOI: 10.1016/j.pbb.2012.07.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.pbb.2012.07.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=22884707" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlGqtL7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2012&pages=111-118&author=K.+T.+Warnockauthor=A.+R.+Yangauthor=H.+S.+Yiauthor=H.+L.+Juneauthor=T.+Kellyauthor=A.+S.+Basileauthor=P.+Skolnickauthor=H.+L.+June&title=Amitifadine%2C+a+triple+monoamine+uptake+inhibitor%2C+reduces+binge+drinking+and+negative+affect+in+an+animal+model+of+co-occurring+alcoholism+and+depression+symptomatology&doi=10.1016%2Fj.pbb.2012.07.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Amitifadine, a triple monoamine uptake inhibitor, reduces binge drinking and negative affect in an animal model of co-occurring alcoholism and depression symptomatology</span></div><div class="casAuthors">Warnock, Kaitlin T.; Yang, Andrew R. S. T.; Yi, Heon S.; June, Harry L., Jr.; Kelly, Timothy; Basile, Anthony S.; Skolnick, Phil; June, Harry L., Sr.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology, Biochemistry and Behavior</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">111-118</span>CODEN:
                <span class="NLM_cas:coden">PBBHAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-3057</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The co-occurrence of alcoholism and depression is highly prevalent and difficult to treat.  In an animal model of binge drinking that exhibits abstinence-induced behaviors reminiscent of neg. affective states, the triple monoamine uptake inhibitor, amitifadine, produced a selective, dose dependent attenuation of binge drinking.  Amitifadine also reversed abstinence-induced increases in the intracranial self-stimulation threshold, a model of anhedonia, and immobility in the forced swim test, reflecting behavioral despair.  In view of the safety profile of amitifadine in humans, including low risk for wt. gain, lack of sexual side effects, and low potential for abuse, we hypothesize that amitifadine will be effective in treating co-occurring alcoholism and depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorH3-qgzywA7Vg90H21EOLACvtfcHk0lheTnC1lkWkcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlGqtL7L&md5=94866704cecdcda652b1a1bf647e4120</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1016%2Fj.pbb.2012.07.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pbb.2012.07.014%26sid%3Dliteratum%253Aachs%26aulast%3DWarnock%26aufirst%3DK.%2BT.%26aulast%3DYang%26aufirst%3DA.%2BR.%26aulast%3DYi%26aufirst%3DH.%2BS.%26aulast%3DJune%26aufirst%3DH.%2BL.%26aulast%3DKelly%26aufirst%3DT.%26aulast%3DBasile%26aufirst%3DA.%2BS.%26aulast%3DSkolnick%26aufirst%3DP.%26aulast%3DJune%26aufirst%3DH.%2BL.%26atitle%3DAmitifadine%252C%2520a%2520triple%2520monoamine%2520uptake%2520inhibitor%252C%2520reduces%2520binge%2520drinking%2520and%2520negative%2520affect%2520in%2520an%2520animal%2520model%2520of%2520co-occurring%2520alcoholism%2520and%2520depression%2520symptomatology%26jtitle%3DPharmacol.%252C%2520Biochem.%2520Behav.%26date%3D2012%26volume%3D103%26spage%3D111%26epage%3D118%26doi%3D10.1016%2Fj.pbb.2012.07.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tizzano, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stribling, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Tilve, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strack, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frassetto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, R. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shearman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krieter, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschop, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skolnick, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basile, A. S.</span></span> <span> </span><span class="NLM_article-title">The triple uptake inhibitor (1R,5S)-(+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0] hexane hydrochloride (DOV 21947) reduces body weight and plasma triglycerides in rodent models of diet-induced obesity</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>324</i></span>,  <span class="NLM_fpage">1111</span>– <span class="NLM_lpage">1126</span>, <span class="refDoi"> DOI: 10.1124/jpet.107.133132</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1124%2Fjpet.107.133132" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=18089843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BD1cXivVajsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=324&publication_year=2008&pages=1111-1126&author=J.+P.+Tizzanoauthor=D.+S.+Striblingauthor=D.+Perez-Tilveauthor=A.+Strackauthor=A.+Frassettoauthor=R.+Z.+Chenauthor=T.+M.+Fongauthor=L.+Shearmanauthor=P.+A.+Krieterauthor=M.+H.+Tschopauthor=P.+Skolnickauthor=A.+S.+Basile&title=The+triple+uptake+inhibitor+%281R%2C5S%29-%28%2B%29-1-%283%2C4-dichlorophenyl%29-3-azabicyclo%5B3.1.0%5D+hexane+hydrochloride+%28DOV+21947%29+reduces+body+weight+and+plasma+triglycerides+in+rodent+models+of+diet-induced+obesity&doi=10.1124%2Fjpet.107.133132"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">The triple uptake inhibitor (1R,5S)-(+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane hydrochloride (DOV 21947) reduces body weight and plasma triglycerides in rodent models of diet-induced obesity</span></div><div class="casAuthors">Tizzano, Joseph P.; Stribling, D. Sloan; Perez-Tilve, Diego; Strack, Alison; Frassetto, Andrea; Chen, Richard Z.; Fong, Tung M.; Shearman, Lauren; Krieter, Philip A.; Tschop, Matthias H.; Skolnick, Phil; Basile, Anthony S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">324</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1111-1126</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Selective inhibitors of biogenic amine (e.g., serotonin, norepinephrine, and dopamine) uptake exhibit varying degrees of safety and efficacy as antiobesity agents.  Moreover, preclin. findings suggest that the combined inhibition of monoamine neurotransmitter transporters synergistically enhances antiobesity activity.  (1R,5S)-(+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0] hexane hydrochloride (DOV 21947) inhibits norepinephrine, 5-hydroxytryptamine, and dopamine uptake, and it reduces body wt. in rodent models of diet-induced obesity (DIO).  DIO rats treated orally with DOV 21947 for 1 to 24 days showed significantly lower body wts. than vehicle-treated DIO rats.  The decrease in body wt. resulted specifically from a loss of retroperitoneal and mesenteric depots of white adipose tissue.  DOV 21947 also reduced daily food intake in DIO rats, but consumption returned to control levels after 11 days of treatment.  With the exception of a decrease in triglyceride levels, blood chem. was unaltered after 24 days of DOV 21947 treatments.  DOV 21947 had no effect on motor activity.  Although DOV 21947 increased respiratory rate and decreased the tidal vol. of normal rats, it did not alter the minute vol.  In addn., DOV 21947 did not significantly affect blood pressure, heart rate, electrocardiog. indexes or body temp. in telemeterized dogs.  However, it caused a sustained, but reversible redn. in the rate of body wt. gain for as long as 6 mo in normal rats, and for up to 1 yr in normal dogs.  In summary, DOV 21947 is effective in causing a sustained and selective redn. in fat content and triglyceride levels in animal models of obesity without significantly altering vital organ function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAGaRULYopOrVg90H21EOLACvtfcHk0li-Np8TLZ6K7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXivVajsLk%253D&md5=07f9fe5d76f9695fa8c8be51f0019493</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1124%2Fjpet.107.133132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.107.133132%26sid%3Dliteratum%253Aachs%26aulast%3DTizzano%26aufirst%3DJ.%2BP.%26aulast%3DStribling%26aufirst%3DD.%2BS.%26aulast%3DPerez-Tilve%26aufirst%3DD.%26aulast%3DStrack%26aufirst%3DA.%26aulast%3DFrassetto%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DR.%2BZ.%26aulast%3DFong%26aufirst%3DT.%2BM.%26aulast%3DShearman%26aufirst%3DL.%26aulast%3DKrieter%26aufirst%3DP.%2BA.%26aulast%3DTschop%26aufirst%3DM.%2BH.%26aulast%3DSkolnick%26aufirst%3DP.%26aulast%3DBasile%26aufirst%3DA.%2BS.%26atitle%3DThe%2520triple%2520uptake%2520inhibitor%2520%25281R%252C5S%2529-%2528%252B%2529-1-%25283%252C4-dichlorophenyl%2529-3-azabicyclo%255B3.1.0%255D%2520hexane%2520hydrochloride%2520%2528DOV%252021947%2529%2520reduces%2520body%2520weight%2520and%2520plasma%2520triglycerides%2520in%2520rodent%2520models%2520of%2520diet-induced%2520obesity%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2008%26volume%3D324%26spage%3D1111%26epage%3D1126%26doi%3D10.1124%2Fjpet.107.133132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tran, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skolnick, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czobor, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, N. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradshaw, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKinney, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fava, M.</span></span> <span> </span><span class="NLM_article-title">Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial</span>. <i>J. Psychiatr. Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">64</span>– <span class="NLM_lpage">71</span>, <span class="refDoi"> DOI: 10.1016/j.jpsychires.2011.09.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.jpsychires.2011.09.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=21925682" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A280%3ADC%252BC38%252Fit1egtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2012&pages=64-71&author=P.+Tranauthor=P.+Skolnickauthor=P.+Czoborauthor=N.+Y.+Huangauthor=M.+Bradshawauthor=A.+McKinneyauthor=M.+Fava&title=Efficacy+and+tolerability+of+the+novel+triple+reuptake+inhibitor+amitifadine+in+the+treatment+of+patients+with+major+depressive+disorder%3A+a+randomized%2C+double-blind%2C+placebo-controlled+trial&doi=10.1016%2Fj.jpsychires.2011.09.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial</span></div><div class="casAuthors">Tran Pierre; Skolnick Phil; Czobor Pal; Huang N Y; Bradshaw Mark; McKinney Anthony; Fava Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of psychiatric research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">64-71</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Amitifadine (EB-1010, formerly DOV 21,947) is a serotonin-preferring triple reuptake inhibitor with a relative potency to inhibit serotonin, norepinephrine, and dopamine uptake of ∼1:2:8, respectively.  This 6-week, multicenter, randomized, double-blind, parallel, placebo-controlled study evaluated the efficacy and tolerability of amitifadine in 63 patients with major depressive disorder.  Eligible patients (17-item Hamilton Depression Rating Scale [HAMD-17] ≥ 22 at baseline) were randomized to amitifadine 25 mg twice daily (BID) for 2 weeks, then 50 mg BID for 4 weeks or placebo.  Mean baseline scores in the modified intent-to-treat population (n = 56) were 31.4 for the Montgomery-ÅAsberg Depression Rating Scale (MADRS), 29.6 for the HAMD-17, and 25.4 for the Derogatis Interview for Sexual Functioning - Self Report (DISF-SR).  At the end of the 6-week double-blind treatment, estimated least squares mean change from baseline (mixed-model repeated measures [MMRM]) in MADRS total score was statistically significantly superior for amitifadine compared to placebo (18.2 vs. 22.0; p = 0.028), with an overall statistical effect size of -0.601 (Cohen's d).  Amitifadine also was statistically significantly superior to placebo (p = 0.03) for the Clinical Global Impression of Change - Improvement.  An anhedonia factor score grouping of MADRS Items 1 (apparent sadness), 2 (reported sadness), 6 (concentration difficulties), 7 (lassitude), and 8 (inability to feel) demonstrated a statistically significant difference in favor of amitifadine compared to placebo (p = 0.049).  No differences were observed between treatments in DISF-SR scores.  Amitifadine was well-tolerated.  Two patients on each treatment discontinued the study early due to adverse events; however, no serious adverse events were reported.  This initial clinical trial in patients with severe major depression demonstrated significant antidepressant activity with amitifadine, including attenuating symptoms of anhedonia, and a tolerability profile that was comparable to placebo.  The efficacy and tolerability of amitifadine for major depressive disorder are being investigated in additional clinical trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTmctIp6zqMcTjk2McQZ6XmfW6udTcc2eahSL_c1KRRJbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38%252Fit1egtg%253D%253D&md5=b5d126b873f147394eecae3c1172332d</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1016%2Fj.jpsychires.2011.09.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpsychires.2011.09.003%26sid%3Dliteratum%253Aachs%26aulast%3DTran%26aufirst%3DP.%26aulast%3DSkolnick%26aufirst%3DP.%26aulast%3DCzobor%26aufirst%3DP.%26aulast%3DHuang%26aufirst%3DN.%2BY.%26aulast%3DBradshaw%26aufirst%3DM.%26aulast%3DMcKinney%26aufirst%3DA.%26aulast%3DFava%26aufirst%3DM.%26atitle%3DEfficacy%2520and%2520tolerability%2520of%2520the%2520novel%2520triple%2520reuptake%2520inhibitor%2520amitifadine%2520in%2520the%2520treatment%2520of%2520patients%2520with%2520major%2520depressive%2520disorder%253A%2520a%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520trial%26jtitle%3DJ.%2520Psychiatr.%2520Res.%26date%3D2012%26volume%3D46%26spage%3D64%26epage%3D71%26doi%3D10.1016%2Fj.jpsychires.2011.09.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span> <i>Euthymics Reports Top-Line Results from Triade
Trial of Amitifadine
for Major Depressive Disorder</i>; <span class="NLM_publisher-name">Euthymics
Bioscience</span>: <span class="NLM_publisher-loc">Cambridge, MA</span>, May 29, <span class="NLM_year">2013</span>; <a href="http://euthymics.com/wp-content/uploads/2013/05/FINAL_Euthymics_TRIADE_Results_052913.pdf" class="extLink">http://euthymics.com/wp-content/uploads/2013/05/FINAL_Euthymics_TRIADE_Results_052913.pdf</a> (accessed May 29, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Euthymics+Reports+Top-Line+Results+from+Triade%0ATrial+of+Amitifadine%0Afor+Major+Depressive+Disorder%3B+Euthymics%0ABioscience%3A+Cambridge%2C+MA%2C+May+29%2C+2013%3B+http%3A%2F%2Feuthymics.com%2Fwp-content%2Fuploads%2F2013%2F05%2FFINAL_Euthymics_TRIADE_Results_052913.pdf+%28accessed+May+29%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DEuthymics%2520Reports%2520Top-Line%2520Results%2520from%2520Triade%250ATrial%2520of%2520Amitifadine%250Afor%2520Major%2520Depressive%2520Disorder%26pub%3DEuthymics%250ABioscience%26date%3D2013%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lehr, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staab, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tillmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trommeshauser, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raschig, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kloft, C.</span></span> <span> </span><span class="NLM_article-title">Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer’s disease</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">36</span>– <span class="NLM_lpage">48</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2125.2007.02855.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1111%2Fj.1365-2125.2007.02855.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=17324246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BD2sXosFSns70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2007&pages=36-48&author=T.+Lehrauthor=A.+Staabauthor=C.+Tillmannauthor=D.+Trommeshauserauthor=A.+Raschigauthor=H.+G.+Schaeferauthor=C.+Kloft&title=Population+pharmacokinetic+modelling+of+NS2330+%28tesofensine%29+and+its+major+metabolite+in+patients+with+Alzheimer%E2%80%99s+disease&doi=10.1111%2Fj.1365-2125.2007.02855.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's disease</span></div><div class="casAuthors">Lehr, Thorsten; Staab, Alexander; Tillmann, Christiane; Trommeshauser, Dirk; Raschig, Andreas; Schaefer, Hans Guenter; Kloft, Charlotte</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">36-48</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">To develop a population pharmacokinetic model for NS2330 and its major metabolite M1 based on data from a 14 wk proof of concept study in patients with Alzheimer's disease, and to identify covariates that might influence the pharmacokinetic characteristics of the drug and/or its metabolite.  Plasma data from 320 subjects undergoing multiple oral dosing, and consisting of 1969 NS2330 and 1714 metabolite concns. were fitted simultaneously using NONMEM.  Plasma concn.-time profiles of NS2330 and M1 were best described by one-compartment models with first-order elimination for both compds.  Absorption of NS2330 was best modelled by a first-order process.  Low apparent clearances together with large apparent vols. of distribution resulted in long half-lives of 234 h (NS2330) and 374 h (M1).  The covariate anal. identified wt., sex, CLCR, BMI and age as influencing the pharmacokinetics of NS2330 and/or M1.  However, simulations performed revealed that only CLCR and sex had a significant effect on the steady-state plasma concn.-time profiles.  Females with a creatinine clearance of 35.6 mL min-1 showed a 62% increased exposure compared with males without renal impairment.  The robustness and accuracy of the model were demonstrated by the successful predictivity of an external dataset.  A descriptive, robust and predictive model for NS2330 and its M1 metabolite was developed.  Important covariates influencing pharmacokinetics were identified, which might guide the further development of NS2330 and optimize its long-term use in the treatment of Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvoTGTNOJg7LVg90H21EOLACvtfcHk0li-Np8TLZ6K7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXosFSns70%253D&md5=14979b8efaad2481febe1ef463f51b7e</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2007.02855.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2007.02855.x%26sid%3Dliteratum%253Aachs%26aulast%3DLehr%26aufirst%3DT.%26aulast%3DStaab%26aufirst%3DA.%26aulast%3DTillmann%26aufirst%3DC.%26aulast%3DTrommeshauser%26aufirst%3DD.%26aulast%3DRaschig%26aufirst%3DA.%26aulast%3DSchaefer%26aufirst%3DH.%2BG.%26aulast%3DKloft%26aufirst%3DC.%26atitle%3DPopulation%2520pharmacokinetic%2520modelling%2520of%2520NS2330%2520%2528tesofensine%2529%2520and%2520its%2520major%2520metabolite%2520in%2520patients%2520with%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2007%26volume%3D64%26spage%3D36%26epage%3D48%26doi%3D10.1111%2Fj.1365-2125.2007.02855.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sjodin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasteyger, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raben, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikkelsen, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meier, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Astrup, A.</span></span> <span> </span><span class="NLM_article-title">The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men</span>. <i>Int. J. Obes.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">1634</span>– <span class="NLM_lpage">1643</span>, <span class="refDoi"> DOI: 10.1038/ijo.2010.87</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1038%2Fijo.2010.87" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A280%3ADC%252BC3cbms1ChsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2010&pages=1634-1643&author=A.+Sjodinauthor=C.+Gasteygerauthor=A.+L.+Nielsenauthor=A.+Rabenauthor=J.+D.+Mikkelsenauthor=J.+K.+Jensenauthor=D.+Meierauthor=A.+Astrup&title=The+effect+of+the+triple+monoamine+reuptake+inhibitor+tesofensine+on+energy+metabolism+and+appetite+in+overweight+and+moderately+obese+men&doi=10.1038%2Fijo.2010.87"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men</span></div><div class="casAuthors">Sjodin A; Gasteyger C; Nielsen A-Lh; Raben A; Mikkelsen J D; Jensen J K S; Meier D; Astrup A</div><div class="citationInfo"><span class="NLM_cas:title">International journal of obesity (2005)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1634-43</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Tesofensine (TE) is a new drug producing twice the weight loss in obese individuals as seen with currently marketed drugs.  It inhibits the presynaptic reuptake of the neurotransmitters noradrenaline, dopamine and serotonin, and is thought to enhance the neurotransmission of all three monoamines.  The mechanisms by which it produces weight loss in humans are unresolved.  OBJECTIVE:  The aim of this study is to investigate the mechanism(s) behind weight reduction by measuring energy expenditure and appetite sensations in overweight and obese individuals.  DESIGN:  Thirty-two healthy, overweight or moderately obese men were treated with 2.0 mg TE daily for 7 days followed by an additional 7 days with 1.0 mg TE daily or corresponding placebo (PL) in a randomized, controlled trial.  They were instructed to maintain habitual food intake and physical activity throughout.  Twenty-four-hour energy expenditure (24-h EE), fat oxidation and spontaneous physical activity were measured in a respiration chamber before and after treatment.  Body composition was assessed by dual-energy X-ray absorption and appetite was evaluated by visual analogue scales in conjunction with a standardized dinner.  RESULTS:  Despite efforts to keep body weight and composition constant, TE induced a 1.8 kg weight loss above PL after 2 weeks' treatment (P<0.0001).  TE also induced higher ratings of satiety and fullness and concomitantly lower prospective food intake than placebo.  No significant effect of TE on total 24-h EE could be demonstrated compared with PL, but higher energy expenditure was observed during the night period (4.6%; P<0.05) when adjusted for changes in body composition.  Furthermore, TE increased 24-h fat oxidation as compared with PL (18 g; P<0.001).  CONCLUSION:  TE has a pronounced effect on appetite sensations and a slight effect on energy expenditure at night-both effects can contribute to the strong weight-reducing effect of TE.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR_wBLt_dxV7jMsgLhIoICsfW6udTcc2eYzDbztkgYb6rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cbms1ChsA%253D%253D&md5=59ca0be72654f390c5e85283b5dcb676</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1038%2Fijo.2010.87&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fijo.2010.87%26sid%3Dliteratum%253Aachs%26aulast%3DSjodin%26aufirst%3DA.%26aulast%3DGasteyger%26aufirst%3DC.%26aulast%3DNielsen%26aufirst%3DA.%2BL.%26aulast%3DRaben%26aufirst%3DA.%26aulast%3DMikkelsen%26aufirst%3DJ.%2BD.%26aulast%3DJensen%26aufirst%3DJ.%2BK.%26aulast%3DMeier%26aufirst%3DD.%26aulast%3DAstrup%26aufirst%3DA.%26atitle%3DThe%2520effect%2520of%2520the%2520triple%2520monoamine%2520reuptake%2520inhibitor%2520tesofensine%2520on%2520energy%2520metabolism%2520and%2520appetite%2520in%2520overweight%2520and%2520moderately%2520obese%2520men%26jtitle%3DInt.%2520J.%2520Obes.%26date%3D2010%26volume%3D34%26spage%3D1634%26epage%3D1643%26doi%3D10.1038%2Fijo.2010.87" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bentzen, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grunnet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyveled-Nielsen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundgreen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lassen, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, H. H.</span></span> <span> </span><span class="NLM_article-title">Anti-hypertensive treatment preserves appetite suppression while preventing cardiovascular adverse effects of tesofensine in rats</span>. <i>Obesity</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">985</span>– <span class="NLM_lpage">992</span>, <span class="refDoi"> DOI: 10.1002/oby.20122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1002%2Foby.20122" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=23784901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvFaksb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=985-992&author=B.+H.+Bentzenauthor=M.+Grunnetauthor=L.+Hyveled-Nielsenauthor=C.+Sundgreenauthor=J.+B.+Lassenauthor=H.+H.+Hansen&title=Anti-hypertensive+treatment+preserves+appetite+suppression+while+preventing+cardiovascular+adverse+effects+of+tesofensine+in+rats&doi=10.1002%2Foby.20122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-hypertensive treatment preserves appetite suppression while preventing cardiovascular adverse effects of tesofensine in rats</span></div><div class="casAuthors">Bentzen, Bo Hjorth; Grunnet, Morten; Hyveled-Nielsen, Lars; Sundgreen, Claus; Lassen, Jorgen Buus; Hansen, Henrik H.</div><div class="citationInfo"><span class="NLM_cas:title">Obesity</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">985-992</span>CODEN:
                <span class="NLM_cas:coden">OBESAX</span>;
        ISSN:<span class="NLM_cas:issn">1930-7381</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Tesofensine is a novel triple monoamine reuptake inhibitor which is in development for the treatment of obesity.  Preclin. and clin. data suggest that appetite suppression is an important mechanism by which tesofensine exerts its robust wt. reducing effect.  Notably, the strong hypophagic response to tesofensine treatment is demonstrated to be linked to central stimulation of noradrenergic and dopaminergic neurotransmission.  The sympathomimetic mode of action of tesofensine may also assoc. with the elevated heart rate and blood pressure obsd. in clin. settings, and we therefore sought exptl. to address this issue.  The anorexigenic and cardiovascular effects of tesofensine were studied simultaneously in telemetrized conscious rats in a combined real-time food intake and cardiovascular telemetry monitoring system.  Acute administration of tesofensine caused a dose-dependent hypophagic effect as well as increased heart rate and blood pressure.  Interestingly, combined treatment with metoprolol (b1 adrenoceptor blocker, 10-20 mg/kg, p.o.) fully prevented the cardiovascular sympathetic effects of tesofensine while leaving the robust inhibitory efficacy on food intake unaffected.  Similarly, the angiotensin AT1 receptor antagonist telmisartan (1.0-3.0 mg/kg, p.o.) did not interfere with the anti-obesity effects of tesofensine, however, telmisartan only partially reversed the increase in systolic blood pressure and had no effect on the elevated heart rate induced by tesofensine.  These data suggests that tesofensine causes elevations in heart rate and blood pressure by increasing sympathetic activity, and that different adrenoceptor subtypes may be responsible for the anti-obesity and cardiovascular effects of tesofensine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYdI04qUz3SLVg90H21EOLACvtfcHk0lg4ZbK6dwrc5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvFaksb8%253D&md5=ffd4c6fccca0796e37be27ef6c13deb1</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1002%2Foby.20122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Foby.20122%26sid%3Dliteratum%253Aachs%26aulast%3DBentzen%26aufirst%3DB.%2BH.%26aulast%3DGrunnet%26aufirst%3DM.%26aulast%3DHyveled-Nielsen%26aufirst%3DL.%26aulast%3DSundgreen%26aufirst%3DC.%26aulast%3DLassen%26aufirst%3DJ.%2BB.%26aulast%3DHansen%26aufirst%3DH.%2BH.%26atitle%3DAnti-hypertensive%2520treatment%2520preserves%2520appetite%2520suppression%2520while%2520preventing%2520cardiovascular%2520adverse%2520effects%2520of%2520tesofensine%2520in%2520rats%26jtitle%3DObesity%26date%3D2013%26volume%3D21%26spage%3D985%26epage%3D992%26doi%3D10.1002%2Foby.20122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Learned, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graff, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roychowdhury, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moate, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnan, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Archer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modell, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamuner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavergne, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evoniuk, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratti, E.</span></span> <span> </span><span class="NLM_article-title">Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials</span>. <i>J. Psychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">653</span>– <span class="NLM_lpage">662</span>, <span class="refDoi"> DOI: 10.1177/0269881111424931</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1177%2F0269881111424931" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=22048884" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsVCgtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=653-662&author=S.+Learnedauthor=O.+Graffauthor=S.+Roychowdhuryauthor=R.+Moateauthor=K.+R.+Krishnanauthor=G.+Archerauthor=J.+G.+Modellauthor=R.+Alexanderauthor=S.+Zamunerauthor=A.+Lavergneauthor=G.+Evoniukauthor=E.+Ratti&title=Efficacy%2C+safety%2C+and+tolerability+of+a+triple+reuptake+inhibitor+GSK372475+in+the+treatment+of+patients+with+major+depressive+disorder%3A+two+randomized%2C+placebo-+and+active-controlled+clinical+trials&doi=10.1177%2F0269881111424931"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials</span></div><div class="casAuthors">Learned, Susan; Graff, Ole; Roychowdhury, Suraja; Moate, Rachel; Krishnan, K. Ranga; Archer, Graeme; Modell, Jack G.; Alexander, Robert; Zamuner, Stefano; Lavergne, Agnes; Evoniuk, Gary; Ratti, Emiliangelo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Psychopharmacology (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">653-662, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">JOPSEQ</span>;
        ISSN:<span class="NLM_cas:issn">0269-8811</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">GSK372475 is a triple reuptake inhibitor with approx. equipotent inhibition of serotonin, norepinephrine, and dopamine transporters.  Two randomized, placebo- and active-controlled, double-blind studies examd. the efficacy and safety of GSK372475 in outpatients (aged 18-64 years) with a diagnosis of major depressive episode assocd. with major depressive disorder (MDD).  Patients were randomized 1:1:1 to placebo, GSK372475 (1-2 mg/d), or active control (Study 1: venlafaxine XR 150-225 mg/d; Study 2: paroxetine 20-30 mg/d).  GSK372475 did not significantly differ from placebo on any of the key efficacy endpoints (six-item Bech scale, IDS-Clinician Rated, MADRS) in either study.  Both active controls demonstrated significant antidepressant activity compared with placebo on both primary and secondary endpoints.  The most common adverse effects (AEs) with GSK372475 were dry mouth, headache, insomnia, and nausea.  AEs were more frequent for GSK372475 vs. placebo for sleep, anxiety-related, gastrointestinal, and tachycardia events.  Increases in mean change from baseline in heart rate and sitting blood pressure were greater for GSK372475 than obsd. for either placebo or active control groups.  Completion rates were lower for GSK372475 (49%, 58%) compared with placebo (67%, 74%), venlafaxine XR (63%), or paroxetine (77%).  GSK372475 was neither efficacious nor well tolerated in patients with MDD in two 10-wk studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqc_gZoKR0_G7Vg90H21EOLACvtfcHk0lg4ZbK6dwrc5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsVCgtL4%253D&md5=eea1c4e6cfaf50ef27fb632cae119034</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1177%2F0269881111424931&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0269881111424931%26sid%3Dliteratum%253Aachs%26aulast%3DLearned%26aufirst%3DS.%26aulast%3DGraff%26aufirst%3DO.%26aulast%3DRoychowdhury%26aufirst%3DS.%26aulast%3DMoate%26aufirst%3DR.%26aulast%3DKrishnan%26aufirst%3DK.%2BR.%26aulast%3DArcher%26aufirst%3DG.%26aulast%3DModell%26aufirst%3DJ.%2BG.%26aulast%3DAlexander%26aufirst%3DR.%26aulast%3DZamuner%26aufirst%3DS.%26aulast%3DLavergne%26aufirst%3DA.%26aulast%3DEvoniuk%26aufirst%3DG.%26aulast%3DRatti%26aufirst%3DE.%26atitle%3DEfficacy%252C%2520safety%252C%2520and%2520tolerability%2520of%2520a%2520triple%2520reuptake%2520inhibitor%2520GSK372475%2520in%2520the%2520treatment%2520of%2520patients%2520with%2520major%2520depressive%2520disorder%253A%2520two%2520randomized%252C%2520placebo-%2520and%2520active-controlled%2520clinical%2520trials%26jtitle%3DJ.%2520Psychopharmacol.%26date%3D2012%26volume%3D26%26spage%3D653%26epage%3D662%26doi%3D10.1177%2F0269881111424931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peters, D.</span>; <span class="NLM_string-name">Nielsen, E. O.</span>; <span class="NLM_string-name">Nielsen, K. S.</span>; <span class="NLM_string-name">Munro, G.</span></span> <span> </span><span class="NLM_article-title">Chromen-2-one Derivatives of Tropine, and Their Preparation and Use as Monoamine Neurotransmitter Re-uptake Inhibitors</span>. <span class="NLM_patent">WO2010130620A1</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=D.+Peters&author=E.+O.+Nielsen&author=K.+S.+Nielsen&author=G.+Munro&title=Chromen-2-one+Derivatives+of+Tropine%2C+and+Their+Preparation+and+Use+as+Monoamine+Neurotransmitter+Re-uptake+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DD.%26atitle%3DChromen-2-one%2520Derivatives%2520of%2520Tropine%252C%2520and%2520Their%2520Preparation%2520and%2520Use%2520as%2520Monoamine%2520Neurotransmitter%2520Re-uptake%2520Inhibitors%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jerussi, T. P.</span>; <span class="NLM_string-name">Fang, Q. K.</span>; <span class="NLM_string-name">Currie, M.</span></span> <span> </span><span class="NLM_article-title">Preparation of <i>trans</i>-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine for Treatment of CNS Disorders</span>. <span class="NLM_patent">WO2004024669A1</span>, <span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=T.+P.+Jerussi&author=Q.+K.+Fang&author=M.+Currie&title=Preparation+of+trans-4-%283%2C4-Dichlorophenyl%29-1%2C2%2C3%2C4-tetrahydro-1-naphthalenamine+for+Treatment+of+CNS+Disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJerussi%26aufirst%3DT.%2BP.%26atitle%3DPreparation%2520of%2520trans-4-%25283%252C4-Dichlorophenyl%2529-1%252C2%252C3%252C4-tetrahydro-1-naphthalenamine%2520for%2520Treatment%2520of%2520CNS%2520Disorders%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malcolm, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hewitt, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, U. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bush, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spicer, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engel, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saraswat, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spear, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varney, M. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">663</span>– <span class="NLM_lpage">676</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2010.10.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.bmc.2010.10.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=21093273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1ejtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=663-676&author=L.+Shaoauthor=F.+Wangauthor=S.+C.+Malcolmauthor=J.+Maauthor=M.+C.+Hewittauthor=U.+C.+Campbellauthor=L.+R.+Bushauthor=N.+A.+Spicerauthor=S.+R.+Engelauthor=L.+D.+Saraswatauthor=L.+W.+Hardyauthor=P.+Kochauthor=R.+Schreiberauthor=K.+L.+Spearauthor=M.+A.+Varney&title=Synthesis+and+pharmacological+evaluation+of+4-%283%2C4-dichlorophenyl%29-N-methyl-1%2C2%2C3%2C4-tetrahydronaphthalenyl+amines+as+triple+reuptake+inhibitors&doi=10.1016%2Fj.bmc.2010.10.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors</span></div><div class="casAuthors">Shao, Liming; Wang, Fengjiang; Malcolm, Scott C.; Ma, Jianguo; Hewitt, Michael C.; Campbell, Una C.; Bush, Larry R.; Spicer, Nancy A.; Engel, Sharon R.; Saraswat, Lakshmi D.; Hardy, Larry W.; Koch, Patrick; Schreiber, Rudy; Spear, Kerry L.; Varney, Mark A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">663-676</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The present work describes a series of novel chiral amines that potently inhibit the in vitro reuptake of serotonin, norepinephrine and dopamine (triple reuptake inhibitors) and were active in vivo in a mouse model predictive of antidepressant like activity.  The detailed synthesis and in vitro activity and ADME profile of compds. is described, which represent a previously undisclosed triple reuptake inhibitor chemotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpb6Xgrr_h6-bVg90H21EOLACvtfcHk0ljG1zV-o43o-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1ejtg%253D%253D&md5=e8088a4fff884e9ac83dc4d597395595</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.10.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.10.034%26sid%3Dliteratum%253Aachs%26aulast%3DShao%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DMalcolm%26aufirst%3DS.%2BC.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DHewitt%26aufirst%3DM.%2BC.%26aulast%3DCampbell%26aufirst%3DU.%2BC.%26aulast%3DBush%26aufirst%3DL.%2BR.%26aulast%3DSpicer%26aufirst%3DN.%2BA.%26aulast%3DEngel%26aufirst%3DS.%2BR.%26aulast%3DSaraswat%26aufirst%3DL.%2BD.%26aulast%3DHardy%26aufirst%3DL.%2BW.%26aulast%3DKoch%26aufirst%3DP.%26aulast%3DSchreiber%26aufirst%3DR.%26aulast%3DSpear%26aufirst%3DK.%2BL.%26aulast%3DVarney%26aufirst%3DM.%2BA.%26atitle%3DSynthesis%2520and%2520pharmacological%2520evaluation%2520of%25204-%25283%252C4-dichlorophenyl%2529-N-methyl-1%252C2%252C3%252C4-tetrahydronaphthalenyl%2520amines%2520as%2520triple%2520reuptake%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2011%26volume%3D19%26spage%3D663%26epage%3D676%26doi%3D10.1016%2Fj.bmc.2010.10.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hewitt, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malcolm, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, U. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spicer, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engel, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Z. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spear, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varney, M. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">5283</span>– <span class="NLM_lpage">5295</span>, <span class="refDoi"> DOI: 10.1021/jm101312a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101312a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=5283-5295&author=L.+Shaoauthor=M.+C.+Hewittauthor=S.+C.+Malcolmauthor=F.+Wangauthor=J.+Maauthor=U.+C.+Campbellauthor=N.+A.+Spicerauthor=S.+R.+Engelauthor=L.+W.+Hardyauthor=Z.+D.+Jiangauthor=R.+Schreiberauthor=K.+L.+Spearauthor=M.+A.+Varney&title=Synthesis+and+pharmacological+characterization+of+bicyclic+triple+reuptake+inhibitor+3-aryl+octahydrocyclopenta%5Bc%5Dpyrrole+analogues&doi=10.1021%2Fjm101312a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1021%2Fjm101312a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101312a%26sid%3Dliteratum%253Aachs%26aulast%3DShao%26aufirst%3DL.%26aulast%3DHewitt%26aufirst%3DM.%2BC.%26aulast%3DMalcolm%26aufirst%3DS.%2BC.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DCampbell%26aufirst%3DU.%2BC.%26aulast%3DSpicer%26aufirst%3DN.%2BA.%26aulast%3DEngel%26aufirst%3DS.%2BR.%26aulast%3DHardy%26aufirst%3DL.%2BW.%26aulast%3DJiang%26aufirst%3DZ.%2BD.%26aulast%3DSchreiber%26aufirst%3DR.%26aulast%3DSpear%26aufirst%3DK.%2BL.%26aulast%3DVarney%26aufirst%3DM.%2BA.%26atitle%3DSynthesis%2520and%2520pharmacological%2520characterization%2520of%2520bicyclic%2520triple%2520reuptake%2520inhibitor%25203-aryl%2520octahydrocyclopenta%255Bc%255Dpyrrole%2520analogues%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D5283%26epage%3D5295%26doi%3D10.1021%2Fjm101312a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hewitt, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malcolm, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, U. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engel, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spicer, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spear, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varney, M. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of N-methyl-1-(1-phenylcyclohexyl)ethanamine, a novel triple serotonin, norepinephrine and dopamine reuptake inhibitor</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1434</span>– <span class="NLM_lpage">1437</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.01.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.bmcl.2011.01.019" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=1434-1437&author=L.+Shaoauthor=M.+C.+Hewittauthor=F.+Wangauthor=S.+C.+Malcolmauthor=J.+Maauthor=J.+E.+Campbellauthor=U.+C.+Campbellauthor=S.+R.+Engelauthor=N.+A.+Spicerauthor=L.+W.+Hardyauthor=R.+Schreiberauthor=K.+L.+Spearauthor=M.+A.+Varney&title=Discovery+of+N-methyl-1-%281-phenylcyclohexyl%29ethanamine%2C+a+novel+triple+serotonin%2C+norepinephrine+and+dopamine+reuptake+inhibitor&doi=10.1016%2Fj.bmcl.2011.01.019"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.01.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.01.019%26sid%3Dliteratum%253Aachs%26aulast%3DShao%26aufirst%3DL.%26aulast%3DHewitt%26aufirst%3DM.%2BC.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DMalcolm%26aufirst%3DS.%2BC.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DCampbell%26aufirst%3DJ.%2BE.%26aulast%3DCampbell%26aufirst%3DU.%2BC.%26aulast%3DEngel%26aufirst%3DS.%2BR.%26aulast%3DSpicer%26aufirst%3DN.%2BA.%26aulast%3DHardy%26aufirst%3DL.%2BW.%26aulast%3DSchreiber%26aufirst%3DR.%26aulast%3DSpear%26aufirst%3DK.%2BL.%26aulast%3DVarney%26aufirst%3DM.%2BA.%26atitle%3DDiscovery%2520of%2520N-methyl-1-%25281-phenylcyclohexyl%2529ethanamine%252C%2520a%2520novel%2520triple%2520serotonin%252C%2520norepinephrine%2520and%2520dopamine%2520reuptake%2520inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D1434%26epage%3D1437%26doi%3D10.1016%2Fj.bmcl.2011.01.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shao, L.</span>; <span class="NLM_string-name">Wang, F.</span>; <span class="NLM_string-name">Malcolm, S. C.</span>; <span class="NLM_string-name">Hewitt, M. C.</span>; <span class="NLM_string-name">Bush, L. R.</span>; <span class="NLM_string-name">Ma, J.</span>; <span class="NLM_string-name">Varney, M. A.</span>; <span class="NLM_string-name">Campbell, U.</span>; <span class="NLM_string-name">Engel, S. R.</span>; <span class="NLM_string-name">Hardy, L. W.</span>; <span class="NLM_string-name">Koch, P.</span>; <span class="NLM_string-name">Campbell, J. E.</span></span> <span> </span><span class="NLM_article-title">Cycloalkylamines as Monoamine Reuptake Inhibitors and Their Preparation, Pharmaceutical Compositions and Use in the Treatment of nervous system agents</span>. <span class="NLM_patent">WO2007081857A2</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=L.+Shao&author=F.+Wang&author=S.+C.+Malcolm&author=M.+C.+Hewitt&author=L.+R.+Bush&author=J.+Ma&author=M.+A.+Varney&author=U.+Campbell&author=S.+R.+Engel&author=L.+W.+Hardy&author=P.+Koch&author=J.+E.+Campbell&title=Cycloalkylamines+as+Monoamine+Reuptake+Inhibitors+and+Their+Preparation%2C+Pharmaceutical+Compositions+and+Use+in+the+Treatment+of+nervous+system+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DShao%26aufirst%3DL.%26atitle%3DCycloalkylamines%2520as%2520Monoamine%2520Reuptake%2520Inhibitors%2520and%2520Their%2520Preparation%252C%2520Pharmaceutical%2520Compositions%2520and%2520Use%2520in%2520the%2520Treatment%2520of%2520nervous%2520system%2520agents%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Comley, R.
A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salinas, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slifstein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennacef, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shotbolt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Aart, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iavarone, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomeni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laruelle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunn, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabiner, E. A.</span></span> <span> </span><span class="NLM_article-title">Monoamine transporter occupancy of a novel triple reuptake inhibitor in baboons and humans using positron emission tomography</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>346</i></span>,  <span class="NLM_fpage">311</span>– <span class="NLM_lpage">317</span>, <span class="refDoi"> DOI: 10.1124/jpet.112.202895</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1124%2Fjpet.112.202895" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=23685546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOjsbfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=346&publication_year=2013&pages=311-317&author=R.%0AA.+Comleyauthor=C.+A.+Salinasauthor=M.+Slifsteinauthor=M.+Petroneauthor=C.+Marzanoauthor=I.+Bennacefauthor=P.+Shotboltauthor=J.+Van+der+Aartauthor=M.+Neveauthor=L.+Iavaroneauthor=R.+Gomeniauthor=M.+Laruelleauthor=F.+A.+Grayauthor=R.+N.+Gunnauthor=E.+A.+Rabiner&title=Monoamine+transporter+occupancy+of+a+novel+triple+reuptake+inhibitor+in+baboons+and+humans+using+positron+emission+tomography&doi=10.1124%2Fjpet.112.202895"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Monoamine transporter occupancy of a novel triple reuptake inhibitor in baboons and humans using positron emission tomography</span></div><div class="casAuthors">Comley, Robert A.; Salinas, Cristian A.; Slifstein, Mark; Petrone, Marcella; Marzano, Carmine; Bennacef, Idriss; Shotbolt, Paul; Van der Aart, Jasper; Neve, Marta; Iavarone, Laura; Gomeni, Roberto; Laruelle, Marc; Gray, Frank A.; Gunn, Roger N.; Rabiner, Eugenii A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">346</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">311-317</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The selection of a therapeutically meaningful dose of a novel pharmaceutical is a crucial step in drug development.  Positron emission tomog. (PET) allows the in vivo estn. of the relationship between the plasma concn. of a drug and its target occupancy, optimizing dose selection and reducing the time and cost of early development.  Triple reuptake inhibitors (TRIs), also referred to as serotonin-norepinephrine-dopamine reuptake inhibitors, enhance monoaminergic neurotransmission by blocking the action of the monoamine transporters, raising extracellular concns. of those neurotransmitters.  GSK1360707 [(1R,6S)-1-(3,4-dichlorophenyl)-6-(methoxymethyl)-4-azabicyclo[4.1.0]heptane] is a novel TRI that until recently was under development for the treatment of major depressive disorder; its development was put on hold for strategic reasons.  We present the results of an in vivo assessment of the relationship between plasma exposure and transporter blockade (occupancy).  Studies were performed in baboons (Papio anubis) to det. the relationship between plasma concn. and occupancy of brain serotonin reuptake transporter (SERT), dopamine reuptake transporter (DAT), and norepinephrine uptake transporter (NET) using the radioligands [11C]DASB [(N,N-dimethyl-2-(2-amino-4-cyanophenylthio) benzylamine], [11C]PE2I [N-(3-iodoprop-2E-enyl)-2β-carbomethoxy-3β-(4-methylphenyl)nortropane], and [11C]2-[(2-methoxyphenoxy)phenylmethyl]morpholine (also known as [11C]MRB) and in humans using [11C]DASB and [11C]PE2I.  In P. anubis, plasma concns. resulting in half-maximal occupancy at SERT, DAT, and NET were 15.16, 15.56, and 0.97 ng/mL, resp.  In humans, the corresponding values for SERT and DAT were 6.80 and 18.00 ng/mL.  GSK1360707 dose-dependently blocked the signal of SERT-, DAT-, and NET-selective PET ligands, confirming its penetration across the blood-brain barrier and blockade of all three monoamine transporters in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeOk3b2TA00rVg90H21EOLACvtfcHk0liml3ZYuH2a6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOjsbfE&md5=b92262955a074c2d981015dc436127bb</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1124%2Fjpet.112.202895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.112.202895%26sid%3Dliteratum%253Aachs%26aulast%3DComley%26aufirst%3DR.%2BA.%26aulast%3DSalinas%26aufirst%3DC.%2BA.%26aulast%3DSlifstein%26aufirst%3DM.%26aulast%3DPetrone%26aufirst%3DM.%26aulast%3DMarzano%26aufirst%3DC.%26aulast%3DBennacef%26aufirst%3DI.%26aulast%3DShotbolt%26aufirst%3DP.%26aulast%3DVan%2Bder%2BAart%26aufirst%3DJ.%26aulast%3DNeve%26aufirst%3DM.%26aulast%3DIavarone%26aufirst%3DL.%26aulast%3DGomeni%26aufirst%3DR.%26aulast%3DLaruelle%26aufirst%3DM.%26aulast%3DGray%26aufirst%3DF.%2BA.%26aulast%3DGunn%26aufirst%3DR.%2BN.%26aulast%3DRabiner%26aufirst%3DE.%2BA.%26atitle%3DMonoamine%2520transporter%2520occupancy%2520of%2520a%2520novel%2520triple%2520reuptake%2520inhibitor%2520in%2520baboons%2520and%2520humans%2520using%2520positron%2520emission%2520tomography%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D346%26spage%3D311%26epage%3D317%26doi%3D10.1124%2Fjpet.112.202895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Micheli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavanni, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bettati, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonanomi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Fabio, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fazzolari, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchioro, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roscic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarsi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visentini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zonzini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Worby, A.</span></span> <span> </span><span class="NLM_article-title">1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: further insights into a class of triple re-uptake inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">3451</span>– <span class="NLM_lpage">3461</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2011.04.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.bmc.2011.04.032" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=3451-3461&author=F.+Micheliauthor=P.+Cavanniauthor=M.+Bettatiauthor=G.+Bonanomiauthor=R.+Di+Fabioauthor=E.+Fazzolariauthor=C.+Marchioroauthor=M.+Roscicauthor=L.+Tarsiauthor=F.+Visentiniauthor=L.+Zonziniauthor=A.+Worby&title=1-Heteroaryl-6-%283%2C4-dichlorophenyl%29-3-azabicyclo%5B4.1.0%5Dheptane%3A+further+insights+into+a+class+of+triple+re-uptake+inhibitors&doi=10.1016%2Fj.bmc.2011.04.032"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2011.04.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2011.04.032%26sid%3Dliteratum%253Aachs%26aulast%3DMicheli%26aufirst%3DF.%26aulast%3DCavanni%26aufirst%3DP.%26aulast%3DBettati%26aufirst%3DM.%26aulast%3DBonanomi%26aufirst%3DG.%26aulast%3DDi%2BFabio%26aufirst%3DR.%26aulast%3DFazzolari%26aufirst%3DE.%26aulast%3DMarchioro%26aufirst%3DC.%26aulast%3DRoscic%26aufirst%3DM.%26aulast%3DTarsi%26aufirst%3DL.%26aulast%3DVisentini%26aufirst%3DF.%26aulast%3DZonzini%26aufirst%3DL.%26aulast%3DWorby%26aufirst%3DA.%26atitle%3D1-Heteroaryl-6-%25283%252C4-dichlorophenyl%2529-3-azabicyclo%255B4.1.0%255Dheptane%253A%2520further%2520insights%2520into%2520a%2520class%2520of%2520triple%2520re-uptake%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2011%26volume%3D19%26spage%3D3451%26epage%3D3461%26doi%3D10.1016%2Fj.bmc.2011.04.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Profeta, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferroni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreotti, D.</span></span> <span> </span><span class="NLM_article-title">Synthesis of 5-(3,4-dichlorophenyl)-4-[(methyloxy)methyl]-2-azabicyclo[3.2.1]octane derivatives as constrained aryl-piperidines with activity as triple re-uptake inhibitors</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">5521</span>– <span class="NLM_lpage">5524</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2010.07.145</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.tetlet.2010.07.145" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2010&pages=5521-5524&author=R.+Profetaauthor=J.+Kleinauthor=S.+Spadaauthor=F.+Ferroniauthor=A.+Paioauthor=D.+Andreotti&title=Synthesis+of+5-%283%2C4-dichlorophenyl%29-4-%5B%28methyloxy%29methyl%5D-2-azabicyclo%5B3.2.1%5Doctane+derivatives+as+constrained+aryl-piperidines+with+activity+as+triple+re-uptake+inhibitors&doi=10.1016%2Fj.tetlet.2010.07.145"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2010.07.145&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2010.07.145%26sid%3Dliteratum%253Aachs%26aulast%3DProfeta%26aufirst%3DR.%26aulast%3DKlein%26aufirst%3DJ.%26aulast%3DSpada%26aufirst%3DS.%26aulast%3DFerroni%26aufirst%3DF.%26aulast%3DPaio%26aufirst%3DA.%26aulast%3DAndreotti%26aufirst%3DD.%26atitle%3DSynthesis%2520of%25205-%25283%252C4-dichlorophenyl%2529-4-%255B%2528methyloxy%2529methyl%255D-2-azabicyclo%255B3.2.1%255Doctane%2520derivatives%2520as%2520constrained%2520aryl-piperidines%2520with%2520activity%2520as%2520triple%2520re-uptake%2520inhibitors%26jtitle%3DTetrahedron%2520Lett.%26date%3D2010%26volume%3D51%26spage%3D5521%26epage%3D5524%26doi%3D10.1016%2Fj.tetlet.2010.07.145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bettati, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavanni, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Fabio, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliosi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perini, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheid, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tedesco, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zonzini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Micheli, F.</span></span> <span> </span><span class="NLM_article-title">Oxa-azaspiro derivatives: a novel class of triple re-uptake inhibitors</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">361</span>– <span class="NLM_lpage">366</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200900482</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1002%2Fcmdc.200900482" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=361-366&author=M.+Bettatiauthor=P.+Cavanniauthor=R.+Di+Fabioauthor=B.+Oliosiauthor=O.+Periniauthor=G.+Scheidauthor=G.+Tedescoauthor=L.+Zonziniauthor=F.+Micheli&title=Oxa-azaspiro+derivatives%3A+a+novel+class+of+triple+re-uptake+inhibitors&doi=10.1002%2Fcmdc.200900482"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200900482&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200900482%26sid%3Dliteratum%253Aachs%26aulast%3DBettati%26aufirst%3DM.%26aulast%3DCavanni%26aufirst%3DP.%26aulast%3DDi%2BFabio%26aufirst%3DR.%26aulast%3DOliosi%26aufirst%3DB.%26aulast%3DPerini%26aufirst%3DO.%26aulast%3DScheid%26aufirst%3DG.%26aulast%3DTedesco%26aufirst%3DG.%26aulast%3DZonzini%26aufirst%3DL.%26aulast%3DMicheli%26aufirst%3DF.%26atitle%3DOxa-azaspiro%2520derivatives%253A%2520a%2520novel%2520class%2520of%2520triple%2520re-uptake%2520inhibitors%26jtitle%3DChemMedChem%26date%3D2010%26volume%3D5%26spage%3D361%26epage%3D366%26doi%3D10.1002%2Fcmdc.200900482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zha, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacro, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatt, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sambandam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isherwood, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herr, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebeltoft, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pechulis, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payen-Fornicola, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milanowski, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cotterill, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mozhaev, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khmelnitsky, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzzo, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sargent, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molino, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lelas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haskell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertekap, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodge, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaczek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of 4-heteroaryl 1,2,3,4-tetrahydroisoquinolines as triple reuptake inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">760</span>– <span class="NLM_lpage">765</span>, <span class="refDoi"> DOI: 10.1021/ml500053b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500053b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVaht7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=760-765&author=S.+Liuauthor=C.+Zhaauthor=K.+Nacroauthor=M.+Huauthor=W.+Cuiauthor=Y.+L.+Yangauthor=U.+Bhattauthor=A.+Sambandamauthor=M.+Isherwoodauthor=L.+Yetauthor=M.+T.+Herrauthor=S.+Ebeltoftauthor=C.+Hasslerauthor=L.+Flemingauthor=A.+D.+Pechulisauthor=A.+Payen-Fornicolaauthor=N.+Holmanauthor=D.+Milanowskiauthor=I.+Cotterillauthor=V.+Mozhaevauthor=Y.+Khmelnitskyauthor=P.+R.+Guzzoauthor=B.+J.+Sargentauthor=B.+F.+Molinoauthor=R.+Olsonauthor=D.+Kingauthor=S.+Lelasauthor=Y.+W.+Liauthor=K.+Johnsonauthor=T.+Molskiauthor=A.+Orieauthor=A.+Ngauthor=R.+Haskellauthor=W.+Clarkeauthor=R.+Bertekapauthor=J.+O%E2%80%99Connellauthor=N.+Lodgeauthor=M.+Sinzauthor=S.+Adamsauthor=R.+Zaczekauthor=J.+E.+Macor&title=Design+and+synthesis+of+4-heteroaryl+1%2C2%2C3%2C4-tetrahydroisoquinolines+as+triple+reuptake+inhibitors&doi=10.1021%2Fml500053b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of 4-Heteroaryl 1,2,3,4-Tetrahydroisoquinolines as Triple Reuptake Inhibitors</span></div><div class="casAuthors">Liu, Shuang; Zha, Congxiang; Nacro, Kassoum; Hu, Min; Cui, Wenge; Yang, Yuh-Lin; Bhatt, Ulhas; Sambandam, Aruna; Isherwood, Matthew; Yet, Larry; Herr, Michael T.; Ebeltoft, Sarah; Hassler, Carla; Fleming, Linda; Pechulis, Anthony D.; Payen-Fornicola, Anne; Holman, Nicholas; Milanowski, Dennis; Cotterill, Ian; Mozhaev, Vadim; Khmelnitsky, Yuri; Guzzo, Peter R.; Sargent, Bruce J.; Molino, Bruce F.; Olson, Richard; King, Dalton; Lelas, Snjezana; Li, Yu-Wen; Johnson, Kim; Molski, Thaddeus; Orie, Anitra; Ng, Alicia; Haskell, Roy; Clarke, Wendy; Bertekap, Robert; O'Connell, Jonathan; Lodge, Nicholas; Sinz, Michael; Adams, Stephen; Zaczek, Robert; Macor, John E.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">760-765</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">4-(Bicycloheteroaryl)-7-substituted 1,2,3,4-tetrahydroisoquinolines such as I (R = 4-morpholinyl) were prepd. as serotonin-, norepinephrine-, and dopamine-reuptake inhibitors for potential use as antidepressant agents; their structure-activity relations were detd.  I (R = 4-morpholinyl) inhibited serotonin, norepinephrine, and dopamine transporters with IC50 values of 3.0 nM, 8.3 nM, and 3.1 nM, inhibited depression in rodent models, and exhibited substantial occupancy levels at the three transporters in both rat and mouse brain after efficacious oral doses; its pharmacokinetics (clearance, vol. of distribution, and bioavailability) in rats and monkeys was detd.  I (R = 4-morpholinyl) generated a metabolite I (R = HOCH2CH2NH) in monkeys which inhibited serotonin, norepinephrine, and dopamine transporters with similar IC50 values to I (R = 4-morpholinyl), was present in rat brain at significant concns. after direct administration, and inhibited CYP2D6 with IC50 = 1 μM.  The structure of the monomaleate salt of I (R = 4-morpholinyl) was detd. by X-ray crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbllrIpn3vqbVg90H21EOLACvtfcHk0lijrAOJ8J-Gmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVaht7k%253D&md5=9b0a3838c9f22fb12e2630ec8b917662</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1021%2Fml500053b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500053b%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DZha%26aufirst%3DC.%26aulast%3DNacro%26aufirst%3DK.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DCui%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DY.%2BL.%26aulast%3DBhatt%26aufirst%3DU.%26aulast%3DSambandam%26aufirst%3DA.%26aulast%3DIsherwood%26aufirst%3DM.%26aulast%3DYet%26aufirst%3DL.%26aulast%3DHerr%26aufirst%3DM.%2BT.%26aulast%3DEbeltoft%26aufirst%3DS.%26aulast%3DHassler%26aufirst%3DC.%26aulast%3DFleming%26aufirst%3DL.%26aulast%3DPechulis%26aufirst%3DA.%2BD.%26aulast%3DPayen-Fornicola%26aufirst%3DA.%26aulast%3DHolman%26aufirst%3DN.%26aulast%3DMilanowski%26aufirst%3DD.%26aulast%3DCotterill%26aufirst%3DI.%26aulast%3DMozhaev%26aufirst%3DV.%26aulast%3DKhmelnitsky%26aufirst%3DY.%26aulast%3DGuzzo%26aufirst%3DP.%2BR.%26aulast%3DSargent%26aufirst%3DB.%2BJ.%26aulast%3DMolino%26aufirst%3DB.%2BF.%26aulast%3DOlson%26aufirst%3DR.%26aulast%3DKing%26aufirst%3DD.%26aulast%3DLelas%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DY.%2BW.%26aulast%3DJohnson%26aufirst%3DK.%26aulast%3DMolski%26aufirst%3DT.%26aulast%3DOrie%26aufirst%3DA.%26aulast%3DNg%26aufirst%3DA.%26aulast%3DHaskell%26aufirst%3DR.%26aulast%3DClarke%26aufirst%3DW.%26aulast%3DBertekap%26aufirst%3DR.%26aulast%3DO%25E2%2580%2599Connell%26aufirst%3DJ.%26aulast%3DLodge%26aufirst%3DN.%26aulast%3DSinz%26aufirst%3DM.%26aulast%3DAdams%26aufirst%3DS.%26aulast%3DZaczek%26aufirst%3DR.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26atitle%3DDesign%2520and%2520synthesis%2520of%25204-heteroaryl%25201%252C2%252C3%252C4-tetrahydroisoquinolines%2520as%2520triple%2520reuptake%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26spage%3D760%26epage%3D765%26doi%3D10.1021%2Fml500053b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhagwagar, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torbeyns, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennicken, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunlop, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisler, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shelton, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thase, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, R.</span></span> <span> </span><span class="NLM_article-title">Assessment of the efficacy and safety of BMS-820836 in patients with treatment-resistant major depression: results from 2 randomized, double-blind studies</span>. <i>J. Clin. Psychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">454</span>– <span class="NLM_lpage">459</span>, <span class="refDoi"> DOI: 10.1097/JCP.0000000000000335</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1097%2FJCP.0000000000000335" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=25961781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFWhu7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2015&pages=454-459&author=Z.+Bhagwagarauthor=A.+Torbeynsauthor=D.+Hennickenauthor=M.+Zhengauthor=B.+W.+Dunlopauthor=S.+J.+Mathewauthor=A.+Khanauthor=R.+Weislerauthor=C.+Nelsonauthor=R.+Sheltonauthor=M.+E.+Thaseauthor=R.+Lane&title=Assessment+of+the+efficacy+and+safety+of+BMS-820836+in+patients+with+treatment-resistant+major+depression%3A+results+from+2+randomized%2C+double-blind+studies&doi=10.1097%2FJCP.0000000000000335"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Assessment of the Efficacy and Safety of BMS-820836 in Patients With Treatment-Resistant Major Depression: Results From 2 Randomized, Double-Blind Studies</span></div><div class="casAuthors">Bhagwagar, Zubin; Torbeyns, Anne; Hennicken, Delphine; Zheng, Ming; Dunlop, Boadie W.; Mathew, Sanjay J.; Khan, Arif; Weisler, Richard; Nelson, Craig; Shelton, Richard; Thase, Michael E.; Lane, Roger</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Psychopharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">454-459</span>CODEN:
                <span class="NLM_cas:coden">JCPYDR</span>;
        ISSN:<span class="NLM_cas:issn">0271-0749</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Two phase 2B, randomized, double-blind studies assessed the efficacy and safety of fixed or flexible dose of triple monoamine uptake inhibitor BMS-820836 in patients with treatment-resistant depression to demonstrate whether switching to BMS-820836 was superior to the continuation of std. antidepressant treatment.  Patients with a history of inadequate response to 1 to 3 adequate trials of antidepressant therapies were prospectively treated with duloxetine 60 mg/d for 8 wk (CN162-006) or duloxetine 60 mg/d or escitalopram 20 mg/d for 7 wk (CN162-007).  Inadequate responders were randomized to continue their prospective phase treatment or switch to flexible-dose (0.5-2 mg/d; CN162-006) or fixed-dose (0.25, 0.5, 1, or 2 mg/d; CN162-007) BMS-820836 for 6 wk.  The primary end point in both studies was mean change in Montgomery-Åsberg Depression Rating Scale (MADRS) total score from randomization to study end point.  BMS-820836 flexible (0.5-2 mg/d) or fixed dose of 1 mg/d or greater showed efficacy similar to the continuation of antidepressant treatment, with no statistically significant or clin. meaningful differences.  In the CN162-006 study, the adjusted mean (SE) change in MADRS total score was -8.7 (0.661) and -8.1 (0.656) for BMS-820836 and duloxetine, resp. (P = 0.526).  In the CN162-007 study, the adjusted mean (SE) change in MADRS total score was -7.3 (0.830) and -6.6 (0.842) for BMS-820836 of 1 and 2 mg, resp., and -6.9 (0.602) for the continuation group (P = 0.910).  Thus, BMS-820836 was well tolerated, with no evidence of dose-dependent discontinuations due to adverse events, but it failed to demonstrate superiority to the continuation of an existing antidepressant in patients with treatment-resistant depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEz-lABCAwwbVg90H21EOLACvtfcHk0lijrAOJ8J-Gmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFWhu7vP&md5=6abe3efb9009a4a27e28494372765848</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1097%2FJCP.0000000000000335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJCP.0000000000000335%26sid%3Dliteratum%253Aachs%26aulast%3DBhagwagar%26aufirst%3DZ.%26aulast%3DTorbeyns%26aufirst%3DA.%26aulast%3DHennicken%26aufirst%3DD.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DDunlop%26aufirst%3DB.%2BW.%26aulast%3DMathew%26aufirst%3DS.%2BJ.%26aulast%3DKhan%26aufirst%3DA.%26aulast%3DWeisler%26aufirst%3DR.%26aulast%3DNelson%26aufirst%3DC.%26aulast%3DShelton%26aufirst%3DR.%26aulast%3DThase%26aufirst%3DM.%2BE.%26aulast%3DLane%26aufirst%3DR.%26atitle%3DAssessment%2520of%2520the%2520efficacy%2520and%2520safety%2520of%2520BMS-820836%2520in%2520patients%2520with%2520treatment-resistant%2520major%2520depression%253A%2520results%2520from%25202%2520randomized%252C%2520double-blind%2520studies%26jtitle%3DJ.%2520Clin.%2520Psychopharmacol.%26date%3D2015%26volume%3D35%26spage%3D454%26epage%3D459%26doi%3D10.1097%2FJCP.0000000000000335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Risinger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhagwagar, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cahir, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miler, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendonza, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, W.</span></span> <span> </span><span class="NLM_article-title">Evaluation of safety and tolerability, pharmacokinetics, and pharmacodynamics of BMS-820836 in healthy subjects: a placebo-controlled, ascending single-dose study</span>. <i>Psychopharmacology (Berl.)</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>231</i></span>,  <span class="NLM_fpage">2299</span>– <span class="NLM_lpage">2310</span>, <span class="refDoi"> DOI: 10.1007/s00213-013-3391-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1007%2Fs00213-013-3391-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=24337079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A280%3ADC%252BC2c3mtlyitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=231&publication_year=2014&pages=2299-2310&author=R.+Risingerauthor=Z.+Bhagwagarauthor=F.+Luoauthor=M.+Cahirauthor=L.+Milerauthor=A.+E.+Mendonzaauthor=J.+H.+Meyerauthor=M.+Zhengauthor=W.+Hayes&title=Evaluation+of+safety+and+tolerability%2C+pharmacokinetics%2C+and+pharmacodynamics+of+BMS-820836+in+healthy+subjects%3A+a+placebo-controlled%2C+ascending+single-dose+study&doi=10.1007%2Fs00213-013-3391-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of safety and tolerability, pharmacokinetics, and pharmacodynamics of BMS-820836 in healthy subjects: a placebo-controlled, ascending single-dose study</span></div><div class="casAuthors">Risinger Robert; Bhagwagar Zubin; Luo Feng; Cahir Matthew; Miler Laura; Mendonza Anisha E; Meyer Jeffrey H; Zheng Ming; Hayes Wendy</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">231</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2299-310</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">RATIONALE:  BMS-820836, a novel triple monoamine reuptake inhibitor, is an experimental monotherapy for sufferers of major depressive disorder who have had an inadequate response to an existing antidepressant treatment.  OBJECTIVES:  This study was conducted to evaluate the safety and tolerability, pharmacokinetics (PK), and serotonin transporter (SERT) and dopamine transporter (DAT) occupancy for single doses of BMS-820836 in healthy subjects.  METHODS:  Healthy subjects were assigned to seven BMS-820836 dose panels (0.025, 0.1, 0.5, 1, 2, 3, and 5 mg; n = 8 each), in which subjects were randomly allocated 3:1 to a single BMS-820836 dose or matched placebo.  Serial blood samples were collected on Days 1, 2, 3, 4, 7, and 14 to characterize the PK of BMS-820836.  Following evaluation of the maximum tolerated dose, SERT occupancy was determined by applying [(11)C]DASB positron emission tomography (PET) after single-dose BMS-820836 (0.5 or 3 mg; n = 3 each) and DAT occupancy by applying [(11)C]PE2I PET after single-dose BMS-820836 (3 mg; n = 6).  RESULTS:  Single oral doses of BMS-820836 (0.025-3 mg) were generally safe and well tolerated.  BMS-820836 had a median T max of 5.0-7.2 h and a mean apparent terminal T 1/2 of 34-57 h.  Mean striatal SERT occupancies were 19 ± 9 % and 82 ± 8 % after single doses of 0.5 and 3 mg BMS-820836, respectively.  The mean striatal DAT occupancy was 19 ± 9 % after a single 3 mg BMS-820836 dose.  CONCLUSIONS:  Single doses of BMS-820836 have meaningful SERT and DAT occupancy and demonstrate an acceptable safety and tolerability profile in healthy control subjects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQKcK_Pc4CY0vcsfMJQC1ZdfW6udTcc2ebgnn_rQOasULntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c3mtlyitQ%253D%253D&md5=f570b71231063bc297942d5ba657adb7</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1007%2Fs00213-013-3391-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-013-3391-3%26sid%3Dliteratum%253Aachs%26aulast%3DRisinger%26aufirst%3DR.%26aulast%3DBhagwagar%26aufirst%3DZ.%26aulast%3DLuo%26aufirst%3DF.%26aulast%3DCahir%26aufirst%3DM.%26aulast%3DMiler%26aufirst%3DL.%26aulast%3DMendonza%26aufirst%3DA.%2BE.%26aulast%3DMeyer%26aufirst%3DJ.%2BH.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DHayes%26aufirst%3DW.%26atitle%3DEvaluation%2520of%2520safety%2520and%2520tolerability%252C%2520pharmacokinetics%252C%2520and%2520pharmacodynamics%2520of%2520BMS-820836%2520in%2520healthy%2520subjects%253A%2520a%2520placebo-controlled%252C%2520ascending%2520single-dose%2520study%26jtitle%3DPsychopharmacology%2520%2528Berl.%2529%26date%3D2014%26volume%3D231%26spage%3D2299%26epage%3D2310%26doi%3D10.1007%2Fs00213-013-3391-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carlier, P. R.</span>; <span class="NLM_string-name">Richelson, E.</span></span> <span> </span><span class="NLM_article-title">Preparation of <i>N</i>,<i>N</i>-Dimethyl-3-cyclohexyl-3-hydroxy-2-(2-naphthyl)propylamines as Neurotransmitter Reuptake Inhibitors</span>. <span class="NLM_patent">WO2005120200A2</span>, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=P.+R.+Carlier&author=E.+Richelson&title=Preparation+of+N%2CN-Dimethyl-3-cyclohexyl-3-hydroxy-2-%282-naphthyl%29propylamines+as+Neurotransmitter+Reuptake+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCarlier%26aufirst%3DP.%2BR.%26atitle%3DPreparation%2520of%2520N%252CN-Dimethyl-3-cyclohexyl-3-hydroxy-2-%25282-naphthyl%2529propylamines%2520as%2520Neurotransmitter%2520Reuptake%2520Inhibitors%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boules, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlier, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richelson, E.</span></span> <span> </span><span class="NLM_article-title">Antidepressant-like effects of novel triple reuptake inhibitors, PRC025 and PRC050</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>555</i></span>,  <span class="NLM_fpage">30</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2006.10.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.ejphar.2006.10.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=17109850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsFKhtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=555&publication_year=2007&pages=30-36&author=A.+M.+Shawauthor=M.+Boulesauthor=Y.+Zhangauthor=K.+Williamsauthor=J.+Robinsonauthor=P.+R.+Carlierauthor=E.+Richelson&title=Antidepressant-like+effects+of+novel+triple+reuptake+inhibitors%2C+PRC025+and+PRC050&doi=10.1016%2Fj.ejphar.2006.10.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Antidepressant-like effects of novel triple reuptake inhibitors, PRC025 and PRC050</span></div><div class="casAuthors">Shaw, Amanda M.; Boules, Mona; Zhang, Yiqun; Williams, Katrina; Robinson, Jessica; Carlier, Paul R.; Richelson, Elliott</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">555</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">30-36</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Most currently prescribed antidepressants act by selectively increasing the synaptic availability of serotonin or norepinephrine, or through action on both serotonin and norepinephrine.  However, most therapies require several weeks of treatment before improvement of symptoms is obsd. and not all patients respond to antidepressant treatment.  One strategy that has emerged in new antidepressant development is the use of triple reuptake inhibitors, which inhibit reuptake of serotonin, norepinephrine, and dopamine.  These compds. have been hypothesized to have a more rapid onset of activity and better efficacy over single or dual reuptake inhibitor antidepressants in part due to the addn. of the dopamine component.  The authors have developed novel compds. that are analogs of venlafaxine, of which two, racemic PRC025 ((2SR, 3RS)-N,N-dimethyl-3-cyclohexyl-3-hydroxy-2-(2'-naphthyl)propylamine) and PRC050 ((2RS,3RS)-N-methyl-3-hydroxy-2-(2'-naphthyl)-3-phenylpropylamine), are highly potent at human serotonin, norepinephrine, and dopamine transporters and inhibit the reuptake of serotonin, norepinephrine, and dopamine into rat brain synaptosomes.  These compds. were tested in animal models used to evaluate potential antidepressants: the forced swim test in rats and the tail suspension test in mice.  In the forced swim test, both PRC025 and PRC050 reduced the time spent immobile and increased the time spent swimming, comparable to the effects seen with imipramine, a tricyclic antidepressant.  In addn., both PRC025 and PRC050 were effective in reducing the time spent immobile in the tail suspension test, again with effects comparable to imipramine.  Therefore it appears that our compds. may possess antidepressant activity and represent a new class of triple reuptake inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNFgOGIhoBvLVg90H21EOLACvtfcHk0liRGjkOur4ebA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsFKhtw%253D%253D&md5=27ba548eac72b50abedf771e55174fab</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2006.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2006.10.004%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BM.%26aulast%3DBoules%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWilliams%26aufirst%3DK.%26aulast%3DRobinson%26aufirst%3DJ.%26aulast%3DCarlier%26aufirst%3DP.%2BR.%26aulast%3DRichelson%26aufirst%3DE.%26atitle%3DAntidepressant-like%2520effects%2520of%2520novel%2520triple%2520reuptake%2520inhibitors%252C%2520PRC025%2520and%2520PRC050%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2007%26volume%3D555%26spage%3D30%26epage%3D36%26doi%3D10.1016%2Fj.ejphar.2006.10.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielenstein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caccese, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heathcote, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stong, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bodes, E.</span></span> <span> </span><span class="NLM_article-title">Assessment of biomarkers of drug-induced kidney injury in cynomolgus monkeys treated with a triple reuptake inhibitor</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">269</span>– <span class="NLM_lpage">283</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfr013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1093%2Ftoxsci%2Fkfr013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=21258088" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvFejt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2011&pages=269-283&author=M.+Guhaauthor=A.+Heierauthor=S.+Priceauthor=M.+Bielensteinauthor=R.+G.+Cacceseauthor=D.+I.+Heathcoteauthor=T.+R.+Simpsonauthor=D.+B.+Stongauthor=E.+Bodes&title=Assessment+of+biomarkers+of+drug-induced+kidney+injury+in+cynomolgus+monkeys+treated+with+a+triple+reuptake+inhibitor&doi=10.1093%2Ftoxsci%2Fkfr013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Assessment of Biomarkers of Drug-Induced Kidney Injury in Cynomolgus Monkeys Treated with a Triple Reuptake Inhibitor</span></div><div class="casAuthors">Guha, Mausumee; Heier, Annabelle; Price, Sally; Bielenstein, Margareta; Caccese, Robert G.; Heathcote, Daniel I.; Simpson, Thomas R.; Stong, David B.; Bodes, Elmarie</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">269-283</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-6080</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Drug-induced kidney injury (DIKI) results in attrition during drug development; new DIKI urinary biomarkers offer potential to detect and monitor DIKI progression and regression, but frequently only in rats.  The triple reuptake inhibitor (TRI) PRC200-SS represents a new class of antidepressants that elevate synaptic levels of serotonin, norepinephrine, and dopamine and is expected to produce more rapid onset and better antidepressant efficacy than single or dual inhibitors.  Although preclin. studies and recent clin. trials lend support to this concept of superior efficacy for TRIs, there is little information on the safety profile of this class of compds.  Using histopathol. and DIKI biomarkers, in single- and repeat dose toxicol. studies in cynomolgus monkeys, PRC200-SS demonstrated dose-proportional kidney toxicity.  Characterization of the histopathol. lesions, using a combination of immunohistochem. (IHC) and urinary biomarker anal., indicated that the compd. is a distal tubule and collecting duct toxicant.  Segment specificity for the lesions was shown using a newly developed triple IHC combination method with antibodies against calbindin D28, aquaporin 2, and aquaporin 1.  Urinary biomarker analyses, using multiplex immunoassays, confirmed a dose-proportional increase in the excretion of calbindin D28 and clusterin in compd.-treated monkeys with levels returning to baseline during the drug-free recovery period.  These results constitute the validation of distal nephron DIKI biomarkers in the cynomolgus monkey and demonstrate the utility of calbindin D28 and clusterin to monitor the progression of distal nephron DIKI, representing potential early biomarkers of DIKI for the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq19x9Km6Ry67Vg90H21EOLACvtfcHk0liRGjkOur4ebA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvFejt74%253D&md5=76bfb7b4e85b62055221eaa1930c6ad3</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfr013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfr013%26sid%3Dliteratum%253Aachs%26aulast%3DGuha%26aufirst%3DM.%26aulast%3DHeier%26aufirst%3DA.%26aulast%3DPrice%26aufirst%3DS.%26aulast%3DBielenstein%26aufirst%3DM.%26aulast%3DCaccese%26aufirst%3DR.%2BG.%26aulast%3DHeathcote%26aufirst%3DD.%2BI.%26aulast%3DSimpson%26aufirst%3DT.%2BR.%26aulast%3DStong%26aufirst%3DD.%2BB.%26aulast%3DBodes%26aufirst%3DE.%26atitle%3DAssessment%2520of%2520biomarkers%2520of%2520drug-induced%2520kidney%2520injury%2520in%2520cynomolgus%2520monkeys%2520treated%2520with%2520a%2520triple%2520reuptake%2520inhibitor%26jtitle%3DToxicol.%2520Sci.%26date%3D2011%26volume%3D120%26spage%3D269%26epage%3D283%26doi%3D10.1093%2Ftoxsci%2Fkfr013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bannwart, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choy, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenhouse, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaime-Figueroa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madera, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozboya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raptova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roetz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoenfeld, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weikert, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, Y.</span></span> <span> </span><span class="NLM_article-title">Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">6062</span>– <span class="NLM_lpage">6066</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.10.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.bmcl.2008.10.025" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=6062-6066&author=L.+M.+Bannwartauthor=D.+S.+Carterauthor=H.-Y.+Caiauthor=J.+C.+Choyauthor=R.+Greenhouseauthor=S.+Jaime-Figueroaauthor=P.+S.+Iyerauthor=C.+J.+Linauthor=E.+K.+Leeauthor=M.+C.+Lucasauthor=S.+M.+Lynchauthor=A.+M.+Maderaauthor=A.+Mooreauthor=K.+Ozboyaauthor=L.+Raptovaauthor=R.+Roetzauthor=R.+C.+Schoenfeldauthor=K.+A.+Steinauthor=S.+Steinerauthor=M.+Villaauthor=R.+J.+Weikertauthor=Y.+Zhai&title=Novel+3%2C3-disubstituted+pyrrolidines+as+selective+triple+serotonin%2Fnorepinephrine%2Fdopamine+reuptake+inhibitors&doi=10.1016%2Fj.bmcl.2008.10.025"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.10.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.10.025%26sid%3Dliteratum%253Aachs%26aulast%3DBannwart%26aufirst%3DL.%2BM.%26aulast%3DCarter%26aufirst%3DD.%2BS.%26aulast%3DCai%26aufirst%3DH.-Y.%26aulast%3DChoy%26aufirst%3DJ.%2BC.%26aulast%3DGreenhouse%26aufirst%3DR.%26aulast%3DJaime-Figueroa%26aufirst%3DS.%26aulast%3DIyer%26aufirst%3DP.%2BS.%26aulast%3DLin%26aufirst%3DC.%2BJ.%26aulast%3DLee%26aufirst%3DE.%2BK.%26aulast%3DLucas%26aufirst%3DM.%2BC.%26aulast%3DLynch%26aufirst%3DS.%2BM.%26aulast%3DMadera%26aufirst%3DA.%2BM.%26aulast%3DMoore%26aufirst%3DA.%26aulast%3DOzboya%26aufirst%3DK.%26aulast%3DRaptova%26aufirst%3DL.%26aulast%3DRoetz%26aufirst%3DR.%26aulast%3DSchoenfeld%26aufirst%3DR.%2BC.%26aulast%3DStein%26aufirst%3DK.%2BA.%26aulast%3DSteiner%26aufirst%3DS.%26aulast%3DVilla%26aufirst%3DM.%26aulast%3DWeikert%26aufirst%3DR.%2BJ.%26aulast%3DZhai%26aufirst%3DY.%26atitle%3DNovel%25203%252C3-disubstituted%2520pyrrolidines%2520as%2520selective%2520triple%2520serotonin%252Fnorepinephrine%252Fdopamine%2520reuptake%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D6062%26epage%3D6066%26doi%3D10.1016%2Fj.bmcl.2008.10.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weikert, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenhouse, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madera, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozboya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoenfeld, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, S. M.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">5559</span>– <span class="NLM_lpage">5566</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.07.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.bmcl.2010.07.020" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=5559-5566&author=M.+C.+Lucasauthor=R.+J.+Weikertauthor=D.+S.+Carterauthor=H.-Y.+Caiauthor=R.+Greenhouseauthor=P.+S.+Iyerauthor=C.+J.+Linauthor=E.+K.+Leeauthor=A.+M.+Maderaauthor=A.+Mooreauthor=K.+Ozboyaauthor=R.+C.+Schoenfeldauthor=S.+Steinerauthor=Y.+Zhaiauthor=S.+M.+Lynch&title=Design%2C+synthesis%2C+and+biological+evaluation+of+new+monoamine+reuptake+inhibitors+with+potential+therapeutic+utility+in+depression+and+pain&doi=10.1016%2Fj.bmcl.2010.07.020"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.07.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.07.020%26sid%3Dliteratum%253Aachs%26aulast%3DLucas%26aufirst%3DM.%2BC.%26aulast%3DWeikert%26aufirst%3DR.%2BJ.%26aulast%3DCarter%26aufirst%3DD.%2BS.%26aulast%3DCai%26aufirst%3DH.-Y.%26aulast%3DGreenhouse%26aufirst%3DR.%26aulast%3DIyer%26aufirst%3DP.%2BS.%26aulast%3DLin%26aufirst%3DC.%2BJ.%26aulast%3DLee%26aufirst%3DE.%2BK.%26aulast%3DMadera%26aufirst%3DA.%2BM.%26aulast%3DMoore%26aufirst%3DA.%26aulast%3DOzboya%26aufirst%3DK.%26aulast%3DSchoenfeld%26aufirst%3DR.%2BC.%26aulast%3DSteiner%26aufirst%3DS.%26aulast%3DZhai%26aufirst%3DY.%26aulast%3DLynch%26aufirst%3DS.%2BM.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520new%2520monoamine%2520reuptake%2520inhibitors%2520with%2520potential%2520therapeutic%2520utility%2520in%2520depression%2520and%2520pain%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D5559%26epage%3D5566%26doi%3D10.1016%2Fj.bmcl.2010.07.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoenfeld, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weikert, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, P. S.</span></span> <span> </span><span class="NLM_article-title">Novel, achiral aminoheterocycles as selective monoamine reuptake inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">4630</span>– <span class="NLM_lpage">4633</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.06.076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.bmcl.2009.06.076" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=4630-4633&author=M.+C.+Lucasauthor=D.+S.+Carterauthor=H.-Y.+Caiauthor=E.+K.+Leeauthor=R.+C.+Schoenfeldauthor=S.+Steinerauthor=M.+Villaauthor=R.+J.+Weikertauthor=P.+S.+Iyer&title=Novel%2C+achiral+aminoheterocycles+as+selective+monoamine+reuptake+inhibitors&doi=10.1016%2Fj.bmcl.2009.06.076"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.06.076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.06.076%26sid%3Dliteratum%253Aachs%26aulast%3DLucas%26aufirst%3DM.%2BC.%26aulast%3DCarter%26aufirst%3DD.%2BS.%26aulast%3DCai%26aufirst%3DH.-Y.%26aulast%3DLee%26aufirst%3DE.%2BK.%26aulast%3DSchoenfeld%26aufirst%3DR.%2BC.%26aulast%3DSteiner%26aufirst%3DS.%26aulast%3DVilla%26aufirst%3DM.%26aulast%3DWeikert%26aufirst%3DR.%2BJ.%26aulast%3DIyer%26aufirst%3DP.%2BS.%26atitle%3DNovel%252C%2520achiral%2520aminoheterocycles%2520as%2520selective%2520monoamine%2520reuptake%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D4630%26epage%3D4633%26doi%3D10.1016%2Fj.bmcl.2009.06.076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carter, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roetz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoenfeld, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weikert, R. J.</span></span> <span> </span><span class="NLM_article-title">2-Substituted N-aryl piperazines as novel triple reuptake inhibitors for the treatment of depression</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">3941</span>– <span class="NLM_lpage">3945</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.05.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.bmcl.2010.05.008" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=3941-3945&author=D.+S.+Carterauthor=H.-Y.+Caiauthor=E.+K.+Leeauthor=P.+S.+Iyerauthor=M.+C.+Lucasauthor=R.+Roetzauthor=R.+C.+Schoenfeldauthor=R.+J.+Weikert&title=2-Substituted+N-aryl+piperazines+as+novel+triple+reuptake+inhibitors+for+the+treatment+of+depression&doi=10.1016%2Fj.bmcl.2010.05.008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.05.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.05.008%26sid%3Dliteratum%253Aachs%26aulast%3DCarter%26aufirst%3DD.%2BS.%26aulast%3DCai%26aufirst%3DH.-Y.%26aulast%3DLee%26aufirst%3DE.%2BK.%26aulast%3DIyer%26aufirst%3DP.%2BS.%26aulast%3DLucas%26aufirst%3DM.%2BC.%26aulast%3DRoetz%26aufirst%3DR.%26aulast%3DSchoenfeld%26aufirst%3DR.%2BC.%26aulast%3DWeikert%26aufirst%3DR.%2BJ.%26atitle%3D2-Substituted%2520N-aryl%2520piperazines%2520as%2520novel%2520triple%2520reuptake%2520inhibitors%2520for%2520the%2520treatment%2520of%2520depression%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D3941%26epage%3D3945%26doi%3D10.1016%2Fj.bmcl.2010.05.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Honda, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishichi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshikawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanzaki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arakawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terauchi, J.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological activities of 1-aryl-1,4-diazepan-2-one derivatives as novel triple reuptake inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">3898</span>– <span class="NLM_lpage">3902</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.06.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.bmcl.2014.06.046" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=3898-3902&author=E.+Hondaauthor=Y.+Ishichiauthor=E.+Kimuraauthor=M.+Yoshikawaauthor=N.+Kanzakiauthor=H.+Nakagawaauthor=Y.+Teraoauthor=A.+Suzukiauthor=T.+Kawaiauthor=Y.+Arakawaauthor=H.+Ohtaauthor=J.+Terauchi&title=Design%2C+synthesis%2C+and+biological+activities+of+1-aryl-1%2C4-diazepan-2-one+derivatives+as+novel+triple+reuptake+inhibitors&doi=10.1016%2Fj.bmcl.2014.06.046"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.06.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.06.046%26sid%3Dliteratum%253Aachs%26aulast%3DHonda%26aufirst%3DE.%26aulast%3DIshichi%26aufirst%3DY.%26aulast%3DKimura%26aufirst%3DE.%26aulast%3DYoshikawa%26aufirst%3DM.%26aulast%3DKanzaki%26aufirst%3DN.%26aulast%3DNakagawa%26aufirst%3DH.%26aulast%3DTerao%26aufirst%3DY.%26aulast%3DSuzuki%26aufirst%3DA.%26aulast%3DKawai%26aufirst%3DT.%26aulast%3DArakawa%26aufirst%3DY.%26aulast%3DOhta%26aufirst%3DH.%26aulast%3DTerauchi%26aufirst%3DJ.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520activities%2520of%25201-aryl-1%252C4-diazepan-2-one%2520derivatives%2520as%2520novel%2520triple%2520reuptake%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D3898%26epage%3D3902%26doi%3D10.1016%2Fj.bmcl.2014.06.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishichi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honda, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshikawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakahata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arakawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanzaki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terauchi, J.</span></span> <span> </span><span class="NLM_article-title">Novel triple reuptake inhibitors with low risk of CAD associated liabilities: design, synthesis and biological activities of 4-[(1S)-1-(3,4-dichlorophenyl)-2-methoxyethyl]piperidine and related compounds</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">4600</span>– <span class="NLM_lpage">4613</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.05.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.bmc.2013.05.025" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=4600-4613&author=Y.+Ishichiauthor=E.+Kimuraauthor=E.+Hondaauthor=M.+Yoshikawaauthor=T.+Nakahataauthor=Y.+Teraoauthor=A.+Suzukiauthor=T.+Kawaiauthor=Y.+Arakawaauthor=H.+Ohtaauthor=N.+Kanzakiauthor=H.+Nakagawaauthor=J.+Terauchi&title=Novel+triple+reuptake+inhibitors+with+low+risk+of+CAD+associated+liabilities%3A+design%2C+synthesis+and+biological+activities+of+4-%5B%281S%29-1-%283%2C4-dichlorophenyl%29-2-methoxyethyl%5Dpiperidine+and+related+compounds&doi=10.1016%2Fj.bmc.2013.05.025"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.05.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.05.025%26sid%3Dliteratum%253Aachs%26aulast%3DIshichi%26aufirst%3DY.%26aulast%3DKimura%26aufirst%3DE.%26aulast%3DHonda%26aufirst%3DE.%26aulast%3DYoshikawa%26aufirst%3DM.%26aulast%3DNakahata%26aufirst%3DT.%26aulast%3DTerao%26aufirst%3DY.%26aulast%3DSuzuki%26aufirst%3DA.%26aulast%3DKawai%26aufirst%3DT.%26aulast%3DArakawa%26aufirst%3DY.%26aulast%3DOhta%26aufirst%3DH.%26aulast%3DKanzaki%26aufirst%3DN.%26aulast%3DNakagawa%26aufirst%3DH.%26aulast%3DTerauchi%26aufirst%3DJ.%26atitle%3DNovel%2520triple%2520reuptake%2520inhibitors%2520with%2520low%2520risk%2520of%2520CAD%2520associated%2520liabilities%253A%2520design%252C%2520synthesis%2520and%2520biological%2520activities%2520of%25204-%255B%25281S%2529-1-%25283%252C4-dichlorophenyl%2529-2-methoxyethyl%255Dpiperidine%2520and%2520related%2520compounds%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D4600%26epage%3D4613%26doi%3D10.1016%2Fj.bmc.2013.05.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo characterization of PA01, a novel promising triple reuptake inhibitor</span>. <i>Physiol. Behav.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">149</span>, <span class="refDoi"> DOI: 10.1016/j.physbeh.2014.10.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.physbeh.2014.10.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2015&pages=141-149&author=J.+Houauthor=Y.+Xingauthor=D.+Zuoauthor=Y.+Wuauthor=J.+Tianauthor=Q.+Mengauthor=M.+Yang&title=In+vitro+and+in+vivo+characterization+of+PA01%2C+a+novel+promising+triple+reuptake+inhibitor&doi=10.1016%2Fj.physbeh.2014.10.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1016%2Fj.physbeh.2014.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.physbeh.2014.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DXing%26aufirst%3DY.%26aulast%3DZuo%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DTian%26aufirst%3DJ.%26aulast%3DMeng%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DM.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520characterization%2520of%2520PA01%252C%2520a%2520novel%2520promising%2520triple%2520reuptake%2520inhibitor%26jtitle%3DPhysiol.%2520Behav.%26date%3D2015%26volume%3D138%26spage%3D141%26epage%3D149%26doi%3D10.1016%2Fj.physbeh.2014.10.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span> <span> </span><span class="NLM_article-title">The effects of LPM570065, a novel triple reuptake inhibitor, on extracellular serotonin, dopamine and norepinephrine levels in rats</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">e91775</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0091775</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1371%2Fjournal.pone.0091775" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=e91775&author=R.+Zhangauthor=X.+Liauthor=Y.+Shiauthor=Y.+Shaoauthor=K.+Sunauthor=A.+Wangauthor=F.+Sunauthor=W.+Liuauthor=D.+Wangauthor=J.+Jinauthor=Y.+Li&title=The+effects+of+LPM570065%2C+a+novel+triple+reuptake+inhibitor%2C+on+extracellular+serotonin%2C+dopamine+and+norepinephrine+levels+in+rats&doi=10.1371%2Fjournal.pone.0091775"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0091775&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0091775%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DShao%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26atitle%3DThe%2520effects%2520of%2520LPM570065%252C%2520a%2520novel%2520triple%2520reuptake%2520inhibitor%252C%2520on%2520extracellular%2520serotonin%252C%2520dopamine%2520and%2520norepinephrine%2520levels%2520in%2520rats%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26spage%3De91775%26doi%3D10.1371%2Fjournal.pone.0091775" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debnath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonio, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reith, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutta, A.</span></span> <span> </span><span class="NLM_article-title">Flexible and biomimetic analogs of triple uptake inhibitor 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: Synthesis, biological characterization, and development of a pharmacophore model</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">311</span>– <span class="NLM_lpage">324</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.11.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.bmc.2013.11.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=24315194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFOhu7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=311-324&author=H.+Sharmaauthor=S.+Santraauthor=J.+Debnathauthor=T.+Antonioauthor=M.+Reithauthor=A.+Dutta&title=Flexible+and+biomimetic+analogs+of+triple+uptake+inhibitor+4-%28%28%28%283S%2C6S%29-6-benzhydryltetrahydro-2H-pyran-3-yl%29amino%29methyl%29phenol%3A+Synthesis%2C+biological+characterization%2C+and+development+of+a+pharmacophore+model&doi=10.1016%2Fj.bmc.2013.11.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Flexible and biomimetic analogs of triple uptake inhibitor 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: Synthesis, biological characterization, and development of a pharmacophore model</span></div><div class="casAuthors">Sharma, Horrick; Santra, Soumava; Debnath, Joy; Antonio, Tamara; Reith, Maarten; Dutta, Aloke</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">311-324</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In this study we have generated a pharmacophore model of triple uptake inhibitor compds. based on novel asym. pyran derivs. and the newly developed asym. furan derivs.  The model revealed features important for inhibitors to exhibit a balanced activity against dopamine transporter (DAT), serotonin transporter (SERT), and norepinephrine transporter (NET).  In particular, a 'folded' conformation was found common to the active pyran compds. in the training set and was crucial to triple uptake inhibitory activity.  Furthermore, the distances between the benzhydryl moiety and the N-benzyl group as well as the orientation of the secondary nitrogen were also important for TUI activity.  We have validated our findings by synthesizing and testing novel asym. pyran analogs.  The present work has also resulted in the discovery of a new series of asym. THF derivs. as novel TUIs.  Lead compds. I (R = OH, OMe) exhibited moderate TUI activity.  Interestingly, the highest TUI activity by lead THF compds. for example, I (R = OH, OMe), was exhibited in a stereochem. preference similar to pyran TUI for example, D-161 (II).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpoPTnQdBuWLVg90H21EOLACvtfcHk0ljNo7-Ab1x2Hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFOhu7%252FM&md5=0594221d44641fce17db71101d075cb2</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.11.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.11.017%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DH.%26aulast%3DSantra%26aufirst%3DS.%26aulast%3DDebnath%26aufirst%3DJ.%26aulast%3DAntonio%26aufirst%3DT.%26aulast%3DReith%26aufirst%3DM.%26aulast%3DDutta%26aufirst%3DA.%26atitle%3DFlexible%2520and%2520biomimetic%2520analogs%2520of%2520triple%2520uptake%2520inhibitor%25204-%2528%2528%2528%25283S%252C6S%2529-6-benzhydryltetrahydro-2H-pyran-3-yl%2529amino%2529methyl%2529phenol%253A%2520Synthesis%252C%2520biological%2520characterization%252C%2520and%2520development%2520of%2520a%2520pharmacophore%2520model%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D311%26epage%3D324%26doi%3D10.1016%2Fj.bmc.2013.11.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutta, A.</span></span> <span> </span><span class="NLM_article-title">Triple reuptake inhibitors as potential next-generation antidepressants: a new hope?</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">2385</span>– <span class="NLM_lpage">2406</span>, <span class="refDoi"> DOI: 10.4155/fmc.15.134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.4155%2Ffmc.15.134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=26619226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFKlu77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=2385-2406&author=H.+Sharmaauthor=S.+Santraauthor=A.+Dutta&title=Triple+reuptake+inhibitors+as+potential+next-generation+antidepressants%3A+a+new+hope%3F&doi=10.4155%2Ffmc.15.134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Triple reuptake inhibitors as potential next-generation antidepressants: a new hope?</span></div><div class="casAuthors">Sharma, Horrick; Santra, Soumava; Dutta, Aloke</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2385-2406</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">The current therapy for depression is less than ideal with remission rates of only 25-35% and a slow onset of action with other assocd. side effects.  The persistence of anhedonia originating from depressed dopaminergic activity is one of the most treatment-resistant symptoms of depression.  Therefore, it has been hypothesized that triple reuptake inhibitors (TRIs) with potency to block dopamine reuptake in addn. to serotonin and norepinephrine transporters should produce higher efficacy.  The current review comprehensively describes the development of TRIs and discusses the importance of evaluation of in vivo transporter occupancy of TRIs, which should correlate with efficacy in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrShosMLktZJbVg90H21EOLACvtfcHk0ljNo7-Ab1x2Hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFKlu77I&md5=1130f331ad0e8ecfcdf5a8c3fe915596</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.4155%2Ffmc.15.134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.15.134%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DH.%26aulast%3DSantra%26aufirst%3DS.%26aulast%3DDutta%26aufirst%3DA.%26atitle%3DTriple%2520reuptake%2520inhibitors%2520as%2520potential%2520next-generation%2520antidepressants%253A%2520a%2520new%2520hope%253F%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2015%26volume%3D7%26spage%3D2385%26epage%3D2406%26doi%3D10.4155%2Ffmc.15.134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reith, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutta, A. K.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel trisubstituted asymmetric derivatives of (2S,4R,5R)-2-benzhydryl-5-benzylaminotetrahydropyran-4-ol, exhibiting high affinity for serotonin and norepinephrine transporters in a stereospecific manner</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">4962</span>– <span class="NLM_lpage">4971</span>, <span class="refDoi"> DOI: 10.1021/jm049021k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049021k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltlGhtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=4962-4971&author=S.+Zhangauthor=J.+Zhenauthor=M.+E.+Reithauthor=A.+K.+Dutta&title=Discovery+of+novel+trisubstituted+asymmetric+derivatives+of+%282S%2C4R%2C5R%29-2-benzhydryl-5-benzylaminotetrahydropyran-4-ol%2C+exhibiting+high+affinity+for+serotonin+and+norepinephrine+transporters+in+a+stereospecific+manner&doi=10.1021%2Fjm049021k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Trisubstituted Asymmetric Derivatives of (2S,4R,5R)-2-benzhydryl-5-benzylaminotetrahydropyran-4-ol, Exhibiting High Affinity for Serotonin and Norepinephrine Transporters in a Stereospecific Manner</span></div><div class="casAuthors">Zhang, Shijun; Zhen, Juan; Reith, Maarten E. A.; Dutta, Aloke K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4962-4971</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In a structure-activity relationship study on 3,6-disubstituted pyran derivs., the asym. synthesis and biol. characterization of trisubstituted (2S,4R,5R)-2-benzhydryl-5-benzylaminotetrahydropyran-4-ol and (3S,4R,6S)-6-benzhydryl-4-benzylaminotetrahydropyran-3-ol derivs. and their enantiomers were carried out.  All synthesized derivs. were tested for their affinities for the dopamine transporter (DAT), serotonin transporter (SERT), and norepinephrine transporter (NET) in the brain by measuring their potency in inhibiting the uptake of [3H]DA, [3H]-5-HT, and [3H]NE, resp.  Compds. were also tested for their binding affinity at the DAT by their inhibition of [3H]WIN 35,428.  Biol. results indicated that regioselectivity and stereoselectivity played important roles in detg. activity for monoamine transporters as only (-)-isomers of 2-benzhydryl-5-benzylaminotetrahydropyran-4-ol derivs. exhibited appreciable potency for the monoamine transporters, in particular for the SERT and NET.  Among the active analogs, (2S,4R,5R)-(-)-2-benzhydryl-5-benzylaminotetrahydropyran-4-ol exhibited potent and selective affinity at the NET (Ki, [3H]NE = 4.92 nM; DAT/NET = 91 and SERT/NET = 140).  (2S,4R,5R)-(-)-2-benzhydryl-5-(4-methoxybenzylamino)tetrahydropyran-4-ol was potent at both SERT and NET (Ki, [3H]-5-HT = 25.9 and [3H]NE = 15.8 nM, resp.).  In the analogs of these compds. a cis-relationship between the biphenyl and the amino moiety was maintained for the SERT and NET interactions, as was obsd. earlier for 3,6-disubstituted pyran compds. for the DAT interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWGm1U2Ni3vLVg90H21EOLACvtfcHk0li6jhdm6_-6_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltlGhtb0%253D&md5=a48e2fe37663009c240415df18d64c94</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1021%2Fjm049021k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049021k%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DZhen%26aufirst%3DJ.%26aulast%3DReith%26aufirst%3DM.%2BE.%26aulast%3DDutta%26aufirst%3DA.%2BK.%26atitle%3DDiscovery%2520of%2520novel%2520trisubstituted%2520asymmetric%2520derivatives%2520of%2520%25282S%252C4R%252C5R%2529-2-benzhydryl-5-benzylaminotetrahydropyran-4-ol%252C%2520exhibiting%2520high%2520affinity%2520for%2520serotonin%2520and%2520norepinephrine%2520transporters%2520in%2520a%2520stereospecific%2520manner%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D4962%26epage%3D4971%26doi%3D10.1021%2Fjm049021k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dutta, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopishetty, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gogoi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reith, M.</span></span> <span> </span><span class="NLM_article-title">The novel trisubstituted pyran derivative D-142 has triple monoamine reuptake inhibitory activity and exerts potent antidepressant-like activity in rodents</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>671</i></span>,  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">44</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2011.09.162</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.ejphar.2011.09.162" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=21963455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVaqurzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=671&publication_year=2011&pages=39-44&author=A.+K.+Duttaauthor=B.+Gopishettyauthor=S.+Gogoiauthor=S.+Aliauthor=J.+Zhenauthor=M.+Reith&title=The+novel+trisubstituted+pyran+derivative+D-142+has+triple+monoamine+reuptake+inhibitory+activity+and+exerts+potent+antidepressant-like+activity+in+rodents&doi=10.1016%2Fj.ejphar.2011.09.162"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">The novel trisubstituted pyran derivative D-142 has triple monoamine reuptake inhibitory activity and exerts potent antidepressant-like activity in rodents</span></div><div class="casAuthors">Dutta, Aloke K.; Gopishetty, Bhaskar; Gogoi, Sanjib; Ali, Solav; Zhen, Juan; Reith, Maarten</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">671</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">39-44</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Major depression disorder is a significant health problem with 10-20% of all adults suffering from this disease.  The underlying causes of depression are still unclear and 15% of depressed patients are resistant to all known therapies.  Monoamine therapies have so far been the most successful approach for treating depression.  Triple monoamine reuptake inhibitors have recently been implicated in generation of potent antidepressant activity while possibly exhibiting a low side-effect profile in addn. to treating anhedonia.  The addnl., previously under-appreciated involvement of dopaminergic systems in depression prompted our efforts to develop novel asym. trisubstituted and disubstituted pyran derivs. as triple reuptake inhibitors.  One of the lead compds., D-142, exhibited uptake inhibition (Ki) values of 29.3 nM, 14.7 nM and 59.3 ± 13.7 nM for norepinephrine, serotonin and dopamine transporters, resp.  Its affinity for serotonin transporter was comparable to fluoxetine, a well known SSRI.  In the rat forced swimming test, compd. D-142 exhibited potent antidepressant activity in the dose range tested (2.5, 5 and 10 mg/kg) and was far more efficacious than the ref. compd. imipramine.  In the mouse tail suspension test, compd. D-142 reduced immobility in a dose (2.5, 5 and 10 mg/kg) dependent manner, indicating a potent antidepressant effect.  In locomotor activity tests, compd. D-142 did not exhibit any stimulation in the same dose ranges.  In the extended CNS receptors screening assay this mol. exhibited little or no non-specific interaction in the CNS, indicating high specificity for monoamine transporters.  These results advance D-142 as a potential potent antidepressant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGPlqH4cledLVg90H21EOLACvtfcHk0li6jhdm6_-6_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVaqurzE&md5=69a1504c78c1083e7980c26a7179ac89</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2011.09.162&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2011.09.162%26sid%3Dliteratum%253Aachs%26aulast%3DDutta%26aufirst%3DA.%2BK.%26aulast%3DGopishetty%26aufirst%3DB.%26aulast%3DGogoi%26aufirst%3DS.%26aulast%3DAli%26aufirst%3DS.%26aulast%3DZhen%26aufirst%3DJ.%26aulast%3DReith%26aufirst%3DM.%26atitle%3DThe%2520novel%2520trisubstituted%2520pyran%2520derivative%2520D-142%2520has%2520triple%2520monoamine%2520reuptake%2520inhibitory%2520activity%2520and%2520exerts%2520potent%2520antidepressant-like%2520activity%2520in%2520rodents%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D671%26spage%3D39%26epage%3D44%26doi%3D10.1016%2Fj.ejphar.2011.09.162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dutta, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voshavar, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mabrouk, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonio, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reith, M. E. A.</span></span> <span> </span><span class="NLM_article-title">Pharmacological and behavioral characterization of D-473, an orally active triple reuptake inhibitor targeting dopamine, serotonin and norepinephrine transporters</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">e113420</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0113420</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1371%2Fjournal.pone.0113420" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=25427177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFOlsL%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=e113420&author=A.+K.+Duttaauthor=S.+Santraauthor=H.+Sharmaauthor=C.+Voshavarauthor=L.+Xuauthor=O.+Mabroukauthor=T.+Antonioauthor=M.+E.+A.+Reith&title=Pharmacological+and+behavioral+characterization+of+D-473%2C+an+orally+active+triple+reuptake+inhibitor+targeting+dopamine%2C+serotonin+and+norepinephrine+transporters&doi=10.1371%2Fjournal.pone.0113420"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological and behavioral characterization of D-473, an orally active triple reuptake inhibitor targeting dopamine, serotonin and norepinephrine transporters</span></div><div class="casAuthors">Dutta, Aloke K.; Santra, Soumava; Sharma, Horrick; Voshavar, Chandrashekhar; Xu, Liping; Mabrouk, Omar; Antonio, Tamara; Reith, Maarten E. A.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e113420/1-e113420/23, 23 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Major depressive disorder (MDD) is a debilitating disease affecting a wide cross section of people around the world.  The current therapy for depression is less than adequate and there is a considerable unmet need for more efficacious treatment.  Dopamine has been shown to play a significant role in depression including prodn. of anhedonia which has been one of the untreated symptoms in MDD.  It has been hypothesized that drugs acting at all three monoamine transporters including dopamine transporter should provide more efficacious antidepressants activity.  This has led to the development of triple reuptake inhibitor D-473 which is a novel pyran based mol. and interacts with all three monoamine transporters.  The monoamine uptake inhibition activity in the cloned human transporters expressed in HEK-293 cells (70.4, 9.18 and 39.7 for DAT, SERT and NET, resp.) indicates a serotonin preferring triple reuptake inhibition profile for this drug.  The drug D-473 exhibited good brain penetration and produced efficacious activity in rat forced swim test under oral administration.  The optimal efficacy dose did not produce any locomotor activation.  Microdialysis expt. demonstrated that systemic administration of D-473 elevated extracellular level of the three monoamines DA, 5-HT, and NE efficaciously in the dorsal lateral striatum (DLS) and the medial prefrontal cortex (mPFC) area, indicating in vivo blockade of all three monoamine transporters by D-473.  Thus, the current biol. data from D-473 indicate potent antidepressant activity of the mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgZUFxM6yY0LVg90H21EOLACvtfcHk0li6jhdm6_-6_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFOlsL%252FO&md5=1ac592d450a1d6bce9bff124bf891b3b</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0113420&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0113420%26sid%3Dliteratum%253Aachs%26aulast%3DDutta%26aufirst%3DA.%2BK.%26aulast%3DSantra%26aufirst%3DS.%26aulast%3DSharma%26aufirst%3DH.%26aulast%3DVoshavar%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DMabrouk%26aufirst%3DO.%26aulast%3DAntonio%26aufirst%3DT.%26aulast%3DReith%26aufirst%3DM.%2BE.%2BA.%26atitle%3DPharmacological%2520and%2520behavioral%2520characterization%2520of%2520D-473%252C%2520an%2520orally%2520active%2520triple%2520reuptake%2520inhibitor%2520targeting%2520dopamine%252C%2520serotonin%2520and%2520norepinephrine%2520transporters%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26spage%3De113420%26doi%3D10.1371%2Fjournal.pone.0113420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span> <i>Wayne State University Technology Enters Exclusive License
Agreement
with TRImaran Pharma Inc. to Develop New Class of Drugs</i>; <span class="NLM_publisher-name">Wayne State University</span>: <span class="NLM_publisher-loc">Detroit,
MI</span>, February 6, <span class="NLM_year">2016</span>; <a href="http://www.trimaranpharmainc.com/news.html" class="extLink">http://www.trimaranpharmainc.com/news.html</a> (accessed May 29, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Wayne+State+University+Technology+Enters+Exclusive+License%0AAgreement%0Awith+TRImaran+Pharma+Inc.+to+Develop+New+Class+of+Drugs%3B+Wayne+State+University%3A+Detroit%2C%0AMI%2C+February+6%2C+2016%3B+http%3A%2F%2Fwww.trimaranpharmainc.com%2Fnews.html+%28accessed+May+29%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DWayne%2520State%2520University%2520Technology%2520Enters%2520Exclusive%2520License%250AAgreement%250Awith%2520TRImaran%2520Pharma%2520Inc.%2520to%2520Develop%2520New%2520Class%2520of%2520Drugs%26pub%3DWayne%2520State%2520University%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maryanoff, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McComsey, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costanzo, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setler, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardocki, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shank, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, C. R.</span></span> <span> </span><span class="NLM_article-title">Pyrroloisoquinoline antidepressants. potent, enantioselective inhibition of tetrabenazine-induced ptosis and neuronal uptake of norepinephrine, dopamine, and serotonin</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">943</span>– <span class="NLM_lpage">946</span>, <span class="refDoi"> DOI: 10.1021/jm00374a001</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00374a001" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1984&pages=943-946&author=B.+E.+Maryanoffauthor=D.+F.+McComseyauthor=M.+J.+Costanzoauthor=P.+E.+Setlerauthor=J.+F.+Gardockiauthor=R.+P.+Shankauthor=C.+R.+Schneider&title=Pyrroloisoquinoline+antidepressants.+potent%2C+enantioselective+inhibition+of+tetrabenazine-induced+ptosis+and+neuronal+uptake+of+norepinephrine%2C+dopamine%2C+and+serotonin&doi=10.1021%2Fjm00374a001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1021%2Fjm00374a001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00374a001%26sid%3Dliteratum%253Aachs%26aulast%3DMaryanoff%26aufirst%3DB.%2BE.%26aulast%3DMcComsey%26aufirst%3DD.%2BF.%26aulast%3DCostanzo%26aufirst%3DM.%2BJ.%26aulast%3DSetler%26aufirst%3DP.%2BE.%26aulast%3DGardocki%26aufirst%3DJ.%2BF.%26aulast%3DShank%26aufirst%3DR.%2BP.%26aulast%3DSchneider%26aufirst%3DC.%2BR.%26atitle%3DPyrroloisoquinoline%2520antidepressants.%2520potent%252C%2520enantioselective%2520inhibition%2520of%2520tetrabenazine-induced%2520ptosis%2520and%2520neuronal%2520uptake%2520of%2520norepinephrine%252C%2520dopamine%252C%2520and%2520serotonin%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1984%26volume%3D27%26spage%3D943%26epage%3D946%26doi%3D10.1021%2Fjm00374a001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maryanoff, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McComsey, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardocki, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shank, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costanzo, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nortey, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setler, P. E.</span></span> <span> </span><span class="NLM_article-title">Pyrroloisoquinoline antidepressants. 2. in-depth exploration of structure-activity relationships</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">1433</span>– <span class="NLM_lpage">1454</span>, <span class="refDoi"> DOI: 10.1021/jm00391a028</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00391a028" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1987&pages=1433-1454&author=B.+E.+Maryanoffauthor=D.+F.+McComseyauthor=J.+F.+Gardockiauthor=R.+P.+Shankauthor=M.+J.+Costanzoauthor=S.+O.+Norteyauthor=C.+R.+Schneiderauthor=P.+E.+Setler&title=Pyrroloisoquinoline+antidepressants.+2.+in-depth+exploration+of+structure-activity+relationships&doi=10.1021%2Fjm00391a028"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1021%2Fjm00391a028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00391a028%26sid%3Dliteratum%253Aachs%26aulast%3DMaryanoff%26aufirst%3DB.%2BE.%26aulast%3DMcComsey%26aufirst%3DD.%2BF.%26aulast%3DGardocki%26aufirst%3DJ.%2BF.%26aulast%3DShank%26aufirst%3DR.%2BP.%26aulast%3DCostanzo%26aufirst%3DM.%2BJ.%26aulast%3DNortey%26aufirst%3DS.%2BO.%26aulast%3DSchneider%26aufirst%3DC.%2BR.%26aulast%3DSetler%26aufirst%3DP.%2BE.%26atitle%3DPyrroloisoquinoline%2520antidepressants.%25202.%2520in-depth%2520exploration%2520of%2520structure-activity%2520relationships%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1987%26volume%3D30%26spage%3D1433%26epage%3D1454%26doi%3D10.1021%2Fjm00391a028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aluisio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lord, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbier, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraser, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggs, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dvorak, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Letavic, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maryanoff, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carruthers, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonaventure, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovenberg, T. W.</span></span> <span> </span><span class="NLM_article-title">In-vitro and in-vivo characterization of JNJ-7925476, a novel triple monoamine uptake inhibitor</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>587</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">146</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2008.04.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.ejphar.2008.04.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=18499098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsFGltbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=587&publication_year=2008&pages=141-146&author=L.+Aluisioauthor=B.+Lordauthor=A.+J.+Barbierauthor=I.+C.+Fraserauthor=S.+J.+Wilsonauthor=J.+Boggsauthor=L.+K.+Dvorakauthor=M.+A.+Letavicauthor=B.+E.+Maryanoffauthor=N.+I.+Carruthersauthor=P.+Bonaventureauthor=T.+W.+Lovenberg&title=In-vitro+and+in-vivo+characterization+of+JNJ-7925476%2C+a+novel+triple+monoamine+uptake+inhibitor&doi=10.1016%2Fj.ejphar.2008.04.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">In-vitro and in-vivo characterization of JNJ-7925476, a novel triple monoamine uptake inhibitor</span></div><div class="casAuthors">Aluisio, Leah; Lord, Brian; Barbier, Ann J.; Fraser, Ian C.; Wilson, Sandy J.; Boggs, Jamin; Dvorak, Lisa K.; Letavic, Michael A.; Maryanoff, Bruce E.; Carruthers, Nicholas I.; Bonaventure, Pascal; Lovenberg, Timothy W.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">587</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">141-146</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Triple reuptake inhibitors, which block the serotonin transporter (SERT), norepinephrine transporter (NET) and dopamine transporter (DAT) in the central nervous system have been described as therapeutic alternatives for classical selective serotonin reuptake inhibitors, with advantages due to their multiple mechanisms of action.  JNJ-7925476 (trans-6-(4-ethynylphenyl)-1,2,3,5,6,10b-hexahydropyrrolo[2,1-a]isoquinoline) is a selective and potent inhibitor of the SERT, NET, and DAT (K i = 0.9, 17 and 5.2 nM, resp.).  Following s.c. dosing in rat, JNJ-7925476 was rapidly absorbed into the plasma, and drug concns. in the brain tracked with those in the plasma but were 7-fold higher.  The ED50 values for JNJ-7925476 occupancy of the SERT, NET, and DAT in rat brain were 0.18, 0.09 and 2.4 mg/kg, resp.  JNJ-7925476 (0.1-10 mg/kg, s.c.) rapidly induced a robust, dose-dependent increase in extracellular serotonin, dopamine, and norepinephrine levels in rat cerebral cortex.  The compd. also showed potent antidepressant-like activity in the mouse tail suspension test (ED50 = 0.3 mg/kg, i.p.).  These results demonstrate that JNJ-7925476 is a triple reuptake inhibitor with in-vivo efficacy in biochem. and behavioral models of depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrLdkhiOEPU7Vg90H21EOLACvtfcHk0ljara2wudTCBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsFGltbc%253D&md5=e55497330670d8ce48403bb2283efe3d</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2008.04.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2008.04.008%26sid%3Dliteratum%253Aachs%26aulast%3DAluisio%26aufirst%3DL.%26aulast%3DLord%26aufirst%3DB.%26aulast%3DBarbier%26aufirst%3DA.%2BJ.%26aulast%3DFraser%26aufirst%3DI.%2BC.%26aulast%3DWilson%26aufirst%3DS.%2BJ.%26aulast%3DBoggs%26aufirst%3DJ.%26aulast%3DDvorak%26aufirst%3DL.%2BK.%26aulast%3DLetavic%26aufirst%3DM.%2BA.%26aulast%3DMaryanoff%26aufirst%3DB.%2BE.%26aulast%3DCarruthers%26aufirst%3DN.%2BI.%26aulast%3DBonaventure%26aufirst%3DP.%26aulast%3DLovenberg%26aufirst%3DT.%2BW.%26atitle%3DIn-vitro%2520and%2520in-vivo%2520characterization%2520of%2520JNJ-7925476%252C%2520a%2520novel%2520triple%2520monoamine%2520uptake%2520inhibitor%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2008%26volume%3D587%26spage%3D141%26epage%3D146%26doi%3D10.1016%2Fj.ejphar.2008.04.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roggen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kehler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stensbol, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, T.</span></span> <span> </span><span class="NLM_article-title">Synthesis of enantiomerically pure milnacipran analogs and inhibition of dopamine, serotonin, and norepinephrine transporters</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">2834</span>– <span class="NLM_lpage">2837</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2007.02.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.bmcl.2007.02.054" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=2834-2837&author=H.+Roggenauthor=J.+Kehlerauthor=T.+B.+Stensbolauthor=T.+Hansen&title=Synthesis+of+enantiomerically+pure+milnacipran+analogs+and+inhibition+of+dopamine%2C+serotonin%2C+and+norepinephrine+transporters&doi=10.1016%2Fj.bmcl.2007.02.054"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.02.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.02.054%26sid%3Dliteratum%253Aachs%26aulast%3DRoggen%26aufirst%3DH.%26aulast%3DKehler%26aufirst%3DJ.%26aulast%3DStensbol%26aufirst%3DT.%2BB.%26aulast%3DHansen%26aufirst%3DT.%26atitle%3DSynthesis%2520of%2520enantiomerically%2520pure%2520milnacipran%2520analogs%2520and%2520inhibition%2520of%2520dopamine%252C%2520serotonin%252C%2520and%2520norepinephrine%2520transporters%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D2834%26epage%3D2837%26doi%3D10.1016%2Fj.bmcl.2007.02.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Axford, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boot, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hotten, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keenan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milutinovic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pullar, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tupper, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Belle, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vivien, V.</span></span> <span> </span><span class="NLM_article-title">Bicyclo[2.2.1]heptanes as novel triple re-uptake inhibitors for the treatment of depression</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">3277</span>– <span class="NLM_lpage">3280</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(03)00660-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2FS0960-894X%2803%2900660-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=3277-3280&author=L.+Axfordauthor=J.+R.+Bootauthor=T.+M.+Hottenauthor=M.+Keenanauthor=F.+M.+Martinauthor=S.+Milutinovicauthor=N.+A.+Mooreauthor=M.+F.+O%E2%80%99Neillauthor=I.+A.+Pullarauthor=D.+E.+Tupperauthor=K.+R.+Van+Belleauthor=V.+Vivien&title=Bicyclo%5B2.2.1%5Dheptanes+as+novel+triple+re-uptake+inhibitors+for+the+treatment+of+depression&doi=10.1016%2FS0960-894X%2803%2900660-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2803%2900660-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252803%252900660-7%26sid%3Dliteratum%253Aachs%26aulast%3DAxford%26aufirst%3DL.%26aulast%3DBoot%26aufirst%3DJ.%2BR.%26aulast%3DHotten%26aufirst%3DT.%2BM.%26aulast%3DKeenan%26aufirst%3DM.%26aulast%3DMartin%26aufirst%3DF.%2BM.%26aulast%3DMilutinovic%26aufirst%3DS.%26aulast%3DMoore%26aufirst%3DN.%2BA.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DM.%2BF.%26aulast%3DPullar%26aufirst%3DI.%2BA.%26aulast%3DTupper%26aufirst%3DD.%2BE.%26aulast%3DVan%2BBelle%26aufirst%3DK.%2BR.%26aulast%3DVivien%26aufirst%3DV.%26atitle%3DBicyclo%255B2.2.1%255Dheptanes%2520as%2520novel%2520triple%2520re-uptake%2520inhibitors%2520for%2520the%2520treatment%2520of%2520depression%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2003%26volume%3D13%26spage%3D3277%26epage%3D3280%26doi%3D10.1016%2FS0960-894X%2803%2900660-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caldarone, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paterson, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westphal, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korte-Bouws, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prins, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korte, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghavami, A.</span></span> <span> </span><span class="NLM_article-title">The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>335</i></span>,  <span class="NLM_fpage">762</span>– <span class="NLM_lpage">770</span>, <span class="refDoi"> DOI: 10.1124/jpet.110.174011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1124%2Fjpet.110.174011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=20864506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFOmsrfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=335&publication_year=2010&pages=762-770&author=B.+J.+Caldaroneauthor=N.+E.+Patersonauthor=J.+Zhouauthor=D.+Brunnerauthor=A.+P.+Kozikowskiauthor=K.+G.+Westphalauthor=G.+A.+Korte-Bouwsauthor=J.+Prinsauthor=S.+M.+Korteauthor=B.+Olivierauthor=A.+Ghavami&title=The+novel+triple+reuptake+inhibitor+JZAD-IV-22+exhibits+an+antidepressant+pharmacological+profile+without+locomotor+stimulant+or+sensitization+properties&doi=10.1124%2Fjpet.110.174011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties</span></div><div class="casAuthors">Caldarone, Barbara J.; Paterson, Neil E.; Zhou, Jia; Brunner, Daniela; Kozikowski, Alan P.; Westphal, Koen G. C.; Korte-Bouws, Gerdien A. H.; Prins, Jolanda; Korte, S. Mechiel; Olivier, Berend; Ghavami, Afshin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">335</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">762-770</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Triple reuptake inhibitors (TRIs) that block the dopamine transporter (DAT), norepinephrine transporter, and serotonin transporter are being developed as a new class of antidepressant that may have better efficacy and fewer side effects compared with traditional antidepressants.  We describe a novel TRI, 2-[4-(4-chlorophenyl)-1-methylpiperidin-3-ylmethylsulfanyl]-1-(3-methylpiperidin-1-yl)-ethanone (JZAD-IV-22), that inhibits all three monoamine transporters with approx. equal potency in vitro.  (+/-)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane hydrochloride (DOV 216,303), a TRI shown to be an effective antidepressant in a clin. trial, shows reuptake inhibition similar to that of JZAD-IV-22 in vitro.  Furthermore, both JZAD-IV-22 and DOV 216,303 increase levels of dopamine, norepinephrine, and serotonin in the mouse prefrontal cortex when administered by peripheral injection.  JZAD-IV-22 and DOV 216,303 exhibited antidepressant-like efficacy in the mouse forced-swim and tail-suspension tests at doses that increased neurotransmitter levels.  Because development of DAT inhibitors could be hindered by abuse liability, both JZAD-IV-22 and DOV 216,303 were compared in two assays that are markers of abuse potential.  Both JZAD-IV-22 and DOV 216,303 partially substituted for cocaine in a drug discrimination assay in rats, and high doses of DOV 216,303 produced locomotor sensitization in mice.  JZAD-IV-22 showed no evidence of sensitization at any dose tested.  These results demonstrate that JZAD-IV-22 is a TRI with antidepressant-like activity similar to that of DOV 216,303.  The striking feature that distinguishes the two TRIs is that locomotor sensitization, a common underlying feature of drugs of abuse, is seen with DOV 216,303 but is completely lacking in JZAD-IV-22.  These findings may have implications for the potential for abuse liability in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdzWmAhCBC4rVg90H21EOLACvtfcHk0lhmftmzQEiJBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFOmsrfM&md5=ae8ba4e5786c465f14068e5c3a59ab80</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1124%2Fjpet.110.174011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.110.174011%26sid%3Dliteratum%253Aachs%26aulast%3DCaldarone%26aufirst%3DB.%2BJ.%26aulast%3DPaterson%26aufirst%3DN.%2BE.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DBrunner%26aufirst%3DD.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26aulast%3DWestphal%26aufirst%3DK.%2BG.%26aulast%3DKorte-Bouws%26aufirst%3DG.%2BA.%26aulast%3DPrins%26aufirst%3DJ.%26aulast%3DKorte%26aufirst%3DS.%2BM.%26aulast%3DOlivier%26aufirst%3DB.%26aulast%3DGhavami%26aufirst%3DA.%26atitle%3DThe%2520novel%2520triple%2520reuptake%2520inhibitor%2520JZAD-IV-22%2520exhibits%2520an%2520antidepressant%2520pharmacological%2520profile%2520without%2520locomotor%2520stimulant%2520or%2520sensitization%2520properties%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2010%26volume%3D335%26spage%3D762%26epage%3D770%26doi%3D10.1124%2Fjpet.110.174011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Piperidine-based nocaine/modafinil hybrid ligands as highly potent monoamine transporter inhibitors: efficient drug discovery by rational lead hybridization</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">5821</span>– <span class="NLM_lpage">5824</span>, <span class="refDoi"> DOI: 10.1021/jm040117o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm040117o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=5821-5824&author=J.+Zhouauthor=R.+Heauthor=K.+M.+Johnsonauthor=Y.+Yeauthor=A.+P.+Kozikowski&title=Piperidine-based+nocaine%2Fmodafinil+hybrid+ligands+as+highly+potent+monoamine+transporter+inhibitors%3A+efficient+drug+discovery+by+rational+lead+hybridization&doi=10.1021%2Fjm040117o"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1021%2Fjm040117o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040117o%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DR.%26aulast%3DJohnson%26aufirst%3DK.%2BM.%26aulast%3DYe%26aufirst%3DY.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DPiperidine-based%2520nocaine%252Fmodafinil%2520hybrid%2520ligands%2520as%2520highly%2520potent%2520monoamine%2520transporter%2520inhibitors%253A%2520efficient%2520drug%2520discovery%2520by%2520rational%2520lead%2520hybridization%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D5821%26epage%3D5824%26doi%3D10.1021%2Fjm040117o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, H.-G.</span></span> <span> </span><span class="NLM_article-title">Exploration of novel 3-substituted azetidine derivatives as triple reuptake inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">8188</span>– <span class="NLM_lpage">8192</span>, <span class="refDoi"> DOI: 10.1021/jm3008294</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3008294" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht12it77L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8188-8192&author=Y.+Hanauthor=M.+Hanauthor=D.+Shinauthor=C.+Songauthor=H.-G.+Hahn&title=Exploration+of+novel+3-substituted+azetidine+derivatives+as+triple+reuptake+inhibitors&doi=10.1021%2Fjm3008294"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Exploration of Novel 3-Substituted Azetidine Derivatives As Triple Reuptake Inhibitors</span></div><div class="casAuthors">Han, Younghue; Han, Minsoo; Shin, Dongyun; Song, Chiman; Hahn, Hoh-Gyu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8188-8192</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">α-Aryl and α-benzyl azetidinemethanol hydrochlorides I•HCl (R = H; R1 = Ph, 4-ClC6H4, 3,4-Cl2C6H3, PhCH2), (aryl)azetidinemethyl ether hydrochlorides I•HCl (R = Me, Et, EtCH2, PhCH2, Ph, 2-MeC6H4, 3-MeC6H4, 4-MeC6H4, 2-FC6H4, 3-FC6H4, 4-FC6H4, 2-ClC6H4, 3-ClC6H4, 4-ClC6H4, 2-F3COC6H4, 3-F3COC6H4, 4-F3COC6H4, 3,4-F2C6H3, 3,4-Cl2C6H3; R1 = Ph, 4-ClC6H4, 3,4-Cl2C6H3, 2-MeC6H4, 2-naphthyl, 4-Cl-3-FC6H3, 3-Cl-4-FC6H3, 3,4-F2C6H3), and α-arylazetidinemethanol benzoate hydrochlorides I•HCl (R = PhCOO; R1 = Ph, 4-ClC6H4, 3,4-Cl2C6H3, 4-Cl-3-FC6H3) were prepd. and tested as simultaneous inhibitors of norepinephrine, serotonin, and dopamine transporters (triple reuptake inhibitors).  1-Boc-3-azetidinecarboxylic acid was converted in three steps to Boc-protected α-substituted azetidinemethanols; direct deprotection provided the free alc. hydrochlorides.  Alternatively, O-alkylation of Boc-protected α-substituted azetidinemethanols using alkyl halides or benzyl bromide followed by deprotection yielded (aryl)azetidinemethyl alkyl ether hydrochlorides; Mitsunobu reactions of Boc-protected α-substituted azetidinemethanols with phenols followed by deprotection yielded (aryl)azetidinemethyl aryl ether hydrochlorides.  Benzoylation of the Boc-protected α-substituted azetidinemethanols and Boc group cleavage yielded α-arylazetidinemethanol benzoate hydrochlorides.  The inhibition of human cytochrome P450 isoforms 1A2, 2D6, 2C9, and 3A4, the microsomal stabilities, and the inhibition of hERG by selected compds. were detd.  Of the compds. prepd., I•HCl (R = 2-naphthyl; R1 = EtCH2, Ph) were found to be the most promising triple reuptake inhibitors; their blood-brain barrier penetration, oral pharmacokinetics, and their antidepressant activities upon oral and i.v. administration (using the rat forced swimming test) were detd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEA0JC6_2D8LVg90H21EOLACvtfcHk0lhmftmzQEiJBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht12it77L&md5=9a1c7e86cf7fc4fbd8b4536416e1d311</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1021%2Fjm3008294&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3008294%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DM.%26aulast%3DShin%26aufirst%3DD.%26aulast%3DSong%26aufirst%3DC.%26aulast%3DHahn%26aufirst%3DH.-G.%26atitle%3DExploration%2520of%2520novel%25203-substituted%2520azetidine%2520derivatives%2520as%2520triple%2520reuptake%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8188%26epage%3D8192%26doi%3D10.1021%2Fjm3008294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheon, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, H. G.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">3234</span>– <span class="NLM_lpage">3237</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.06.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.bmcl.2014.06.026" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=3234-3237&author=J.+Yunauthor=M.+Hanauthor=C.+Songauthor=S.+H.+Cheonauthor=K.+Choiauthor=H.+G.+Hahn&title=Synthesis+and+biological+evaluation+of+3-phenethylazetidine+derivatives+as+triple+reuptake+inhibitors&doi=10.1016%2Fj.bmcl.2014.06.026"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.06.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.06.026%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DJ.%26aulast%3DHan%26aufirst%3DM.%26aulast%3DSong%26aufirst%3DC.%26aulast%3DCheon%26aufirst%3DS.%2BH.%26aulast%3DChoi%26aufirst%3DK.%26aulast%3DHahn%26aufirst%3DH.%2BG.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%25203-phenethylazetidine%2520derivatives%2520as%2520triple%2520reuptake%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D3234%26epage%3D3237%26doi%3D10.1016%2Fj.bmcl.2014.06.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, H. G.</span></span> <span> </span><span class="NLM_article-title">Exploration of 3-aminoazetidines as triple reuptake inhibitors by bioisosteric modification of 3-alpha-oxyazetidine</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">999</span>– <span class="NLM_lpage">1004</span>, <span class="refDoi"> DOI: 10.1021/ml500187a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500187a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=999-1004&author=M.+Hanauthor=C.+Songauthor=N.+Jeongauthor=H.+G.+Hahn&title=Exploration+of+3-aminoazetidines+as+triple+reuptake+inhibitors+by+bioisosteric+modification+of+3-alpha-oxyazetidine&doi=10.1021%2Fml500187a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1021%2Fml500187a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500187a%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DM.%26aulast%3DSong%26aufirst%3DC.%26aulast%3DJeong%26aufirst%3DN.%26aulast%3DHahn%26aufirst%3DH.%2BG.%26atitle%3DExploration%2520of%25203-aminoazetidines%2520as%2520triple%2520reuptake%2520inhibitors%2520by%2520bioisosteric%2520modification%2520of%25203-alpha-oxyazetidine%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26spage%3D999%26epage%3D1004%26doi%3D10.1021%2Fml500187a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antidepressant activity of optical isomers of 2-(4-benzylpiperazin-1-yl)-1-(5-chloro-6-methoxynaphthalen-2-yl) propan-1-ol (SIPI5056)</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1256</span>– <span class="NLM_lpage">1259</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.11.108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.bmcl.2009.11.108" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1256-1259&author=Z.+Wengauthor=J.+Li&title=Synthesis+and+antidepressant+activity+of+optical+isomers+of+2-%284-benzylpiperazin-1-yl%29-1-%285-chloro-6-methoxynaphthalen-2-yl%29+propan-1-ol+%28SIPI5056%29&doi=10.1016%2Fj.bmcl.2009.11.108"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.11.108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.11.108%26sid%3Dliteratum%253Aachs%26aulast%3DWeng%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DSynthesis%2520and%2520antidepressant%2520activity%2520of%2520optical%2520isomers%2520of%25202-%25284-benzylpiperazin-1-yl%2529-1-%25285-chloro-6-methoxynaphthalen-2-yl%2529%2520propan-1-ol%2520%2528SIPI5056%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D1256%26epage%3D1259%26doi%3D10.1016%2Fj.bmcl.2009.11.108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhen, X. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. Q.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antidepressant activity of arylalkanol-piperidine derivatives as triple reuptake inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">136</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2012.04.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.ejmech.2012.04.030" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2012&pages=123-136&author=Y.+Y.+Zhengauthor=L.+Guoauthor=X.+C.+Zhenauthor=J.+Q.+Li&title=Synthesis+and+antidepressant+activity+of+arylalkanol-piperidine+derivatives+as+triple+reuptake+inhibitors&doi=10.1016%2Fj.ejmech.2012.04.030"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2012.04.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2012.04.030%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DY.%2BY.%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DZhen%26aufirst%3DX.%2BC.%26aulast%3DLi%26aufirst%3DJ.%2BQ.%26atitle%3DSynthesis%2520and%2520antidepressant%2520activity%2520of%2520arylalkanol-piperidine%2520derivatives%2520as%2520triple%2520reuptake%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2012%26volume%3D54%26spage%3D123%26epage%3D136%26doi%3D10.1016%2Fj.ejmech.2012.04.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, Z. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, L. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. Q.</span></span> <span> </span><span class="NLM_article-title">Synthesis and pharmacological investigation of aralkyl diamine derivatives as potential triple reuptake inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">234</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.08.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.ejmech.2014.08.045" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2014&pages=219-234&author=Y.+Y.+Zhengauthor=Z.+J.+Wengauthor=P.+Xieauthor=M.+Y.+Zhuauthor=L.+X.+Xingauthor=J.+Q.+Li&title=Synthesis+and+pharmacological+investigation+of+aralkyl+diamine+derivatives+as+potential+triple+reuptake+inhibitors&doi=10.1016%2Fj.ejmech.2014.08.045"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.08.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.08.045%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DY.%2BY.%26aulast%3DWeng%26aufirst%3DZ.%2BJ.%26aulast%3DXie%26aufirst%3DP.%26aulast%3DZhu%26aufirst%3DM.%2BY.%26aulast%3DXing%26aufirst%3DL.%2BX.%26aulast%3DLi%26aufirst%3DJ.%2BQ.%26atitle%3DSynthesis%2520and%2520pharmacological%2520investigation%2520of%2520aralkyl%2520diamine%2520derivatives%2520as%2520potential%2520triple%2520reuptake%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D86%26spage%3D219%26epage%3D234%26doi%3D10.1016%2Fj.ejmech.2014.08.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McKinney, A.</span>; <span class="NLM_string-name">Bymaster, F.</span></span> <span> </span><span class="NLM_article-title">Methods for Inhibiting Native and Promiscuous Uptake of Monoamine Neurotransmitters Using a Triple Reuptake Inhibitor</span>. <span class="NLM_patent">US20140228421A1</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=A.+McKinney&author=F.+Bymaster&title=Methods+for+Inhibiting+Native+and+Promiscuous+Uptake+of+Monoamine+Neurotransmitters+Using+a+Triple+Reuptake+Inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMcKinney%26aufirst%3DA.%26atitle%3DMethods%2520for%2520Inhibiting%2520Native%2520and%2520Promiscuous%2520Uptake%2520of%2520Monoamine%2520Neurotransmitters%2520Using%2520a%2520Triple%2520Reuptake%2520Inhibitor%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pankevich, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altevogt, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunlop, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gage, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyman, S. E.</span></span> <span> </span><span class="NLM_article-title">Improving and accelerating drug development for nervous system disorders</span>. <i>Neuron</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">546</span>– <span class="NLM_lpage">553</span>, <span class="refDoi"> DOI: 10.1016/j.neuron.2014.10.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=10.1016%2Fj.neuron.2014.10.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=25442933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvV2mtrfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2014&pages=546-553&author=D.+E.+Pankevichauthor=B.+M.+Altevogtauthor=J.+Dunlopauthor=F.+H.+Gageauthor=S.+E.+Hyman&title=Improving+and+accelerating+drug+development+for+nervous+system+disorders&doi=10.1016%2Fj.neuron.2014.10.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Improving and Accelerating Drug Development for Nervous System Disorders</span></div><div class="casAuthors">Pankevich, Diana E.; Altevogt, Bruce M.; Dunlop, John; Gage, Fred H.; Hyman, Steve E.</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">546-553</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Advances in the neurosciences have placed the field in the position where it is poised to significantly reduce the burden of nervous system disorders.  However, drug discovery, development, and translation for nervous system disorders still pose many unique challenges.  The key scientific challenges can be summarized as follows: mechanisms of disease, target identification and validation, predictive models, biomarkers for patient stratification and as endpoints for clin. trials, clear regulatory pathways, reliability and reproducibility of published data, and data sharing and collaboration.  To accelerate nervous system drug development, the Institute of Medicine's Forum on Neuroscience and Nervous System Disorders has hosted a series of public workshops that brought together representatives of industry, government (including both research funding and regulatory agencies), academia, and patient groups to discuss these challenges and offer potential strategies to improve the translational neuroscience.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOqebkslCjwLVg90H21EOLACvtfcHk0lijrgh1AMM84Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvV2mtrfN&md5=05ec61c206c935d6a4ffd3adbdaba808</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1016%2Fj.neuron.2014.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuron.2014.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DPankevich%26aufirst%3DD.%2BE.%26aulast%3DAltevogt%26aufirst%3DB.%2BM.%26aulast%3DDunlop%26aufirst%3DJ.%26aulast%3DGage%26aufirst%3DF.%2BH.%26aulast%3DHyman%26aufirst%3DS.%2BE.%26atitle%3DImproving%2520and%2520accelerating%2520drug%2520development%2520for%2520nervous%2520system%2520disorders%26jtitle%3DNeuron%26date%3D2014%26volume%3D84%26spage%3D546%26epage%3D553%26doi%3D10.1016%2Fj.neuron.2014.10.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b01827&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-6%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b01827%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b01827" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                8MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67991bdbdef83cee","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
